<SEC-DOCUMENT>0000950123-21-006611.txt : 20210609
<SEC-HEADER>0000950123-21-006611.hdr.sgml : 20210609
<ACCEPTANCE-DATETIME>20210514172403
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-21-006611
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		25
FILED AS OF DATE:		20210514
<PUBLIC-REL-DATE>20210609
DATE AS OF CHANGE:		20210514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acumen Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001576885
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-04647
		FILM NUMBER:		21926160

	BUSINESS ADDRESS:	
		STREET 1:		4435 NORTH FIRST STREET, SUITE 360
		CITY:			LIVERMORE
		STATE:			CA
		ZIP:			94551
		BUSINESS PHONE:		925-368-8508

	MAIL ADDRESS:	
		STREET 1:		4435 NORTH FIRST STREET, SUITE 360
		CITY:			LIVERMORE
		STATE:			CA
		ZIP:			94551
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>As submitted to the Securities and Exchange Commission confidentially on May 14,
2021. </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all
information herein remains strictly confidential. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right"><B>Registration
No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Acumen Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">13-6410829</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>427 Park St. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Charlottesville, VA 22902 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(434) <FONT STYLE="white-space:nowrap">297-1000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Daniel O&#146;Connell </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Acumen Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>427 Park St. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Charlottesville, VA 22902 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(434) <FONT STYLE="white-space:nowrap">297-1000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Darren DeStefano</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Katherine Denby</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cooley
LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>11951 Freedom Dr.&nbsp;#1500</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Reston, Virginia 20190</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(703) <FONT STYLE="white-space:nowrap">456-8039</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Patrick O&#146;Brien</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Thomas J. Danielski</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Ropes&nbsp;&amp; Gray LLP<BR>Prudential Tower<BR>800 Boylston Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02199</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">951-7000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8.5pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this Registration Statement is declared
effective. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8.5pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8.5pt; font-family:Times New Roman">If this Form is filed to register additional securities for
an offering pursuant to Rule 462(b)&nbsp;under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744;
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8.5pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities To Be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>Maximum<BR>Aggregate<BR>Offering&nbsp;Price(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration&nbsp;Fee(2)</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Common Stock, $0.0001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the
Securities Act of 1933, as amended. Includes the offering price of additional shares that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="left">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8.5pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall
become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#c21128">The information in this preliminary prospectus is not complete and may be changed.
These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities nor does it seek an offer to buy these securities
in any jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128">Subject to completion, dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021 </FONT></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>PRELIMINARY PROSPECTUS </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g21g20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This is Acumen
Pharmaceuticals, Inc.&#146;s initial public offering. We are selling &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect the public offering price to be between
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. Currently, no public market exists for
the shares of our common stock. We intend to apply to list our common stock on The Nasdaq Global Market under the trading symbol &#147;ABOS.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>We are an &#147;emerging growth company&#148; as defined under the U.S. federal securities laws and, as such, will be subject to reduced
public company reporting requirements for this prospectus and future filings. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves risks that
are described in the &#147;<A HREF="#cov104413_500">Risk&nbsp;Factors</A>&#148; section beginning on page&nbsp;11 of this prospectus. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:8%;border-bottom:1px solid #000000; width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the section titled &#147;Underwriting&#148; for additional information regarding underwriting compensation.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters may also exercise their option to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock from us, at the public offering price, less the underwriting discount, for 30 days after the date of this prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or
passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares of
common stock will be ready for delivery on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:18pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="top"><B>BofA&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Credit&nbsp;Suisse</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Stifel</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><FONT STYLE="font-size:14pt"><B>UBS Investment Bank</B></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_4">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_10">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_13">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_14">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_15">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_18">Material U.S. Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_20">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_22">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc104413_23">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in
this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide you. We are offering to
sell, and seeking offers to buy, shares of common stock only in jurisdictions where such offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of
delivery of this prospectus or of any sale of the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: we have not, and the
underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States
who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for
convenience, the trademarks and trade names in this prospectus may be referred to without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references
should not be construed as any indicator that their respective owners will not assert their rights thereto. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights, and is qualified in its entirety by, information contained elsewhere in this prospectus. This summary does not
contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, especially the sections titled &#147;Risk Factors,&#148; &#147;Business,&#148; and &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes appearing elsewhere in this prospectus, before making an investment decision. As used in this prospectus, unless the
context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;the company,&#148; &#147;Acumen&#148; and &#147;Acumen Pharmaceuticals&#148; refer to Acumen Pharmaceuticals, Inc. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer&#146;s disease, or AD. Alzheimer&#146;s disease is a progressive neurodegenerative disease of
the brain that leads to loss of memory and cognitive functions and ultimately results in death. Our scientific founders pioneered research on soluble amyloid-beta oligomers, or A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, globular assemblies
of the amyloid-beta, or A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>, peptide that are distinct from A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and amyloid plaques. Based on decades of research and supporting evidence, A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os have gained increasing scientific acceptance as a primary toxin involved in the initiation and propagation of AD pathology. We are currently focused on advancing a targeted immunotherapy drug candidate,
ACU193, and establishing proof of mechanism in early AD patients. ACU193 is a humanized monoclonal antibody that selectively targets A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, has demonstrated functional and protective effects in in vitro
assays, and has demonstrated in vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. We initiated our Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its
safety and tolerability and explore its pharmacokinetics and target engagement. This trial is enrolling patients with mild dementia or mild cognitive impairment, or MCI, due to AD, conditions referred to as &#147;early AD.&#148; Our ACU193 Phase 1
data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by the fourth quarter of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Understanding the Foundation of Our Therapeutic Approach </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Historically, the primary hypothesis of decades of AD research, known as the amyloid hypothesis, held that AD dementia is the clinical
consequence of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> peptide monomers accumulating into extracellular amyloid plaques, or amyloid plaques, which in turn contribute to the formation of intracellular neurofibrillary tangles composed of the
tau protein and cause inflammation, ultimately leading to neuronal cell loss and progressive dementia. Based on this hypothesis, a number of monoclonal antibodies currently or previously in development for AD have primarily targeted either A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers or amyloid plaques; we refer to this broadly defined &#147;class&#148; as <FONT STYLE="white-space:nowrap">anti-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>/plaque antibodies. Several of
these antibodies are currently in late-stage development or are awaiting regulatory approval, and collectively they have provided a biological foothold for treating AD. However, the clinical data available to date indicate some of the potential
limitations of these approaches with respect to clinically meaningful patient benefit and safety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our therapeutic approach focuses on
targeting A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, which we believe are the most toxic and pathogenic form of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> relative to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and amyloid
plaques. Growing evidence, spurred by advances in AD research and analytic techniques, supports our view that A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os are the main instigators of AD neurodegeneration.
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os have been observed to be potent neurotoxins that cause both acute synaptic toxicity and induce neurodegeneration. Experimentally in animal models, the accumulation of
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os is associated with core AD neuropathologies, including synapse deterioration and loss, tau phosphorylation, and inflammation. Research has also shown that the accumulation of A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os is associated with <FONT STYLE="white-space:nowrap">AD-related</FONT> behavioral deficits, such as learning and memory impairment. In light of this evidence, we believe that blocking the toxicity of A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is the most promising approach for the treatment of AD, which led us to discover and develop ACU193. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ACU193 for the Treatment of AD </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
product candidate, ACU193, is the first clinical-stage humanized monoclonal antibody discovered and developed to target soluble A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os and was developed in partnership with Merck &amp; Co., Inc., or Merck.
We believe that ACU193 represents a differentiated approach from current and prior AD immunotherapies because it is highly selective for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. ACU193 has a nanomolar affinity for A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, over <FONT STYLE="white-space:nowrap">500-fold</FONT> greater selectivity for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os over A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers, and limited or
no binding to amyloid plaques. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe ACU193 has characteristics that make it a promising potential treatment for AD relative to
other antibodies that do not selectively target A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. ACU193 has been engineered to reduce immune effector function signaling and designed to avoid binding to vascular amyloid. These attributes of ACU193
are expected to reduce the incidence of amyloid-related imaging abnormalities, or ARIA, a common adverse event observed with amyloid plaque-targeting immunotherapies currently in development for AD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Differentiated Approach to the Treatment of AD </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe ACU193 has several potential advantages in comparison to other AD drugs that are currently approved or in development: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Differentiated mechanism of action: </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potentially addresses an underlying cause of AD: A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, a novel, more
toxic and more pathogenic target; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selectively binds to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Binds to a broad spectrum of toxic A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential for symptomatic improvement and disease modification: </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By selectively targeting and neutralizing A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O toxicity, we believe
that ACU193 has the potential to provide a reduction in cognitive decline in addition to disease-modifying effects, including synaptic protection and decreased neurodegeneration. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential for higher dosing: </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selectivity for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os is likely to result in greatly reduced rates of
ARIA, allowing a broad therapeutic window. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Clinical Development Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the second quarter of 2021, we initiated a U.S.-based, multi-center, randomized, double-blind, placebo-controlled, single and multiple
ascending dose Phase 1 clinical trial of ACU193 in patients with early AD. The early AD patient group is comprised of individuals who have mild dementia or MCI due to AD, and our trial excludes patients with moderate to severe AD dementia. We plan
to enroll 62 patients across seven cohorts, consisting of a single-ascending dose Part A (32 participants) and an overlapping multiple-ascending dose Part B (30 participants). </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The main objectives of the trial are to evaluate the safety, tolerability,
pharmacokinetics, pharmacodynamics, and A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O target engagement of single and multiple ascending doses of ACU193 administered by intravenous infusion. Exploratory outcomes include cognitive scales and
computerized cognitive testing. Our goal is to establish proof of mechanism of ACU193 in early AD patients in order to enable rapid progression into an adaptive Phase 2/3 clinical trial in 2023. We intend to provide periodic updates of the status of
the Phase 1 trial and anticipate reporting proof of mechanism results in the fourth quarter of 2022. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Our Nonclinical Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In nonclinical studies conducted by Merck and Acumen, ACU193 has demonstrated promising characteristics which indicate its potential as a
therapy for the treatment of AD. ACU193 has high selectivity, with binding affinity studies showing that it has over <FONT STYLE="white-space:nowrap">500-fold</FONT> binding selectivity for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os compared
to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and an ex vivo study we conducted with brain tissue from AD patients showing limited or no binding to amyloid plaques. ACU193 binds to a broad spectrum of small to large soluble A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. Additionally, ACU193 has been shown in ex vivo animal studies to offer protection from synaptic toxicity by inhibiting binding of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os to primary hippocampal
neurons. ACU193 has also demonstrated suitable in vivo pharmacology, target engagement, blood-brain barrier penetration and reduction of behavioral deficits. Based on nonclinical studies conducted using animal models,
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O target engagement has the potential to be achieved at doses of ACU193 that will be tested in the clinic. Lastly, ACU193 has been shown to have an adequate safety margin in Good Laboratory Practice, or
GLP, toxicity studies conducted in two animal species. These data indicate that ACU193 has the potential to offer patients a reduction in cognitive decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our objective is to
transform the treatment of AD, and potentially other diseases, by developing innovative therapeutics that target the primary drivers of disease pathology. Our initial therapeutic approach is focused on inhibiting and reducing the toxic activity of A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, which may allow for synaptic protection and decreased neurodegeneration, leading to more effective treatment for patients with early AD. To achieve this objective, we are pursuing the following strategies:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rapidly advance ACU193 through clinical development in patients with early AD; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Evaluate combination approaches to complement our core ACU193 monotherapy strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selectively explore potential of ACU193 for other diseases; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand our product portfolio by developing additional molecules; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Optimize value of ACU193 and future drug candidates in major markets.</P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are led by an experienced
management team with deep scientific and drug development knowledge and a strong commitment to developing safe and effective therapies for patients. Collectively, our management team has a rich set of experiences in industry as well as in academia,
leading clinical development programs for both public and venture-backed clinical-stage companies, as well as with large biopharmaceutical companies, such as Eli Lilly&nbsp;&amp; Co, or Eli Lilly. We are led by our President and Chief Executive
Officer, Daniel O&#146;Connell, our Chief Medical Officer, Eric Siemers, M.D. and our Chief Operating Officer, Russell Barton. Our executive team is complemented by our drug development experts, approximately half of whom hold Ph.D. or M.D. degrees
and are former members of Eli Lilly&#146;s global AD clinical development organization. These team members, including Dr.&nbsp;Siemers and Mr.&nbsp;Barton, have worked for over a decade on early- through late-phase AD
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
drug development, including numerous early-phase AD trials and five large multi-national Phase 3 studies in AD. Together, our management team brings expertise across relevant disciplines,
including neuroscience, neurology, translational science, protein manufacturing, biomarker development and quality and regulatory affairs. We believe our team&#146;s experience and longstanding working relationships position us to take ACU193
through late-stage clinical development and potentially through registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our company is supported by a group of institutional
investors, and we have raised approximately $67.5&nbsp;million in funding as of December&nbsp;31, 2020. Our key investors include BlackRock, PBM Capital, RA Capital Management, Rock Springs Capital, Sands Capital and several other private investors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Factors Summary </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
business is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in the section titled &#147;Risk Factors&#148; and include, among others: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a clinical-stage biopharmaceutical company with a limited operating history. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have no product candidates approved for commercial sale, we have never generated any revenue from sales and we
may never be profitable. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will require substantial additional funding to finance our operations,
complete the development and commercialization of ACU193 for AD and evaluate future product candidates. If we are unable to raise this funding when needed, we may be forced to delay, reduce or eliminate our drug development programs or other
operations. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are substantially dependent on the success of ACU193, our sole product candidate, which will require
significant clinical testing before we can seek regulatory approval and potentially launch commercial sales, and which may not be successful in clinical trials, receive regulatory approval or be successfully commercialized, even if approved.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have concentrated our research and development efforts on the treatment of AD, a field that has to date seen
very limited success in drug development. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our approach to the potential treatment of AD is based on a novel therapeutic approach, which exposes us to
unforeseen risks. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nonclinical and clinical drug development involves a lengthy, expensive and uncertain process. The results of
nonclinical studies and early clinical trials are not always predictive of future results. ACU193 or any other product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive
marketing approval. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical failure can occur at any stage of clinical development and we have never completed a clinical trial or
submitted a biologics license application, or BLA, or marketing authorization application, or MAA. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the
development and commercialization of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We currently rely on CMOs to supply components of and manufacture ACU193. The loss of any of these CMOs or the
failure of any of them to meet their obligations to us could affect our ability to develop ACU193 in a timely manner. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We intend to rely on CROs and other third parties to conduct, supervise and monitor a significant portion of our
research and nonclinical testing and clinical trials for our product candidates, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or otherwise perform satisfactorily, we may not
be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face significant competition in an environment of rapid technological and scientific change, and there is a
possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more effective than ours. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to enter into a commercial collaboration or, alternatively, establish internal sales, marketing
and distribution capabilities, for ACU193 or any other product candidate that may receive regulatory approval, we may not be successful in commercializing those product candidates if and when they are approved. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidate,
and other proprietary technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to
successfully commercialize our product candidate, and other proprietary technologies if approved, may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have identified a material weakness in our internal control over financial reporting which could, if not
remediated, result in material misstatements in our financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Implications of Being an Emerging Growth Company and a
Smaller Reporting Company </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups
Act of 2012, or the JOBS Act. For so long as we remain an emerging growth company, we may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions
include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced obligations with respect to financial data, including only being required to present two years of audited
financial statements, in addition to any required unaudited interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exception from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced obligations with respect to disclosure about our executive compensation arrangements in our periodic
reports, proxy statements and registration statements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation or golden parachute arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#146;s report on financial statements. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until the last day of the fiscal year ending after
the fifth anniversary of this offering or such earlier time that we no longer qualify as an emerging growth company. We will cease to qualify as an emerging growth company on the date that is the earliest of: (i)&nbsp;the last day of our fiscal year
following the fifth anniversary of the date of the completion of this offering, (ii)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in total annual gross revenues, (iii)&nbsp;the date on which we are deemed to be
a &#147;large accelerated filer&#148; under the rules of the U.S. Securities and Exchange Commission, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million
as of the prior June 30th, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over the prior three-year period. We may choose to take advantage of some but not
all of these reduced reporting burdens. We have taken advantage of certain reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different than you might obtain from other public companies in which
you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting
standards until such time as those standards apply to private companies. We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure
requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging
growth companies, which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information that we provide in this prospectus may be different than the information you may receive
from other public companies in which you hold equity interests. In addition, it is possible that some investors will find our common stock less attractive as a result of these elections, which may result in a less active trading market for our
common stock and higher volatility in our share price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; meaning that the market value
of our shares held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;plus</FONT> the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue was less than
$100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our shares held
<FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our shares held
<FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than $700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain
disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report <FONT
STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-K&nbsp;and,</FONT> similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Information </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were
incorporated under the laws of the State of Delaware in 1996. Our principal executive offices are located at 427 Park St., Charlottesville, Virginia 22902<B> </B>and our telephone number is (434) <FONT STYLE="white-space:nowrap">297-1000.</FONT> Our
website address is http://www.acumenpharm.com/. The information contained on, or accessible through, our website is not incorporated by reference into this prospectus. We have included our website in this prospectus solely as an inactive textual
reference. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="59%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase additional shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
(or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise in full their option to purchase additional shares).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, (or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise in full their option to
purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock), assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions
and estimated offering expenses payable by us.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We currently intend to use the net
proceeds from this offering, together with our existing cash and cash equivalents, to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the remainder for working capital and other general corporate purposes. See the
section titled &#147;Use of Proceeds&#148; for additional information.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You should read the section titled &#147;Risk Factors&#148; for a discussion of factors you should consider carefully, together with all the other information included in this prospectus, before deciding to invest in our common
stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;ABOS&#148;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding as of December&nbsp;31, 2020, after giving effect to the conversion of all outstanding shares of our convertible
preferred stock, including 711,203 shares of our Series&nbsp;A convertible preferred stock, 11,231,511 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, and 17,674,469 shares of our Series B convertible
preferred stock, into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, as well as the automatic conversion of an outstanding preferred stock warrant convertible
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and excludes: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,492,303 shares of our common stock issuable upon the exercise of options under our Amended and Restated Stock
Performance Plan, or the Prior Plan, outstanding as of December&nbsp;31, 2020, at a weighted-average exercise price of $0.76; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock issuable upon the exercise of options under the Prior Plan granted subsequent to December&nbsp;31, 2020, at a weighted-average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">574,760 shares of our common stock issuable upon the exercise of common stock warrants outstanding as of
December&nbsp;31, 2020 at an exercise price of $3.00; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock reserved for future issuance under the Prior Plan, which shares will cease to be available for issuance at the time our 2021 Equity Incentive Plan, or the 2021 Plan, becomes effective and will be added to, and become available for
issuance under, the 2021 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock reserved for future issuance under our 2021 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2021 Plan;
and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan, or the ESPP, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for
future issuance under the ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information contained in this prospectus, including the
number of shares of common stock that will be outstanding after this offering, assumes or gives effect to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all outstanding shares of our convertible preferred stock into
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, which will occur upon the
closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic exercise and conversion of an outstanding preferred stock warrant convertible into
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, which will occur upon the
closing of this offering (based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the
cover page of this prospectus); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">30-for-1</FONT></FONT> reverse&nbsp;stock
split of our common stock and preferred stock effected on&nbsp;November 20, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reverse&nbsp;stock</FONT></FONT> split of our common stock effected
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation upon the closing of this
offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options and common stock warrants referred to above after December&nbsp;31, 2020;
and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock.
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following tables set forth our summary financial data for our business. We have derived the statement of operations data for the years
ended December&nbsp;31, 2019 and 2020 and the balance sheet data as of December&nbsp;31, 2020 from our audited financial statements appearing elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that
should be expected in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should read the following summary financial data together with our financial statements and the
related notes thereto included elsewhere in this prospectus and the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; The summary financial data in this section
are not intended to replace our financial statements and are qualified in their entirety by our financial statements and related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except share and<BR>per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant and other revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,907</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contribution related to common stock exchanged for Series&nbsp;A convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">642,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">624,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share, basic and diluted (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used to compute pro forma net loss per&nbsp;share, basic and diluted
(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The unaudited pro forma net loss per share for the year ended December&nbsp;31, 2020 was computed using the
weighted-average number of shares of common stock outstanding, including the pro forma effect of the conversion of all outstanding shares of convertible preferred stock into shares of common stock, as well as the automatic exercise and conversion of
an outstanding preferred stock warrant into common stock and the settlement of the preferred stock tranche rights liability, as if such conversions had occurred at the beginning of the period, regardless of their issuance dates.
</P></TD></TR></TABLE>  <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro<BR>Forma(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro Forma<BR>As&nbsp;Adjusted(2)<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,062</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,429</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche rights liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,653</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,965</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,591</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Gives effect to the conversion of all of the outstanding shares of our convertible preferred stock into an
aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock upon the closing of this offering, as well as the automatic exercise and conversion of an outstanding preferred
stock warrant into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock (based on assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus) as well as the settlement of the preferred stock
tranche rights liability, as if such conversions had occurred on December&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Gives further effect to the sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting fees and
commissions and estimated offering expenses payable by us. This pro forma as adjusted information is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00
increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of
this prospectus, would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase or decrease of 1.0&nbsp;million in the number of shares we are offering would increase or decrease the pro forma as adjusted amount of each
of cash and cash equivalents, working capital, total assets and stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial public
offering price per share and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. For further details regarding our current
assets and current liabilities, see our financial statements appearing elsewhere in this prospectus. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_2"></A><A NAME="cov104413_500"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all
of the other information in this prospectus, including our financial statements and related notes, before deciding whether to purchase shares of our common stock. The risks and uncertainties described below are not the only ones we face. Additional
risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks are realized, our business, financial condition, results of operations and
prospects could be materially and adversely affected. In that event, the price of our common stock could decline, and you could lose part or all of your investment. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Financial Position and Capital Needs </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage biopharmaceutical company with a limited operating history. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company with a limited operating history focused on pioneering a novel disease-modifying therapeutic approach to
treat Alzheimer&#146;s disease, or AD. We were incorporated in 1996 and were party to an exclusive license and research collaboration with Merck&nbsp;&amp; Co., Inc., or Merck, in 2003. Although we acquired the exclusive rights to ACU193 from Merck
in 2011, following Merck&#146;s strategic decision to focus its AD development efforts on a different product candidate, we did not recommence meaningful operations until we completed our first institutional fundraising in 2018. As a result, we have
a very limited operating history, which may make it difficult to evaluate the success of our business to date and assess our future viability. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We received
clearance of our Investigational New Drug application, or IND, for our sole product candidate, ACU193, and initiated our Phase 1 clinical trial in the second quarter of 2021. To date, we have not completed a clinical trial, initiated a pivotal
trial, obtained marketing approval for any product candidate, manufactured a commercial scale product candidate, arranged for a third party to do so on our behalf or conducted sales or marketing activities necessary for successful product candidate
commercialization. Our short operating history makes any assessment of our future success and viability subject to significant uncertainty. We will likely encounter risks and difficulties frequently experienced by early-stage biopharmaceutical
companies in rapidly evolving fields, and we have not yet demonstrated an ability to overcome such risks and difficulties successfully. If we do not address these risks and difficulties successfully, our business will suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no product candidates approved for commercial sale, we have never generated any revenue from sales and we may never be profitable. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no product candidates approved for sale, have never generated any revenue from sales, have never been profitable and do not expect to be profitable in
the foreseeable future. We have incurred net losses in each year since our inception. For the years ended December&nbsp;31, 2019 and 2020, our net losses were $7.9&nbsp;million and $7.3&nbsp;million, respectively. We had an accumulated deficit of
$27.0&nbsp;million as of December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have devoted most of our financial resources to research and development of ACU193,
including our nonclinical development activities of ACU193, and corporate overhead. We expect that it will be several years, if ever, before we have a product candidate approved and ready for commercialization. We expect to continue to incur losses
for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, ACU193 and any other product candidate we may develop in the future, prepare for and begin the commercialization
of any approved product candidates and add infrastructure and personnel to support our drug development efforts and operations as a public company. We anticipate that any such losses could be significant for the next several years. These net losses
and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#146; equity and working capital. Further, these net losses may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year.</FONT></FONT> To become and remain profitable, we must develop and eventually commercialize ACU193 or
another drug with significant revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may never succeed in developing a commercial drug and, even if we succeed in commercializing one or more
product candidates, we may never generate revenues that are large enough to achieve profitability. In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown challenges. Because of these
numerous risks and uncertainties, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to generate revenues or achieve profitability. If we do achieve profitability, we may not be able to
sustain or increase profitability on a quarterly or annual basis, and we will continue to incur substantial research and development costs and other expenditures to develop and market additional product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful, we will require substantial additional funding to finance our operations, complete the development and
commercialization of ACU193 for AD and evaluate future product candidates. If we are unable to raise this funding when needed, we may be forced to delay, reduce or eliminate our drug development programs or other operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have used substantial amounts of cash to fund our operations, and we expect our expenses to increase substantially in the foreseeable future in
connection with our ongoing activities, particularly as we continue the research and development, conduct clinical trials of, and seek marketing approval for, ACU193. Developing ACU193 and conducting clinical trials for the treatment of AD and any
other product candidates or indications that we may pursue in the future will require substantial amounts of capital. In addition, if we obtain marketing approval for ACU193 or any future product candidates, we expect to incur significant
commercialization expenses related to the commercialization of the product, whether we are commercializing alone or with a collaborator. Furthermore, upon the closing of this offering, we expect to incur additional significant expenses associated
with operating as a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. As
of December&nbsp;31, 2020, we had $43.8&nbsp;million in cash and cash equivalents. We believe that our existing capital resources, together with the net proceeds from this offering, will be sufficient to fund our projected operations
through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. However, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to
spend more money than currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress, costs, timing and results of our Phase 1 trial and other clinical trials of ACU193, including for
potential additional indications that we may pursue beyond AD; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirements of the U.S. Food and Drug Administration, or the FDA, and European Medicines Agency, or the EMA,
for clinical trials and nonclinical studies and other work, for review and approval of ACU193 for AD; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome, costs and timing of seeking and obtaining FDA, EMA and any other regulatory approvals;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and characteristics of product candidates that we pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain sufficient quantities of our product candidates from our third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to expand our research and development activities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with securing and establishing commercialization capabilities if we were to elect to
commercialize one or more products on our own; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the economics and other terms, timing of and success of any collaboration, licensing or other arrangements into
which we may enter for the commercialization of our products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and other terms, timing and success, of acquiring, <FONT STYLE="white-space:nowrap">in-licensing</FONT>
or investing in businesses, product candidates and technologies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount
and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need and ability to retain management and hire scientific and clinical personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing drugs and product candidates and other market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional funding may not be available to us on acceptable terms or at all. Any such funding may result in dilution to stockholders,
imposition of debt covenants and repayment obligations or other restrictions that may affect our business. We also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights
to some of our technologies or product candidates or otherwise agree to terms unfavorable to us. Any funds we raise may not be sufficient to enable us to continue to implement our long-term business strategy. Further, our ability to raise additional
capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If we are unable to raise sufficient additional capital on a timely basis, we could be forced to curtail our planned operations and the pursuit of our business strategy, which would have a
material adverse effect on the value of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Development of our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are substantially dependent on the success of ACU193, our sole product candidate, which will require significant clinical testing before we can seek
regulatory approval and potentially launch commercial sales, and which may not be successful in clinical trials, receive regulatory approval or be successfully commercialized, even if approved. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are early in our development efforts. To date, we have invested substantially all of our efforts and financial resources in the research and development of
ACU193, which is currently our only product candidate. Before seeking marketing approval from regulatory authorities for the sale of ACU193, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the drug in humans. We
are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA, or comparable foreign regulatory authorities, and we may never receive such regulatory approval. We cannot be certain that
ACU193 will be successful in clinical trials. Further, ACU193 may not receive regulatory approval even if it is successful in clinical trials. If we do not receive regulatory approvals for ACU193, we may not be able to continue our operations. Our
prospects, including our ability to finance our operations and generate revenue, will depend entirely on the successful development, regulatory approval and commercialization of ACU193 by us or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by one or more of our partners. The clinical and commercial success of ACU193 will depend on a number of factors, including the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful patient enrollment in our Phase 1 and other clinical trials of ACU193; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sufficiency of our financial and other resources to complete the necessary clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results from our Phase 1 clinical trial and future clinical trials of ACU193; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the frequency and severity of adverse effects of ACU193; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of third-party manufacturers to manufacture supplies of ACU193 and to develop, validate and maintain
a commercial-scale manufacturing process that is compliant with current good manufacturing practices, or cGMP; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate ACU193&#146;s safety and efficacy to the satisfaction of the FDA and foreign
regulatory authorities in order to receive necessary marketing approvals for ACU193; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we are required by the FDA to conduct additional clinical trials prior to the approval to market ACU193
and whether the FDA may disagree with the number, design, size, conduct, implementation or other aspects of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the FDA may require implementation of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition
of approval or post-approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize ACU193, if approved for marketing and sale by the FDA or foreign
regulatory authorities, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our success in educating physicians and patients about the benefits, administration and use of ACU193;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of ACU193 as safe and effective by patients and the medical community; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and
competing treatments; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieving and maintaining compliance with all regulatory requirements applicable to ACU193, including any
required post-marketing approval commitments; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively competing with other AD therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our own or any future collaborators&#146; marketing, pricing, coverage and reimbursement,
sales and distribution strategies and operations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our existing patents and obtain newly issued patents that cover ACU193 and to enforce
such patents and other intellectual property rights in and to ACU193; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to avoid third-party intellectual property claims; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of third-party coverage and adequate reimbursement for ACU193 and any other product candidates,
once approved; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a continued acceptable safety, tolerability and efficacy profile of ACU193 following approval.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of these factors are beyond our control. Accordingly, we cannot assure you that we will ever be able to
generate revenue through the sale of ACU193. If we are not successful in commercializing ACU193, or are significantly delayed in doing so, our business will be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have concentrated our research and development efforts on the treatment of AD, a field that has to date seen very limited success in drug
development. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have focused our research and development efforts solely on developing effective treatments for AD. Collectively, efforts by
pharmaceutical companies in the field of AD have seen very limited successes in drug development. There are few approved products available for patients with AD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future success is highly dependent on the successful development of ACU193 for treating AD. The development and, if approved, commercialization of ACU193
subjects us to a number of challenges, including ensuring that we select an effective dose of ACU193, executing appropriate clinical trials to test for safety and efficacy and obtaining regulatory approval from the FDA and other regulatory
authorities. We cannot be sure that ACU193, or any other product candidate we develop, will ultimately prove to be safe and effective, scalable or profitable. Moreover, public perception of drug safety issues, including adoption of new therapeutics
or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians to prescribe novel treatments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our approach to the potential treatment of AD is based on a novel therapeutic approach, which exposes us to unforeseen risks. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no current scientific or general consensus on the causation of AD or method of action to treat AD. We have discovered and are developing ACU193, a
humanized monoclonal antibody that selectively targets amyloid-beta oligomers, or A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, to treat AD. Our approach is based on research on A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, globular
assemblies of the amyloid-beta, or A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>, peptide that are distinct from other forms of amyloid. A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os have gained scientific acceptance as primary toxins involved
in the initiation and propagation of AD pathology. Based on the results of our nonclinical studies to date, we believe ACU193 is different from current and prior clinical-stage anti-amyloid drugs and product candidates based on its selectivity for A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. We believe that this is a novel mechanism which has the potential to provide more clinically meaningful benefits, with a possible improved safety profile, as compared to approved therapies and product
candidates in development and may potentially slow disease progression. However, we may ultimately discover that ACU193 does not possess properties required for therapeutic effectiveness. We have no evidence regarding the efficacy, safety or
tolerability of ACU193 in humans. We may spend substantial funds attempting to develop ACU193 or other product candidates and never succeed in doing so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market for any products that we successfully develop, if any, will also depend on the cost of the product. We do not yet have sufficient information to
reliably estimate what it would cost to commercially manufacture ACU193, and the actual cost to manufacture ACU193 or any drug we develop in the future could materially and adversely affect the commercial viability of the drug. We may also find that
the manufacture of our product candidates is more difficult than anticipated, resulting in an inability to produce a sufficient amount of our product candidates for our clinical trials or, if approved, commercial supply. If we do not successfully
develop ACU193 or any other drug we develop with drug product cannot be reliably and economically manufactured at scale, we will not become profitable, which would materially and adversely affect the value of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nonclinical and clinical drug development involves a lengthy, expensive and uncertain process. The results of nonclinical studies and early clinical
trials are not always predictive of future results. ACU193 or any other product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The research and development of product candidates is extremely risky. Only a small percentage of product candidates that enter the development process ever
receive marketing approval. Before obtaining marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval from regulatory authorities for the sale of any product candidate, we must complete nonclinical development and then conduct extensive clinical trials to demonstrate the safety and
efficacy of our product candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of nonclinical studies and early clinical trials are not necessarily predictive of future results and ACU193, or any other product candidate that
we may develop, may not be further developed or have favorable results in later studies or trials. Clinical trial failure may result from a multitude of factors including, but not limited to, flaws in study design, dose selection, placebo effect,
patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the pharmaceutical industry have suffered setbacks in the
advancement of their product candidates into later-stage clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding results in earlier nonclinical studies or clinical trials. We intend to enroll 62 patients with early AD in
our Phase 1 clinical trial of ACU193. Even if the results of our Phase 1 clinical trial are positive, it may not be predictive of the results of outcomes in our later-stage clinical trials. The results of clinical trials in one set of patients or
disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors,
including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial
participants. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. This is
particularly true in AD, where failure rates historically are higher than in most other disease areas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of negative or inconclusive results,
we may decide, or regulatory authorities may require us, to conduct additional clinical trials or nonclinical studies. In addition, data obtained from clinical trials and nonclinical studies is susceptible to varying interpretations, and regulatory
authorities may not interpret our data as favorably as we do, which may further delay, limit or prevent development efforts, clinical trials or marketing approval. Furthermore, as more competing product candidates within a particular class of drugs
proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to complete nonclinical studies or clinical trials of ACU193 or future product candidates, due to safety concerns or otherwise, or if the
results of these trials are not sufficient to convince regulatory authorities of their safety or efficacy, we will not be able to obtain marketing approval for commercialization on a timely basis or at all. Even if we are able to obtain marketing
approval for ACU193 or any future product candidates, those approvals may be for indications or dose levels that deviate from our desired approach or may contain other limitations that would adversely affect our ability to generate revenue from
sales of those product candidates. Moreover, if we are not able to differentiate our product candidate against other approved product candidates within the same class of drugs, or if any of the other circumstances described above occur, our business
would be harmed and our ability to generate revenue from that class of drugs would be severely impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical failure can occur at any stage of
clinical development and we have never completed a clinical trial or submitted a biologics license application, or BLA, or marketing authorization application, or MAA. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are early in our development efforts for ACU193, and will need to successfully complete our ongoing and planned clinical trials, including pivotal clinical
trials, in order to obtain FDA approval to market ACU193 or any other product candidate we seek to develop. Carrying out clinical trials and the submission of a successful BLA is a complicated process. Although members of the Acumen team have
significant experience in clinical development of drugs through regulatory approval, as an organization, Acumen has just begun conducting its first clinical trial, has no experience in conducting any clinical trials, has limited experience in
preparing regulatory submissions and has not previously submitted a BLA for any product candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we have had limited interactions with the FDA and cannot be certain how many clinical trials of
ACU193 will be required or how such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to BLA submission and approval of ACU193 or any other
product candidate. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical
trials, could prevent us from or delay us in commercializing ACU193 or any future product candidates we may develop, and failure to successfully complete any of these activities in a timely manner could have a material adverse impact on our business
and financial performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development
and commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience numerous unforeseen events during, or as a result of, clinical trials that
could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities, Institutional Review Boards, or IRBs, or Ethics Committees, or ECs, may not authorize us
or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or we may fail to reach a consensus with regulatory authorities on trial design; for example, our initial submission of the IND for ACU193 was
placed on clinical hold by the FDA until we were able to address the FDA&#146;s initial concerns regarding potential <FONT STYLE="white-space:nowrap">off-target</FONT> binding of ACU193 with an additional nonclinical tissue cross reactivity study,
after which the FDA permitted us to initiate the Phase 1 clinical trial of ACU193 in April 2021; </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities in jurisdictions in which we seek to conduct clinical trials may differ from each other on
our trial design, and it may be difficult or impossible to satisfy all such authorities with one approach; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical
trial protocols with prospective trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different contract research organizations, or CROs, and trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to add or be delayed in adding a sufficient number of clinical trial sites and obtaining IRB or
independent EC approval at each clinical trial site; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates may fail to show safety or efficacy or otherwise produce negative or
inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials or abandon drug development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enrollment in our clinical trials may be slower than we anticipate or participants may drop out of these clinical
trials at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in having subjects complete a clinical trial or returning for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to clinical trial protocols; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors, including clinical investigators, contract manufacturers and vendors may fail to
comply with applicable regulatory requirements, lose their licenses or permits, or otherwise fail, or lose the ability to, meet their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might have to suspend or terminate clinical trials of our product candidates for various reasons, including a
finding that the participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities or IRBs may require that we or our investigators suspend or terminate clinical research
for various reasons, including noncompliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or that the participants are being exposed to unacceptable health
risks; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates may be greater than we anticipate, and we may lack adequate
funding to continue one or more clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our
product candidates may be insufficient or inadequate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites may deviate from clinical trial protocol or drop out of a clinical trial; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adverse side effects, properties or other safety risks associated with ACU193 or any future product candidates could delay or
preclude approval, cause us to suspend or discontinue clinical trials, abandon further development, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with pharmaceuticals generally, it is possible that there may be side effects and adverse events associated with the use of ACU193 or any
future product candidates we may develop. Results of our Phase 1 trial of ACU193, or future clinical trials, could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics as the clinical trials progress
to greater exposures and a larger number of patients. Undesirable side effects caused by, or unexpected or unacceptable characteristics associated with, ACU193 or any future product candidates we may develop, could result in the delay, suspension or
termination of clinical trials by us, the FDA or other regulatory authorities, or IRBs for a number of reasons. We may also elect to limit their development to more narrow uses or subpopulations in which the undesirable side effects or other
characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for such product candidate if approved. If we elect or are required to further delay, suspend or
terminate any clinical trial of any product candidates we may develop, the commercial prospects of such product candidates will be harmed and our ability to generate drug revenues from any such product candidates will be delayed or eliminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that, as we test ACU193 in our Phase 1 trial or future trials, or as the use of ACU193 becomes more widespread if it receives regulatory
approval, we may identify additional adverse events that were not identified or not considered significant in our earlier trials. If such side effects become later known in development or upon approval, if any, such findings may harm our business,
financial condition, results of operations and prospects significantly. If we or others later identify undesirable side effects, a number of potentially significant negative consequences could result, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw, suspend or limit approval of ACU193 or any future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to recall a drug or change the way such drug is administered to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings or statements in the labeling, such as a boxed warning or
a contraindication or issue safety alerts, press releases or other communications containing warnings or other safety information about the product candidate, for example, field alerts to physicians and pharmacies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require us to implement a REMS to ensure that the benefits of the drug outweigh its
risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a drug is distributed or administered, conduct additional clinical trials or
be required to conduct additional post-marketing studies or surveillance; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to regulatory investigations and government enforcement actions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may decide to remove such product candidates from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of the drug may decrease significantly or ACU193 or any future drug could become less competitive; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of ACU193 or any future product candidates, if approved, and could
significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may experience delays or difficulties in the
enrollment and retention of patients in clinical trials, which could delay or prevent our receipt of necessary regulatory approvals. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Successful
and timely completion of clinical trials will require that we enroll a sufficient number of patients. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the
patient population and competition for patients eligible for our clinical trials with competitors which may have ongoing clinical trials for product candidates that are under development to treat the same indications as one or more of our product
candidates or approved products for the conditions for which we are developing our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trials may be subject to delays as a result of
patient enrollment taking longer than anticipated or patient withdrawal. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to
participate in these trials as required by the FDA, EMA or foreign regulatory authorities. We cannot predict how successful we will be at enrolling subjects in future clinical trials. Subject enrollment is affected by other factors including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity and difficulty of diagnosing the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the eligibility and exclusion criteria for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the patient population and process for identifying patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the perceived risks and benefits of the product candidate in the trial, including relating to cell therapy
approaches; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of competing commercially available therapies and other competing therapeutic candidates&#146;
clinical trials for the disease or condition under investigation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to be enrolled in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including
difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented, and other factors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity and availability of clinical trial sites for prospective patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more
clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.
Furthermore, we expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we will have limited influence over their performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such
patients in our clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary results from our clinical
trials that we announce or publish from time to time may change as more data become available and is subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim, <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary results from our clinical trials. Interim results
from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or
<FONT STYLE="white-space:nowrap">top-line</FONT> results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim
and preliminary data should be viewed with caution until the final data are reported. Differences between preliminary, <FONT STYLE="white-space:nowrap">top-line</FONT> or interim data and final data could significantly harm our business prospects
and may cause the trading price of our common stock to fluctuate significantly. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and
carefully evaluate all data. As a result, the <FONT STYLE="white-space:nowrap">top-line</FONT> results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once
additional data have been received and fully evaluated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies may not accept or agree with our assumptions,
estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular development program, the approvability or commercialization of the particular product
candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed meaningful by you or others with respect to future decisions, conclusions,
views, activities or otherwise regarding a particular product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidate or our business. If the interim, <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary data that we report differ from actual results, or if others, including regulatory
authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot be certain that ACU193 or any of our future product candidates will receive regulatory approval, and without regulatory approval we will not
be able to market our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have no product candidates approved for sale and we cannot guarantee that we will ever
have marketable product candidates. ACU193 is our sole product candidate designed for the treatment of AD. Our ability to generate revenue related to sales of ACU193, if ever, will depend on the successful development and regulatory approval of
ACU193 for the treatment of AD and, potentially, other indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development of a product candidate and its approval and commercialization,
including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to extensive regulation by the FDA, the EMA and regulatory
authorities in other countries, with regulations differing from country to country. We are not permitted to market our product candidates in the United States, Europe or other countries until we receive approval of a BLA from the FDA or MAA from the
EMA, respectively. We have not submitted any marketing applications for ACU193. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BLAs and MAAs must include extensive nonclinical and clinical data and
supporting information to establish the product candidate&#146;s safety and effectiveness for each desired indication. BLAs and MAAs must also include significant information regarding the chemistry, manufacturing and controls for the drug.
Obtaining approval of a BLA or a MAA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The FDA and the EMA review processes can take years to complete and approval is never guaranteed. If we submit a
BLA to the FDA, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA. Regulators of other jurisdictions, such as the EMA, have their
own procedures for approval of product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a drug is approved, the FDA or the EMA, as the case may be, may limit the indications for
which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United States and
Europe also have requirements for approval of product candidates with which we must comply prior with marketing in those countries. Obtaining regulatory approval for marketing of a product candidate in one country does not ensure that we will be
able to obtain regulatory approval in any other country. In addition, delays in approvals or rejections of marketing applications in the United States, Europe or other countries may be based upon many factors, including regulatory requests for
additional analyses, reports, data, nonclinical studies and clinical trials, regulatory questions regarding different interpretations of data and results, changes in regulatory policy during the period of drug development and the emergence of new
information regarding ACU193 or other product candidates we may develop in the future. Also, regulatory approval for any of our product candidates may be withdrawn. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We initiated our Phase 1 trial in patients with AD in the second quarter of 2021. Before we submit a BLA to the FDA or a MAA to the EMA for ACU193 for the
treatment of patients with AD, we will be required to successfully complete our Phase 1 clinical trial and at least one additional late-stage clinical trial. The FDA generally requires two pivotal clinical trials to support approval. In addition, we
must scale up manufacturing and complete other standard nonclinical and clinical studies. We cannot predict whether our current or future trials will be successful or whether regulators will agree with our conclusions regarding the nonclinical
studies and the clinical trials we conduct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may in the future conduct clinical trials for our product candidates outside the United States, and
the FDA, EMA and other foreign regulatory authorities may not accept data from such trials. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may in the future choose to conduct one or more of
our clinical trials outside the United States, including in Europe. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, EMA or applicable foreign regulatory authorities may be
subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the
basis of foreign data alone unless (i)&nbsp;the data are applicable to the United States population and United States medical practice; and (ii)&nbsp;the trials were performed by clinical investigators of recognized competence and pursuant to
current good clinical practice, or cGCP, regulations. Additionally, the FDA&#146;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar
approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any other foreign regulatory authority
will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which
would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to build a pipeline of additional product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our sole product candidate is ACU193. We may not be able to identify and successfully develop new product candidates in addition to ACU193. Even if we are
successful in building our product pipeline, the potential product candidates that we identify may not be suitable for clinical development or, if deemed suitable for clinical development, successful in any clinical trials. For example, product
candidates may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be successfully developed, much less receive marketing approval and achieve market acceptance. If we do not successfully develop
and commercialize product candidates, we will not be able to obtain product revenue in future periods, which would result in significant harm to our financial position and adversely affect our stock price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may estimate the timing of the accomplishment of various scientific, clinical, regulatory, manufacturing and other product
development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of nonclinical studies and clinical trials and the submission of regulatory filings, including BLA submissions. From time to
time, we may publicly announce the expected timing of some of these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual timing of these milestones can vary significantly compared to our estimates, in
some cases for reasons beyond our control. We may experience numerous unforeseen events during, or as a result of, any future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval or commercialize our
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations may be adversely affected by the evolving and ongoing
<FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business and operations may be adversely affected by the effects of the
recent and evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> virus, which was declared a global pandemic by the World Health Organization in March 2020. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted in travel and
other restrictions in order to reduce the spread of the disease, including public health directives and orders in the United States and the European Union that, among other things and for various periods of time, directed individuals to shelter at
their places of residence, directed businesses and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
governmental agencies to cease <FONT STYLE="white-space:nowrap">non-essential</FONT> operations at physical locations, prohibited certain <FONT STYLE="white-space:nowrap">non-essential</FONT>
gatherings and events and ordered cessation of <FONT STYLE="white-space:nowrap">non-essential</FONT> travel. Future remote work policies and similar government orders or other restrictions on the conduct of business operations related to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic may negatively impact productivity and may disrupt our ongoing research and development activities and our clinical programs and timelines, the magnitude of which will depend, in part, on the
length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Further, such orders also may impact the availability or cost of materials, which would disrupt our supply chain and
manufacturing efforts and could affect our ability to conduct ongoing and planned clinical trials and preparatory activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we do not believe
our operations have been materially impacted by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to date, we may experience related disruptions in the future that could severely impact our clinical trials, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruptions in our ability to obtain drug supply for our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruptions in our ability to obtain clinical test kits for our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in receiving authorizations from regulatory authorities to initiate our planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, difficulties or a suspension in clinical site initiation, including difficulties in recruiting clinical
site investigators and clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in enrolling and retaining patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals
serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
outbreak that may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs or to discontinue the clinical trials altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site monitoring, and the ability or
willingness of subjects to travel to trial sites due to limitations on travel imposed or recommended by federal or state governments, employers and others; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk that participants enrolled in our clinical trials will contract
<FONT STYLE="white-space:nowrap">COVID-19</FONT> while the trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials,
including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruptions of, or delays in receiving, supplies of our product candidates from our contract manufacturing
organizations, or CMOs, due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to accept data from clinical trials in these affected geographies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which has caused a broad impact globally, may materially affect us economically. While the
potential economic impact brought by, and the duration of, <FONT STYLE="white-space:nowrap">COVID-19</FONT> may be difficult to assess or predict, the continued widespread pandemic could result in significant disruption of global financial markets,
reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially affect
our business and the value of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to rapidly evolve. The
extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our business and operations, including our clinical development and regulatory efforts, will depend on future developments that are highly uncertain and cannot be
predicted with confidence at the time of this prospectus, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and effect of business disruptions and the short-term effects and ultimate effectiveness of
the travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat the disease. Accordingly, we do not yet know the full extent of potential delays or impacts on
our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these impacts could adversely affect our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, to the extent the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business and results of operations, it
may also have the effect of heightening many of the other risks and uncertainties described in this &#147;Risk Factors&#148; section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may
develop ACU193 and future product candidates for use in combination with other therapies, which could expose us to additional regulatory risks. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may develop ACU193 and future product candidates for use in combination with one or more other approved therapies for AD. Even if any product candidate we
develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risk that the FDA, EMA or comparable foreign regulatory authorities could revoke approval of
the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less
successful commercially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, we will not be able to market and sell any product candidate we develop in combination with an unapproved AD therapy
for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved AD therapies face the same risks described with respect to our product
candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As product candidates proceed through nonclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that
various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and product characteristics. For example, we recently changed the storage conditions for future
lots of ACU193 drug product, which required a change in contract manufacturer and submission of stability data to FDA in an IND amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The change in contract manufacturer IND amendment was filed with the FDA on April&nbsp;8, 2021. The FDA has
confirmed there is no plan for a 30 day review or wait at the agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such changes carry the risk that they will not achieve our intended objectives. Any
such changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require
additional testing, FDA notification approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our
product candidates and jeopardize our ability to commence sales and generate revenue. In addition, we may be required to make significant changes to our upstream and downstream processes across our pipeline, which could delay the development of our
future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Commercialization of our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if ACU193 or any other product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by
physicians, patients, third-party payors and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If ACU193 or any other product
candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If our product candidates do not achieve an adequate
level of acceptance, we may not generate significant revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which our product candidates are licensed; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy, safety and potential advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate the advantages of our product candidates over other medicines; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or product insert requirements of the FDA, EMA or other foreign regulatory authorities,
including any limitations or warnings contained in a product&#146;s approved labeling, including any black box warning or REMS; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new treatments and of physicians to prescribe these
treatments; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize the product either in collaboration with a third party or on our own;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of our product candidates as well as competitive products;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of third-party coverage and adequate reimbursement for ACU193 and any other product candidates,
once approved; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our products together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to enter into a commercial collaboration or, alternatively, establish internal sales, marketing and distribution capabilities, for
ACU193 or any other product candidate that may receive regulatory approval, we may not be successful in commercializing those product candidates if and when they are approved. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have sales or marketing infrastructure. To achieve commercial success for ACU193 or any other product candidate for which we may obtain marketing
approval, we will either need to establish a commercial collaboration with a pharmaceutical company that has a sales and marketing organization or we will be required to develop these capabilities internally. There are risks and limitations
associated with entering into a commercial collaboration. For example, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are
favorable to us. Even if we are able to enter into a collaboration, our revenue and profitability, if any, are likely to be significantly lower than if we were able to successfully commercialize a product ourselves. In addition, we likely would have
little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the same time, there are significant risks associated with establishing our own sales, marketing and distribution capabilities. For example, recruiting and
training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any
reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This would be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to market our products on our own include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians in order to educate physicians about our product
candidates, once approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not establish sales, marketing and distribution capabilities successfully, either in collaboration with third parties or on
our own, we will not be successful in commercializing our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The affected populations for ACU193 or any other product candidate we
may develop may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
projections of the number of people who have AD, as well as the subset of people with AD who have the potential to benefit from treatment with ACU193, are estimates based on our knowledge and understanding of the disease. These estimates may prove
to be incorrect and new studies may further reduce the estimated incidence or prevalence of the disease or narrow the universe of patients who would be understood to potentially benefit for treatment with ACU193, if approved. The number of patients
in the United States, the European Union and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates or patients may become increasingly difficult to identify and access, all of which would adversely affect our business, financial condition, results of operations and prospects.
Further, even if we obtain approval for ACU193, the FDA or other regulators may limit their approved indications to more narrow uses or subpopulations within the populations for which we are targeting development of ACU193. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total addressable market opportunity for our product candidates will ultimately depend upon a number of factors including the diagnosis and treatment
criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient access and product pricing and reimbursement. Incidence and prevalence estimates are frequently based on information
and assumptions that are not exact and may not be appropriate, and the methodology is forward-looking and speculative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated incidence and
prevalence ranges included herein have been derived from data from multiple sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Accordingly, the incidence and
prevalence estimates included in this prospectus should be viewed with caution. Further, the data and statistical information used in this prospectus, including estimates derived from them, may differ from information and estimates made by our
competitors or from current or future studies conducted by independent sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Off-label</FONT> use or misuse of
our products may harm our reputation in the marketplace, result in injuries that lead to costly product liability suits, and subject us to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any
product. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If ACU193 or any other product candidate we develop is approved by the FDA, we may only promote or market our product candidate for its
specifically approved indications and consistent with its approved labeling. We or any third party collaborator responsible for commercialization of our products will train the marketing and sales forces responsible for our products against
promoting them for uses outside of their approved indications for use, known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> uses.&#148; However, neither we, nor any future commercial partner of ours will be able to prevent a physician
from using our products <FONT STYLE="white-space:nowrap">off-label,</FONT> when in the physician&#146;s independent professional medical judgment he or she deems it appropriate. Furthermore, the use of our products for indications other than those
approved by the FDA may not effectively treat such conditions. Any such <FONT STYLE="white-space:nowrap">off-label</FONT> use of our product candidates could harm our reputation in the marketplace among physicians and patients. There may also be an
increased risk of injury to patients if physicians attempt to use our products for these uses for which they are not approved, which could lead to product liability suits that that might require significant financial and management resources and
that could harm our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized
by the FDA, the U.S. Federal Trade Commission, the Department of Justice, or DOJ, the Office of Inspector General of the U.S. Department of Health and Human Services, or HHS, state attorneys general, members of the U.S. Congress and the public.
Additionally, advertising and promotion of any product candidate that obtains approval outside of the United States will be heavily scrutinized by comparable foreign entities and stakeholders. Violations, including actual or alleged promotion of our
products for unapproved or <FONT STYLE="white-space:nowrap">off-label</FONT> uses, are subject to enforcement or warning letters, mandates to issue corrective information to healthcare practitioners, inquiries, investigations, injunctions and civil
and criminal sanctions by the FDA, DOJ or comparable foreign bodies. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> use and as
enjoined several companies from engaging in an <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition in an
environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more effective than ours. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of new drugs is highly competitive. Moreover, the AD field is characterized by strong competition and a strong emphasis
on intellectual property. We may face competition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies
worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research,
development, manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If approved, ACU193 will compete with therapies currently approved for the treatment of AD, which have
primarily been developed to treat the symptoms of AD rather than the underlying cause of the disease, such as memantine and cholinesterase inhibitors. ACU193 may also compete with one or more potentially disease-modifying therapeutics currently in
development that target A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> or amyloid plaques, the most advanced of which is Biogen Inc.&#146;s aducanumab, which is pending regulatory approval in the United States, Europe and Japan. Other companies
known to be developing therapies with A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>/amyloid plaque-related targets include Alzheon, Inc., Alzinova AB, Chugai Pharmaceutical Co. Ltd., Cognition Therapeutics, Inc., Eisai Co., Ltd., Eli Lilly and
Company, Grifols, S.A., KalGene Pharmaceuticals, Inc., Neurimmune AG, Novartis AG, ProMIS Neurosciences, Inc., Prothena Biosciences, Inc., Roche Holding AG (including Genentech, its wholly owned subsidiary) and Wren Therapeutics, Inc.. Additionally,
ACU193, if approved, may also compete with other potential therapies intended to address underlying causes of AD that are being developed by several companies, including AbbVie Inc., AC Immune SA, Alector, Inc., Anavex Life Sciences Corp., Annovis
Bio, Inc., Athira Pharma, Inc., Biohaven Pharmaceuticals, Inc., Cassava Sciences, Inc., Cortexyme, Inc., Denali Therapeutics, Inc., Johnson&nbsp;&amp; Johnson (including Janssen, its wholly-owned subsidiary) and Takeda Pharmaceutical Co. Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in
research and development, manufacturing, nonclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved product candidates than we do. Mergers and acquisitions in the pharmaceutical and biotechnology
industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side
effects, are more convenient, or are less expensive than any product candidates that we may develop. Furthermore, currently approved product candidates could be discovered to have application for treatment of AD, which could give such product
candidates significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours
from the FDA, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, product candidates or technologies developed by our competitors may render our potential product
candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our
competitors market product candidates that are more effective, safer or less expensive than our product candidates, if approved, or that reach the market sooner than our product candidates, we may not achieve commercial success. In addition, the
pharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or product candidates developed by our competitors
may render our technologies or product candidates obsolete, less competitive or not economical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidates for which we intend to seek
approval as biologic products may face competition sooner than anticipated. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are successful in achieving regulatory approval to
commercialize any biologic product candidate that we develop, it may face competition from biosimilar products. In the United States, ACU193 is, and we expect that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any other product candidate we may seek to develop likely will be, regulated by the FDA as a biologic product subject to approval under the BLA pathway. The Patient Protection and Affordable Care
Act, as amended by the Health Care and Education Reconciliation Act, collectively, the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for
biological products that are biosimilar to or interchangeable with <FONT STYLE="white-space:nowrap">an&nbsp;FDA-licensed&nbsp;reference</FONT> biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the
FDA until four (4)&nbsp;years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference
product was first licensed by the FDA. During <FONT STYLE="white-space:nowrap">this&nbsp;12-year&nbsp;period</FONT> of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the
competing product containing the sponsor&#146;s own&nbsp;nonclinical&nbsp;data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for
<FONT STYLE="white-space:nowrap">the&nbsp;12-year&nbsp;period</FONT> of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference
products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that
is similar to traditional generic substitution <FONT STYLE="white-space:nowrap">for&nbsp;non-biological&nbsp;products</FONT> will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain
marketing approval for biosimilars referencing our candidates, if approved, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The success of our product candidates will depend significantly on coverage and adequate reimbursement or the willingness of patients to pay for these
therapies. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our success depends on obtaining and maintaining coverage and adequate reimbursement from third- party payors for ACU193
and any other product candidate we successfully develop, and the extent to which patients will be willing to pay <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> for such products, in the absence of
reimbursement for all or part of the cost. In the United States and in other countries, patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their
treatment. The availability of coverage and adequacy of reimbursement for our products by third-party payors, including government health care programs (e.g., Medicare, Medicaid, TRICARE), managed care providers, private health insurers, health
maintenance organizations, and other organizations is essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates. Third-party payors often rely upon Medicare coverage policy and
payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis. One payor&#146;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage, and adequate reimbursement. The principal decisions
about reimbursement for new medicines are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, an agency within the HHS. CMS decides whether and to what extent products will be covered and reimbursed under Medicare and
private payors tend to follow CMS to a substantial degree. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors determine which products and procedures they will cover and establish
reimbursement levels. Even if a third-party payor covers a particular product or procedure, the resulting reimbursement payment rates may not be adequate. Patients who are treated <FONT STYLE="white-space:nowrap">in-office</FONT> for a medical
condition generally rely on third-party payors to reimburse all or part of the costs associated with the procedure, including costs associated with products used during the procedure, and may be unwilling to undergo such procedures in the absence of
such coverage and adequate reimbursement. Physicians may be unlikely to offer procedures for such treatment if they are not covered by insurance and may be unlikely to purchase and use our product candidates, if approved, for our stated indications
unless coverage is provided and reimbursement is adequate. In addition, for products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often
associated with such drugs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reimbursement by a third-party payor may depend upon a number of factors, including the third-party
payor&#146;s determination that a procedure is safe, effective and medically necessary; appropriate for the specific patient; cost-effective; supported by peer-reviewed medical journals; included in clinical practice guidelines; and neither
cosmetic, experimental nor investigational. Further, increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for
newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to
purchasers, private health plans or government healthcare programs. Our product candidates may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to
other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. We expect to experience pricing
pressures from third-party payors in connection with the potential sale of any of our product candidates. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage
and patient demand for the product and also have a material adverse effect on sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign governments also have their own healthcare reimbursement
systems, which vary significantly by country and region, and we cannot be sure that coverage and adequate reimbursement will be made available with respect to the treatments in which our products are used under any foreign reimbursement system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that ACU193 or any other product candidate, if approved for sale in the United States or in other countries, will be considered
medically reasonable and necessary, that it will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available or that reimbursement policies and practices in the United States and in
foreign countries where our products are sold will not adversely affect our ability to sell our product candidates profitably, if they are approved for sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may
develop. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and
will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or drugs caused injuries, we will incur substantial liabilities.
Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidates or drugs that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards paid to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced resources of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any products that we may develop. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all
liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to
maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to a variety of
privacy and data security laws, and our failure to comply with them could harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a large quantity of sensitive
information, including confidential business and personal information in connection with the conduct of our clinical trials and related to our employees, and we are subject to laws and regulations governing the privacy and security of such
information. In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information
privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus
on privacy and data protection issues, which may affect our business and is expected to increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations could apply to our operations or
the operations of our partners, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations (e.g. Section&nbsp;5 of the Federal Trade Commission Act), that
govern the collection, use, disclosure and protection of health-related and other personal information. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that
are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and regulations promulgated
thereunder. Depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use or disclose individually identifiable health information in a manner that is not authorized or permitted by HIPAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Europe, the General Data Protection Regulation, or GDPR, took effect in May 2018. The GDPR governs the collection, use, disclosure, transfer or other
processing of personal data of individuals within the European Economic Area, or EEA, including clinical trial data. Among other things, the GDPR imposes requirements regarding the security of personal data and notification of data processing
obligations to the competent national data processing authorities, requires having lawful bases on which personal data can be processed, requires changes to informed consent practices, and more detailed notices for clinical trial subjects and
investigators. In addition, the GDPR increases the scrutiny of transfers of personal data from the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#147;adequate&#148; data protection laws.
In July 2020, the Court of Justice of the European Union limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield and
imposing further restrictions on use of the standard contractual clauses, which could increase our costs and our ability to efficiently process personal data from the EEA. The GDPR imposes substantial fines for breaches and violations (up to the
greater of &#128;20&nbsp;million or four percent (4%) of our consolidated annual worldwide gross revenue) and confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek
judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Relatedly, following the United Kingdom&#146;s, or U.K., withdrawal from the EEA and the European Union, and the expiry of the transition period, which
ended on January&nbsp;1, 2021, companies have to comply with both the GDPR and the GDPR as incorporated into U.K. national law, the latter regime having the ability to separately fine up to the greater of &pound;17.5&nbsp;million or four percent
(4%) of global turnover. On January&nbsp;1, 2021, the U.K. became a third country for the purposes of the GDPR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The relationship between the U.K. and the
European Union in relation to certain aspects of data protection law remains unclear. For example, it is unclear how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk. Pursuant to the <FONT
STYLE="white-space:nowrap">EU-U.K.</FONT> Trade and Cooperation Agreement of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;24, 2020, transfers of personal data from the European Union to the U.K. may continue to take place without a need for additional safeguards during a further transition period, to
expire on (1)&nbsp;the date on which an adequacy decision with respect to the U.K. is adopted by the EU Commission; or (2)&nbsp;the expiry of four (4)&nbsp;months, which shall be extended by a further two (2)&nbsp;months unless either the European
Union or the U.K. objects. It remains unclear whether the EU Commission will adopt an adequacy decision with respect to the U.K. In the absence of such decision after the expiry of the additional transition period, we may need to put in place
additional safeguards for transfers of personal data from the European Union to the U.K., such as standard contractual clauses approved by the EU Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required
to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial
condition and results of operations. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly. In addition, states are constantly adopting new laws or amending existing laws, requiring attention to
frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act, or CCPA, which took effect on January&nbsp;1, 2020, became enforceable by the California Attorney General on July&nbsp;1, 2020, and has
been dubbed the first &#147;GDPR-like&#148; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, receive detailed information
about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to <FONT STYLE="white-space:nowrap">opt-out</FONT>
of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act,
or CPRA, recently passed in California. The CPRA will impose additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for
higher risk data and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The
majority of the provisions will go into effect on January&nbsp;1, 2023, and additional compliance investment and potential business process changes may be required. Although the CCPA currently exempts certain health-related information, including
clinical trial data, the CCPA and the CPRA may increase our compliance costs and potential liability. Similar laws have been proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements
that would make compliance challenging. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and
safety laws and regulations, we could become subject to fines or penalties or incur costs that could seriously harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and any
contract manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health, and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation,
handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of
hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of
contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain
environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our
research, product development and manufacturing efforts. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#146; compensation insurance to cover us for
costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste
insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of
contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could seriously harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently rely on CMOs to supply components of and manufacture ACU193. The loss of any of these CMOs or the failure of any of them to meet their
obligations to us could affect our ability to develop ACU193 in a timely manner. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities and rely on a
limited number of CMOs to manufacture our product candidates. We have entered into agreements with third-party CMOs to manufacture ACU193 and supply the Phase 1 clinical trial material, in compliance with applicable regulatory and quality standards.
We intend to continue to rely on third-party CMOs to manufacture our clinical supply for the foreseeable future. Any replacement of a third-party CMO could require significant effort and expertise because there may be a limited number of qualified
replacements. Any delays in obtaining adequate clinical supply that meets the necessary quality standards may delay our development or commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our reliance on CMOs for manufacturing activities will reduce our control over these activities but will not relieve us of our responsibility to ensure
compliance with all required regulations. Under certain circumstances, these CMOs may be entitled to terminate their engagements with us. If a CMO terminates its engagement with us, or does not successfully carry out its contractual duties, meet
expected deadlines or manufacture ACU193 or any other product candidate that we develop in accordance with regulatory requirements, or if there are disagreements between us and a CMO, we may not be able to complete, or may be delayed in completing,
the nonclinical studies required to support clinical trials required for approval of ACU193 or any other product candidate. In such instance, we may need to enter into an appropriate replacement third-party relationship, which may not be readily
available or available on acceptable terms, which would cause additional delay or increased expense prior to the approval of ACU193 or any future product candidate and would thereby have a negative impact on our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may rely on additional third parties to manufacture ingredients of our product candidates in the future and to
perform quality testing. Reliance on CMOs and other third-party service providers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced control for certain aspects of manufacturing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or nonrenewal of the applicable manufacturing and service agreements in a manner or at a time that is
costly or damaging to us; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach by our third-party manufacturers and service providers of our agreements with them;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of our third-party manufacturers and service providers to comply with applicable regulatory
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions to the operations of our third-party manufacturers and service providers caused by conditions
unrelated to our business or operations, including the bankruptcy of the manufacturer or service provider; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could lead to clinical trial delays or failure to obtain regulatory
approval, impact our ability to successfully commercialize any of our product candidates or otherwise harm our business, financial condition, results of operations, stock price and prospects. Some of these events could be the basis for FDA or other
regulatory authority action, including injunction, recall, seizure or total or partial suspension of product manufacture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We intend to rely on CROs
and other third parties to conduct, supervise and monitor a significant portion of our research and nonclinical testing and clinical trials for our product candidates, and if those third parties do not successfully carry out their contractual
duties, comply with regulatory requirements or otherwise perform satisfactorily, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be
substantially harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to engage CROs and other third parties to conduct our planned nonclinical studies or clinical trials, including
our Phase 1 trial and future clinical trials of ACU193, and to monitor and manage data. We expect to continue to rely on third parties, including clinical data management organizations, medical institutions and clinical investigators, in the future.
Any of these third parties may terminate their engagements with us, some in the event of an uncured material breach and some at any time for convenience. If any of our relationships with these third parties terminate, we may not be able to timely
enter into arrangements with alternative third parties or to do so on commercially reasonable terms, if at all. Switching or adding CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition
period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no
assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. Further, the performance of our CROs and other
third parties conducting our trials may also be interrupted by the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including due to travel or quarantine policies, heightened exposure of a CRO or clinical site or other vendor staff
who are healthcare providers to <FONT STYLE="white-space:nowrap">COVID-19</FONT> or prioritization of resources toward the pandemic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, any
third parties conducting our clinical trials will not be our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our clinical
programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the
failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product
candidates. Consequently, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on these parties for execution of our nonclinical studies and clinical trials and generally do not control their activities. Our reliance on these
third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted
in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with GCPs, which are standards for conducting, recording and reporting the results of clinical trials to assure that data and
reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. If we or any of our CROs or other third parties, including trial sites, fail to comply with applicable GCPs, the
clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure
you that upon inspection by a given regulatory authority, such regulatory authority will determine that any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP conditions. Our failure to comply with these regulations
may require us to repeat clinical trials, which would delay the regulatory approval process, or may result in fines, adverse publicity and civil and criminal sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also are required to register certain ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database,
ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of
these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the
integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may
ultimately lead to the denial of marketing approval for ACU193 or any other product candidate we develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also expect to rely on other third parties
to store and distribute product supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products,
producing additional losses and depriving us of potential revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any of our third-party manufacturers encounter difficulties in production of
ACU193 or any future product candidate we develop, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or, if approved, for commercial sale could be delayed or
stopped, or we may be unable to maintain a commercially viable cost structure. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The processes involved in manufacturing ACU193 and any other
product candidate we may develop are highly-regulated and subject to multiple risks. As product candidates are developed through nonclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various
aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes
could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical
data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our third-party manufacturers, such facilities
may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to conduct clinical trials of our product candidates, or supply commercial product candidates, if approved, we will need to manufacture them in both
small and large quantities. We currently rely on third parties to manufacture ACU193 for clinical trial purposes, and our manufacturing partners will have to modify and <FONT STYLE="white-space:nowrap">scale-up</FONT> the manufacturing process when
we transition to commercialization of our product candidates. Our manufacturing partners may be unable to successfully modify or <FONT STYLE="white-space:nowrap">scale-up</FONT> the manufacturing capacity for any of our product candidates in a
timely or cost-effective manner, or at all. In addition, quality issues may arise during <FONT STYLE="white-space:nowrap">scale-up</FONT> activities. If our manufacturing partners are unable to successfully
<FONT STYLE="white-space:nowrap">scale-up</FONT> the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or become infeasible, and regulatory
approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. The same risks would apply to our internal manufacturing facilities, should we in the future decide to build internal
manufacturing capacity. In addition, building internal manufacturing capacity would carry significant risks in terms of being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
able to plan, design and execute on a complex project to build manufacturing facilities in a timely and cost-efficient manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the manufacturing process for any product candidates that we may develop is subject to FDA, EMA and foreign regulatory requirements, and
continuous oversight, and we will need to contract with manufacturers who can meet all applicable FDA, EMA and foreign regulatory authority requirements, including complying cGMPs on an ongoing basis. If we or our third-party manufacturers are
unable to reliably produce product candidates in accordance with the requirements of the FDA, EMA or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize such product candidates. Even if we obtain
regulatory approval for any of our product candidates, there is no assurance that either we or our third party contract manufacturers will be able to manufacture the approved product in accordance with the requirements of the FDA, EMA or other
regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging
clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods and have an adverse effect on our business,
financial condition, results of operations and growth prospects. Significant <FONT STYLE="white-space:nowrap">non-compliance</FONT> could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions, civil
penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal
prosecutions, any of which could damage our reputation and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will likely seek collaborations with third parties for the development
or commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates, including ACU193. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will likely seek third-party collaborators for the commercialization of ACU193 and any of our future product candidates, in the United States and may enter
into collaboration agreements for the development and commercialization of any of our product candidates outside the United States. In the United States, commercialization partners are likely to include large biotechnology or pharmaceutical
companies. Our likely collaborators outside the United States would most likely include regional and national pharmaceutical companies and biotechnology companies. If we enter into such arrangements with any third parties, we will likely have
limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#146;
abilities to successfully perform the functions assigned to them in these arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaborations involving our product candidates would pose the
following risks to us: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory
approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that
divert resources or create competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with
their own product candidates or drugs, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve
regulatory approval may not commit sufficient resources to the marketing and distribution of such products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the
preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in
litigation or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or
their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation
and potential liability; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required
to raise additional capital to pursue further development or commercialization of the applicable product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration
agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our
product development or commercialization program could be delayed, diminished or terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate
collaborators. Whether we reach a definitive agreement for any collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the
proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or similar regulatory authorities outside the United States, the potential
market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology,
which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar
indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there
have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all.
If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any
sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may
need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be exposed to a variety of international risks that could materially adversely affect our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may enter into agreements with third parties for the development and commercialization of product candidates in international markets. International
business relationships will subject us to additional risks that may materially adversely affect our ability to attain or sustain profitable operations, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing regulatory requirements for product approvals internationally; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential third-party patent rights in countries outside of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;parallel importing,&#148; which is what
occurs when a local seller, faced with relatively high local prices, opts to import goods from another jurisdiction with relatively low prices, rather than buying them locally; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pricing pressure and differing reimbursement regimes: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability, particularly in
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> economies and markets, including several countries in Europe; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">taxes in other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including
war and terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, pandemics, epidemics, floods, hurricanes and fires. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we engage in acquisitions, we will incur a variety of costs and we may never realize the anticipated benefits of such acquisitions. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we currently have no plans to do so, we may attempt to acquire businesses, technologies or drug candidates that we believe are a strategic fit with
our business. If we do undertake any acquisitions, the process </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of integrating an acquired business, technology or drug candidates into our business may result in unforeseen operating difficulties and expenditures, including diversion of resources and
management&#146;s attention from our core business. In addition, we may fail to retain key executives and employees of the companies we acquire, which may reduce the value of the acquisition or give rise to additional integration costs. Future
acquisitions could result in additional issuances of equity securities that would dilute the ownership of existing stockholders. Future acquisitions could also result in the incurrence of debt, contingent liabilities or the amortization of expenses
related to other intangible assets, any of which could adversely affect our operating results. In addition, we may fail to realize the anticipated benefits or synergies of any acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
are unable to obtain and maintain sufficient intellectual property protection for our product candidate, and other proprietary technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our
competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidate, and other proprietary technologies if approved, may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success will depend in part on our ability to obtain and maintain a combination of patents, trade secret protection and confidentiality
agreements to protect the intellectual property related to our product candidate, and other proprietary technologies we develop. If we are unable to obtain or maintain patent protection with respect to our product candidate, and other proprietary
technologies we may develop, our business, financial condition, results of operations, and prospects could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent position of
biotechnology and pharmaceutical companies is highly uncertain and involves complex legal, scientific, and factual questions and has been the subject of frequent litigation in recent years. As a result, the issuance, scope, validity, enforceability,
and commercial value of our patent rights are highly uncertain. Our patent applications may not result in patents being issued that protect our product candidate and other proprietary technologies we may develop or that effectively prevent others
from commercializing competitive technologies and products. Further, no consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States or in many jurisdictions outside of the United
States. Changes in either the patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be enforced in
the patents that may be issued from the applications we may own or license from third parties. Further, if any patents we obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our technology could be
adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our
actual or potential future collaborators will be successful in protecting our product candidate and other proprietary technologies and their uses by obtaining, defending and enforcing patents. These risks and uncertainties include the following:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the United States Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require
compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of
patent rights in the relevant jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or may
otherwise not provide any competitive advantage; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made
significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use and sell our product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other parties may have designed around our claims or developed technologies that may be related or competitive to
ours, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications and/or patents, either by claiming the same composition of matter, methods or formulations or by
claiming subject matter that could dominate our patent position; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the
practice of our technologies or the successful commercialization of any product candidate that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">because patent applications in the United States and most other countries are confidential for a period of time
after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidate and other proprietary technologies and their uses; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the
first to invent any of the subject matter covered by the patent claims of any application with an effective filing date before March&nbsp;16, 2013; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope
of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S.
courts, allowing foreign competitors a better opportunity to create, develop, and market competing product candidate in those countries. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, or maintain all necessary or desirable
patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific
collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek
patent protection for such output. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art.
Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some
cases not at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not
adequately protect our rights or permit us to gain or keep our competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our product candidate and other proprietary
technologies and erode or negate any competitive advantage we may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have, which could have a material adverse effect on our financial condition and results of operations. For example: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make compounds that are similar to our product candidate but that are not covered by the
claims of our patents; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to file patent applications for these inventions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any patents that we obtain may not provide us with any competitive advantages; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights
or where patent protection is weak and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we cannot ensure that we will be able to successfully commercialize our product candidate on a substantial scale,
if approved, before the relevant patents that we own or license expire; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Others have filed, and in the future are likely to file, patent applications covering products and technologies that are similar, identical or competitive to
ours or important to our business. We cannot be certain that any patent application owned by a third party will not have priority over patent applications filed or <FONT STYLE="white-space:nowrap">in-licensed</FONT> by us, or that we or our
licensors will not be involved in interference, opposition or invalidity proceedings before U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent offices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be certain that claims in an issued patent covering our product candidate will be considered patentable by the USPTO, courts in the United States,
or by patent offices and courts in foreign countries. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter
significant problems in protecting and defending our intellectual property internationally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The strength of patents in the biotechnology and
pharmaceutical fields involves complex legal and scientific questions and can be uncertain. Patent applications that we file or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover our
product candidate in the United States or in foreign countries. Even if such patents do successfully issue, third parties may challenge the ownership, validity, enforceability, or scope thereof, which may result in such patents being narrowed,
invalidated, or held unenforceable. Any successful opposition to our patents could deprive us of exclusive rights necessary for the successful commercialization of our product candidate. Furthermore, even if they are unchallenged, our patents may
not adequately protect our intellectual property, provide exclusivity for our product candidate or prevent others from designing around our claims. If the breadth or strength of protection provided by our patents with respect to our product
candidate is threatened, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize our product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For U.S. patent applications in which claims are entitled to a priority date before March&nbsp;16, 2013, an interference proceeding can be provoked by a third
party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or
to attempt to license rights from the prevailing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our participation in an interference proceeding may fail and, even if
successful, may result in substantial costs and distract our management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For U.S. patent applications containing a claim not entitled
to priority before March&nbsp;16, 2013, there is greater level of uncertainty in the patent law. In September 2011, the Leahy-Smith America Invents Act, or America Invents Act, was signed into law. The America Invents Act includes a number of
significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The USPTO is developing regulations and procedures to govern the administration of the
America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and in particular, the &#147;first to file&#148; provisions, were enacted on March&nbsp;16, 2013. This will require us to be cognizant
going forward of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. It remains unclear what impact
the America Invents Act will have on the operation of our business. As such, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense
of our issued patents, all of which could have a material adverse effect on our business and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to
protect our competitive position on our product candidate for an adequate amount of time. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of any individual patent depends on applicable
law in the country where the patent is granted. In the United States, provided all maintenance fees are timely paid, a patent generally has a term of 20 years from its application filing date or earliest claimed
<FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. When the terms of all patents covering
our product candidate expire, our business may become subject to competition from competitive products, including biosimilar version of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
product candidate is protected by patents covering the composition of matter and methods of using ACU193. The patents in this portfolio are predicted to expire in 2031 without taking into account any possible extensions and assuming payment of all
appropriate maintenance, renewal, annuity, or other governmental fees. We cannot be certain that we will file and, if filed, obtain patent protection for our product candidate beyond our rights in the current ACU193 patent portfolio. If we are
unable to obtain additional patent protection on ACU193, our primary protection from biosimilar market entry will be limited to regulatory biologic exclusivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain patent term extension for our product candidate our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration, and specifics of any FDA marketing approval of our product candidate, one or more of patents issuing from U.S. patent
applications that we file or license may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension
term, or PTE, of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only
one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar patent term restoration provisions to compensate for commercialization delay caused by
regulatory review are also available in certain foreign jurisdictions, such as in Europe under Supplemental Protection Certificate, or SPC. If we encounter delays in our development efforts, including our future clinical trials, the period of time
during which we could market our product candidate under patent protection would be reduced. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents, or
otherwise fail to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration, or the term of any
such extension is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following
our patent expiration, and our revenue could be reduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the agreements under which we license
intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property rights is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may
arise between us and our licensors regarding intellectual property rights subject to a license agreement, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property rights of the
licensor that are not subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense intellectual property rights to third parties under collaborative development
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidate, and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property rights that
we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms and/or to secure the our rights to the licensed intellectual property, our business, results of operations, financial condition, and
prospects may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were a party to a collaboration agreement with Merck to research, discover and develop certain technology related to amyloid beta-derived diffusible
ligands, or ADDLs. This collaboration was initiated in 2003 and was later terminated by Merck in 2011. During the collaboration, ACU193, an ADDL-binding antibody, was developed and intellectual property was filed by Merck. Under the surviving
provisions of the collaboration agreement, Merck exclusively licensed Merck&#146;s interest in patent rights claiming ADDL antibodies, ADDL antigens and/or products to Acumen. If a dispute were to arise in the future as to our rights to the
intellectual property under the agreement, our ability to commercialize ACU193 may be jeopardized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The USPTO and various foreign governmental patent agencies
require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or
applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ outside counsel to pay these fees
due to foreign patent agencies. While an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors
might be able to enter the market with similar or identical products or technology earlier than should otherwise have been the case, which would have a material adverse effect on our business, financial condition, results of operations, and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product
candidate. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property,
particularly on obtaining and enforcing patents. Our patent rights may be affected by developments or uncertainty in U.S. or foreign patent statutes, patent case law, USPTO rules and regulations or the rules and regulations of foreign patent
offices. Obtaining and enforcing patents in the biotechnology and pharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United States may, at any
time, enact changes to U.S. patent law and regulations, including by legislation, by regulatory rule-making, or by judicial precedent, that adversely affect the scope of patent protection available and weaken the rights of patent owners to obtain
patents, enforce patent infringement and obtain injunctions and/or damages. For example, the scope of patentable subject matter under 35 U.S.C. 101 has evolved significantly over the past several years as the Court of Appeals for the Federal Circuit
and the Supreme Court issued various opinions, and the USPTO modified its guidance for practitioners on multiple occasions. Other countries may likewise enact changes to their patent laws in ways that adversely diminish the scope of patent
protection and weaken the rights of patent owners to obtain patents, enforce patent infringement, and obtain injunctions and/or damages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the
United States and other governments may, at any time, enact changes to law and regulation that create new avenues for challenging the validity of issued patents. For example, the America Invents Act created new administrative post-grant proceedings,
including post-grant review, inter partes review, and derivation proceedings that allow third parties to challenge the validity of issued patents. This applies to all of our U.S. patents, even those issued before March&nbsp;16, 2013. Because of a
lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to
hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this
combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in
unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents are of national or regional effect. Filing, prosecuting, and defending patents on our product candidate, and other proprietary technologies we develop
in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights in the same manner and to the same extent as laws in the United States. Consequently,
we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products
and further, may export otherwise infringing products to territories where we have patent protection, but enforcement of such patent protection is not as strong as that in the United States. These products may compete with our products and our
patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The requirements for patentability may
differ in certain countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claimed drug. In India, unlike the United States, there is no link between regulatory approval for a drug and its patent status. In addition to India, certain countries in Europe and developing
countries, including China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government
contractors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which
could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial
advantage from the intellectual property that we own or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending
intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection,
particularly those relating to biotechnology or pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to
enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and could
provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees (including former employees of our licensors), collaborators or other third parties have an interest in our
patents rights, trade secrets, or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being
unenforceable. For example, we may have inventorship disputes arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development
of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidate or as a result of questions regarding <FONT STYLE="white-space:nowrap">co-ownership</FONT> of potential joint inventions.
Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse
effect on our business, financial condition, results of operations and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through <FONT
STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presently we have intellectual property rights to our product candidate, through a license from
Merck. We also have an intellectual property license through a license with Northwestern University and, if this agreement remains in place, we could be required to pay low single digit royalties to Northwestern in the future. Because our program
may require the use of additional proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use these proprietary rights. In
addition, our product candidate may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license,</FONT> on reasonable terms,
proprietary rights related to any compositions, formulations, methods of use, processes or other intellectual property rights from third parties that we identify as being necessary for our product candidate. Even if we are able to obtain a license
to such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proprietary rights, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be
required to expend significant time and resources to develop or license replacement technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where we obtain licenses from or collaborate with third
parties, we may not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain or enforce the patents, covering technology that we license from third parties, or such activities, if controlled by us,
may require the input of such third parties. If any of our licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by
payment of all applicable fees for patents covering our product candidate, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidate may be
adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed from
third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution. We may also require the cooperation
of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our
business, or in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, we will likely have obligations under our current or future licenses, including making royalty and milestone payments, and any failure to satisfy
those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, could have a material adverse impact on our business. Our business would
suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or
unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the
freedom to seek regulatory approval of, and to market, products identical or similar to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless
of their merit, that we are infringing or otherwise violating the licensor&#146;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the
amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop
and commercialize products, we may be unable to achieve or maintain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party proprietary rights is a
competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to
commercialize our product candidate. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, we have collaborated and may in the future collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or
development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate an exclusive license to any of the institution&#146;s proprietary rights in technology resulting from the
collaboration. Regardless of such option to negotiate a license, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer, on an exclusive
basis, their proprietary rights to other parties, potentially blocking our ability to pursue our program. In addition, disputes may arise under our existing or future license agreements with these institutions or with other counterparties which may,
among other things, lead to the termination or renegotiation of these agreements, or otherwise require us to incur significant financial obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to
us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully
obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to commercialize our products, and our business, financial condition, and prospects for growth, could suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims alleging intellectual property infringement may prevent or delay our drug discovery and development efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation,
both within and outside the United States, involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including inter partes review,
interference and reexamination proceedings before the USPTO, or oppositions and other comparable proceedings in foreign jurisdictions. The America Invents Act introduced new procedures including inter partes review and post grant review. The
implementation of these procedures brings uncertainty to the possibility of challenges to our patents in the future and the outcome of such challenges. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by
third parties, exist in the fields in which we are developing our product candidate. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our activities related to our product candidate may
give rise to claims of infringement of the patent rights of others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries have produced a proliferation of
patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always
uniform. We cannot assure you that any of our current or future product candidate will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party might assert are infringed by one of our
current or future product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization. There may be
third-party patents of which we are currently unaware with claims to materials, compositions, formulations, methods of manufacture or methods for treatment related to our product candidate, or the use or manufacture of our product candidate. Because
patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our product candidate, and
other proprietary technologies may infringe, or which such third parties claim are infringed by the use of our technologies. Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and
obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidate. Defense of these claims, regardless of their merit, could involve substantial expenses and could be a
substantial diversion of management and other employee resources from our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we collaborate with third parties in the development of technology
in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or
proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree
to indemnify our commercial collaborators against certain intellectual property infringement claims brought by third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any claims of patent
infringement asserted by third parties would be time-consuming and could: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">result in costly litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">divert the time and attention of our technical personnel and management; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cause development delays; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevent us from commercializing our product candidate until the asserted patent expires or is finally held
invalid, unenforceable, or not infringed in a court of law; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be
possible on a cost-effective basis; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which
may include treble damages if we are found to have been willfully infringing such intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to pay the attorney&#146;s fees and costs of litigation to the party whose intellectual property
rights we may be found to be willfully infringing; and/or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to enter into royalty or license agreements, which may not be available on commercially reasonable
terms, or at all. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not
infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do either. Proving invalidity or unenforceability is difficult. For example, in the United States, proving invalidity
before federal courts requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#146;s
time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an
infringement action or challenge the validity or enforceability of the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do
not obtain a license, develop or obtain <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, fail to defend an infringement action successfully or have infringed patents declared invalid or unenforceable, we may incur substantial
monetary damages, encounter significant delays in bringing our product candidate to market and be precluded from developing, manufacturing or selling our product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. We cannot be certain that any of our or
our licensors&#146; patent searches or analyses, including but not limited to the identification of relevant patents, analysis of the scope of relevant patent claims or determination of the expiration of relevant patents, are complete or thorough,
nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of our product candidate in any
jurisdiction, because: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">some patent applications in the United States may be maintained in secrecy until the patents are issued;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications in the United States and elsewhere can be pending for many years before issuance, or
unintentionally abandoned patents or applications can be revived; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pending patent applications that have been published can, subject to certain limitations, be later amended in a
manner that could cover our technologies, our product candidate or their uses; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification of third-party patent rights that may be relevant to our technology is difficult because patent
searching is imperfect due to differences in terminology among patents, incomplete databases, and the difficulty in assessing the meaning of patent claims; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications in the United States are typically not published until 18 months after the priority date; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publications in the scientific literature often lag behind actual discoveries. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#146;s prosecution
history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. Further,
we may incorrectly determine that our technologies or product candidate are not covered by a third party patent or may incorrectly predict whether a third party&#146;s pending patent application will issue with claims of relevant scope. Our
determination of the expiration date of any patent in the United States or internationally that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours, and others may have or obtain patents or
proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidate or future products or impair our competitive position. Numerous third-party U.S. and foreign issued patents and pending patent
applications exist in the fields in which we are developing product candidate. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or
manufacture of our product candidate. Any such patent application may have priority over one of our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S.
patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is
possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such
inventions. Other countries have similar laws that permit secrecy of patent applications and may be entitled to priority over our applications in such jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater
resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a third party prevails in a patent infringement lawsuit against us, we may have to stop making and selling the infringing product, pay substantial damages,
including treble damages and attorneys&#146; fees if we are found to be willfully infringing a third party&#146;s patents, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or
require substantial time and monetary expenditure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict whether any such license would be available at all or whether it would be available
on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidate. We may fail to obtain any of these
licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidate, which could harm our business significantly. Even if we were able to obtain a license, the
rights may be nonexclusive, which may give our competitors access to the same intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that we have
wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the
development of our product candidate, and other proprietary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technologies. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other
pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their
former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or
personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming, and
unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court, and we may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties including competitors may infringe, misappropriate or otherwise violate our patents, patents that may issue to us in the future, or
the patents of our licensors that are licensed to us. To counter infringement or unauthorized use, we may need to or choose to file infringement claims, which can be expensive and time-consuming. We may not be able to prevent, alone or with our
licensors, infringement, misappropriation, or other violation of our intellectual property, particularly in countries where the laws may not protect those rights as fully as in the United States, or if we require, but do not receive, the consent or
cooperation of our licensors to enforce such intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we choose to go to court to stop another party from using the inventions claimed
in our patents, that individual or company has the right to ask the court to rule that such patents are invalid, unenforceable, or should not be enforced against that third party for any number of reasons. In patent litigation in the United States,
defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements for patentability, including lack of novelty, obviousness,
lack of written description, indefiniteness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant
information from the USPTO or made a misleading statement during prosecution, i.e., committed inequitable conduct. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for
challenging the validity and enforceability of a patent exist in foreign patent offices and courts and may result in the revocation, cancellation, or amendment of any foreign patents we or our licensors hold now or in the future. The outcome
following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we
would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of
inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business
could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license is offered and our competitors gain access to the same technology.
Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material
adverse effect on our ability to raise the funds necessary to conduct our future clinical trials, continue our research programs, license necessary technology from third parties, or enter into development or manufacturing partnerships that would
help us bring our product candidate to market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not have sufficient financial or other resources to conduct such litigation or proceedings
adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent
litigation or other proceedings could compromise our ability to compete in the marketplace. Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses
and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments and if securities
analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources
available for development activities or any future sales, marketing, or distribution activities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of
our confidential information could be compromised by disclosure during this type of litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to enforce our patent rights depends on our
ability to establish standing in a court of competent jurisdiction. Whether a patent holder or licensee of a patent has standing can be uncertain and the considerations complex. However, if a licensor is required to be joined, and they are unwilling
to do so, we may be unable to proceed with an infringement action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to enforce our patent rights depends on our ability to detect
infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a
competitor&#146;s or potential competitor&#146;s product or service. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent or patents that
may issue from patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may
decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <FONT STYLE="white-space:nowrap">non-litigious</FONT> action or solution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. Our reliance on third
parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However,
trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, and/or other advisors, and inventions agreements with employees,
consultants, and advisors, to protect our trade secrets and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and
technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information and may not provide an
adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is
currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the
FDA&#146;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a
trade secret by an employee, consultant, customer, or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a competitor, and
recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary
technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Even though we use commonly accepted security measures, the criteria for protection of
trade secrets can vary among different jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult,
expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, third parties may still obtain this information or may
come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. Trade secrets will over time be disseminated within the industry through independent
development, the publication of journal articles, and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. Though our agreements with third parties typically restrict the ability of our
advisors, employees, collaborators, licensors, suppliers, third-party contractors, and/or consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. If any of our trade
secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Because from
time to time we expect to rely on third parties in the development, manufacture, and distribution of our products and provision of our services, we must, at times, share trade secrets with them. Despite employing the contractual and other security
precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these
agreements. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to
such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and
our business may be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our trademarks or trade names, once registered, may be challenged, infringed, circumvented or declared
generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times,
competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought
by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we
may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks
and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or
protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights, or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect
our financial condition or results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, any names we may propose to use with our product candidate in the United States must be approved
by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the
FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that
would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA. Similar requirements exist in Europe. Furthermore, in many countries, owning and maintaining a trademark registration may
not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to
build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our
registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark
infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any
collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our future products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and
activities of our collaborators. Collaborations are subject to numerous risks, which may include that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of our products or may elect not to continue or
renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business combination that
diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with marketing, manufacturing, and distribution rights to one or more products may not commit
sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual
property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between us and a collaborator that causes the delay or termination of the research,
development, or commercialization of our current or future products or that results in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue
further development or commercialization of the applicable current or future products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our
products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator&#146;s sales and marketing activities or other operations may not be in compliance with applicable
laws resulting in civil or criminal proceedings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property discovered through government funded programs may be
subject to federal regulations such as <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and
limit our ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our patents may have been generated
through the use of U.S. government funding, and we may acquire or license in the future intellectual property rights that have been generated through the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S.
government has certain rights in inventions developed with government funding. These U.S. government rights include a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable
worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to any of these inventions to a third party if it determines that: (1)&nbsp;adequate steps have not been taken to commercialize the invention; (2)&nbsp;government action is necessary to
meet public health or safety needs; or (3)&nbsp;government action is necessary to meet requirements for public use under federal regulations (also referred to as <FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights&#148;). If the
U.S.&nbsp;government exercised its <FONT STYLE="white-space:nowrap">march-in</FONT> rights in our existing or future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be forced to license
or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also
has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property
generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these
inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the
intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances
domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> product manufacturers for products covered by such intellectual property.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Legal and Regulatory Compliance Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers, healthcare providers, including physicians, and third-party payors are subject, directly or indirectly, to federal and
state healthcare fraud and abuse laws, false claims laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthcare providers, including physicians, and third-party payors in the United States and elsewhere will play a primary role in the recommendation and
prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third- party payors subject us to various federal
and state fraud and abuse laws and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments
Sunshine Act and regulations promulgated under such laws. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational programs, and other interactions with healthcare professionals. In addition, we
may be subject to patient privacy laws by both the federal government and the states in which we conduct or may conduct our business. The laws that will affect our operations include, but are not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, individuals or entities from knowingly
and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind in return for, or to induce, either the referral of an individual, or
the purchase, lease, order or arrangement for or recommendation of the purchase, lease, order or arrangement for any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the
Medicare and Medicaid programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from
prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an
exception or safe harbor. A person does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws, including, without limitation, the federal False Claims Act,
which can be enforced by private citizens through civil whistleblower or qui tam actions, and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for
payment or approval from the federal government, including Medicare, Medicaid and other government payors, that are false or fraudulent or knowingly making, using or causing to be made or used a false record or statement material to a false or
fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government. A claim includes &#147;any request or demand&#148; for money or property presented to the U.S. federal government. Several pharmaceutical and
other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing
false claims to be submitted because of the companies&#146; marketing of products for unapproved, and thus <FONT STYLE="white-space:nowrap">non-reimbursable,</FONT> uses. In addition, the government may assert that a claim including items or
services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA which created additional federal criminal statutes which prohibit, among other things, a person from
knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of
the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal transparency laws, including the federal Physician Payments Sunshine Act, which requires certain
manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#146;s Health Insurance Program, with specific exceptions, to report annually to the CMS,
information related to: (i)&nbsp;payments or other &#147;transfers of value&#146;&#146; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and (ii)&nbsp;ownership and
investment interests held by physicians and their immediate family members. Effective January&nbsp;1, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
2022, these reporting obligations will extend to include transfers of value made during the previous year to physician assistants, nurse practitioners, clinical nurse specialists,
anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations; state laws that require manufacturers to report information
related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government, or that otherwise restrict payments that may be made to healthcare providers; and state and local laws that require the registration of pharmaceutical
sales representatives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors
available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices may not comply with current or future
statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may
be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in federal and state funded healthcare programs, such as
Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws,
contractual damages, diminished profits and future earnings, reputational harm and the curtailment or restructuring of our operations, any of which could harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory
authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs.
Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. The shifting compliance
environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and reporting requirements increases the possibility that a healthcare company may run afoul of one or more
of the requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approval for ACU193 or any future product candidates, they will remain subject to ongoing
regulatory oversight, which may result in significant additional expense. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain any regulatory approval for ACU193 or any future
product candidates, such product candidates will be subject to ongoing regulatory requirements applicable to research, development, testing, manufacturing, labeling, packaging, storage, advertising, promoting, sampling, record-keeping and submission
of safety and other post-market information, among other things. Any regulatory approvals that we receive for ACU193 or any future product candidates may also be subject to REMS, limitations on the approved indicated uses for which the drug may be
marketed or to the conditions of approval or requirements that we conduct potentially costly post-marketing testing and surveillance studies, including Phase 4 trials and surveillance to monitor the quality, safety and efficacy of the drug. An
unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. We will further be required to immediately report any serious and unexpected adverse events and certain quality or production
problems with our products to regulatory authorities along with other periodic reports. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. We
cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or
sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers are subject to payment of user fees and continual review and periodic inspections by the FDA and
other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse
events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory authority may impose
restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable regulatory requirements following approval of ACU193 or any future product candidates, a regulatory authority may: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue an untitled letter or warning letter asserting that we are in violation of the law; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue a safety alert, Dear Healthcare Provider letter, press release or other communication containing warnings
or safety information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandate corrections to promotional materials and labeling or issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend or withdraw regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend any ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to approve a pending marketing application or supplement to an approved application or comparable foreign
marketing application (or any supplements thereto) submitted by us or our strategic partners; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrict the marketing or manufacturing of the drug; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seize or detain the drug or otherwise require the withdrawal of the drug from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to permit the import or export of products or product candidates; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to allow us to enter into supply contracts, including government contracts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative
publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize ACU193 or any future product candidates and harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA or EMA approval any of our product candidates in the United States or European Union, we may never obtain approval for or
commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market any
products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;country-by-country&nbsp;basis</FONT></FONT> regarding
safety and efficacy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval by the FDA in the United States or the EMA in the European Union does not ensure approval by
regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be
accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. In many
jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional nonclinical studies or clinical trials
which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any
jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required
approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems
with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative
initiatives. For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other
things: (i)&nbsp;established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government
healthcare programs; (ii)&nbsp;expanded the entities eligible for discounts under the 340B drug pricing program; (iii)&nbsp;increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of
the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP; (iv)&nbsp;expanded the eligibility criteria for Medicaid
programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new eligibility categories for individuals with income at or below 133% (as calculated, it constitutes 138%) of the federal poverty
level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; (v)&nbsp;addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics
that are inhaled, infused, instilled, implanted or injected; (vi)&nbsp;introduced a new Medicare Part D coverage gap discount program in which manufacturers must now agree to offer 70%
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D (increased from 50%, effective January&nbsp;1, 2019, pursuant to the Bipartisan Budget Act of 2018); (vii) created a new Patient-Centered Outcomes Research Institute to
oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and (viii)&nbsp;established the Center for Medicare and Medicaid Innovation at CMS to test
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal
legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 (the Tax Act) included a provision that repealed, effective January&nbsp;1, 2019, the <FONT
STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual
mandate.&#148; On December&nbsp;14, 2018, a Texas United States District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress as part of the Tax Act. Additionally, on
December&nbsp;18, 2019, the United States Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining
provisions of the ACA are invalid as well. The United States Supreme Court is currently reviewing this case, although it is unclear when a decision will be made. Although the United States Supreme Court has not yet ruled on the constitutionality of
the ACA, on January&nbsp;28, 2021, President Biden issued an executive order to initiate a special enrollment period from February&nbsp;15, 2021 through May&nbsp;15, 2021 for purposes of obtaining health insurance coverage through the ACA
marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver
programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is also unclear how the Supreme Court ruling, other such litigation and the
healthcare reform measures of the Biden administration will impact the ACA or our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted
since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013, and due to subsequent legislative amendments to the
statute, including the Bipartisan Budget Act of 2018, will remain in effect through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020 through March&nbsp;31, 2021, unless additional Congressional action is taken. Legislation is
currently pending in Congress that would further extend the suspension through December&nbsp;31, 2021. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals, and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding, which could have an adverse effect
on customers for our product candidates, if approved, and, accordingly, our financial operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, there has been heightened governmental
scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state
legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the
federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July&nbsp;24, 2020 and September&nbsp;13,
2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#146;s proposals. As a result, the FDA also released a final rule on September&nbsp;24, 2020
providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November&nbsp;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan
sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January&nbsp;1, 2022 to January&nbsp;1, 2023
in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a safe harbor for certain
fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January&nbsp;1, 2023. Further, in November 2020, CMS issued </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an interim final rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest
price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita.&nbsp;The MFN Model regulations mandate participation by identified Part B providers and will apply
in all U.S. states and territories for a seven-year period beginning January&nbsp;1, 2021 and ending December&nbsp;31, 2027.&nbsp;On December&nbsp;28, 2020, the United States District Court in Northern California issued a nationwide preliminary
injunction against implementation of the interim final rule. The likelihood of implementation of any of the other Trump administration reform initiatives is uncertain, particularly in light of the new Biden administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional
downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs. It is also possible that additional governmental action is taken to address the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, FDA regulations and guidance may be revised or reinterpreted by the FDA in ways
that may significantly affect our business and our products. For example, the results of the 2020 U.S. Presidential election may impact our business and industry. The Trump administration took several executive actions, including the issuance of a
number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review
and approval of marketing applications. It is difficult to predict whether or how these requirements will be interpreted and implemented, or whether they will be rescinded and replaced under the Biden administration. The policies and priorities of
the new administration are unknown and could materially impact the regulations governing our product candidates. Any new regulations or guidance, or revisions or reinterpretations of existing regulations or guidance, may impose additional costs or
lengthen FDA review times for ACU193 or any other product candidate we may develop. We cannot determine how changes in regulations, statutes, policies, or interpretations when and if issued, enacted or adopted, may affect our business in the future.
Such changes could, among other things, require: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional clinical trials to be conducted prior to obtaining approval; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to manufacturing methods; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recalls, replacements, or discontinuance of one or more of our products; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional recordkeeping. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such changes would likely require substantial time and impose significant costs, or could reduce the potential commercial value of ACU193 or other product
candidates, and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any other products would harm our business, financial condition and results
of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business activities may be subject to the U.S. Foreign Corrupt Practices Act of 1977, or FCPA, and similar anti-bribery and
anti-corruption laws. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business activities may be subject to the FCPA, U.S. domestic bribery statutes, and similar anti-bribery or
anti-corruption laws, regulations or rules of other countries in which we may operate, including the U.K. Bribery Act of 2010. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly
or indirectly, to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and
therefore involves significant interaction with public officials, including officials of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments. Additionally, in many other countries, hospitals are owned and operated by the government, and
doctors and other hospital employees would be considered foreign officials under the FCPA. There is no certainty that all of our employees, agents, contractors or those of our affiliates, will comply with all applicable laws and regulations,
particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, implementation of
compliance programs and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our product candidates in one or more countries and could materially damage our reputation, our brand, our
international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including
noncompliance with regulatory standards and requirements and insider trading, which could significantly harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the
risk of fraud or other misconduct by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulators, provide accurate information to the FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulators, comply with health care fraud and abuse laws and regulations in the United States and
abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to
prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and
other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible
to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions
or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, those actions could have a significant impact on our business, including the imposition of significant fines or other
sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured
liabilities. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain
include general liability, products liability and directors&#146; and officers&#146; insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Our inability to obtain sufficient product liability
insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of ACU193 or any other product candidate. Any significant uninsured liability may require us to pay substantial
amounts, which would adversely affect our financial position and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing our Growth
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we advance ACU193 through clinical development, and potentially expand the number of our drug development programs, we will need to increase our drug
development, scientific and administrative headcount to manage these programs. In addition, to meet our obligations as a public company, we will need to increase our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
general and administrative capabilities. Our management, personnel and systems currently in place may not be adequate to support this future growth. Our need to effectively manage our operations,
growth and various projects requires that we: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully attract and recruit new employees or consultants with the expertise and experience we will require;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manage our clinical programs effectively, which we anticipate being conducted at numerous clinical sites;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop a marketing and sales infrastructure; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to improve our operational, financial and management controls, reporting systems and procedures.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to successfully manage this growth and increased complexity of operations, our business may be adversely affected.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to attract or retain qualified management, finance, scientific and clinical personnel and consultants due to the intense competition for
qualified personnel and consultants among biotechnology, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel
and consultants to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business
strategy. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the research and
development, clinical, regulatory and business development expertise of Daniel O&#146;Connell, President and Chief Executive Officer, Eric Siemers, M.D., our Chief Medical Officer and Russell Barton, our Chief Operating Officer. If we lose the
services of any of these individuals, our ability to implement our business strategy successfully could be seriously harmed. Any of our executive officers or key employees or consultants may terminate their employment at any time. Replacing
executive officers, key employees and consultants may be difficult and may take an extended period because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval
of and commercialize product candidates successfully. Competition to hire and retain employees and consultants from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel and consultants.
Our failure to retain key personnel or consultants could materially harm our business. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have scientific and clinical advisors and consultants who
assist us in formulating our research, development and clinical strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. <FONT
STYLE="white-space:nowrap">Non-compete</FONT> agreements are not permissible or are limited by law in certain jurisdictions and, even where they are permitted, these individuals typically will not enter into
<FONT STYLE="white-space:nowrap">non-compete</FONT> agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition, our advisors may have arrangements with
other companies to assist those companies in developing product candidates or technologies that may compete with ours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified a material weakness in our internal control over financial reporting which could,
if not remediated, result in material misstatements in our financial statements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the preparation and audit of our consolidated
financial statements as of December&nbsp;31, 2020 and 2019 and for the years then ended, a material weakness was identified in our internal control over financial reporting. In addition, we have in the past identified other material weaknesses in
our internal controls over financial accounting, which have since been remediated. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a
material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Our existing material weakness is related to segregation of duties related to roles and responsibilities in our accounting
department which is lacking in various circumstances, including with respect to account reconciliation and receipt/disbursement duties, independent review of journal entries and access to the accounting systems. Our existing material weakness did
not result in a misstatement to our financial statements, however, it could result in a misstatement of account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that
would not be prevented or detected. We plan to remediate this material weakness by hiring additional accounting staff and upgrading our accounting systems, though there is no guarantee that these remediation efforts will be successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to maintain and improve the effectiveness of our internal control over financial reporting, we have expended, and anticipate that we will continue to
expend, significant resources, including accounting-related costs and significant management oversight. Our independent registered public accounting firm is not required to formally attest to the effectiveness of its internal control over financial
reporting until after it is no longer an &#147;emerging growth company&#148; as defined in the JOBS Act. At such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the
level at which its internal control over financial reporting is documented, designed, or operating. Any failure to maintain effective disclosure controls and internal control over financial reporting could adversely affect our business and operating
results and could cause a decline in the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to build our finance infrastructure and improve our accounting
systems and controls, we may be unable to comply with the financial reporting and internal controls requirements for publicly traded companies. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, we will operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act of 2002, or
the Sarbanes-Oxley Act, the regulations of Nasdaq Global Market, or Nasdaq, the rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities
required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial
reports and are important to help prevent financial fraud. Commencing with our fiscal year ending the year after this offering is completed, we must perform system and process evaluation and testing of our internal controls over financial reporting
to allow management to report on the effectiveness of our internal controls over financial reporting in our Form <FONT STYLE="white-space:nowrap">10-K</FONT> filing for that year, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. Prior to
this offering, we have never been required to test our internal controls within a specified period and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that the process of building our accounting and financial functions and infrastructure will require significant additional professional fees,
internal costs and management efforts. We expect that we will need to implement a new internal system to combine and streamline the management of our financial, accounting, human resources and other functions. However, such a system would likely
require us to complete many processes and procedures for the effective use of the system or to run our business using the system, which may result in substantial costs. Any disruptions or difficulties in implementing or using such a system could
adversely affect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our controls and harm our business. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. In addition, we may discover weaknesses in
our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A
control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#146;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of
controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper
and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose
confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the Commission or other regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering, Ownership of our Common Stock and our Status as a Public Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not develop and you may not be able to resell your shares of our common stock at or above the initial
offering price, if at all. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. The initial public offering price for
our common stock was determined through negotiations with the underwriters and may not be indicative of the price at which our common stock will trade after the closing of this offering. Although our common stock has been approved for listing on
Nasdaq, an active trading market for our shares may never develop or be sustained following this offering. If an active market for our common stock does not develop or is not sustained, it may be difficult for you to sell shares you purchased in
this offering at an attractive price or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of the shares of our common stock may be volatile, and purchasers of our common
stock could incur substantial losses. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stock price may be volatile. The stock market in general and the market for biopharmaceutical companies
in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for
the shares. The market price for our common stock may be influenced by many factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement, enrollment or results of our clinical trials, including the Phase 1 clinical trial of ACU193
and any future clinical trials we may conduct, or changes in the development status of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay in our regulatory filings for ACU193 or any other product candidate we may develop, and any adverse
development or perceived adverse development with respect to the applicable regulatory authority&#146;s review of such filings, including without limitation the FDA&#146;s issuance of a &#147;refusal to file&#148; letter or a request for additional
information; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in, or termination of, clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to the use of ACU193 or any other product candidate we develop;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by us or by any equity research analysts who might cover our stock;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions or trends in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by our competitors of new product candidates or technologies, or the results of clinical trials or
regulatory decisions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the
biopharmaceutical industry; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of
research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our relationships with our collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors&#146; general perception of our company and our business; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our
ability to obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stock market in general, Nasdaq and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been
unrelated or disproportionate to the operating performance of these companies, including very recently in connection with the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which has resulted in decreased stock prices for many
companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to
the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of
other risks, including those described in this section, could have a significant and material adverse impact on the market price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and
biotechnology companies following periods of volatility in the market prices of these companies&#146; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#146;s attention and resources
from our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because the public offering price of our common stock will be substantially higher than the net tangible book value per share of
our outstanding common stock following this offering, new investors will experience immediate and substantial dilution. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The public offering price
of our common stock is substantially higher than the net tangible book value per share of our common stock immediately following this offering based on the total value of our tangible assets less our total liabilities. Therefore, if you purchase
shares of our common stock in this offering, you will experience immediate dilution of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the difference between the assumed
initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and the net
tangible book value per share of our common stock as of December&nbsp;31, 2020, after giving effect to the issuance of shares of our common stock in this offering. Furthermore, if the underwriters exercise their option to purchase additional shares,
or outstanding options and warrants are exercised, you could experience further dilution. For a further description of the dilution that you will experience immediately after the offering, see the section of this prospectus captioned
&#147;Dilution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our
business or our market, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced by the
research and reports that equity research analysts publish about us and our business. As a newly public company, we have only limited research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage
of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions
included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or
fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of our common stock in the public market could cause our share price to fall. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market after this offering, or the perception that these sales might occur, could
depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. Based on the number of shares of common stock outstanding as of December&nbsp;31, 2020, upon the closing of
this offering, we will have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding (and no exercise of the underwriters&#146; option to purchase additional shares from us)
or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock if the underwriters&#146; option to purchase additional shares is exercised in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the common stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act of 1933, as
amended, or the Securities Act, except for any shares held by our affiliates as defined in Rule 144 under the Securities Act. The remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
common stock outstanding after this offering, based on shares outstanding as of December&nbsp;31, 2020, will be restricted as a result of securities laws, <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements or other contractual restrictions
that restrict transfers for at least 180 days after the date of this prospectus. The underwriters may, in their sole discretion, release all or some portion of the shares subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the
underwriters prior to expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. For additional information, see the section of this prospectus captioned &#147;Shares Eligible for Future Sale.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our
outstanding common stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis as of December&nbsp;31, 2020, will be entitled to rights with respect to registration of such shares under the Securities Act pursuant to an investor rights
agreement between such holders and us. If such holders, by exercising their registration rights, sell a large number of shares, they could adversely affect the market price for our common stock. If we file a registration statement for the purpose of
selling additional shares to raise capital, we may be required to offer these holders the right to participate in the offering and, if we are required to include shares held by these holders pursuant to the exercise of their registration rights, our
ability to raise capital may be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the
Securities Act to register&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares subject to outstanding stock options issued under the Prior Plan and shares of common stock reserved for issuance under
the 2021 Plan and the 2021 ESPP. Both the 2021 Plan and the 2021 ESPP provide provides for annual automatic increases in the shares reserved for issuance under the plans which could result in additional dilution to our stockholders. Once we register
the issuance of shares under these plans, they can be freely sold in the public market upon issuance, subject to the vesting of the equity awards, other restrictions provided under the terms of the applicable plan or equity award, and the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period with respect to this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our corporate charter documents and under Delaware
law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are provisions in our certificate of incorporation and bylaws to be in effect upon the closing of this offering that may make it difficult for a third
party to acquire, or attempt to acquire, control of our company, even if a change of control was considered favorable by you and other stockholders. For example, our board of directors will have the authority to issue up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock. The board of directors can fix the price, rights, preferences, privileges and
restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change of control transaction. As a result, the market price of our common stock and the
voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our charter documents will also contain other provisions that could have an anti-takeover effect, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">only one of our three classes of directors will be elected each year; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stockholders will not be entitled to remove directors other than by a 66 2/3% vote and only for cause;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stockholders will not be permitted to take actions by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stockholders cannot call a special meeting of stockholders; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stockholders must give advance notice to nominate directors or submit proposals for consideration at stockholder
meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we are subject to the anti-takeover provisions of Section&nbsp;203 of the Delaware General Corporation Law, or
DGCL, which regulates corporate acquisitions by prohibiting Delaware corporations from engaging in specified business combinations with particular stockholders of those companies. These provisions could discourage potential acquisition proposals and
could delay or prevent a change of control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also
prevent changes in our management or limit the price that investors are willing to pay for our stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of ownership of our common stock among our existing executive officers, directors and
principal stockholders may prevent new investors from influencing significant corporate decisions. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on their shareholdings as of March 31,
2021, our directors, executive officers and beneficial owners of greater than 5% of our outstanding stock and their respective affiliates will beneficially own, in the aggregate, approximately&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock
upon the closing of this offering, assuming no purchase by them of any shares in this offering. As a result, these persons, acting together, would be able to significantly influence all matters requiring stockholder approval, including the election
and removal of directors, any merger, consolidation, sale of all or substantially all of our assets or other significant corporate transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of
these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their shares at prices substantially below the estimated public offering price and have held their shares for a longer
period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; and, as a result of the reduced disclosure and governance
requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
are an &#147;emerging growth company&#148; as defined in the JOBS Act and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies,
including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold a nonbinding advisory vote on executive compensation and stockholder approval of any
golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict if investors will find our common stock less attractive because we
will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting
exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of the last day of the fiscal year (i)&nbsp;following the fifth anniversary of the closing of our initial public offering,
(ii)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion, or (iii)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th, and the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior
three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those
standards apply to private companies. We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth
companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the
information that we provide in this prospectus may be different than the information you may receive from other public companies in which you hold equity interests. In addition, it is possible that some investors will find our common stock less
attractive as a result of these elections, which may result in a less active trading market for our common stock and higher volatility in our share price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company&#148; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. We may continue to be
a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting
and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than $250&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenues
are more than $100&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than
$700&nbsp;million measured on the last business day of our second fiscal quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management team may invest or spend the proceeds of this
offering in ways with which you may not agree or in ways which may not yield a return. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the
application of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Accordingly, investors will need to rely on our judgment with respect to the
use of these proceeds. We intend to use the net proceeds from this offering to fund our Phase 1 clinical trial for ACU193, and to support future clinical and nonclinical activities, as well as for working capital and general corporate purposes,
including the costs of operating as a public company. While we have no current agreements, commitments or understandings for any specific strategic acquisitions or <FONT STYLE="white-space:nowrap">in-licenses</FONT> at this time, we may use a
portion of the net proceeds for these purposes. For more information see, &#147;Use of Proceeds.&#148; The failure by our management to apply these funds effectively could adversely affect our ability to continue maintaining and expanding our
business. Until the net proceeds are used, they may be placed in investments that do not produce significant income or that may lose value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have
never paid dividends on our capital stock and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future. We anticipate
that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors
must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to meet Nasdaq&#146;s continued listing requirements could result in a delisting of our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, after listing, we fail to satisfy Nasdaq&#146;s continued listing requirements, such as the corporate governance requirements or the minimum closing bid
price requirement. Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In
the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common
stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Nasdaq&#146;s listing requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated certificate of incorporation will provide that the Court of Chancery of the
State of Delaware and the U.S. federal district courts will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes
with us or our directors, officers or employees. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation, as will be in effect upon the completion
of this offering, will provide that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative claim or cause of action brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any claim or cause of action asserting a breach of fiduciary duty; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any claim or cause of action against us arising under DGCL; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any claim or cause of action arising under or seeking to interpret our amended and restated certificate of
incorporation or our amended and restated bylaws; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any claim or cause of action against us that is governed by the internal affairs doctrine. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions.
Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations,
our amended and restated certificate of incorporation will further provide that the U.S. federal district courts will be the exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act,
including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to
such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a
venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation.
This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These exclusive forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or
our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation
to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may
reduce the amount of money available to us. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we
will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as permitted by Section&nbsp;145 of the DGCL, our amended and restated bylaws and our
indemnification agreements that we have entered into with our directors and officers provide that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors and officers for serving us in those capacities or for serving other business
enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not
opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#146;s conduct was unlawful; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is
permitted by applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a
proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to
proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into
indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification
obligations to directors, officers, employees and agents. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs and demands upon management as a result of being a public company. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company listed in the United States, we will incur significant additional legal, accounting and other costs. These additional costs could
negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the Commission and Nasdaq, may increase legal and financial
compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by
regulatory and governing bodies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in
increased general and administrative expenses and a diversion of management&#146;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we
fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to comply with these rules might
also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or
similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be
limited. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred net operating losses (NOLs) during our history, we expect to continue to incur significant NOLs for the foreseeable
future, and we may not achieve profitability prior to the time that certain of our NOLs expire. As of December&nbsp;31, 2020, we had federal and state NOL carryforwards of $22.3&nbsp;million and $31.0&nbsp;million, respectively, that will begin
expiring in the year 2028 for both federal and state NOLs if not utilized. We also have $15.9&nbsp;million of federal net operating loss carryforwards as of December&nbsp;31, 2020, that do not expire as a result of recent tax law changes. Our NOL
carryforwards are subject to review and possible adjustment by U.S. and state tax authorities. Our NOL carryforwards could expire unused or be unavailable to offset future income tax liabilities because of their limited duration or because of
restrictions under U.S. tax law. Federal NOLs generated in tax years ending on or prior to December&nbsp;31, 2017 are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law. Under the Tax Act, as modified by
the Coronavirus Aid, Relief, and Economic Security Act (CARES) Act signed into law on March&nbsp;27, federal NOLs arising in tax years beginning after December&nbsp;31, 2017, and before January&nbsp;1, 2021 may be carried back to each of the five
tax years preceding the tax year of such loss, and federal NOLs arising in tax years beginning after December&nbsp;31, 2020 may not be carried back. Moreover, under the Tax Act as modified by the CARES Act, federal NOLs generated in tax years ending
after December&nbsp;31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of current year taxable income for tax years beginning after December&nbsp;31, 2020. In addition, at the state level,
there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California recently imposed limits on the usability of California state NOL
carryforwards to offset taxable income in taxable years beginning after 2019 and before 2023. It is generally uncertain if and to what extent various states will conform to the Tax Act or the CARES Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we continue to generate business tax credits, including research and development tax credits, which generally may be carried forward to offset a
portion of future taxable income, if any, subject to expiration of such credit carryforwards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under Sections 382 and 383 of the Internal
Revenue Code of 1986, as amended, if a corporation undergoes an &#147;ownership change&#148; (generally defined as a cumulative change in our ownership by <FONT STYLE="white-space:nowrap">&#147;5-percent</FONT> shareholders&#148; that exceeds 50
percentage points over a rolling three-year period), the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and certain other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as
research and development tax credits) to offset its post-change income and taxes may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the
future as a result of this offering or subsequent shifts in our stock ownership, some of which may be outside our control. We have not conducted any studies to determine annual limitations, if any, that could result from such changes in the
ownership. Our ability to utilize those NOLs could be limited by an &#147;ownership change&#148; as described above and consequently, we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have an
adverse effect on our cash flows and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive tax reform legislation could adversely affect our business and financial
condition. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could
adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Act enacted many
significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation.
Furthermore, the CARES Act modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the
realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax
assets, could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result in significant <FONT STYLE="white-space:nowrap">one-time</FONT> charges, and could increase our future U.S. tax expense. Among the changes made by the Tax Act was a reduction of the
business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as &#147;orphan drugs.&#148; We continue to examine the impact this tax reform legislation may
have on our business. We urge investors to consult with their legal and tax advisers regarding the implications of the Tax Act and potential changes in U.S. tax laws on an investment in our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency in our cybersecurity or a natural
disaster. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are
vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyberattacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons
with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as
the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product
development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To
the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability and damage
to our reputation, and the further development of our product candidates could be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions at the FDA, the Commission and other
government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner
or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to
hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the Commission and
other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or biologics to be reviewed and approved by necessary government
agencies, which would adversely affect our business. For example, over the last several years, including most recently from December&nbsp;22, 2018 to January&nbsp;25, 2019, the U.S. government has shut down several times and certain regulatory
agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely
review and process our regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FDA and regulatory authorities outside the
United States may adopt policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may experience delays in their regulatory activities. In response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, on March&nbsp;10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products while local, national and international conditions warrant. On March&nbsp;18, 2020, the FDA announced its
intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials, which the FDA continues </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to update. As of June&nbsp;23, 2020, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. As of July 2020, utilizing a rating system to assist
in determining when and where it is safest to conduct such inspections based on data about the virus&#146; trajectory in a given state and locality and the rules and guidelines that are put in place by state and local governments, FDA is either
continuing to, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, conduct only mission critical inspections, or, where possible to do so safely, resuming prioritized domestic inspections, which
generally include <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections. Foreign <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections that are not deemed mission-critical remain postponed, while those deemed mission-critical
will be considered for inspection on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. FDA will use similar data to inform resumption of prioritized operations abroad as it becomes feasible and
advisable to do so. The FDA may not be able to maintain this pace and delays or setbacks are possible in the future. Should FDA determine that an inspection is necessary for approval, and an inspection cannot be completed during the review cycle due
to restrictions on travel, FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA may defer action on the application
until an inspection can be completed. Additionally, regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may experience
delays in their regulatory activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory
authorities from conducting business as usual or conducting inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a
material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition or results
of operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial
markets. Portions of our future clinical trials may be conducted outside of the United States and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make those clinical trials more costly to operate. Furthermore, a
severe or prolonged economic downturn, including a recession or depression resulting from the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or political disruption could result in a variety of risks to our business, including
weakened demand for our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption, including any
international trade disputes, could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential products. Any of the foregoing could seriously harm our
business, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could seriously harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are
contained principally in the sections titled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; &#147;Business&#148; and elsewhere in this
prospectus. In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148;
&#147;target,&#148; &#147;project,&#148; &#147;estimate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions intended to
identify statements about the future. These statements speak only as of the date of this prospectus and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events
and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include, without limitation, statements about the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital
expenditure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations, including funding necessary to develop and commercialize
ACU193, subject to necessary regulatory approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our clinical trials to demonstrate the safety and efficacy of ACU193, and other positive results;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success, cost and timing of our development activities, nonclinical studies and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and focus of our future clinical trials, and the reporting of data from those trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to commercializing ACU193, subject to obtaining necessary regulatory approvals;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and clinical personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct clinical trials of ACU193, and for the manufacture of ACU193 for
nonclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans and ability to obtain or protect our intellectual property rights, including extensions of existing
patent terms where available; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering ACU193
and technology; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential claims relating to our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">existing regulations and regulatory developments in the United States and other jurisdictions;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of ACU193, and any related restrictions, limitations
and/or warnings in the label of any approved product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to the further development and manufacturing of ACU193, including additional therapeutic
indications which we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the&nbsp;JOBS Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, you should refer to the &#147;Risk Factors&#148; section of this prospectus for a discussion of important
factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Other sections of this prospectus may include additional factors that could harm our business and financial
performance. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we
cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a
result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks and other information we describe in the reports we will file from time to time with the SEC after the date of this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or
quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this
prospectus, the events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration
statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_4"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We obtained the industry, statistical and market data included in this prospectus from our own internal estimates and research as well as from
industry and general publications and research, surveys and studies conducted by third parties. All of the market data used in this prospectus involve a number of assumptions and limitations, and the sources of such data cannot guarantee the
accuracy or completeness of such information. While we are not aware of any misstatements regarding the third-party information and we believe that each of these studies and publications is reliable, the industry in which we operate is subject to a
high degree of uncertainty and risk due to a variety of important factors, including those described in the section titled &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the
estimates made by third parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the
underwriters exercise in full their option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares), assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the net proceeds to us from this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. Each increase or decrease of 1.0&nbsp;million in the number of shares we are offering would increase or decrease the net proceeds to us from this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, assuming the assumed initial public offering price
stays the same. We do not expect that a change in the offering price or the number of shares by these amounts would have a material effect on our intended uses of the net proceeds from this offering, although it may impact the amount of time prior
to which we may need to seek additional capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we had cash and cash equivalents of $43.8 million. We
intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for working capital and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may also use a portion of the remaining net proceeds to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in
complementary businesses, technologies, products or assets, although we have no current agreements, commitments or understandings to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the net proceeds of this offering, together with our existing cash and cash equivalents, will enable us to fund our operations
through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Based on our current operational plans and assumptions, we expect the net proceeds from this offering, together with our cash and cash equivalents, will be sufficient
to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based these estimates on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This expected use of net proceeds from this offering and our existing cash and cash equivalents represents our intentions based upon our
current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of
our development, the status of and results from clinical trials, as well as any collaborations that we may enter into with third parties for ACU193 and any other product candidates we develop, and any unforeseen cash needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering, and investors will be relying on the
judgment of our management regarding the application of those net proceeds. The timing and amount of our actual expenditures will be based on many factors, including cash flows from operations and the anticipated growth of our business. Pending
their use, we plan to invest the net proceeds from this offering in short-term, interest bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have never declared or paid, and do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock.
We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and our capitalization as of December&nbsp;31, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to the conversion of all of the outstanding preferred shares of our
convertible preferred stock into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock upon the closing of this offering, as well as the automatic exercise and conversion of an outstanding
preferred stock warrant into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock and the settlement of the preferred stock tranche rights liability, as if such conversions had occurred on
December&nbsp;31, 2020; and </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give further effect&nbsp;our issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share,
which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting fees and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our capitalization following the closing of this offering will depend on the actual initial public offering price and other terms of this
offering determined at pricing. You should read this information in conjunction with our financial statements and the related notes appearing at the end of this prospectus, the section of this prospectus titled &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; and other financial information contained in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December 31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,777</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche rights liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock, $0.0001 par value; 711,203 shares authorized, 711,203 issued
and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, $0.0001 par value;
11,898,177 shares authorized, 11,231,511 shares issued and outstanding, actual; no shares authorized, issued or outstanding pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.0001 par value; 29,457,450 shares authorized, 17,674,469
shares issued and outstanding, no shares authorized, issued or outstanding pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; no shares authorized, issued or outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December 31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 50,500,000 shares authorized, 624,635 shares issued and
outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;issued and outstanding, pro forma; shares authorized, shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Additional&nbsp;paid-in&nbsp;capital</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,965</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,591</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each $1.00 increase or decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted amount of each of cash
and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million,
assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each
increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint
of the price range set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted amount of each of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; deficit and total
capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and
commissions, and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of our common stock outstanding in the table above excludes: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,492,303 shares of our common stock issuable upon the exercise of options under the Prior Plan outstanding as of
December&nbsp;31, 2020 at a weighted-average exercise price of $0.76 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock issuable upon
the exercise of options under the Prior Plan granted subsequent to December&nbsp;31, 2020, at a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">574,760 shares of our common stock issuable upon the exercise of common stock warrants outstanding as of
December&nbsp;31, 2020 at an exercise price of $3.00; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock reserved for
future issuance under the Prior Plan, which shares will cease to be available for issuance at the time the 2021 Plan becomes effective and will be added to, and become available for issuance under, the 2021 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock reserved for
future issuance under our 2021 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2021 Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock reserved for
future issuance under the ESPP, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we had a historical net tangible book value (deficit) of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. Our historical net tangible book value (deficit) per share
represents total tangible assets less total liabilities, divided by the number of shares of our common stock outstanding as of December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of December&nbsp;31, 2020 was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock. Pro forma net tangible book value represents the amount of
our total tangible assets less our total liabilities, after giving effect to the conversion of all of the outstanding preferred shares of our convertible preferred stock into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock upon the closing of this offering, as well as the automatic exercise and conversion of an outstanding preferred stock warrant
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock (based on assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is
the midpoint of the price range set forth on the cover page of this prospectus), as if such conversions had occurred on December&nbsp;31, 2020. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the
total number of shares outstanding as of December&nbsp;31, 2020, after giving effect to the pro forma adjustment described&nbsp;above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After giving further effect to the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in
this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of December&nbsp;31, 2020 would have been
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This amount represents an immediate increase in pro forma net tangible book
value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders and immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors
in this offering. We determine dilution by subtracting the pro forma as adjusted net tangible book value per share after this offering from the amount of cash that a new investor paid for a share of common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in net tangible book value (deficit) per share attributable to the pro forma
transactions described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The dilution information discussed above is illustrative only and will change based on the actual initial
public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which
is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted net tangible book value per share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and dilution in pro forma net tangible book value per share to new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the
number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
estimated offering expenses payable by us. An increase of 1.0&nbsp;million shares in the number of shares we are offering would increase the pro forma as adjusted net tangible book value per
share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and decrease the dilution per share to new investors participating in this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price per share and after deducting the estimated underwriting discounts and commissions and estimated offering
expenses payable by us. A decrease of 1.0&nbsp;million shares in the number of shares we are offering would decrease the pro forma as adjusted net tangible book value per share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and increase the dilution per share to new investors participating in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no
change in the assumed initial public offering price per share and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares of our common stock in full, the pro forma as adjusted net tangible
book value after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase in pro forma net tangible book value would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and the dilution to new investors would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, in each case assuming an initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of December&nbsp;31, 2020, on the pro forma as adjusted basis described above, the differences between the
number of shares purchased from us, the total consideration paid to us in cash and the average price per share that existing stockholders and new investors paid for such shares. This calculation is based on an assumed initial public offering price
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting the estimated underwriting discounts and commissions
and estimated offering expenses payable by us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>Average<BR>Price&nbsp;Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The foregoing tables and calculations are based on the number of shares of our common stock outstanding as of
December&nbsp;31, 2020, after giving effect to the conversion of all of the outstanding preferred shares of our convertible preferred stock into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock upon the closing of this offering, as well as the automatic exercise and conversion of an outstanding preferred stock warrant into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock (based
on assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus), as if such conversions had
occurred on December&nbsp;31, 2020, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,492,303 shares of our common stock issuable upon the exercise of options under the Prior Plan outstanding as of
December&nbsp;31, 2020 at a weighted-average exercise price of $0.76 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock issuable upon
the exercise of options under the Prior Plan granted subsequent to December&nbsp;31, 2020, at a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">574,760 shares of our common stock issuable upon the exercise of common stock warrants outstanding as of
December&nbsp;31, 2020 at an exercise price of $3.00; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock reserved for
future issuance under the Prior Plan, which shares will cease to be available for issuance at the time the 2021 Plan becomes effective and will be added to, and become available for issuance under, the 2021 Plan; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock reserved for
future issuance under our 2021 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2021 Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock reserved for
future issuance under the ESPP, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent that stock options or warrants are exercised, new stock options or other equity awards are issued under our equity incentive
plan or we issue additional shares of common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic
considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in
further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis should be read in conjunction with our financial statements and related
notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based upon current beliefs that involve risks, uncertainties and assumptions, such as statements
regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those described in or implied by these forward-looking statements as a result of several
factors, including those set forth under &#147;Risk Factors&#148; and elsewhere in this prospectus. You should carefully read the &#147;Risk Factors&#148; section of this prospectus to gain an understanding of the important factors that could cause
actual results to differ materially from our forward-looking statements. Please also see the section entitled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical
company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer&#146;s disease (AD). Alzheimer&#146;s disease is a progressive neurodegenerative disease of the brain that leads to loss of
memory and cognitive functions and ultimately results in death. Our scientific founders pioneered research on soluble amyloid-beta oligomers (A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os), globular assemblies of the amyloid-beta (A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>) peptide that are distinct from other forms of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> and amyloid. We are currently focused on advancing a targeted immunotherapy drug candidate, ACU193, through
clinical proof of mechanism in early AD patients. We initiated our Phase 1 clinical trial of ACU193 in the second quarter of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated
in 1996 and were party to an exclusive license and research collaboration with Merck in 2003. Although we acquired the exclusive rights to ACU193 from Merck in 2011 following Merck&#146;s strategic decision to focus its AD development efforts on a
different product candidate, we did not recommence meaningful operations until we completed our first institutional fundraising in 2018. Since 2018, we have devoted substantially all of our efforts to organizing and staffing our company, business
planning, raising capital, conducting discovery, research and development activities, and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated any revenue from
product sales. We have funded our operations primarily through the sale of our convertible preferred stock and common stock, the issuance of notes, grant revenue and during our collaboration with Merck, certain payments received under our
collaboration agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From inception through December&nbsp;31, 2020, we have raised an aggregate of $67.5&nbsp;million of gross proceeds through the
issuance of convertible preferred stock, as well as sales of common stock and issuance of notes that were converted to preferred stock, with the vast majority of this capital being raised since our Series <FONT STYLE="white-space:nowrap">A-1</FONT>
convertible preferred stock, or Series <FONT STYLE="white-space:nowrap">A-1,</FONT> financing in 2018. In 2020, we conducted a Series B convertible preferred stock, or Series B, financing, with the funding to occur in two tranches. We closed the
first tranche of the Series B financing in November 2020, selling 17,674,469 shares of Series B at $2.55 per share for gross proceeds of $45.1&nbsp;million. We are obligated to issue and sell additional shares of Series B in the second tranche, in
the aggregate amount of $30.0&nbsp;million to the Series B purchasers upon the achievement of a certain defined clinical milestone. The determination as to whether the milestone event has been met is subject to certification by our board of
directors and the holders of 67% of the outstanding Series B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred net losses and negative cash flows from operations since our inception.
Our net loss for the year ended December&nbsp;31, 2020 was $7.3&nbsp;million and as of December&nbsp;31, 2020, we had an accumulated deficit of $27.0&nbsp;million. Our net losses and cash flows from operations may fluctuate significantly from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of nonclinical studies, clinical
trials and our expenditures on other research and development activities. We expect our expenses and operating losses will increase substantially for the foreseeable future as we advance ACU193 into clinical trials, seek to expand our product
candidate portfolio </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
through developing additional product candidates, grow our clinical, regulatory and quality capabilities, and incur additional costs associated with operating as a public company. It is likely
that we will seek third-party collaborators for the future commercialization of ACU193 or any other product candidate that is approved for marketing. However, we may seek to commercialize our products at our own expense, which would require us to
incur significant additional expenses for marketing, sales, manufacturing and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2020, the World Health Organization declared <FONT
STYLE="white-space:nowrap">COVID-19</FONT> a global pandemic and the United States declared a national emergency with respect to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> In response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, a number of governmental orders and other public health guidance measures have been implemented across much of the United States, including in the locations of our office, clinical trial sites and third parties on whom we rely. We
implemented a work-from-home policy allowing employees and consultants who can work from home to do so. Business travel has been limited, and online video and teleconference technology is used to meet virtually rather than in person. We have taken
measures to secure our research and development activities, while work in laboratories by our partners has been organized to reduce risk of <FONT STYLE="white-space:nowrap">COVID-19</FONT> transmission. Although to date, our business has not been
materially impacted by <FONT STYLE="white-space:nowrap">COVID-19,</FONT> it is possible that our clinical development timelines could be negatively affected by <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which could materially and adversely
affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not generate revenue from product sales unless and until we successfully
complete clinical development and obtain regulatory approval for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur
significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate
significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances
and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to raise capital or enter into such agreements as, and when needed,
could have a material adverse effect on our business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we had cash and cash
equivalents of $43.8&nbsp;million. Without giving effect to the second tranche of the Series B financing, or the anticipated net proceeds from this offering, based on our current operating plan, we believe we have sufficient cash and cash
equivalents on hand to support current operations through the third quarter of 2022. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See
&#147;&#151;Liquidity and capital resources.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of our Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grants and Other Revenue </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have not
generated any revenues from the commercial sale of any products, and we do not expect to generate revenues from the commercial sale of any products for the foreseeable future, if ever. For the years ended December&nbsp;31, 2019 and 2020, we derived
revenue from a grant awarded by the National Institutes of Health in September 2017 and renewed annually in 2018 through 2020. The grant provides us with funding to support the completion of preclinical chemistry, manufacturing and control studies,
toxicology and pharmacokinetic studies, submit an IND dossier to the FDA, and then conduct first in human clinical safety trials for ACU193. We recognize revenue from this grant&nbsp;when the related costs are incurred and the right to payment is
realized. As of December&nbsp;31, 2020, we have been awarded a total of $3.9&nbsp;million under this grant, all of which has been recognized as revenue prior to or during the years ended December&nbsp;31, 2019 and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operating expenses consist of (i)&nbsp;research and development expenses and (ii)&nbsp;general and administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development costs primarily consist of direct costs associated with consultants and materials, biologic storage, third party, contract research organization costs and contract development and manufacturing expenses, salaries and other
personnel-related expenses. Research and development costs are expensed as incurred. More specifically, these costs include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of funding research performed by third parties that conduct research and development and nonclinical and
clinical activities on our behalf; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of manufacturing drug supply and drug product; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of conducting nonclinical studies and clinical trials of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consulting and professional fees related to research and development activities, including equity-based
compensation to <FONT STYLE="white-space:nowrap">non-employees;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to compliance with clinical regulatory requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related expenses, including salaries, benefits and stock-based compensation expense for our research and
development personnel. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs for certain activities are recognized based on an evaluation of the progress to completion of specific
tasks using data such as information provided to us by our vendors and analyzing the progress of our nonclinical and clinical studies or other services performed. Significant judgment and estimates are made in determining the accrued expense
balances at the end of any reporting period. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense
as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we currently only have one product candidate, ACU193, in development, we do not separately track expenses by program. Further, as we have historically
relied exclusively on consultants for research and development activities, we did not have any material internal research and development costs for the years ended December&nbsp;31, 2019 and 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that our research and development expenses will increase substantially in connection with our clinical development activities for our ACU193
program. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the clinical development of, or obtain regulatory approval for, any of our current or future product
candidates. This is due to the numerous risks and uncertainties associated with product development and commercialization, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to add and retain key research and development personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our successful enrollment in and completion of clinical trials, including our ability to generate positive data
from any such trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and cost of any future clinical trials for existing or future product candidates in our pipeline;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with the development of any additional programs we identify
<FONT STYLE="white-space:nowrap">in-house</FONT> or acquire through collaborations and other arrangements and the success of such collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of any additional collaborations, license or other arrangement, including the timing of any
payments thereunder; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain agreements and operate with third-party manufacturers for clinical supply
for our clinical trials and commercial manufacturing, if any of our product candidates are approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to manufacturing of our product candidates or to account for any future changes in our
manufacturing plans; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patents, trade secret and other intellectual property protection and
regulatory exclusivity for our product candidates, both in the United States and internationally; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain third-party insurance coverage and adequate reimbursement for our product
candidates, if and when approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acceptance of our product candidates, if approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively competing with other products if our product candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of any business interruptions to our operations, including the timing and enrollment of patients in
our planned clinical trials, or to those of our manufacturers, suppliers, or other vendors resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or similar public health crisis; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain a continued acceptable safety profile for our therapies following approval.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of our product candidates could significantly change
the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses consist primarily of management and business consultants and other related costs, including stock-based compensation. General and administrative expenses also include board of directors&#146; expenses and professional fees
for legal, patent, consulting, accounting, auditing, tax services and insurance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that our general and administrative expenses will
increase as our organization and headcount needed&nbsp;in the future grows to support continued research and development activities and potential commercialization of our product candidates. These increases will likely include increased costs
related to the hiring of additional personnel and fees to outside consultants, attorneys and accountants, among other expenses. Additionally, we expect to incur increased expenses associated with being a public company, including costs of additional
personnel, accounting, audit, legal, regulatory and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with exchange listing and Securities and Exchange Commission, or SEC, requirements, director and
officer insurance costs, and investor and public relations costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income (expense) primarily includes changes in fair value of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> warrant liability and the Series B
tranche rights and interest income, net. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series <FONT STYLE="white-space:nowrap">A-1</FONT> warrant was issued in October 2018 in connection with the
Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred financing. The warrant liability met the definition of a freestanding financial instrument, as it was legally detachable and separately exercisable from the initial closing of the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock. The warrant liability was initially recorded at fair value as a liability on our balance sheet and was subsequently <FONT STYLE="white-space:nowrap">re-measured</FONT> at fair value
at the end of each reporting period. The changes in the fair value were recognized as a component of other income (expense). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Included in the terms of the
Series B stock purchase agreement in November 2020 were tranche rights granted to the holders of the Series B. The tranche rights provide the Series B holders with the right to purchase additional shares of Series B at $2.55 per share in an
additional tranche after the achievement of a certain milestone event. Alternatively, any time after the initial closing, the Series B investors may elect to purchase the additional shares even if the milestone event has not yet been achieved by
notifying us of their election to do so. The tranche rights met the definition of a freestanding financial instrument as the tranche rights are legally detachable and separately exercisable from the Series B. The tranche rights were initially
recorded at fair value as a liability on our balance sheet. The tranche rights are subsequently <FONT STYLE="white-space:nowrap">re-measured</FONT> at fair value at the end of each reporting period and at settlement. Changes in the fair value are
recognized as a component of other income (expense). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of the Years Ended December&nbsp;31, 2019 and 2020 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&nbsp;31, 2019 and 2020 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Grant and other revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Costs and operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights liability and preferred stock warrant
liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,907</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Grant and Other Revenue </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue related to our NIH grant was $1.7&nbsp;million and $1.4&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectfully, and was
recognized when the related costs were incurred and the right to payment was realized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses</I><B> </B><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses were $8.6&nbsp;million and $8.0&nbsp;million for the years ended December&nbsp;21, 2019 and 2020, respectively. The
$0.6&nbsp;million decrease was primarily due to decreases for nonclinical materials and consulting costs of $1.9&nbsp;million and $0.4&nbsp;million, respectively; net of increases for contract research organizations and drug safety testing of
$1.0&nbsp;million and $0.6&nbsp;million, respectively, due to our progression towards and submission of our IND to the FDA in the fourth quarter of 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expense was $0.9&nbsp;million and $1.4&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively. The $0.4&nbsp;million increase was primarily due to higher executive compensation and increased business
development consulting costs, as well as increased franchise taxes and accounting expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income (expense) increased by $0.7&nbsp;million due to a total gain of $0.6&nbsp;million related to decreases in the fair value of both the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> warrant liability and the Series B tranche liability for the year ended December&nbsp;31, 2020, as compared to a $0.1&nbsp;million increase in the fair value of the
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> warrant liability for the year ended December&nbsp;31, 2019. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital
Resources </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since
our inception, we have funded our operations primarily through the sale of our convertible preferred stock and common stock, the issuance of notes, grant revenue and, during our collaboration with Merck, certain payments received under our
collaboration agreement. We do not have any products approved for sale and have not generated any revenue from product sales. From inception through December&nbsp;31, 2020, we have raised an aggregate of $67.5&nbsp;million of gross proceeds through
the issuance of convertible preferred stock, as well as sales of common stock and issuance of notes that were converted to preferred stock, with the vast majority of this capital being raised since our
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> financing in 2018. In 2020, we conducted a Series&nbsp;B financing, with the funding to occur in two tranches. We closed the first tranche of the Series&nbsp;B financing in November 2020 for
gross proceeds of $45.1&nbsp;million. Upon achievement of a certain milestone event for ACU193, or upon election of the Series&nbsp;B investors to waive the requirement for the milestone event to be achieved prior to its achievement, we are
obligated to issue and sell a second tranche of Series&nbsp;B shares to the Series&nbsp;B purchasers for gross proceeds of $30.0&nbsp;million. As of December&nbsp;31, 2020, our cash and cash equivalents totaled $43.8&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our
sources and uses of cash for the years ended December&nbsp;31, 2019 and 2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,818</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,450</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $6.8&nbsp;million and $7.5&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively. Net cash
used in operating activities in 2019 was primarily due to our net loss of $7.9&nbsp;million, which was partially offset by an increase in accrued liabilities and accounts payable of $0.6&nbsp;million. In 2020, net cash used in operating activities
was primarily due to our net loss of $7.3&nbsp;million and income from the change in the fair values of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> warrant liability and the Series B tranche liability, which totaled $0.6&nbsp;million;
partially offset by changes in our working capital, partially offset by $0.3&nbsp;million increase in accounts payable and a $0.1&nbsp;million decrease in long-term prepaid service agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing
activities was $6.2&nbsp;million and $44.7&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively, and was due to the issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock in 2019 and
Series B in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
expect our expenses to increase in connection with our ongoing activities, particularly as we continue our research and development, conduct clinical trials, and seek marketing approval for our current and any of our future product candidates.
Furthermore, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. It is likely that we will seek third-party collaborators for the future commercialization of ACU193 or any other
product candidate that is approved for marketing. However, we may seek to commercialize our products at our own expense, which would require us to incur significant additional expenses for marketing, sales, manufacturing and distribution., which
costs we may seek to offset through entry into collaboration agreements with third parties. As a result, we expect that we will need to obtain substantial additional funding in connection with our future operations. If we are unable to raise capital
when needed or on acceptable terms, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that the net proceeds from this offering, together with our existing cash and cash equivalents as of December&nbsp;31, 2020, will enable us to fund
our operating expenses and capital expenditure requirements through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital
resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of discovery, nonclinical development, laboratory testing and clinical
trials for other potential product candidates we may develop, if any; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations on favorable terms, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of milestones or occurrence of other developments that trigger payments under the Series B
agreement or any collaboration agreements we might have at such time; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including product sales, marketing, manufacturing
and distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our
product candidates receive marketing approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our
intellectual property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our headcount growth and associated costs as we expand our business operations and our research and development
activities; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt
financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your
ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. Any debt financing, if available, may involve agreements that include
restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required
to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the periods presented we did not have, nor do we currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as defined
under SEC rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2020, we have an operating lease obligation associated with a lease for our executive office space that totals approximately $3,000 for the remainder of the lease term. This amount is due in equal monthly installments over the
remaining lease term, which expires on August&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have been subleasing space in Indiana since March&nbsp;1, 2020 under a lease that expired
on December&nbsp;31, 2020. We executed a new sublease for this space that was effective February&nbsp;1, 2021. The term of the sublease is for 31 months, expiring on August&nbsp;30, 2023. We pay monthly rent of $12,719 and we are also allowing
others to sublease a portion of the space from us for less than a <FONT STYLE="white-space:nowrap">one-year</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We enter into contracts in the
normal course of business with CROs and CMOs for clinical trials, nonclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts do not contain any minimum purchase commitments and are
generally cancelable by us upon prior notice of 30&nbsp;days. Payments due upon cancelation consist only of payments for services provided and expenses incurred up to the date of cancelation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Estimates and Policies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The
preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assets and liabilities in our financial statements. In accordance with U.S. GAAP, we evaluate our estimates and judgments on an ongoing basis, including those related to accrued expenses, the
preferred stock tranche and warrant liabilities and stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We define our critical accounting policies as those accounting principles that require us to make subjective estimates and judgments about matters that are
uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. While our significant accounting policies are more fully described in Note 2
to our audited financial statements appearing elsewhere in this prospectus, we believe the following are the critical accounting policies used in the preparation of our financial statements that require significant estimates and judgments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, identifying services that have been
performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each
balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and
development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced. Since our inception, we have not experienced any material
differences between accrued or prepaid costs and actual costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We base our expenses related to research and development activities on our estimates of
the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may
result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the
time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense
accordingly. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based
compensation expense represents the grant date fair value of equity awards recognized in the period using the Black-Scholes option pricing model. We recognize the expense for equity awards on a straight-line basis over the requisite service periods
of the awards, which is usually the vesting period. Forfeitures are recognized as they occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimating the fair value of equity awards pursuant to the
Black-Scholes option pricing model requires us to make assumptions regarding a number of variables, including the risk-free interest rate, the expected stock price volatility, the expected term of stock options, the expected dividend yield and the
fair value of the underlying common stock on the date of grant. Changes in these assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally
require significant judgment. We determine these assumptions in the following manner: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Fair Value of Common Stock.</I></B> See the subsection titled &#147;&#151;Common Stock Valuations&#148;
below. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Expected Term.</I></B> The expected term of stock options represents the period of time that the awards are
expected to be outstanding. Because we do not have sufficient historical exercise behavior, we determine the expected term assumption using the simplified method, which calculates the expected term as the average <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">time-to-vesting</FONT></FONT> and the contractual life of the award. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Expected Volatility.</I></B> As we are not yet a public company and do not have a trading history for our
common stock, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Risk-Free Interest Rate.</I></B> The risk-free rate assumption is based on the U.S. Treasury yield in
effect at the time of the grant with maturities consistent with the expected term of the awards. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Expected Dividend Yield. </I></B>The expected dividend yield assumption is based on our history and
expectation of dividend payouts. The Company has not paid and does not intend to pay dividends and, therefore, used an expected dividend yield of zero. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 6 to our financial statements included elsewhere in this prospectus for more information concerning certain of the specific assumptions we used in
applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected
outcomes change and we use significantly different assumptions or estimates, our stock-based compensation could be materially different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recorded
stock-based compensation expense of $0.2&nbsp;million for each of the years ended December&nbsp;31, 2019 and 2020. As of December&nbsp;31, 2020, there was $0.1&nbsp;million of total unrecognized stock-based compensation expense related to unvested
stock options which we expect to recognize over a remaining weighted-average period of one year. We expect to continue to grant stock options and other equity-based awards in the future, and to the extent that we do, our stock-based compensation
expense recognized in future periods will likely increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;4, 2021, we granted options to purchase an aggregate of 3,694,711 shares of
common stock to certain employees, directors, advisors and consultants with an exercise price per share of $0.80. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair Value of Common Stock </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair values of the shares of common stock underlying our options were estimated on each grant date by our board of directors. In order to determine the
fair value, our board of directors considered, among other things, contemporaneous valuations of our common stock prepared by unrelated third-party valuation firms in accordance with the guidance provided by the American Institute of Certified
Public Accountants Audit and Accounting Practice Aid Series: Valuation of Privately-Held-Company Equity Securities Issued as Compensation, or the Practice Aid. Given the absence of a public trading market of our capital stock, our board of directors
will exercise reasonable judgment and consider a number of objective and subjective factors to determine the best estimate of the fair value of our common and preferred stock, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contemporaneous third-party valuations of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices, rights, preferences and privileges of our convertible preferred stock relative to our common stock;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business, financial condition and results of operations, including related industry trends affecting our
operations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event, such as an initial public offering or sale of our company, given
prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of marketability of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. and global economic and capital market conditions and outlook. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The valuations prepared as of December&nbsp;31, 2018, December&nbsp;31, 2019, November&nbsp;20, 2020 and December&nbsp;31, 2020 resulted in a valuation of our
common stock of $0.48, $0.56, $0.67 and $0.56 per share, respectively, as of those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Common Stock Valuation Methodology </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining the estimated fair value of common stock, our board of directors considered the subjective factors discussed above in conjunction with the most
recent valuations of our common stock that were prepared by an independent third-party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In estimating the fair market value of our common stock, our
board of directors first determined the equity value of our business using accepted valuation methods. For valuations as of December&nbsp;31, 2018, December&nbsp;31, 2019, November&nbsp;20, 2020 and December&nbsp;31, 2020 we used the option-pricing
model, or OPM, under which shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred and common stock are
inferred by analyzing these options. Specifically, we use the OPM backsolve method to estimate the fair value of our common stock, which derives the implied equity value for one type of equity security from a contemporaneous transaction involving
another type of security, such as the shares of our Series&nbsp;A, <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> and Series&nbsp;B convertible preferred stock. We used the OPM backsolve method because we were at an early stage of
development and future liquidity events were difficult to forecast. We applied a discount for lack of marketability to account for a lack of access to an active public market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Tranche Rights Liability </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
determined that our obligation to issue, and the investors&#146; right to purchase, additional shares of Series&nbsp;B pursuant to the milestone closings represent a freestanding financial instrument, or the tranche liability. The tranche liability
was initially recorded at fair value. The proceeds from the sale of the convertible preferred stock are first allocated to the fair value of the tranche liability, with the remaining proceeds from the sale of the convertible preferred stock
allocated to the Series&nbsp;B convertible preferred stock. The tranche liability is remeasured at each reporting period and upon the exercise or expiration of the obligation, with gains and losses arising from subsequent changes in its fair value
recognized as a component of other income (expense) in the statement of operations. At the time of the exercise or expiration of the tranche liability, any remaining value of the tranche liability is reclassified to convertible preferred stock on
the balance sheet. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimated the fair value of the tranche liability using the OPM backsolve method at the initial issuance date. As of
November&nbsp;20, 2020, the simulations occurred based on our implied aggregate equity value derived from the Series&nbsp;B convertible preferred stock offering price of $2.55 per share, along with, in part, the following subjective assumptions:
risk-free rate of 0.16%, an expected volatility of 90%, the expected term to a liquidity event of 2.1 years and a 70% probability of achieving the milestone event and timing thereof. Subsequently, we estimated the fair value of the tranche liability
using an OPM backsolve approach at December&nbsp;31, 2020, which was calculated based on our aggregate equity value derived from the Series&nbsp;B convertible preferred stock offering price of $2.55 per share. The subsequent remeasurement also
considered, in part, a risk-free rate of 0.13%, an expected volatility of 90%, the expected term to a liquidity event of 2.0 years and a 65% probability of achieving the milestone event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Warrant Liability </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We determined that the warrant liability met the definition of a freestanding financial instrument, as it was legally detachable and separately exercisable
from the initial closing of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock. The warrant liability is remeasured at each reporting period until the earlier of the exercise or expiration of the applicable warrant,
with gains and losses arising from subsequent changes in its fair value recognized in other income (expense) in the statement of operations. At the time of the exercise or expiration of the warrant liability, any remaining value of the warrant
liability is reclassified to convertible preferred stock on the balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimated the initial and subsequent fair values of the warrant
liability at the end of each reporting period using the OPM backsolve method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 2 to our financial statements included elsewhere in this prospectus for information about recent accounting pronouncements, the timing of their
adoption, and our assessment, if any, of their potential impact on our financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative
Disclosures About Market Risk </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to market risk related to changes in interest rates. As of December&nbsp;31, 2019 and 2020, our cash
equivalents consisted of interest-bearing checking accounts and money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term
nature and the low risk profile of our interest-bearing accounts, an immediate 10% change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents or on our financial position or results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inflation generally affects us by increasing our costs. We do not believe that inflation had a material effect on our business, financial
condition or results of operations during the years ended December&nbsp;31, 2019 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company and Smaller Reporting Company
Status </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act, and we may remain an emerging growth company for up to five years following the
completion of this offering. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our internal control
over financial reporting audited by our independent registered public accounting firm pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy
statements, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved and an exemption from compliance with the requirements regarding the communication
of critical audit matters in the auditor&#146;s report on financial statements. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation-related
information that would be required if we were not an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until
such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will not be subject to the same new or revised accounting standards as public
companies that are not emerging growth companies. As a result of this election, our financial statements may not be comparable to those of companies that are not emerging growth companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest to occur of: (i)&nbsp;the last day of the
fiscal year in which we have at least $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated filer,&#148; as defined in Rule
<FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day
of the second fiscal quarter of such year; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt securities during the prior three-year period; and (iv)&nbsp;the last day of the fiscal year ending after the
fifth anniversary of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our shares held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue was less than $100.0&nbsp;million during the most
recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million;
or (ii)&nbsp;our annual revenue was less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If
we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller
reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting
companies have reduced disclosure obligations regarding executive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer&#146;s disease, or AD. Alzheimer&#146;s disease is a progressive neurodegenerative disease of the brain that
leads to loss of memory and cognitive functions and ultimately results in death. Our scientific founders pioneered research on soluble amyloid-beta oligomers, or A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, which are globular assemblies of the
amyloid-beta, or A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>, peptide that are distinct from A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and amyloid plaques. Based on decades of research and supporting evidence, A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os have gained increasing scientific acceptance as a primary toxin involved in the initiation and propagation of AD pathology. We are currently focused on advancing a targeted immunotherapy drug candidate,
ACU193, through clinical proof of mechanism trials in early AD patients. ACU193 is a humanized monoclonal antibody, or mAb, that selectively targets A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, has demonstrated functional and protective
effects in in vitro assays, and has demonstrated in vivo safety and pharmacologic activity in multiple animal species, including transgenic models for AD. We initiated our Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the
objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is enrolling patients with mild dementia or mild cognitive impairment, or MCI, due to AD, conditions referred to as &#147;early
AD.&#148; Data from this trial are expected by the fourth quarter of 2022. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ACU193 is the result of over a decade of research and
development undertaken by the company, which included a drug discovery partnership with Merck &amp; Co., Inc., or Merck, from 2003 to 2011. ACU193&#146;s mechanism of action is intended to slow disease progression and potentially preserve or improve
memory function in early AD patients by binding to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os are known to bind to neurons, leading to synaptic malfunction, memory deficits, cognitive
impairment and, ultimately, neurodegeneration and cell death. As such, we believe A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os are the most toxic and pathogenic form of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> in the brains of AD
patients relative to other forms of amyloid, including A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and amyloid plaques. We believe the development and commercialization of a drug that reduces toxicity of
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os is one of the most promising approaches for the potential treatment and prevention of the progression of AD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In our nonclinical studies, we observed that ACU193 has over <FONT STYLE="white-space:nowrap">500-fold</FONT> greater selectivity for A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os over A<B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B></B> monomers and has limited or no binding to amyloid plaques. Also, ACU193 potently prevents binding of
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os to hippocampal neurons. Recent laboratory studies conducted by us and others suggest that inhibiting A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os may enable damaged brain circuits to regain some
function and prevent further degeneration from occurring. ACU193 has demonstrated in vivo biochemical and behavioral activity in several AD mouse models, including crossing the blood-brain barrier and forming complexes with A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os in a dose-dependent manner. ACU193 has shown consistent pharmacokinetics and brain penetration properties in four animal species. Safety toxicology studies in rats and monkeys provide acceptable margins for
dosing in the clinic. Additionally, studies in transgenic mice indicate low potential for microhemorrhage. Based in part on its binding affinity for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os rather than amyloid plaques, ACU193 has the
potential to have a lower rate of amyloid-related imaging abnormalities, or ARIA, than the plaque-clearing anti-amyloid antibody therapies currently in development. ARIA is a common adverse event for antibodies targeting amyloid plaque and can be a
dose-limiting safety liability for those antibodies. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Phase 1 trial is a U.S.-based, multi-center, randomized, double-blind,
placebo-controlled clinical trial with overlapping single ascending dose, or SAD, and multiple ascending dose, or MAD, cohorts involving 62 patients with early AD. The overall objective of the trial is to evaluate the safety and tolerability, and
establish clinical proof of mechanism of ACU193 administered intravenously in single and multiple escalating doses. The primary trial endpoints are focused on safety and immunogenicity. An important safety measure will be the use of magnetic
resonance imaging, or MRI, to assess the presence or absence of ARIA. Secondary endpoints include pharmacokinetics in plasma and cerebrospinal fluid, or CSF, and target engagement as evidenced by detection of ACU193 bound to A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os in CSF. Clinical scales typically used in AD trials as well as computerized cognitive testing are included as exploratory measures. We expect to report proof of mechanism results by the fourth quarter of
2022, with periodic updates including trial progress and cohort advancement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Alzheimer&#146;s disease currently affects over 6&nbsp;million people in the United States
and approximately 32&nbsp;million people worldwide and is the sixth-leading cause of death in the United States. However, due to the aging population, patient populations in the United States impacted by AD are expected to triple by 2050 without
effective preventative measures or disease-modifying treatments. By 2050, healthcare costs for AD in the United States alone are estimated to exceed $1 trillion. While medications that provide a modest improvement in AD symptoms are available, no
therapies are currently approved to address the underlying cause of and slow the inexorable progression of the disease. The need for a medical breakthrough in AD treatment and prevention becomes more urgent with each passing year, and we believe
that our novel approach can potentially help address this pressing need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Understanding the Foundation of Our Therapeutic Approach </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While the pathology of AD was first described by Dr.&nbsp;Alois Alzheimer in 1906, the amyloid hypothesis was not developed until the A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> peptide was first identified as a major constituent of amyloid plaques in the 1980s. Historically, the primary hypothesis of decades of AD research, known as the amyloid hypothesis, held that AD dementia is
the clinical consequence of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> peptide monomers accumulating into extracellular amyloid plaques, or amyloid plaques, which in turn contribute to the formation of intracellular neurofibrillary tangles
composed of the tau protein and cause inflammation, ultimately leading to neuronal cell loss and progressive dementia. The primary constituent of amyloid plaques is the A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> peptide, although other proteins
are present to lesser degrees. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amyloid hypothesis was more firmly established when a series of genetic mutations causing AD were
discovered in the early to <FONT STYLE="white-space:nowrap">mid-1990s.</FONT> These mutations were found in genes coding for the Amyloid Precursor Protein, or APP, and the genes coding for one of the enzymes which cleaves APP, creating the A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> peptide. Based on this hypothesis, a number of monoclonal antibodies currently or previously in clinical development for AD have primarily targeted either A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>
monomers or amyloid plaques; for our purposes, this broadly defined class is referred to as <FONT STYLE="white-space:nowrap">anti-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>/plaque antibodies. Several of these antibodies are currently in
late-stage development or are awaiting regulatory approval, and collectively they have provided a biological foothold for treating AD. However, the clinical data available to date indicate some of the potential limitations of these approaches with
respect to clinically meaningful patient benefit and safety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Though alternative hypotheses to the amyloid hypothesis propose that amyloid
accumulation is a consequence of another process such as infection, the field has now developed an understanding that the three predominant pools of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> species exist in vivo: A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers (single A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> peptide), amyloid plaques (insoluble fibrillar A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>), and soluble
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os (dimers and up to <FONT STYLE="white-space:nowrap">200-mers).</FONT> The more recent appreciation of the crucial role of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os in the pathologic process is
the central tenet of our therapeutic approach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our therapeutic approach focuses on targeting
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, which we believe are the most toxic and pathogenic form of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> relative to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and amyloid plaques.
Growing evidence, spurred by advances in AD research and analytic techniques, supports our view that A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os are the main instigators of AD neurodegeneration.
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os have been observed to be potent neurotoxins that cause both acute synaptic toxicity and induce neurodegeneration. Experimentally in animal models, the accumulation of
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os is associated with core AD neuropathologies, including synapse deterioration and loss, tau phosphorylation, and inflammation. Research has also shown that the accumulation of A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os is associated with <FONT STYLE="white-space:nowrap">AD-related</FONT> behavioral deficits, such as learning and memory impairment. In light of this evidence, we believe that blocking the toxicity of A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os is the most promising approach for the treatment of AD, which led us to discover and develop ACU193. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidate </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our product
candidate, ACU193, is a humanized monoclonal antibody that targets soluble A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. We are developing ACU193 for intravenous, or IV, administration every four weeks for the treatment of early AD. We believe
that ACU193 represents a differentiated approach from current and prior <FONT STYLE="white-space:nowrap">anti-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>/plaque immunotherapies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
because it is highly selective for soluble A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. ACU193 has a nanomolar affinity for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, over <FONT
STYLE="white-space:nowrap">500-fold</FONT> greater selectivity for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os over A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers, and limited or no binding to dense core amyloid plaques. We believe
ACU193 is the most advanced immunotherapy candidate in development that selectively targets A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe ACU193 has characteristics that make it a promising potential treatment for AD relative to other antibodies that do not selectively
target oligomers. ACU193 is engineered to reduce immune effector function signaling and to avoid binding to vascular amyloid, which we expect will reduce the incidence of ARIA observed with amyloid plaque-targeting immunotherapies currently in
development for AD. We are currently assessing ACU193 in a proof of mechanism Phase 1 clinical trial involving early AD patients, which we expect to follow with an adaptive Phase 2/3 clinical trial in 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Clinical Development Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the second quarter of 2021, we initiated a U.S.-based, multi-center, randomized, placebo-controlled, single and multiple ascending dose
Phase 1 clinical trial of ACU193 in patients with early AD. The early AD patient group is comprised of individuals who have mild dementia or MCI due to AD, and our trial excludes patients with moderate to severe AD dementia. We plan to enroll 62
patients across seven cohorts, consisting of a single ascending dose Part A (32 participants) and an overlapping multiple ascending dose Part B (30 participants). Part A will contain Cohorts 1 through 4; each cohort will receive a single IV dose
between 2mg/kg and 60 mg/kg, or placebo. Part B will contain Cohorts 5 through 7; each cohort will receive a total of three doses of ACU193 or placebo as follows: 10 mg/kg every four weeks (Q4W), 60 mg/kg Q4W, or 60 mg/kg every two weeks (Q2W). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The main objectives of the trial are to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and target engagement of single
and multiple ascending doses of ACU193 administered by intravenous infusion. Exploratory outcomes will include cognitive scales and computerized cognitive testing. Our goal is to establish proof of mechanism of ACU193 in early AD patients in order
to enable rapid progression into an adaptive Phase 2/3 clinical trial. We intend to provide periodic updates of the status of the Phase 1 trial and anticipate reporting proof of mechanism results in the fourth quarter of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Our Nonclinical Data </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
nonclinical studies, ACU193 has demonstrated promising characteristics that indicate its potential to inhibit A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os as a possible therapeutic treatment of AD. ACU193 has high selectivity, with over <FONT
STYLE="white-space:nowrap">500-fold</FONT> binding selectivity for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os compared to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and has limited or no binding to amyloid plaques. ACU193 binds
to a broad spectrum of small to large soluble A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. Additionally, ACU193 has been shown to offer protection from synaptic toxicity by inhibiting binding of
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os to primary hippocampal neurons. ACU193 has also demonstrated suitable in vivo pharmacology, target engagement, blood-brain barrier penetration and reduction of behavioral deficits. Based on
nonclinical studies, A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O target engagement has the potential to be achieved at doses of ACU193 that will be tested in our Phase 1 clinical trial. Lastly, ACU193 has been shown to have an adequate safety
margin in Good Laboratory Practice, or GLP, toxicity studies conducted in two animal species. These data indicate that ACU193 has the potential to offer patients a reduction in cognitive decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our objective is to
transform the treatment of AD, and potentially other diseases, by developing innovative therapeutics that target primary drivers of disease pathology. Our initial therapeutic approach is focused on inhibiting and reducing the toxic activity of A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, which may allow for synaptic protection and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
decreased neurodegeneration, leading to more effective treatment for patients with early AD. To achieve this objective, we are pursuing the following strategies: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Rapidly advance ACU193 through clinical development in patients with early AD.</B>&nbsp;Based on the strength
of the data we observed in our nonclinical studies, we initiated a Phase 1 clinical trial in the second quarter of 2021 designed to evaluate safety and tolerability and establish proof of mechanism of ACU193 in early AD patients, which we expect to
follow with an adaptive Phase 2/3 clinical trial. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Evaluate combination approaches to complement our core ACU193 monotherapy strategy. </B>Using ACU193 as the
foundation of our AD therapy, we will evaluate its potential to be used in combination with drugs currently in development that have complementary mechanisms, which, if successful, could provide additive or even synergistic effects when used with
ACU193. These other drugs include various antibodies and small molecules targeting tau, investigational drugs targeting inflammation (TREM2), regenerative drugs (hepatocyte growth factor/MET receptor stimulator) and drugs which putatively improve
astrocyte function. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Selectively explore potential of ACU193 for other diseases.</B>&nbsp;Toxic
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os have been implicated in several disease pathologies in nonclinical and epidemiological studies (e.g., dementia associated with Down Syndrome, glaucoma and retinopathies associated with <FONT
STYLE="white-space:nowrap">age-related</FONT> macular degeneration). Where both human observational data and nonclinical experiments support its therapeutic potential, we may conduct clinical trials of ACU193 in other indications.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand our portfolio by developing additional molecules.</B>&nbsp;In the long term, a key element of our
portfolio strategy is to advance additional molecule development through <FONT STYLE="white-space:nowrap">in-licensing</FONT> or development of alternative formulations for or derivatives of ACU193. Additional molecules may utilize complementary
mechanisms to ACU193, making them candidates for combination therapies or as next-generation products. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Optimize value of ACU193 and future drug candidates in major markets.</B>&nbsp;We have an exclusive license
from Merck to patents claiming the composition and method of use of ACU193. We plan to develop and pursue approval of ACU193 and other future drug candidates in major markets. We anticipate entering into strategic collaborations and partnerships to
maximize the commercial potential of ACU193 and any future programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are led by an experienced management team with deep scientific and drug development knowledge and a strong commitment to developing safe
and effective therapies for patients. Collectively, our management team has a rich set of experiences in industry as well as in academia, and has led clinical development programs at both public and venture-backed clinical-stage companies, as well
as with large biopharmaceutical companies such as Eli Lilly&nbsp;&amp; Co., or Eli Lilly. We are led by our President and Chief Executive Officer, Daniel O&#146;Connell, our Chief Medical Officer, Eric Siemers, M.D. and our Chief Operating Officer,
Russell Barton. Our executive team is complemented our drug development experts, approximately half of whom hold Ph.D. or M.D. degrees and are former members of Eli Lilly&#146;s global AD clinical development organization. These team members,
including Dr.&nbsp;Siemers and Mr.&nbsp;Barton, have worked for over a decade on early- through late-phase AD drug development, including numerous early-phase AD trials and five large multi-national Phase 3 studies in AD. Together, our management
team brings expertise across relevant disciplines, including neuroscience, neurology, translational science, protein manufacturing, biomarker development and quality and regulatory affairs. We believe our team&#146;s experience and longstanding
working relationships position us to take ACU193 through late-stage clinical development and potentially regulatory approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors is comprised of our CEO and industry leaders that bring relevant
biopharma and finance experience, including Jeffrey Ives, Ph.D., Venture Partner at New Leaf Venture Partners; Jeffrey Sevigny, M.D., Chief Medical Officer at Prevail Therapeutics; Sean Stalfort, President at PBM Capital; Laura Stoppel, Ph.D.,
Principal at RA Capital Management; and Stephen Zachary, Ph.D., Partner at Sands Capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were founded by Caleb Finch, Ph.D., Grant
Krafft, Ph.D. and William Klein, Ph.D., and Drs. Krafft and Klein currently serve as Scientific Advisors. Our clinical and scientific advisory board is comprised of leading researchers in the fields of AD, neurodegeneration and medicine, including
Jeffrey Cummings, M.D., Sc.D., director for Transformative Neuroscience at the University of Nevada, Las Vegas; Steven DeKosky, M.D., deputy director at McKnight Brain Institute at the University of Florida; Cynthia Lemere, Ph.D., associate
professor of neurology in the Ann Romney Center for Neurologic Diseases at Brigham and Women&#146;s Hospital and Harvard Medical School; Colin Masters, M.D., professor and laboratory head of neuropathology and neurodegeneration at The Florey
Institute; Stephen Salloway, M.D., M.S., director of neurology at Butler Hospital and professor at Brown University; Jeffrey Sevigny, M.D., who also sits on the Company&#146;s board of directors; Reisa Sperling, M.D., professor of neurology at
Harvard Medical School; and Michael Weiner, M.D., professor in residence in radiology and biomedical imaging, medicine, psychiatry, and neurology at the University of California, San Francisco. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our company is supported by a group of institutional investors, and we have raised approximately $67.5&nbsp;million in funding as of
December&nbsp;31, 2020. Our key investors include BlackRock, PBM Capital, RA Capital Management, Rock Springs Capital, Sands Capital and several other private investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact of AD </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Alzheimer&#146;s disease
represents a significant unmet medical need and there are no marketed treatments that address the underlying cause of the disease. Alzheimer&#146;s disease is a progressive neurodegenerative disease that destroys memory and other important cognitive
functions and ultimately leads to patient death. Alzheimer&#146;s disease is the sixth-leading cause of death in the United States. The disease afflicts more than 6&nbsp;million people in the United States and more than 32&nbsp;million people
worldwide, and the patient population in the United States is expected to grow to approximately 13&nbsp;million people in the United States by 2050. Alzheimer&#146;s disease can have a significant burden on family and caretakers. In 2020, these
caregivers provided an estimated 15.3&nbsp;billion hours of care valued at nearly $257&nbsp;billion. The direct costs of caring for individuals with AD and other dementias in the United States were estimated to total $355&nbsp;billion in 2021, and
are projected to increase to $1.1 trillion by 2050, according to the Alzheimer&#146;s Association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Therapeutic Approaches to AD </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The development of effective therapeutics addressing the underlying cause of AD is one of the greatest medical challenges facing society.
Existing treatments for AD consist of drugs that provide modest improvements in symptoms but have no impact on the underlying disease and are unable to halt or slow disease progression. While the pathology of AD was first described by Dr.&nbsp;Alois
Alzheimer in 1906, the amyloid hypothesis was not developed until the A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> peptide was first identified as a major constituent of amyloid plaques in the 1980s. The hypothesis was more firmly established
when a series of genetic mutations causing the disease were discovered in the early to <FONT STYLE="white-space:nowrap">mid-1990s.</FONT> These mutations were found in genes coding for APP or in genes coding for one of the enzymes which cleaves APP,
creating the A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> peptide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Available Treatments: Symptomatic Treatments </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Currently available symptomatic treatments include memantine, an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">N-methyl-D-aspartate</FONT></FONT></FONT> receptor antagonist, and cholinesterase inhibitors, a class of drugs that block the normal breakdown of acetylcholine. The first approved cholinesterase inhibitor, tacrine, was
approved in 1993, but was later withdrawn from the market due to liver toxicity. Three other cholinesterase inhibitors were subsequently approved and continue to be used </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinically. Memantine is the most recently approved drug for AD in 2003 and is indicated for use in moderate to severe AD patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential Disease-Modifying Approaches focusing on A</I><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because of the lack of significant improvement provided by these symptomatic drugs, there remains a significant need for therapies that target
underlying disease pathology and potentially slow or halt disease progression. Based on the strong linkage between A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> and AD pathology established by decades of research, a range of treatment modalities
focusing on A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> have been explored as potential disease-modifying treatments, including <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>-secretase inhibitors,
<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>-site <FONT STYLE="white-space:nowrap">APP-cleaving</FONT> enzyme, or BACE, inhibitors and monoclonal antibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Initial attempts at disease modification were made using <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>-secretase inhibitors and BACE
inhibitors, each of which inhibited a different enzyme necessary to produce the A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> peptide. The first Phase 3 clinical trial results from a <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>-secretase
inhibitor, semagacestat, were reported in 2010 and unexpectedly showed modest cognitive worsening. Development of the other <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>-secretase inhibitor, avagacestat, was also stopped due to cognitive worsening
observed in the clinic. At least four BACE inhibitors have reached clinical trials; however, during 2018 and 2019, Phase 3 clinical trial results for many BACE inhibitors, including verubecestat and elenbecestat, also unexpectedly showed modest
clinical worsening. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A third class of potential disease-modifying agents, monoclonal antibodies, or mAbs, have targeted A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers or amyloid plaques directly. Some of these monoclonal antibodies, such as solanezumab (an Eli Lilly product), target A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers, while others, such as
aducanumab (a Biogen product), target deposited amyloid plaque, and these monoclonal antibodies have been evaluated in Phase 2 and Phase 3 trials over the period from 2012 to 2021. The most clinically advanced monoclonal antibody for the treatment
of AD is aducanumab, for which Biogen has applied for regulatory approval from the Food and Drug Administration, or FDA, European Medicines Agency, or EMA, and Pharmaceuticals and Medical Devises Agency, or PMDA, in the United States, Europe, and
Japan, respectively. As shown in Table 1 below, several of these antibodies have demonstrated some degree of slowing of disease progression in clinical trials, as measured by customary assessments of cognition and function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Table 1: Percent Slowing of Cognitive/Functional Decline* </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Measured Outcome**</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>solanezumab</B><br><B>EXPEDITION&nbsp;3<BR>(Phase 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>aducanumab<BR>EMERGE</B><br><B>(Phase 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>aducanumab<BR>ENGAGE&#134;</B><br><B>(Phase 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>BAN2401</B><br><B>(Phase 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>donanemab</B><br><B>(Phase 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ADAS-cog</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-27%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-12%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-47%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ADCS-ADL</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-40%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-18%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">CDR-SB</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-23%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-26%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MMSE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-15%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">iADRS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N.A.</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-32</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Percent Slowing= <FONT STYLE="white-space:nowrap">[1-</FONT> [(endpoint score-baseline score)active/(endpoint
score-baseline <FONT STYLE="white-space:nowrap">score)placebo]]*100%*(-1)</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;ADAS-cog:</FONT> Alzheimer&#146;s Disease Assessment Scale &#150;
Cognitive Subscale <B> </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">ADCS-ADL:</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Alzheimer&#146;s Disease Cooperative Study &#150; Activities of Daily Living <B> </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">CDR-SB:</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Clinical Dementia Rating &#150; Sum of Boxes <B> </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">MMSE:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Mini-Mental State Examination <B> </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">iADRS:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Integrated Alzheimer&#146;s Disease Rating Scale </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">ENGAGE Post-Protocol Version 4 &#150; patients who received at least 14 doses of 10 mg/kg, High Dose cohort
achieved 27% improvement on CDR-SB compared to placebo. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A potential limitation of the amyloid plaque-targeting
antibodies under development is an adverse effect known as ARIA. ARIA has two different forms, <FONT STYLE="white-space:nowrap">ARIA-E,</FONT> or cerebral edema, formerly called vasogenic edema, and <FONT STYLE="white-space:nowrap">ARIA-H,</FONT> or
cerebral microhemorrhages. While the mechanism of ARIA is not known with certainty, the prevailing theory is that ARIAs are related to the presence of amyloid plaques around blood vessels in the vast majority of people with AD, a condition known as
cerebral amyloid angiopathy. It is generally believed that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
removal of these amyloid plaques by the antibody can result in small hemorrhages, or <FONT STYLE="white-space:nowrap">ARIA-H.</FONT> <FONT STYLE="white-space:nowrap">ARIA-H</FONT> occurs in
untreated individuals with AD and is increased in individuals treated with antibodies that target amyloid plaques. Increased <FONT STYLE="white-space:nowrap">ARIA-H</FONT> is correlated with worsening cognition. In contrast to <FONT
STYLE="white-space:nowrap">ARIA-H,</FONT> <FONT STYLE="white-space:nowrap">ARIA-E</FONT> is hypothesized to result from the leakage of fluid from the blood vessels into the interstitial spaces in the brain, causing edema, or <FONT
STYLE="white-space:nowrap">ARIA-E.</FONT> <FONT STYLE="white-space:nowrap">ARIA-E,</FONT> in particular, is sometimes associated with symptoms that include worsening of cognition, headache, and gait disturbance, which can be severe enough to lead to
hospitalization. <FONT STYLE="white-space:nowrap">ARIA-E</FONT> usually resolves weeks to months following the cessation of treatment. In clinical trials for
<FONT STYLE="white-space:nowrap">anti-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>/plaque mAbs, surveillance MRI scans are required to detect asymptomatic ARIA. Table 2 below illustrates the rates of ARIA observed in Phase 2 or 3 studies
for the most advanced mAbs. Given observed rates of ARIA, from approximately 10% to over 40%, we believe that MRI scans to assess for ARIA are likely to be required in clinical practice for any amyloid plaque-targeting monoclonal antibody that
receives regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Table 2: Percent of ARIA Events for Anti-A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>/plaque mAbs*
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Targeting&nbsp;A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>&nbsp;Monomers</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="38" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Targeting Amyloid Plaques</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>solanezumab</B><br><B>EXPEDITION&nbsp;3</B><br><B>(Phase 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>aducanumab</B><br><B>EMERGE<BR>(Phase 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>aducanumab</B><br><B>ENGAGE</B><br><B>(Phase&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>BAN2401</B><br><B>(Phase2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>donanemab</B><br><B>(Phase 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;PC&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Treated&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Treated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ARIA-E</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">ApoE <FONT STYLE="FONT-FAMILY:SYMBOL">&#101;</FONT>4 carriers</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">ApoE <FONT STYLE="FONT-FAMILY:SYMBOL">&#101;</FONT>4
<FONT STYLE="white-space:nowrap">non-carriers</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Any ARIA E or&nbsp;H</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;N.A.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">PC =
Placebo, Low = Low Dose; High = High Dose </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">*Shows the absence of ARIA after treatment with antibodies targeting
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers (solanezumab) in comparison to the increasing presence of ARIA after treatment at increasing dose levels with antibodies targeting amyloid plaques (aducanumab, BAN2401, and donanemab),
indicate that ARIA results from the removal of amyloid plaques around blood vessels and likely does not result, from treatment with antibodies that target other species of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>, i.e. A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Table 3: AD Product Candidates and Target
Selectivity and ARIA Profile </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Target Selectivity<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ARIA Profile</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Product Candidate</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amyloid&nbsp;plaque</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B><BR>fibrils</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>&nbsp;monomers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>&nbsp;oligomers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Lack&nbsp;of&nbsp;ARIA</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">ACU193</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">untested</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">aducanumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">lecanemab BAN2401</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">gantenerumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">donanemab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">untested</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">solanezumab*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">crenezumab*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">bapineuzumab*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">x</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">*Phase 3 discontinued for primary AD indication </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">+ There have been
no head-to-head clinical trials between any of the product candidates listed above. Study designs and protocols for each product candidate were different, and results may not be comparable between product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional Treatment Modalities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> and amyloid are generally considered to be the proximal cause of AD pathology, and
alternative hypotheses to the amyloid hypothesis propose that amyloid accumulation is a consequence of other processes such as infection and that other pathogens lead to amyloid accumulation, downstream targets such as tau, inflammation-related
targets, and growth factors may eventually be useful approaches in the treatment of AD and are being explored. Some of these treatment modalities have made nonclinical and early stage clinical progress, although these efforts are still significantly
less advanced than those approaches targeting A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> or amyloid plaques. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential Combination Approaches </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The pathology of AD is complex, and many experts in the field expect that combination therapy using drugs with different mechanisms of action,
such as tau-based therapies and immune inflammatory modulation, will ultimately prove most successful, similar to cutting edge approaches used in oncology. We believe that a drug targeting A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os will
likely be an important component of a combination treatment. In addition, because symptomatic treatments, such as memantine and cholinesterase inhibitors, affect neurotransmitter systems rather than the underlying AD pathology, we believe that it is
likely that they will be used together with disease-modifying treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Growing Interest in the <FONT STYLE="white-space:nowrap">Anti-A</FONT></B><FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>O Hypothesis and A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>Os as a Drug Target for AD </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An important refinement of the amyloid hypothesis is the recognition that at least three pools of
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> species exist in vivo&#151;A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers, A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, and amyloid plaques. Because these pools exist in equilibria,
manipulation of one pool may have indirect effects on other pools. For example, reduction of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers may reduce A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os to some degree. Limited successes in
the clinic have been demonstrated with antibodies targeting A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers, even though A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers themselves are not widely accepted to have toxic properties.
Similarly, limited successes in the clinic have been demonstrated using antibodies that target amyloid plaques, although insoluble fibrillar A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> and <FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>-amyloid
plaques exhibit relatively low in vitro toxicity and may even serve as an in vivo mechanism for removal of the more toxic soluble A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> species. Both A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers
and amyloid plaques can act as sources of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. The positive results of monoclonal antibodies targeting A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and amyloid plaques, even in the absence of
targeting A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os directly, support the significance of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> and amyloid in AD and have led to a growing confidence in the field in the amyloid hypothesis broadly.
In contrast to the <FONT STYLE="white-space:nowrap">non-toxic</FONT> A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and relatively <FONT STYLE="white-space:nowrap">non-toxic</FONT> amyloid plaques,
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os are known to bind to neurons, causing synaptic dysfunction and possibly contributing to cognitive impairment, neurodegeneration and cell death. As a result,
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os are now generally believed to be the most toxic form of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>. The acute synaptic and chronic neurodegenerative toxicity of
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, coupled with their very low in vivo levels, suggests that they may be an optimal therapeutic target compared to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and fibrillar A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> species. Therefore, we believe that drugs that directly target A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os could represent a promising new approach to the potential treatment of AD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 1: A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B> related species and pathophysiology of AD </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g92p79.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The precise mechanism of toxicity of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os is
not fully understood, however numerous studies suggest a mechanism that may include initial reversible memory loss caused by acute A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><FONT STYLE="white-space:nowrap">O-induced</FONT> disruptions of
synaptic plasticity, with progressive dementia attributable, at least in part, to neuronal degeneration induced by chronic exposure to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os bind to
synapses on hippocampal and cortical neurons. In rodent hippocampal slice preparations, A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os cause rapid inhibition of long-term potentiation, or LTP, and direct injection of A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O solutions into rodent brains leads to reversible impairment of cognitive function. These findings support the view that A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os may interfere acutely with normal
synaptic functions and contribute significantly to the memory loss and cognitive dysfunction characteristic of AD. With regard to neurodegeneration, binding of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os to neurons also causes damage within
neurons, such as calcium influx and the hyperphosphorylation of tau, which leads to neurofibrillary tangles, another downstream hallmark of AD pathology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Differentiated Approach to the Treatment of AD </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that, based on its differentiated mechanism of action, potential for symptomatic improvement and disease modification, and
potential for higher dosing, ACU193 has several potential advantages in comparison to other AD drugs that are currently approved or in development: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Differentiated mechanism of action: </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Potentially addresses an underlying cause of AD</B>. A growing body of evidence indicates that A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, rather than A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers or amyloid plaques, are the primary toxic species that impair neuronal synaptic function and contribute to impairment in memory and
cognition and neurodegeneration. We believe that A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os are an optimal therapeutic target relative to other A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> species and that ACU193 has the potential to be
the first <FONT STYLE="white-space:nowrap">anti-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O directed treatment to prevent or slow the progression of AD. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Selectively binds to A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>O.</B> ACU193 is the first
monoclonal antibody discovered and designed to selectively target A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. In our nonclinical studies, ACU193 demonstrated a greater than <FONT STYLE="white-space:nowrap">500-fold</FONT> affinity to bind to
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os over monomers and did not bind vascular amyloid or dense core amyloid plaques. In comparison, other <FONT STYLE="white-space:nowrap">non-selective</FONT>
<FONT STYLE="white-space:nowrap">anti-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>/amyloid antibodies in development bind primarily to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers or amyloid plaques. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Binds to a broad spectrum of toxic A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>Os. </B>A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os are present in the brain in a wide range of sizes.<B> </B>ACU193 has the ability to bind to a broad spectrum of toxic A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os across various molecular weights.
Nonclinical data shows that ACU193 binds to <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-sized</FONT> molecular weight oligomeric species. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential for symptomatic improvement and disease modification: </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>May provide symptomatic improvement in addition to disease modification.</B> While recent <FONT
STYLE="white-space:nowrap">anti-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monoclonal antibody results have established a biological foothold for disease-modifying treatments for AD, they fail to demonstrate clinically meaningful
symptomatic improvement as measured by AD clinical assessments. Recent nonclinical studies show that A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os are acutely toxic to neuronal function. By selectively targeting and neutralizing A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O toxicity, we believe that ACU193 has the potential to build upon this biological foothold and provide improvements in cognitive function in addition to disease-modifying effects. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential for higher dosing: </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><B>Selectivity for A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>Os is likely to result in
greatly reduced rates of ARIA, allowing a broad therapeutic window.</B> Amyloid plaque binding antibodies have been associated with ARIA, with IgG1 monoclonal antibodies in particular showing elevated rates of ARIA, which presents a safety concern.
In contrast, ACU193 was engineered as an IgG2m4 subclass monoclonal antibody, which lacks the inflammatory effector functions of other IgG subclasses. Because ACU193 exhibits </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
limited or no binding to amyloid plaques and lacks inflammatory effector functions, we believe that treatment with ACU193 is likely to result in greatly reduced rates of ARIA adverse events
relative to IgG1 monoclonal antibodies that bind to plaque. ACU193 has demonstrated a favorable pharmacokinetic profile in nonclinical studies. Based on the results of GLP safety studies in rats and monkeys, we believe that ACU193 has the potential
to be clinically well-tolerated at doses up to 60 mg/kg. While certain <FONT STYLE="white-space:nowrap">anti-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>/plaque antibodies have dose limitations due to ARIA, we believe that ACU193 may be
well-tolerated at higher doses. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ACU193: First AD Immunotherapy Candidate to Selectively Target
A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>Os </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our product candidate, ACU193, is a humanized, affinity-matured,
immunoglobulin G2m4, or IgG2m4, subclass monoclonal antibody, derived from the murine immunoglobulin G1, or IgG1, parent, ACU3B3. ACU193 lacks the inflammatory effector functions of other IgG subclasses. ACU193 binds with high selectivity to soluble
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os (over <FONT STYLE="white-space:nowrap">500-fold</FONT> versus A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomer in a competitive assay), differentiating ACU193 from other therapeutic monoclonal
antibodies, which primarily bind A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers or fibrillar forms of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>. Binding of ACU193 to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os may improve
synaptic function and decrease neurodegeneration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 2: Summary comparison of ACU193 to <FONT STYLE="white-space:nowrap">anti-A</FONT></B><FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>/plaque antibodies in clinical development </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g00q15.jpg" ALT="LOGO">
 </P>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">All IgG1 monoclonal antibodies that bind amyloid plaque have shown high rates of ARIA-E. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Despite recognition that A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os are key structures contributing to AD memory dysfunction, cognitive
deficits, and neurodegeneration, drug discovery efforts targeting these species have been hampered by technical difficulties of generating physiologically relevant preparations of synthetic A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, or <FONT
STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. Our founders and early-stage researchers were instrumental in the development of well-characterized preparations of
<FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, initially termed A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> Derived Diffusible Ligands, or ADDLs. ADDL preparations were used as the immunogen to
generate and discover ACU3B3, the murine IgG1 parent of ACU193. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2003, we entered into an exclusive license and research
and development collaboration agreement with Merck for the research, discovery, development, and commercialization of immunotherapies for AD. From 2003 to 2011, Merck carried out extensive research leading to the humanization of ACU3B3 and creation
of ACU193. ACU193 emerged as the lead product candidate based on its preferential A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O binding, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
favorable immunogenicity profile, and an absence of <FONT STYLE="white-space:nowrap">off-target</FONT> binding. In 2011, Merck chose to terminate the program largely based on internal strategic
priorities. Consequently, we regained an exclusive, perpetual, irrevocable, royalty-free, worldwide license for the research, development, manufacturing or commercialization of ADDL antibodies, ADDL antigens, or products, including ACU193. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product Profile </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are developing
ACU193, a humanized monoclonal antibody targeting soluble A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, as an IV administered treatment for early AD patients. The early AD population is defined as individuals with clinical symptoms consistent
with MCI, or consistent with mild dementia who have demonstrated amyloid pathology as assessed with either a positron emission tomography, or PET, or cerebrospinal fluid analysis. A blood test to determine amyloid status may become available in the
future. We believe ACU193 has the potential to reduce the rate of cognitive decline by at least 35%, which would be broadly considered as clinically meaningful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ACU193 is a humanized, affinity-matured, mAb with high selectivity for toxic A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os versus A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers (greater than <FONT STYLE="white-space:nowrap">500-fold)</FONT> and amyloid plaques. With its selective targeting of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, we believe that ACU193 could
demonstrate a number of potential valuable clinical outcomes, including the slowing of disease progression and downstream changes in tau and neurofibrillary tangles. Additionally, given the acute toxicity of
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os in laboratory studies, we believe that some patients could experience an improvement in cognitive function. ACU193&#146;s epitope is composed of a configuration of the
<FONT STYLE="white-space:nowrap">N-terminal</FONT> regions of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers within A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os form when A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers associate <FONT STYLE="white-space:nowrap">co-linearly</FONT> along the central alpha helical domains through <FONT STYLE="white-space:nowrap">C-terminal</FONT> regions via stacking phenylalanine
polar bonding associations. This presents an advantage for ACU193 binding because the <FONT STYLE="white-space:nowrap">co-linear</FONT> association sterically restricts spatial configuration of the <FONT STYLE="white-space:nowrap">N-terminal</FONT>
regions presented by A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. The <FONT STYLE="white-space:nowrap">N-termini</FONT> within A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os are anionic and repel one another, resulting in presentation of <FONT
STYLE="white-space:nowrap">N-terminal</FONT> amino acids, which lead to high affinity for ACU193 binding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In its current formulation,
ACU193 deamidates at physiological pH and body temperature. The rate of deamidation is specific to the matrix and temperature, and results in reduced target binding. To prevent deamidation prior to administration of ACU193 in the clinic, the current
drug product is stored frozen at <FONT STYLE="white-space:nowrap">-20&deg;C.</FONT> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ACU193 is an IgG2m4 subclass mAb which lacks the
inflammatory effector function signaling stimulated by other IgG subclasses. The product is expected to be given as an IV infusion once every four weeks. Given the indication, ACU193 treatment would be initiated for patients diagnosed with mild
dementia or MCI and would likely be continued for several years. Based on the target and lack of inflammatory effector function, we believe the rate of ARIA may be reduced compared to approaches targeting amyloid plaques. Finally, ACU193 could be
used in combination with other therapies that might become available for AD, especially those targeting the tau protein or modulating the immune system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nonclinical Data Package </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Nonclinical
Studies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In our nonclinical studies, ACU193 has demonstrated: (i)&nbsp;preferential selectivity for binding to A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os versus other forms of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and amyloid plaques in in vitro assays, human AD tissue samples and in vivo transgenic mouse models; (ii)&nbsp;consistent data
in support of ACU193 protective effects against A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O synaptic toxicity in in vitro and ex vivo assays; (iii)&nbsp;in vivo pharmacology in multiple species confirming blood-brain barrier penetration, target
engagement, and behavioral effects; and (iv)&nbsp;safety data in multiple species including GLP toxicology studies in Sprague-Dawley rats and cynomolgus monkeys confirming an adequate safety margin for the first in human clinical trial. Based on the
strength of the data we observed in our nonclinical studies, we initiated a Phase 1 clinical trial in the second quarter of 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Characteristics and Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selectivity</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Binding characterization studies of ACU193 and its murine parent ACU3B3 show significant
preferential selectivity for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os versus monomeric and amyloid plaques.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.60em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#150;&#8195;&#8201;&#8201;Competitive <FONT STYLE="white-space:nowrap">enzyme-linked</FONT> immunosorbent assay, or
ELISA, data show ACU193 binding to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os is <FONT STYLE="white-space:nowrap">556-fold</FONT> greater than to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomer based on monomer equivalent weight. This
selectivity value is even higher when adjusted for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os&#146; molecular weight.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.60em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#150;&#8195;&#8201;&#8201;ACU193 binding in brain tissues of transgenic mice following IV dosing shows significant,
preferential binding to <FONT STYLE="white-space:nowrap">non-fibrillar,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">thioflavin-S-negative</FONT></FONT> A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> structures. The
occasional <FONT STYLE="white-space:nowrap">co-localization</FONT> observed with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">thioflavin-S-positive</FONT></FONT> fibrillar plaques suggests binding to A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os reported to surround amyloid plaques.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;ACU193 binds a broad range of synthetic and human-derived low, mid, and higher molecular
weight A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os (dimers to 200-mers).</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Protection from A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><FONT STYLE="white-space:nowrap">O-induced</FONT> synaptic toxicity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;ACU193 and ACU3B3 prevent binding of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os to
primary hippocampal neurons in vitro (the average IC50 of ACU193 is 17 nM).</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;ACU193 and ACU3B3 block A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os&#146; inhibition
of long-term potentiation ex vivo.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;ACU3B3 blocks A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O mediated intracellular
calcium influx in vitro.</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">In vivo pharmacology</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;ACU193 crosses the blood-brain barrier and demonstrates dose-dependent target engagement in
the brain following peripheral administration of antibody.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Blinded studies in transgenic mouse models for AD over a broad range of ages show that
treatment with ACU3B3 reduces multiple behavioral deficits.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;QPS study of nine- to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ten-month-old</FONT></FONT> transgenic mice treated weekly with 20 mg/kg ACU3B3 for four weeks demonstrated significant behavioral improvements during water maze learning test.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Stanford University
study of five- to <FONT STYLE="white-space:nowrap">seven-month-old</FONT> transgenic mice treated weekly with 20 and 30 mg/kg ACU3B3 showed significant improvements during open field and <FONT STYLE="white-space:nowrap">Y-maze</FONT> tests after
four to five weeks of treatment.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Gladstone Institute studies of younger three- to
<FONT STYLE="white-space:nowrap">five-month-old</FONT> transgenic mice with <FONT STYLE="white-space:nowrap">sub-chronic</FONT> weekly administration of ACU3B3 demonstrated significant behavioral improvements to hyperactivity, emotional response
alterations and procedural learning deficits.</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Safety</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;GLP studies via IV route established no observed adverse effect level, or NOAEL, of 300
mg/kg/dose in a <FONT STYLE="white-space:nowrap">14-week</FONT> cynomolgus monkey study and 250 mg/kg/dose in&nbsp;a <FONT STYLE="white-space:nowrap">28-day&nbsp;rat</FONT> study.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Studies in transgenic
mice indicated low potential for cerebral microhemorrhage.</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selectivity for A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>Os </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to understand ACU193 selectivity for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, we performed biochemical assays and
immunohistochemistry experiments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selectivity for A</I></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B><I></I></B><B><I>Os versus A</I></B><FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B><I></I></B><B><I> monomers </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We demonstrated that ACU193 shows significant preferential
selectivity for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os compared to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers. In a competition ELISA assay, ACU193&#146;s binding to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os was <FONT
STYLE="white-space:nowrap">556-fold</FONT> greater than binding to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
monomers. Figure 3A shows comparative <FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O versus A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomer
affinity data for ACU193, and illustrates the high selectivity of ACU193 for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. Further evidence of ACU193 selectivity for
<FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os was obtained using a very high concentration of monomeric A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>, 5 &micro;m, which did not decrease binding to <FONT
STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os (Figure 3B). We believe ACU193&#146;s selectivity for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os in the presence of abundant A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers is representative of the in vivo levels of these A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> species in AD patients. Thus, ACU193 does not experience &#147;target distraction&#148; from <FONT
STYLE="white-space:nowrap">non-toxic</FONT> A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers in an environment simulating brain interstitial fluid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 3: [A] Competitive ELISA for ACU193 binding to
<FONT STYLE="white-space:nowrap">syn-A</FONT></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>O or monomeric A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B><SUB STYLE="font-size:85%; vertical-align:bottom">40</SUB> [B]
5&micro;M monomeric A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B> did not substantially change binding to <FONT STYLE="white-space:nowrap">syn-A</FONT></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>O </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g71z61.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g30s55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These results support the conclusion that selectivity of ACU193 for A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os is
maintained in a biochemical environment simulating the brain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selectivity for
A</I></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B><I></I></B><B><I>Os versus amyloid plaques </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have shown in our
nonclinical data that ACU193 binds A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os from AD patients with limited or no binding to amyloid plaques. In Figure 4 below, thioflavin <FONT STYLE="white-space:nowrap">S-positive</FONT> <FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>-amyloid plaques are shown in green </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fluorescence while ACU193 binding is shown in red fluorescence. ACU193 binds significantly in regions that are
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">thioflavin-S-negative,</FONT></FONT> i.e., without amyloid plaques (Figure 4, Panels B and E), but only infrequently and minimally binds to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">thioflavin-S-positive</FONT></FONT> fibrillar A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> structures (Figure 4, Panel D); close examination shows possible <FONT STYLE="white-space:nowrap">co-localization</FONT> of
ACU193 with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">thioflavin-S-positive</FONT></FONT> A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> deposits in their periphery (Figure 4, Panel F). We believe the most likely explanation
of ACU193 infrequent binding near the periphery of some amyloid plaques is due to binding to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os that surround the periphery of amyloid plaques. Taken together, these results are consistent with the
concept that ACU193 binds endogenous A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, does not block binding by <FONT STYLE="white-space:nowrap">thioflavin-S,</FONT> and, importantly, preferentially binds
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os versus fibrillar A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 4: ACU193 binding to A</B><FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>Os versus amyloid plaques </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g03a03.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The upper
left portion of the immunohistochemistry figure shows that in areas with no amyloid plaque binding (no green fluorescence staining, A) there is substantial binding by ACU193 (red fluorescence staining, B) that is not related to amyloid plaque. The
merge of these panels (Panel E) shows ACU193 binding with no amyloid plaque present. On the upper right portion of the Figure, the area that is positive for amyloid plaque (green fluorescence staining, C) shows minimal ACU193 binding (red
fluorescence staining, D). The merge of these panels (F)&nbsp;shows the minimal binding of ACU193 (red fluorescence staining) on the periphery of the amyloid plaque (green fluorescence staining), most likely related to A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O binding in the halo of the amyloid plaque. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 5: AD stages based on AD neuropathic change, or ADNC,
scoring </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g64m48.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">ADNC
scoring is a combination of amyloid plaque levels, neuritic plaque levels, and neurogibrillary tangle pathology, or NFT, levels (Braak stage). In human tissue samples, ACU193 shows a disease state-relevant signal based on immunohistochemistry
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">
shown on the left from aged controls, intermediate AD pathology, and advanced AD pathology. On the far-right panel, ACU193 detects A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os in soluble
hippocampal extracts from an autosomal dominant AD patient, but not from a cognitively normal patient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, we have demonstrated
that ACU193 does not bind to amyloid plaque surrounding blood vessels (cerebral amyloid angiopathy). In a study of transgenic mice, we did not observe binding to vascular amyloid, in contrast to hu3D6 (bapineuzumab), which displayed significant
binding at all dose levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 6: ACU193 versus hu3D6 binding to vascular amyloids </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g04q02.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">ACU193 (A
and C) shows no binding to the vascular amyloid that is visible in the vessels stained by <FONT STYLE="white-space:nowrap">thioflavin-S</FONT> (green fluorescence, B and D) in the brain 24 hours following IV dosing of 10 or 50 mg/kg in seven- to <FONT
STYLE="white-space:nowrap">eight-month-old</FONT> Tg2576 mice. In contrast, hu3D6 (bapineuzumab) binds vascular amyloid (E)&nbsp;at all dose levels assessed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The data above related to vascular plaque binding support our belief that ACU193 is unlikely to have an ARIA liability. Given that the amyloid
plaque-binding properties of multiple antibodies have been associated with ARIA (e.g., aducanumab, BAN2401, gantenerumab, and donanemab), we believe that ACU193&#146;s negligible binding of amyloid plaques, including amyloid plaques associated with
cerebral amyloid angiopathy, provides evidence that ARIA is unlikely to be associated with this antibody. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Binding to a broad spectrum of molecular
weight A</I></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B><I></I></B><B><I>Os </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we demonstrated that ACU193
binds a broad spectrum of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os across various molecular weights. In another series of experiments, <FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os were
fractionated by size exclusion chromatography and characterized by ELISA using ACU193, hu3D6 (bapineuzumab) or hu266 (solanezumab) as the capture antibody and biotinylated anti-human A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> antibody 82E1 for
detection. These data show ACU193 binds mid to higher molecular weight A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os, with preferential binding to <FONT STYLE="white-space:nowrap">mid-molecular</FONT> weight oligomers compared to hu266. This
range of molecular weights is very similar to the range of molecular weights of oligomers thought to be most toxic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 7. Binding of humanized antibodies to size exclusion chromatography fractions of synthetic A</B><FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B> species </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g20a69.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Size exclusion chromatography fractionation of syn-A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O prep with sandwich ELISA detection. hu3D6 is also known as
bapineuzumab; hu266 is also known as solanezumab. These data demonstrate the specificity of ACU193 for oligomers versus monomers, and also demonstrate a range of oligomers that are bound by ACU193. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Collectively the data show that ACU193 binds A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os with
<FONT STYLE="white-space:nowrap">556-fold</FONT> selectivity versus A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> monomers and demonstrates limited to no binding to amyloid plaques, but does bind to a broad range of synthetic and endogenous low,
mid, and higher molecular weight A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. Based on these and other data, we believe that ACU193 can target therapeutically relevant A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os in the brain of early AD
patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Protection from A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B><FONT STYLE="white-space:nowrap">O-induced</FONT> synaptic
toxicity </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to understand ACU193&#146;s ability to either neutralize or limit A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><FONT
STYLE="white-space:nowrap">O-induced</FONT> physiological changes, we performed ex vivo studies using brain slices or cell cultures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prevention of
A</I></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B><I></I></B><B><I>O toxic effects on neuronal electrophysiology </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In ex
vivo studies using the murine hippocampal slice LTP model, <FONT STYLE="white-space:nowrap">pre-incubation</FONT> with ACU193 or ACU3B3 has been shown to prevent the LTP deficit caused by A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os (formed by
administration of 50nM A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><SUB STYLE="font-size:85%; vertical-align:bottom"><FONT STYLE="white-space:nowrap">1-42</FONT></SUB>). Long term potentiation is an electrophysiological phenomenon demonstrated in
neurons that may be associated with memory formation and other important neurological functions. Disruption of LTP has been associated with animal models in a variety of central nervous system disease states. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 8. Effects of ACU3B3 and ACU193 on
A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>O-induced change in LTP </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g22y47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note that A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os disrupted normal LTP findings, but that pre-incubation with
ACU3B3 prevented that disruption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prevention of toxic effects of A</I></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B><I></I></B><B><I>Os on
calcium homeostasis </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Exposure to ACU3B3 has been shown to prevent calcium overload in cortical neuronal cultures induced by
direct application of <FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os (Figure 9). Disruptions in calcium homeostasis that cause cellular dysfunction have been implicated in a number of disease states,
including myocardial infarction and stroke. Further, A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os have been shown to cause disruption of calcium homeostasis, and thus, restoration of intracellular calcium to normal levels could serve as a
functional indicator of potential treatment effect in AD. Multiphoton microscopy was used to examine the relationship of <FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O and neuronal calcium homeostasis in
vitro (Figure 9). Direct application of <FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os elicited calcium elevations in cortical neuronal cultures. Prior exposure to antibodies ACU3B3 and 3D6 prevented
this calcium elevation (Figure 9). These results demonstrate that <FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os induce elevated concentrations of intracellular neuronal calcium and that ACU3B3
prevented the <FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><FONT STYLE="white-space:nowrap">O-induced</FONT> calcium overload. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 9: Effect of ACU3B3 on calcium homeostasis </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g52c34.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The relationship of <FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O and neuronal calcium homeostasis in the
presence and absence of ACU3B3 was studied in primary cultures of transgenic <FONT STYLE="white-space:nowrap">APP-PS1</FONT> mouse cortical neurons. Multiphoton microscopy was used to obtain images of neuronal cultures at 12&#150;14 days in vitro,
or DIV, or 21 DIV. Cortical regions were identified and reimaged before and after topical applications of <FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os to allow comparison of resting calcium within the
same neuronal compartments. After baseline calcium was obtained, the cultures were treated with antibody-immunodepleted <FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os (1 mL of 3 nM <FONT
STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os with 9 &micro;g of antibody) or <FONT STYLE="white-space:nowrap">syn-A</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os alone for 45 minutes. The cultures
were then <FONT STYLE="white-space:nowrap">re-imaged</FONT> in the same areas in the dish. Taken together, these studies show that ACU3B3 prevents the toxic effect of A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os on calcium homeostasis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In Vivo Pharmacology </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to
understand the effects of ACU193 in intact animals, we performed behavioral studies in transgenic mice with genetic alterations that overproduce a mutant amyloid precursor protein that forms amyloid plaques. The transgenic mouse models are generally
based on autosomal dominant mutations in the APP gene causing rare forms of human AD. Transgenic mouse models using these mutations may not cause the full spectrum of AD pathology, but they do provide relevant animal models for drug development in
AD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In vivo behavioral studies in multiple transgenic mouse models for AD </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The behavioral studies described below, performed at three different laboratories, indicate in vivo central pharmacologic activity of
peripherally administered ACU3B3. The behavioral effects seen in these studies indicate that sufficient amounts of ACU3B3 cross the blood-brain barrier to engage the target, resulting in behavioral improvements in these transgenic mice. The Phase 1
clinical trial includes doses in the range used in these nonclinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A study conducted at QPS and using nine- to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ten-month-old</FONT></FONT> APP/SL transgenic mice treated weekly with 20 mg/kg ACU3B3 for four weeks demonstrated statistically significant behavioral improvements in swim path length and
swim speed during the water maze learning test (Figure 10). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 10: Results of ACU3B3 treatment in mice study </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g89k52.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">ACU3B3 treatment in nine- to <FONT STYLE="white-space:nowrap">ten-month-old</FONT> APPSL mice (n=10/group) improves performance on the first day of water maze
training (A; p=0.057), decreases swim path length (B; p=0.034), and reverses a swim speed abnormality (C; p&lt;0.02). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In a separate study
conducted at Stanford University, the hyperactivity phenotype of five- to <FONT STYLE="white-space:nowrap">seven-month-old</FONT> Thy1-hAPP/SL transgenic mice in the open field and <FONT STYLE="white-space:nowrap">Y-maze</FONT> tests was also
significantly reduced after four to five weeks of treatment with ACU3B3 (20 and 30 mg/kg, weekly). Prior to dosing, Thy1-hAPP/SL mice showed increased activity in the activity chamber compared to wild-type mice. After treatment with ACU3B3,
Thy1-hAPP/SL mice activity fell to a level comparable to wild-type mice, particularly activity in the center of the test arena (Figure 11A). Similar effects of ACU3B3 were found with changes in <FONT STYLE="white-space:nowrap">Y-maze</FONT> behavior
(Figure 11B) and passive avoidance (Figure 11C). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 11: ACU3B3 treatment at 20 mg/kg in five- to
<FONT STYLE="white-space:nowrap">seven-month-old</FONT> Thy1-hAPP/SL mice <FONT STYLE="white-space:nowrap">(n=13-14/group,</FONT> means + SEM) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g98x03.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">[A] Open
field total distance measurement, <FONT STYLE="white-space:nowrap">APP-Veh</FONT> vs. <FONT STYLE="white-space:nowrap">APP-3B3,</FONT> *p=0.029. [B] <FONT STYLE="white-space:nowrap">Y-maze</FONT> arm entries,
<FONT STYLE="white-space:nowrap">APP-Veh</FONT> vs <FONT STYLE="white-space:nowrap">APP-3B3,</FONT> *p=0.045; <FONT STYLE="white-space:nowrap">APP-Veh</FONT> vs <FONT STYLE="white-space:nowrap">WT-Veh,</FONT> **p=0.007. [C] Passive avoidance
latency, APPSL-APP3B3 vs. <FONT STYLE="white-space:nowrap">APPSL-Veh</FONT> trended for drug effect, but was not statistically significant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In separate studies conducted at the Gladstone Institute in young three- to <FONT STYLE="white-space:nowrap">five-month-old</FONT> hAPP/J20
mice, behavioral abnormalities in these mice were reduced after chronic treatment with ACU3B3. Treatment ameliorated the hyperactivity phenotype, emotional response alterations and procedural learning deficits in this mouse model and hyperactivity
in the <FONT STYLE="white-space:nowrap">Y-maze</FONT> test was reduced dose-dependently (5 &lt; 10 = 20 mg/kg) (Figure&nbsp;12). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 12: Open field and <FONT STYLE="white-space:nowrap">water-maze</FONT> behavior in three- to <FONT
STYLE="white-space:nowrap">five-month-old</FONT> hAPP/J20 mice following repeat weekly IP dosing with ACU3B3 <FONT STYLE="white-space:nowrap">(n=13-14/group)</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g51i08.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">[A] Open
field activity after four weekly doses. [B], [C] <FONT STYLE="white-space:nowrap">Water-maze</FONT> behavior following eight weekly doses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 13: <FONT
STYLE="white-space:nowrap">Y-maze</FONT> and elevated <FONT STYLE="white-space:nowrap">plus-maze</FONT> behavior in three- to <FONT STYLE="white-space:nowrap">five-month-old</FONT> hAPP/J20 mice following repeat, weekly IP dosing with ACU3B3 <FONT
STYLE="white-space:nowrap">(n=13-14/group)</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g89w33.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">[A] <FONT
STYLE="white-space:nowrap">Y-maze</FONT> activity after six weekly doses. [B], [C] Elevated <FONT STYLE="white-space:nowrap">plus-maze</FONT> behavior following nine weekly doses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Taken together, these behavioral studies, performed at three different laboratories, indicate in vivo central pharmacologic activity of
peripherally administered ACU3B3. The behavioral effects seen in these studies indicate that sufficient amounts of ACU3B3 cross the blood-brain barrier to engage the target, resulting in behavioral improvements in these transgenic mice. The range of
doses used in these nonclinical studies is covered in the Phase 1 clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pharmacokinetics and Pharmacodynamics </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ACU193 has demonstrated favorable pharmacokinetics and pharmacodynamics based on a number of nonclinical studies. ACU193 could be detected in
plasma, CSF, and brain tissue of Tg2576 mice, rats, dogs, and rhesus monkeys following IV injection. Penetration of ACU193 into the brain was demonstrated by direct measurements of brain levels in Tg2576 mice, rats, and dogs, and by measurements of
CSF levels in rats and rhesus monkeys. Brain levels were approximately 0.02% of plasma levels and CSF levels ranged from 0.05 to 0.15% of plasma levels, showing penetration of ACU193 into the brain. Toxicokinetic data collected as part of GLP
toxicity studies in Sprague Dawley rats and cynomolgus monkeys showed clearance of 1 to 3 mL/h/kg and terminal half-life of approximately seven days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Brain penetration and in vivo binding of ACU193 was explored in <FONT STYLE="white-space:nowrap">seven-month-old</FONT> Tg2576 mice dosed
intravenously with 2, 10 and 50 mg/kg of ACU193 or hu3D6 (bapineuzumab), and perfused brain tissue was collected 24 hours after dosing for analysis. A dose dependent increase in brain levels of ACU193 (Figure 14A) and ACU193/A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O complex (Figure 14B) was demonstrated, with a minimum effective dose for target engagement of 10 mg/kg. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 14: Levels of ACU193 and A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>O/ACU193 complexes in the brain 24 hours following IV dosing
in <FONT STYLE="white-space:nowrap">seven-month-old</FONT> Tg2576 mice (n = 4/cohort) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g82e41.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">These
results show ACU193 can penetrate the blood-brain barrier and bind endogenous A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, a study of pharmacokinetics in CSF was conducted in rhesus monkeys. An intrathecal catheter was implanted in the monkeys, and
two doses at 20 mg/kg IV were administered. As shown in Figure&nbsp;15, the concentrations of ACU193 in CSF should provide adequate target engagement with every four week dosing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 15: Comparison of ACU193 levels in rhesus CSF to CSF Levels of
A</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT><B></B><B>O in human AD patients </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g56t67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following two doses of 20 mg/kg ACU193 CSF concentrations were sufficient to provide target engagement at 28 days. An
estimate of 1 fmole/mL for oligomer concentration is conservative given that it is based on oligomers consisting of trimers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Safety Profile
</I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Good Laboratory Practice studies using IV administration of ACU193 established a
<FONT STYLE="white-space:nowrap">no-observed-adverse-effect</FONT> level, or NOAEL, of 250 mg/kg/dose, which was the maximum feasible dose, given every two weeks in&nbsp;a <FONT STYLE="white-space:nowrap">28-day</FONT> study in
Sprague-Dawley&nbsp;rats. The NOAEL in cynomolgus monkeys was 300 mg/kg/dose in a <FONT STYLE="white-space:nowrap">14-week</FONT> study in cynomolgus monkeys using IV dosing every two weeks. In Sprague Dawley rats, no adverse findings were noted. In
the <FONT STYLE="white-space:nowrap">14-week</FONT> study in cynomolgus monkeys, doses of 60, 300, or 600 mg/kg/dose ACU193 once every two weeks were administered. Three animals administered the highest 600 mg/kg/dose were sacrificed early for
humane reasons on Days 43 or 60 due to ACU193-related, anaphylactoid-type reactions. Thus, the 300 mg/kg/dose is considered the NOAEL for cynomolgus monkeys. The NOAELs of 300 mg/kg and 250 mg/kg compare favorably to the highest dose of ACU193 being
used in our Phase 1 clinical trial (60 mg/kg). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based in part on binding to A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>Os rather
than amyloid plaque, ACU193 has the potential to have a lower rate of ARIA than plaque-clearing anti-amyloid antibodies. Additionally, ACU3B3 showed no apparent increased risk of microhemorrhage when administered in vivo for three months in aged
Tg2576 mice, as compared with 3D6, a plaque binding antibody used as a positive control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">With regard to effector function and possible
inflammatory effects generally, ACU193 is an IgG2m4 subclass antibody which lacks inflammatory effector function signaling stimulated by other IgG subclasses. Thus, the risk for inflammatory effector function using ACU193 is considered to be low.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investigational New Drug Application </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2020, we submitted an investigational new drug, or IND, application for ACU193 to the FDA. The FDA initially placed the IND on
clinical hold until we were able to address the FDA&#146;s concerns regarding potential <FONT STYLE="white-space:nowrap">off-target</FONT> binding of ACU193 with an additional nonclinical tissue cross reactivity (TCR) study in human, monkey, and rat
samples. The supplemental TCR study supported the in-vivo GLP safety results. On April 9, 2021, we received an FDA letter advising us that the clinical hold had been removed and authorizing us to proceed with a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human,</FONT></FONT> Phase 1 clinical trial. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Development Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1 Clinical Trial in AD </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the second quarter of 2021, we initiated a multi-center, randomized, placebo-controlled, single and multiple ascending dose Phase 1
clinical trial of ACU193 in 62 patients with early AD. The early AD patient set is comprised of individuals who have mild dementia or MCI due to AD. Patients with moderate to severe dementia will not be included. The main objectives of the trial are
to evaluate the safety, tolerability, pharmacokinetics, and target engagement of single and multiple ascending doses of ACU193 administered by IV infusion. Pharmacodynamics effects including cognitive testing will be performed on an exploratory
basis. The trial will be conducted in two overlapping parts: Part A (the single ascending dose portion) and Part B (the multiple ascending dose portion). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 16: Design of Study <FONT STYLE="white-space:nowrap">ACU-001</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g11t00.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Trial Design Part A &#150; Single Ascending Dose </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to enroll 32 participants in Part A of our clinical trial, with the participants randomized in a 6:2 ratio into one of four cohorts
to receive a single dose of ACU193 or placebo as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 1: One IV dose of ACU193 (2 mg/kg) or placebo. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 2: One IV dose of ACU193 (10 mg/kg) or placebo. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 3: One IV dose of ACU193 (25 mg/kg) or placebo. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 4: One IV dose of ACU193 (60 mg/kg) or placebo. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The double-blind treatment period for Cohorts <FONT STYLE="white-space:nowrap">1-4</FONT> of Part A will be approximately 20 weeks and will
include ten visits (four inpatient and six outpatient). A sequential dosing scheme will be followed for each cohort in Part A. Dosing of Cohorts <FONT STYLE="white-space:nowrap">1-3</FONT> will begin at least one week after all participants in the
immediately preceding lower-dose cohort have received one administration of study drug and safety data have been reviewed by our internal blinded safety team. Dosing of Cohort 4 will begin at least one week after all participants in Cohort 3 have
received one administration of study drug and these safety data, along with Cohort 2 aggregate pharmacokinetic data, have been reviewed by our internal blinded safety team. An unblinded, independent Data Monitoring Committee, or DMC, will also
monitor the trial and can review safety data on an ad hoc basis if requested by the blinded study team. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Trial Design Part B &#150; Multiple Ascending
Dose </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to enroll 30 participants in Part B of our clinical trial, with the participants randomized in an 8:2 ratio into one
of three cohorts to receive a total of three doses of ACU193 or placebo as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 5: One IV dose of ACU193 (10 mg/kg) or placebo once every four weeks. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 6: One IV dose of ACU193 (60 mg/kg) or placebo once every four weeks. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 7: One IV dose of ACU193 (60 mg/kg) or placebo once every two weeks. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Participants in Cohorts 5 and 6 will be evaluated over approximately 35 weeks, consisting of a seven-week screening period followed by a <FONT
STYLE="white-space:nowrap">28-week,</FONT> double-blind treatment period. A <FONT STYLE="white-space:nowrap">follow-up</FONT> safety check will be performed approximately eight weeks after the final visit of the double-blind treatment period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Participants in Cohort 7 will be evaluated over approximately 31 weeks, consisting of a seven-week screening period, followed by a <FONT
STYLE="white-space:nowrap">24-week,</FONT> double-blind treatment period. A <FONT STYLE="white-space:nowrap">follow-up</FONT> safety check will be performed approximately eight weeks after the final visit of the double-blind treatment period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to maintain participant safety for Part B of the clinical trial, dosing of Cohort 5 will begin at least one week after all
participants in Cohort 2 of Part A have received one administration of ACU193 or placebo and the Cohort 2 safety data have been reviewed by our internal blinded safety team. For Cohort 6, dosing will begin at least one week after all participants in
Cohort 4 of Part A have received one administration of ACU193 or placebo and the Cohort 4 safety data have been reviewed by our internal blinded safety team. Dosing of Cohort 7 will begin after four or more participants in Cohort 6 have been
administered two doses of ACU193 or placebo and the Cohort 6 safety data, along with aggregated pharmacokinetic data from Cohort 4, have been reviewed by our internal blinded safety team. If a potential safety signal, an unexpected adverse reaction,
or higher than expected exposure occurs, our internal blinded safety team will notify the independent, unblinded DMC to review the safety and pharmacokinetic data and advise on dose escalation. Cohort 7 will allow for additional pharmacokinetic
modeling to more accurately determine the half-life of ACU193 if every <FONT STYLE="white-space:nowrap">two-week</FONT> dosing is necessary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Endpoints </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our goal for the Phase 1 trial is to establish clinical proof of mechanism of ACU193 in patients with early AD. The endpoints we will measure
as part of this trial include: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Primary Endpoint </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safety and immunogenicity, including assessment for ARIA; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Secondary Endpoints and Exploratory Objectives </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pharmacokinetics in plasma; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determination of CSF concentrations of ACU193; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluation of central target engagement as measured by levels of ACU193
A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O complex in CSF; </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluation of possible changes in concentration of biomarkers for AD in CSF or blood; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluation of possible changes in amyloid plaque load as determined by PET imaging; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluation of possible changes in cerebral blood flow as determined by MRI imaging, using Arterial Spin Labeling
(ASL) pulse sequence; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluation of possible changes in cognitive, functional, and behavioral measures using computerized testing and
standard clinical measures for AD. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to report proof of mechanism results by the fourth quarter of 2022, with
periodic updates including trial progress and cohort advancement. Safety will be evaluated periodically during the trial both by a blinded study team and an unblinded monitoring committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future Clinical Trials </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to
establishment of proof of mechanism of ACU193 and the safety and immunogenicity results of the Phase 1 clinical trial, we intend to advance ACU193 into later stage clinical trials. We plan to explore a proposed therapeutic dose of ACU193 in a future
Phase 2/3 clinical trial based on safety, pharmacokinetics and pharmacodynamics assessments of the various dosing cohorts in the Phase 1 trial. The Phase 2/3 trial is being designed as an adaptive trial, such that after a planned interim analysis of
clinical and biomarker changes, a decision could be made to increase the enrollment of the trial to be adequately powered as a Phase 3 pivotal trial, or to continue the trial as a Phase 2 clinical trial. The Phase 2/3 trial will utilize standard
cognitive measures that are widely employed in AD trials and most highly sensitive to changes in mild AD patients, including <FONT STYLE="white-space:nowrap">ADAS-COG</FONT> 13, <FONT STYLE="white-space:nowrap">CDR-sb,</FONT> ADCS-iADL, iADRS, MMSE,
and potentially others including computerized neuropsychological testing. Additionally, a number of biomarkers may be studied including blood flow as determined by ASL pulse sequence on MRI, plasma or CSF
<FONT STYLE="white-space:nowrap">p-tau,</FONT> amyloid PET scanning, and tau PET scanning. Selected endpoints will be used to inform the interim decision whether to expand the trial and whether to initiate a second Phase 3 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Combination Potential </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While ACU193, if
successful, will likely be a foundational treatment for people with early AD, it also could be used as part of a combination treatment regimen. The pathology of AD is complex, and many experts in the field expect that combination therapy using drugs
with different mechanisms of action, such as tau, immune modulation, glial cells such as microglia and astrocytes, and growth factors, will ultimately prove most successful, similar to cutting edge approaches used in oncology. In addition, because
symptomatic treatments, such as memantine and cholinesterase inhibitors, affect neurotransmitter systems rather than the underlying AD pathology, we believe that it is likely that they will be used together with disease-modifying treatments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not currently own or operate facilities for product manufacturing, storage and distribution, or testing. We contract with third parties
for the manufacture of ACU193. Because we rely on contract manufacturers, we employ personnel with extensive technical, manufacturing, analytical and quality experience. Our staff has strong project management discipline to oversee contract
manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Manufacturing
is subject to extensive regulation that imposes various procedural and documentation requirements and that governs record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, and more. Our systems and our
contractors are required to be in compliance with these regulations, and compliance is assessed regularly through monitoring of performance and a formal audit program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current supply chains for ACU193 involve several manufacturers that specialize in specific operations of the manufacturing process,
including raw materials manufacturing, drug substance manufacturing and drug product manufacturing. We currently operate under work order programs for ACU193 with master services agreements in place that include specific supply timelines, volume and
quality specifications. We believe our current manufacturers have the scale, the systems, and the experience to supply our currently planned clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We face competition from
several different institutions, including pharmaceutical and biotechnology companies, research institutions, governmental organizations and universities developing novel therapies for AD. We believe that the key factors affecting the clinical and
commercial success of ACU193 will include safety profile, efficacy, cost, method of administration, level of marketing activity, insurance reimbursement and intellectual property protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If approved, ACU193 will compete with therapies currently approved for the treatment of AD, which have primarily been developed to treat the
symptoms of AD rather than the underlying cause of the disease, such as memantine and cholinesterase inhibitors. ACU193 may also compete with one or more potentially disease-modifying therapeutics currently in development that target A<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> or amyloid plaques, the most advanced of which is Biogen Inc.&#146;s aducanumab, for which regulatory approval is pending in the United States, Europe and Japan. Other companies known to be developing
therapies with A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>/amyloid plaque-related targets include Alzheon, Inc., Alzinova AB, Chugai Pharmaceutical Co. Ltd., Cognition Therapeutics, Inc., Eisai Co., Ltd., Eli Lilly and Company, Grifols, S.A.,
KalGene Pharmaceuticals, Inc., Neurimmune AG, Novartis AG, ProMIS Neurosciences, Inc., Prothena Biosciences, Inc., Roche Holding AG (including Genentech, its wholly owned subsidiary) and Wren Therapeutics, Inc. Additionally, ACU193, if approved, may
also compete with other potential therapies intended to address underlying causes of AD that are being developed by several companies, including AbbVie Inc., AC Immune SA, Alector, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Athira Pharma,
Inc., Biohaven Pharmaceuticals, Inc., Cassava Sciences, Inc., Cortexyme, Inc., Denali Therapeutics, Inc., Johnson&nbsp;&amp; Johnson (including Janssen, its wholly-owned subsidiary) and Takeda Pharmaceutical Co. Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration Agreement with Merck </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
December 2003, we entered into an exclusive license and research and development collaboration agreement with Merck to research, discover and develop certain technology related to amyloid beta-derived diffusible ligands, or ADDL, which agreement was
amended and restated in October 2006.&nbsp;The agreement generally provided that, during the course of the collaboration, Merck would be responsible for the preclinical and clinical development and commercialization of any products covered by the
agreement and, in return, we were eligible to receive potential nonclinical, clinical and regulatory milestone payments and royalties on future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product sales.&nbsp;During the collaboration, Merck developed ACU193, an ADDL antibody, and intellectual property related to ACU193 was filed by Merck. In 2011, Merck elected to voluntarily
terminate the collaboration agreement.&nbsp;Pursuant to the surviving provisions of the agreement, effective upon termination of the collaboration, Merck granted us an exclusive, perpetual, irrevocable, royalty-free, worldwide license, with right to
sublicense, under Merck&#146;s interest in the patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> necessary for the research, development, manufacturing or commercialization of ADDL antibodies, ADDL antigens or products, including
ACU193.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
intellectual property is critical to our business and we strive to protect it, including by obtaining and maintaining patent protection in the United States and internationally for our product candidate. We also rely on the skills, knowledge and
experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is not patentable, we rely on
confidentiality agreements to protect our interests. We require our employees, consultants, scientific advisors and contractors to enter into confidentiality agreements prohibiting the disclosure of confidential information and requiring disclosure
and assignment to us of the ideas, developments, discoveries and inventions important to our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The main form of commercial
exclusivity for our product candidate, ACU193, is expected to come from biologic regulatory exclusivity. We expect that once approved by regulatory agencies, ACU193 will receive the benefit of 12 years of market exclusivity in the U.S. and 10 to 11
years of data and market exclusivity in Europe, in each case, against competitors seeking approval for a biosimilar product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have an
exclusive license grant from Merck to patents claiming the composition and method of use of our product candidate, ACU193. The license grant arose from our collaboration agreement with Merck to research, discover, and develop technology related to
ADDLs. During our collaboration, ACU193, an ADDL antibody, was developed and intellectual property was filed by Merck. In 2011, the collaboration agreement terminated and Merck exclusively licensed to Acumen, Merck&#146;s interest in patent rights
claiming ADDL antibodies, including ACU193, ADDL Antigens and/or Products to Acumen. In the nine years subsequent to the termination of the collaboration with Merck, Acumen has controlled and directed and continues to control and direct prosecution
of the licensed ACU193 patent portfolio. Acumen has also paid for and continues to pay all costs and fees associated with the prosecution and maintenance of the licensed ACU193 patent portfolio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of November&nbsp;6, 2020, Acumen licenses from Merck 1 issued U.S. patent, 16 issued foreign patents including issued patents in China,
Canada, Australia, Japan, France, Germany and the UK, and two pending foreign applications drawn to our product candidate, ACU193. These patents and patent applications, once issued, are projected to expire in July of 2031, without taking into
account any possible extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Throughout the development of our product candidate, we seek to identify additional means of obtaining patent protection that would
potentially enhance commercial success, including by protecting inventions related to additional methods of use, processes of making, formulation, and dosing regimens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term and Term Extensions </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The terms of individual patents are determined based primarily on the date of filing of the patent application or the date of patent issuance
and the legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the United States are granted a term of 20 years from the earliest effective filing date of <FONT
STYLE="white-space:nowrap">a&nbsp;non-provisional&nbsp;patent</FONT> application. In addition, in certain instances, the term of a U.S. patent can be extended to recapture a portion of the United States Patent and Trademark Office, or USPTO, delay
in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
review period. However, as to the FDA component, the restoration period cannot be longer than five years and the restoration period cannot extend the patent term beyond 14 years from FDA approval
for the product covered by that patent. In addition, only one patent applicable to an approved drug may receive the extension, and the extension applies only to coverage for the approved drug, methods for using it and methods of manufacturing it,
even if the claims cover other products or product candidate. Where one patent covers multiple products or product candidate, it may only receive an extension for one of the covered products; any extension related to a second product or product
candidate must be applied to a different patent. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date of
<FONT STYLE="white-space:nowrap">a&nbsp;non-provisional&nbsp;patent</FONT> application, such as a Patent Cooperation Treaty, or PCT, application. All taxes, annuities or maintenance fees for a patent, as required by the USPTO and various foreign
jurisdictions, must be timely paid in order for the patent to remain in force during this period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The actual protection afforded
by a patent may vary on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, from country to country, and can depend upon many factors, including the type of patent, the scope of its coverage,
the availability of regulatory-related extensions and the availability of legal remedies in a particular country and the validity and enforceability of the patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our patents and patent applications may be subject to procedural or legal challenges by others. We may be unable to obtain, maintain and
protect the intellectual property rights necessary to conduct our business, and we may be subject to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business. For more
information, see the section titled &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks <FONT
STYLE="white-space:nowrap">and&nbsp;Know-How</FONT> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the ongoing development and advancement of our products
and services in the United States and various international jurisdictions, we seek to create protection for our marks and enhance their value by pursuing trademarks and service marks where available and when appropriate. We rely <FONT
STYLE="white-space:nowrap">upon&nbsp;know-how&nbsp;and</FONT> continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by using confidentiality agreements with our
commercial partners, collaborators, employees and consultants, and invention assignment agreements with our employees and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment
agreements, to grant us ownership of technologies that are developed by our employees and through relationships with third parties. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade
secrets may otherwise become known or be independently discovered by competitors. To the extent that our contractors, commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us,
disputes may arise as to the rights in related or <FONT STYLE="white-space:nowrap">resulting&nbsp;know-how&nbsp;and</FONT> inventions. For more information, see the section titled &#147;Risk Factors&#151;Risks Related to Our Intellectual
Property.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among
other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring,
and post-approval reporting of biologics such as those we are developing. We, along with our third-party contractors, will be required to navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing
regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and
foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable regulatory requirements at any time during the product development process or
post-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval may subject an applicant to delays in development or approval, as well as administrative and judicial sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Biologics Regulation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the
United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Service Act, or PHSA, and other federal, state, local and foreign statutes and regulations. The process required
by the FDA before biologics may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#146;s Good
Laboratory Practice requirements, or GLPs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an investigational new drug application, or IND, which must become effective before
clinical trials may begin and must be updated annually and when certain changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an institutional review board, or IRB, or independent ethics committee at each clinical site before
the trial is commenced; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice, or
GCP, requirements and other clinical trial-related regulations to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation of and submission to the FDA of a biologics license application, or BLA, after completion of all
pivotal clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of user fees for FDA review of the BLA; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA Advisory Committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the
manufacturing facility or facilities at which the proposed product is produced to assess compliance with current Good Manufacturing Practices, or cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological
product&#146;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for
use in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical and Clinical Trials </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to beginning the first clinical trial with a product candidate in the United States, the product candidate must undergo rigorous
preclinical testing. Preclinical studies include laboratory evaluations of chemistry, formulation and stability, as well as <I>in vitro </I>and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The
conduct of preclinical studies is subject to federal and state regulations and requirements, including GLP requirements for safety and toxicology studies. In the United States, the results of the preclinical studies, together with manufacturing
information and analytical data must be submitted to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational new drug to humans. The central focus of an IND submission is on the general
investigational </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
plan and the protocol(s) for clinical studies. The IND also includes results of animal and <I>in vitro</I> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic
characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin.
The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or questions about the proposed clinical trial. In such a case,
the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a
clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of
qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among
other things, the objectives of the study, the dosing procedures, subject selection and exclusion criteria, and the parameters and criteria to be used in monitoring safety and effectiveness. A separate submission to the existing IND must be made for
each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical
trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While
clinical trials are ongoing, the FDA may impose a partial or complete clinical hold based on concerns for patient safety and/or noncompliance with regulatory requirements. This order issued by the FDA would cause the suspension of an ongoing study,
or part of an ongoing study, until all outstanding concerns have been adequately addressed, and the FDA has notified the company that investigations may proceed. Imposition of a clinical hold could cause significant delays or difficulties in
completing planned clinical studies in a timely manner. In addition, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that
the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for
whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no
demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. In the United States, information about applicable clinical trials, including clinical trials
results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Progress reports detailing
the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the
information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing suggest a significant risk for human participants exposed to the drug or biologic, or for any
clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction
as soon as possible but in no case later than seven calendar days after the sponsor&#146;s initial receipt of the information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For
purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1&#151;The investigational product is initially introduced into a limited population of healthy human
subjects or patients with the target disease or condition. These studies are designed to test the safety, dose response, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing
doses, and, if possible, to gain early evidence on effectiveness. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2&#151;The investigational product is administered to a limited patient population with a specified disease
or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger
and more expensive Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3&#151;The investigational product is administered to an expanded patient population to further evaluate
dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit
ratio of the investigational product and to provide an adequate basis for product approval. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more
information about the product. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 studies may also be made a condition to approval of the BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological
characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of
the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted
to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life and to identify appropriate storage conditions for the product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>BLA Submission and Review by the FDA </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product
development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include data available from preclinical and clinical studies,
including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from
company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by independent investigators. To support marketing approval, the data
submitted must be sufficient in quality and quantity to establish the safety, purity and potency of the investigational biologic, to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United
States. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before
the FDA accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional
information. Once a BLA has been accepted for filing, the FDA&#146;s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the
application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe,
pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#146;s continued safety, purity and potency. The FDA may also convene an advisory committee to provide clinical
insight on application review questions. An advisory committee is a panel of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what
conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA
will typically inspect one or more clinical sites to assure compliance with GCP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the FDA determines that the application,
manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its
drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will
describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required
inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional
information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or
efficacy of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such approval will be granted for particular indications and may
entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a
safety strategy implemented to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician
communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the
development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur
after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization, and may limit further
marketing of the product based on the results of these post-marketing studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expedited Development and Review Programs </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA offers a number of expedited development and review programs for qualifying product candidates. These programs include fast track
designation, breakthrough therapy designation, priority review, and accelerated approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fast track program is intended to expedite
or facilitate the process for reviewing new products that are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation
applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the applicable FDA review team during product development
and, once a BLA is submitted, the product candidate may be eligible for priority review. A fast track product may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule
for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy
designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or
biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track
program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers and
experienced review staff in a cross-disciplinary review, where appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any marketing application for a drug or biologic submitted to
the FDA for approval, including a product candidate with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority
review and accelerated approval. A product candidate is eligible for priority review if it is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant improvement in safety or effectiveness
compared to available alternatives for such disease or condition. For original BLAs, priority review designation means the FDA&#146;s goal is to take action on the marketing application within six months of the
<FONT STYLE="white-space:nowrap">60-day</FONT> filing date (as compared to ten months under standard review). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, product
candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably
likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit,
taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and
well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures
if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval
<FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial launch of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Fast track designation, breakthrough therapy designation, and priority review, accelerated approval do not change the standards for approval
but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period
for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Orphan Drug Designation and Exclusivity </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined
as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of
developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan
drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation subsequently receives the first FDA approval
for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same
biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown
that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a
different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA
application user fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than
the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above,
if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of
patients with the rare disease or condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-approval Requirements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Biologics are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to
record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and complying with advertising and promotion requirements, which include restrictions on promoting products for unapproved uses or patient
populations (known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe approved products for <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT>
uses, including not only by Company employees but also by agents of the Company or those speaking on the Company&#146;s behalf, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be
subject to significant liability. Promotional materials for approved biologics must be submitted to the FDA in conjunction with their first use or first publication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review
and approval. There also are continuing, annual program fees for any marketed products. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to
periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements up. Changes to the manufacturing process are strictly regulated, and, depending on the
significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements. Accordingly, manufacturers must continue to
expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program.
Other potential consequences include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or
other safety information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical holds on clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">and the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>United States Biosimilars and Exclusivity </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Patient
Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act, or BPCIA,
which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. The FDA has issued several guidance documents
outlining an approach to review and approval of biosimilars in the United States. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity,
and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to
produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been
previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
BPCIA, a reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and an application for a biosimilar product may not be submitted to the FDA until four years following the date that the
reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT
STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#146;s own preclinical
data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture,
it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the <FONT
STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the Patient Protection and Affordable Care Act, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent
litigation. As a result, the ultimate impact, implementation, and regulatory interpretation of the BPCIA remain subject to significant uncertainty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Healthcare Laws </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the
states and foreign jurisdictions in which they conduct their business and may constrain the financial arrangements and relationships through which we research, as well as, sell, market and distribute any products for which we obtain marketing
approval. Such laws include, without limitation, federal and state anti-kickback, fraud and abuse, false claims, data privacy and security and physician and other health care provider transparency laws and regulations. If our significant operations
are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, significant administrative, civil and criminal penalties, damages, fines,
disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Coverage and Reimbursement </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sales of any
product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of
reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT>
basis. These third-party payors are increasingly reducing reimbursements for medical products, drugs and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs,
including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with
existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the
product and also have a material adverse effect on sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Healthcare Reform </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each as
amended, collectively known as the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA contains a number of
provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. For example, the ACA: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%
of the average manufacturer price; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required collection of rebates for drugs paid by Medicaid managed care organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer
70&nbsp;percent <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for
the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposed a <FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or
importers who sell &#147;branded prescription drugs&#148; to specified federal government programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since its
enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on March&nbsp;2, 2020 the United States Supreme Court granted the petitions for writs of certiorari to review the U.S. Court of Appeals for the 5th Circuit ruling that the individual mandate was
unconstitutional and to determine the constitutionality of the ACA in its entirety. It is uncertain when the Supreme Court will rule on this case. Other legislative changes have been proposed and adopted since the ACA was enacted, including
aggregate reductions of Medicare payments to providers of 2% per year, which was temporarily suspended from May&nbsp;1, 2020 through March&nbsp;31, 2021 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and reduced payments to
several types of Medicare providers. Legislation is currently pending in Congress that would further extend the suspension through December&nbsp;31, 2021. Moreover, there has recently been heightened governmental scrutiny over the manner in which
manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries, proposed and enacted legislation and executive orders issued by the prior presidential administration designed to, among other things, bring
more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. It is also possible that additional governmental action is
taken in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our human capital objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new
employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of stock-based compensation awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, we had seven employees, including five in research and development and two in general and administrative functions.
We also utilize eight consultants, six in various roles related to research and development and two in general and administrative functions. We believe our employee relations are good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are not currently
subject to any material legal proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are currently located in Charlottesville, Virginia, where we lease 950 square feet of office space pursuant to a
lease agreement that expires in August 2021. We also lease 8,573 square feet of office space in Carmel, IN pursuant to a lease agreement that expires in August 2023. We believe that these facilities will be adequate for our near-term needs. If
required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
following table provides information regarding our current executive officers and directors, including their ages as of March&nbsp;31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Position(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel O&#146;Connell.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Siemers, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">66</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell Barton, M.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey L. Ives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">69</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Sevigny, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sean Stalfort</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Stoppel, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">35</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Zachary, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">38</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Daniel
O&#146;Connell</I></B> Mr.&nbsp;O&#146;Connell has served as our President and Chief Executive since December 2014. Mr.&nbsp;O&#146;Connell previously <FONT STYLE="white-space:nowrap">co-founded</FONT> and served as CEO of Functional NeuroModulation
Ltd., or FNM, a clinical-stage company developing deep brain stimulation therapies for Alzheimer&#146;s disease. Mr.&nbsp;O&#146;Connell is a founding member and former managing partner of NeuroVentures Capital, LLC, a firm he helped to invest in
emerging neurosciences companies. He earned a BA from Brown University and MBA from the University of Virginia. Our board of directors believes Mr.&nbsp;O&#146;Connell is qualified to serve as a director based on his experience in venture capital
and in the neurosciences. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Eric Siemers, M.D</I></B><B><I>.</I></B> Dr.&nbsp;Siemers has served as our Chief Medical Officer
since June 2018, prior to which, in April 2018, he began consulting for us. Prior to joining us, from November 1998 to December 2017, he served in various roles for Eli Lilly and Company, including most recently as Distinguished Medical Fellow, from
October 2014 to December 2017, and was responsible for several clinical trials for Alzheimer&#146;s disease compounds, including five Phase&nbsp;3 studies as well as Phase 1 and 2 studies. Prior to Eli Lilly, Dr.&nbsp;Siemers founded the Indiana
University Movement Disorder Clinic, where his research included Parkinson&#146;s and Huntington&#146;s disease. Dr.&nbsp;Siemers served on the NIA/Alzheimer&#146;s Association working group that proposed new research nomenclature for
Alzheimer&#146;s disease utilizing biomarkers and clinical symptoms. He was a founding member of the Alzheimer&#146;s Association Research Roundtable and is on the steering committee for the Alzheimer&#146;s Disease Neuroimaging Initiative.
Dr.&nbsp;Siemers earned his M.D. from the Indiana University School of Medicine with Highest Distinction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Russell Barton,
MS</I></B> Mr. Barton has served as our Chief Operating Officer since April 2019. Mr.&nbsp;Barton also serves as Director of Clinical Operations at AgeneBio, a role he has held since October 2018. From 1979 to 2017, he served in various roles for
Eli Lilly and Company, including as COO of the company&#146;s Global Alzheimer&#146;s Disease Platform Team for 10 years from 2007 to 2017. Mr. Barton was an active participant in the design and startup of the Global Alzheimer&#146;s Platform, which
was developed through a collaboration between the Global CEO initiative on Alzheimer&#146;s disease and the New York Academy of Sciences. Mr. Barton received a BS in chemistry from Illinois State University and an MS in chemistry from Purdue
University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Jeffrey L. Ives</I></B> Dr.&nbsp;Ives has served as a member of our board of directors since May 2014. Dr.&nbsp;Ives has served as a
director on the board of Cara Therapeutics since 2014. He currently also serves on the boards of several neurodegenerative disease companies including Pinteon Therapeutics, Orthogonal Neuroscience, and Astrocyte Pharmaceuticals. From 2008 until
2013, Dr.&nbsp;Ives served as the Chief Executive Officer of Satori Pharmaceuticals, Inc., a company focused on Alzheimer&#146;s disease. Prior to Satori, he served as senior vice president at Pfizer, leading the neurodegenerative diseases,
psychiatry and pain research areas. Dr.&nbsp;Ives received his doctorate and master&#146;s degrees from Yale University and received his BA from Colgate University. Our board of directors believes Dr.&nbsp;Ives is qualified to serve as a director
based on experience in neurodegenerative diseases, particularly AD. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Jeffrey Sevigny, M.D. </I></B>Dr. Sevigny has served as a
member of our board of directors since July 2019. Dr. Sevigny is the Chief Medical Officer of Prevail Therapeutics, where he has served in such capacity since March 2018. Prior to his tenure at Prevail, he served as Vice President and Global Head of
Translational Medicine Neuroscience at Roche from January 2016 to March 2018. Prior to Roche, he was Senior Director of Clinical Development at Biogen Inc., a multinational biotechnology company, from September 2010 to January 2016. Previously, he
served as Principal Medical Scientific Expert of Neuroscience at Novartis AG, a multinational pharmaceutical company, and as Associate Director of Neuroscience at Merck. Dr.&nbsp;Sevigny has also held academic appointments as Assistant Professor of
Neurology at Albert Einstein School of Medicine and Assistant Professor of Clinical Neurology at Columbia University College of Physicians and Surgeons. Dr.&nbsp;Sevigny received an M.D. from Tufts University School of Medicine and an A.B. in
biochemistry from Bowdoin College. He completed a neurology residency at the Neurological Institute of New York at Columbia University Medical Center and a fellowship in Aging &amp; Dementia and Neuro Epidemiology at Sergievsky Center at Columbia
University and Columbia University Mailman School of Public Health. Our board of directors believes Dr.&nbsp;Sevigny is qualified to serve as a director based on his over 15 years of experience in neurology, and specifically neurodegenerative
disorders.<B><I></I></B> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Sean Stalfort </I></B>Mr. Stalfort has served as a member of our board of directors since October
2018. Mr. Stalfort is President of PBM Capital Group, LLC, a private equity and venture capital investment firm in the business of investing in healthcare and life-science related companies, and has worked at PBM Capital since 2010. Mr. Stalfort is
a director of Verrica Pharmaceuticals, Inc., a biopharmaceutical company, and he previously served as a director of Dova Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining PBM Capital, he was the executive vice president for new
business development/M&amp;A for PBM Products. Mr. Stalfort is also a founding partner of Octagon Partners and Octagon Finance, historic tax credit real estate companies. Mr. Stalfort received a B.A. in business economics and political science from
Brown University. Our board of directors believes Mr. Stalfort is qualified to serve as a director based on his experience in venture capital, particularly related to healthcare. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Laura Stoppel, PhD </I></B>Dr.&nbsp;Stoppel has served as a member of our board of directors since November 2020. Dr.&nbsp;Stoppel
currently serves as a Principal on the Investment Team at RA Capital Management and has previously served in various roles at RA Capital since 2016. Dr.&nbsp;Stoppel serves on the board of directors for Artiva Biotherapeutics and Nimbus
Therapeutics. Dr.&nbsp;Stoppel holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Our board of directors believes Dr.&nbsp;Stoppel is qualified to serve as a director based on her experience in venture
capital and the neurosciences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Stephen Zachary, PhD </I></B>Dr.&nbsp;Zachary has served as a member of our board since October
2018. Dr.&nbsp;Zachary has served as a Partner and Portfolio Manager at Sands Capital since 2016 and serves on the boards of directors of DiCE Molecules, Selux Diagnostics, and Day Zero Diagnostics. Dr.&nbsp;Zachary received his PhD in Neuroscience
from Johns Hopkins School of Medicine, and received a B.A. in Philosophy from Washington&nbsp;&amp; Lee University. He is a member of the Kauffman Fellowship (Class 23). Our board of directors believes Dr.&nbsp;Zachary is qualified to serve as a
director based on his experience in venture capital and the neurosciences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our board of directors, which currently consists of six members. Our directors
were elected to, and currently serve on, the board pursuant to a voting agreement among us and certain of our stockholders and voting rights granted by our current amended and restated certificate of incorporation. The voting agreement will
terminate upon the closing of this offering, after which there will be no further contractual obligations regarding the election of our directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with our amended and restated certificate of incorporation that will be in effect upon the closing of this offering, our board
of directors will be divided into three classes, each of which will consist, as nearly as possible, of <FONT STYLE="white-space:nowrap">one-third</FONT> of the total number of directors constituting our entire board and which will serve staggered
three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will
be divided among the three classes as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;I, which will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our first annual meeting of stockholders to be held after the
closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;II, which will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our second annual meeting of stockholders to be held after the
closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;III, which will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our third annual meeting of stockholders to be held after the
closing of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws, which will become effective upon the closing of this
offering, will provide that the authorized number of directors may be changed only by resolution approved by a majority of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed
among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered three-year terms may
delay or prevent a change of our management or a change of control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Applicable Nasdaq rules, or the Nasdaq Listing Rules, require a majority of a listed company&#146;s board of directors to be comprised of
independent directors within one year of listing. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and corporate governance committees be
independent and that audit committee members also satisfy independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act of 1934, as amended, or the Exchange Act. The Nasdaq independence definition
includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees, and that neither the director nor any of his or her family members has engaged in various types of business
dealings with us. In addition, under applicable Nasdaq rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed company&#146;s board of directors, that person does not have a relationship that would
interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has
determined that all of our directors other than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of
our&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; directors, are &#147;independent directors&#148; as defined under applicable Nasdaq rules. In making such determination, our board of directors considered the current and
prior relationships that each such director has with our company and all other facts and circumstances that our board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by
each director and the transactions described in the section titled &#147;Certain Relationships and Related Party Transactions.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">One
of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through the board
of directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing
strategic risk exposure. Following the completion of this offering, we intend for our audit committee to have the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control
these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee will also monitor compliance with legal and regulatory requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors
has established an audit committee, compensation committee and a nominating and corporate governance committee, each of which operate pursuant to a committee charter. Our board of directors may establish other committees to facilitate the management
of our business. The composition and functions of each committee are described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our audit committee will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serving as chair of the audit committee. Our board of directors has determined that each of these individuals meets the independence requirements of Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, or the Exchange Act, and the applicable listing standards of Nasdaq. Each member of our audit committee can read and understand fundamental financial statements in
accordance with Nasdaq audit committee requirements. Our board of directors has also determined that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; qualifies as an audit committee financial expert within the meaning of SEC
regulations and meets the financial sophistication requirements of the Nasdaq Listing Rules. In arriving at these determinations, the board has examined each audit committee member&#146;s scope of experience and the nature of their prior and/or
current employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The functions of this committee include, among other things: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our board of directors oversee our corporate accounting and financial reporting processes;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as
the independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and reviewing a report by the independent registered public accounting firm at least annually that
describes our internal quality control procedures, any material issues with such procedures and any steps taken to deal with such issues when required by applicable law; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the composition and functioning of our audit committee will comply with all applicable SEC and Nasdaq rules and regulations.
We intend to comply with future requirements to the extent they become applicable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our compensation committee will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serving as chair of the compensation committee. Each of these individuals is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined in Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. Our board of directors has determined that each of these individuals is &#145;&#145;independent&#146;&#146; as defined under the applicable listing standards of Nasdaq,
including the standards specific to members of a compensation committee. The functions of this committee include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full board of
directors regarding) our overall compensation strategy and policies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations to the full board of directors regarding the compensation and other terms of employment of
our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full board of directors regarding performance goals and objectives
relevant to the compensation of our executive officers and assessing their performance against these goals and objectives; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors
regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating risks associated with our compensation policies and practices and assessing whether risks arising from
our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full board of directors regarding the type and amount of compensation
to be paid or awarded to our <FONT STYLE="white-space:nowrap">non-employee</FONT> board members; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies with respect to votes by our stockholders to approve executive compensation to the extent
required by Section&nbsp;14A of the Exchange Act and, if applicable, determining our recommendations regarding the frequency of advisory votes on executive compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as
required by Section&nbsp;10C of the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies with respect to equity compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our
compensation policy and strategy in achieving expected benefits to us; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full board of directors regarding the terms of any employment
agreements, severance arrangements, change in control protections and any other compensatory arrangements for our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and approving our disclosures under the caption &#147;Compensation Discussion and
Analysis&#148; in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating on an annual basis the performance of the compensation committee and the compensation
committee charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the composition and functioning of our compensation committee will comply with all
applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our nominating and corporate governance committee will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serving as chair of the nominating and corporate governance committee. Our board of directors has
determined that each of these individuals is &#145;&#145;independent&#146;&#146; as defined under the applicable listing standards of Nasdaq and SEC rules and regulations. The functions of this committee include, among other things: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, reviewing and evaluating candidates to serve on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining the minimum qualifications for service on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating director performance on the board and applicable committees of the board and determining whether
continued service on our board is appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating, nominating and recommending individuals for membership on our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating nominations by stockholders of candidates for election to our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and assessing the independence of members of our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing a set of corporate governance policies and principles and recommending to our board of directors any
changes to such policies and principles; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the board of directors with respect to management succession planning;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering questions of possible conflicts of interest of directors as such questions arise; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating on an annual basis the performance of the nominating and corporate governance committee
and the nominating and corporate governance committee charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the composition and functioning of our
nominating and corporate governance committee will comply with all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Effective upon the closing of this offering, we will adopt a Code of Business Conduct and Ethics, or the Code of Conduct, applicable to all of
our employees, executive officers and directors. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. Following the closing of this
offering, the full text of the Code of Conduct will be available on our website at http://www.acumenpharm.com/. We intend to post on our website all disclosures that are required by law or the Nasdaq Listing Rules concerning any amendments to, or
waivers from, any provision of the Code of Conduct. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus. We have included our website in this prospectus solely as an inactive
textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not currently have a formal director compensation policy. We intend to adopt a <FONT STYLE="white-space:nowrap">non-employee</FONT>
director compensation policy, pursuant to which our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will be eligible to receive compensation for service on our board of directors and committees of our board of directors, to be
effective following the completion of this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year ended December 31, 2020, we paid to each of Drs.&nbsp;Ives,
Sevigny and Krafft, each a non-employee director, an annual cash retainer of $42,000 for serving on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Jeffrey Sevigny, a current member of our board of directors, provided advisory services to our company during 2020 pursuant to an
Advisory Board Consulting Agreement with us dated February&nbsp;20, 2019. During the year ended December 31, 2020, we did not pay fees to Dr.&nbsp;Sevigny for his advisory services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr. Grant Krafft, who resigned from our board of directors in November 2020, provided consulting services to our company during 2020 pursuant
to a Consulting Agreement with us dated February 27, 2019 and pursuant to an Amended and Restated Consulting Agreement with us dated December 1, 2020. During the year ended December&nbsp;31, 2020, we paid Dr.&nbsp;Krafft $30,000 for his consulting
services. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Director Compensation Table </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the compensation earned for service on our board of directors in 2020 by our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. Daniel O&#146;Connell, our Chief Executive Officer, is also a member of our board of directors but did not receive any additional compensation for service as a director. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name (3)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fees<BR>Earned&nbsp;or<BR>Paid&nbsp;in&nbsp;Cash</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey L. Ives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Sevigny, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sean Stalfort</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Stoppel, PhD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Zachary, PhD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant Krafft, PhD<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph Andrasko<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr. Krafft resigned from our board of directors in November 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Andrasko resigned from our board of directors in November 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No stock options were granted to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during
2020. The table below shows the aggregate number of option awards outstanding for each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as of December&nbsp;31, 2020: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Outstanding<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey L. Ives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,999</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Sevigny, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sean Stalfort</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Stoppel, PhD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Zachary, PhD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This section describes the material elements of compensation awarded to, earned by or paid to each of our named executive officers in 2020. We
are an &#147;emerging growth company,&#148; within the meaning of the Jumpstart Our Business Startups Act of 2012, as amended, or JOBS Act, and have elected to comply with the reduced compensation disclosure requirements available to emerging growth
companies under the JOBS Act. Our named executive officers for 2020 were Daniel O&#146;Connell, Eric Siemers, M.D. and Russell Barton, M.S. This section also provides qualitative information regarding the manner and context in which compensation is
awarded to and earned by our named executive officers and is intended to place in perspective the data presented in the tables and narrative that follow. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
following table sets forth information regarding compensation awarded to, earned by and paid to our named executive officers with respect to the year ended December&nbsp;31, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Salary<BR>($)(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bonus</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>($)(2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel O&#146;Connell&nbsp;(3)&nbsp;<BR><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Siemers, M.D. <BR><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell Barton, MS <BR><I>Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of our named executive officers served as a consultant to the company prior to January&nbsp;1, 2021.
Amounts included in the &#147;Salary&#148; column represent consulting fees paid to each named executive officer for services rendered to us during 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects annual discretionary bonuses received in respect of 2020 services. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;O&#146;Connell is also a member of our Board, but he did not receive any additional compensation in
his capacity as a director in 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding outstanding equity awards held by our named executive officers as of December&nbsp;31,
2020. All awards were granted pursuant to the Prior Plan. See &#147;&#151;Equity Incentive Plans&#151;Prior Plan&#148; below for additional information. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Option Awards(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options(#)<BR>Exercisable</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options(#)<BR>Unexercisable</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options(#)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option<BR>Exercise<BR>Price($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option<BR>Expiration<BR>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel O&#146;Connell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/14/2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/14/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/17/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/17/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/27/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/27/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,787</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/1/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Siemers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,018</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/1/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell Barton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,953</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/1/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All option awards listed in this table were granted pursuant to our Prior Plan, the terms of which are
described below under &#147;&#151;Equity Incentive Plans&#151;Prior Plan&#148;. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying this option vest in equal monthly installments over a period of 36 months from the date
of grant, subject to the named executive officer&#146;s continuous service through each vesting date. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with our Named Executive Officers and Potential Payments upon Termination of Employment </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with each of our named executive officers. The agreements generally provide for employment without
any specific term and set forth the named executive officer&#146;s base salary, bonus potential, eligibility for employee benefits and severance benefits upon a qualifying termination of employment, subject to certain confidentiality, <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> provisions. Any potential payments and benefits due upon a qualifying termination of employment or a change in control are further
described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Daniel O&#146;Connell </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Executive Employment Agreement </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;1, 2021, we entered into an executive employment agreement with Mr.&nbsp;O&#146;Connell, pursuant to which Mr.&nbsp;O&#146;Connell serves as our President and Chief Executive Officer and as an employee
<FONT STYLE="white-space:nowrap">at-will.</FONT> Under his executive employment agreement, Mr.&nbsp;O&#146;Connell is entitled to an annual base salary of $512,000, which base salary will be reviewed and may be adjusted by the board of directors on
an annual basis. Additionally, Mr.&nbsp;O&#146;Connell is eligible to receive an annual performance bonus with a target equal to 50% of his then-current base salary, contingent upon satisfaction of individual and company performance goals. In 2020,
we paid Mr.&nbsp;O&#146;Connell an annual performance bonus of $96,000 based upon the achievement of 2020 individual and company performance milestones as determined by our board of directors. As contemplated by his executive employment agreement,
on January&nbsp;4, 2021, we granted to Mr.&nbsp;O&#146;Connell an option to purchase 1,767,656 shares of our common stock pursuant to our Prior Plan at an exercise price of $0.80 per share, which grant will vest as to 25% of the shares on the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the grant, with the remainder vesting monthly over the following 36 months, subject to Mr.&nbsp;O&#146;Connell&#146;s continuous service through such vesting dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under Mr.&nbsp;O&#146;Connell&#146;s executive employment agreement, if he resigns for &#147;good reason&#148; or we terminate
Mr.&nbsp;O&#146;Connell&#146;s employment without &#147;cause&#148; not in connection with a change in control (as defined in the executive employment agreement, and excluding a termination on account of Mr.&nbsp;O&#146;Connell&#146;s death or
disability), Mr.&nbsp;O&#146;Connell shall be eligible to receive the following severance benefits: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an amount equal to 12 months of his annual base salary; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment for health premiums until the earlier of (i) 12 months; (ii)&nbsp;the date he becomes eligible for
substantially equivalent health benefits; or (iii)&nbsp;the date he ceases to be eligible for COBRA continuation coverage at the level existing on the termination date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a condition to receiving the foregoing severance benefits, Mr.&nbsp;O&#146;Connell must sign and not revoke a general release contained in
a separation agreement in the form presented by us, return all company property and confidential information in his possession, comply with his post-termination obligations, and resign from any positions held with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amended and Restated Consulting Agreement </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2018, we entered into an amended and restated consulting agreement with Fastnet BioVentures, LLC, pursuant to which
Mr.&nbsp;O&#146;Connell, as sole member of Fastnet BioVentures, LLC, agreed to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
serve as our President and Chief Executive Officer. Pursuant to the amended and restated consulting agreement, Mr.&nbsp;O&#146;Connell was responsible for leading the planning, development and
execution of our growth and development efforts, as described in the agreement. The amended and restated consulting agreement had a term continuing through December&nbsp;31, 2021 and was terminated early in accordance with its terms upon execution
of Mr.&nbsp;O&#146;Connell&#146;s executive employment agreement in January 2021. Under the amended and restated consulting agreement, Mr.&nbsp;O&#146;Connell was entitled to receive compensation including a fee of $20,000 per month. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eric Siemers </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Executive Employment Agreement
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2021, we entered into an executive employment agreement with Dr.&nbsp;Siemers, pursuant to which Dr.&nbsp;Siemers
serves as our Chief Medical Officer and as an employee <FONT STYLE="white-space:nowrap">at-will.</FONT> Under his executive employment agreement, Dr.&nbsp;Siemers is entitled to an annual base salary of $332,000, which base salary will be reviewed
and may be adjusted by the board of directors on an annual basis. Additionally, Dr.&nbsp;Siemers is eligible to receive an annual performance bonus with a target equal to 40% of his then-current base salary, contingent upon satisfaction of
individual and company performance goals. In 2020, we paid Dr.&nbsp;Siemers an annual performance bonus of $57,600 based upon the achievement of 2020 individual and company performance milestones as determined by our board of directors. As
contemplated by his executive employment agreement, on January&nbsp;4, 2021, we granted to Dr.&nbsp;Siemers an option to purchase 463,374 shares of our common stock pursuant to our Prior Plan at an exercise price of $0.80 per share, which grant will
vest as to 25% of the shares on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the grant, with the remainder vesting monthly over the following 36 months, subject to Dr.&nbsp;Siemers&#146; continuous service through such vesting
dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under Dr.&nbsp;Siemers&#146; executive employment agreement, if he resigns for &#147;good reason&#148; or we terminate
Dr.&nbsp;Siemers&#146; employment without &#147;cause&#148; not in connection with a change in control (as defined in the executive employment agreement, and excluding a termination on account of Dr.&nbsp;Siemers&#146; death or disability),
Dr.&nbsp;Siemers&#146; shall be eligible to receive the following severance benefits: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an amount equal to six months of his annual base salary; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment for health premiums until the earlier of (i) 12 months; (ii)&nbsp;the date he becomes eligible for
substantially equivalent health benefits; or (iii)&nbsp;the date he ceases to be eligible for COBRA continuation coverage at the level existing on the termination date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a condition to receiving the foregoing severance benefits, Dr.&nbsp;Siemers must sign and not revoke a general release contained in a
separation agreement in the form presented by us, return all company property and confidential information in his possession, comply with his post-termination obligations, and resign from any positions held with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amended and Restated Consulting Agreement </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;1, 2019, we entered into an amended and restated consulting agreement with Siemers Integration LLC, pursuant to which
Dr.&nbsp;Siemers, as President of Siemers Integration LLC, agreed to serve as our lead clinical development consultant with the title of Chief Medical Officer and to provide additional consulting services as described in the amended and restated
consulting agreement. The amended and restated consulting agreement had a term of 36&nbsp;months and was terminated early in accordance with its terms upon execution of Dr.&nbsp;Siemers&#146; executive employment agreement in January 2021. Under the
amended and restated consulting agreement, Dr.&nbsp;Siemers was entitled to receive compensation including a fee of $15,000 per month and an option to purchase 8,350,000&nbsp;shares of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Russell Barton </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Executive Employment Agreement </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;1, 2021, we entered into an executive employment agreement with Mr.&nbsp;Barton, pursuant to which Mr.&nbsp;Barton serves as our Chief Operating Officer and as an employee <FONT STYLE="white-space:nowrap">at-will.</FONT> Under his
executive employment agreement, Mr.&nbsp;Barton is entitled to an annual base salary of $260,000, which base salary will be reviewed and may be adjusted by the board of directors on an annual basis. Additionally, Mr.&nbsp;Barton is eligible to
receive an annual performance bonus with a target equal to 40% of his then-current base salary, contingent upon satisfaction of individual and company performance goals. In 2020, we paid Mr.&nbsp;Barton an annual performance bonus of $55,680 based
upon the achievement of 2020 individual and company performance milestones as determined by our board of directors. As contemplated by his executive employment agreement, on January&nbsp;4, 2021, we granted at an exercise price of $0.80 per share to
Mr.&nbsp;Barton an option to purchase 425,305 shares of our common stock in pursuant to our Prior Plan, which grant will vest as to 25% of the shares on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the grant, with the
remainder vesting monthly over the following 36 months, subject to Mr.&nbsp;Barton&#146;s continuous service through such vesting dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under Mr.&nbsp;Barton&#146;s executive employment agreement, if he resigns for &#147;good reason&#148; or we terminate Mr.&nbsp;Barton&#146;s
employment without &#147;cause&#148; not in connection with a change in control (as defined in the executive employment agreement, and excluding a termination on account of Mr.&nbsp;Barton&#146;s death or disability), Mr.&nbsp;Barton shall be
eligible to receive the following severance benefits: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an amount equal to six months of his annual base salary; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment for health premiums until the earlier of (i) 12 months; (ii)&nbsp;the date he becomes eligible for
substantially equivalent health benefits; or (iii)&nbsp;the date he ceases to be eligible for COBRA continuation coverage at the level existing on the termination date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a condition to receiving the foregoing severance benefits, Mr.&nbsp;Barton must sign and not revoke a general release contained in a
separation agreement in the form presented by us, return all company property and confidential information in his possession, comply with his post-termination obligations, and resign from any positions held with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Consulting Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On April 1, 2019, we entered into an amended and restated consulting agreement with Pharmasagacity Consulting, LLC, pursuant to which Mr.
Barton, as President of Pharmasagacity Consulting, LLC, agreed to serve as our IND Team Leader and Head of Clinical Operations to provide project management services as described in the amended and restated consulting agreement. The amended and
restated consulting agreement had a term of 24 months and was terminated early in accordance with its terms upon execution of Mr. Barton&#146;s executive employment agreement in January 2021. Under the amended and restated consulting agreement,
Mr.&nbsp;Barton was entitled to receive compensation including a fee of $14,000 per month and an option to purchase 2,075,000 shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>2021
Equity Incentive Plan </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted our 2021 Plan in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2021 and our stockholders approved our 2021 Plan in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021. Our 2021 Plan provides for the grant of incentive stock options (ISOs) to employees, including employees of any parent or
subsidiary, and for the grant of nonstatutory stock options (NSOs) stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other forms of stock awards to employees, directors, and consultants, including employees and consultants of our affiliates. Our 2021 Plan is a successor to and continuation of our Prior Plan,
which is described below. The 2021 Plan will become effective immediately prior to and contingent upon the execution of the underwriting agreement related to this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares.</I> Initially, the maximum number of shares of our common stock that may be issued under our 2021 Plan after it becomes
effective will not exceed &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares, which is the sum of (1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new shares, plus (2)&nbsp;the number of
shares that remain available for issuance under our Prior Plan at the time our 2021 Plan becomes effective, plus (3)&nbsp;any shares subject to outstanding stock options or other stock awards that were granted under our Prior Plan that, on or after
the 2021 Plan becomes effective, terminate or expire prior to exercise or settlement; are settled in cash; are forfeited or repurchased because of the failure to vest; or are reacquired or withheld to satisfy a tax withholding obligation or the
purchase or exercise price in accordance with the terms of the Prior Plan. In addition, the number of shares of our common stock reserved for issuance under our 2021 Plan will automatically increase on January&nbsp;1 of each calendar year, starting
on January&nbsp;1, 2022 (assuming the 2021 Plan becomes effective in 2021) through January&nbsp;1, 2031, in an amount equal to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common
stock outstanding on December&nbsp;31 of the fiscal year before the date of each automatic increase, or a lesser number of shares determined by our board of directors prior to the applicable January 1. The maximum number of shares of our common
stock that may be issued upon the exercise of incentive stock options under our 2021 Plan is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Shares subject to stock awards granted under our 2021 Plan that expire or terminate without being exercised in full, or that are paid out in
cash rather than in shares, do not reduce the number of shares available for issuance under our 2021 Plan. Additionally, shares become available for future grant under our 2021 Plan if they were issued under stock awards under our 2021 Plan if we
repurchase them or they are forfeited. This includes shares used to pay the exercise price of a stock award or to satisfy the tax withholding obligations related to a stock award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration.</I> Our board of directors, or a duly authorized committee of our board of directors, will administer our 2021 Plan.
Our board of directors has delegated concurrent authority to administer our 2021 Plan to the compensation committee. We refer to the board of directors, or the applicable committee with the power to administer our 2021 Plan, as the plan
administrator. Our plan administrator may also delegate to one or more of our officers the authority to (1)&nbsp;designate employees (other than officers) to receive specified stock awards and (2)&nbsp;determine the number of shares subject to such
stock awards. Under our 2021 Plan, our board of directors has the authority to determine award recipients, grant dates, the numbers and types of stock awards to be granted, the applicable fair market value, and the provisions of each stock award,
including the period of exercisability and the vesting schedule applicable to a stock award. The plan administrator has the power to modify outstanding awards under our 2021 Plan. Subject to the terms of our 2021 Plan, the plan administrator has the
authority to reprice any outstanding stock award, cancel and <FONT STYLE="white-space:nowrap">re-grant</FONT> any outstanding stock award in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a
repricing under generally accepted accounting principles, with the consent of any adversely affected participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Stock Options.</I>
ISOs and NSOs are granted under stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2021 Plan, provided that the exercise price of
a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2021 Plan vest at the rate specified in the stock option agreement as determined by the plan
administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Tax Limitations on ISOs.</I> The aggregate fair market value, determined at the time of grant, of our common stock with
respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO
may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affiliates unless (1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and (2)&nbsp;the term of the ISO does not
exceed five years from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Unit Awards</I>. Restricted stock units are granted under restricted stock
unit award agreements adopted by the plan administrator. Restricted stock units may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted
stock unit may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit agreement. Additionally, dividend
equivalents may be credited in respect of shares covered by a restricted stock unit. Except as otherwise provided in the applicable award agreement or other written agreement between us and the participant, restricted stock units that have not
vested will be forfeited once the participant&#146;s continuous service ends for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards</I>. Restricted
stock awards are granted under restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, services to us, or any other form of legal
consideration that may be acceptable to our board of directors and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a
participant&#146;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture
condition or a repurchase right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>. Stock appreciation rights are granted under stock appreciation grant
agreements adopted by the plan administrator. The plan administrator determines the purchase price or strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the date of
grant. A stock appreciation right granted under the 2021 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Performance Awards</I>. The 2021 Plan permits the grant of performance-based stock and cash awards. The plan administrator may structure
awards so that the shares of our stock, cash, or other property will be issued or paid only following the achievement of certain <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance period. The
performance criteria that will be used to establish such performance goals may be based on any measure of performance selected by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The performance goals may be based on a company-wide basis, with respect to one or more business units, divisions, affiliates, or business
segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (i)&nbsp;in the award agreement at the time the award is granted
or (ii)&nbsp;in such other document setting forth the performance goals at the time the goals are established, we will appropriately make adjustments in the method of calculating the attainment of performance goals as follows: (1)&nbsp;to exclude
restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to
corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of
acquisitions or joint ventures; (7)&nbsp;to assume that any portion of our business which is divested achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (8)&nbsp;to exclude the
effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or
exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans;
(10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (11)&nbsp;to exclude the goodwill and intangible asset impairment
charges that are required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be recorded under generally accepted accounting principles. In addition, we retain the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of the goals.
The performance goals may differ from participant to participant and from award to award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Other Stock Awards</I>. The plan
administrator may grant other awards based in whole or in part by reference to our common stock. The plan administrator will set the number of shares under the stock award (or cash equivalent) and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit</I>. The aggregate value of all compensation granted or
paid to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any calendar year, including stock awards granted and cash fees paid by us to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director, will not
exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in total value, or in the event such <FONT STYLE="white-space:nowrap">non-employee</FONT> director is first appointed or elected to the board during such annual period,
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in total value (in each case, calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting purposes). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. In the event there is a specified type of change in our capital structure, such as a stock split, reverse
stock split, or recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and maximum number of shares reserved for issuance under the 2021 Plan, (2)&nbsp;the class and maximum number of shares by which the share reserve may
increase automatically each year, (3)&nbsp;the class and maximum number of shares that may be issued upon the exercise of incentive stock options, and (4)&nbsp;the class and number of shares and exercise price, strike price, or purchase price, if
applicable, of all outstanding stock awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. The following applies to stock awards under the 2021 Plan in
the event of a corporate transaction, unless otherwise provided in a participant&#146;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the plan administrator at the time of
grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction, any stock awards outstanding under the 2021 Plan may be assumed, continued or substituted
for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent company). If the surviving or acquiring
corporation (or its parent company) does not assume, continue or substitute for such stock awards, then with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to the effective time of
the transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full to a date prior to the effective time of the transaction (contingent upon the effectiveness of the
transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent
upon the effectiveness of the transaction). With respect to performance awards with multiple vesting levels depending on performance level, unless otherwise provided by an award agreement or by the administrator, the award will accelerate at 100% of
target. If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then with respect to any such stock awards that are held by persons other than current participants, such awards
will terminate if not exercised (if applicable) prior to the effective time of the transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised
notwithstanding the transaction. The plan administrator is not obligated to treat all stock awards or portions of stock awards in the same manner and is not obligated to take the same actions with respect to all participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event a stock award will terminate if not exercised prior to the effective time of a corporate transaction, the plan administrator may
provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (1)&nbsp;the value of the property the participant would have received
upon the exercise of the stock award over (2)&nbsp;any exercise price payable by such holder in connection with such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under our 2021 Plan, a corporate transaction is defined to include the consummation of:
(1)&nbsp;a sale of all or substantially all of our assets, (2)&nbsp;the sale or disposition of at least 50% of our outstanding securities, (3)&nbsp;a merger or consolidation where we do not survive the transaction, and (4)&nbsp;a merger or
consolidation where we do survive the transaction but the shares of our common stock outstanding before such transaction are converted or exchanged into other property by virtue of the transaction, unless otherwise provided in an award agreement or
other written agreement between us and the award holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Change in Control</I>. Awards granted under the 2021 Plan may be subject to
acceleration of vesting and exercisability upon or after a change in control (as defined in the 2021 Plan) as may be provided in the applicable stock award agreement or in any other written agreement between us or any affiliate and the participant,
but in the absence of such provision, no such acceleration will automatically occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the 2021 Plan, a change in control is defined
to include (1)&nbsp;the acquisition by any person or company of more than 50% of the combined voting power of our then outstanding stock; (2)&nbsp;a consummated merger, consolidation or similar transaction in which our stockholders immediately
before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity); (3) the approval by the stockholders or the board of directors of a plan of
complete dissolution or liquidation of the company, or the occurrence of a complete dissolution or liquidation of the company, except for a liquidation into a parent corporation; (4)&nbsp;a consummated sale, lease, exclusive license or other
disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders; and (5)&nbsp;an unapproved change in the majority of the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. A participant may not transfer stock awards under our 2021 Plan other than by will, the laws of descent and
distribution, or as otherwise provided under our 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment or Termination</I>. Our board of directors has the
authority to amend, suspend, or terminate our 2021 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the
approval of our stockholders. No incentive stock options may be granted after the tenth anniversary of the date our board of directors adopted our 2021 Plan. No stock awards may be granted under our 2021 Plan while it is suspended or after it is
terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Stock Performance Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Amended and Restated Stock Performance Plan (the Prior Plan) was originally adopted by our board of directors and approved by our
stockholders in April&nbsp;8, 2013, and most recently amended and approved by our board of directors and our stockholders on November 20, 2020. The Prior Plan provides for the grant of ISOs, NSOs, restricted stock awards, restricted stock units,
stock appreciation rights, performance share awards and other stock-based awards. Our employees, officers, directors, consultants and advisors are eligible to receive awards under the Prior Plan; however, ISOs may only be granted to our employees.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Stock Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;As of <U></U>December&nbsp;31, 2020, there were <U></U>1,492,303&nbsp;shares of common stock
issuable upon the exercise of stock options outstanding under the Prior Plan at a weighted-average exercise price of $0.76 per share, options to purchase 9,463&nbsp;shares of our common stock had been exercised and 4,688,586&nbsp;shares of common
stock were available for future issuance under the Prior Plan. On and after the effective date of the 2021 Plan described above, we will grant no further stock options or other awards under the Prior Plan. However, any shares of common stock subject
to awards under our Prior Plan that expire, terminate, or otherwise are surrendered or canceled without being fully exercised, are forfeited or results in any common stock not being issued will become available for issuance under our 2021 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. Our board of directors, or a committee appointed by our board, administers the Prior Plan and, subject to any
limitations set forth in the Prior Plan, will select the recipients of awards, determine the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of shares of common stock to be subject to such stock awards and specify the other terms and conditions, including the exercise price or purchase price and vesting schedule, applicable to
such stock awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Share Reserve</I>. The Prior Plan provides that a maximum of 6,227,011&nbsp;shares of our common stock are
authorized for issuance under the plan. Our board of directors may amend, suspend, or terminate the Prior Plan at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If an award
under the Prior expires or becomes unexercisable without having been exercised in full, or is surrendered pursuant to an option exchange program, the unpurchased shares which were subject thereto shall become available for future grant or sale under
the Prior Plan. Shares of our common stock that have actually been issued under the Prior Plan, shall not be returned to the Prior Plan, except that if shares of restricted stock are repurchased at their original purchase price, such shares of our
common stock shall become available for future grant under the Plan. Upon closing of this offering, any shares that would otherwise be returned to the Prior Plan will instead be added to the shares of common stock available for issuance under the
2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Options</I>. The exercise price per share of ISOs and NSOs granted under our Prior Plan cannot be less than 100% of the
fair market value per share of our common stock on the grant date. Subject to the provisions of our Prior Plan, our board of directors determines the other terms of options, including any vesting and exercisability requirements, the method of
payment of the option exercise price, the option expiration date, and the period following termination of service during which options may remain exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. Upon the occurrence of any stock split, reverse stock split, stock dividend, combination or
reclassification of shares, or any other increase or decrease in the number of issued shares of our common stock effected without receipt of consideration by us, the number of shares covered by an award, the number of shares authorized for issuance
under the Prior Plan as well as the price per share of our common stock subject to an award shall be proportionately adjusted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Change
in Control</I>. In the event of a change in control, all unvested awards shall become immediately vested unless otherwise provided in an award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. A participant generally may not transfer stock awards under the Prior Plan other than by will, the laws of descent and
distribution, except as our board of directors may otherwise determine or provide in the award agreement or as otherwise provided under the Prior Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination</I>. Our board of directors has the authority to amend, suspend or terminate the Prior Plan. No amendment,
alteration, suspension or termination of the Prior Plan shall impair the rights of any participant, unless mutually agreed otherwise between the participant and the board in writing. Unless terminated sooner by our board of directors, the Prior Plan
will automatically terminate on April 8, 2023. Our board of directors has determined not to make any further awards under the Prior Plan following the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>2021 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted our 2021 Employee Stock Purchase Plan (ESPP) on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 and our stockholders approved our ESPP on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. The ESPP will become effective immediately prior to and contingent upon the execution of the underwriting agreement
related to this offering. The purpose of the ESPP is to secure the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that of our
affiliates. The ESPP includes two components. One component is designed to allow eligible U.S. employees to purchase our common stock in a manner that may qualify for favorable tax treatment under Section&nbsp;423 of the Code. In addition, purchase
rights may be granted under a component that does not qualify for such favorable tax treatment because of deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S. while complying
with applicable foreign laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Share Reserve</I>. Following this offering, the ESPP authorizes the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of our common stock reserved
for issuance will automatically increase on January&nbsp;1 of each calendar year, beginning on January&nbsp;1, 2022 (assuming the ESPP becomes effective in 2021) through January&nbsp;1, 2031, by the lesser of (1)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding on the last day of the fiscal year before the date of the automatic increase, and (2)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares; provided that before the date of any such increase, our board of directors may determine that such increase will be less than the amount set forth in clauses
(1)&nbsp;and (2). As of the date hereof, no shares of our common stock have been purchased under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. Our
board of directors administers the ESPP and may delegate its authority to administer the ESPP to our compensation committee. The ESPP is implemented through a series of offerings under which eligible employees are granted purchase rights to purchase
shares of our common stock on specified dates during such offerings. Under the ESPP, we may specify offerings with durations of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or
more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. An offering under the ESPP may be terminated under certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Payroll Deductions</I>. Generally, all regular employees, including executive officers, employed by us or by any of our designated
affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of their earnings (as defined in the ESPP) for the purchase of our
common stock under the ESPP. Unless otherwise determined by our board of directors, common stock will be purchased for the accounts of employees participating in the ESPP at a price per share that is at least the lesser of (1) 85% of the fair market
value of a share of our common stock on the first date of an offering, or (2) 85% of the fair market value of a share of our common stock on the date of purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Limitations</I>. Employees may have to satisfy one or more of the following service requirements before participating in the ESPP, as
determined by our board of directors, including: (1)&nbsp;being customarily employed for more than 20 hours per week, (2)&nbsp;being customarily employed for more than five months per calendar year, or (3)&nbsp;continuous employment with us or one
of our affiliates for a period of time (not to exceed two years). No employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of our common stock based on the fair market value per share of our common stock at the beginning
of an offering for each calendar year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee has voting power over
5% or more of our outstanding capital stock measured by vote or value under Section&nbsp;424(d) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital
Structure</I>. In the event that there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash,
large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, the board of directors will make appropriate adjustments to: (1)&nbsp;the class(es) and maximum
number of shares reserved under the ESPP, (2)&nbsp;the class(es) and maximum number of shares by which the share reserve may increase automatically each year, (3)&nbsp;the class(es) and number of shares subject to and purchase price applicable to
outstanding offerings and purchase rights, and (4)&nbsp;the number of shares that are subject to purchase limits under ongoing offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. In the event of certain significant corporate transactions, including the consummation of (1)&nbsp;a sale of
all or substantially all of our assets, (2)&nbsp;the sale or disposition of more than 50% of our outstanding securities, (3)&nbsp;a merger or consolidation where we do not survive the transaction, or (4)&nbsp;a merger or consolidation where we do
survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the transaction, any then-outstanding rights to purchase our stock under the ESPP
may be assumed, continued or substituted for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue, or substitute for such purchase rights,
then the participants&#146; accumulated payroll contributions will be used to purchase shares of our common stock within ten business days before such corporate transaction, and such purchase rights will terminate immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>ESPP Amendment or Termination</I>. Our board of directors has the authority to amend or terminate our ESPP, provided that except in certain
circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#146;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by applicable law or listing
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our amended and restated certificate of incorporation will contain provisions that limit the liability of
our current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as
directors, except liability for: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the Delaware General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These limitations of liability do not apply to liabilities arising under federal securities laws and does not affect the availability of
equitable remedies such as injunctive relief or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and
restated bylaws that will be in effect upon the closing of this offering will provide that we are required to indemnify our directors to the fullest extent permitted by Delaware law. Our amended and restated bylaws will also provide that, upon
satisfaction of certain conditions, we are required to advance expenses incurred by a director in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other
agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. Our amended and restated bylaws will also provide our
board of directors with discretion to indemnify our officers and employees when determined appropriate by the board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have entered into
indemnification agreements with each of our directors and expect to enter into indemnification agreements with each of our executive officers prior to the closing of this offering. With certain exceptions, these agreements provide for
indemnification for related expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and
indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers. We also maintain customary directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated
bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if
successful, might benefit us and other stockholders. Further, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification
provisions. At present, there is no pending litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought and we are not aware of any threatened litigation that may result in claims for
indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted for our directors,
executive officers or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> Sales Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers may adopt written plans, known as <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> plans, in
which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> plan, a broker executes trades pursuant to parameters established by the director
or officer when entering into the plan, without further direction from them. The director or officer may amend a <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> plan in some circumstances and may terminate a plan at any time. Our directors
and executive officers also may buy or sell additional shares outside of a <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> plan when they are not in possession of material nonpublic information subject to compliance with the terms of our
insider trading policy. Prior to 180&nbsp;days after the date of this offering, subject to early termination, the sale of any shares under such plans would be prohibited by the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement that the
director or officer has entered into with the underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a description of transactions since January&nbsp;1, 2018 to which we have been a participant in which the amount involved
exceeded or will exceed $120,000, and in which any of our directors, executive officers or holders of more than 5% of our capital stock, or any members of their immediately family, had or will have a direct or indirect material interest, other than
compensation arrangements that are described under &#147;Management&#151;Non-Employee Director Compensation&#148; and &#147;Executive Compensation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placements of Our Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Promissory Notes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2018 we issued a convertible promissory note to James&nbsp;B. Murray,&nbsp;Jr. Revocable Trust U/A/D 8/8/1991 in the aggregate
principal amount of $237,500. James&nbsp;B. Murray,&nbsp;Jr. is the trustee of the James&nbsp;B. Murray,&nbsp;Jr. Revocable Trust U/A/D 8/5/1991 and is the Manager of Praxis Technologies. Entities affiliated with James&nbsp;B. Murray,&nbsp;Jr.
collectively beneficially own more than 5% of our capital stock. In conjunction with the <FONT STYLE="white-space:nowrap">Series&nbsp;A/A-1</FONT> financing round, this note along with accrued interest converted into shares of <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> preferred stock and is reflected in the aggregate purchase price and the aggregate shares issued to entities affiliated with James&nbsp;B. Murray,&nbsp;Jr. in the tables below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Series A and <FONT STYLE="white-space:nowrap">A-1</FONT> Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From October 2018 to November 2019, (1) we issued an aggregate of 2,043,757 shares of our Series&nbsp;A convertible preferred stock upon the
conversion of the aggregate principal amount and interest on certain then-outstanding promissory notes, (2)&nbsp;we issued an aggregate of 115,575 shares of our Series&nbsp;A convertible preferred stock upon the optional conversion of certain shares
of then-outstanding common stock, (3)&nbsp;we issued and sold an aggregate of 9,600,066 shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible preferred stock at a purchase price of $1.50 per share for aggregate gross
proceeds of $14.4&nbsp;million, (4)&nbsp;we issued an aggregate of 183,333 shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible preferred stock upon the conversion of the aggregate principal amount and interest on
certain then-outstanding promissory notes, and (5)&nbsp;we issued an aggregate of 1,448,113 shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible preferred stock upon the optional conversion of certain shares of
then-outstanding Series&nbsp;A convertible preferred stock. Each share of our Series&nbsp;A convertible preferred stock and <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible preferred stock will convert into common stock upon the
closing of this offering. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series&nbsp;A<BR>Convertible<BR>Preferred<BR>Stock<BR>Received<BR>Upon<BR>Conversion<BR>of Notes<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Note<BR>Principal<BR>and<BR>Interest<BR>Converted<BR>into shares<BR>of Series A<BR>Convertible<BR>Preferred<BR>Stock<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series&nbsp;A<BR>Convertible<BR>Preferred<BR>Stock<BR>Received<BR>Upon<BR>Exchange<BR>of Shares of<BR>Common<BR>Stock<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares of<BR>Common<BR>Stock<BR>Exchanged<BR>for Shares<BR>of Series A<BR>Convertible<BR>Preferred<BR>Stock<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with BVF Investments, LLC&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NV Acumen Holdings LLC&nbsp;(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">414,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PBM Capital Investments, LLC&nbsp;(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">524,274</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">786,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with James&nbsp;B. Murray,&nbsp;Jr.&nbsp;(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543,700</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">815,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents 129,367 shares of Series A convertible preferred stock issued to Biotechnology Value Fund, L.P. upon
conversion of $194,051 note principal and interest, 73,233 shares of Series A preferred stock issued to Biotechnology Value Fund II, L.P. upon conversion of $109,850 note principal and interest, and 36,805 shares of Series A preferred stock issued
to Investment 10, LLC upon conversion of $55,208 note principal and interest. Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Investment 10, LLC are affiliates of BVF Investments, LLC. At the time of the Series <FONT
STYLE="white-space:nowrap">A/A-1</FONT> convertible preferred stock financing, entities affiliated with BVF Investments, LLC collectively beneficially owned more than 5% of our capital stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">NV Acumen Holdings LLC was a special purpose vehicle organized by NeuroVentures Capital to invest in the
Company. At the time of the Series <FONT STYLE="white-space:nowrap">A/A-1</FONT> convertible preferred stock financing, entities affiliated with NeuroVentures Fund collectively beneficially owned more than 5% of our capital stock. Daniel
O&#146;Connell, our Chief Executive Officer and a member of our board of directors, served as managing partner of NeuroVentures Capital, LLC, the general partner to NeuroVentures Fund, L.P. which has sole voting and investment power with respect to
the shares held by NeuroVentures Fund, L.P. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">PBM Capital Investments, LLC is affiliated with PBM Capital Group, LLC. Entities affiliated with PBM Capital
Group, LLC collectively beneficially own more than 5% of our capital stock. Sean Stalfort, President of PBM Capital Group, LLC, is a director of the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents (a) 539,619 shares of Series A convertible preferred stock issued to James B. Murray, Jr. Revocable
Trust U/A/D 8/5/1991 consisting of (i)&nbsp;525,378 shares of Series A convertible preferred stock issued upon conversion of $788,067 note principal and interest, and (ii)&nbsp;14,241 shares of Series A convertible preferred stock issued in exchange
for 14,241 shares of common stock; and (b)&nbsp;41,555 shares of Series A convertible preferred stock issued to Praxis Technologies L.P. consisting of (i)&nbsp;18,322 shares of Series A convertible preferred stock issued upon conversion of $27,484
note principal and interest, and (ii)&nbsp;23,233 shares of Series&nbsp;A convertible preferred stock issued in exchange for 23,233 shares of common stock. James B. Murray, Jr. is the trustee of James&nbsp;B. Murray,&nbsp;Jr. Revocable Trust U/A/D
8/5/1991 and is the Manager of Praxis Technologies. Entities affiliated with James&nbsp;B. Murray,&nbsp;Jr. collectively beneficially own more than 5% of our capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the preferred stock purchase and exchange agreement, the stockholder elected to convert certain
Series&nbsp;A convertible preferred stock shares into <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible preferred stock shares, as shown in the table below. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares of<BR><FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT><BR>Preferred<BR>Stock<BR>Received<BR>Upon<BR>Exchange&nbsp;of<BR>Shares
of<BR>Series&nbsp;A<BR>Preferred<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares
of<BR>Series&nbsp;A<BR>Preferred<BR>Stock<BR>Exchanged<BR>for&nbsp;Shares&nbsp;of<BR><FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT><BR>Preferred<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT><BR>Convertible<BR>Preferred<BR>Stock<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Purchase<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PBM Capital Investments, LLC&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">524,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">524,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,675,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,513,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Knollwood Investment Fund LLC&nbsp;(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,675,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,514,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Robert&nbsp;D. Hardie&nbsp;(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,675,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,514,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sands Capital Ventures Discovery Fund&nbsp;III, L.P.&nbsp;(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,675,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,513,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with James&nbsp;B. Murray, Jr.&nbsp;(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">857,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">PBM Capital Investments, LLC is affiliated with PBM Capital Group, LLC. Entities affiliated with PBM Capital
Group, LLC collectively beneficially own more than 5% of our capital stock. Sean Stalfort, President of PBM Capital Group, LLC, is a director of the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Knollwood Investment Fund LLC is a beneficial owner of greater than 5% of our capital stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents 837,999 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock
purchased by H7 Holdings, LLC and 837,999 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible preferred stock purchased by Level One Partners, LLC. Robert&nbsp;D. Hardie is the Manager of both H7 Holdings, LLC and Level One
Partners, LLC. Entities affiliated with Robert&nbsp;D. Hardie collectively beneficially own more than 5% of our capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Sands Capital Ventures eFund II, L.P. is affiliated with Sands Capital Management, LLC. Entities affiliated with
Sands Capital Management, LLC collectively beneficially own more than 5% of our capital stock. Dr.&nbsp;Stephen Zachary, a Partner at Sands Capital Management, is a director of the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents (a)&nbsp;1,249,251 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred
stock issued to James B. Murray, Jr. Revocable Trust U/A/D 8/5/1991 consisting of (i)&nbsp;559,012 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock issued in exchange for 559,012 shares of Series&nbsp;A
convertible preferred stock, and (ii) 690,239 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible preferred stock issued upon purchase and conversion of $261,250 note principal and interest, and (b)&nbsp;209,139 shares of <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible preferred stock issued to Praxis Technologies L.P consisting of (i)&nbsp;41,555 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible preferred stock issued in
exchange for 41,555 shares of Series&nbsp;A convertible preferred stock, and (ii)&nbsp;167,584 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible preferred stock issued upon purchase. Entities affiliated with James&nbsp;B.
Murray,&nbsp;Jr. collectively beneficially own more than 5% of our capital stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the Series <FONT
STYLE="white-space:nowrap">A/A-1</FONT> financing, we issued a warrant to purchase up to 666,666 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock at an initial exercise price of $1.875 to PBM Capital
Investments, LLC. PBM Capital Investments, LLC is affiliated with PBM Capital Group, LLC. Entities affiliated with PBM Capital </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Group, LLC collectively beneficially own more than 5% of our capital stock. Sean Stalfort, President of PBM Capital Group, LLC, is a director of the Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series&nbsp;B<BR>Convertible<BR>Preferred<BR>Stock<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Purchase<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with RA Capital&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,058,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PBM ACU Holdings II, LLC&nbsp;(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,955,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,987,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Knollwood Investment Fund LLC&nbsp;(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">588,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Sands Capital&nbsp;(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,647,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,199,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James&nbsp;B. Murray, Jr. Revocable Trust U/A/D 8/5/1991&nbsp;(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,176,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Robert&nbsp;D. Hardie&nbsp;(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,856,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,733,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents 5,473,567 shares of Series B convertible preferred stock purchased by RA Capital Healthcare Fund,
L.P., 1,058,824 shares of Series B convertible preferred stock purchased by RA Capital Nexus Fund II, L.P., and 526,433 shares of Series B convertible preferred stock purchased by Blackwell Partners LLC &#150; Series A. RA Capital Healthcare Fund,
L.P., RA Capital Nexus Fund II, L.P., and Blackwell Partners LLC &#150; Series A are affiliated with RA Capital Management, L.P. Entities affiliated with RA Capital Management, L.P. collectively beneficially own more than 5% of our capital stock.
Dr.&nbsp;Laura Stoppel, a Principal at RA Capital Management, is a director of the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">PBM ACU Holdings II, LLC is affiliated with PBM Capital Group, LLC. Entities affiliated with PBM Capital Group,
LLC collectively beneficially own more than 5% of our capital stock. Sean Stalfort, President of PBM Capital Group, LLC, is a director of the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Knollwood Investment Fund LLC is a beneficial owner of greater than 5% of our capital stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents 823,529 shares of Series B convertible preferred stock purchased by Sands Capital Global Venture Fund
II, L.P. and 823,529 shares of Series B convertible preferred stock purchased by Sands Capital Life Sciences Pulse Fund, LLC. Sands Capital Global Venture Fund II, L.P. and Sands Capital Life Sciences Pulse Fund, LLC are affiliated with Sands
Capital Management, LLC. Entities affiliated with Sands Capital Management, LLC collectively beneficially own more than 5% of our capital stock. Dr.&nbsp;Stephen Zachary, a Partner at Sands Capital Management, is a director of the Company.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">James B. Murray, Jr. is the trustee of James B. Murray, Jr. Revocable Trust U/A/D 8/5/1991, the purchaser.
Entities affiliated with James B. Murray, Jr. collectively beneficially own more than 5% of our capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents 928,118 shares of Series B convertible preferred stock purchased by H7 Holdings, LLC and 928,118
shares of Series&nbsp;B convertible preferred stock purchased by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC. Entities affiliated with Robert D. Hardie collectively beneficially own
greater than 5% of our capital stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, pursuant to the Series B purchase agreement, participating investors
agreed to purchase 11,782,981 additional shares of Series B convertible preferred stock at a purchase price of $2.55 per share (as adjusted for stock splits, dividends and other similar events), for an aggregate purchase price of $30.0&nbsp;million
upon the occurrence of a milestone event, defined in the Series&nbsp;B purchase agreement as the successful completion of cohort 3 of the single ascending dose portion of the ACU193 Phase 1 clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The table below sets forth the aggregate number of shares of Series B convertible
preferred stock to be issued to our related parties upon occurrence of the milestone event: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series B<BR>Convertible<BR>Preferred<BR>Stock<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Purchase<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with RA Capital&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,705,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PBM ACU Holdings II, LLC&nbsp;(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,303,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,325,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Knollwood Investment Fund LLC&nbsp;(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Sands Capital&nbsp;(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,800,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James&nbsp;B. Murray, Jr. Revocable Trust U/A/D 8/5/1991&nbsp;(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">784,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Robert D. Hardie&nbsp;(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,155,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents 3,649,045 shares of Series B convertible preferred stock to be purchased by RA Capital Healthcare
Fund, L.P., 705,882 shares of Series B convertible preferred stock to be purchased by RA Capital Nexus Fund II, L.P, and 350,955 shares of Series B convertible preferred stock to be purchased by Blackwell Partners LLC &#150; Series A. RA Capital
Healthcare Fund, L.P., RA Capital Nexus Fund II, L.P., and Blackwell Partners LLC &#150; Series A are affiliated with RA Capital Management, L.P. Entities affiliated with RA Capital Management, L.P. collectively beneficially own more than 5% of our
capital stock. Dr.&nbsp;Laura Stoppel, a Principal at RA Capital, is a director of the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">PBM ACU Holdings II, LLC is affiliated with PBM Capital Group, LLC. Entities affiliated with PBM Capital Group,
LLC collectively beneficially own more than 5% of our capital stock. Sean Stalfort, President of PBM Capital, LLC, is a director of the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Knollwood Investment Fund LLC is a beneficial owner of greater than 5% of our capital stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents 549,020 shares of Series B convertible preferred stock to be purchased by Sands Capital Global
Venture Fund II, L.P. and 549,020 shares of Series B convertible preferred stock to be purchased by Sands Capital Life Sciences Pulse Fund, LLC. Sands Capital Global Venture Fund II, L.P. and Sands Capital Life Sciences Pulse Fund, LLC are
affiliated with Sands Capital Management, LLC. Entities affiliated with Sands Capital Management, LLC collectively beneficially own more than 5% of our capital stock. Dr.&nbsp;Stephen Zachary, a Partner at Sands Capital Management, is a director of
the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">James B. Murray, Jr. is the trustee of James B. Murray, Jr. Revocable Trust U/A/D 8/5/1991, the purchaser.
Entities affiliated with James B. Murray, Jr. collectively beneficially own more than 5% of our capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents 618,745 shares of Series B convertible preferred stock to be purchased by H7 Holdings, LLC and
618,745 shares of Series B convertible preferred stock to be purchased by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC. Entities affiliated with Robert D. Hardie collectively
beneficially own greater than 5% of our capital stock. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights, Voting and Right of First Refusal Agreements
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the sales of convertible preferred stock described above, we entered into an amended and restated investors&#146;
rights agreement, an amended and restated voting agreement and an amended and restated right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement containing registration rights, information rights, voting rights and rights
of first refusal, among other things, with the holders of our convertible preferred stock. These agreements will terminate upon the closing of this offering, except for the registration rights granted under our amended and restated investors&#146;
rights agreement, as more fully described in the section of this prospectus titled &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have entered
into employment agreements, consulting agreements or offer letter agreements with certain of our executive officers. For more information regarding our employment agreements and consulting agreements with Daniel O&#146;Connell, Eric Siemers, and
Russel Barton, see &#147;Executive Compensation&#151;Agreements with our Named Executive Officers and Potential Payments upon Termination of Employment.&#148; We have also entered into an advisory board consulting agreement with Dr. Jeffrey Sevigny,
one of our current board members. For more information regarding our consulting agreement with Dr. Sevigny, see &#147;Management&#151;Non-Employee Director Compensation.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation that will be in effect upon the closing of this offering will contain provisions
limiting the liability of directors, and our amended and restated bylaws will provide that we will indemnify each of our directors to the fullest extent permitted under Delaware law. Our amended and restated certificate of incorporation and amended
and restated bylaws will also provide our board of directors with discretion to indemnify our officers and employees when determined appropriate by the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we have entered into indemnification agreements with each of our directors, and we expect to enter into indemnification
agreements with each of our executive officers prior to the closing of this offering. For more information regarding these agreements, see &#147;Executive Compensation&#151;Limitations on Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transaction Policy </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior
to this offering, we have not had a formal policy regarding approval of transactions with related parties. In connection with this offering, we have adopted a related person transaction policy that sets forth our procedures for the identification,
review, consideration and approval or ratification of related person transactions, which policy will become effective immediately upon the execution of the underwriting agreement for this offering. For purposes of our policy only, a related person
transaction will be a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000.
Transactions involving compensation for services provided to us as an employee or director will not be covered by this policy. A related person will be any executive officer, director or beneficial owner of more than 5% of any class of our voting
securities, including any of their immediate family members and any entity owned or controlled by such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the policy, if a
transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction
prior to consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our board of directors, for
review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether
the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from
each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our Code of Conduct
that we expect to adopt prior to the closing of this offering, our employees and directors will have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest.
In considering related person transactions, our audit committee, or other independent body of our board of directors, will take into account the relevant available facts and circumstances including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#146;s independence in the event that the related person is a director, immediate family
member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The policy will require that, in determining whether to approve, ratify or reject a related
person transaction, our audit committee, or other independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our
stockholders, as our audit committee, or other independent body of our board of directors, determines in the good faith exercise of its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All of the transactions described in this section were entered into prior to the adoption of this policy. Although we have not had a written
policy for the review and approval of transactions with related persons, our board of directors has historically reviewed and approved any transaction where a director or officer had a financial interest, including the transactions described above.
Prior to approving such a transaction, the material facts as to a director&#146;s or officer&#146;s relationship or interest in the agreement or transaction were disclosed to our board of directors. Our board of directors took this information into
account when evaluating the transaction and in determining whether such transaction was fair to us and in the best interest of all our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding beneficial ownership of our capital stock by: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our named executive officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC. Under these rules, beneficial ownership includes any shares
of common stock as to which the individual or entity has sole or shared voting power or investment power. Applicable percentage ownership is based
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, after
giving effect to the conversion of all of our convertible preferred stock. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options held by
such person that are currently exercisable or will become exercisable within 60 days of March 31, 2021 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other
person. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless noted otherwise, the address of all listed stockholders is c/o Acumen Pharmaceuticals, Inc., 427 Park St.,
Charlottesville, Virginia 22902. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except as indicated by the footnotes below, we believe, based on information furnished to us, that each
of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percentage&nbsp;of&nbsp;Shares&nbsp;Beneficially<BR>Owned</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name and Address of Beneficial Owner (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Before<BR>Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>After<BR>Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Greater than 5% Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,058,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with PBM Capital Group, LLC (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,980,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Robert D. Hardie (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Sands Capital Management LLC (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,322,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with James B. Murray, Jr. (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,852,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Knollwood Investment Fund LLC (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,264,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel O&#146;Connell (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Siemers, M.D. (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell Barton, MS (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey L. Ives (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Sevigny, M.D. (12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sean Stalfort</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Stoppel, PhD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Zachary, PhD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (8 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,007,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise indicated, the business address of each of the directors and executive officers of the company
is c/o Acumen Pharmaceuticals Inc., 427 Park St., Charlottesville, VA 22902. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 5,473,567 shares of common stock issuable upon conversion of Series&nbsp;B convertible
preferred stock held by RA Capital Healthcare Fund, L.P. (&#147;RACHF&#148;), (b) 1,058,824 shares of common stock issuable upon conversion of Series&nbsp;B convertible preferred stock held by RA Capital Nexus Fund II, L.P. (&#147;Nexus II&#148;),
and (c) 526,433 shares of common stock issuable upon conversion of Series&nbsp;B convertible preferred stock held by Blackwell Partners LLC &#150; Series&nbsp;A (&#147;Blackwell&#148;). RA Capital Management, LP (&#147;RACM&#148;) is the investment
adviser to RACHF, Nexus II and Blackwell. RA Capital Healthcare Fund GP, LLC is the general partner of RACHF. The general partner of Nexus II is RA Capital Nexus Fund II GP, LLC. Peter Kolchinsky and Rajeev Shah are the managing members of RACM, RA
Capital Healthcare Fund GP, LLC and RA Capital Nexus Fund II GP, LLC and have the power to vote or dispose of the shares held by each entity. The address for Dr. Kolchinsky, Mr. Shah, RACHF and Nexus II is 200 Berkeley Street, 18<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, Massachusetts 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 1,955,882 shares of common stock issuable upon conversion of Series B convertible preferred
stock held by PBM ACU Holdings II, LLC, and (b) 2,200,121 shares of common stock issuable upon conversion of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, 157,332 shares of common stock issuable upon the exercise of
common stock warrants exercisable within 60 days of March&nbsp;31, 2021 and 666,666 shares of common stock issuable upon the exercise and conversion of preferred stock warrants exercisable within 60 days of March&nbsp;31, 2021 held by PBM ACU
Holdings, LLC. The manager of PBM ACU Holdings II, LLC and PBM ACU Holdings, LLC is PBM Capital Group, LLC. Paul B. Manning is the Chief Executive Officer of PBM Capital Group, LLC and has the power to vote or dispose of the shares held by PBM ACU
Holdings II, LLC and PBM ACU Holdings, LLC. The address for PBM ACU Holdings II, LLC, PBM ACU Holdings, LLC, and Paul B. Manning is 200 Garrett Street, Suite S, Charlottesville, VA 22902. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 928,118 shares of common stock issuable upon conversion of Series B convertible preferred stock
and 837,999 shares of common stock issuable upon conversion of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock held by H7 Holdings LLC, and (b) 928,118 shares of common stock issuable upon conversion of Series B convertible
preferred stock and 837,999 shares of common stock issuable upon conversion of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One
Partners, LLC and has the power to vote or dispose of the shares held by each entity. The address for Robert D. Hardie, H7 Holdings, LLC and Level One Partners, LLC is 210 Ridge McIntire Road, Suite 350, Charlottesville, VA 22903.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 823,529 shares of common stock issuable upon conversion of Series B convertible preferred stock
held by Sands Capital Global Venture Fund II, L.P., (b) 823,529 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Sands Capital Life Sciences Pulse Fund, LLC, (c) 1,675,847 shares of common stock
issuable upon conversion of Series A-1 convertible preferred stock held by Sands Capital Ventures Discovery Fund III, L.P. The sole general partner of Sands Capital Ventures Discovery Fund III, L.P. is Sands Capital Ventures Discovery Fund III-GP,
LLC. The sole general partner of Sands Capital Global Venture Fund II, L.P. is Sands Capital Global Venture Fund II-GP, L.P., and the sole general partner of Sands Capital Global Venture Fund II-GP, L.P. is Sands Capital Global Venture Fund II-GP,
LLC. Each of the funds is advised by Sands Capital Ventures, LLC, a registered investment adviser (the &#147;Adviser&#148;). The proxy voting power of the Adviser is exercised by the investment lead covering the company. Frank Sands Jr. holds
dispositive power over the shares held by Sands Capital Ventures Discovery Fund III, L.P. Frank Sands Jr., Ian Ratcliffe, and Michael Graninger, acting unanimously, hold dispositive power over the shares held by Sands Capital Global Venture Fund II,
L.P. Ian Ratcliffe and Stephen Zachary, acting unanimously, hold dispositive power over the shares held by Sands Capital Life Sciences Pulse Fund, LLC. The address for Sands Capital Global Venture Fund II, L.P., Sands Capital Life Sciences Pulse
Fund, LLC, and Sands Capital Ventures Discovery Fund III, L.P., Sands Capital Ventures, LLC and each above-named person holding dispositive power over the shares held by these entities is 1000 Wilson Blvd, Suite 3000, Arlington, VA 22209.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 53 shares of common stock, 43,692 shares of common stock issuable upon conversion of Series A
convertible preferred stock, 1,249,251 shares of common stock issuable upon conversion of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, 1,176,471 shares of common stock issuable upon conversion of Series B
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
convertible preferred stock, and 169,143 shares of common stock issuable upon the exercise of common stock warrants exercisable within 60 days of March&nbsp;31, 2021 held by James B. Murray, Jr.
Revocable Trust U/A/D 8/5/1991, and (b) 209,139 shares of common stock issuable upon conversion of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 5,250 shares of common stock issuable upon the exercise of common
stock warrants exercisable within 60 days of March&nbsp;31, 2021 held by Praxis Technologies L.P. James B. Murray, Jr. is the trustee of James B. Murray, Jr. Revocable Trust U/A/D 8/5/1991 and the Manager of Praxis Technologies, L.P. and has the
power to vote or dispose of shares held by each entity. The address for James&nbsp;B. Murray, Jr., James B. Murray, Jr. Revocable Trust U/A/D 8/5/1991, and Praxis Technologies, L.P. is 427 Park St., Charlottesville, VA 22902. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 588,235 shares of common stock issuable upon conversion of Series B convertible preferred stock and
1,675,999 shares of common stock issuable upon conversion of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock held by Knollwood Investment Fund LLC. Knollwood Investment Advisory, LLC is the Managing Member of Knollwood
Investment Fund LLC. Kevin D. Irwin is the President of Knollwood Investment Advisory, LLC and has the power to vote or dispose of the shares held by Knollwood Investment Fund LLC. The address for Knollwood Investment Fund LLC., Knollwood Investment
Advisory, LLC, and Kevin&nbsp;D. Irwin is 217 International Cir., Hunt Valley, MD 21030. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,110 shares of common stock, 184 shares of common stock issuable upon conversion of Series&nbsp;A
convertible preferred stock, 53 shares of common stock issuable upon the exercise of common stock warrants exercisable within 60 days of March&nbsp;31, 2021, and 608,120 shares of common stock issuable upon the exercise of options exercisable within
60 days of March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 239,675 shares of common stock issuable upon the exercise of options exercisable within 60 days of
March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 48,031 shares of common stock issuable upon the exercise of options exercisable within 60 days of
March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 63,287 shares of common stock issuable upon the exercise of options exercisable within 60 days of
March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 46,158 shares of common stock issuable upon the exercise of options exercisable within 60 days of
March&nbsp;31, 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>The following description of our capital stock, certain provisions of our amended and restated certificate of incorporation and amended and
restated bylaws, as each will be in effect following the completion of this offering, and certain provisions of Delaware law are summaries. You should also refer to the amended and restated certificate of incorporation and the amended and restated
bylaws, which are filed as exhibits to the registration statement of which this prospectus is part. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our amended and restated certificate of incorporation will authorize us to issue up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, $0.0001 par value per share,
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock, $0.0001 par value per share, all of which shares of preferred stock will be undesignated. Our board of directors may
establish the rights and preferences of the preferred stock from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we had outstanding 624,635
shares of common stock, held by 79 stockholders of record. As of December&nbsp;31, 2020, after giving effect to the conversion of all of the outstanding shares of our convertible preferred stock, including 711,203 shares of our Series A convertible
preferred stock, 11,231,511 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 17,674,469 shares of our Series B convertible preferred stock issued,
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, there would have been&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock issued and outstanding, held by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stockholders of record. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders,
including the election of directors. The affirmative vote of holders of at least 66<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the voting power of all of the then-outstanding
shares of capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified
board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably
those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net
assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions
applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the right of the holders of shares of any series of preferred stock that we may designate in the
future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, there were 29,617,183 shares of our preferred stock outstanding consisting of 711,203 shares of our Series A
convertible preferred stock, 11,231,511 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, and 17,674,469 shares of our Series B convertible preferred stock. All currently outstanding shares of convertible
preferred stock will be converted into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following the closing of this offering, our board of directors will have the authority under our amended and restated certificate of
incorporation, without further action by our stockholders, to issue up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock in one or more series, to establish from time to time
the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number
of shares of any such series, but not below the number of shares of such series then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize
the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The purpose of authorizing our board of directors to issue preferred stock and
determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes,
could, among other things, have the effect of delaying, deferring or preventing a change in control of us and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. It is not
possible to state the actual effect of the issuance of any shares of preferred stock on the rights of holders of common stock until the board of directors determines the specific rights attached to that preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have no present plans to issue any shares of preferred stock following the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020,
there were options to purchase shares of common stock outstanding. For additional information regarding the terms of our Amended and Restated Stock Performance Plan and our 2021 Equity Incentive Plan, see &#147;Executive Compensation&#151;Equity
Incentive Plans.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As
of December&nbsp;31, 2020, there were outstanding immediately exercisable warrants to purchase up to 574,760 shares of our common stock at an exercise price of $3.00 per share and 666,666 shares of our Series
<FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock at an exercise price of $1.875 per share. Upon completion of this offering, the warrant to purchase shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock will be
automatically exercised for the purchase of an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, the holders of
our existing convertible preferred stock and certain holders of our existing common stock have entered into an amended and restated investors&#146; rights agreement. The registration rights provisions of this agreement provide those holders with
demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights with respect to the shares of common stock currently held by them and issuable to them upon conversion of our convertible preferred stock in connection
with our initial public offering. These shares are collectively referred to herein as registrable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At any time beginning 180 days following the effective date of the registration statement of which this prospectus is a part, the holders of a
majority of registrable securities then outstanding have the right to demand that we file a registration statement covering registrable securities then outstanding having an aggregate offering price of at least $5.0&nbsp;million, net of certain
selling expenses. These registration rights are subject to specified conditions and limitations, including the right of the underwriters, if any, to limit the number of shares included in any such registration under specified circumstances. Upon
such a request, we are required to effect the registration as soon as practicable, but in any event no later than 60 days after the receipt of such request. An aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be entitled to these demand registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we propose to register any of our securities under the Securities Act either for our own account or for the account of other stockholders,
the holders of registrable securities will each be entitled to notice of the registration and will be entitled to include their shares of common stock in the registration statement. These piggyback registration rights are subject to specified
conditions and limitations, including the right of the underwriters to limit the number of shares included in any such registration under specified circumstances. An aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock will be entitled to these piggyback registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Registration on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At any time after we become eligible to file&nbsp;a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> the
holders of at least 30% of registrable securities then outstanding will be entitled to request to have such shares registered by us on a <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration statement. These <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights are subject to other specified conditions and limitations, including the condition that the anticipated aggregate offering price, net of certain selling expenses, is at least
$5.0&nbsp;million. Upon receipt of this request, the holders of registrable securities will each be entitled to participate in this registration. An aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock will be entitled to these <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of Registration </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are required to pay all expenses, including fees and expenses of one counsel to represent the selling stockholders (up to $50,000 total),
relating to any demand, piggyback or <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration, other than underwriting discounts and commissions, stock transfer taxes and any additional fees of counsel for the selling stockholders, subject
to specified conditions and limitations. We are not required to pay registration expenses if a demand registration request is withdrawn at the request of a majority of holders of registrable securities to be registered, unless holders of a majority
of the registrable securities agree to forfeit their right to one demand registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amended and restated investors&#146; rights
agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the applicable registration statement attributable to us,
and the selling stockholders are obligated to indemnify us for material misstatements or omissions in the registration statement attributable to them, subject to certain limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Termination of Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The registration rights granted under the investors&#146; rights agreement will terminate with respect to any particular stockholder upon the
earlier of (a)&nbsp;the closing of a deemed liquidation event, as defined in our certificate of incorporation, (b)&nbsp;the third anniversary of the closing of this offering and (c)&nbsp;with respect to each stockholder, at such time such
stockholder is able to sell all of its shares pursuant to Rule 144 or another similar exemption under the Securities Act during a three-month period without registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any
business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the
interested stockholder, those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual
or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the outstanding voting
stock that is not owned by the interested stockholder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines a &#147;business
combination&#148; to include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation or any direct or indirect majority-owned subsidiary of the
corporation and the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder (in one transaction or a series of transactions); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation or by
any direct or indirect majority-owned subsidiary of the corporation of any stock of the corporation or of such subsidiary to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation or any direct or indirect majority-owned subsidiary of the corporation
that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested
stockholder&#148; as an entity or person who, together with the person&#146;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the
outstanding voting stock of the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation to be in effect upon the completion of this offering, or our restated
certificate, will provide for our board of directors to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the shares of
common stock outstanding will be able to elect all of our directors. Our restated certificate and our amended and restated bylaws to be effective upon the completion of this offering, or our restated bylaws, will also provide that directors may be
removed by the stockholders only for cause upon the vote of 66<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% or more of our outstanding common stock. Furthermore, the authorized
number of directors may be changed only by resolution of the board of directors, and vacancies and newly created directorships on the board of directors may, except as otherwise required by law or determined by the board, only be filled by a
majority vote of the directors then serving on the board, even though less than a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under our restated certificate of incorporation
and amended and restated bylaws our stockholders will not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing
for election, if they should so choose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated certificate and restated bylaws will also provide that all stockholder actions must
be effected at a duly called meeting of stockholders and will eliminate the right of stockholders to act by written consent without a meeting. Our restated bylaws will also provide that only our Chairman of the board, Chief Executive Officer or the
board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors may call a special meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated bylaws will also provide that stockholders seeking to present proposals before a meeting of stockholders to nominate candidates
for election as directors at a meeting of stockholders must provide timely advance notice in writing, and will specify requirements as to the form and content of a stockholder&#146;s notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated certificate and restated bylaws will provide that the stockholders cannot amend many of the provisions described above except by
a vote of 66<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% or more of our outstanding common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As described in &#147;&#151;Preferred Stock&#148; above, our restated certificate will give our board of directors the authority, without
further action by our stockholders, to issue up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock in one or more series, with any rights, preferences and privileges as they
may designate, including the right to approve an acquisition or other change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The combination of these provisions will make it
more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers,
these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue
preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These
provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to
reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect
of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these
provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals,
because negotiation of takeover proposals could result in an improvement of their terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation to be effective on the completion of this offering will provide that the Court of
Chancery of the State of Delaware (or, if and only if, the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if, all such state courts lack subject
matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action brought under Delaware statutory or common law:
(1)&nbsp;any derivative claim or action brought on our behalf; (2)&nbsp;any claim or cause of action asserting a breach of fiduciary duty by any of our current or former director, officer or other employee; (3)&nbsp;any claim or cause of action
asserting a claim against us arising out of, or pursuant to, the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; (4)&nbsp;any claim or cause of action seeking to interpret, apply, enforce or determine
the validity of our amended and restated certificate of incorporation or our amended and restated bylaws (including any right, obligation, or remedy thereunder); (5) any claim or cause of action as to which the DGCL confers jurisdiction to the Court
of Chancery of the State of Delaware; or (6)&nbsp;any claim or cause of action asserting a claim against us or any of our directors, officers or other employees, that is governed by the internal affairs doctrine, in all cases to the fullest extent
permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. The aforementioned provision will not apply to claims or causes of action brought to enforce a duty or liability created by
the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our
amended and restated certificate of incorporation will further provide that, unless we consent writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum, to the fullest
extent permitted by law, for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision
is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or
entity and who has prepared or certified any part of the documents underlying the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The enforceability of similar choice of forum
provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with one or more actions or proceedings described above, a court could find the choice of forum
provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent&#146;s address is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to apply for listing
of our common stock on the Nasdaq Global Market under the trading symbol &#147;ABOS.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to this offering, no public market existed for our common stock. Future sales of our common stock in the public market, or the
availability of such shares for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to
contractual and legal restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time
and our ability to raise equity capital in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on the number of shares outstanding as of December&nbsp;31, 2020, upon the
closing of this offering and assuming no exercise of the underwriters&#146; option to purchase additional shares, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock will be
outstanding, assuming no outstanding options are exercised. All of the shares of common stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, except for any shares sold to our
&#147;affiliates,&#148; as that term is defined under Rule 144 under the Securities Act. The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock held by existing
stockholders are &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act. Restricted securities may be sold in the public market only if registered or if their resale qualifies for exemption from registration
described below under Rule 144 promulgated under the Securities Act or another available exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described below and the provisions of Rules 144 and 701 under the Securities Act, the shares of common stock that will be deemed restricted securities after this offering will be available for
sale in the public market as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">none of the existing shares will be eligible for immediate sale upon the completion of this offering; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be eligible for sale in the
public market upon expiration of <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements 180 days after the date of this prospectus, subject in certain circumstances to the volume, manner of sale and other limitations under Rule 144 and
Rule&nbsp;701 under the Securities Act, which are summarized below. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, <FONT STYLE="white-space:nowrap">non-affiliate</FONT> persons who have beneficially owned restricted shares of our common stock
for at least six months, and any affiliate of the company who owns either restricted or unrestricted shares of our common stock, are entitled to sell their securities without registration with the SEC under an exemption from registration provided by
Rule 144 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliates</FONT> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any person who is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale may
sell an unlimited number of restricted securities under Rule&nbsp;144 if: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the restricted securities have been held for at least six months, including the holding period of any prior owner
other than one of our affiliates (subject to certain exceptions); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale;
and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are current in our Exchange Act reporting at the time of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any person who is not deemed to have been an affiliate of ours at the time of, or at any time during the three months preceding, a sale and
has held the restricted securities for at least one year, including the holding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period of any prior owner other than one of our affiliates, will be entitled to sell an unlimited number of restricted securities without regard to the length of time we have been subject to
Exchange Act periodic reporting or whether we are current in our Exchange Act reporting. <FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule 144.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Affiliates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Persons seeking to sell restricted securities who are our affiliates at the time of, or any time during the three months preceding, a sale,
would be subject to the restrictions described above. They are also subject to additional restrictions, by which such person would be required to comply with the manner of sale and notice provisions of Rule 144 and would be entitled to sell within
any three-month period only that number of securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares immediately after the completion of this offering based on the number of shares outstanding as of December&nbsp;31, 2020; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on the stock exchange on which our shares are listed during
the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, persons
who are our affiliates at the time of, or any time during the three months preceding, a sale may sell unrestricted securities under the requirements of Rule 144 described above, without regard to the <FONT STYLE="white-space:nowrap">six-month</FONT>
holding period of Rule 144, which does not apply to sales of unrestricted securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Rule 701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule 144 but
without compliance with certain restrictions of Rule 144, including the holding period requirement. Most of our employees, executive officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on
the resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares. However, substantially all Rule 701 shares are subject to <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and in the section titled &#147;Underwriting&#148; and will become eligible for sale upon the expiration of the restrictions set forth in those agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register
all shares of common stock subject to outstanding stock options and common stock issued or issuable under our equity plans. We expect to file the registration statement covering shares offered pursuant to our stock plans as soon as practicable after
the closing of this offering, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without restriction under the Securities Act and the sale by affiliates in the public market, subject
to compliance with the resale provisions of Rule 144 and expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and substantially all of the holders of our common stock outstanding on the date of this prospectus
have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters or otherwise agreed, subject to certain exceptions, that we and they will not, directly or indirectly, offer, sell, contract to sell, pledge, grant
any option to purchase, make any short sale, or otherwise dispose of or hedge any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our shares of common stock, any options or warrants to purchase shares of our common stock, or any securities convertible into, or exchangeable for or that represent the right to receive
shares of our common stock, without the prior written consent of <U></U>BofA Securities, Inc. for a period of 180 days from the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the restrictions contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above, we have entered
into an agreement with the holders of our convertible preferred stock that contains market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions imposing restrictions on the ability of such security holders to sell or otherwise transfer or
dispose of any registrable securities for a period of 180 days following the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, the holders of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, including common stock issuable upon the conversion of our convertible preferred stock, or their transferees, will be
entitled to specified rights with respect to the registration of their registrable shares under the Securities Act, subject to certain limitations and the expiration, waiver or termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act immediately upon effectiveness of the registration. See &#147;Description of Capital
Stock&#151;Registration Rights&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_18"></A>CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a summary of certain material U.S. federal income tax
consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering. This discussion is not a complete analysis of all potential
U.S. federal income tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, and does not address any estate or gift tax consequences or any tax consequences arising
under any state, local or foreign tax laws, or any other U.S. federal tax laws. This discussion is based on the Internal Revenue Code of 1986, as amended (the Code), Treasury Regulations promulgated thereunder, judicial decisions, and published
rulings and administrative pronouncements of the Internal Revenue Service (IRS), all as in effect on the date of this prospectus. These authorities are subject to differing interpretations and may change, possibly retroactively, resulting in U.S.
federal income tax consequences different from those discussed below. We have not requested a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or
a court will agree with such statements and conclusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This discussion is limited to <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders who purchase our common stock pursuant to this offering and who hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not
address all of the U.S. federal income tax consequences that may be relevant to an individual <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s particular
circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to special rules under the U.S. federal income tax laws, including:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other pass-through entities (entities or arrangements treated as partnerships for U.S. federal
income tax purposes and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;passive foreign investment companies&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, financial institutions, investment funds, insurance companies, brokers, dealers or traders in securities;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations and governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or acquire our common stock through the exercise of an option or otherwise as compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">qualified foreign pension funds as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to special tax accounting rules under Section&nbsp;451(b) of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own or have owned, actually or constructively, more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who have elected to mark securities to market; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedging or conversion transaction or straddle, or a constructive
sale, or other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If an entity or arrangement that is classified as a
partnership for U.S. federal income tax purposes holds our common stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner, the activities of the partnership and certain
determinations made at the partner level. Partnerships holding our common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them of holding and disposing
of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS
REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR FOREIGN TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is any beneficial owner of our common stock that is
not a &#147;U.S. holder&#148; or a partnership (including any entity or arrangement treated as a partnership) for U.S. federal income tax purposes. A U.S. holder is any person that, for U.S. federal income tax purposes, is or is treated as any of
the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation created or organized under the laws of the United States, any state thereof or the District of
Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (1)&nbsp;whose administration is subject to the primary supervision of a U.S. court and which has one or
more U.S. persons (within the meaning of Section 7701(a)(30) of the Code) who have the authority to control all substantial decisions of the trust or (2)&nbsp;that has a valid election in effect under applicable Treasury Regulations to be treated as
a U.S. person. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As described under the section titled &#147;Dividend Policy,&#148; we do not anticipate declaring or paying, in the foreseeable future, any
cash distributions on our capital stock. However, if we distribute cash or other property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated
earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and will first be applied against and reduce a holder&#146;s tax
basis in our common stock, but not below zero. Any excess will be treated as gain realized on the sale or other disposition of our common stock and will be treated as described under the section titled &#147; &#151;Gain on Disposition of Our Common
Stock&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding effectively connected income, backup withholding and FATCA (as defined
below), dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate specified by
an applicable income tax treaty. To receive the benefit of a reduced treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must furnish us or our withholding agent with a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT>
(in the case of individuals) or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(in the case of entities), or other appropriate form, certifying such holder&#146;s qualification for the reduced rate. This certification must be provided to us or our withholding agent before
the payment of dividends and must be updated periodically. In the case of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder that is an entity, Treasury Regulations and the relevant tax treaty provide rules to determine whether, for purposes
of determining the applicability of the tax treaty, dividends will be treated as paid to the entity or to those holding an interest in the entity. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock through a
financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide appropriate documentation to the agent,
which then will be required to provide certification to us or our withholding agent, either directly or through other intermediaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If
a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock in connection with the conduct of a trade or business in the United States, and dividends paid on our common stock are effectively connected with such holder&#146;s
U.S. trade or business (and are attributable to such holder&#146;s permanent establishment or fixed base in the United States if required by an applicable tax treaty), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be exempt from
U.S. federal withholding tax. To claim the exemption, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must generally furnish a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form) to the applicable
withholding agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">However, any such effectively connected dividends paid on our common stock generally will be subject to U.S. federal
income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may
be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not provide the required certification on a timely basis, but that qualify
for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any
applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding backup withholding and FATCA (as defined below), a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder generally will not be subject to U.S. federal income tax on any gain realized on the sale or other taxable disposition of our common stock, unless: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct
of a trade or business in the United States and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United
States; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition, and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a &#147;United States real property interest&#148; (USRPI) by reason of our status
as a United States real property holding corporation (USRPHC) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
holding period for our common stock, and our common stock is not regularly traded on an established securities market during the calendar year in which the sale or other disposition occurs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Determining whether we are a USRPHC depends on the fair market value of our USRPIs interests relative to the fair market value of our other
trade or business assets and our foreign real property interests. We believe that we are not currently and we do not anticipate becoming a USRPHC for U.S. federal income tax purposes, although there can be no assurance we will not in the future
become a USRPHC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income
basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower
rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. Gain described in the second bullet point above will be subject to U.S. federal income tax at a
flat 30% rate (or such lower rate specified by an applicable income tax treaty), but may be offset by certain U.S.-source capital losses (even though the individual is not considered a resident of the United States), provided that the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income tax returns with respect to such losses. Gain described in the third bullet point above will generally be subject to U.S. federal income tax in the same manner as
gain that is effectively connected with the conduct of a U.S. trade or business, except that the branch profits tax generally will not apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any applicable income tax treaties that
may provide for different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Annual reports are required to be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder indicating
the distributions on our common stock paid to such holder and any tax withheld with respect to those distributions. These information reporting requirements apply even if no withholding was required because the distributions were effectively
connected with the holder&#146;s conduct of a U.S. trade or business, or withholding was reduced or eliminated by an applicable income tax treaty. This information also may be made available under a specific treaty or agreement with the tax
authorities in the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is established. Backup withholding, currently at a 24% rate, generally will not apply to payments to a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of dividends on or the gross proceeds of a disposition of our common stock provided the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder furnishes the required certification for its <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or IRS Form <FONT
STYLE="white-space:nowrap">W-8ECI,</FONT> otherwise establishes an exemption, and if the payor does not have actual knowledge, or reason to know, that the holder is a U.S. person who is not an exempt recipient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. If any amount is withheld under the backup withholding rules, the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder should consult with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a credit against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
U.S. federal income tax liability, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withholding on Foreign Entities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sections 1471 through 1474 of the Code, which are commonly referred to as FATCA, impose a U.S. federal withholding tax of 30% on certain
payments made to a &#147;foreign financial institution&#148; (as specially defined under these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S.
tax authorities substantial information regarding certain U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or
an exemption applies. FATCA also generally will impose a U.S. federal withholding tax of 30% on certain payments made to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity unless such entity provides the withholding agent a
certification identifying certain direct and indirect U.S. owners of the entity or an exemption applies. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Under certain
circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. FATCA currently applies to dividends paid on our common stock and would have applied also to payments of gross proceeds
from the sale or other disposition of our common stock. The U.S. Treasury Department has released proposed regulations under FATCA providing for the elimination of the federal withholding tax of 30% applicable to gross proceeds of a sale or other
disposition of our common stock. Under these proposed Treasury Regulations (which may be relied upon by taxpayers prior to finalization), FATCA will not apply to gross proceeds from sales or other dispositions of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prospective investors are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment
in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc., Credit Suisse Securities (USA) LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated are acting as representatives
of each of the underwriters named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not
jointly, to purchase from us, the number of shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Underwriter</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.15em; text-indent:-5.15em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credit Suisse Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UBS Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.15em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting
underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set
forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the initial offering, the
public offering price, concession or any other term of the offering may be changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price,
underwriting discount and proceeds before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Without&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>With&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expenses of the offering, not including the underwriting discount, are estimated at
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and are payable by us. We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry
Regulatory Authority and other regulatory fees up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated,
subject to conditions contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, our
executive officers and directors and our other existing security holders that collectively own &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our stock before this offering have agreed not to
sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days after the date of this prospectus without first obtaining the written consent of BofA Securities, Inc.
Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell or contract to sell any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell any option or contract to purchase any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase any option or contract to sell any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant any option, right or warrant for the sale of any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lend or otherwise dispose of or transfer any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">request or demand that we file or make a confidential submission of a registration statement related to the
common stock, or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership
of any common stock whether any such swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock and to securities convertible into or exchangeable or
exercisable for or repayable with common stock, or the Lock-Up Securities. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of
disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The agreements of our officers, directors and holders of substantially all of our common stock do not apply to (a)&nbsp;(i)
transfers made as a <I>bona fide</I> gift or gifts, including, without limitation, to a charitable organization or educational institution, or for <I>bona fide</I> estate planning purposes, (ii)&nbsp;transfers to any immediate family member of such
holder or to any trust for the direct or indirect benefit of such holder or the immediate family of such holder, (iii)&nbsp;if such holder is a trust, transfers to a trustor, trustee or beneficiary of such trust or to the estate of a trustor,
trustee or beneficiary of such trust, (iv)&nbsp;transfers made as a distribution to partners, members, managers, equity holders or stockholders of such holder, or (v)&nbsp;transfers to such holder&#146;s affiliates or to any investment fund or other
entity controlled or managed by, controlling or managing, or under common control with, such holder or affiliates of such holder, <I>provided that </I>the transferee or distributee agrees to such restrictions for the remainder of the <FONT
STYLE="white-space:nowrap">180-day</FONT> period, any such transfer does not involve a disposition for value, and such transfers or distributions are not required to be reported with the SEC on Form 4 and no public filing or report regarding such
transfers is voluntarily effected during the remainder of the <FONT STYLE="white-space:nowrap">180-day</FONT> period; (b)&nbsp;transfers made (i)&nbsp;by will, other testamentary document or intestate succession to the legal representative, heir,
beneficiary or any immediate family of such holder, (ii)&nbsp;pursuant to a court or regulatory agency order, a qualified domestic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
order or in connection with a divorce settlement; or (iii)&nbsp;to us pursuant to any contractual arrangement that provides us with an option to repurchase such
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities in connection with the termination of such holder&#146;s employment or other service relationship with us, or pursuant to a right of first refusal with respect to transfers of such <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities or to cover taxes due upon or the consideration required in connection with the vesting, conversion or exercise of securities issued under an equity incentive plan or stock purchase plan of the
Company, including through the withholding of shares by, or surrender of shares to, us pursuant to a &#147;cashless&#148; or &#147;net exercise&#148; settlement feature, <I>provided that </I>the transferee or distributee agrees to such restrictions
for the remainder of the <FONT STYLE="white-space:nowrap">180-day</FONT> period, in the case of any transfer pursuant to (b)(i) above, such transfer does not involve a disposition for value, and any filing under the Exchange Act required to be made
during the remainder of the <FONT STYLE="white-space:nowrap">180-day</FONT> period shall clearly indicate in the footnotes thereto that the filing relates to circumstances described above; (c)&nbsp;prevent or restrict (i)&nbsp;the exercise, vesting
or settlement of any outstanding warrant, or any option to purchase common stock or other equity awards pursuant to any stock incentive plan or stock purchase plan of the Company (including in each case by &#147;net&#148; or &#147;cashless&#148;
exercise), <I>provided that</I> the underlying shares shall continue to be subject to the transfer restrictions, (ii)&nbsp;the establishment of a plan of disposition that complies with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the
Exchange Act (a <FONT STYLE="white-space:nowrap">&#147;10b5-1</FONT> Plan&#148;), or the amendment of an existing <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan, so long as such plan does not provide for sales of
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities during the remainder of the <FONT STYLE="white-space:nowrap">180-day</FONT> period; and <I>provided that</I> the establishment of a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan or the
amendment of a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan, in either case, providing for sales of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall only be permitted if (1)&nbsp;the establishment or amendment of such plan is
not required to be reported during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period in any public report or filing with the SEC or otherwise, and (2)&nbsp;such holder does not otherwise voluntarily effect any public filing or report
regarding the establishment or amendment of such plan during the remainder of the 180-day period, (iii)&nbsp;the conversion of the outstanding shares of preferred stock of the Company into shares of common stock, provided that any such shares of
common stock received upon such conversion shall be subject to the transfer restrictions, or (iv)&nbsp;the transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities pursuant to a bona fide third party tender offer, merger, consolidation
or other similar transaction made to all holders of common stock and involving a change of control of the Company, provided that in the event that the tender offer, merger, consolidation or other such transaction is not complete, the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities owned by such shall remain subject to the restrictions contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; (d)&nbsp;sales of common stock purchased by such holder in this
offering if and only if (i)&nbsp;such sales are not required to be reported in any public report or filing with the SEC, or otherwise and (2)&nbsp;such holder does not otherwise voluntarily effect any public filing or report regarding such sales; or
(e)&nbsp;sales of common stock purchased by such holder in the open market after the date of this prospectus, provided that any filing under the Exchange Act required to be made during the reminder of the 180-day period with respect to such sale
shall clearly indicate in the footnotes thereto that such common stock was purchased in the open market after the date of this offering and is not subject to the terms of the transfer restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market Listing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect
the shares to be approved for listing on the Nasdaq Global Market, subject to notice of issuance, under the symbol &#147;ABOS.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before this offering, there has been no public market for our common stock. The initial public offering price will be determined through
negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price are </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us,
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial information, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the history of, and the prospects for, our company and the industry in which we compete, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management, its past and present operations, and the prospects for, and timing of, our
future revenues, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the present state of our development, and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in
activities similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after the
offering the shares will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters do not expect to
sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions
and Penalty Bids </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from
bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing
shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect
investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open
market.&nbsp;&nbsp;&nbsp;&nbsp;The underwriters may conduct these transactions on the Nasdaq Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the
transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once
commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic
Area </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each a &#147;Relevant State&#148;), no offer of shares which are
the subject of this offering has been, or will be, made to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where
appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation), except that offers of shares may be made to the public in that Relevant State at any
time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require the Issuer or any underwriter to publish a prospectus pursuant to Article 3 of the
Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant State who
initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with the Company and the underwriters that it is a qualified investor within the meaning of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each
such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have
they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior
consent of the representatives has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company, the underwriters and their
affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the purposes of
this provision, the expression an &#147;offer to the public&#148; in relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU)
2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling restrictions set out below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters are not acting for anyone other than the issuer and will not be responsible to anyone other
than the issuer for providing the protections afforded to their clients nor for providing advice in relation to the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective
Investors in the United Kingdom </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In relation to the United Kingdom, or the UK, no offer of shares which are the subject of this
offering has been, or will be, made to the public in the UK prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and
the FSMA, except that offers of shares may be made to the public in the UK at any time under the following exemptions under the UK Prospectus Regulation and the FSMA: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the UK Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at any time in other circumstances falling within section 86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require the Issuer or any underwriter to publish a prospectus pursuant to Section&nbsp;85 of the
FSMA or Article 3 of the UK Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each
person in the UK who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with the Company and the underwriters that it is a qualified investor within the meaning of the UK
Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the UK
Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT>
basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in the UK to qualified investors, in circumstances in
which the prior consent of the representatives has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company, the underwriters and
their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the
purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares in the UK means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered
so as to enable an investor to decide to purchase or subscribe for any shares, the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act
2018, and the expression &#147;FSMA&#148; means the Financial Services and Markets Act 2000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters are not acting for anyone other than the
issuer and will not be responsible to anyone other than the issuer for providing the protections afforded to their clients nor for providing advice in relation to the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This document is for distribution only to persons who (i)&nbsp;have professional experience in matters relating to investments and who qualify
as investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the &#147;Financial Promotion Order&#148;), (ii) are persons falling within Article 49(2)(a)
to (d) (&#147;high net worth companies, unincorporated associations etc.&#148;) of the Financial Promotion Order, (iii)&nbsp;are outside the United Kingdom, or (iv)&nbsp;are persons to whom an invitation or inducement to engage in investment
activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000, as amended, or FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such
persons together being referred to as &#147;relevant persons&#148;). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which
this document relates is available only to relevant persons and will be engaged in only with relevant persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
Switzerland </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any
other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure
standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating
to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither this document nor
any other offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares
will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection
afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective
Investors in the Dubai International Financial Centre </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered
Securities Rules of the Dubai Financial Services Authority, or DFSA. This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any
other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility
for the prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not
understand the contents of this prospectus you should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities
and Investments Commission, or ASIC, in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#147;Corporations Act&#148;), and
does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt
Investors&#148;) who are &#147;sophisticated investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to
one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of
allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is
pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular
needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or
may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and
Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or
to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph,
&#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the shares were not offered or
sold or caused to be made the subject of an invitation for subscription or purchase and will not be offered or sold or caused to be made the subject of an invitation for subscription or purchase, and this prospectus or any other document or material
in connection with the offer or sale, or invitation for subscription or purchase, of the shares, has not been circulated or distributed, nor will it be circulated or distributed, whether directly or indirectly, to any person in Singapore other than
(i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from time to time (the &#147;SFA&#148;)) pursuant to Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of
the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable
provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities or securities-based derivatives contracts (each
term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the
shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the transfer is by operation of law; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a
purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed
by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or
consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a <FONT
STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the representatives
are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Cooley LLP, Reston, Virginia. Certain legal matters
will be passed upon for the underwriters by Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_21"></A>EXPERTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The financial statements of Acumen Pharmaceuticals, Inc. as of December&nbsp;31, 2019 and 2020 and for the years then ended,
appearing in this prospectus and registration statement have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance
upon such report given on the authority of such firm as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc104413_22"></A>WHERE YOU CAN
FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under
the Securities Act with respect to the shares of common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its
exhibits. For further information with respect to our company and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or
any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by
this reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You can read our SEC filings, including the registration statement, over the internet at the SEC&#146;s website at
www.sec.gov. Upon completion of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other
information will be available at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also maintain a website at www.acumenpharm.com, at which you may access these materials
free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated into, this
prospectus. We have included our website in this prospectus solely as an inactive textual reference. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc1"></A><A NAME="toc104413_23"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin104413_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin104413_2">Balance Sheets as of December&nbsp;31, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin104413_3">Statements of Operations for the years ended December&nbsp;
31, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin104413_4">Statement of Changes in Convertible Preferred Stock and Stockholders&#146;
 Equity for the years ended December&nbsp;31, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin104413_5">Statements of Cash Flows for the years ended December&nbsp;
31, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin104413_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin104413_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders and the Board of Directors of Acumen Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying balance sheets of Acumen Pharmaceuticals, Inc. (the Company) as of December&nbsp;31, 2020 and 2019, the related statements of operations, changes in convertible preferred stock and stockholders&#146; deficit and cash flows for the years
then ended, and the related notes<B>&nbsp;</B>(collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at
December&nbsp;31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of
America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our
audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst &amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditors since 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tysons, Virginia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;9, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin104413_2"></A>BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 43,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid service agreements, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 7,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 44,429</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche rights liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock, $0.0001 par value; 802,972 and 711,203 shares authorized as
of December&nbsp;31, 2019 and 2020; 711,203 shares issued and outstanding as of December&nbsp;31, 2019 and 2020; liquidation preference of $1,067 as of December&nbsp;31, 2019 and 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, $0.0001 par value;
12,710,059 and 11,898,177 shares authorized as of December&nbsp;31, 2019 and 2020; 11,231,511 shares issued and outstanding as of December&nbsp;31, 2019 and 2020; liquidation preference of $16,847 as of December&nbsp;31, 2019 and 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.0001 par value; 29,457,450 shares authorized as of
December&nbsp;31, 2020; 17,674,469 shares issued and outstanding as of December&nbsp;31, 2020; liquidation preference of $45,070 as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 17,400,000 and 50,500,000 shares authorized as of
December&nbsp;31, 2019 and 2020, respectively; 624,635 shares issued and outstanding as of December&nbsp;31, 2019 and 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,965</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,420</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,591</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities, convertible preferred stock and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 7,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 44,429</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin104413_3"></A>STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Grant and other revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights liability and preferred stock warrant
liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,907</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,325</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contribution related to common stock exchanged for Series A convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to common stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,686</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,325</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">642,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">624,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin104413_4"></A>STATEMENT OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFICIT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands,
except share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>774,352</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,162</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,959,649</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,929</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>666,687</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,116</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,733</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,617</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exchange of common stock for Series A convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,515</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exchange of Series A convertible preferred stock for Series
<FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, net of
$4 issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,157,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,907</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,907</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>711,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,067</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,231,511</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,333</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>624,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,220</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(19,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,420</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B convertible preferred stock for cash, net of issuance costs of $395</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,674,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>711,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,067</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,231,511</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,333</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,674,469</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>39,253</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>624,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,374</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(26,965</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(18,591</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin104413_5"></A>STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,907</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights liability and preferred stock warrant
liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(586</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,818</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,450</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from stock options exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, at the beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents, at the end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,552</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43,777</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange of common stock for Series A convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange of Series A convertible preferred stock for Series
<FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin104413_6"></A>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acumen Pharmaceuticals, Inc. (&#147;Acumen&#148; or the &#147;Company&#148;) was incorporated in 1996 in the state of Delaware. Acumen discovers and develops
targeted therapies for the treatment of Alzheimer&#146;s disease. Acumen&#146;s lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers (A<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>O).
Acumen and Merck&nbsp;&amp; Co. discovered and developed ACU193 through an eight-year research collaboration. Acumen currently holds exclusive rights to the program. The Company submitted an Investigation Drug Application (&#147;IND&#148;) for
ACU193 to the Food and Drug Administration (&#147;FDA&#148;) in the fourth quarter of 2020. We initiated a Phase 1 clinical trial of ACU193 in patients with early Alzheimer&#146;s disease in the second quarter of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to the uncertainty of whether the Company&#146;s intellectual property will develop into successful commercial products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;20, 2020,
the Company effected a 1:30 reverse stock split of its authorized, issued and outstanding shares of common stock and convertible preferred stock. Accordingly, all share and per share amounts for the periods presented in the accompanying financial
statements and these notes have been adjusted retroactively, where applicable, to reflect this reverse stock split. On November&nbsp;20, 2020, the Company also increased the number of shares of preferred stock and common stock authorized for
issuance (see Note 5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Capital Resources </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may
never become profitable. As of December&nbsp;31, 2020, the Company had an accumulated deficit of $27.0&nbsp;million. The Company has relied on raising capital from venture capital firms and private investors and funding from a government grant to
finance its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;20, 2020, the Company closed on the sale of an aggregate of 17,674,469 shares of Series B convertible preferred
stock for gross proceeds of $45.1&nbsp;million (the &#147;Initial Closing&#148;). Net proceeds from the Initial Closing, after deducting offering expenses, were $44.7&nbsp;million. Subject to the terms and conditions of the Series B Preferred Stock
Purchase Agreement (the &#147;Series B Agreement&#148;), if, after the Initial Closing, the Company achieves the milestone set forth in the Series B Agreement, then, as soon as practicable following the mutual determination by the Board of Directors
(&#147;Board&#148;) and the holders of at least 67% of the outstanding Series B convertible preferred stock shares then held by the Series B purchasers (the &#147;Requisite Investors&#148;) that the milestone event has occurred or has been waived,
the Company shall deliver a written notice to each Series B purchaser stating that the milestone event has been achieved. Notwithstanding the foregoing, at any time after the Initial Closing, the Requisite Investors may elect to waive the
achievement of the milestone event and consummate the subsequent closing (the &#147;Milestone Closing&#148;) by delivering a written election to the Company. At the Milestone Closing, the Company will sell an additional 11,782,981 shares of Series B
convertible preferred stock at $2.55 per share for gross proceeds of $30.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the Initial Closing, management believes that its
existing financial resources are sufficient to continue operating activities for at least one year past the issuance date of these financial statements. Future capital requirements will depend upon many factors, including the timing and extent of
spending on research and development, the achievement of the milestone event and related Milestone Closing, future receipt of grant revenue and market acceptance of the Company&#146;s products. The Company will need to obtain additional financing in
order to complete clinical trials and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available on terms acceptable to the Company, or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Capital Resources (continued) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The impact of the coronavirus <FONT STYLE="white-space:nowrap">(&#147;COVID-19&#148;)</FONT> outbreak on the Company&#146;s results of operations, financial
position and cash flows will depend on future developments, including the duration and spread of the outbreak and related advisories and restrictions. These developments and the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on the
financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#146;s results of operations, financial position and cash
flows may be materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2. BASIS OF PRESENTATION, SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING
PRONOUNCEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America
(&#147;U.S. GAAP&#148;) as determined by the Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, new
accounting pronouncements are issued by the FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not
have a material impact on the Company&#146;s financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended, the Company meets the definition of an emerging growth company and has elected the extended
transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and
the reported amounts of expenses during the reporting period. These estimates and assumptions are based on current facts and historical experience, as well as other pertinent industry and regulatory authority information, including the potential
future effects of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other
sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#146;s future results of operations will be affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers
all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company&#146;s cash equivalents consist of funds held in a money market account. The Company had $4.2&nbsp;million
and $36.8&nbsp;million in cash equivalents as of December&nbsp;31, 2019 and 2020, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents.
Periodically, the Company may maintain deposits in financial institutions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#146;s deposits are held at financial institutions that
management believes to be of high credit quality. The Company has not experienced any losses on these deposits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial assets and liabilities are accounted for in accordance with ASC 820,<I> Fair Value Measurements and Disclosures</I>
which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market
participants on the measurement date. The fair value hierarchy requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;1&#151;Observable inputs, such as quoted prices in active markets for identical assets or liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level 2&#151;Inputs other than Level&nbsp;1 inputs that are either directly or indirectly observable, such as quoted prices for similar assets or liabilities;
quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#146;s anticipated life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level 3&#151;Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires
more judgement. Accordingly, the degree of judgement exercised by management in determining fair value is greatest for instruments categorized as Level&nbsp;3. A financial instrument&#146;s level within the fair value hierarchy is based on the
lowest level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables present the Company&#146;s fair value hierarchy for its
money market securities, preferred stock tranche rights liability and preferred stock warrant liability measured at fair value on a recurring basis at December&nbsp;31, 2019 and 2020 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair Value Measured at December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active&nbsp;Markets&nbsp;for<BR>Identical Assets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant Other<BR>Observable&nbsp;Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>Unobservable<BR>Inputs<BR>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair Value at<BR>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets included in:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities included in:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair Value Measured at December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Quoted&nbsp;Prices in<BR>Active&nbsp;Markets&nbsp;for<BR>Identical Assets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant Other<BR>Observable&nbsp;Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>Unobservable<BR>Inputs<BR>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair Value at<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets included in:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities included in:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche rights liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying values reported in the Company&#146;s balance sheet for cash and cash equivalents, accounts payable, and accrued
expenses are reasonable estimates of their fair values due to the short-term nature of these items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Refer to Note 4 for further information about the
Level&nbsp;3 rollforward of activity and Level&nbsp;3 inputs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grant Receivable </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grant receivable consists of research expenses reimbursable under a grant from the National Institute of Health (&#147;NIH&#148;). The Company carries its
grant receivable at the unreimbursed amount. On a periodic basis, the Company evaluates its grant receivable to determine whether an allowance is required. The allowance is management&#146;s best estimate of probable losses. Management determined
that no allowance was necessary as of December&nbsp;31, 2019 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company has
applied the guidance in ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99-3A,</FONT></FONT></FONT><I> SEC Staff Announcement: Classification and Measurement of Redeemable Securities</I>
and has therefore classified the Series&nbsp;A, Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series B convertible preferred stock as mezzanine equity. The convertible preferred stock is recorded outside of stockholders&#146; deficit
because, in the event of certain deemed liquidation events considered not solely within the Company&#146;s control, such as a merger, acquisition and sale of all or substantially all of the Company&#146;s assets (a &#147;Deemed Liquidation
Event&#148;), the convertible preferred stock will become redeemable at the option of the holders. In the event of a change of control of the Company, proceeds received from the sale of such shares will be distributed in accordance with the
corresponding liquidation preferences. The Company did not adjust the carrying values of the convertible preferred stock to the deemed liquidation values of such shares since a liquidation event was not probable at any of the reporting dates.
Subsequent adjustments to increase or decrease the carrying values to the ultimate liquidation values will be made only if and when it becomes probable that such a liquidation event will occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Tranche Rights Liability </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company has determined that its obligation to issue, and the Company&#146;s investors&#146; right to purchase, additional shares of Series B convertible preferred stock pursuant to the Milestone Closing (see Note 4) represents a freestanding
financial instrument (the &#147;tranche liability&#148;). The tranche liability was initially recorded </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at fair value. The proceeds from the sale of the convertible preferred stock are first allocated to the fair value of the tranche liability with the remaining proceeds from the sale of the
convertible preferred stock allocated to the Series B convertible preferred stock. The tranche liability is remeasured at each reporting period and upon the exercise or expiration of the obligation, with gains and losses arising from subsequent
changes in its fair value recognized in other income and expense in the statement of operations. At the time of the exercise or expiration of the tranche liability, any remaining value of the tranche liability will be reclassified to convertible
preferred stock on the balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Warrant Liability </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for the warrant to purchase Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock as a liability as this warrant
is a freestanding financial instrument that may require the Company to transfer assets upon exercise. The warrant liability was initially recorded at fair value. The warrant liability is remeasured at each reporting period until the earlier of the
exercise or expiration of the applicable warrant, with gains and losses arising from subsequent changes in its fair value recognized in other income and expense in the statement of operations. At the time of the exercise or expiration of the warrant
liability, any remaining value of the warrant liability will be reclassified to convertible preferred stock on the balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock
Warrants </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were
(1)&nbsp;indexed to the Company&#146;s own stock and (2)&nbsp;classified in stockholders&#146; equity in accordance with FASB&nbsp;ASC Topic 815,<I>&nbsp;Derivatives and Hedging</I>. As such the Company has concluded the warrants meet the scope
exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders&#146; equity.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grant and
Other Revenue Recognition </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s NIH grant is not within the scope of ASC 606, <I>Revenue from Contracts with Customers,</I> as the
grant does not meet the definition of a contract with a customer. The Company has concluded that the grant meets the definition of a contribution and is a <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transaction, and management has also
concluded that Subtopic <FONT STYLE="white-space:nowrap">958-605,</FONT><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&nbsp;Not-for-Profit-Entities-Revenue</FONT></FONT> Recognition</I>&nbsp;does not apply, as Acumen is a
business entity and the grant is with a governmental agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the absence of applicable guidance under U.S. GAAP, the Company&#146;s policy is to
recognize grant revenue when the related costs are incurred and the right to payment is realized. Costs incurred are recorded in research and development and general and administrative expenses on the accompanying statements of operations</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a
service over time under ASC 606. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses primarily consist of consultants and materials, biologic storage, salaries and other personnel-related expenses related to
research and development activities and are expensed as incurred. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected on the balance sheet as
prepaid or accrued expenses. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events,
invoices received and contracted costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses stock-based compensation to employees, <FONT STYLE="white-space:nowrap">non-employees</FONT> and board members over the requisite service
period based on the estimated grant-date fair value of the awards and actual forfeitures. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, which requires the use of a number of complex
assumptions including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends, and the expected term of the option. The assumptions used in calculating the fair value of stock-based awards represent
management&#146;s best estimates and involve inherent uncertainties and the application of management&#146;s judgment. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for
each separately vesting portion of the award. All stock-based compensation costs are recorded in research and development expense or general and administrative expense in the statements of operations based upon the respective employee&#146;s or <FONT
STYLE="white-space:nowrap">non-employee&#146;s</FONT> roles within the Company. Forfeitures are recorded as they occur. See also Note 6 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income taxes are recorded in
accordance with ASC 740, <I>Income Taxes</I> (&#147;ASC 740&#148;), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of
events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in
effect for the year in which the differences are expected to reverse, and net operating loss (&#147;NOL&#148;) carryforwards and research and development tax credit (&#147;R&amp;D Credit&#148;) carryforwards. Valuation allowances are provided if,
based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In
the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset valuation allowance would increase income in the period such
determination was made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions
exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than
not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. There were no uncertain tax positions that require accrual or disclosure in the financial statements as of
December&nbsp;31, 2019 and 2020. The Company&#146;s policy is to record interest and penalties, if any, as part of income tax benefit. No interest or penalties were recorded for the years ended December&nbsp;31, 2019 and 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share of Common Stock </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net
loss per share of common stock is calculated using the <FONT STYLE="white-space:nowrap">two-class</FONT> method under which earnings are allocated to both common shares and participating securities based on their participation rights. Net loss
attributable to common stockholders is not allocated to the convertible preferred stock as the holders of the convertible preferred stock do not have a contractual obligation to share in any losses.&nbsp;Basic net loss per share is calculated by
dividing the net loss attributable to common shares by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed by dividing the net loss using the weighted-average
number of shares of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of stock options and warrants to purchase common stock (using the treasury stock method), and the conversion
of convertible preferred stock and the preferred warrant (using the <FONT STYLE="white-space:nowrap">if-converted</FONT> method). See Note 9 below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating
decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in&nbsp;one&nbsp;segment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
August 2018, the FASB issued&nbsp;ASU&nbsp;No. <FONT STYLE="white-space:nowrap">2018-13,</FONT><I>&nbsp;Fair Value Measurement (Topic 820): Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement.</I> This new
guidance removes certain disclosure requirements related to the fair value hierarchy, modifies existing disclosure requirements related to measurement uncertainty and adds new disclosure requirements. The new disclosure requirements include
disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level&nbsp;3 fair value measurements held at the end of the reporting period and the range and weighted-average of significant
unobservable inputs used to develop Level&nbsp;3 fair value measurements. This new guidance was effective for the Company beginning on January&nbsp;1, 2020 and did not have a material impact on the Company&#146;s financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT><I> Leases (Topic 842)</I>, as amended, with guidance regarding the accounting for and disclosure of leases. This update requires lessees to recognize the
liabilities related to all leases, including operating leases, with a term greater than 12 months on the balance sheet. This update also requires lessees and lessors to disclose key information about their leasing transactions. This guidance will
become effective for the Company for annual reporting periods beginning after December&nbsp;15, 2021 and interim periods within fiscal years beginning after December&nbsp;15, 2022. The adoption of Topic 842 is not expected to have a material impact
on the financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Income Taxes (Topic 740):
Simplifying the Accounting for Income Taxes </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2019-12&#148;),</FONT> which is intended to simplify various aspects related to accounting for income taxes. ASU
<FONT STYLE="white-space:nowrap">2019-12</FONT> removes certain exceptions to the general principles in ASC 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and
interim periods within those fiscal years, beginning after December&nbsp;15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 3. SUPPLEMENTAL FINANCIAL INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid
expenses and other current assets consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid raw materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 4. CONVERTIBLE PREFERRED STOCK, TRANCHE RIGHTS LIABILITY AND WARRANT LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31,
2019 and 2020, convertible preferred stock consisted of the following (in thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Issuance Price<BR>per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">802,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">711,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,710,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,231,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,513,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,942,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="20"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;Issued&nbsp;and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Issuance&nbsp;Price<BR>per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">711,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">711,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,898,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,231,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,457,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,674,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,066,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,617,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;20, 2020, the Company entered into the Series B Agreement for a private placement of up to 29,457,450 shares
of Series B convertible preferred stock, $0.0001 par value per share, at an original issuance price of $2.55 per share, subject to separate closings, including: (1) 17,674,469 shares at the Initial Closing on November&nbsp;20, 2020, and (2)
11,782,981 shares at a subsequent closing that would be triggered by the achievement of a specific clinical milestone. The Series B Agreement obligates the Company to issue and sell and the Series B purchasers to purchase up to a total of 11,782,981
additional shares of Series B convertible preferred stock (the &#147;Milestone Shares&#148;) at the same price per share upon the achievement of a certain defined clinical milestone. The determination as to whether the milestone event has been met
is subject to certification by the Board and the Requisite Investors. Each Series B convertible preferred stock investor has the right, but not the obligation, to purchase all or any portion of the Milestone Shares at any time in its sole option and
in its sole and absolute discretion, whether or not the Company achieves the applicable clinical milestone. However, in the event that the Milestone Closing occurs, if any Series B purchaser fails to purchase its respective portion of the Milestone
Shares, each existing share of Series B convertible preferred stock held by such stockholder will automatically convert into one share of common stock. See &#147;<I>Series B Convertible Preferred Stock Tranche Rights Liability</I>&#148; below). </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;19, 2018, the Company entered into the Series <FONT STYLE="white-space:nowrap">A-1</FONT> and
Series A Preferred Stock Purchase and Exchange Agreements (the &#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series A Agreements&#148;). Under the Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series A Agreements, the Company
sold 5,442,867 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, $0.0001 par value per share, at a purchase price of $1.50 per share for gross proceeds of $8.2&nbsp;million. Convertible notes issued in 2018
including accrued interest thereon totaling $275,000, were converted into 183,333 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and convertible notes issued in 2014 through 2017 including accrued interest
thereon, totaling $3.1&nbsp;million were converted into 2,043,757 shares of Series A convertible preferred stock, $0.0001 par value per share, in each case at a conversion rate of $1.50 per share. Additionally, the holders of Series A convertible
preferred stock and the holders of common stock were given the option to exchange their respective shares into shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and Series A convertible preferred stock,
respectively, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis. A total of 1,333,449 shares of Series A convertible preferred stock were exchanged for Series
<FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and a total of 64,060 shares of common stock were exchanged for Series A convertible preferred stock. The difference between the book value of the common shares and the issuance
price of the Series A convertible preferred shares for which they were exchanged was recorded as a contribution in the statement of stockholders&#146; deficit. On October&nbsp;19, 2018, the Company also issued a warrant to purchase 666,666 shares of
Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock at an exercise price of $1.875. This warrant has a term of 10 years and an aggregate grant date fair value of $430,000 (see &#147;<I>Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Convertible Preferred Stock Warrant Liability&#148; below</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2019, the Company sold an additional
4,157,198 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock at a purchase price of $1.50 per share for gross proceeds of $6.2&nbsp;million. Additionally, a total of 114,664 shares of Series A convertible
preferred stock were exchanged for Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and a total of 51,515 shares of common stock were exchanged for Series A convertible preferred stock. The exchange of Series A
convertible preferred stock for Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock was accounted for on a prospective basis as the exchange was not considered to be a significant modification, and the Company reclassified
$1.50 per share from Series A convertible preferred stock to Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock. The exchange of common stock for Series A convertible stock was accounted for as an extinguishment as the
exchange was considered to be a significant modification, and the common shares were retired by the Company at the common shares&#146; book value, with the difference between that and the Series A convertible preferred stock issuance price of $1.50
per share recorded as a contribution in the statement of stockholders&#146; deficit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Series B, Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series A convertible preferred stock are entitled to receive dividends ahead
of, or simultaneously with, common stockholders in an amount equal to the product of (A)&nbsp;the dividend payable on each share of the class or series of convertible preferred stock determined, if applicable, as if all shares of such class or
series of convertible preferred stock had been converted into common stock and (B)&nbsp;the number of shares of common stock issuable upon conversion of a share of preferred stock. No dividends have been declared since inception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation preference </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or
involuntary liquidation, dissolution or winding up of the Company, holders of Series B convertible preferred stock are entitled to receive, prior and in preference to, holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible
preferred stock, Series A convertible preferred stock, and holders of common stock, in the amount of the original issue price plus any declared but unpaid dividends thereon. If upon occurrence of such an event, the assets and funds to be distributed
among the holders of Series B convertible preferred stock are insufficient to permit full payment to such holders, the entire assets and funds of the Company legally available for distribution will be distributed ratably among the holders of the
Series B convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, holders
of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock are entitled to receive, prior and in preference to, holders of Series A convertible preferred stock and holders of common stock, in the amount of the original issue
price plus any declared but unpaid dividends thereon. If upon occurrence of such an event, the assets and funds to be distributed among the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock are insufficient to
permit full payment to such holders, the entire assets and funds of the Company legally available for distribution will be distributed ratably among the holders of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, holders of Series A convertible preferred stock are
entitled to receive, prior and in preference to, holders of common stock, in the amount of the original issue price plus any declared but unpaid dividends thereon. If upon occurrence of such an event, the assets and funds to be distributed among the
holders of Series A convertible preferred stock are insufficient to permit full payment to such holders, the entire assets and funds of the Company legally available for distribution will be distributed ratably among the holders of the Series A
convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of all series of convertible preferred stock are convertible into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT>
shares of common stock as determined by dividing the original issuance price for such series by the applicable conversion price for such series then in effect. The initial conversion price per share for each series of convertible preferred stock is
the original issue price applicable to such series as shown in the table above, subject to adjustment in the event of certain dilutive issuances. The convertible preferred stock original issuance price and conversion price are each subject to
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of convertible preferred stock is convertible at any time at the option of the holder at the conversion ratio then in effect. In addition, each
share of convertible preferred stock will be automatically converted into common stock at the conversion ratio then in effect upon either (a)&nbsp;the closing of an underwritten public offering resulting in gross proceeds to the Company of at least
$75&nbsp;million and at a price per share equal to at least two times the Series B convertible preferred stock original issuance price, or $5.10 (subject to adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to the Series B convertible preferred stock), or (b)&nbsp;the date and time, or the occurrence of an event, specified in such vote or written consent of at least 67% of the holders of the then outstanding shares of
Series B convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Two days after the closing for the Milestone Shares occurs, if ever, each share of Series B convertible preferred
stock held by a purchaser that fails to purchase its applicable Milestone Shares shall be automatically converted into one fully-paid, <FONT STYLE="white-space:nowrap">non-assessable</FONT> share of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting rights </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of convertible preferred stock
are entitled to vote as a single class together with the holders of common stock and have one vote for each share of common stock into which the convertible preferred stock is convertible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Series B convertible preferred stock are entitled to elect two directors to the Board, and the holders of Series A and Series <FONT
STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, voting together as a single class, are also entitled to elect two directors to the Board. The holders of common stock, exclusively and as a separate class, are entitled
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to elect two directors to the Board. The final director to the Board is designated by the holders of a majority of the shares of the preferred stock and common stock, voting together as a single
class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A majority of the outstanding shares of convertible preferred stock is necessary for approving certain matters, including the ability to either
increase or decrease the authorized number of directors constituting the Board, pursuant to protective provisions in the Company&#146;s amended and restated certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series B Convertible Preferred Stock Tranche Rights Liability </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company concluded that the tranche liability met the definition of a freestanding financial instrument, as it was legally detachable and separately
exercisable from the initial closing of the Series B convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair value of the tranche liability was determined using
the option pricing method (&#147;OPM&#148;) backsolve approach, which was calculated based on the aggregate equity value of the Company derived from the Series B convertible preferred stock offering price of $2.55 per share at the initial issuance
date. As of November&nbsp;20, 2020, the estimated fair value of the tranche liability was $5,422,000. The initial valuation also considered, in part, the following subjective assumptions: risk-free rate of 0.16%, an expected volatility of 90%, the
expected term to a liquidity event of 2.1 years, and a 70% probability of achieving the milestone event, or Milestone Closing. At December&nbsp;31, 2020, the estimated fair value of the tranche liability was $5,033,000 and was again determined using
the OPM backsolve method, which was calculated based on the aggregate equity value of the Company derived from the Series B convertible preferred stock offering price of $2.55 per share. The subsequent remeasurement also considered, in part, a
risk-free rate of 0.13%, an expected volatility of 90%, the expected term to a liquidity event of 2.0 years, and a 65% probability of achieving the Milestone Closing. The resulting difference of $389,000 has been recognized as a change in fair value
within other income in the accompanying statements of operations. The tranche liability will be revalued each reporting period with the change in fair value recorded in the accompanying statements of operations until the Milestone Shares are issued,
or it becomes apparent that the milestone event will not be achieved and the Milestone Shares will never be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Convertible Preferred Stock Warrant Liability </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;19, 2018, the Company issued a <FONT
STYLE="white-space:nowrap">10-year</FONT> warrant (the &#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Warrant&#148;) to purchase up to an aggregate of 666,666 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible
preferred stock at an exercise price of $1.875 on or before October&nbsp;18, 2028. The Series <FONT STYLE="white-space:nowrap">A-1</FONT> Warrant was issued in connection with the Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series A
Agreements. As of December&nbsp;31, 2019 and 2020, this Series <FONT STYLE="white-space:nowrap">A-1</FONT> Warrant remained outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrant
liability met the definition of a freestanding financial instrument, as it was legally detachable and separately exercisable from the initial closing of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock. As such, it
is revalued each reporting period with the change in fair value recorded in the accompanying statements of operations until the warrant is exercised or expires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the warrant liability was estimated using the OPM backsolve method using the following assumptions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of the tranche liability and warrant liability measured at fair
value using Level&nbsp;3 significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT><BR>Preferred&nbsp;Stock<BR>Warrant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series&nbsp;B&nbsp;Tranche<BR>Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, January&nbsp;1, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at issuance of Series B convertible preferred stock (November&nbsp;2020)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(586</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 5. STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Authorized Shares </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company amended its
certificate of incorporation on November&nbsp;20, 2020, such that the total number of shares of common stock authorized to be issued was increased to 50,500,000, and the total number of shares of preferred stock authorized to be issued was increased
to 42,066,830, of which 711,203 are designated Series A convertible preferred stock, 11,898,177 are designated as Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 29,457,450 are designated as Series B convertible
preferred stock. The certificate of incorporation was also amended for the reverse stock split that became effective on November&nbsp;20, 2020 (see Note 1). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the
Company&#146;s Amended and Restated Certificate of Incorporation authorized the issuance of 50,500,000 shares of common stock, $0.0001 par value per share. Each share of common stock is entitled to one voting right. The holders of common stock are
entitled to elect two directors to the Board. Holders of common stock, voting together as a single class with the holders of preferred stock, may also designate an additional director to the Board. Common stock owners are entitled to dividends when
funds are legally available and declared by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock Warrants </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019 and 2020, the outstanding warrants to purchase the Company&#146;s common stock were comprised of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Equity&nbsp;Upon</B><br><B>Exercise</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Expiration<BR>Dates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants issued in 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Common&nbsp;Stock</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">3/21/2024<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">6/30/2025</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;-&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants issued in 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Common Stock</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/30/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants issued in 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Common Stock</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/30/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants issued in 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Common Stock</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/30/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">574,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">574,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 6. STOCK-BASED COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;8, 2013, the Board and stockholders adopted the Company&#146;s Amended and Restated Stock Performance Plan (as amended from time to time, most
recently on November&nbsp;20, 2020, the &#147;Plan&#148;). The Plan provides for the grant of incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, issuance of shares of restricted stock and other equity
awards to the Company&#146;s employees, officers, directors, consultants and advisors. As of December&nbsp;31, 2020, the aggregate number of shares authorized for issuance under the Plan totaled 6,227,011 and there were 4,688,586 shares available
for future grants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Black-Scholes option-pricing model was used to estimate the fair value of stock options with the following weighted average
assumptions for the year ended December&nbsp;31, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.9%&nbsp;-&nbsp;2.6%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5.4&nbsp;-&nbsp;5.8</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">85%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s common stock underlying the stock options has historically been determined by the Board
with assistance from management and, occasionally with input from an independent third-party valuation firm. For the years ended December&nbsp;31, 2019 and 2020, management engaged an independent third-party valuation firm to provide an estimate of
the fair value of its common stock. The fair value of common stock was determined considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial
performance, the lack of liquidity of the Company&#146;s common stock and the general and industry-specific economic outlook.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019
and 2020, management, with the assistance of independent third-party valuation firms, estimated the fair value of a share of common stock to be $0.56 and $0.56, respectively. The range of assumptions used in these valuations were: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.1%&nbsp;-&nbsp;2.5%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected time to liquidity event in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">2.0&nbsp;-&nbsp;4.0</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">85%&nbsp;-&nbsp;90%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stock options granted after December&nbsp;31, 2017 vest monthly over 24 or 36 months and have a <FONT
STYLE="white-space:nowrap">ten-year</FONT> contractual term. Stock options granted prior to December&nbsp;31, 2017 were either fully vested upon grant or generally vested monthly over a range of three to 24 months and have a <FONT
STYLE="white-space:nowrap">ten-year</FONT> term. The Company lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of
peer companies. Due to the lack of historical exercise history, the expected term of the Company&#146;s stock options has been determined using the &#147;simplified&#148; method for awards. The risk-free interest rate is determined by reference to
the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and
does not expect to pay any cash dividends in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted average grant date fair value of options granted during the year ended
December&nbsp;31, 2019 was $0.34 per share. There were no options granted during the year ended December&nbsp;31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table reflects summarized stock option activity during the years ended December&nbsp;31, 2019
and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Stock&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted&nbsp;Average<BR>Exercise Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual&nbsp;Life<BR>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value<BR>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,359,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options forfeited or canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,497,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,492,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and exercisable at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,075,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intrinsic value of stock options exercised during the year ended December&nbsp;31, 2019 was $0. As of December&nbsp;31,
2020, the total unrecognized compensation costs related to unvested stock option awards granted was approximately $136,000, which the Company expects to recognize over a weighted-average period of approximately one year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded stock-based compensation expense in the following expense categories of its statements of operations for the years ended
December&nbsp;31, 2019 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 7. INCOME TAXES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No
provision for federal income taxes has been recorded for the years ended December&nbsp;31, 2019 and 2020. Current income taxes are based upon the year&#146;s income taxable for federal and state tax reporting purposes. Deferred income taxes
(benefits) are provided for certain income and expenses, which are recognized in different periods for tax and financial reporting purposes. Deferred tax assets and liabilities are computed for differences between the financial statements and tax
bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the period in which the differences are expected to affect taxable income, and net operating loss
(&#147;NOL&#148;) carryforwards and research and development (&#147;R&amp;D&#148;) tax credit carryforwards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the expected tax computed at the U.S. statutory federal income tax rate to the total
benefit for income taxes for the years ended December&nbsp;31, 2019 and 2020 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory federal income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State tax, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#146;s deferred tax assets as of December&nbsp;31, 2019 and 2020 were as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,784</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets, net of allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In assessing the realizability of deferred tax assets as of December&nbsp;31, 2019 and 2020, management considered whether it
is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary
differences become deductible or the NOL carryforwards and R&amp;D tax credit carryforwards will be used. The Company has determined that it is not more likely than not that its deferred tax assets will be realized. Accordingly, a valuation
allowance has been recorded as of December&nbsp;31, 2019 and 2020, to fully offset the net deferred tax assets of $5.8&nbsp;million and $8.1&nbsp;million, respectively. The change in the valuation allowance from December&nbsp;31, 2019 to
December&nbsp;31, 2020 is due to the current year pretax loss incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had approximately $22.3&nbsp;million of
NOL carryforwards available for federal tax purposes which begin to expire on December&nbsp;31, 2028. As a result of the Tax Act of 2017, for U.S. income tax purposes, NOLs generated prior to December&nbsp;31, 2017 can still be carried forward for
up to 20&nbsp;years, but NOLs generated after December&nbsp;31, 2017 carryforward indefinitely, but are limited to 80% utilization against taxable income. Of the total federal NOL of $22.3&nbsp;million, $6.4&nbsp;million will begin to expire in 2028
and $15.9&nbsp;million will not expire but will only offset 80% of future taxable income. The Coronavirus Aid, Relief, and Economic Security Act (&#147;CARES Act&#148;), signed into law on March&nbsp;27, 2020, provided that NOLs generated in a
taxable year beginning in 2018, 2019, or 2020, may now be carried back five years and forward indefinitely. In addition, the 80% taxable income limitation is temporarily removed, allowing NOLs to fully offset net taxable income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company also had a combined total of approximately $31.0&nbsp;million of state NOL carryforwards. The state NOLs begin to
expire on December&nbsp;31, 2028. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had approximately $1.7&nbsp;million of R&amp;D credit carryforwards
available for federal tax purposes, which begin to expire on December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOL carryforwards and R&amp;D carryforwards may be subject to a
substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section&nbsp;382 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), as well as similar
state and foreign provisions. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be used annually to offset future taxable income and tax, respectively. In general, an &#147;ownership change&#148; as
defined by Section&nbsp;382 of the Code results from a transaction or series of transactions over a&nbsp;three-year&nbsp;period resulting in an ownership change of more than 50% of the outstanding stock of a company by certain stockholders. The
Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#146;s formation due to the complexity and cost associated with such study, and the fact
that there may be additional such ownership changes in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company conducts intensive research and experimentation activities, generating
R&amp;D tax credits for federal and state purposes under section 41 of the Code. The Company has not performed a formal study validating these credits claimed in the tax returns. Once a study is prepared, the amount of R&amp;D tax credits available
could vary from what was originally claimed on the tax returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to U.S. federal and various state taxes. Generally, the tax years
remain open for examination by the federal statute under a three-year statute of limitation; however, states generally keep their statutes open for four years. However, the Company&#146;s tax years from 2003 and after are subject to examination by
the United States and state taxing authorities due to the carry forward of unused NOLs and R&amp;D credits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 8. COMMITMENTS AND CONTINGENCIES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may
be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 9. NET LOSS PER SHARE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company computes loss per common share of the common stock using the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for participating
securities. Basic and diluted loss per share was the same for each period presented as the inclusion of all potential common stock outstanding would have been anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per common share because to do so would be
anti-dilutive: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issuable upon conversion of Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">711,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">711,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issuable upon conversion of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,231,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,231,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issuable upon conversion of Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,674,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issuable upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,497,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,492,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issuable upon exercise of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">574,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">574,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issuable upon exercise of preferred stock warrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,681,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,350,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 10. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has completed an evaluation of all subsequent events through April&nbsp;9, 2021 to ensure that these financial statements include appropriate
disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements. Except as described below, the Company has concluded that no subsequent event has occurred that requires
disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Incentive Plan </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
January&nbsp;4, 2021, options to purchase 3,694,711 shares of common stock under the Plan were awarded to certain employees, directors, advisors and consultants of the Company with an exercise price per share of $0.80. The January&nbsp;4, 2021
option grants have a <FONT STYLE="white-space:nowrap">ten-year</FONT> term and nearly all of the award vest monthly over a four-year period after a <FONT STYLE="white-space:nowrap">one-year</FONT> cliff. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lease </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has been subleasing space in
Indiana since March&nbsp;1, 2020 under a lease that expired on December&nbsp;31, 2020. The Company executed a new sublease for this space that was effective February&nbsp;1, 2021. The term of the sublease is for 31 months, expiring on
August&nbsp;30, 2023. The Company will pay monthly rent of $12,719 and is also allowing others to sublease a portion of the space from the Company for less than a <FONT STYLE="white-space:nowrap">one-year</FONT> period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Through and
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (the 25th day after the commencement of this offering), all dealers that buy, sell or trade shares of our common stock, whether or not
participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or
subscriptions. </P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g104413g21g20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>BofA&nbsp;Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Credit&nbsp;Suisse </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Stifel </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UBS Investment
Bank </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P><center>
<P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Item&nbsp;13.&nbsp;Other&nbsp;Expenses of Issuance and Distribution. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than
underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission, or SEC, registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and
the Nasdaq Global Market initial listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;Amount&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market initial listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be provided by amendment </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Item&nbsp;14. Indemnification of Directors and Officers. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the State of Delaware. Section&nbsp;102 of the Delaware General Corporation Law permits a corporation to
eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good
faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee
or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlements actually and reasonably
incurred by the person in connection with an action, suit or proceeding to which he is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed
to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification
shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite
the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As permitted by the Delaware General Corporation Law, our amended and restated certificate of incorporation and bylaws to be in effect upon
the closing of this offering will provide that: (i)&nbsp;we are required to indemnify our directors to the fullest extent permitted by the Delaware General Corporation Law; (ii)&nbsp;we may, in our discretion, indemnify our officers, employees and
agents as set forth in the Delaware General Corporation Law; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(iii)&nbsp;we are required, upon satisfaction of certain conditions, to advance all expenses incurred by our directors in connection with certain legal proceedings; (iv)&nbsp;the rights conferred
in the bylaws are not exclusive; and (v)&nbsp;we are authorized to enter into indemnification agreements with our directors, officers, employees and agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we expect to enter into indemnification agreements with each of our directors and executive officers that
require us to indemnify them against expenses, judgments, fines, settlements and other amounts that any such person becomes legally obligated to pay (including with respect to a derivative action) in connection with any proceeding, whether actual or
threatened, to which such person may be made a party by reason of the fact that such person is or was a director or officer of us or any of our affiliates, provided such person acted in good faith and in a manner such person reasonably believed to
be in, or not opposed to, our best interests. The indemnification agreements will also set forth certain procedures that will apply in the event of a claim for indemnification thereunder. We intend to enter into similar indemnification agreements
with our executive officers prior to the completion of this offering. At present, no litigation or proceeding is pending that involves any of our directors or officers regarding which indemnification is sought, nor are we aware of any threatened
litigation that may result in claims for indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We maintain a directors&#146; and officers&#146; liability insurance policy.
The policy insures directors and officers against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses us for those losses for which we have lawfully indemnified the directors and
officers. The policy contains various exclusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the underwriting agreement filed as Exhibit 1.1 to this Registration
Statement provides for indemnification by the underwriters of us and our officers and directors for certain liabilities arising under the Securities Act, or otherwise. Our amended and restated investor rights agreement with certain investors also
provides for cross-indemnification in connection with the registration of our common stock on behalf of such investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Item&nbsp;15. Recent Sales
of Unregistered Securities. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following list sets forth information regarding all unregistered securities sold by us since
January 2018 through the date of the prospectus that forms a part of this registration statement. None of the following transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise specified
above, we believe these transactions were exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act (and Regulation D promulgated thereunder) or Rule 701 promulgated under Section 3(b) of the Securities
Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions
to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate
access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Common Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have not issued any common stock since January 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Convertible Notes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2018, we issued and sold convertible promissory notes to two individual and institutional accredited investors, pursuant to which we
issued and sold $250,000 aggregate principal amount of convertible promissory notes in exchange for $250,000 in gross proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2018 with subsequent closings through November 2019, we issued 2,159,332 shares of our Series A convertible preferred stock and
11,231,512 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock to 46 individual and institutional accredited investors. Of these shares, we sold an aggregate of 9,600,066 shares of our Series <FONT
STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock for $1.50 per share, for aggregate consideration of $14.4&nbsp;million. The remaining shares were issued as conversions of notes and shares of common stock into shares of Series A
convertible preferred stock and conversions of Series A convertible preferred stock into shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2020, we issued 17,674,469 shares of our Series B convertible preferred stock to 31 individual and institutional accredited
investors for $2.55 per share, for aggregate consideration of $45.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Warrants </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2018, we issued a warrant to purchase 666,666 shares of our Series A-1 preferred stock, with a per-share exercise price of $1.875
per share to an accredited institutional investor. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Issuances Pursuant to our Equity Plans </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From January&nbsp;1, 2018 through the date of this registration statement, we granted options under our Amended and Restated Stock Performance
Plan to purchase an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, at </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a weighted
average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, to our employees and consultants. Of these, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares have been issued upon the
exercise of options, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;options have been cancelled. We have also granted no restricted stock awards under our Amended and Restated Stock Performance Plan during the same
time period. The recipients of these securities were employees, directors or bona fide consultants of the Registrant and received the securities under the Prior Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Item&nbsp;16. Exhibits and Financial Statement Schedules. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Exhibits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The exhibits
listed below are filed as part of this registration. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d104413dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant (as amended and currently in effect) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d104413dex32.htm">Amended and Restated Bylaws of the Registrant (currently in effect) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation of the Registrant (to be effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws of the Registrant (to be effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d104413dex41.htm">Amended and Restated Investors&#146; Rights Agreement, by and among the Registrant and certain of its stockholders, dated November 20, 2020 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Cooley LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Collaboration Agreement, by and between the Registrant and Merck&nbsp;&amp; Co., Inc., dated December&nbsp;22, 2003, as amended and restated as of October&nbsp;18, 2006</TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2021 Equity Incentive Plan and Forms of Option Grant Notice and Agreement, Exercise Notice, Early Exercise Notice and Restricted Stock Award Notice</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2021 Stock Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2021 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2013 Amended and Restated Stock Performance Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement with Executive Officers and Directors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d104413dex107.htm">Executive Employment Agreement, by and between the Registrant and Daniel O&#146;Connell </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d104413dex108.htm">Employment Agreement by and between the Registrant and Eric Siemers, M.D. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d104413dex109.htm">Employment Agreement by and between the Registrant and Russell Barton </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Cooley LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page)</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment will be requested for portions of this agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Financial Statement Schedules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the
financial statements or notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Item&nbsp;17. Undertakings. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement,
certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit
or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the
form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be
part of this Registration Statement as of the time it was declared effective. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment
that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized in the City of Charlottesville, Commonwealth of Virginia, on this &nbsp;&nbsp;&nbsp;&nbsp;day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>Acumen Pharmaceuticals, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Daniel O&#146;Connell</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and
appoints Daniel O&#146;Connell and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and each of them, as his or her true and lawful agents, proxies and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to (i)&nbsp;act on, sign and file with the Securities
and Exchange Commission any and all amendments (including post-effective amendments) to this registration statement together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under the
Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii)&nbsp;act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith,
(iii)&nbsp;act on and file any supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and
(iv)&nbsp;take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> or any of his substitutes may lawfully do or cause to be done by virtue thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="19%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Chief Executive Officer and Director<BR><I>(Principal Executive Officer,<BR>Principal Financial Officer and<BR>Principal Accounting Officer)</I></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel O&#146;Connell</P> <P STYLE="font-size:36pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jeffrey L. Ives, PhD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sean Stalfort</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Laura Stoppel, PhD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stephen Zachary, PhD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jeffrey Sevigny, M.D.</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN
PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Sections 242 and 245 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acumen Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the
State of Delaware (the <B>&#147;General Corporation Law&#148;), </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1. </B>That the name of this corporation is Acumen Pharmaceuticals, Inc., and that this corporation was originally incorporated pursuant to
the General Corporation Law on January&nbsp;4, 1996 under the name &#147;Acumen Pharmaceuticals, Inc.&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2. </B>That the Board of
Directors duly adopted resolutions proposing to amend and restate the Certificate of incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and
authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED, </B>that the Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FIRST: </B>The name of this corporation is Acumen Pharmaceuticals, Inc. (the &#147;<B>Corporation</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECOND: </B>The address of the registered office of the Corporation in the State of Delaware is 251 Little Falls Drive, in
the City of Wilmington 19808, County of New Castle. The name of its registered agent at such address is Corporation Service Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIRD: </B>The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for
which corporations may be organized under the General Corporation Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FOURTH: </B>The total number of shares of all
classes of stock which the Corporation shall have authority to issue is (i) 50,500,000 shares of Common Stock, $0.0001 par value per share <B>(&#147;Common Stock&#148;) </B>and (ii) 42,066,830 shares of Preferred Stock, $0.0001 par value per share
<B>(&#147;Preferred Stock&#148;). </B>Immediately upon the filing of this Amended and Restated Certificate with the Secretary of State of the State of Delaware (the <B>&#147;Effective Time&#148;), </B>(i) every 30 shares of Common Stock issued and
outstanding immediately prior to the Effective Time shall be combined into one share of Common Stock, (ii)&nbsp;every 30 shares of Series A Preferred Stock issued and outstanding immediately prior to the Effective Time shall be combined into one
share of Series A Preferred Stock and (iii)&nbsp;every 30 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock issued and outstanding immediately prior to the Effective Time shall be combined into one share of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (the <B>&#147;Reverse Stock Split&#148;), </B>in each case automatically and without any action on the part of the respective holders thereof; <I>provided, however, </I>that the Corporation shall
issue no fractional shares of Common Stock, Series A Preferred Stock or Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock as a result of the Reverse </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Stock Split, but shall instead pay to any stockholder who would be entitled to receive a fractional share as a result of the Reverse Stock Split a sum in cash equal to the fair market value of
the shares constituting such fractional share as determined by the Board of Directors of the Corporation. The Reverse Stock Split shall be effected on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">certificate-by-certificate</FONT></FONT> basis and shall occur whether or not the certificates representing such shares of Common Stock, Series A Preferred Stock or Series&nbsp;A-1
Preferred Stock are surrendered to the Corporation. No further adjustment of the Series A Conversion Price or Series <FONT STYLE="white-space:nowrap">A-1</FONT> Conversion Price, preference, price or right set forth in this Article Fourth shall be
made as a result of the Reverse Stock Split, as all share amounts, amounts per share and per share numbers set forth in this Restated Certificate have been appropriately adjusted to reflect the Reverse Stock Split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions
thereof in respect of each class of capital stock of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. COMMON STOCK </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>General</U>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights,
powers and preferences of the holders of the Preferred Stock set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Voting</U>. The holders of the Common Stock are
entitled to one vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings). There shall be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased
(but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of this Amended and Restated Certificate of Incorporation) the
affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of
Section&nbsp;242(b)(2) of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. PREFERRED STOCK </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">711,203 shares of the authorized Preferred Stock of the Corporation are hereby designated <B>&#147;Series A Preferred Stock&#148;,
</B>11,898,177 shares of the authorized Preferred Stock of the Corporation are hereby designated <B>&#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock&#148; </B>and 29,457,450 shares of the authorized and unissued Preferred
Stock of the Corporation are hereby designated <B>&#147;Series B Preferred Stock&#148;, </B>each with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. The Series A Preferred Stock, Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and Series B Preferred Stock may collectively be referred to as the <B>&#147;Preferred Stock&#148;. </B>Unless otherwise indicated, references to &#147;sections&#148; or &#147;subsections&#148;
in this Part B of this Article Fourth refer to sections and subsections of Part B of this Article Fourth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Dividends</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation
(other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in this Amended and Restated Certificate of Incorporation) the holders of the Preferred Stock
then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Preferred Stock in an amount at least equal to (i)&nbsp;in the case of a dividend on Common Stock or any class or series that is convertible
into Common Stock, that dividend per share of Preferred Stock as would equal the product of (A)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such class or series had been converted into Common Stock and (B)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Preferred Stock, in each case calculated on the
record date for determination of holders entitled to receive such dividend or (ii)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Preferred Stock determined by
(A)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (B)&nbsp;multiplying such fraction by an amount equal to the Applicable Original Issue Price (as defined below); provided that, if the
Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Preferred Stock pursuant to this <U>Section&nbsp;1</U>
shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Preferred Stock dividend. The &#147;<B>Series A Original Issue Price</B>&#148; shall mean $1.50 per share of Series A Preferred
Stock, the &#147;<B>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Original Issue Price</B>&#148; shall mean $1.50 per share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and the &#147;<B>Series B Original Issue
Price</B>&#148; shall mean $2.55 per share of Series B Preferred Stock, in each case subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such series of
Preferred Stock. The Series A Original Issue Price, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Original Issue Price and Series B Original Issue Price may be referred to herein, for each series of Preferred Stock, as applicable, as the
&#147;<B>Applicable Original Issue Price</B>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and
Asset Sales</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Preferential Payments to Holders of Series B Preferred Stock</U>. In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Corporation, the holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, and in
the event of a Deemed Liquidation Event (as defined below), the holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of
the Available Proceeds (as defined below), as applicable, before any payment shall be made to the holders of Common Stock, Series A Preferred Stock or Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock by reason of their respective
ownership thereof, an amount per share equal to the Series B Original Issue Price, plus any dividends declared but unpaid thereon. If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of
the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series B Preferred Stock the full amount to which they shall be entitled under this <U>Section&nbsp;2.1</U>, the holders of shares
of Series B Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all
amounts payable on or with respect to such shares were paid in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Preferential Payments to Holders of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, after the payment to the holders of Series B Preferred Stock in accordance with
<U>Section&nbsp;2.1</U>, the holders of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders,
and in the event of a Deemed Liquidation Event (as defined below), the holders of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to
stockholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any payment shall be made to the holders of Common Stock or Series A Preferred Stock by reason of their respective ownership
thereof, an amount per share equal to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Original Issue Price plus any dividends declared but unpaid thereon. If upon any such liquidation, dissolution or winding up of the Corporation or Deemed
Liquidation Event, the assets of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock the full
amount to which they shall be entitled under this <U>Section&nbsp;2.2</U>, the holders of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock shall share ratably in any distribution of the assets available for distribution
in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Preferential Payments to Holders of Series A Preferred Stock</U>. In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Corporation, after the payment to the holders of Series B Preferred Stock in accordance with <U>Section&nbsp;2.1</U> and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in accordance with
<U>Section&nbsp;2.2</U>, the holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, and in the event of a Deemed Liquidation
Event (as defined below), the holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined
below), as applicable, before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the Series A Original Issue Price, plus any dividends declared but unpaid thereon. If upon any
such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series A Preferred Stock
the full amount to which they shall be entitled under this <U>Section&nbsp;2.3</U>, the holders of shares of Series A Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective
amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.4 <U>Distribution of Remaining Assets</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the
Corporation, after the payment to the holders of shares of Preferred Stock in accordance with <U>Sections 2.1</U>, <U>2.2</U> and <U>2.3</U>, the remaining assets of the Corporation available for distribution to its stockholders or, in the case of a
Deemed Liquidation Event, the consideration not payable to the holders of shares of Preferred Stock pursuant to <U>Sections 2.1</U>, <U>2.2</U> and <U>2.3</U> or the remaining Available Proceeds, as the case may be, shall be distributed among the
holders of the shares of Preferred Stock and Common Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted to Common Stock pursuant to the terms of this
Amended and Restated Certificate of Incorporation immediately prior to such liquidation, dissolution or winding up of the Corporation, provided, however, that (i)&nbsp;if the aggregate amount per share of Series B Preferred Stock which the holders
of Series B Preferred Stock would be entitled to receive under <U>Sections 2.1</U> and <U>2.4</U> would exceed two times the Series B Original Issue Price, (ii)&nbsp;if the aggregate amount per share of Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock which the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock would be entitled to receive under <U>Sections 2.2</U> and <U>2.4</U> would exceed two times the
Series <FONT STYLE="white-space:nowrap">A-1</FONT> Original Issue Price, or (iii)&nbsp;if the aggregate amount per share of Series A Preferred Stock which the holders of Series A Preferred Stock would be entitled to receive under <U>Sections 2.3</U>
and <U>2.4</U> would exceed two times the Series A Original Issue Price (as applicable, the <B>&#147;Maximum Participation Amount&#148;), </B>then in lieu of receiving such aggregate amount per share of such series of Preferred Stock, each holder of
such series of Preferred Stock shall instead be entitled to receive upon such liquidation, dissolution or winding up of the Corporation the greater of (i)&nbsp;the Maximum Participation Amount per share of such series of Preferred Stock or
(ii)&nbsp;the amount per share of such series of Preferred Stock such holder would have received if all shares of such series of Preferred Stock had been converted into Common Stock immediately prior to such liquidation, dissolution or winding up of
the Corporation. The amount which a holder of shares of a series of Preferred Stock is entitled to receive under <U>Sections 2.1</U>, <U>2.2</U>, <U>2.3</U> and <U>2.4</U> is hereinafter referred to, for each such series of Preferred Stock, as the
<B>&#147;Applicable Liquidation Amount&#148;. </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.5 <U>Deemed Liquidation Events</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.5.1 <U>Definition</U>. Each of the following events shall be considered a <B>&#147;Deemed Liquidation Event&#148; </B>unless the holders of
at least sixty-seven percent (67%) of the outstanding shares of Series B Preferred Stock (the <B>&#147;Requisite Holders&#148;), </B>elect otherwise by written notice sent to the Corporation at least 10 days prior to the effective date of any such
event: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) a merger or consolidation in which </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporation is a constituent party or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="24%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock
pursuant to such merger or consolidation, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except any such merger or consolidation involving the Corporation or a subsidiary in which
the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or
consolidation, a majority, by voting power, of the capital stock of (l) the surviving or resulting corporation; or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such
merger or consolidation, the parent corporation of such surviving or resulting corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;(1) the sale, lease, transfer,
exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a
whole, or (2)&nbsp;the sale or disposition (whether by merger, consolidation or otherwise, and whether in a single transaction or a series of related transactions) of one or more subsidiaries of the Corporation if substantially all of the assets of
the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.5.2 <U>Effecting a Deemed Liquidation Event</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in <U>Section&nbsp;2.5.1(a)(i)</U> unless the
agreement or plan of merger or consolidation for such transaction (the <B>&#147;Merger Agreement&#148;) </B>provides that the consideration payable to the stockholders of the Corporation in such Deemed Liquidation Event shall be paid to the holders
of capital stock of the Corporation in accordance with <U>Sections 2.1</U>, <U>2.2</U>, <U>2.3</U> and <U>2.4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) In the event of a
Deemed Liquidation Event referred to in <U>Section&nbsp;2.5.1(a)(ii)</U> or <U>2.5.l(b)</U>, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within 90 days after such Deemed Liquidation Event,
then (i)&nbsp;the Corporation shall send a written notice to each holder of Preferred Stock no later than the 90th day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) to
require the redemption of such shares of Preferred Stock, and (ii)&nbsp;if the Requisite Holders so request in a written instrument delivered to the Corporation not later than 120 days after such Deemed Liquidation Event, the Corporation shall use
the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board of Directors of the Corporation),
together with any other assets of the Corporation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (the &#147;<B>Available Proceeds</B>&#148;), on the 150<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day after such Deemed Liquidation Event, to redeem all outstanding shares of Preferred Stock at a price per share equal to the Applicable Liquidation Amount. Notwithstanding the foregoing, in the
event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation shall redeem a pro rata portion of each holder&#146;s shares of Preferred
Stock to the fullest extent of such Available Proceeds, based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Available Proceeds were sufficient to redeem all such shares, and shall redeem
the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. Prior to the distribution or redemption provided for in this <U>Section&nbsp;2.5.2(b)</U>, the Corporation shall not expend or
dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred in connection with such Deemed Liquidation Event or in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.5.3 <U>Amount Deemed Paid or Distributed</U>. The amount deemed paid or distributed to the holders of capital stock of the Corporation upon
any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities to be paid or distributed to such holders pursuant to such Deemed Liquidation
Event. The value of such property, rights or securities shall be determined in good faith by the Board of Directors of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.5.4 <U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event pursuant to
<U>Section&nbsp;2.5.1(a)(i)</U>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#147;<B>Additional Consideration</B>&#148;), the Merger Agreement shall
provide that (a)&nbsp;the portion of such consideration that is not Additional Consideration (such portion, the &#147;<B>Initial Consideration</B>&#148;) shall be allocated among the holders of capital stock of the Corporation in accordance with
<U>Sections 2.1</U>, <U>2.2</U>, <U>2.3</U> and <U>2.4</U> as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b)&nbsp;any Additional Consideration which becomes payable to the
stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Sections 2.1</U>, <U>2.2</U>, <U>2.3</U> and <U>2.4</U> after taking into account
the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this <U>Section 2.5.4</U>, consideration placed into escrow or retained as a holdback to be available for satisfaction of indemnification or
similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Voting</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1 <U>General</U>. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of
stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into
which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of this Amended and Restated Certificate
of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election of Directors</U>. The holders of record of the shares of Series B Preferred Stock, voting together as a separate class, shall
be entitled to elect two directors of the Corporation (each, a &#147;<B>Series B Director</B>&#148;), the holders of record of the shares of Series A Preferred Stock and Series A-1 Preferred Stock, voting together as a single class, shall be
entitled to elect two directors of the Corporation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(each, a <B>&#147;</B><B>Series <FONT STYLE="white-space:nowrap">A/A-l</FONT> Director</B><B>&#148;</B><B> </B>and together with the Series <B></B>B<B> </B>Directors, the
<B>&#147;</B><B>Preferred Directors</B><B>&#148;</B><B>) </B>and the holders of record of the shares of Common Stock, exclusively and as a separate class, shall be entitled to elect two directors of the Corporation (the <B>&#147;</B><B>Common
Directors</B><B>&#148;</B><B>); </B><U>provided</U>, <U>however</U>, for administrative convenience, the initial Series B Directors may also be appointed by the Board of Directors in connection with the approval of the initial issuance of Preferred
Stock without a separate action by the holders of Preferred Stock. Any director elected as provided in the preceding sentence may be removed without cause by, and only by, the affirmative vote of the holders of the shares of the class or series of
capital stock entitled to elect such director or directors, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders. If the holders of shares of Preferred Stock or Common
Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, voting exclusively and as a separate class, pursuant to the first sentence of this
<U>Section</U><U></U><U>&nbsp;3.2</U>, then any directorship not so filled shall remain vacant until such time as the holders of Preferred Stock or Common Stock, as the case may be, elect a person to fill such directorship by vote or written consent
in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation that are entitled to elect a person to fill such directorship, voting exclusively and as a separate
class. The holders of record of the shares of Common Stock and Preferred Stock, exclusively and voting together as a single class, shall be entitled to elect the balance of the total number of directors of the Corporation. At any meeting held for
the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such director.
Except as otherwise provided in this <U>Section&nbsp;3.2</U>, a vacancy in any directorship filled by the holders of any class or classes or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or
classes or series or by any remaining director or directors elected by the holders of such class or classes or series pursuant to this <U>Section</U><U></U><U>&nbsp;3.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Preferred Stock Protective Provisions</U>. At any time when shares of Series <FONT STYLE="white-space:nowrap">A-l</FONT> and Series B
Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or this Amended and Restated
Certificate of Incorporation) the written consent or affirmative vote of the Requisite Holders given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or transaction entered into
without such consent or vote shall be null and void ab initio, and of no force or effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.1 liquidate, dissolve or <FONT
STYLE="white-space:nowrap">wind-up</FONT> the business and affairs of the Corporation, effect any merger or consolidation or any other Deemed Liquidation Event; or consent to any of the foregoing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.2 amend, alter or repeal any provision of the Certificate of Incorporation or Bylaws of the Corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.3 create, or authorize the creation of, or issue any additional class or series of capital stock unless the same ranks junior to the
Series B Preferred Stock, Series A Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of
dividends and rights of redemption, or increase or decrease the authorized number of shares of Series B Preferred Stock, Series A Preferred Stock or Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock or increase or decrease the
authorized number of shares of any additional class or series of capital stock of the Corporation unless the same ranks junior to the Series B Preferred Stock, Series A Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred
Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of redemption; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.4 (i) reclassify, alter or amend any existing security of the Corporation that is
<I>pari passu</I> with the Series B Preferred Stock, Series A Preferred Stock or Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the
Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to the Series B Preferred Stock, Series A Preferred Stock or Series <FONT
STYLE="white-space:nowrap">A-l</FONT> Preferred Stock in respect of any such right, preference, or privilege or (ii)&nbsp;reclassify, alter or amend any existing security of the Corporation that is junior to the Series B Preferred Stock, Series A
Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if
such reclassification, alteration or amendment would render such other security senior to or <I>pari passu</I> with the Series B Preferred Stock, Series A Preferred Stock or Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock in
respect of any such right, preference or privilege; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.5 purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or
declare any dividend or make any distribution on, any shares of capital stock of the Corporation other than (i)&nbsp;redemptions of or dividends or distributions on the Preferred Stock as expressly authorized herein, (ii)&nbsp;dividends or other
distributions payable on the Common Stock solely in the form of additional shares of Common Stock or (iii)&nbsp;repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation
or any subsidiary in connection with the cessation of such employment or service at the lower of the original purchase price or the then- current fair market value thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.6 create, or authorize the creation of, or issue, or authorize the issuance of any debt security or create any lien or security interest
(except for purchase money liens or statutory liens of landlords, mechanics, materialmen, workmen, warehousemen and other similar persons arising or incurred in the ordinary course of business) or incur other indebtedness for borrowed money,
including but not limited to obligations and contingent obligations under guarantees, or permit any subsidiary to take any such action with respect to any debt security lien, security interest or other indebtedness for borrowed money, if the
aggregate indebtedness of the Corporation and its subsidiaries for borrowed money following such action would exceed $500,000 other than equipment leases, bank lines of credit or trade payables incurred in the ordinary course unless such debt
security has received the prior approval of the Board of Directors, including the approval of a majority of the Preferred Directors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.7 approve the Corporation&#146;s budget for a fiscal year or make any revision to such approved budget or authorize any expenditure or
any commitment to make any expenditure not contemplated by such approved budget, unless approved by the Board of Directors, including the approval of a majority of the Preferred Directors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.8 create, or hold capital stock in, any subsidiary that is not wholly owned (either directly or through one or more other subsidiaries)
by the Corporation, or permit any subsidiary to create, or authorize the creation of, or issue or obligate itself to issue, any shares of any class or series of capital stock, or sell, transfer or otherwise dispose of any capital stock of any direct
or indirect subsidiary of the Corporation, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the
assets of such subsidiary; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.9 increase or decrease the authorized number of directors constituting the Board of Directors or change
the number of votes entitled to be cast by any director or directors on any matter; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.10 create, adopt, amend, terminate or repeal any equity (or equity-linked) compensation
plan or amend or waive any of the terms of any option or other grants pursuant to any such plan unless such amendment or waiver is approved by the Board of Directors, including the approval of a majority of the Preferred Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.4 <U>Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock Protective Provisions</U>. At any time when shares of Series <FONT
STYLE="white-space:nowrap">A-l</FONT> Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly, by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote
required by law or this Amended and Restated Certificate), the written consent or affirmative vote of the holders of a majority of the then outstanding shares of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, given in writing or
by vote at a meeting, consenting or voting (as the case may be) separately as a class: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.1 amend, alter or repeal any provision of
this Amended and Restated Certificate or Bylaws in a manner that adversely affects the powers, preferences or rights of the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock in a manner different than any other series of Preferred
Stock (it being understood that a series of Preferred Stock shall not be affected differently because of (i)&nbsp;the proportional differences in the amounts of respective issue prices, liquidation preferences and redemption prices that arise out of
differences in the original issue price <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> other series of Preferred Stock or (ii)&nbsp;the creation of a any additional class or series of capital stock
that ranks senior to a series of Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of redemption); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.2 increase or decrease the authorized number of shares of Series <FONT STYLE="white-space:nowrap">A-</FONT> 1 Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.5 <U>Series A Preferred Stock Protective Provisions</U>. At any time when shares of Series A Preferred Stock are outstanding, the
Corporation shall not, either directly or indirectly, by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or this Amended and Restated Certificate), the written consent or
affirmative vote of the holders of a majority of the then outstanding shares of Series A Preferred Stock, given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.1 amend, alter or repeal any provision of this Amended and Restated Certificate or Bylaws in a manner that adversely affects the powers,
preferences or rights of the Series A Preferred Stock in a manner different than any other series of Preferred Stock (it being understood that a series of Preferred Stock shall not be affected differently because of (i)&nbsp;the proportional
differences in the amounts of respective issue prices, liquidation preferences and redemption prices that arise out of differences in the original issue price
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> other series of Preferred Stock or (ii)&nbsp;the creation of a any additional class or series of capital stock that ranks senior to a series of
Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of redemption); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.2 increase or decrease the authorized number of shares of Series A Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Optional Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock shall have conversion rights as follows (the &#147;<B>Conversion Rights</B>&#148;): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right to Convert</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.1 <U>Conversion Ratio</U>. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from
time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock as is determined by dividing the Applicable
Original Issue Price by the Applicable Conversion Price (as defined below) in effect at the time of conversion. The <B>&#147;Series A Conversion Price&#148; </B>shall initially be equal to the Series <B>A </B>Original Issue Price. The
<B>&#147;Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price&#148; </B>shall initially be equal to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Original Issue Price. The <B>&#147;Series B Conversion Price&#148; </B>shall
initially be equal to the Series B Original Issue Price. The Series A Conversion Price, Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price and Series B Conversion Price shall be referred to as <B></B>the<B> &#147;Conversion
Price&#148; </B>and, individually, as the <B>&#147;Applicable Conversion Price.&#148; </B>Each such initial Conversion Price, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, shall be subject to
adjustment as provided below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.2 <U>Termination of Conversion Rights</U>. In the event of a liquidation, dissolution or winding up of
the Corporation or a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred
Stock; <U>provided</U> that the foregoing termination of Conversion Rights shall not affect the amount(s) otherwise paid or payable in accordance with <U>Sections 2.1</U>, <U>2.2</U>, <U>2.3</U> and <U>2.4</U> to the holders of Preferred Stock
pursuant to such liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2 <U>Fractional Shares</U>.
No fractional shares of Common Stock shall be issued upon conversion of the Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the
fair market value of a share of Common Stock as determined in good faith by the Board of Directors of the Corporation. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of
shares of Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.3 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.1 <U>Notice of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of
Common Stock, such holder shall (a)&nbsp;provide written notice to the Corporation&#146;s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own
transfer agent) that such holder elects to convert all or any number of such holder&#146;s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such holder&#146;s shares are certificated,
surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the
Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the
principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice shall state such holder&#146;s name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required
by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its
attorney duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if applicable, certificates (or lost certificate
affidavit and agreement) shall be the time of conversion (the <B>&#147;Conversion</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>Time&#148;), </B>and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as
practicable after the Conversion Time (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in
accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, (ii)&nbsp;pay in cash such amount as provided in
<U>Section</U><U></U><U>&nbsp;4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and (iii)&nbsp;pay all declared but unpaid dividends on the shares of Preferred Stock converted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.2 <U>Reservation of Shares</U>. The Corporation shall at all times when the Preferred Stock shall be outstanding, reserve and keep
available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the
conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation
shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain
the requisite stockholder approval of any necessary amendment to this Amended and Restated Certificate of Incorporation. Before taking any action which would cause an adjustment reducing the Applicable Conversion Price below the then par value of
the shares of Common Stock issuable upon conversion of the Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid
and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock at such adjusted Applicable Conversion Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.3
<U>Effect of Conversion</U>. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and
terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in
<U>Section</U><U></U><U>&nbsp;4.2</U> and to receive payment of any dividends declared but unpaid thereon. Any shares of Preferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the
Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.4 <U>No Further Adjustment</U>. Upon any such conversion, no adjustment to the Applicable Conversion Price shall be made for any declared
but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.5
<U>Taxes</U>. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this
<U>Section</U><U></U><U>&nbsp;4</U>. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which
the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to
the satisfaction of the Corporation, that such tax has been paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.4 <U>Adjustments to Applicable Conversion Price for Diluting Issues.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.1 <U>Special Definitions</U>. For purposes of this Article Fourth, the following definitions shall apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) <B>&#147;Option&#148; </B>shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or
Convertible Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) <B>&#147;Original Issue Date&#148; </B>shall mean the date on which the first share of Series B Preferred
Stock was issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) <B>&#147;Convertible Securities&#148; </B>shall mean any evidences of indebtedness, shares or other securities
directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) <B>&#147;Additional Shares of
Common Stock&#148; </B>shall mean all shares of Common Stock issued (or, pursuant to <U>Section</U><U></U><U>&nbsp;4.4.3</U> below, deemed to be issued) by the Corporation after the Original Issue Date, other than (1)&nbsp;the following shares of
Common Stock and (2)&nbsp;shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1)&nbsp;and (2), collectively, <B>&#147;Exempted Securities&#148;):</B> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on Preferred
Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, <FONT
STYLE="white-space:nowrap">split-up</FONT> or other distribution on shares of Common Stock that is covered by <U>Section&nbsp;4.5</U>, <U>4.6</U>, <U>4.7</U> or <U>4.8</U>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the
Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors of the Corporation, including the approval of a majority of the Preferred Directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of
Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial
institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="29%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
approved by the Board of Directors of the Corporation, including the approval of a majority of the Preferred Directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.2 <U>No Adjustment of Applicable Conversion Price</U>. No adjustment in the Applicable Conversion Price shall be made as the result of
the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Holders agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such
Additional Shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.3 <U>Deemed Issue of Additional Shares of Common Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) If the Corporation at any time or from time to time after the Original Issue Date shall issue any Options or Convertible Securities
(excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the
maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a
subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of
Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Applicable Conversion Price
pursuant to the terms of <U>Section&nbsp;4.4.4</U>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms
pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any
such Option or Convertible Security or (2)&nbsp;any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the
Applicable Conversion Price computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Applicable Conversion Price as would have obtained had
such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this clause (b)&nbsp;shall have the effect of increasing the Applicable
Conversion Price to an amount which exceeds the lower of (i)&nbsp;the Applicable Conversion Price in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)&nbsp;the
Applicable Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security)
between the original adjustment date and such readjustment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) If the terms of any Option or Convertible Security (excluding
Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to the Applicable Conversion Price pursuant to the terms of <U>Section</U><U></U><U>&nbsp;4.4.4 </U>(either because
the consideration per share (determined pursuant to <U>Section&nbsp;4.4.5</U>) of the Additional Shares of Common Stock subject thereto was equal to or greater than the Applicable Conversion Price then in effect, or because such Option or
Convertible Security was issued before the Original Issue Date), are revised after the Original Issue Date as a result of an amendment to such terms or any other adjustment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible
Security) to provide for either (1)&nbsp;any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2)&nbsp;any decrease in the consideration payable to the
Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in
<U>Section&nbsp;4.4.3(a)</U>) shall be deemed to have been issued effective upon such increase or decrease becoming effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) Upon
the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Applicable
Conversion Price pursuant to the terms of <U>Section</U><U></U><U>&nbsp;4.4.4</U>, the Applicable Conversion Price shall be readjusted to such Applicable Conversion Price as would have obtained had such Option or Convertible Security (or portion
thereof) never been issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any
Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is subject to adjustment based
upon subsequent events, any adjustment to the Applicable Conversion Price provided for in this <U>Section</U><U></U><U>&nbsp;4.4.3</U> shall be effected at the time of such issuance or amendment based on such number of shares or amount of
consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in clauses (b)&nbsp;and (c) of this <U>Section&nbsp;4.4.3</U>). If the number of shares of Common Stock issuable
upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible
Security is issued or amended, any adjustment to the Applicable Conversion Price that would result under the terms of this <U>Section</U><U></U><U>&nbsp;4.4.3</U> at the time of such issuance or amendment shall instead be effected at the time such
number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the Applicable Conversion Price that such issuance or amendment took place at
the time such calculation can first be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.4 <U>Adjustment of Applicable Conversion Price Upon Issuance of Additional Shares of
Common Stock</U>. In the event the Corporation shall at any time after the Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <U>Section&nbsp;4.4.3</U>), without
consideration or for a consideration per share less than the Applicable Conversion Price in effect immediately prior to such issuance or deemed issuance, then the Applicable Conversion Price shall be reduced, concurrently with such issue, to a price
(calculated to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a cent) determined in accordance with the following formula: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CP<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB> = CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>* (A + B) &divide; (A
+ C). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing formula, the following definitions shall apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;CP<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>&#148; shall mean the Applicable Conversion Price in effect immediately
after such issuance or deemed issuance of Additional Shares of Common Stock </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)
&#147;CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>&#148; shall mean the Applicable Conversion Price in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;A&#148; shall mean the number of shares of Common Stock outstanding immediately
prior to such issuance or deemed issuance of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issuance or deemed issuance
or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;B&#148; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had
been issued or deemed issued at a price per share equal to CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP<SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB>); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) &#147;C&#148; shall mean the number of such Additional Shares of Common
Stock issued in such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.5 <U>Determination of Consideration</U>. For purposes of this
<U>Section</U><U></U><U>&nbsp;4.4</U>, the consideration received by the Corporation for the issuance or deemed issuance of any Additional Shares of Common Stock shall be computed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) <U>Cash and Property</U>: Such consideration shall: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation,
excluding amounts paid or payable for accrued interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of
such issue, as determined in good faith by the Board of Directors of the Corporation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event Additional Shares of Common Stock are issued together with other shares or securities or other
assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (i)&nbsp;and (ii) above, as determined in good faith by the Board of Directors of the Corporation.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) <U>Options and Convertible Securities</U>. The consideration per share received by the Corporation for Additional
Shares of Common Stock deemed to have been issued pursuant to <U>Section&nbsp;4.4.3</U>, relating to Options and Convertible Securities, shall be determined by dividing: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The total amount, if any, received or receivable by the Corporation as consideration for the issue of such
Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="31%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
such consideration) payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible
Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities, by </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="29%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the
exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.6 <U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that
are a part of one transaction or a series of related transactions and that would result in an adjustment to the Applicable Conversion Price pursuant to the terms of <U>Section</U><U></U><U>&nbsp;4.4.4</U> then, upon the final such issuance, the
Applicable Conversion Price shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances
within such period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.5 <U>Adjustment for Stock Splits and Combinations</U>. If the Corporation shall at any time or from time to time
after the Original Issue Date effect a subdivision of the outstanding Common Stock, the Applicable Conversion Price in effect immediately before that subdivision shall be proportionately decreased so that the number of shares of Common Stock
issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Original Issue
Date combine the outstanding shares of Common Stock, the Applicable Conversion Price in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of
such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this subsection shall become effective at the close of business on the date the subdivision or
combination becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.6 <U>Adjustment for Certain Dividends and Distributions</U>. In the event the Corporation at any time
or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in additional shares of
Common Stock, then and in each such event the Applicable Conversion Price in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of
business on such record date, by multiplying the Applicable Conversion Price then in effect by a fraction: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) the numerator of which shall be the total number of shares of Common Stock issued and
outstanding immediately prior to the time of such issuance or the close of business on such record date, and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) the denominator of
which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such
dividend or distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing (a)&nbsp;if such record date shall have been fixed and such dividend is not fully paid or if such
distribution is not fully made on the date fixed therefor, the Applicable Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Applicable Conversion Price shall be adjusted pursuant to
this subsection as of the time of actual payment of such dividends or distributions; and (b)&nbsp;that no such adjustment shall be made if the holders of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common
Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.7 <U>Adjustments for Other Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after the
Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of
Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <U>Section</U><U></U><U>&nbsp;1</U> do not apply to such dividend or distribution, then and in each such event the holders of Preferred Stock
shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they would have
received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.8 <U>Adjustment
for Merger or Reorganization, etc</U>. Subject to the provisions of <U>Section&nbsp;2.5</U>, if there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock
(but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by <U>Sections 4.4</U>, <U>4.6</U> or <U>4.7</U>), then, following any such reorganization, recapitalization,
reclassification, consolidation or merger, each share of Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property
which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one share of Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been
entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board of Directors of the Corporation) shall be made in the application of the provisions in this
<U>Section</U><U></U><U>&nbsp;4</U> with respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set forth in this <U>Section</U><U></U><U>&nbsp;4</U> (including provisions with respect to
changes in and other adjustments of the Applicable Conversion Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of the Preferred Stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.9 <U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of the Applicable Conversion Price
pursuant to this <U>Section&nbsp;4</U>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than 10 days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and
furnish to each holder of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities, cash or other property into which the Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as
promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock (but in any event not later than 10 days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i)&nbsp;the
Applicable Conversion Price then in effect, and (ii)&nbsp;the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.10 <U>Notice of Record Date</U>. In the event: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon
conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or
to receive any other security; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) of any capital reorganization of the Corporation, any reclassification of the Common Stock of the
Corporation, or any Deemed Liquidation Event; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) of the voluntary or involuntary dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, and in each such case, the Corporation will send or cause to be sent to the
holders of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii)&nbsp;the effective date on which
such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> is proposed to take place, and the time, if any is to be fixed, as of which the holders of record
of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or
other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> and the amount per share and character of such exchange
applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least 10 days prior to the record date or effective date for the event specified in such notice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Mandatory Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 <U>Trigger Events</U>. Upon either (a)&nbsp;the closing of the sale of shares of Common Stock to in a firm-commitment underwritten public
offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $75,000,000 of gross proceeds to the Corporation and at a price per share equal to at least two (2)&nbsp;times the Series B
Original Issue Price (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred Stock) (a <B>&#147;Qualified IPO&#148;) </B>or (b)&nbsp;the
date and time, or the occurrence of an event, specified by vote or written consent of the Requisite Holders (the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is referred to
herein as the <B>&#147;Mandatory Conversion Time&#148;), </B>then (i)&nbsp;all outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to
<U>Section</U><U></U><U>&nbsp;4.1.1.</U> and (ii)&nbsp;such shares may not be reissued by the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 <U>Procedural
Requirements</U>. All holders of record of shares of Preferred Stock shall be sent written notice of the Mandatory Conversion Time and the place designated for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>. Such notice need not be sent in advance of the occurrence of the Mandatory
Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been
lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or
destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of
transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to
<U>Section</U><U></U><U>&nbsp;5.1,</U> including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof
to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items
provided for in the next sentence of this <U>Section</U><U></U><U>&nbsp;5.2</U>. As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and
agreement) for Preferred Stock, the Corporation shall (a)&nbsp;issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance
with the provisions hereof and (b)&nbsp;pay cash as provided in <U>Section</U><U></U><U>&nbsp;4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on
the shares of Preferred Stock converted. Such converted Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for
stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Special Mandatory
Conversion</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.1 Two days after the Milestone Closing (as defined in that certain Series B Preferred Stock Purchase Agreement by and
between the Corporation and the other parties thereto (the <B>&#147;SPA&#148;</B>))<B> </B>occurs, if ever, each share of Series B Preferred Stock held by a Defaulting Purchaser (as defined in the SPA) shall be automatically, and without any further
action on the part of such Defaulting Purchaser, converted into one (1)&nbsp;fully-paid, nonassessable share of Common Stock (a <B>&#147;Special Conversion&#148;</B>).<B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.2 <U>Procedural Requirements</U>. Upon a Special Conversion, each holder of shares of Series B Preferred Stock converted pursuant to this
<U>Section 6</U> shall be sent written notice of such Special Conversion and the place designated for mandatory conversion of all such shares of Series B Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;6</U>. Upon receipt of such
notice, each holder of such shares of Series B Preferred Stock in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that any such certificate has been lost, stolen or
destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such
certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form
satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Series B Preferred Stock converted pursuant to this <U>Section&nbsp;6</U>, including
the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the time of the Special Conversion (notwithstanding the failure of the holder or holders thereof to surrender any certificates for such
shares at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders therefor (or lost certificate affidavit and agreement), to receive the items provided for in the next
sentence </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of this <U>Section</U><U></U><U>&nbsp;6.2</U>. As soon as practicable after the Special Conversion and, if applicable, the surrender of any certificate or certificates (or lost certificate
affidavit and agreement) for Series B Preferred Stock so converted, the Corporation shall (i)&nbsp;issue and deliver to such holder of Series B Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full
shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and (ii)&nbsp;pay in cash such amount as provided in <U>Section</U><U></U><U>&nbsp;4.2</U> in lieu of any fraction of a share of Common Stock otherwise
issuable upon such conversion. Such converted Series B Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder
action) as may be necessary to reduce the authorized number of shares of Series B Preferred Stock accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Redemption</U>.
Other than as set forth in <U>Section</U><U></U><U>&nbsp;2.5.2(b)</U>, the Preferred Stock is not redeemable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Redeemed or Otherwise
Acquired Shares</U>. Any shares of Preferred Stock that are redeemed or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred.
Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Waiver</U>. Any of the rights, powers, preferences and other terms of the Preferred Stock set forth herein may be waived on behalf of
all holders of Preferred Stock by the affirmative written consent or vote of the Requisite Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10. <U>Notices</U>. Any notice
required or permitted by the provisions of this Article Fourth to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic
communication in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FIFTH: </B>Subject to any additional vote required by this Amended and Restated Certificate of Incorporation or Bylaws, in
furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SIXTH: </B>Subject to any additional vote required by this Amended and Restated Certificate of Incorporation, the number of
directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. Each director shall be entitled to one vote on each matter presented to the Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SEVENTH: </B>Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>EIGHTH: </B>Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the
Corporation may provide. The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NINTH: </B>To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the
Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
is amended after approval by the stockholders of this Article Ninth to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a
director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended. Any repeal or modification of the foregoing provisions of this Article Ninth by the stockholders of the
Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such director occurring
prior to, such repeal or modification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>TENTH: </B>To the fullest extent permitted by applicable law, the Corporation is
authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification) through Bylaw
provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&nbsp;145 of the General Corporation Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of the foregoing provisions of this Article Tenth shall not (a)&nbsp;adversely affect any
right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification or (b)&nbsp;increase the liability of any director of the Corporation with respect to any acts or omissions
of such director, officer or agent occurring prior to, such amendment, repeal or modification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>ELEVENTH: </B>In the
event that a director of the Corporation who is also a partner or employee of an entity that is a holder of Preferred Stock or any of its affiliates and that is in the business of investing and reinvesting in other entities (each, a
<B>&#147;Fund&#148;), </B>acquires knowledge of a potential transaction or matter in such person&#146;s capacity as a partner or employee of the Fund and that may be a corporate opportunity for both the Corporation and such Fund, such director shall
to the fullest extent permitted by law be deemed to have fully satisfied and fulfilled such director&#146;s fiduciary duty to the Corporation and its stockholders with respect to such corporate opportunity, and the Corporation to the fullest extent
permitted by law renounces and waives any claim that such business opportunity constituted a corporate opportunity that should have been presented to the Corporation or any of its affiliates, if such director acts in good faith in a manner
consistent with the following policy: a corporate opportunity offered to any person who is a director of the Corporation, and who is also a partner, member, employee, service provider, affiliate or agent of a Fund, shall belong to such Fund, unless
such opportunity was expressly offered to such person solely in his or her capacity as a director of the Corporation, while such person is performing services in such capacity. Any repeal or modification of this Article Eleventh will only be
prospective and will not affect the rights under this Article Eleventh in effect at the time of the occurrence of any actions or omissions to act giving rise to liability. Notwithstanding anything to the contrary contained elsewhere in this Amended
and Restated Certificate of Incorporation, the affirmative vote of the Requisite Holders, will be required to amend or repeal, or to adopt any provisions inconsistent with this Article Eleventh. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>TWELFTH: </B>Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in
the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of
breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim against the Corporation, its directors, officers or
employees arising pursuant to any provision of the Delaware General Corporation Law or the Corporation&#146;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting a claim against the Corporation, its directors, officers or
employees governed by the internal affairs doctrine, except for, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
as to each of (i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery
(and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within 10 days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or
for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this Article Twelfth shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason
whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article Twelfth (including, without limitation, each portion of
any sentence of this Article Twelfth containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and
circumstances shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. That the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in
accordance with Section&nbsp;228 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. That this Certificate of Incorporation, which restates and integrates
and further amends the provisions of this Corporation&#146;s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amended and Restated Certificate of Incorporation has been executed by a duly
authorized officer of the Corporation on November&nbsp;20, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel J. O&#146;Connell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Daniel O&#146;Connell, Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED <FONT STYLE="white-space:nowrap">BY-LAWS</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACUMEN
PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(A Delaware corporation) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OFFICES:
REGISTERED AGENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 1&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Registered Office and Agent</U><U>.</U> </B>The corporation shall
maintain in the State of Delaware a registered office and a registered agent whose business office is identical with such registered office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 2&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Principal Business Office</U><U>.</U> </B>The corporation shall have its principal business office at
such location within or without the State of Delaware as the board of directors may from time to time determine. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STOCKHOLDERS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 1&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Annual Meeting</U><U>.</U> </B>The annual meeting of the stockholders shall be held on the first
Tuesday of April each year, at the hour of 10:00 a.m., for the purpose of electing directors and for the transaction of such other business as may properly come before the meeting. If the day fixed for the annual meeting shall be a legal holiday,
such meeting shall be held on the next succeeding business day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 2&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Special Meetings</U><U>.</U>
</B>Special meetings of the stockholders of for any purpose or purposes may be called by the Chairman, the Board of Directors or by the President. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 3&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Place of Meetings</U><U>.</U> </B>The board of directors may designate any place, either within or
without the State of Delaware, as the place of meeting for any annual meeting or for any special meeting called by the board of directors, but if no designation is made, or if a special meeting be otherwise called, the place of meeting shall be the
principal business office of the corporation; provided, however, that for any meeting of the stockholders for which a waiver of notice designating a place is signed by all of the stockholders, then that shall be the place for the holding of such
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 4&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Notice of Meetings</U><U>.</U> </B>Written or printed notice stating the place, date and
hour of the meeting of the stockholders and, in the case of a special meeting, the purpose or purposes for which the meeting is called, shall be given to each stockholder of record entitled to vote at the meeting, not less than 10 nor more than 60
days before the date of the meeting, or in the case of a meeting called for the purpose of acting upon a merger or consolidation not less than 20 nor </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
more than 60 days before the meeting. Such notice shall be given by or at the direction of the secretary. If mailed, such notice shall be deemed to be given when deposited in the United States
mail addressed to the stockholder at his or her address as it appears on the records of the corporation, with postage thereon prepaid. If delivered (rather than mailed) to such address, such notice shall be deemed to be given when so delivered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place thereof are
announced at the meeting at which the adjournment is taken, unless the adjournment is for more than 30 days or unless a new record date is fixed for the adjourned meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 5&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Waiver of Notice</U><U>.</U> </B>A waiver of notice in writing signed by a stockholder entitled to such
notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice. Attendance of a stockholder in person or by proxy at a meeting of stockholders shall constitute a waiver of notice of such meeting
except when the stockholder or his or her proxy attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 6&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Meeting of All Stockholders</U><U>.</U> </B>If all of the stockholders shall meet at any time and
place, either within or without the State of Delaware, and shall, in writing signed by all of the stockholders, waive notice of, and consent to the holding of, a meeting at such time and place, such meeting shall be valid without call or notice, and
at such meeting any corporate action may be taken. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 7&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Record Dates</U><U>.</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any
adjournment thereof, the board of directors may fix a record date, which record date shall not precede the date on which the resolution fixing the record date is adopted by the board of directors, and which record date shall not be more than 60 nor
less than 10 days before the date of such meeting (or 20 days if a merger or consolidation is to be acted upon at such meeting). If no record date is fixed by the board of directors, the record date for determining stockholders entitled to notice of
or to vote at a meeting of stockholders shall be at the close of business on the next day preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A
determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the board of directors may fix a new record date for the adjourned meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In order that the corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting,
the board of directors may fix a record date, which record date shall not precede the date on which the resolution fixing the record date is adopted by the board of directors, and which date shall not be more than 10 days after the date upon which
the resolution fixing the record date is adopted by the board of directors. If no record date has been fixed by the board of directors, the record date for determining stockholders entitled to consent to corporate action in writing without a
meeting, when no prior action by the board of directors is required by the certificate of incorporation of the corporation or by statute, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered in the manner required by law to the corporation at its registered
office in the State of Delaware or at its principal place of business or to an officer or agent of the corporation having custody of the book in which proceedings of meetings of the corporation&#146;s stockholders are recorded. If no record date has
been fixed by the board of directors and prior action by the board of directors is required by the certificate of incorporation or by statute, the record date for determining stockholders entitled to consent to corporate action in writing without a
meeting shall be at the close of business on the day on which the board of directors adopts the resolution taking such prior action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or
exchange of stock, or for the purpose of any other lawful action, the board of directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall not
be more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the board of directors adopts the resolution relating
thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Only those who shall be stockholders of record on the record date so fixed as aforesaid shall be entitled to such notice of,
and to vote at, such meeting and any adjournment thereof, or to consent to such corporate action in writing, or to receive payment of such dividend or other distribution, or to receive such allotment of rights, or to exercise such rights, as the
case may be, notwithstanding the transfer of any stock on the books of the corporation after the applicable record date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167;
8&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Lists Of Stockholders</U></B><U>.</U> The officer who has charge of the stock ledger of the corporation shall prepare and make, at least 10 days before each meeting of stockholders, a complete list of the stockholders
entitled to vote thereat, arranged in alphabetical order, and showing the address of and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the
meeting, during ordinary business hours, for a period of at least 10 days prior to the meeting, either at a place within the municipality where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so
specified, at the place where said meeting is to be held, and the list shall be produced and kept at the time and place of meeting during the whole time thereof, for inspection by any stockholder who may be present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 9&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Quorum and Vote Required For Action</U><U>.</U> </B>Except as may otherwise be provided in the
certificate of incorporation of the corporation, the holders of stock of the corporation having a majority of the total votes which all of the outstanding stock of the corporation would be entitled to cast at the meeting, when present in person or
by proxy, shall constitute a quorum at any meeting of the stockholders; provided, however, that where a separate vote by a class or classes of stock is required, the holders of stock of such class or classes having a majority of the total votes
which all of the outstanding stock of such class or classes would be entitled to cast at the meeting, when present in person or by proxy, shall constitute a quorum entitled to take action with respect to the vote on the matter. Unless a different
number of votes is required by statute </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or the certificate of incorporation of the corporation, (a)&nbsp;if a quorum is present with respect to the election of directors, directors shall be elected by a plurality of the votes cast by
those stockholders present in person or represented by proxy at the meeting and entitled to vote on the election of directors, and (b)&nbsp;in all matters other than the election of directors, if a quorum is present at any meeting of the
stockholders, a majority of the votes entitled to be cast by those stockholders present in person or by proxy shall be the act of the stockholders except where a separate vote by class or classes of stock is required, in which case, if a quorum of
such class or classes is present, a majority of the votes entitled to be cast by those stockholders of such class or classes present in person or by proxy shall be the act of the stockholders of such class or classes. If a quorum is not present at
any meeting of stockholders, then holders of stock of the corporation who are present in person or by proxy representing a majority of the votes cast may adjourn the meeting from time to time without further notice and, where a separate vote by a
class or classes of stock is required on any matter, then holders of stock of such class or classes who are present in person or by proxy representing a majority of the votes of such class or classes cast may adjourn the meeting with respect to the
vote on that matter from time to time without further notice. At any adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the original meeting. Withdrawal of stockholders from any meeting
shall not cause failure of a duly constituted quorum at that meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 10&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Proxies</U></B><U>.</U>
Each stockholder entitled to vote at a meeting of the stockholders or to express consent to corporate action in writing without a meeting may authorize another person or persons to act for him by proxy, but no proxy shall be valid after three years
from its date unless otherwise provided in the proxy. Such proxy shall be in writing and shall be filed with the secretary of the corporation before or at the time of the meeting or the giving of such written consent, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 11&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Voting of Shares</U></B><U>.</U> Each stockholder of the corporation shall be entitled to such vote
(in person or by proxy) for each share of stock having voting power held of record by such stockholder as shall be provided in the certificate of incorporation of the corporation or, absent provision therein fixing or denying voting rights, shall be
entitled to one vote per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 12&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Voting By Ballot</U><U>.</U> </B>Any question or any election at
a meeting of the stockholders may be decided by voice vote unless the presiding officer shall order that voting be by ballot or unless otherwise provided in the certificate of incorporation of the corporation or required by statute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 13&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Inspectors</U><U>.</U> </B>At any meeting of the stockholders the presiding officer may, or upon the
request of any stockholder shall, appoint one or more persons as inspectors for such meeting. Such inspectors shall ascertain and report the number of shares represented at the meeting, based upon their determination of the validity and effect of
proxies; count all votes and report the results; and do such other acts as are proper to conduct the election and voting with impartiality and fairness to all the stockholders. Each report of an inspector shall be in writing and signed by him or a
majority of them if there is more than one inspector acting at such meeting. If there is more than one inspector, the report of a majority shall be the report of the inspectors. The report of the inspector or inspectors on the number of shares
represented at the meeting and the results of the voting shall be prima facie evidence thereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 14&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Informal Action</U><U>.</U> </B>Any corporate action
upon which a vote of stockholders is required or permitted may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock
having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the corporation in the manner
required by law at its registered office within the State of Delaware or at its principal place of business or to an officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders of the corporation
are recorded. Every written consent shall bear the date of signature of each stockholder who signs the consent and no written consent shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated
consent delivered, as aforesaid, written consents signed by a sufficient number of holders to take action are delivered to the corporation in the manner required by law at its registered office within the State of Delaware or at its principal place
of business or to an officer or agent of the corporation having or at its principal place of business or to an officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders of the corporation are
recorded. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not so consented in writing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DIRECTORS
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 1&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Powers</U><U>.</U> </B>The business and affairs of the corporation shall be managed under
the direction of its board of directors which may do all such lawful acts and things as are not by statute or by the certificate of incorporation of the corporation or by these <FONT STYLE="white-space:nowrap">by-laws</FONT> directed or required to
be exercised or done by the stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 2&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Number, Election Term of Office and
Qualifications</U><U>.</U> </B>The number of directors which shall constitute the whole board shall be that number determined by the board from time to time. The directors shall be elected at the annual meeting of the stockholders, except as
provided in &#167; 3.3, and each director elected shall hold office until his or her successor is elected and qualified or until his or her earlier death, resignation or removal in a manner permitted by statute or these by-laws. Directors need not
be stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 3&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Vacancies</U><U>.</U> </B>Vacancies occurring in the board of directors and
newly-created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director, and any director so chosen shall
hold office until the next annual election of directors and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal in a manner permitted by statute or these
<FONT STYLE="white-space:nowrap">by-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 4&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Regular Meetings</U><U>.</U> </B>A regular
meeting of the board of directors shall be held immediately following the close of, and at the same place as, each annual meeting of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders. No notice of any such meeting, other than this <FONT STYLE="white-space:nowrap">by-law,</FONT> shall be necessary in order legally to constitute the meeting, provided a quorum shall
be present. In the event such meeting is not held at such time and place the meeting may be held at such time and place as shall be specified in a notice given as hereinafter provided for special meetings of the board of directors or as shall be
specified in a written waiver signed by all of the directors. The board of directors may provide, by resolution, the time and place for the holding of additional regular meetings without notice other than such resolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 5 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Meetings.</U> </B>Special meetings of the board may be called by the president or any two
directors. The person or persons calling a special meeting of the board shall fix the time and place at which the meeting shall be held and such time and place shall be specified in the notice of such meeting, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 6 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice.</U> </B>Notice of any special meeting of the board of directors shall be given at least 2 days
previous thereto by written notice to each director at his or her business address or such other address as he or she may have advised the secretary of the corporation to use for such purpose. If delivered, such notice shall be deemed to be given
when delivered to such address or to the person to be notified. If mailed, such notice shall be deemed to be given two business days after deposit in the United States mail so addressed, with postage thereon prepaid. If given by telegraph, such
notice shall be deemed to be given the next business day following the day the telegram is given to the telegraph company. Such notice may also be given by telephone or other means not specified herein, and in each such case shall be deemed to be
given when actually received by the director to be notified. Notice of any meeting of the board of directors shall set forth the time and place of the meeting. Neither the business to be transacted at, nor the purpose of, any meeting of the board of
directors (regular or special) need be specified in the notice or waiver of notice of such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 7
<B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver Of Notice.</U> </B>A written waiver of notice, signed by a director entitled to notice of a meeting of the board of directors or of a committee of such board of which the director is a member, whether before or
after the time stated therein, shall be deemed equivalent to the giving of such notice to that director. Attendance of a director at a meeting of the board of directors or of a committee of such board of which the director is a member shall
constitute a waiver of notice of such meeting except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or
convened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 8 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Quorum and Vote Required For Action.</U> </B>At all meetings of the board of directors,
a majority of the number of directors fixed by these <FONT STYLE="white-space:nowrap">by-laws</FONT> shall constitute a quorum for the transaction of business and the act of a majority of the directors present at any meeting at which there is a
quorum shall be the act of the board of directors except as may be otherwise specifically provided by statute, the certificate of incorporation of the corporation or these <FONT STYLE="white-space:nowrap">by-laws.</FONT> If a quorum shall not be
present at any meeting of the board of directors, a majority of the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 9 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Attendance By Conference Telephone.</U> </B>Members of the board of directors or any committee
designated by the board may participate in a meeting of such board or committee by </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall
constitute presence in person at such a meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 10 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Presumption Of Assent.</U> </B>A director of the
corporation who is present at a duly convened meeting of the board of directors at which action on any corporate matter is taken shall be conclusively presumed to have assented to the action taken unless his or her dissent shall be entered in the
minutes of the meeting or unless he or she shall file his or her written dissent to such action with the person acting as the secretary of the meeting before the adjournment thereof or shall forward such dissent by registered or certified mail to
the secretary of the corporation immediately after the adjournment of the meeting. Such right to dissent shall not apply to a director who voted in favor of such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 11 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Informal Action.</U> </B>Unless otherwise restricted by statute, the certificate of incorporation of
the corporation or these <FONT STYLE="white-space:nowrap">by-laws,</FONT> any action required or permitted to be taken at any meeting of the board of directors or of any committee thereof may be taken without a meeting, if a written consent thereto
is signed by all the directors or by all the members of such committee, as the case may be, and such written consent is filed with the minutes of proceedings of the board of directors or of such committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 12 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation.</U> </B>The directors may be paid their expenses, if any, of attendance at each meeting
of the board of directors and at each meeting of a committee of the board of directors of which they are members. The board of directors, irrespective of any personal interest of any of its members, shall have authority to fix compensation of all
directors for services to the corporation as directors, officers or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 13 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal.</U>
</B>Any director or the entire board of directors may be removed by the stockholders, with or without cause, by a majority of the votes entitled to be cast at an election of directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COMMITTEES </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167;
1 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Committees.</U> </B>By resolution passed by a majority of the whole Board, the Board of Directors may designate one or more committees, each such committee to consist of two or more directors of the Corporation. The
Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member of any meeting of the committee. Any such committee, to the extent provided in the resolution or in these by laws,
shall have and may exercise the powers of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it. In the absence or
disqualification of any member of such committee or committees, the member or members thereof present at the meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board
of Directors to act at the meeting in the place of such absent or disqualified member. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OFFICERS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 1
<B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Designation, Number, Election.</U> </B>The board of directors, at its initial meeting and thereafter at its first regular meeting after each annual meeting of stockholders, shall choose the officers of the corporation.
Such officers shall be a chairman, a president, a secretary, and a treasurer, and such vice presidents, assistant secretaries and assistant treasurers as the board of directors may choose. The board of directors may appoint such other officers and
agents as it shall deem necessary who shall hold their offices for such terms and shall exercise such powers and perform such duties as shall be determined from time to time by the board. Any two or more offices may be held by the same person.
Except as provided in Article 6, election or appointment as an officer shall not of itself create contract rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 2
<B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Salaries.</U> </B>The salaries of all officers and agents of the corporation chosen by the board of directors shall be fixed by the board of directors, and no officer shall be prevented from receiving such salary by
reason of the fact that he is also a director of the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 3 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Term Of Office Removal:
Vacancies.</U> </B>Each officer of the corporation chosen by the board of directors shall hold office until the next annual appointment of officers by the board of directors and until his or her successor is appointed and qualified, or until his or
her earlier death, resignation or removal in the manner hereinafter provided. Any officer or agent chosen by the board of directors may be removed at any time by the board of directors whenever in its judgment the best interests of the corporation
would be served thereby, but such removal shall be without prejudice to the contract rights, if any, of the person so removed. Any vacancy occurring in any office of the corporation at any time or any new offices may be filled by the board of
directors for the unexpired portion of the term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 4 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Chairman.</U> </B>The chairman of the board, if
appointed, shall, if present, preside at all meetings of the Board of Directors and exercise and perform such other powers and duties as may be from time to time assigned to him by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 5 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>President.</U> </B>The president shall be the chief executive officer of the corporation and, subject
to the direction and control of the board of directors, shall be in charge of the business of the corporation. In general, the president shall discharge all duties incident to the principal executive office of the corporation and such other duties
as may be prescribed by the board of directors from time to time. Without limiting the generality of the foregoing, the president shall see that the resolutions and directions of the board of directors are carried into effect except in those
instances in which that responsibility is specifically assigned to some other person by the board of directors; shall preside at all meetings of the stockholders and, if he or she is a director of the corporation, of the board of directors; and,
except in those instances in which the authority to execute is expressly delegated to another officer or agent of the corporation or a different mode of execution is expressly prescribed by the board of directors, may execute for the corporation
certificates for its shares of stock (the issue of which shall have been authorized by the board of directors), and any contracts, deeds, mortgages, bonds, or other instruments which the board of directors has authorized, and may (without previous
authorization by the board of directors) execute such contracts and other instruments as the conduct of the corporation&#146;s business in its ordinary course requires, and may accomplish such execution in each case either under or without
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the seal of the corporation and either individually or with the secretary, any assistant secretary, or any other officer thereunto authorized by the board of directors, according to the
requirements of the form of the instrument. The president may vote all securities which the corporation is entitled to vote except as and to the extent such authority shall be vested in a different officer or agent of the corporation by the board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 6 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Vice Presidents.</U> </B>The vice president (and, in the event there is more than one
vice president, each of the vice presidents) shall render such assistance to the president in the discharge of his or her duties as the president may direct and shall perform such other duties as from time to time may be assigned by the president or
by the board of directors. In the absence of the president or in the event of his or her inability or refusal to act, the vice president (or in the event there may be more than one vice president, the vice presidents in the order designated by the
board of directors, or by the president if the board of directors has not made such a designation, or in the absence of any designation, then in the order of seniority of tenure as vice president) shall perform the duties of the president, and when
so acting, shall have all the powers of and be subject to all the restrictions upon the president. Except in those instances in which the authority to execute is expressly delegated to another officer or agent of the corporation or a different mode
of execution is expressly prescribed by the board of directors or these <FONT STYLE="white-space:nowrap">by-laws,</FONT> the vice president (or each of them if there are more than one) may execute for the corporation certificates for its shares of
stock (the issue of which shall have been authorized by the board of directors), and any contracts, deeds, mortgages, bonds or other instruments which the board of directors has authorized, and may (without previous authorization by the board of
directors) execute such contracts and other instruments as the conduct of the corporation&#146;s business in its ordinary course requires, and may accomplish such execution in each case either under or without the seal of the corporation and either
individually or with the secretary, any assistant secretary, or any other officer thereunto authorized by the board of directors, according to the requirements of the form of the instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 7 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Treasurer</U>.</B> The treasurer shall be the principal accounting and financial officer of the
corporation and as such shall perform all the duties incident to the office of treasurer and such other duties as from time to time may be assigned by the board of directors or the president. Without limiting the generality of the foregoing, the
treasurer shall have charge of and be responsible for the maintenance of adequate books of account for the corporation and shall have charge and custody of all funds and securities of the corporation and be responsible therefor and for the receipt
and disbursement thereof. If required by the board of directors, the treasurer shall give a bond for the faithful discharge of his or her duties in such sum and with such surety or sureties as the board of directors may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 8 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Secretary.</U></B> The secretary shall perform all duties incident to the office of secretary and such
other duties as from time to time may be assigned by the board of directors or president. Without limiting the generality of the foregoing, the secretary shall (a)&nbsp;record the minutes of the meetings of the stockholders and the board of
directors in one or more books provided for that purpose and shall include in such books the actions by written consent of the stockholders and the board of directors; (b)&nbsp;see that all notices are duly given in accordance with the provisions of
these <FONT STYLE="white-space:nowrap">by-laws</FONT> or as required by statute; (c)&nbsp;be the custodian of the corporate records and the seal of the corporation; (d)&nbsp;keep a register of the post office address of each
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholder which shall be furnished to the secretary by such stockholder; (e)&nbsp;sign with the president, or a vice president, or any other officer thereunto authorized by the board of
directors, certificates for shares of stock of the corporation (the issue of which shall have been authorized by the board of directors), and any contracts, deeds, mortgages, bonds, or other instruments which the board of directors has authorized,
and may (without previous authorization by the board of directors) sign with such other officers as aforesaid such contracts and other instruments as the conduct of the corporation&#146;s business in its ordinary course requires, in each case
according to the requirements of the form of the instrument, except when a different mode of execution is expressly prescribed by the board of directors; and (f)&nbsp;have general charge of the stock transfer books of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 9 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Assistant Treasurers And Assistant Secretaries.</U></B> The assistant treasurers and assistant
secretaries shall perform such duties as shall be assigned to them by the treasurer, in the case of assistant treasurers, or the secretary, in the case of assistant secretaries, or by the board of directors or president in either case. Each
assistant secretary may sign with the president, or a vice president, or any other officer thereunto authorized by the board of directors, certificates for shares of stock of the corporation (the issue of which shall have been authorized by the
board of directors), and any contracts, deeds, mortgages, bonds, or other instruments which the board of directors has authorized, and may (without previous authorization by the board of directors) sign with such other officers as aforesaid such
contracts and other instruments as the conduct of the corporation&#146;s business in its ordinary course requires, in each case according to the requirements of the form of the instrument, except when a different mode of execution is expressly
prescribed by the board of directors. The assistant treasurers shall, if required by the board of directors, give bonds for the faithful discharge of their duties in such sums and with such sureties as the board of directors shall determine. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INDEMNIFICATION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 1 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification of Directors and Officers.</U></B> The corporation shall, to the fullest extent to
which it is empowered to do so by the General Corporation Law of Delaware or any other applicable laws, as may from time to time be in effect, indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending
or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was a director or officer of the corporation, or is or was serving at the request of the corporation as a
director or officer of another corporation, partnership, joint venture, trust or other enterprise, against all expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person
in connection with such action, suit or proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 2 <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Advancement of Expenses.</U></B> Expenses
incurred by an officer or director of the corporation in defending a civil or criminal action, suit or proceeding shall be paid by the corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking
by or on behalf of such director or officer to repay such amount if it shall be ultimately determined that he or she is not entitled to be indemnified as authorized by the General Corporation Law of Delaware, as amended. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 3&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Contract With the Corporation</U><U>.</U></B> The
provisions of this Article 6 shall be deemed to be a contract between the corporation and each person who serves as such officer or director in any such capacity at any time while this Article and the relevant provisions of the General Corporation
Law of Delaware, as amended, or other applicable laws, if any, are in effect, and any repeal or modification of any such law or of this Article 6 shall not affect any rights or obligations then existing with respect to any state of facts then or
theretofore existing or any action, suit or proceeding theretofore or thereafter brought or threatened based in whole or in part upon any such state of facts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 4&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Indemnification of Employees And Agents</U><U>.</U></B> Persons who are not covered by the foregoing
provisions of this Article 6 and who are or were employees or agents of the corporation, or are or were serving at the request of the corporation as employees or agents of another corporation, partnership, joint venture, trust or other enterprise,
may be indemnified to the extent authorized at any time or from time to time by the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 5&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Other Rights of Indemnification</U><U>.</U></B> The indemnification and the advancement of expenses provided or permitted by this Article 6 shall not be deemed exclusive of any other rights to which those indemnified may be entitled by law or
otherwise, and shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such person. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LIMITATION ON DIRECTOR&#146;S LIABILITY </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 1&nbsp;&nbsp;&nbsp;&nbsp; The personal liability for monetary damages to the corporation or its stockholders of a person who serves as
a director of the corporation shall be limited if and to the extent provided at the time in the certificate of incorporation of the corporation, as then amended. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFICATES OF STOCK AND THEIR TRANSFER </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 1&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Form And Execution Of Certificates</U><U>.</U></B> Every holder of stock in the corporation shall be
entitled to have a certificate signed by, or in the name of, the corporation by the president or a vice president and by the secretary or an assistant secretary of the corporation, certifying the number of shares owned. Such certificates shall be in
such form as may be determined by the board of directors. During the period while more than one class of stock of the corporation is authorized there will be set forth on the face or back of the certificates which the corporation shall issue to
represent each class or series of stock a statement that the corporation will furnish, without charge to each stockholder who so requests, the designations, preferences and relative, participating, optional or other special rights of each class of
stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. In case any officer, transfer agent or registrar of the corporation who has signed, or whose facsimile signature has been placed upon, any
such certificate shall have ceased to be such officer, transfer agent or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registrar of the corporation before such certificate is issued by the corporation, such certificate may nevertheless be issued and delivered by the corporation with the same effect as if the
officer, transfer agent or registrar who signed, or whose facsimile signature was placed upon, such certificate had not ceased to be such officer, transfer agent or registrar of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 2&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Replacement Certificates</U><U>.</U></B> The board of directors may direct a new certificate to be
issued in place of any certificate evidencing shares of stock of the corporation theretofore issued by the corporation alleged to have been lost, stolen or destroyed, upon the making of an affidavit of the fact by the person claiming the certificate
to be lost, stolen or destroyed. When authorizing such issue of a new certificate, the board of directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost, stolen or destroyed certificate,
or his legal representative, to advertise the same in such manner as it shall require and may require such owner to give the corporation a bond in such sum as it may direct as indemnity against any claim that may be made against the corporation with
respect to the certificate alleged to have been lost, stolen or destroyed. The board of directors may delegate its authority to direct the issuance of replacement stock certificates to the transfer agent or agents of the corporation upon such
conditions precedent as may be prescribed by the board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 3&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Transfers of Stock</U><U>.</U></B> Upon
surrender to the corporation or the transfer agent of the corporation of a certificate for shares of stock of the corporation duly endorsed or accompanied by proper evidence of succession, assignment, or other authority to transfer, it shall be the
duty of the corporation to issue a new certificate to the person entitled thereto, cancel the old certificate and record the transaction upon its books, provided the corporation or a transfer agent of the corporation shall not have received a
notification of adverse interest and that the conditions of <FONT STYLE="white-space:nowrap">Section&nbsp;8-401</FONT> of Title 6 of the Delaware Code have been met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 4&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Registered Stockholders</U><U>.</U></B> The corporation shall be entitled to treat the holder of record
(according to the books of the corporation) of any share or shares of its stock as the holder in fact thereof and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other party
whether or not the corporation shall have express or other notice thereof, except as expressly provided by the laws of the State of Delaware. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONTRACTS, LOANS, CHECKS AND DEPOSITS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 1&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Contracts</U><U>.</U></B> The board of directors may authorize any officer or officers, or agent or
agents, to enter into any contract or execute and deliver any instrument in the name of and on behalf of the corporation, and such authority may be general or confined to specific instances; provided, however, that this &#167; 9.1 shall not be a
limitation on the powers of office granted under Article 5 of these <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167;
2&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Loans</U><U>.</U></B> No loans shall be contracted on behalf of the corporation and no evidences of indebtedness shall be issued in its name unless authorized by a resolution of the board of directors. Such authority
may be general or confined to specific instances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 3&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Checks, Drafts And Other
Instruments</U><U>.</U></B> All checks, drafts or other orders for the payment of money and all notes or other evidences of indebtedness issued in the name of the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation shall be signed by such officer or officers or such agent or agents of the corporation and in such manner as from time to time may be determined by the resolution of the board of
directors or by an officer or officers of the corporation designated by the board of directors to make such determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167;
4&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Deposits</U><U>.</U></B> All funds of the corporation not otherwise employed shall be deposited from time to time to the credit of the corporation in such banks, trust companies or other depositaries as the board of
directors, or an officer or officers designated by the board of directors, may select. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MISCELLANEOUS PROVISIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 1&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Dividends</U></B><U>.</U> Subject to any provisions of any applicable statute or of the certificate of
incorporation, dividends may be declared upon the capital stock of the corporation by the board of directors at any regular or special meeting thereof; and such dividends may be paid in cash, property or shares of stock of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 2&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Reserves</U></B><U>.</U> Before payment of any dividends, there may be set aside out of any funds of
the corporation available for dividends such sum or sums as the board of directors from time to time, in its discretion, determines to be proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or
maintaining any property of the corporation, or for such other purpose as the board of directors shall determine to be conducive to the interests of the corporation, and the directors may modify or abolish any such reserve in the manner in which it
was created. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 3&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Voting Stock Of Other Corporations</U><U>.</U></B> In the absence of specific action
by the board of directors, the president shall have authority to represent the corporation and to vote, on behalf of the corporation, the securities of other corporations, both domestic and foreign, held by the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 4&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Fiscal Year</U><U>.</U></B> The fiscal year of the corporation shall begin on the first day of January
in each year and end on the last day of the next following December. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 5&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Seal</U><U>.</U></B> The
corporate seal shall have inscribed thereon the name of the corporation and the words &#147;Corporate Seal, Delaware&#148;. The seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise applied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 6&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Severability</U><U>.</U></B> If any provision of these <FONT STYLE="white-space:nowrap">by-laws,</FONT>
or its application thereof to any person or circumstances, is held invalid, the remainder of these <FONT STYLE="white-space:nowrap">by-laws</FONT> and the application of such provision to other persons or circumstances shall not be affected thereby.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#167; 7&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Amendment</U><U>.</U></B> These <FONT STYLE="white-space:nowrap">by-laws</FONT> may be amended or
repealed, or new <FONT STYLE="white-space:nowrap">by-laws</FONT> may be adopted, by the board of directors of the corporation. These <FONT STYLE="white-space:nowrap">by-laws</FONT> may also be amended or repealed, or new <FONT
STYLE="white-space:nowrap">by-laws</FONT> may be adopted, by action taken by the stockholders of the corporation. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED INVESTORS&#146; RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AMENDED AND RESTATED INVESTORS&#146; RIGHTS AGREEMENT (this &#147;<B>Agreement</B>&#148;), is made as of November&nbsp;20, 2020, by and
among <B>A<SMALL>CUMEN</SMALL> P<SMALL>HARMACEUTICALS</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation (the &#147;<B>Company</B>&#148;), each of the investors listed on <U>Schedule A</U> hereto, each of which is referred to in this Agreement
as an &#147;<B>Investor</B>&#148; and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with <U>Section&nbsp;6.9</U> hereof. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, certain of the Investors (the &#147;<B>Existing Investors</B>&#148;) hold shares of Series A
Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to
that certain Amended and Restated Investors&#146; Rights Agreement dated as of October&nbsp;19, 2018, by and among the Company and such Existing Investors (as amended, the &#147;<B>Prior Agreement</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, the Existing Investors are holders of a majority of the Registrable Securities (as defined in
the Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">under the Prior Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, certain of the Investors are parties to that certain Series B Preferred Stock Purchase Agreement
of even date herewith by and among the Company and such Investors (the &#147;<B>Purchase Agreement</B>&#148;), under which certain of the Company&#146;s and such Investors&#146; obligations are conditioned upon the execution and delivery of this
Agreement by such Investors, Existing Investors holding at least a majority of the Registrable Securities, and the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL></B><SMALL></SMALL>, <B>T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, the Existing Investors hereby agree that the Prior
Agreement is hereby amended and restated in its entirety by this Agreement, and the parties to this Agreement further agree as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. For purposes of this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; means, with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, limited partner, managing member, officer, director or trustee of such Person, or any investment fund (including,
without limitation, any venture capital fund) or registered investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment advisers of, or shares the same management company or
investment adviser with, such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Board of Directors</B>&#148; means the board of directors of
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Certificate of Incorporation</B>&#148; means the Company&#146;s Amended and Restated
Certificate of Incorporation, as amended and/or restated from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.4&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Common Stock</B>&#148;
means shares of the Company&#146;s common stock, par value $0.0001 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.5&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Damages</B>&#148; means any loss, damage, claim or
liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or
is based upon: (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or
supplements thereto; (ii)&nbsp;an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii)&nbsp;any violation or alleged violation by the
indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.6&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Derivative Securities</B>&#148; means any securities or rights convertible into, or exercisable or
exchangeable for (in each case, directly or indirectly)<B>, </B>Common Stock, including options and warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.7&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.8&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Excluded Registration</B>&#148; means (i)&nbsp;a registration
relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii)&nbsp;a registration relating to an SEC Rule 145 transaction; (iii)&nbsp;a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv)&nbsp;a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.9&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Form <FONT STYLE="white-space:nowrap">S-1</FONT></B>&#148; means such form under the Securities Act as in
effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.10&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Form <FONT STYLE="white-space:nowrap">S-3</FONT></B>&#148; means such form under the Securities Act as in
effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed by the Company with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.11&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>GAAP</B>&#148; means generally accepted accounting principles in the United States as in effect from time
to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.12&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Holder</B>&#148; means any holder of Registrable Securities who is a party to this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.13&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Immediate Family Member</B>&#148; means a child, stepchild, grandchild, parent,
stepparent, grandparent, spouse, life partner or similar statutorily-recognized domestic partner, sibling, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including, adoptive relationships, of a natural person
referred to herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.14&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Initiating Holders</B>&#148; means, collectively, Holders who properly initiate
a registration request under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.15&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IPO</B>&#148; means the Company&#146;s first
underwritten public offering of its Common Stock under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.16&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Key Employee</B>&#148; means any executive-level
employee (including, division director and vice president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase
Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.17&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Major Investor</B>&#148; means (i)&nbsp;any Investor that, individually or together with
such Investor&#146;s Affiliates, holds at least 1,333,333 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof) and
(ii)&nbsp;Blackwell Partners LLC (&#147;<B>Blackwell</B>&#148;) for so long as it holds shares of Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.18&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>New Securities</B>&#148; means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.19&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Person</B>&#148; means any individual, corporation, partnership, trust, limited liability company,
association or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.20&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Preferred Director</B>&#148; means any director of the Company that the
holders of record of a class, classes or series of Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.21&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Preferred Stock</B>&#148; means, collectively, shares of the Series A Preferred Stock, the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and the Series B Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.22&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>RA
Capital</B>&#148; means RA Capital Healthcare Fund, L.P, RA Capital Nexus Fund II, L.P. and their respective Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.23&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Registrable Securities</B>&#148; means (i)&nbsp;the Common Stock issuable or issued upon conversion of
the Preferred Stock, excluding any Common Stock issued upon conversion of the Series B Preferred Stock pursuant to the &#147;Special Mandatory Conversion&#148; provisions of the Certificate of Incorporation; (ii)&nbsp;any Common Stock, or any Common
Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; and (iii)&nbsp;any Common Stock issued as (or issuable upon the conversion or
exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause <U>(i)</U>&nbsp;above; excluding in all cases, however,
any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to <U>Section&nbsp;6.1</U>, and excluding for purposes of <U>Section&nbsp;2</U> any shares for which
registration rights have terminated pursuant to <U>Section&nbsp;2.13</U> of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.24&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Registrable Securities then outstanding</B>&#148; means the number of shares determined by adding the
number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.25&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Restricted Securities</B>&#148; means the securities of the Company required to be notated with the
legend set forth in <U>Section&nbsp;2.12(b)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.26&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sands Capital&#148; </B>means Sands Capital
Ventures Discovery Fund III, L.P., Sands Capital Global Venture Fund II, L.P., Sands Capital Life Sciences Pulse Fund, LLC and/or their respective Affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.27&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>SEC</B>&#148; means the Securities and Exchange
Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.28&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>SEC Rule 144</B>&#148; means Rule 144 promulgated by the SEC under the Securities Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.29&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>SEC Rule 145</B>&#148; means Rule 145 promulgated by the SEC under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.30&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.31&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Selling Expenses</B>&#148; means all underwriting discounts, selling
commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as
provided in <U>Section&nbsp;2.6</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.32&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series A Preferred Stock</B>&#148; means shares of the
Company&#146;s Series A Preferred Stock, par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.33&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</B>&#148; means shares of the Company&#146;s Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, par value $0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.34&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series B Preferred Stock</B>&#148; means shares of the Company&#146;s Series B Preferred Stock, par value
$0.0001 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Rights</U>. The Company covenants and agrees as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 &nbsp;&nbsp;&nbsp;&nbsp;<U>Demand Registration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Form <FONT STYLE="white-space:nowrap">S-1</FONT> Demand</U>. If at any time after the earlier of (i)&nbsp;three
years after the date of this Agreement or (ii) 180 days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that the Company
file a Form <FONT STYLE="white-space:nowrap">S-1</FONT> registration statement with respect to all of the Registrable Securities then outstanding held by such Holders covering the registration of Registrable Securities with an anticipated aggregate
offering price, net of Selling Expenses, of at least $5&nbsp;million, then the Company shall (x)&nbsp;within 10 days after the date such request is given, give notice thereof (the &#147;<B>Demand Notice</B>&#148;) to all Holders other than the
Initiating Holders; and (y)&nbsp;as soon as practicable, and in any event within 60 days after the date such request is given by the Initiating Holders, file a Form <FONT STYLE="white-space:nowrap">S-1</FONT> registration statement under the
Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by
each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of <U>Sections 2.1(c)</U> and <U>2.3.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand</U>. If at any time when it is eligible to use a Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration statement, the Company receives a request from Holders of at least 30% of the Registrable Securities then outstanding that the Company file a Form <FONT STYLE="white-space:nowrap">S-3</FONT>
registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5&nbsp;million, then the Company shall (i)&nbsp;within 10 days after the
date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii)&nbsp;as soon as practicable, and in any event within 45 days after the date such request is given by the Initiating Holders, file a Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration statement under the Securities Act covering all Registrable Securities requested </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case,
subject to the limitations of <U>Sections 2.1(c)</U> and 2.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing obligations, if
the Company furnishes to Holders requesting a registration pursuant to this <U>Section&nbsp;2.1</U> a certificate signed by the Company&#146;s chief executive officer stating that in the good faith judgment of the Board of Directors it would be
materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because it would be
materially detrimental to the Company and its stockholders for such registration statement to be filed and it is therefore necessary to defer the filing of such registration statement, then the Company shall have the right to defer taking action
with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than 120 days after the request of the Initiating Holders is given; <U>provided</U>,
<U>however</U>, that the Company may not invoke this right more than twice in any 12 month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Section&nbsp;2.1(a)</U>&nbsp;(i) during the period that is 60 days before the Company&#146;s good faith estimate of the date of filing of, and
ending on a date that is 180 days after the effective date of, a Company-initiated registration, <U>provided</U> that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become
effective; (ii)&nbsp;after the Company has effected two registrations pursuant to <U>Section&nbsp;2.1(a)</U>; or (iii)&nbsp;if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> pursuant to a request made pursuant to <U>Section&nbsp;2.1(b)</U>. The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Section&nbsp;2.1(b)</U>&nbsp;(i)
during the period that is 30 days before the Company&#146;s good faith estimate of the date of filing of, and ending on a date that is 90 days after the effective date of, a Company-initiated registration, <U>provided</U> that the Company is
actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii)&nbsp;if the Company has effected two registrations pursuant to <U>Section 2.1(b)</U> within the twelve (12)&nbsp;month
period immediately preceding the date of such request. A registration shall not be counted as &#147;effected&#148; for purposes of this <U>Section&nbsp;2.1(d)</U> until such time as the applicable registration statement has been declared effective
by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to <U>Section&nbsp;2.6</U>, in which
case such withdrawn registration statement shall be counted as &#147;effected&#148; for purposes of this <U>Section&nbsp;2.1(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Company Registration</U>. If the Company proposes to register (including, for this purpose, a registration
effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at
such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within 20 days after such notice is given by the Company, the Company shall, subject to the provisions of <U>Section&nbsp;2.3</U>, cause to be
registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this <U>Section&nbsp;2.2</U>
before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in
accordance with <U>Section&nbsp;2.6</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriting Requirements</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If, pursuant to <U>Section&nbsp;2.1</U>, the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to <U>Section&nbsp;2.1</U>, and the Company shall include such information in the Demand Notice. The underwriter(s) will
be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder&#146;s Registrable Securities in such registration shall be conditioned
upon such Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such
underwriting shall (together with the Company as provided in <U>Section 2.4(e))</U> enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting; <U>provided</U>, <U>however</U>, that no Holder (or
any of their assignees) shall be required to make any representations, warranties or indemnities except as they relate to Holder&#146;s ownership of shares, and authority to enter into the underwriting agreement and to such Holder&#146;s intended
method of distribution, and the liability of such Holder shall be several and not joint, and limited to an amount equal to the net proceeds from the offering received by such Holder. Notwithstanding any other provision of this
<U>Section&nbsp;2.3</U>, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating
Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; <U>provided</U>, <U>however</U>, that the number
of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above
provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In connection with any offering involving an underwriting of shares of the Company&#146;s capital stock pursuant
to <U>Section&nbsp;2.2</U>, the Company shall not be required to include any of the Holders&#146; Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its
underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by
stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the
underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in
proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance
with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i)&nbsp;the number of Registrable Securities included in
the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii)&nbsp;the number of Registrable Securities included in the offering be reduced below 25% of
the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder&#146;s
securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are included in such offering. For purposes of the provision in this <U>Section&nbsp;2.3(b)</U> concerning apportionment, for any selling Holder that is a partnership, limited liability company,
or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts
for the benefit of any of the foregoing Persons, shall be deemed to be a single &#147;selling Holder,&#148; and any pro rata reduction with respect to such &#147;selling Holder&#148; shall be based upon the aggregate number of Registrable Securities
owned by all Persons included in such &#147;selling Holder,&#148; as defined in this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;For purposes
of <U>Section&nbsp;2.1</U>, a registration shall not be counted as &#147;effected&#148; if, as a result of an exercise of the underwriter&#146;s cutback provisions in <U>Section&nbsp;2.3(a)</U>, fewer than 50% of the total number of Registrable
Securities that Holders have requested to be included in such registration statement are actually included. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Obligations of the Company</U>. Whenever required under this <U>Section&nbsp;2</U> to effect the registration of
any Registrable Securities, the Company shall, as expeditiously as reasonably possible: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;prepare and file with
the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable
Securities registered thereunder, keep such registration statement effective for a period of up to 120 days or, if earlier, until the distribution contemplated in the registration statement has been completed; <U>provided</U>, <U>however</U>, that
such 120 day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;prepare and file with the SEC such amendments and supplements to such registration statement, and the
prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as
required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;use its commercially reasonable efforts to register and qualify the securities covered by such registration
statement under such other securities or <FONT STYLE="white-space:nowrap">blue-sky</FONT> laws of such jurisdictions as shall be reasonably requested by the selling Holders; <U>provided</U> that the Company shall not be required to qualify to do
business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;in the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the underwriter(s) of such offering; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;use its commercially
reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities
issued by the Company are then listed; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;provide a transfer agent and registrar for all Registrable
Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any
disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of
the Company, and cause the Company&#146;s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or
advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration
statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the
Company amend or supplement such registration statement or prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company shall ensure that, at all times after any
registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company&#146;s directors may implement a trading program under
Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Furnish Information</U>. It shall
be a condition precedent to the obligations of the Company to take any action pursuant to this <U>Section&nbsp;2</U> with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information
regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder&#146;s Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses of Registration</U>. All expenses (other than Selling Expenses) incurred in connection with
registrations, filings, or qualifications pursuant to <U>Section&nbsp;2</U>, including all registration, filing, and qualification fees; printers&#146; and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees
and disbursements, not to exceed $50,000, of one counsel for the selling Holders (&#147;<B>Selling Holder Counsel</B>&#148;), shall be borne and paid by the Company; <U>provided</U>, <U>however</U>, that the Company shall not be required to pay for
any expenses of any registration proceeding begun pursuant to <U>Section&nbsp;2.1</U> if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all
selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to
one registration pursuant to <U>Sections 2.1(a)</U> or <U>2.1(b)</U>, as the case may be then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to <U>Sections 2.1(a)</U> or
2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this <U>Section&nbsp;2</U> shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Delay of Registration</U>. No Holder shall have any right to obtain or seek an injunction restraining or
otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this <U>Section&nbsp;2</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>. If any Registrable Securities are
included in a registration statement under this <U>Section&nbsp;2</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;To the extent permitted by law, the
Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities
Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling
Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; <U>provided</U>,
<U>however</U>, that the indemnity agreement contained in this <U>Section&nbsp;2.8(a)</U> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent
shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on
behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration except to the extent such information has been corrected in a subsequent writing prior to or
concurrently with the sale of Registrable Securities to the Person asserting the claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;To the extent
permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company
within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such
underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of
such selling Holder expressly for use in connection with such registration and has not been corrected in a subsequent writing prior to or concurrently with the sale of Registrable Securities to the Person asserting the claim; and each such selling
Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are
incurred; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in this <U>Section&nbsp;2.8(b)</U> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of
the Holder, which consent shall not be unreasonably withheld; and <U>provided</U> <U>further</U> that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under <U>Sections 2.8(b)</U> and <U>2.8(d)</U>
exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Promptly after receipt by an indemnified party under this <U>Section&nbsp;2.8</U> of notice of the commencement of
any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
<U>Section&nbsp;2.8</U>, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any
other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; <U>provided</U>, <U>however</U>, that an indemnified party (together with all other indemnified parties
that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the
commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this <U>Section&nbsp;2.8</U>, to the extent that such failure materially prejudices the indemnifying party&#146;s ability to defend
such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this <U>Section&nbsp;2.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;To provide for just and equitable contribution to joint liability under the Securities Act in any case in which
either: (i)&nbsp;any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Section&nbsp;2.8</U> but it is judicially determined (by the entry of a final judgment or decree by a court of competent
jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this <U>Section&nbsp;2.8</U> provides for indemnification in such
case, or (ii)&nbsp;contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this <U>Section&nbsp;2.8</U>, then, and in each such case, such parties will contribute to the
aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party
in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of
the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties&#146; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; <U>provided</U>, <U>however</U>, that, in any such case
(x)&nbsp;no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y)&nbsp;no Person guilty of
fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and <U>provided</U> <U>further</U> that in no
event shall a Holder&#146;s liability pursuant to this <U>Section&nbsp;2.8(d)</U>, when combined with the amounts paid or payable by such Holder pursuant to <U>Section&nbsp;2.8(b)</U>, exceed the proceeds from the offering received by such Holder
(net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; <U>provided</U>, <U>however</U>, that any matter
expressly provided for or addressed by the foregoing provisions that is not expressly provided for or addressed by the underwriting agreement shall be controlled by the foregoing provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public
offering, the obligations of the Company and Holders under this <U>Section&nbsp;2.8</U> shall survive the completion of any offering of Registrable Securities in a registration under this <U>Section&nbsp;2</U>, and otherwise shall survive the
termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Reports Under Exchange Act</U>. With a view to making
available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> the Company shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;make and keep available adequate current public
information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents
required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i)&nbsp;to
the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after 90 days after the effective date of the registration statement filed by the Company for the IPO), the
Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT>
(at any time after the Company so qualifies); and (ii)&nbsp;such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at
any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies to use such form). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitations on Subsequent Registration Rights</U>. From and after the date of this Agreement, the Company shall
not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or
prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such
securities will not reduce the number of the Registrable Securities of the Holders that are included; <U>provided</U> that this limitation shall not apply to Registrable Securities acquired by any additional Investor that becomes a party to this
Agreement in accordance with <U>Section&nbsp;6.9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.11&nbsp;&nbsp;&nbsp;&nbsp;<U>&#147;Market
<FONT STYLE="white-space:nowrap">Stand-off&#148;</FONT> Agreement</U>. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus
relating to the registration by the Company of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> and ending on the date specified by
the Company and the managing underwriter (such period not to exceed 180 days, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1)&nbsp;the publication or other distribution of
research reports, and (2)&nbsp;analyst recommendations and opinions, including, but not limited to, the restrictions contained in applicable FINRA rules or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to
sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering or (ii)&nbsp;enter into any swap or other arrangement that transfers
to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or
otherwise. The foregoing provisions of this <U>Section&nbsp;2.11</U> shall apply only to the IPO and shall not apply to (a)&nbsp;the sale of any shares of Common Stock (x)&nbsp;purchased by the Holder in connection with the IPO, whether or not
pursuant to an underwriting agreement, a private placement that is concurrent with the IPO, or otherwise, or (y)&nbsp;acquired in the open market at any time on or after the IPO; (b)&nbsp;the sale of any shares to an underwriter pursuant to an
underwriting agreement, or (c)&nbsp;the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, <U>provided</U> that the trustee of the trust agrees to be bound in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
writing by the restrictions set forth herein, and <U>provided</U> <U>further</U> that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if
all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar agreement from all stockholders individually owning more than 1% of the Company&#146;s outstanding Common Stock
(after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection with such registration are intended third-party beneficiaries of this <U>Section&nbsp;2.11</U> and shall have the right, power
and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with
this <U>Section&nbsp;2.11</U> or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company
stockholders that are subject to such agreements, based on the number of shares subject to such agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions on Transfer</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the
Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure
compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each certificate, instrument,
or book entry representing (i)&nbsp;the Preferred Stock, (ii)&nbsp;the Registrable Securities, and (iii)&nbsp;any other securities issued in respect of the securities referenced in clauses (i)&nbsp;and (ii), upon any stock split, stock dividend,
recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of <U>Section&nbsp;2.12(c))</U> be notated with a legend substantially in the following form: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this <U>Section&nbsp;2.12</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects
with the provisions of this <U>Section&nbsp;2</U>. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder
thereof shall give notice to the Company of such Holder&#146;s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if
reasonably requested </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the Company, shall be accompanied at such Holder&#146;s expense by either (i)&nbsp;a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to
the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii)&nbsp;a &#147;no action&#148; letter from the SEC to the effect that the proposed sale, pledge, or
transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii)&nbsp;any other evidence reasonably satisfactory to counsel to the Company to
the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such
Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or &#147;no action&#148; letter (x)&nbsp;in any transaction in compliance with SEC Rule 144; or
(y)&nbsp;in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; <U>provided</U> that each transferee agrees in writing to be subject to the terms of this
<U>Section&nbsp;2.12</U>. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive
legend set forth in <U>Section&nbsp;2.12(b)</U>, except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in
order to establish compliance with any provisions of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.13&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of Registration
Rights</U>. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to <U>Sections 2.1</U> or <U>2.2</U> shall terminate upon the earliest to occur of: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, in which
the consideration received by the Investors in such Deemed Liquidation Event is in the form of cash and/or publicly traded securities, or if the Investors receive registration rights from the acquiring company or other successor to the Company that
are reasonably comparable to those set forth in this <U>Section&nbsp;2</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;such time after consummation of
the IPO as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder&#146;s shares without limitation during a three-month period without registration (and without the requirement for the
Company to be in compliance with the current public information required under subsection (c)(1) of SEC Rule 144) and such Holder (together with its &#147;affiliates&#148; as determined under SEC Rule 144) holds less than one percent (1%) of the
outstanding capital stock of the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;the third anniversary of the IPO. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Information Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery of Financial Statements</U>. The Company shall deliver to each Major Investor, <I><U>provided</U></I>
that the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company; <I><U>provided further</U></I> that Sands Capital, RA Capital and Blackwell shall not be determined to be a competitor of the Company
for any purpose under this Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;as soon as practicable, but in any event within 120 days after the end
of each fiscal year of the Company (i)&nbsp;a balance sheet as of the end of such year, (ii)&nbsp;statements of income and of cash flows for such year, and a comparison between (x)&nbsp;the actual amounts as of and for such fiscal year and
(y)&nbsp;the comparable amounts for the prior year and as included in the Budget (as defined in <U>Section&nbsp;3.1(e))</U> for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and
applications of funds for such year, and (iii)&nbsp;a statement of stockholders&#146; equity as of the end of such year, all such financial statements audited and certified by independent public accountants of regionally recognized standing selected
by the Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;as soon as practicable, but in any event within 45 days after
the end of each of the first three quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders&#146; equity as of the end of such
fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i)&nbsp;be subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments; and (ii)&nbsp;not contain all notes thereto that may be
required in accordance with GAAP); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;as soon as practicable, but in any event within 30 days after the end of
each month, unaudited statements of income and cash flows for such month, and an unaudited balance sheet and a statement of stockholders&#146; equity as of the end of such month, all prepared in accordance with GAAP (except that such financial
statements may (i)&nbsp;be subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments and (ii)&nbsp;not contain all notes thereto that may be required in accordance with GAAP); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;as soon as practicable, but in any event within 45 days after the end of each quarter of each fiscal year of the
Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or
exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for
issuance, if any, all in a form reasonably acceptable to each Major Investor, in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial
officer or chief executive officer of the Company as being true, complete, and correct; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;as soon as
practicable, but in any event 30 days before the end of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and,
promptly after prepared, any other budgets or revised budgets prepared by the Company (such budget and business plan that is approved by the Board of Directors including the vote of a majority of the Preferred Directors then seated (the
&#147;<B>Requisite Preferred Director Vote</B>&#148;) is collectively referred to herein as the &#147;<B>Budget</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;such other information relating to the financial condition, business, prospects, or corporate affairs of the
Company as any Major Investor may from time to time reasonably request; <U>provided</U>, <U>however</U>, that the Company shall not be obligated under this <U>Section&nbsp;3.1</U> to provide information (i)&nbsp;that the Company reasonably
determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii)&nbsp;the disclosure of which would adversely affect the
attorney-client privilege between the Company and its counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, for any period, the Company has any subsidiary whose accounts are
consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated
subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything else in this <U>Section&nbsp;3.1</U> to the contrary, the Company may cease providing the
information set forth in this <U>Section&nbsp;3.1</U> during the period starting with the date 60 days before the Company&#146;s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply
with the SEC rules applicable to such registration statement and related offering; <U>provided</U> that the Company&#146;s covenants under this <U>Section&nbsp;3.1</U> shall be reinstated at such time as the Company is no longer actively employing
its commercially reasonable efforts to cause such registration statement to become effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Inspection</U>. The Company shall permit each Major Investor,
<U>provided</U> that the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company, at such Major Investor&#146;s expense, to visit and inspect the Company&#146;s properties; examine its books of
account and records; and discuss the Company&#146;s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; <U>provided</U>, <U>however</U>, that the
Company shall not be obligated pursuant to this <U>Section&nbsp;3.2</U> to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable
confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of Information</U>. The covenants set forth in <U>Section&nbsp;3.1</U> and <U>Section 3.2</U> shall
terminate and be of no further force or effect (i)&nbsp;immediately before the consummation of the IPO, (ii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Section&nbsp;12(g) or 15(d) of the Exchange Act, or
(iii)&nbsp;upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first; provided, that, with respect to clause (iii), the covenants set forth in <U>Section&nbsp;3.1</U>
shall only terminate if the consideration received by the Investors in such Deemed Liquidation Event is in the form of cash and/or publicly traded securities or if the Investors receive financial information from the acquiring company or other
successor to the Company comparable to those set forth in <U>Section&nbsp;3.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>.
Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms
of this Agreement (including notice of the Company&#146;s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this <U>Section
3.4</U> by such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company&#146;s confidential information, or (c)&nbsp;is or has been made known or disclosed to such Investor by a third party
without a breach of any obligation of confidentiality such third party may have to the Company; <U>provided</U>, <U>however</U>, that an Investor may disclose confidential information (i)&nbsp;to its attorneys, accountants, consultants, and other
professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii)&nbsp;to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees
to be bound by the provisions of this <U>Section&nbsp;3.4</U>, <U>provided</U> that the Board of Directors has not reasonably determined that such prospective purchaser is a competitor of the Company; (iii)&nbsp;to any Affiliate, any current or
prospective partner, member or stockholder, or any wholly owned subsidiary of such Investor in the ordinary course of business, <U>provided</U> that such Investor informs such Person that such information is confidential and directs such Person to
maintain the confidentiality of such information; or (iv)&nbsp;as may otherwise be required by law, regulation, rule, court order or subpoena, <U>provided</U> that such Investor promptly notifies the Company of such disclosure and takes reasonable
steps to minimize the extent of any such required disclosure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Rights to Future Stock Issuances</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Right of First Offer</U>. Subject to the terms and conditions of this <U>Section&nbsp;4.1</U> and applicable
securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in
such proportions as it deems appropriate, among (i)&nbsp;itself and (ii)&nbsp;its Affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall give notice (the &#147;<B>Offer
Notice</B>&#148;) to each Major Investor, stating (i)&nbsp;its bona fide intention to offer such New Securities, (ii)&nbsp;the number of such New Securities to be offered, and (iii)&nbsp;the price and terms, if any, upon which it proposes to offer
such New Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;By notification to the Company within 20 days after the Offer Notice is given, each
Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor
(including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock
of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and any other Derivative Securities then outstanding). At the expiration of such twenty (20)&nbsp;day period, the Company shall promptly
notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a &#147;<B>Fully Exercising Investor</B>&#148;) of any other Major Investor&#146;s failure to do likewise. During the ten (10)&nbsp;day period
commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for
which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as
applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the
Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this <U>Section&nbsp;4.1(b)</U> shall occur within the later of 90
days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to <U>Section&nbsp;4.1(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in
<U>Section&nbsp;4.1(b)</U>, the Company may, during the 90 day period following the expiration of the periods provided in <U>Section&nbsp;4.1(b)</U>, offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons
at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not
consummated within 30 days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this
<U>Section&nbsp;4.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any provision hereof to the contrary, in lieu of complying with the
provisions of this <U>Section&nbsp;4.1</U>, the Company may elect to give notice to the Major Investors within thirty (30)&nbsp;days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New Securities.
Each Major Investor shall have twenty (20)&nbsp;days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Major Investor, maintain such Major Investor&#146;s percentage-ownership
position, calculated as set forth in <U>Section&nbsp;4.1(b)</U> before giving effect to the issuance of such New Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The right of first offer in this <U>Section&nbsp;4.1</U> shall not be applicable to (i)&nbsp;Exempted Securities
(as defined in the Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii)&nbsp;the issuance of shares of Preferred Stock to Additional Purchasers pursuant to Section&nbsp;1.3 of the Purchase Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. The covenants set forth in
<U>Section&nbsp;4.1</U> shall terminate and be of no further force or effect (i)&nbsp;immediately before the consummation of the Qualified IPO, as such term is defined in the Certificate of Incorporation, (ii)&nbsp;when the Company first becomes
subject to the periodic reporting requirements of Section&nbsp;12(g) or 15(d) of the Exchange Act, or (iii)&nbsp;upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation in which the consideration
received by the Investors in such Deemed Liquidation Event is in the form of cash and/or publicly traded securities, or if the Investors receive participation rights from the acquiring company or other successor to the Company reasonably comparable
to those set forth in this <U>Section&nbsp;4</U>, whichever event occurs first. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Covenants</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>. The Company shall use commercially reasonable efforts to maintain, from financially sound and
reputable insurers Directors and Officers liability insurance in an amount and on terms and conditions satisfactory to the Board of Directors, until such time as the Board of Directors determines that such insurance should be discontinued. The
policy will not be cancelable by the Company without prior approval by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee
Agreements</U>. The Company will cause (i)&nbsp;each Person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or
trade secrets to enter into a nondisclosure and proprietary rights assignment agreement; and (ii)&nbsp;each Key Employee to enter into a one year <FONT STYLE="white-space:nowrap">non-competition</FONT> and
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, substantially in the form approved by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee Stock</U>. Unless otherwise approved by the Board of Directors, all future employees and consultants of
the Company who purchase, receive options to purchase, or receive awards of shares of the Company&#146;s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for
(i)&nbsp;vesting of shares over a 4 year period, with the first 25% of such shares vesting following 12 months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following 36 months, and
(ii)&nbsp;a market <FONT STYLE="white-space:nowrap">stand-off</FONT> provision substantially similar to that in <U>Section&nbsp;2.11</U>. Without the prior approval by the Board of Directors, the Company shall not amend, modify, terminate, waive or
otherwise alter, in whole or in part, any stock purchase, stock restriction or option agreement with any existing employee or service provider if such amendment would cause it to be inconsistent with this <U>Section&nbsp;5.3</U>. In addition, unless
otherwise approved by the Board of Directors, the Company shall retain (and not waive) a &#147;right of first refusal&#148; on employee transfers until the Company&#146;s IPO and shall have the right to repurchase unvested shares at cost upon
termination of employment of a holder of restricted stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Board Matters</U>. Unless otherwise determined
by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the directors for all reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel expenses incurred (consistent with the Company&#146;s travel policy) in connection with attending meetings of the Board of Directors. Each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director shall be entitled in such person&#146;s discretion to be a member of any committee of the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Matters Requiring Preferred Director Approval</U>. During such
time or times as the holders of Preferred Stock are entitled to elect a Preferred Director and such seat is filled, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors,
which approval must include the Requisite Preferred Director Vote: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;make, or permit any subsidiary to make, any
loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any
employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness
except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;make
any investment inconsistent with any investment policy approved by the Board of Directors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;incur any aggregate
indebtedness in excess of $250,000 that is not already included in the Budget (as defined in <U>Section&nbsp;3.1(e))</U>, other than trade credit incurred in the ordinary course of business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or any
&#147;associate&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated under the Exchange Act) of any such Person, including without limitation any &#147;management bonus&#148; or similar plan providing payments to
employees in connection with a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, except for transactions contemplated by this Agreement and the Purchase Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;hire, terminate, or change the compensation of the executive officers, including approving any option grants or
stock awards to executive officers; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;change the principal business of the Company, enter new lines of business,
or exit the current line of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;sell, assign, license, pledge, or encumber material technology or
intellectual property, other than licenses granted in the ordinary course of business; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;enter into any
corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company of money or assets greater than $250,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Successor Indemnification</U>. If the Company or any of its successors or assignees consolidates with or merges
into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the
obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company&#146;s Bylaws, the Certificate of Incorporation,
or elsewhere, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification Matters</U>. The Company hereby acknowledges that one
(1)&nbsp;or more of the Preferred Directors nominated to serve on the Board of Directors by the Investors may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of
their Affiliates (collectively, the &#147;<B>Investor Indemnitors</B>&#148;). The Company hereby </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agrees (a)&nbsp;that it is the indemnitor of first resort (i.e., its obligations to any such Preferred Director are primary and any obligation of the Investor Indemnitors to advance expenses or
to provide indemnification for the same expenses or liabilities incurred by such Preferred Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Preferred Director and shall be liable for the
full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Preferred Director to the extent legally permitted and as required by the Certificate of Incorporation or Bylaws of the Company (or
any agreement between the Company and such Preferred Director), without regard to any rights such Preferred Director may have against the Investor Indemnitors, and, (c)&nbsp;that it irrevocably waives, relinquishes and releases the Investor
Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf
of any such Preferred Director with respect to any claim for which such Preferred Director has sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have a right of contribution and/or be subrogated to
the extent of such advancement or payment to all of the rights of recovery of such Preferred Director against the Company. The Preferred Directors and the Investor Indemnitors are intended third party beneficiaries of this <U>Section&nbsp;5.7</U>
and shall have the right, power and authority to enforce the provisions of this <U>Section&nbsp;5.7</U> as though they were a party to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Right to Conduct Activities</U>. The Company hereby agrees and acknowledges that each of Sands Capital Ventures,
LLC (together with its Affiliates), PBM ACU Holdings, LLC (together with its Affiliates), PBM ACU Holdings II, LLC (together with its Affiliates), Blackwell, and RA Capital (together with its Affiliates) is a professional investment organization,
and as such reviews the business plans and related proprietary information of many enterprises, some of which may compete directly or indirectly with the Company&#146;s business (as currently conducted or as currently propose to be conducted).
Nothing in this Agreement shall preclude or in any way restrict the Investors from evaluating or purchasing securities, including publicly traded securities, of a particular enterprise, or investing or participating in any particular enterprise
whether or not such enterprise has products or services which compete with those of the Company; and the Company hereby agrees that, to the extent permitted under applicable law, Sands Capital Ventures, LLC (and its Affiliates), PBM ACU Holdings,
LLC (together with its Affiliates), PBM ACU Holdings II, LLC (together with its Affiliates), Blackwell and RA Capital (or its Affiliates) shall not be liable to the Company for any claim arising out of, or based upon, (i)&nbsp;the investment by
Sands Capital Ventures, LLC (or its Affiliates), PBM ACU Holdings, LLC (together with its Affiliates), PBM ACU Holdings II, LLC (together with its Affiliates), Blackwell or RA Capital (or its Affiliates) in any entity competitive with the Company,
or (ii)&nbsp;actions taken by any partner, officer, employee or other representative of Sands Capital Ventures, LLC (or its Affiliates), PBM ACU Holdings, LLC (together with its Affiliates), PBM ACU Holdings II, LLC (together with its Affiliates),
Blackwell or RA Capital (or its Affiliates) to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental
effect on the Company; provided, however, that the foregoing shall not relieve (x)&nbsp;any of the Investors from liability associated with the unauthorized disclosure of the Company&#146;s confidential information obtained pursuant to this
Agreement, or (y)&nbsp;any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Side Letters</U>. The Company agrees and covenants that it will promptly notify (and provide a copy to) RA
Capital and Sands Capital if it enters into any separate agreements or side letters with any other shareholder of the Company or an affiliate of any such shareholder (other than the Transaction Agreements (as defined in the Purchase Agreement) and
employment related agreements in the ordinary course). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of Covenants</U>. The covenants set
forth in this <U>Section&nbsp;5</U>, except for <U>Section&nbsp;5.6</U>, shall terminate and be of no further force or effect (i)&nbsp;immediately before the consummation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the IPO, (ii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Section&nbsp;12(g) or 15(d) of the Exchange Act, or (iii)&nbsp;upon a Deemed Liquidation
Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>. The rights under this Agreement may be assigned (but only with all related
obligations) by a Holder to a transferee of Registrable Securities that (i)&nbsp;is an Affiliate of a Holder; (ii)&nbsp;is a Holder&#146;s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder&#146;s
Immediate Family Members; or (iii)&nbsp;after such transfer, holds shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that
(x)&nbsp;the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y)&nbsp;such
transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of <U>Section&nbsp;2.11</U>. For the purposes of determining the number of shares
of Registrable Securities held by a transferee, the holdings of a transferee (1)&nbsp;that is an Affiliate or stockholder of a Holder; (2)&nbsp;who is a Holder&#146;s Immediate Family Member; or (3)&nbsp;that is a trust for the benefit of an
individual Holder or such Holder&#146;s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall, as a
condition to the applicable transfer, establish a single <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for the purpose of exercising any rights, receiving notices, or taking any action under this
Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party
other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This Agreement shall be governed by the internal law of the State of Delaware, without regard
to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement are for convenience only and are not
to be considered in construing or interpreting this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be
deemed effectively given upon the earlier of actual receipt or (i)&nbsp;personal delivery to the party to be notified; (ii)&nbsp;when sent, if sent by electronic mail or facsimile during the recipient&#146;s normal business hours, and if not sent
during normal business hours, then on the recipient&#146;s next business day; (iii)&nbsp;five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv)&nbsp;one business day after the business
day of deposit with a nationally recognized overnight courier, freight prepaid, specifying <FONT STYLE="white-space:nowrap">next-day</FONT> delivery, with written verification of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receipt. All communications shall be sent to the respective parties at their addresses as set forth on <U>Schedule A</U> hereto, or to the principal office of the Company and to the attention of
the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this <U>Section&nbsp;6.5</U>. address as subsequently modified by
written notice given in accordance with this <U>Section&nbsp;6.5</U>. If notice is given to the Company, a copy (which shall not constitute notice) shall also be sent to Cooley LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, DC 20004,
Attention: Brooke Nussbaum. If notice is given to Investors, a copy (which shall not constitute notice) shall also be sent to Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation, 28 State Street, 37th Floor, Boston, MA 02109,
Attention: Jennifer Fang. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Electronic Notice</U>. Each Investor consents to the delivery of any
stockholder notice pursuant to the Delaware General Corporation Law (the &#147;<B>DGCL</B>&#148;), as amended or superseded from time to time, by electronic transmission pursuant to Section&nbsp;232 of the DGCL (or any successor thereto) at the
electronic mail address or the facsimile number set forth below such Investor&#146;s name on the Schedule hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given by means
of electronic transmission is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted electronic notice shall be
ineffective and deemed to not have been given. Each Investor agrees to promptly notify the Company of any change in such stockholder&#146;s electronic mail address, and that failure to do so shall not affect the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments and Waivers</U>. Any term of this Agreement may be amended, modified or terminated and the observance
of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of (i)&nbsp;the Company and (ii)&nbsp;the holders of at least 67% of the shares of
Common Stock issued or issuable upon conversion of the shares of Series B Preferred Stock held by the Investors (voting together as a single class), excluding any Common Stock issued upon conversion of the Series B Preferred Stock pursuant to the
&#147;Special Mandatory Conversion&#148; provisions of the Certificate of Incorporation.; <U>provided</U> that the Company may in its sole discretion waive compliance with <U>Section&nbsp;2.12(c)</U> (and the Company&#146;s failure to object
promptly in writing after notification of a proposed assignment allegedly in violation of <U>Section&nbsp;2.12(c)</U> shall be deemed to be a waiver); and <U>provided</U> <U>further</U> that any provision hereof may be waived by any waiving party on
such party&#146;s own behalf, without the consent of any other party. Notwithstanding the foregoing, (a)&nbsp;this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any
Investor without the written consent of such Investor, unless such amendment, modification, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of <U>Section&nbsp;4</U> with respect to
a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such
transaction) and (b)&nbsp;<U>Sections 3.1</U> and <U>3.2</U>, <U>Section&nbsp;4</U> and any other section of this Agreement applicable to the Major Investors (including this clause (b)&nbsp;of this <U>Section&nbsp;6.6</U>) may not be amended,
modified, terminated or waived without the written consent of the holders of a majority of the Registrable Securities then outstanding and held by the Major Investors. Notwithstanding the foregoing, <U>Schedule A</U> hereto may be amended by the
Company from time to time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties; and <U>Schedule A</U> hereto may also be amended by the Company after the date of
this Agreement without the consent of the other parties to add information regarding any additional Investor who becomes a party to this Agreement in accordance with <U>Section&nbsp;6.9</U>. Any amendment, modification, termination, or waiver
effected in accordance with this <U>Section&nbsp;6.6</U> shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any
one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. In case any one or more of the provisions
contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or
unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Aggregation of Stock</U>. All shares of Registrable Securities held or acquired by Affiliates shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Investors</U>. Notwithstanding anything to the contrary contained herein, if the Company issues
additional shares of the Company&#146;s Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering
an additional counterpart signature page to this Agreement, and thereafter shall be deemed an &#147;Investor&#148; for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such
additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an &#147;Investor&#148; hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement</U>. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and
entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness
of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Dispute Resolution</U>. The parties (a)&nbsp;hereby irrevocably and unconditionally submit to the jurisdiction
of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b)&nbsp;agree not to
commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c)&nbsp;hereby waive, and agree not to assert, by
way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that
the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Delays or Omissions</U>. No delay or omission to exercise any right, power, or remedy accruing to any party
under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any
such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under
this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.13&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Mandatory Conversion</U>. In the event that the
Series B Preferred Stock held by an Investor is converted into Common Stock (the &#147;<B>Converted Stock</B>&#148;) pursuant to the &#147;Special Mandatory Conversion&#148; provisions of the Certificate of Incorporation, such Investor shall cease
to be entitled to any of the rights and privileges granted to an Investor or Major Investor pursuant to this Agreement with respect to such shares of Converted Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>A<SMALL>CUMEN</SMALL> P<SMALL>HARMACEUTICALS</SMALL>, I<SMALL>NC</SMALL>. <SUB STYLE="font-size:85%; vertical-align:bottom"></SUB></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel J. O&#146;Connell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Daniel J. O&#146;Connell</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;427 Park Street</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Charlottesville, VA 22902</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> doconnell@acumenpharm.com</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph Andrasko</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joseph Andrasko</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARROCHAR INVESTMENTS LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Macfarlane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Macfarlane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLACKROCK HEALTH SCIENCES TRUST</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BlackRock Advisors, LLC, its Investment Adviser</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hongying Erin Xie</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hongying Erin Xie</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLACKROCK HEALTH SCIENCES TRUST II</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BlackRock Advisors, LLC, its Investment Adviser</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hongying Erin Xie</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hongying Erin Xie</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLACKWELL PARTNERS LLC &#150; SERIES A</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Abayomi A. Adigun</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Abayomi A. Adigun</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investment Manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">DUMAC, Inc., Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jannine M. Lall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jannine M. Lall</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Head of Finance&nbsp;&amp; Controller</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">DUMAC, Inc., Authorized Signatory</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Blackwell Partners LLC &#150; Series A</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">280 S. Mangum Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Suite 210</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Durham, NC 27701</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Attn: Jannine Lall</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Frank A. Bonsal, Jr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Frank A. Bonsal, Jr.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>B<SMALL>IOTECHNOLOGY</SMALL> V<SMALL>ALUE</SMALL> F<SMALL>UND</SMALL>, LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BVF Partners, L.P., its general partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BVF, Inc., its general partner</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark N. Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark N. Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>I<SMALL>NVESTMENT</SMALL> 10, LLC</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BVF Partners, L.P., its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BVF, Inc., its general partner</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark N. Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark N. Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>B<SMALL>IOTECHNOLOGY</SMALL> V<SMALL>ALUE</SMALL> F<SMALL>UND</SMALL> II, LP</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BVF Partners, L.P., its general partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BVF, Inc., its general partner</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark N. Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark N. Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BVF I<SMALL>NVESTMENTS</SMALL>, L.L.C.</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BVF Partners, L.P., its manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BVF, Inc., its general partner</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark N. Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark N. Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Alex Casdin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alex Casdin</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CHARLOTTESVILLE AREA COMMUNITY FOUNDATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jan
Dorman&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan Dorman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director of Finance</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C<SMALL>LELAND</SMALL> F<SMALL>AMILY</SMALL> III, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bruce Cleland</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bruce Cleland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Partner</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Terrence D.
Daniels&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Terrence D. Daniels</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>T<SMALL>ERRENCE</SMALL> D. D<SMALL>ANIELS</SMALL> 2008 C<SMALL>HILDREN</SMALL>&#146;<SMALL>S</SMALL> T<SMALL>RUST</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Terrence D.
Daniels&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Terrence D. Daniels</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>T<SMALL>ERRENCE</SMALL> D. D<SMALL>ANIELS</SMALL> 2010 G<SMALL>RANDCHILDREN</SMALL>&#146;<SMALL>S</SMALL> T<SMALL>RUST</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Terrence D. Daniels</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Terrence D. Daniels</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Trustee</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tim Davis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tim Davis</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>E<SMALL>UGENE</SMALL> V. F<SMALL>IFE</SMALL> R<SMALL>EVOCABLE</SMALL> T<SMALL>RUST</SMALL> <SMALL>DTD</SMALL> A<SMALL>PRIL</SMALL>&nbsp;24, 2002</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eugene V. Fife</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Eugene V. Fife</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Trustee</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Caleb Finch</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Caleb Finch</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>G<SMALL>LYNN</SMALL> I<SMALL>NVESTMENT</SMALL> C<SMALL>OMPANY</SMALL>, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Glynn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Glynn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Philip Goelet</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Philip Goelet</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>H7 H<SMALL>OLDINGS</SMALL>, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert Hardie</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Robert Hardie</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Co-Chairman</FONT> and CEO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>M<SMALL>ARK</SMALL> J. K<SMALL>INGTON</SMALL>&nbsp;&amp; A<SMALL>NN</SMALL> K<SMALL>INGTON</SMALL>
T<SMALL>BE</SMALL></B><SMALL></SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">c/o Dyson Capital Advisors, LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark J. Kington</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mark J. Kington</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ann Kington</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ann Kington</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>K<SMALL>NOLLWOOD</SMALL> I<SMALL>NVESTMENT</SMALL> F<SMALL>UND</SMALL> LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin D. Irwin, Jr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kevin D. Irwin, Jr.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President of Managing Member</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MA<SMALL>RC</SMALL> D. K<SMALL>OZIN</SMALL> I<SMALL>RREVOCABLE</SMALL> T<SMALL>RUST</SMALL>, D<SMALL>ONNA</SMALL> M. K<SMALL>OZIN</SMALL>, T<SMALL>RUSTEE</SMALL></B><SMALL></SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Donna M. Kozin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Donna M. Kozin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Trustee</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Grant A. Krafft</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant A. Krafft</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>L<SMALL>EVEL</SMALL> O<SMALL>NE</SMALL> P<SMALL>ARTNERS</SMALL>, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert Hardie</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Robert Hardie</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John L. Lewis IV</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John L. Lewis IV</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, <B></B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>D<SMALL>AVID</SMALL> V M<SMALL>ILLIGAN</SMALL> T<SMALL>RUST</SMALL> D<SMALL>ATED</SMALL> O<SMALL>CT</SMALL> </B><B>19,</B><B> 1991</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Milligan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Milligan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Trustee</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>M<SMALL>RW</SMALL> B<SMALL>LIND</SMALL> T<SMALL>RUST</SMALL></B><SMALL></SMALL></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">c/o Dyson Capital Advisors, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nicholas Perrins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Nicholas Perrins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Trustee</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, <B></B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Edward Meigs</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Edward Meigs</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, <B></B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>J<SMALL>AMES</SMALL> B. M<SMALL>URRAY</SMALL>, J<SMALL>R</SMALL>. R<SMALL>EVOCABLE</SMALL> T<SMALL>RUST</SMALL> U/A/D 8/5/1991</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James B. Murray, Jr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">James B. Murray, Jr.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Trustee</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>N<SMALL>EURO</SMALL>V<SMALL>ENTURES</SMALL> C<SMALL>APITAL</SMALL> LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel O&#146;Connell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Daniel O&#146;Connell</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PBM ACU H<SMALL>OLDINGS</SMALL>, LLC</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By PBM Capital Group, LLC, its manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Paul B. Manning</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Paul B. Manning</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">11/20/2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PBM ACU H<SMALL>OLDINGS</SMALL> II, LLC</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: PBM Capital Group, LLC, its manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Paul B. Manning</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Paul B. Manning</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">11/20/2020</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>RAXIS</SMALL> T<SMALL>ECHNOLOGIES</SMALL> L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James B. Murray, Jr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">James B. Murray, Jr.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ROTECTIVE</SMALL> I<SMALL>NSURANCE</SMALL> C<SMALL>OMPANY</SMALL> I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark McNeill</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark McNeill</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Financial Reporting Manager</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RA CAPITAL HEALTHCARE FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: RA Capital Healthcare Fund GP, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Its General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rajeev Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Rajeev Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">RA Capital Management, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">200 Berkeley Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">18<B><SUP
STYLE="font-size:85%; vertical-align:top">th</SUP></B><B> </B>Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Boston, MA 02116</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Attn: General Counsel</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RA CAPITAL NEXUS FUND II, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: RA Capital Nexus Fund II GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Its: General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rajeev Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Rajeev Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">RA Capital Management, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">200 Berkeley Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">18<B><SUP
STYLE="font-size:85%; vertical-align:top">th</SUP></B><B> </B>Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Boston, MA 02116</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Attn: General Counsel</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>R3 C<SMALL>APITAL</SMALL> S<SMALL>TRATEGIES</SMALL>, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert Brown</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Robert Brown</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Owner</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dru Rasmussen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dru Rasmussen</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROCK SPRINGS CAPITAL MASTER FUND LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Rock Springs General Partner LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Bussard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Bussard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FOUR PINES MASTER FUND LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Four Pines General Partner LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Bussard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Bussard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Member</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>S<SMALL>ANDS</SMALL> C<SMALL>APITAL</SMALL> L<SMALL>IFE</SMALL> S<SMALL>CIENCES</SMALL> P<SMALL>ULSE</SMALL> F<SMALL>UND</SMALL>, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Goodman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jonathan Goodman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>S<SMALL>ANDS</SMALL> C<SMALL>APITAL</SMALL> G<SMALL>LOBAL</SMALL> V<SMALL>ENTURE</SMALL> F<SMALL>UND</SMALL> II, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: Sands Capital Global Venture Fund <FONT STYLE="white-space:nowrap">II-GP,</FONT> L.P., Its</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Sands Capital Global Venture Fund <FONT STYLE="white-space:nowrap">II-GP,</FONT> LLC, Its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Goodman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jonathan Goodman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>S<SMALL>ANDS</SMALL> C<SMALL>APITAL</SMALL> V<SMALL>ENTURES</SMALL> D<SMALL>ISCOVERY</SMALL> F<SMALL>UND</SMALL> III, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: Sands Capital Ventures Discovery Fund <FONT STYLE="white-space:nowrap">III-GP,</FONT> LLC,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Goodman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jonathan Goodman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Counsel</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Summa</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">David Summa</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hans Utsch</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hans Utsch</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>V<SMALL>ALINCO</SMALL> I<SMALL>NVESTMENTS</SMALL> L<SMALL>IMITED</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ A.H.D. Weldon</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">A.H.D. Weldon</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Spencer Wheeler</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Spencer Wheeler</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,<B> </B>the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Wm Matthew Zuga</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Wm Matthew Zuga</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MIDDLELAND ENDOWMENT I, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Arthur X. Duffy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Arthur X. Duffy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Amended and Restated
Investors&#146; Rights Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>DALTON TRUST - 1995</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David P. Mixer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David P. Mixer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Trustee</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTORS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:31%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Joseph Andrasko</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">427 Park Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlottesville, VA 22902 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Apple Tree Partners, LLC </B>wmthompson@wmtpc.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrochar Investments LLC</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4626 Slam Gate Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Crozet, VA 22932 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bannon Multi-Manager Private</B> <B>Equity
Fund Lt</B><B>d </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>hg@arthurbellcpas.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Berkshire Investment</B> <B>Management Ltd.</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hvc@berkshire.net </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Biotechnology Value Fund II, LP</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Sansome Street, 30<SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-family:Times New Roman; font-size:6.5pt">th</FONT></SUP><FONT
STYLE="font-family:Times New Roman; font-size:6.5pt"> Floor </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Biotechnology Value Fund, LP</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Sansome Street, 30<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BlackRock Health Sciences</B> <B>Trust</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">40 East 52nd St.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BlackRock Health Sciences Trust
II</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">40 East 52nd St. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Blackwell Partners LLC &#150; Series</B> <B>A</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">280 S.
Mangum Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 210 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durham, NC 27701 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Jannine Lall </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Frank A. Bonsal, Jr</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14040 Mantua Mill Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reisterstown, MD 21136 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BrownIA Partners LLC</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>nmillman@brownadvisory.com
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:32%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Robert Burt</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">roburt130@gmail.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alex Casdin</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">150 E. 52<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> St., Ste. 27001 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Charlottesville Area Community
</B><B>Foundation</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jdorman@cacfonline.org </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cleland
Family III, LLC</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">bruce@orokawa.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commodity
Investment Fund</B> <B>LLC</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">js@greshamllc.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dalton
Trust &#150; 1995 </B>investments@rexcapital.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terrence D. Daniels</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">259 Yellow Mountain Rd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Greenwood, VA 22943 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terrence D. Daniels 2008</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Children&#146;s Trust</B>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">259 Yellow Mountain Rd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Greenwood, VA 22943 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terrence D. Daniels 2010 Grandchildren&#146;s Trust</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">259
Yellow Mountain Rd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Greenwood, VA 22943 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tim Davis</B>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">224 Court Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlottesville, VA 22902 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DLNGR PE LLC</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">dickvento@gmail.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dyson Capital Advisors, LLC</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">201 N. Union Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 300 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alexandria, VA 22314 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Eugene V. Fife Revocable Trust dtd April&nbsp;24, 2002</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2421 Ivy Road, Suite 140 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlosttesville, VA 22902
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:31%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Caleb Finch</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2144 Crescent Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Altadena, CA 91001 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Four Pines Master Fund LP</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Rock Springs Capital
Management LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">650 S Exeter Street Suite 1070 Baltimore, MD 21210 Attn: General Counsel jill@rockspringscapital.com; daphne@rockspringscapital.com;
ops@rockspringscapital.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Practitioner, LLC</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cingoe@redabbey.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Glynn Family Trust</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glynn Capital Management </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3000 Sand Hill Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building 3, Suite 230 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park, CA, 94025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: John Glynn </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Glynn Investment Company, LLC
</B>johnglynn@glynncapital.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Philip Goelet</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4000
Millender Mill Road Reisterstown, MD 21136 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>H7 Holdings LLC</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">210 Ridge McIntire Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 350 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlottesville, VA, 22903 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alan G. Hassenfeld 1998 Rev.
Trust DTD 4/28/1998</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">101 Dyer Street, Suite 401 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Providence, RI 02903 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">alan@hassenfeldfamily.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Franz Hefti</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20 East 74<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Street, 14F </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investment 10, LLC</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Sansome Street, 30<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:31%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mark J. Kington&nbsp;&amp; Ann Kington TBE</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Dyson Capital Advisors, LLC 201 N. Union Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 300
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alexandria, VA 22314 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Knollwood Investment Fund LLC</B>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">217 International Circle </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hunt Valley, MD 21030 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kolinina Limited</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">22 Stasikratous Street, Suite 103 -
104, PO Box 23664, 1685 Nicosia - Cyprus </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marc D. Kozin Irrevocable Trust, Donna M. Kozin, Trustee</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16876 Brightling Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Naples, FL 34110 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grant A. Krafft</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">gkrafft@acumenpharm.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jesse Kramer</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">thejok@verizon.net </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John L. Lewis IV</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">johnlatanelewisiv@gmail.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Level One Partners, LLC</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">210 Ridge McIntire Road, Suite
350 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlottesville, VA, 22903 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lynch 1995 Gift Trust
dtd 3/31/95</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lynchbill@comcast.net </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Edward Meigs</B>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">edward.meigs@feim.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MGE LLC</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">nicholas.perrins@dysoncapital.co m </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Middleland Endowment I,
LLC</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Rex Capital Partners </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">50 Park Row West, Suite
113 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Providence, RI 02903 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>David V Milligan Trust
Dated</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Oct 19, 1991</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">775 S. Green Bay Rd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lake Forest, IL 60045
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:32%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The David V. Milligan Trust dated October&nbsp;19, 1992</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">milligad@me.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The David V. Milligan Trust dated
October&nbsp;19, 1993</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">milligad@me.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MRW Blind
Trust</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Dyson Capital Advisors, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">201 N. Union
Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 300 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alexandria, VA 22314 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James B. Murray, Jr. Revocable Trust U/A/D 8/5/1991</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">427
Park Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlottesville, VA 22902 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: James B.
Murray, Jr. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NeuroVentures Capital LLC</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">djo@neuroventures.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Walter M. Noel, Jr.</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">wmnj19@gmail.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steven M Paul</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1145 Laurelwood </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carmel, IN 46032-8751 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PBM ACU Holdings, LLC</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Garrett Street, Suite O </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlottesville, VA 22902 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PBM ACU Holdings II, LLC</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Garrett Street, Suite O </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlottesville, VA 22902 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Per Eric Krafft</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">pille.krafft@gmail.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Praxis Technologies L.P.</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">427 Park Street
Charlottesville, VA 22902 Attn: James B. Murray, Jr. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Protective Insurance Company Inc.</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mmcneill@protectiveinsurance.co m </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>R3 Capital Strategies,
LLC</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">rbrown@r3capitalstrategies.com
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:31%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RA Capital Healthcare Fund GP, LLC</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o RA Capital Management, L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Berkeley Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02116 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: General Counsel </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RA Capital Nexus Fund II, L.P.</B>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o RA Capital Management, L.P. 200 Berkeley Street 18th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02116 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: General Counsel </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dru Rasmussen</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">224 Court Square Charlottesville, VA 22902
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rock Springs Capital Master Fund LP</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Rock
Springs Capital Management LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">650 S Exeter Street Suite 1070 Baltimore, MD 21210 Attn: General Counsel jill@rockspringscapital.com;
daphne@rockspringscapital.com; ops@rockspringscapital.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sands Capital Global Venture Fund II, L.P.</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1000 Wilson Blvd, Suite 3000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arlington, VA 22209
esoule@sandscap.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sands Capital Life Sciences Pulse Fund, LLC</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1000 Wilson Blvd, Suite 3000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arlington, VA 22209
esoule@sandscap.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sands Capital Ventures Discovery Fund III, L.P.</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1000 Wilson Blvd, Suite 3000 Arlington, VA 22209 esoule@sandscap.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>David Summa</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">250 Brentwood Rd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hillsborough, CA 94010 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hans Utsch</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hansutsch@gmail.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Valinco Investments Limited</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No.&nbsp;29 Middle Road, Devonshire </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DV 02, Bermuda
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Weber Altman Living Trust</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5911 Buena Vista Ave. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oakland, CA 94618 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>R. Ted Weschler</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">rtw@pencapital.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Spencer Wheeler</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1512 Rutledge Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlottesville, VA 22903 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Z&#094;2 Ventures LLC</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">marc@buntaine.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Wm Matthew Zuga</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">matt.zuga@highcape.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>E<SMALL>MPLOYMENT</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (the &#147;<B><I>Agreement</I></B>&#148;) is entered into
effective <B>January</B><B></B><B>&nbsp;1, 2021 </B>(the &#147;<B><I>Effective Date</I></B>&#148;), by and between <B>Daniel J. O&#146;Connell </B>(the &#147;<B><I>Executive</I></B>&#148;) and <B>Acumen Pharmaceuticals, Inc.</B> (the
&#147;<B><I>Company</I></B>&#148;) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to employ Executive and, in connection therewith, to compensate Executive for Executive&#146;s personal services
to the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Executive wishes to be employed by the Company and provide personal services and certain covenants to the
Company in return for certain compensation and benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, in consideration of the mutual promises and covenants contained
herein, the parties agree to the following: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. &nbsp;&nbsp;&nbsp;&nbsp;<U>E<SMALL>MPLOYMENT</SMALL> <SMALL>BY</SMALL>
<SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL></U><SMALL></SMALL>.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.1&nbsp;&nbsp;&nbsp;&nbsp; <U>Position</U></B>.<B> </B>Subject to
the terms set forth herein, the Company agrees to employ Executive, in the position of <B>President and Chief Executive Officer</B>, and Executive hereby accepts such employment. During the term of Executive&#146;s employment with the Company,
Executive will devote Executive&#146;s best efforts and substantially all of his business time and attention to the business of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.2&nbsp;&nbsp;&nbsp;&nbsp; <U>Duties</U></B>. <B></B>Executive will initially report to the Board of Directors<B> (&#147;Board)&#148;</B>
of the Company. Executive shall perform his duties under this Agreement initially principally out of his personal residence and the Company&#146;s corporate office in Charlottesville, VA or such other location as assigned by the Company. In
addition, Executive shall make business trips to such places as may be necessary or advisable for the efficient operations of the Company, including visits to the Company&#146;s offices in Carmel, IN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.3&nbsp;&nbsp;&nbsp;&nbsp; <U>Company Policies and Benefits</U></B>. The employment relationship between the parties shall also be subject
to the Company&#146;s personnel policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the Company&#146;s sole discretion. Executive will be eligible to participate on the same basis as similarly
situated employees in the Company&#146;s benefit plans in effect from time to time during Executive&#146;s employment. All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions
of the such plan. The Executive shall be entitled to paid vacation in accordance with the plans, policies, programs and practices of the Company applicable to its senior executives in effect from time to time, but in no event shall the Executive be
entitled to less than four (4)&nbsp;weeks of vacation per calendar year <FONT STYLE="white-space:nowrap">(pro-rated</FONT> for any partial year of service). The Company reserves the right to change, alter, or terminate any benefit plan in its sole
discretion. Notwithstanding the foregoing, in the event that the terms of this Agreement differ from or are in conflict with the Company&#146;s general employment policies or practices, this Agreement shall control. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.
&nbsp;&nbsp;&nbsp;&nbsp;<U>C<SMALL>OMPENSATION</SMALL></U><SMALL></SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;
<U>Salary</U></B>. Executive shall receive for services to be rendered hereunder an initial base salary of $ 512,000.00 on annualized basis, subject to review and adjustment from time to time by the Board, and payable subject to standard federal and
state payroll withholding requirements in accordance with the Company&#146;s standard payroll practices (&#147;<B><I>Base Salary</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp; <U>Annual Discretionary Bonus</U></B>. Executive shall be eligible for a discretionary annual calendar year
performance bonus (the &#147;<B><I>Annual Bonus</I></B>&#148;) with an annual target of fifty percent (50%) of Executive&#146;s then-current Base Salary (the &#147;<B><I>Target Amount</I></B>&#148;). Whether or not Executive is eligible for any
Annual Bonus will be dependent upon the actual achievement by Executive and the Company of the applicable individual and corporate performance goals, as determined by the Board. No amount of any Annual Bonus is guaranteed at any time and may be
greater or lesser than the Target Amount and may be zero. Any Annual Bonus, if awarded, will be paid in a single installment paid at the same time annual bonuses are generally paid to other similarly-situated employees of the Company and in any
event no later than March 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of the calendar year following the calendar<B> </B>year to which the Annual Bonus is applicable, and will be subject to deductions and withholdings. Executive&#146;s
eligibility for an Annual Bonus and the Target Amount, if any, is subject to change in the discretion of the Board (or any authorized committee thereof). <B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.3&nbsp;&nbsp;&nbsp;&nbsp; <U>Expense Reimbursement</U></B>. The Company will reimburse Executive for reasonable business expenses in
accordance with the Company&#146;s standard expense reimbursement policy, as the same may be modified by the Board from time to time. The Company shall reimburse Executive for all customary and appropriate business-related expenses actually incurred
and documented in accordance with Company policy, as in effect from time to time . For the avoidance of doubt, to the extent that any reimbursements payable to Executive are subject to the provisions of Section&nbsp;409A of the Internal Revenue Code
of 1986, as amended (the &#147;<B><I>Code</I></B>&#148;):<B> </B>(a) any such reimbursements will be paid no later than December&nbsp;31 of the year following the year in which the expense was incurred, (b)&nbsp;the amount of expenses reimbursed in
one year will not affect the amount eligible for reimbursement in any subsequent year, and (c)&nbsp;the right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.4&nbsp;&nbsp;&nbsp;&nbsp; <U>Stock Option</U>.</B> Subject to approval by the Board, the Company anticipates granting to Executive an
option to purchase 1,767,656 shares of the Company&#146;s common stock at the fair market value as determined by the Board as of the date of grant (the &#147;<B><I>Option</I></B>&#148;). The anticipated Option will be governed by the terms and
conditions of the Company&#146;s Equity Incentive Plan<B> </B>(the &#147;<B><I>Plan</I></B>&#148;) and the option grant agreement, and will vest 25% on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of grant, and
thereafter over the ensuing 3 years in a series of <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;successive equal monthly installments, subject to your Continuous Service (as defined in the Plan) as of each such date. <B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.&nbsp;&nbsp;&nbsp;&nbsp; <U>C<SMALL>ONFIDENTIAL</SMALL> I<SMALL>NFORMATION</SMALL>, I<SMALL>NVENTIONS</SMALL>,
N<SMALL>ON</SMALL>-C<SMALL>OMPETITION</SMALL> <SMALL>AND</SMALL> N<SMALL>ON</SMALL>-S<SMALL>OLICITATION</SMALL> O<SMALL>BLIGATIONS</SMALL></U><SMALL></SMALL>.</B> As a condition of employment, Executive agrees to execute and abide by the Employee
Confidential Information, Inventions, <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> and <FONT STYLE="white-space:nowrap">Non-Competition</FONT> Agreement, attached as <B>Exhibit A </B>which may be amended by the parties from time
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to time without regard to this Agreement (the &#147;<B><I>Confidential Information Agreement</I></B>&#148;). The Confidential Information<B> </B>Agreement contains provisions that are intended by
the parties to survive and do survive termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4. &nbsp;&nbsp;&nbsp;&nbsp;<U>O<SMALL>UTSIDE</SMALL>
A<SMALL>CTIVITIES</SMALL> D<SMALL>URING</SMALL> E<SMALL>MPLOYMENT</SMALL></U><SMALL></SMALL>.</B> Except with the prior written consent of the Company, Executive will not, while employed by the Company, undertake or engage in any other employment,
occupation or business enterprise that would interfere with Executive&#146;s responsibilities and the performance of Executive&#146;s duties hereunder except for (i)&nbsp;reasonable time devoted to volunteer services for or on behalf of such
religious, educational, <FONT STYLE="white-space:nowrap">non-profit</FONT> and/or other charitable organization as Executive may wish to serve, (ii)&nbsp;reasonable time devoted to activities in the <FONT STYLE="white-space:nowrap">non-profit</FONT>
and business communities consistent with Executive&#146;s duties; and (iii)&nbsp;such other activities as may be specifically approved in writing by the Company. Company hereby acknowledges consent&#146;s to Executive&#146;s existing Executive
Chairman position at Direct Spinal Therapeutics, Inc. and deems that it complies with this Section&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;
<U>N<SMALL>O</SMALL> C<SMALL>ONFLICT</SMALL> <SMALL>WITH</SMALL> E<SMALL>XISTING</SMALL> O<SMALL>BLIGATIONS</SMALL></U><SMALL></SMALL></B><SMALL></SMALL>. Executive represents that Executive&#146;s performance of all the terms of this Agreement and
as an Executive of the Company do not and will not breach any agreement or obligation of any kind made prior to Executive&#146;s employment by the Company, including agreements or obligations Executive may have with prior employers or entities for
which Executive has provided services. Executive has not entered into, and Executive agrees that Executive will not enter into, any agreement or obligation, either written or oral, in conflict herewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.&nbsp;&nbsp;&nbsp;&nbsp; <U>T<SMALL>ERMINATION</SMALL> O<SMALL>F</SMALL> E<SMALL>MPLOYMENT</SMALL></U><SMALL></SMALL>.</B> The parties
acknowledge that Executive&#146;s employment relationship with the Company is <FONT STYLE="white-space:nowrap">at-will.</FONT> Either Executive or the Company may terminate the employment relationship for any reason whatsoever at any time, with or
without Cause or advance notice. The provisions in this Section govern the amount of compensation, if any, to be provided to Executive upon termination of employment and do not alter this <FONT STYLE="white-space:nowrap">at-will</FONT> status. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.1&nbsp;&nbsp;&nbsp;&nbsp; <U>Termination by the Company without Cause or Resignation by Executive for Good Reason</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp; </B>The Company shall have the right to terminate Executive&#146;s employment with the Company pursuant to this
Section&nbsp;6.1 at any time without Cause (as defined in Section&nbsp;6.2(b) below) by giving notice as described in Section&nbsp;7.1 of this Agreement. A termination pursuant to Section&nbsp;6.4 or 6.5 below is not a termination without Cause for
purposes of receiving the benefits described in this Section&nbsp;6.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp; </B>In the event the Company
terminates Executive&#146;s employment without Cause or Executive Resigns for Good Reason (as defined in Section&nbsp;6.1(g) below), and provided that such termination constitutes a &#147;separation from service&#148; (as defined under Treasury
Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h),</FONT> without regard to any alternative definition thereunder, a &#147;<B><I>Separation from Service</I></B>&#148;), then Executive shall be entitled to receive the Accrued
Obligations (as defined below) and, subject to Executive&#146;s compliance with the obligations in Section&nbsp;6.1(c) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
below, Executive shall be eligible to receive the following severance benefits (the &#147;<B><I>Severance Benefits</I></B>&#148;): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp; </B>The Company will pay Executive an amount equal to Executive&#146;s then current Base Salary for twelve
(12)&nbsp;months, less all applicable withholdings and deductions, and paid in equal installments beginning on the Company&#146;s second regularly scheduled payroll date following the Release Effective Date (as defined in Section&nbsp;6.1(c) below),
with the remaining installments occurring on the Company&#146;s regularly scheduled payroll dates thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp; </B>If Executive timely elects continued coverage under COBRA for Executive and Executive&#146;s dependents
under the Company&#146;s group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue Executive&#146;s and his covered dependents&#146; health insurance coverage in effect for Executive (and
Executive&#146;s covered dependents) on the termination date until the earliest of: (i)&nbsp;twelve (12) months following the termination date (the &#147;<B><I>COBRA Severance Period</I></B>&#148;); (ii) the date when Executive becomes eligible for
substantially equivalent health insurance coverage in connection with new employment or self-employment; or (iii)&nbsp;the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period
from the termination date through the earlier of (i)-(iii), (the &#147;<B><I>COBRA Payment Period</I></B>&#148;). Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on Executive&#146;s behalf
would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of paying COBRA premiums pursuant
to this Section, the Company shall pay Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, subject to applicable tax withholding, for the remainder of
the COBRA Payment Period. Nothing in this Agreement shall deprive Executive of his rights under COBRA or ERISA for benefits under plans and policies arising under his employment by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp; </B>Executive will be paid all of the Accrued Obligations (as defined in Section&nbsp;6.1(d) below) on the
Company&#146;s first payroll date after Executive&#146;s date of termination from employment or earlier if required by law. If eligible to receive the Severance Benefits pursuant to Section&nbsp;6.1(b) of this Agreement, Executive will only receive
such Severance Benefits if: (i)&nbsp;within the time period provided in the separation agreement (which shall be no longer than 60 days following the date of Executive&#146;s Separation from Service), Executive has signed and delivered to the
Company a separation agreement that includes, among other terms, an effective general release of claims in favor of the Company and its affiliates and representatives, in the form presented by the Company (the &#147;<B><I>Release</I></B>&#148;),
which cannot be revoked in whole or part by such date (the date that the Release can no longer be revoked is referred to as the &#147;<B><I>Release Effective Date</I></B>&#148;); and (ii)&nbsp;if Executive holds any other positions with the Company,
he resigns such position(s) to be effective no later than the date of Executive&#146;s termination date (or such other date as requested by the Board); (iii) Executive returns all Company property; (iv)&nbsp;Executive complies with his
post-termination obligations under this Agreement and the Confidential Information Agreement; and (v)&nbsp;Executive complies with the terms of the Release, including, without limitation, any
<FONT STYLE="white-space:nowrap">non-disparagement,</FONT> confidentiality and cooperation provisions contained in Release. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp; </B>For purposes of this Agreement, &#147;<B><I>Accrued
Obligations</I></B>&#148; are (i)&nbsp;Executive&#146;s accrued but unpaid salary through the date of termination, (ii)&nbsp;any unreimbursed business expenses incurred by Executive payable in accordance with the Company&#146;s standard expense
reimbursement policies, and (iii)&nbsp;benefits owed to Executive under any qualified retirement plan or health and welfare benefit plan in which Executive was a participant in accordance with applicable law and the provisions of such plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp; </B>The Severance Benefits provided to Executive pursuant to this Section&nbsp;6.1 are in lieu of, and not in
addition to, any benefits to which Executive may otherwise be entitled under any Company severance plan, policy or program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp; </B>Any damages caused by the termination of Executive&#146;s employment without Cause would be difficult to
ascertain; therefore, the Severance Benefits for which Executive is eligible pursuant to Section&nbsp;6.1(b) above in exchange for the Release is agreed to by the parties as liquidated damages, to serve as full compensation, and not a penalty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(g)&nbsp;&nbsp;&nbsp;&nbsp; </B>&#147;<B><I>Good Reason</I></B>&#148; for purposes of this Agreement shall mean the occurrence of any of
the following conditions without Executive&#146;s consent, after Executive&#146;s provision of written notice to the Company of the existence of such condition (which notice must be provided as described in Section&nbsp;7.1 within thirty
(30)&nbsp;days of the initial existence of the condition and must specify the particular condition in reasonable detail), provided that the Company has not first provided notice to Executive of its intent to terminate Executive&#146;s employment:
(i)&nbsp;a material reduction in Executive&#146;s duties, responsibilities or authorities, provided, however, that neither the conversation of the Company to a subsidiary, division or unit of an acquiring entity, or Executive&#146;s reporting
relationships following a Change in Control, nor a change in title, will be deemed a &#147;material reduction&#148; in and of itself or material adverse alteration in, Executive&#146;s position, title, duties, or responsibilities; (ii)&nbsp;a
material (greater than 10%) reduction by the Company of Executive&#146;s Base Salary (except in the case of either an across the board reduction in salaries or a temporary reduction due to financial exigency); or (iii)&nbsp;the relocation of
Executive&#146;s principal place of employment by fifty (50)&nbsp;or more miles from Executive&#146;s then-current principal place of employment. Notwithstanding the foregoing, Good Reason shall only exist if the Company is provided a thirty
(30)&nbsp;day period to cure the event or condition giving rise to Good Reason, and it fails to do so within that cure period (and, additionally, Executive must resign for such Good Reason condition by giving notice as described in Section&nbsp;7.1
within thirty (30)&nbsp;days after the period for curing the violation or condition has ended). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.2
&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Company for Cause</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp; </B>The Company shall have the
right to terminate Executive&#146;s employment with the Company at any time for Cause by giving notice as described in Section&nbsp;7.1 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp; </B>&#147;Cause&#148; for purposes of this Agreement shall mean that the Company has determined in its sole
discretion that Executive has engaged in any of the following: (i)&nbsp;a material breach of any covenant or condition under this Agreement or any other agreement between the Company and Executive; (ii)&nbsp;any act constituting dishonesty, fraud,
immoral or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disreputable conduct; (iii)&nbsp;any conduct which constitutes a felony under applicable law; (iv)&nbsp;violation of any Company policy or any act of misconduct; (v)&nbsp;refusal to follow or
implement a clear and reasonable directive of Company; (vi)&nbsp;negligence or incompetence in the performance of Executive&#146;s duties or failure to perform such duties in a manner satisfactory to the Company after the expiration of ten
(10)&nbsp;days without cure after written notice of such failure; (vii)&nbsp;failure to pass to the satisfaction of the Company, a preliminary background check or failure to submit proof of legal eligibility to work in the United States; or
(viii)&nbsp;breach of fiduciary duty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp; </B>In the event Executive&#146;s employment is terminated at any
time for Cause, Executive will not receive Severance Benefits, or any other compensation or benefits, except that, pursuant to the Company&#146;s standard payroll policies, the Company shall provide to Executive the Accrued Obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.3&nbsp;&nbsp;&nbsp;&nbsp; <U>Resignation by Executive (other than for Good Reason)</U>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp; </B>Executive may resign from Executive&#146;s employment with the Company at any time by giving notice as
described in Section&nbsp;7.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp; </B>In the event Executive resigns from Executive&#146;s employment with
the Company (other than for Good Reason), Executive will not receive Severance Benefits, or any other compensation or benefits, except that, pursuant to the Company&#146;s standard payroll policies, the Company shall provide to Executive the Accrued
Obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.4&nbsp;&nbsp;&nbsp;&nbsp; <U>Termination by Virtue of Death or Disability of Executive</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp; </B>In the event of Executive&#146;s death while employed pursuant to this Agreement, all obligations of the
parties hereunder shall terminate immediately, and the Company shall, pursuant to the Company&#146;s standard payroll policies, provide to Executive&#146;s legal representatives Executive&#146;s accrued but unpaid salary through the date of death
together with all compensation and benefits payable to Executive based on his participation in any compensation or benefit plan, program or arrangement through the date of termination. <B><I></I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp; </B>Subject to applicable state and federal law, the Company shall at all times have the right, upon written
notice to Executive, to terminate this Agreement based on Executive&#146;s Disability (as defined below). Termination by the Company of Executive&#146;s employment based on &#147;<B><I>Disability</I></B>&#148; shall mean termination because
Executive is unable due to a physical or mental condition to perform the essential functions of Executive&#146;s position with or without reasonable accommodation for one hundred twenty (120)&nbsp;consecutive calendar days or six (6)&nbsp;months in
the aggregate during any twelve (12)&nbsp;month period or based on the written certification by two licensed physicians of the likely continuation of such condition for such period. This definition shall be interpreted and applied consistent with
the Americans with Disabilities Act, the Family and Medical Leave Act, and other applicable law. In the event Executive&#146;s employment is terminated based on Executive&#146;s Disability, Executive will not receive the Severance Benefits, or any
other severance compensation or benefit, except that, pursuant to the Company&#146;s standard payroll policies, the Company shall pay to Executive the accrued but unpaid salary of Executive through the date of termination, together with all
compensation and benefits payable to Executive based on his participation in any compensation or benefit plan, program or arrangement through the date of termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.5&nbsp;&nbsp;&nbsp;&nbsp; <U>[RESERVED]</U></B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.6&nbsp;&nbsp;&nbsp;&nbsp; <U>Notice; Effective Date of Termination</U></B>. <B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp; </B>Termination of Executive&#146;s employment pursuant to this Agreement shall be effective on the earliest
of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp; </B>immediately after the Company gives notice to Executive of Executive&#146;s termination, with or
without Cause, unless pursuant to Section&nbsp;6.2(b)(vi) in which case ten (10)&nbsp;days after notice if not cured or unless the Company specifies a later date, in which case, termination shall be effective as of such later date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp; </B>immediately upon Executive&#146;s death; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp; </B>ten (10)&nbsp;days after the Company gives notice to Executive of Executive&#146;s termination on
account of Executive&#146;s Disability, unless the Company specifies a later date, in which case, termination shall be effective as of such later date, <I>provided</I> that Executive has not returned to the full time performance of Executive&#146;s
duties prior to such date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp; </B>ten (10)&nbsp;days after Executive gives written notice to the Company of
Executive&#146;s resignation, <I>provided </I>that the Company may set a termination date at any time between the date of notice and the date of resignation, in which case Executive&#146;s resignation shall be effective as of such other date.
Executive will receive compensation through any required notice period; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp; </B>for a
termination for Good Reason, immediately upon Executive&#146;s full satisfaction of the requirements of Section&nbsp;6.1(g). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp; </B>In the event notice of a termination under subsections (a)(i) and (iii)&nbsp;is given orally, at the other
party&#146;s request, the party giving notice must provide written confirmation of such notice within five (5)&nbsp;business days of the request in compliance with the requirement of Section&nbsp;7.1 below. In the event of a termination for Cause,
written confirmation shall specify the subsection(s) of the definition of Cause relied on to support the decision to terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.7&nbsp;&nbsp;&nbsp;&nbsp; <U>Cooperation With Company After Termination of Employment</U></B>. Following termination of Executive&#146;s
employment for any reason, Executive shall fully cooperate with the Company in all matters relating to the winding up of Executive&#146;s pending work including, but not limited to, any litigation in which the Company is involved, and the orderly
transfer of any such pending work to such other employees as may be designated by the Company. The Company will reimburse Executive for reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses
Executive incurs in connection with any such cooperation (excluding forgone wages, salary, or other compensation) and will make reasonable efforts to accommodate Executive&#146;s scheduling needs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.8</B>&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Application of Section</U><U>&nbsp;409A</U></B>. It
is intended that all of the benefits and payments under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section&nbsp;409A of the Code provided under Treasury Regulations
<FONT STYLE="white-space:nowrap">1.409A-1(b)(4),</FONT> <FONT STYLE="white-space:nowrap">1.409A-1(b)(5)</FONT> and <FONT STYLE="white-space:nowrap">1.409A-1(b)(9),</FONT> and this Agreement will be construed to the greatest extent possible as
consistent with those provisions. If not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section&nbsp;409A of the Code, and incorporates by reference all required definitions and payment
terms. For purposes of Section&nbsp;409A of the Code (including, without limitation, for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT> Executive&#146;s right to receive any installment
payments under this Agreement (whether severance payments, reimbursements or otherwise) will be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder will at all times be considered a
separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of his Separation from Service to be a &#147;specified employee&#148; for purposes of
Section&nbsp;409A(a)(2)(B)(i) of the Code, and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be &#147;deferred compensation&#148;, then if delayed commencement of
any portion of such payments is required to avoid a prohibited distribution under Section&nbsp;409A(a)(2)(B)(i) of the Code and the related adverse taxation under Section&nbsp;409A of the Code, the timing of the payments upon a Separation from
Service will be delayed as follows: on the earlier to occur of (i)&nbsp;the date that is six months and one day after the effective date of Executive&#146;s Separation from Service, and (ii)&nbsp;the date of Executive&#146;s death (such earlier
date, the &#147;<B><I>Delayed Initial Payment Date</I></B>&#148;), the Company will (A)&nbsp;pay to Executive a lump sum amount equal to the sum of the payments upon Separation from Service that Executive would otherwise have received through the
Delayed Initial Payment Date if the commencement of the payments had not been delayed pursuant to this paragraph, and (B)&nbsp;commence paying the balance of the payments in accordance with the applicable payment schedules set forth above. No
interest will be due on any amounts so deferred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. &nbsp;&nbsp;&nbsp;&nbsp;<U>G<SMALL>ENERAL</SMALL>
P<SMALL>ROVISIONS</SMALL></U><SMALL></SMALL>.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1&nbsp;&nbsp;&nbsp;&nbsp; <U>Notices</U></B>. Any notices required hereunder to be
in writing shall be deemed effectively given: (a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;when sent by electronic mail or confirmed facsimile if sent during normal business hours of the recipient, and if not, then on the
next business day, (c)&nbsp;five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d)&nbsp;one (1) day after deposit with a nationally recognized overnight courier, specifying next day
delivery, with written verification of receipt. All communications shall be sent to the Company at its primary office location and to Executive at Executive&#146;s address as listed on the Company payroll or to Executive&#146;s Company-issued email
address or Executive&#146;s email address as listed in Company records, or at such other address as the Company or Executive may designate by ten (10)&nbsp;days advance written notice to the other. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2&nbsp;&nbsp;&nbsp;&nbsp; <U>Severability</U></B>. Whenever possible, each provision of this Agreement will be interpreted in such manner
as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or
unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.3&nbsp;&nbsp;&nbsp;&nbsp; <U>Survival</U></B>. Provisions of this Agreement which by
their terms must survive the termination of this Agreement in order to effectuate the intent of the parties will survive any such termination, whether by expiration of the term, termination of Executive&#146;s employment, or otherwise, for such
period as may be appropriate under the circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4&nbsp;&nbsp;&nbsp;&nbsp; <U>Waiver</U></B>. If either party should waive any
breach of any provisions of this Agreement, it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5&nbsp;&nbsp;&nbsp;&nbsp; <U>Complete Agreement</U></B>. This Agreement constitutes the entire agreement between Executive and the
Company with regard to the subject matter hereof. This Agreement is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter and supersedes any prior oral discussions or written communications and
agreements. This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in writing signed by Executive and an authorized officer of the
Company. The parties have entered into a separate Confidential Information Agreement and have or may enter into separate agreements related to equity. These separate agreements govern other aspects of the relationship between the parties, have or
may have provisions that survive termination of Executive&#146;s employment under this Agreement, may be amended or superseded by the parties without regard to this Agreement and are enforceable according to their terms without regard to the
enforcement provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.6&nbsp;&nbsp;&nbsp;&nbsp; <U>Counterparts</U></B>. This Agreement may be executed in
separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.7&nbsp;&nbsp;&nbsp;&nbsp; <U>Headings</U></B>. The headings of the sections hereof are inserted for convenience only and shall not be
deemed to constitute a part hereof nor to affect the meaning thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.8&nbsp;&nbsp;&nbsp;&nbsp; <U>Successors and Assigns</U></B>.
The Company shall assign this Agreement and its rights and obligations hereunder in whole, but not in part, to any Company or other entity with or into which the Company may hereafter merge or consolidate or to which the Company may transfer all or
substantially all of its assets, if in any such case said Company or other entity shall by operation of law or expressly in writing assume all obligations of the Company hereunder as fully as if it had been originally made a party hereto, but may
not otherwise assign this Agreement or its rights and obligations hereunder. Executive may not assign or transfer this Agreement or any rights or obligations hereunder, other than to Executive&#146;s estate upon Executive&#146;s death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.9&nbsp;&nbsp;&nbsp;&nbsp; <U>Choice of Law</U></B>. All questions concerning the construction, validity and interpretation of this
Agreement will be governed by the law of the Commonwealth of Virginia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.10&nbsp;&nbsp;&nbsp;&nbsp; <U>Resolution of Disputes</U>. </B>The parties recognize
that litigation in federal or state courts or before federal or state administrative agencies of disputes arising out of Executive&#146;s employment with the Company or out of this Agreement, or Executive&#146;s termination of employment or
termination of this Agreement, may not be in the best interests of either Executive or the Company, and may result in unnecessary costs, delays, complexities, and uncertainty. The parties agree that any dispute between the parties arising out of or
relating to the negotiation, execution, performance or termination of this Agreement or Executive&#146;s employment, including, but not limited to, any claim arising out of this Agreement, claims under Title VII of the Civil Rights Act of 1964, as
amended, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, Section&nbsp;1981 of the Civil Rights Act of 1966, as amended, the Family Medical Leave Act, the Executive
Retirement Income Security Act, and any similar federal, state or local law, statute, regulation, or any common law doctrine, whether that dispute arises during or after employment, shall be settled by binding arbitration in accordance with the
Employment Arbitration Rules and Mediation Procedures of the American Arbitration Association; <I>provided however,</I> that this dispute resolution provision shall not apply to any separate agreements between the parties that do not themselves
specify arbitration as an exclusive remedy. The location for the arbitration shall be the Charlottesville, Virginia area. Any award made by such panel shall be final, binding and conclusive on the parties for all purposes, and judgment upon the
award rendered by the arbitrators may be entered in any court having jurisdiction thereof. The arbitrators&#146; fees and expenses and all administrative fees and expenses associated with the filing of the arbitration shall be borne by the Company;
<I>provided</I> <I>however</I>, that at Executive&#146;s option, Executive may voluntarily pay up to <FONT STYLE="white-space:nowrap">one-half</FONT> the costs and fees. The parties acknowledge and agree that their obligations to arbitrate under
this Section survive the termination of this Agreement and continue after the termination of the employment relationship between Executive and the Company. The parties each further agree that the arbitration provisions of this Agreement shall
provide each party with its <B>exclusive remedy</B>, and each party expressly waives any right it might have to seek redress in any other forum, except as otherwise expressly provided in this Agreement. By election arbitration as the means for final
settlement of all claims, <B>the parties hereby waive their respective rights to, and agree not to, sue each other in any action in a Federal, State or local court with respect to such claims, but may seek to enforce in court an arbitration award
rendered pursuant to this Agreement. The parties specifically agree to waive their respective rights to a trial by jury, and further agree that no demand, request or motion will be made for trial by jury</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE FOLLOWS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> the parties have
executed this Employment Agreement on the day and year written below effective as of the Effective Date (as defined herein). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Acumen Pharmaceuticals, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sean Stalfort</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Sean Stalfort, Chairman</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Executive:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Daniel O&#146;Connell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Daniel O&#146;Connell</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;January 15, 2021</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Date</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>E<SMALL>MPLOYMENT</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (the &#147;<B><I>Agreement</I></B><I>&#148;</I>) is entered into
effective <B>January&nbsp;1, 2021</B> (the <I>&#147;</I><B><I>Effective Date</I></B><I>&#148;</I>), by and between <B>Eric Siemers, MD</B> (the <I>&#147;</I><B><I>Executive</I></B><I>&#148;</I>) and <B>Acumen Pharmaceuticals, Inc.</B> (the
<I>&#147;</I><B><I>Company</I></B><I>&#148;</I>) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to employ Executive and, in connection therewith, to compensate Executive for Executive&#146;s personal services
to the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Executive wishes to be employed by the Company and provide personal services and certain covenants to the
Company in return for certain compensation and benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, in consideration of the mutual promises and covenants contained
herein, the parties agree to the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;E<SMALL>MPLOYMENT</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
C<SMALL>OMPANY</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Position</U>.</B> Subject to the terms set forth herein, the Company
agrees to employ Executive, in the position of <B>Chief Medical Officer</B>, and Executive hereby accepts such employment. During the term of Executive&#146;s employment with the Company, Executive will devote Executive&#146;s best efforts and
substantially all (at least eighty-percent) of his business time and attention to the business of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Duties</U>.</B> Executive will initially report to the Chief Executive Officer (the
&#147;<B>CEO</B>&#148;) of the Company. Executive shall perform his duties under this Agreement initially principally out of his personal residence and the Company&#146;s corporate offices in Carmel, IN or such other location as assigned by the
Company. In addition, Executive shall make business trips to such places as may be necessary or advisable for the efficient operations of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Company Policies and Benefits</U>.</B> The employment relationship between the parties shall also be
subject to the Company&#146;s personnel policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the Company&#146;s sole discretion. Executive will be eligible to participate on the same basis as similarly
situated employees in the Company&#146;s benefit plans in effect from time to time during Executive&#146;s employment. All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions
of the such plan. The Executive shall be entitled to paid vacation in accordance with the plans, policies, programs and practices of the Company applicable to its senior executives in effect from time to time, but in no event shall the Executive be
entitled to less than four (4)&nbsp;weeks of vacation per calendar year <FONT STYLE="white-space:nowrap">(pro-rated</FONT> for any partial year of service). The Company reserves the right to change, alter, or terminate any benefit plan in its sole
discretion. Notwithstanding the foregoing, in the event that the terms of this Agreement differ from or are in conflict with the Company&#146;s general employment policies or practices, this Agreement shall control. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;<U>C<SMALL>OMPENSATION</SMALL></U><SMALL></SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Salary</U>.</B> Executive shall receive for services to be rendered hereunder an initial base salary of $
332,000.00 on annualized basis, subject to review and adjustment from time to time by the Company, and payable subject to standard federal and state payroll withholding requirements in accordance with the Company&#146;s standard payroll practices
(&#147;<B><I>Base Salary</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Discretionary Bonus</U>.</B> Executive shall be eligible
for a discretionary annual calendar year performance bonus (the <I>&#147;</I><B><I>Annual Bonus</I></B><I>&#148;</I>) with an annual target of forty percent (40%) of Executive&#146;s then-current Base Salary (the &#147;<B><I>Target
Amount</I></B>&#148;). Whether or not Executive is eligible for any Annual Bonus will be dependent upon the actual achievement by Executive and the Company of the applicable individual and corporate performance goals, as determined by the Board. No
amount of any Annual Bonus is guaranteed at any time and may be greater or lesser than the Target Amount and may be zero. Any Annual Bonus, if awarded, will be paid in a single installment paid at the same time annual bonuses are generally paid to
other similarly-situated employees of the Company and in any event no later than March 1st of the calendar year following the calendar year to which the Annual Bonus is applicable, and will be subject to deductions and withholdings. Executive&#146;s
eligibility for an Annual Bonus and the Target Amount, if any, is subject to change in the discretion of the Board (or any authorized committee thereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Expense Reimbursement</U>.</B> The Company will reimburse Executive for reasonable business expenses in
accordance with the Company&#146;s standard expense reimbursement policy, as the same may be modified by the Board from time to time. The Company shall reimburse Executive for all customary and appropriate business-related expenses actually incurred
and documented in accordance with Company policy, as in effect from time to time. For the avoidance of doubt, to the extent that any reimbursements payable to Executive are subject to the provisions of Section&nbsp;409A of the Internal Revenue Code
of 1986, as amended (the &#147;<B><I>Code</I></B>&#148;): (a) any such reimbursements will be paid no later than December&nbsp;31 of the year following the year in which the expense was incurred, (b)&nbsp;the amount of expenses reimbursed in one
year will not affect the amount eligible for reimbursement in any subsequent year, and (c)&nbsp;the right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Option</U>.</B> Subject to approval by the Board, the Company anticipates granting to Executive an
option to purchase 463,374 shares of the Company&#146;s common stock at the fair market value as determined by the Board as of the date of grant (the &#147;<B><I>Option</I></B>&#148;). The anticipated Option will be governed by the terms and
conditions of the Company&#146;s Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;) and the option grant agreement, and will vest 25% on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of grant, and thereafter
over the ensuing 3 years in a series of <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;successive equal monthly installments, subject to your Continuous Service (as defined in the Plan) as of each such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;<U>C<SMALL>ONFIDENTIAL</SMALL> I<SMALL>NFORMATION</SMALL>, I<SMALL>NVENTIONS</SMALL>, N<SMALL>ON</SMALL><FONT
STYLE="white-space:nowrap">-C</FONT><SMALL>OMPETITION</SMALL> <SMALL>AND</SMALL> N<SMALL>ON</SMALL>- S<SMALL>OLICITATION</SMALL> O<SMALL>BLIGATIONS</SMALL></U><SMALL></SMALL>.</B> As a condition of employment, Executive agrees to execute and abide
by the Employee Confidential Information, Inventions, <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> and Non-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competition Agreement, attached as <B>Exhibit A</B> which may be amended by the parties from time to time
without regard to this Agreement (the <I>&#147;</I><B><I>Confidential Information Agreement</I></B><I>&#148;</I>). The Confidential Information Agreement contains provisions that are intended by the parties to survive and do survive termination of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;O<SMALL>UTSIDE</SMALL> A<SMALL>CTIVITIES</SMALL> D<SMALL>URING</SMALL>
E<SMALL>MPLOYMENT</SMALL></B><SMALL></SMALL>. Except with the prior written consent of the Company, Executive will not, while employed by the Company, undertake or engage in any other employment, occupation or business enterprise that would
interfere with Executive&#146;s responsibilities and the performance of Executive&#146;s duties hereunder except for (i)&nbsp;reasonable time devoted to volunteer services for or on behalf of such religious, educational, <FONT
STYLE="white-space:nowrap">non-profit</FONT> and/or other charitable organization as Executive may wish to serve, (ii)&nbsp;reasonable time devoted to activities in the <FONT STYLE="white-space:nowrap">non-profit</FONT> and business communities
consistent with Executive&#146;s duties; and (iii)&nbsp;such other activities as may be specifically approved in writing by the Company. [<B><I>Company hereby acknowledges and consents to Executive&#146;s existing positions at other companies
including but not limited to Cogstate Ltd. and Vaccinex Inc. Executive agrees that these outside activities will be adjusted as quickly as possible in order to comply with the terms of this Agreement.</I></B>] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.&nbsp;&nbsp;&nbsp;&nbsp; <U>N<SMALL>O</SMALL> C<SMALL>ONFLICT</SMALL> <SMALL>WITH</SMALL> E<SMALL>XISTING</SMALL>
O<SMALL>BLIGATIONS</SMALL></U><SMALL></SMALL></B><SMALL></SMALL>. Executive represents that Executive&#146;s performance of all the terms of this Agreement and as an Executive of the Company do not and will not breach any agreement or obligation of
any kind made prior to Executive&#146;s employment by the Company, including agreements or obligations Executive may have with prior employers or entities for which Executive has provided services. Executive has not entered into, and Executive
agrees that Executive will not enter into, any agreement or obligation, either written or oral, in conflict herewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;<U>T<SMALL>ERMINATION</SMALL> O<SMALL>F</SMALL> E<SMALL>MPLOYMENT</SMALL></U><SMALL></SMALL>.</B> The parties
acknowledge that Executive&#146;s employment relationship with the Company is <FONT STYLE="white-space:nowrap">at-will.</FONT> Either Executive or the Company may terminate the employment relationship for any reason whatsoever at any time, with or
without Cause or advance notice. The provisions in this Section govern the amount of compensation, if any, to be provided to Executive upon termination of employment and do not alter this <FONT STYLE="white-space:nowrap">at-will</FONT> status. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Company without Cause or Resignation by Executive for Good Reason</U>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp; The Company shall have the right to terminate Executive&#146;s employment with the Company pursuant to
this Section&nbsp;6.1 at any time without Cause (as defined in Section&nbsp;6.2(b) below) by giving notice as described in Section&nbsp;7.1 of this Agreement. A termination pursuant to Section&nbsp;6.4 or 6.5 below is not a termination without Cause
for purposes of receiving the benefits described in this Section&nbsp;6.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp; In the event the Company
terminates Executive&#146;s employment without Cause or Executive Resigns for Good Reason (as defined in Section&nbsp;6.1(g) below), and provided that such termination constitutes a &#147;separation from service&#148; (as defined under Treasury
Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h),</FONT> without regard to any alternative definition thereunder, a <I>&#147;</I><B><I>Separation from Service</I></B><I>&#148;</I>), then Executive shall be entitled to receive the
Accrued Obligations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(as defined below) and, subject to Executive&#146;s compliance with the obligations in Section&nbsp;6.1(c)
below, Executive shall be eligible to receive the following severance benefits (the<B><I> </I></B>&#147;<B><I>Severance Benefits</I></B>&#148;<B><I></I></B>): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp; The Company will pay Executive an amount equal to Executive&#146;s then current Base Salary for six
(6)&nbsp;months, less all applicable withholdings and deductions, and paid in equal installments beginning on the Company&#146;s second regularly scheduled payroll date following the Release Effective Date (as defined in Section&nbsp;6.1(c) below),
with the remaining installments occurring on the Company&#146;s regularly scheduled payroll dates thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp; If Executive timely elects continued coverage under COBRA for Executive and Executive&#146;s dependents
under the Company&#146;s group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue Executive&#146;s and his covered dependents&#146; health insurance coverage in effect for Executive (and
Executive&#146;s covered dependents) on the termination date until the earliest of: (i)&nbsp;twelve (12) months following the termination date (the <B><I></I></B>&#147;<B><I>COBRA Severance Period</I></B>&#148;<B><I></I></B>); (ii) the date when
Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment; or (iii)&nbsp;the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including
plan termination (such period from the termination date through the earlier of (i)-(iii), (the <B><I></I></B>&#147;<B><I>COBRA Payment Period</I></B>&#148;<B><I></I></B>). Notwithstanding the foregoing, if at any time the Company determines that its
payment of COBRA premiums on Executive&#146;s behalf would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation
Act), then in lieu of paying COBRA premiums pursuant to this Section, the Company shall pay Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month,
subject to applicable tax withholding, for the remainder of the COBRA Payment Period. Nothing in this Agreement shall deprive Executive of his rights under COBRA or ERISA for benefits under plans and policies arising under his employment by the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp; Executive will be paid all of the Accrued Obligations (as defined in Section&nbsp;6.1(d)
below) on the Company&#146;s first payroll date after Executive&#146;s date of termination from employment or earlier if required by law. If eligible to receive the Severance Benefits pursuant to Section&nbsp;6.1(b) of this Agreement, Executive will
only receive such Severance Benefits if: (i)&nbsp;within the time period provided in the separation agreement (which shall be no longer than 60 days following the date of Executive&#146;s Separation from Service), Executive has signed and delivered
to the Company a separation agreement that includes, among other terms, an effective general release of claims in favor of the Company and its affiliates and representatives, in the form presented by the Company (the
<B><I></I></B>&#147;<B><I>Release</I></B>&#148;<B><I></I></B>), which cannot be revoked in whole or part by such date (the date that the Release can no longer be revoked is referred to as the <B><I></I></B>&#147;<B><I>Release Effective
Date</I></B>&#148;<B><I></I></B>); and (ii)&nbsp;if Executive holds any other positions with the Company, he resigns such position(s) to be effective no later than the date of Executive&#146;s termination date (or such other date as requested by the
Board); (iii) Executive returns all Company property; (iv)&nbsp;Executive complies with his post-termination obligations under this Agreement and the Confidential Information Agreement; and (v)&nbsp;Executive complies with the terms of the Release,
including, without limitation, any <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> confidentiality and cooperation provisions contained in Release. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp; For purposes of this Agreement, <B><I>&#147;Accrued
Obligations&#148;</I></B> are (i)&nbsp;Executive&#146;s accrued but unpaid salary through the date of termination, (ii)&nbsp;any unreimbursed business expenses incurred by Executive payable in accordance with the Company&#146;s standard expense
reimbursement policies, and (iii)&nbsp;benefits owed to Executive under any qualified retirement plan or health and welfare benefit plan in which Executive was a participant in accordance with applicable law and the provisions of such plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp; The Severance Benefits provided to Executive pursuant to this Section&nbsp;6.1 are in lieu of, and not in
addition to, any benefits to which Executive may otherwise be entitled under any Company severance plan, policy or program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp; Any damages caused by the termination of Executive&#146;s employment without Cause would be difficult to
ascertain; therefore, the Severance Benefits for which Executive is eligible pursuant to Section&nbsp;6.1(b) above in exchange for the Release is agreed to by the parties as liquidated damages, to serve as full compensation, and not a penalty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp; <B><I>&#147;Good Reason&#148;</I></B> for purposes of this Agreement shall mean the occurrence of any of
the following conditions without Executive&#146;s consent, after Executive&#146;s provision of written notice to the Company of the existence of such condition (which notice must be provided as described in Section&nbsp;7.1 within thirty
(30)&nbsp;days of the initial existence of the condition and must specify the particular condition in reasonable detail), provided that the Company has not first provided notice to Executive of its intent to terminate Executive&#146;s employment:
(i)&nbsp;a material reduction in Executive&#146;s duties, responsibilities or authorities, provided, however, that neither the conversation of the Company to a subsidiary, division or unit of an acquiring entity, or Executive&#146;s reporting
relationships following a Change in Control, nor a change in title, will be deemed a &#147;material reduction&#148; in and of itself or material adverse alteration in, Executive&#146;s position, title, duties, or responsibilities; (ii)&nbsp;a
material (greater than 10%) reduction by the Company of Executive&#146;s Base Salary (except in the case of either an across the board reduction in salaries or a temporary reduction due to financial exigency); or (iii)&nbsp;the relocation of
Executive&#146;s principal place of employment by fifty (50)&nbsp;or more miles from Executive&#146;s then-current principal place of employment. Notwithstanding the foregoing, Good Reason shall only exist if the Company is provided a thirty
(30)&nbsp;day period to cure the event or condition giving rise to Good Reason, and it fails to do so within that cure period (and, additionally, Executive must resign for such Good Reason condition by giving notice as described in Section&nbsp;7.1
within thirty (30)&nbsp;days after the period for curing the violation or condition has ended). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.2</B>&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Termination by the Company for Cause</U>.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp; The Company shall have the right to terminate
Executive&#146;s employment with the Company at any time for Cause by giving notice as described in Section&nbsp;7.1 of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp; &#147;Cause&#148; for purposes of this Agreement shall
mean that the Company has determined in its sole discretion that Executive has engaged in any of the following: (i)&nbsp;a material breach of any covenant or condition under this Agreement or any other agreement between the Company and Executive;
(ii)&nbsp;any act constituting dishonesty, fraud, immoral or disreputable conduct; (iii)&nbsp;any conduct which constitutes a felony under applicable law; (iv)&nbsp;violation of any Company policy or any act of misconduct; (v)&nbsp;refusal to follow
or implement a clear and reasonable directive of Company; (vi)&nbsp;negligence or incompetence in the performance of Executive&#146;s duties or failure to perform such duties in a manner satisfactory to the Company after the expiration of ten
(10)&nbsp;days without cure after written notice of such failure; (vii)&nbsp;failure to pass to the satisfaction of the Company, a preliminary background check or failure to submit proof of legal eligibility to work in the United States; or
(viii)&nbsp;breach of fiduciary duty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp; In the event Executive&#146;s employment is terminated at any
time for Cause, Executive will not receive Severance Benefits, or any other compensation or benefits, except that, pursuant to the Company&#146;s standard payroll policies, the Company shall provide to Executive the Accrued Obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.3</B>&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Resignation by Executive (other than for Good Reason).</U></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp; Executive may resign from Executive&#146;s employment with the Company at any time by giving notice as
described in Section&nbsp;7.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp; In the event Executive resigns from Executive&#146;s employment with
the Company (other than for Good Reason), Executive will not receive Severance Benefits, or any other compensation or benefits, except that, pursuant to the Company&#146;s standard payroll policies, the Company shall provide to Executive the Accrued
Obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.4</B>&nbsp;&nbsp;&nbsp;&nbsp; <U><B>Termination by Virtue of Death or Disability of Executive.</B></U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp; In the event of Executive&#146;s death while employed pursuant to this Agreement, all obligations of the
parties hereunder shall terminate immediately, and the Company shall, pursuant to the Company&#146;s standard payroll policies, provide to Executive&#146;s legal representatives Executive&#146;s accrued but unpaid salary through the date of death
together with all compensation and benefits payable to Executive based on his participation in any compensation or benefit plan, program or arrangement through the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp; Subject to applicable state and federal law, the Company shall at all times have the right, upon written
notice to Executive, to terminate this Agreement based on Executive&#146;s Disability (as defined below). Termination by the Company of Executive&#146;s employment based on <B><I></I></B>&#147;<B><I>Disability</I></B>&#148;<B><I></I></B> shall mean
termination because Executive is unable due to a physical or mental condition to perform the essential functions of Executive&#146;s position with or without reasonable accommodation for one hundred twenty (120)&nbsp;consecutive calendar days or six
(6)&nbsp;months in the aggregate during any twelve (12)&nbsp;month period or based on the written certification by two licensed physicians of the likely continuation of such condition for such period. This definition shall be interpreted and applied
consistent with the Americans with Disabilities Act, the Family and Medical Leave Act, and other applicable law. In the event Executive&#146;s employment is terminated based on Executive&#146;s Disability, Executive will not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">receive the Severance Benefits, or any other severance compensation or benefit, except that, pursuant to the
Company&#146;s standard payroll policies, the Company shall pay to Executive the accrued but unpaid salary of Executive through the date of termination, together with all compensation and benefits payable to Executive based on his participation in
any compensation or benefit plan, program or arrangement through the date of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.5</B>&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>[RESERVED]</U></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.6</B>&nbsp;&nbsp;&nbsp;&nbsp; <U><B>Notice; Effective Date of Termination.</B></U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp; Termination of Executive&#146;s employment pursuant to this Agreement shall be effective on the earliest
of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp; immediately after the Company gives notice to Executive of Executive&#146;s termination, with or
without Cause, unless pursuant to Section&nbsp;6.2(b)(vi) in which case ten (10)&nbsp;days after notice if not cured or unless the Company specifies a later date, in which case, termination shall be effective as of such later date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp; immediately upon Executive&#146;s death; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp; ten (10) days after the Company gives notice to Executive of Executive&#146;s termination on account of
Executive&#146;s Disability, unless the Company specifies a later date, in which case, termination shall be effective as of such later date, <I>provided</I> that Executive has not returned to the full time performance of Executive&#146;s duties
prior to such date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp; ten (10) days after Executive gives written notice to the Company of
Executive&#146;s resignation, <I>provided</I> that the Company may set a termination date at any time between the date of notice and the date of resignation, in which case Executive&#146;s resignation shall be effective as of such other date.
Executive will receive compensation through any required notice period; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:2%; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp; for a
termination for Good Reason, immediately upon Executive&#146;s full satisfaction of the requirements of Section&nbsp;6.1(g). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp; In the event notice of a termination under subsections (a)(i) and (iii)&nbsp;is given orally, at the other
party&#146;s request, the party giving notice must provide written confirmation of such notice within five (5)&nbsp;business days of the request in compliance with the requirement of Section&nbsp;7.1 below. In the event of a termination for Cause,
written confirmation shall specify the subsection(s) of the definition of Cause relied on to support the decision to terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.7</B>&nbsp;&nbsp;&nbsp;&nbsp; <U><B>Cooperation With Company After Termination of Employment</B></U>. Following termination of
Executive&#146;s employment for any reason, Executive shall fully cooperate with the Company in all matters relating to the winding up of Executive&#146;s pending work including, but not limited to, any litigation in which the Company is involved,
and the orderly transfer of any such pending work to such other employees as may be designated by the Company. The Company will reimburse Executive for reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses Executive incurs in connection with any such cooperation (excluding forgone wages, salary, or other compensation) and will make reasonable efforts
to accommodate Executive&#146;s scheduling needs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.8</B>&nbsp;&nbsp;&nbsp;&nbsp; <U><B>Application of Section&nbsp;409A</B></U>. It is
intended that all of the benefits and payments under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section&nbsp;409A of the Code provided under Treasury Regulations
<FONT STYLE="white-space:nowrap">1.409A-1(b)(4),</FONT> <FONT STYLE="white-space:nowrap">1.409A-1(b)(5)</FONT> and <FONT STYLE="white-space:nowrap">1.409A-1(b)(9),</FONT> and this Agreement will be construed to the greatest extent possible as
consistent with those provisions. If not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section&nbsp;409A of the Code, and incorporates by reference all required definitions and payment
terms. For purposes of Section&nbsp;409A of the Code (including, without limitation, for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT> Executive&#146;s right to receive any installment
payments under this Agreement (whether severance payments, reimbursements or otherwise) will be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder will at all times be considered a
separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of his Separation from Service to be a &#147;specified employee&#148; for purposes of
Section&nbsp;409A(a)(2)(B)(i) of the Code, and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be &#147;deferred compensation&#148;, then if delayed commencement of
any portion of such payments is required to avoid a prohibited distribution under Section&nbsp;409A(a)(2)(B)(i) of the Code and the related adverse taxation under Section&nbsp;409A of the Code, the timing of the payments upon a Separation from
Service will be delayed as follows: on the earlier to occur of (i)&nbsp;the date that is six months and one day after the effective date of Executive&#146;s Separation from Service, and (ii)&nbsp;the date of Executive&#146;s death (such earlier
date, the <B><I></I></B>&#147;<B><I>Delayed Initial Payment Date</I></B>&#148;<B><I>),</I></B> the Company will (A)&nbsp;pay to Executive a lump sum amount equal to the sum of the payments upon Separation from Service that Executive would otherwise
have received through the Delayed Initial Payment Date if the commencement of the payments had not been delayed pursuant to this paragraph, and (B)&nbsp;commence paying the balance of the payments in accordance with the applicable payment schedules
set forth above. No interest will be due on any amounts so deferred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.&nbsp;&nbsp;&nbsp;&nbsp; <U>G<SMALL>ENERAL</SMALL>
P<SMALL>ROVISIONS</SMALL>.</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1</B>&nbsp;&nbsp;&nbsp;&nbsp; <U><B>Notices</B></U>. Any notices required hereunder to be in
writing shall be deemed effectively given: (a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;when sent by electronic mail or confirmed facsimile if sent during normal business hours of the recipient, and if not, then on the next
business day, (c)&nbsp;five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d)&nbsp;one (1) day after deposit with a nationally recognized overnight courier, specifying next day
delivery, with written verification of receipt. All communications shall be sent to the Company at its primary office location and to Executive at Executive&#146;s address as listed on the Company payroll or to Executive&#146;s Company- issued email
address or Executive&#146;s email address as listed in Company records, or at such other address as the Company or Executive may designate by ten (10)&nbsp;days advance written notice to the other. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2</B>&nbsp;&nbsp;&nbsp;&nbsp; <U><B>Severability</B></U>. Whenever possible, each provision of this Agreement will be interpreted in such
manner as to be effective and valid under applicable law, but if any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.</B> Provisions of this Agreement which by their terms must survive the termination of this
Agreement in order to effectuate the intent of the parties will survive any such termination, whether by expiration of the term, termination of Executive&#146;s employment, or otherwise, for such period as may be appropriate under the circumstances.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>.</B> If either party should waive any breach of any provisions of this Agreement, it shall
not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Complete Agreement</U>.</B> This Agreement constitutes the entire agreement between Executive and the Company
with regard to the subject matter hereof. This Agreement is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter and supersedes any prior oral discussions or written communications and agreements. This
Agreement is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in writing signed by Executive and an authorized officer of the Company. The parties
have entered into a separate Confidential Information Agreement and have or may enter into separate agreements related to equity. These separate agreements govern other aspects of the relationship between the parties, have or may have provisions
that survive termination of Executive&#146;s employment under this Agreement, may be amended or superseded by the parties without regard to this Agreement and are enforceable according to their terms without regard to the enforcement provision of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.</B> This Agreement may be executed in separate counterparts, any one
of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.</B> The headings of the sections hereof are inserted for convenience only and shall not be
deemed to constitute a part hereof nor to affect the meaning thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>.</B>
The Company shall assign this Agreement and its rights and obligations hereunder in whole, but not in part, to any Company or other entity with or into which the Company may hereafter merge or consolidate or to which the Company may transfer all or
substantially all of its assets, if in any such case said Company or other entity shall by operation of law or expressly in writing assume all obligations of the Company hereunder as fully as if it had been originally made a party hereto, but may
not otherwise assign this Agreement or its rights and obligations hereunder. Executive may not assign or transfer this Agreement or any rights or obligations hereunder, other than to Executive&#146;s estate upon Executive&#146;s death. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Choice of Law</U>.</B> All questions concerning the
construction, validity and interpretation of this Agreement will be governed by the law of the State of Indiana. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Resolution of Disputes</U>.</B> The parties recognize that litigation in federal or state courts or before
federal or state administrative agencies of disputes arising out of Executive&#146;s employment with the Company or out of this Agreement, or Executive&#146;s termination of employment or termination of this Agreement, may not be in the best
interests of either Executive or the Company, and may result in unnecessary costs, delays, complexities, and uncertainty. The parties agree that any dispute between the parties arising out of or relating to the negotiation, execution, performance or
termination of this Agreement or Executive&#146;s employment, including, but not limited to, any claim arising out of this Agreement, claims under Title VII of the Civil Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Age
Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, Section&nbsp;1981 of the Civil Rights Act of 1966, as amended, the Family Medical Leave Act, the Executive Retirement Income Security Act, and any similar
federal, state or local law, statute, regulation, or any common law doctrine, whether that dispute arises during or after employment, shall be settled by binding arbitration in accordance with the Employment Arbitration Rules and Mediation
Procedures of the American Arbitration Association; <I>provided however</I>, that this dispute resolution provision shall not apply to any separate agreements between the parties that do not themselves specify arbitration as an exclusive remedy. The
location for the arbitration shall be the Charlottesville, Virginia area. Any award made by such panel shall be final, binding and conclusive on the parties for all purposes, and judgment upon the award rendered by the arbitrators may be entered in
any court having jurisdiction thereof. The arbitrators&#146; fees and expenses and all administrative fees and expenses associated with the filing of the arbitration shall be borne by the Company; <I>provided however</I>, that at Executive&#146;s
option, Executive may voluntarily pay up to <FONT STYLE="white-space:nowrap">one-half</FONT> the costs and fees. The parties acknowledge and agree that their obligations to arbitrate under this Section survive the termination of this Agreement and
continue after the termination of the employment relationship between Executive and the Company. The parties each further agree that the arbitration provisions of this Agreement shall provide each party with its <B>exclusive remedy</B>, and each
party expressly waives any right it might have to seek redress in any other forum, except as otherwise expressly provided in this Agreement. By election arbitration as the means for final settlement of all claims, <B>the parties hereby waive their
respective rights to, and agree not to, sue each other in any action in a Federal, State or local court with respect to such claims, but may seek to enforce in court an arbitration award rendered pursuant to this Agreement. The parties specifically
agree to waive their respective rights to a trial by jury, and further agree that no demand, request or motion will be made for trial by jury.</B> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE FOLLOWS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties have executed this Employment Agreement on the day and year written below effective as of the Effective Date (as defined herein). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Acumen Pharmaceuticals, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel J.O&#146;Connell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Daniel J.O&#146;Connell,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>President and Chief Executive Officer</B></TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Executive:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eric Siemers</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Eric Siemers, MD</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">1/26/2021</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>E<SMALL>MPLOYMENT</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (the &#147;<B><I>Agreement</I></B>&#148;) is entered into
effective <B>January</B><B></B><B>&nbsp;1, 2021 </B>(the &#147;<B><I>Effective Date</I></B>&#148;), by and between <B>Russell Barton </B>(the &#147;<B><I>Executive</I></B>&#148;) and <B>Acumen Pharmaceuticals, Inc.</B> (the
&#147;<B><I>Company</I></B>&#148;) and supersedes and replaces any prior consulting agreement or employment letter between the Parties and any of their affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to employ Executive and, in connection therewith, to compensate Executive for Executive&#146;s personal services
to the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Executive wishes to be employed by the Company and provide personal services and certain covenants to the
Company in return for certain compensation and benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, in consideration of the mutual promises and covenants contained
herein, the parties agree to the following: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1</B>. <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>E<SMALL>MPLOYMENT</SMALL> <SMALL>BY</SMALL>
<SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL></U><SMALL></SMALL>.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.1 &nbsp;&nbsp;&nbsp;&nbsp;<U>Position</U></B>. Subject to the terms
set forth herein, the Company agrees to employ Executive, in the position of <B>Chief Operations Officer</B>, and Executive hereby accepts such employment. During the term of Executive&#146;s employment with the Company, Executive will devote
Executive&#146;s best efforts and substantially all (at least eighty-percent) of his business time and attention to the business of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.2 &nbsp;&nbsp;&nbsp;&nbsp;<U>Duties</U></B>. <B></B>Executive will initially report to the Chief Executive Officer (the
&#147;<B>CEO</B>&#148;)<B> </B>of the Company. Executive shall perform his duties under this Agreement initially principally out of his personal residence and the Company&#146;s corporate offices in Carmel, IN or such other location as assigned by
the Company. In addition, Executive shall make business trips to such places as may be necessary or advisable for the efficient operations of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.3 &nbsp;&nbsp;&nbsp;&nbsp;<U>Company Policies and Benefits</U></B>. The employment relationship between the parties shall also be subject
to the Company&#146;s personnel policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the Company&#146;s sole discretion. Executive will be eligible to participate on the same basis as similarly
situated employees in the Company&#146;s benefit plans in effect from time to time during Executive&#146;s employment. All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions
of the such plan. The Executive shall be entitled to paid vacation in accordance with the plans, policies, programs and practices of the Company applicable to its senior executives in effect from time to time, but in no event shall the Executive be
entitled to less than four (4)&nbsp;weeks of vacation per calendar year <FONT STYLE="white-space:nowrap">(pro-rated</FONT> for any partial year of service). The Company reserves the right to change, alter, or terminate any benefit plan in its sole
discretion. Notwithstanding the foregoing, in the event that the terms of this Agreement differ from or are in conflict with the Company&#146;s general employment policies or practices, this Agreement shall control. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2</B>. <B>&nbsp;&nbsp;&nbsp;&nbsp;<U>C<SMALL>OMPENSATION</SMALL></U><SMALL></SMALL>.</B>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.1 &nbsp;&nbsp;&nbsp;&nbsp;<U>Salary</U></B>. Executive shall receive for services to be rendered hereunder an initial base salary of
$ 260,000.00 on annualized basis, subject to review and adjustment from time to time by the Company, and payable subject to standard federal and state payroll withholding requirements in accordance with the Company&#146;s standard payroll practices
(&#147;<B><I>Base Salary</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2 &nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Discretionary Bonus</U></B>. Executive shall be
eligible for a discretionary annual calendar year performance bonus (the &#147;<B><I>Annual Bonus</I></B>&#148;) with an annual target of forty percent (40%) of Executive&#146;s then-current Base Salary (the &#147;<B><I>Target Amount</I></B>&#148;).
Whether or not Executive is eligible for any Annual Bonus will be dependent upon the actual achievement by Executive and the Company of the applicable individual and corporate performance goals, as determined by the Board. No amount of any Annual
Bonus is guaranteed at any time and may be greater or lesser than the Target Amount and may be zero. Any Annual Bonus, if awarded, will be paid in a single installment paid at the same time annual bonuses are generally paid to other
similarly-situated employees of the Company and in any event no later than March 1st of the calendar year following the calendar<B> </B>year to which the Annual Bonus is applicable, and will be subject to deductions and withholdings.
Executive&#146;s eligibility for an Annual Bonus and the Target Amount, if any, is subject to change in the discretion of the Board (or any authorized committee thereof). <B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.3 &nbsp;&nbsp;&nbsp;&nbsp;<U>Expense Reimbursement</U></B>. The Company will reimburse Executive for reasonable business expenses in
accordance with the Company&#146;s standard expense reimbursement policy, as the same may be modified by the Board from time to time. The Company shall reimburse Executive for all customary and appropriate business-related expenses actually incurred
and documented in accordance with Company policy, as in effect from time to time . For the avoidance of doubt, to the extent that any reimbursements payable to Executive are subject to the provisions of Section&nbsp;409A of the Internal Revenue Code
of 1986, as amended (the &#147;<B><I>Code</I></B>&#148;):<B> </B>(a) any such reimbursements will be paid no later than December&nbsp;31 of the year following the year in which the expense was incurred, (b)&nbsp;the amount of expenses reimbursed in
one year will not affect the amount eligible for reimbursement in any subsequent year, and (c)&nbsp;the right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.4 &nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Option.</U></B> Subject to approval by the Board, the Company anticipates granting to Executive an
option to purchase 425,305 shares of the Company&#146;s common stock at the fair market value as determined by the Board as of the date of grant (the &#147;<B><I>Option</I></B>&#148;). The anticipated Option will be governed by the terms and
conditions of the Company&#146;s Equity Incentive Plan<B> </B>(the &#147;<B><I>Plan</I></B>&#148;) and the option grant agreement, and will vest 25% on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of grant, and
thereafter over the ensuing 3 years in a series of <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;successive equal monthly installments, subject to your Continuous Service (as defined in the Plan) as of each such date. <B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3</B>. &nbsp;&nbsp;&nbsp;&nbsp;<U><B>C<SMALL>ONFIDENTIAL</SMALL> I<SMALL>NFORMATION</SMALL>, I<SMALL>NVENTIONS</SMALL>,
N<SMALL>ON</SMALL>-C<SMALL>OMPETITION</SMALL> <SMALL>AND</SMALL> N<SMALL>ON</SMALL>-S<SMALL>OLICITATION</SMALL> O<SMALL>BLIGATIONS</SMALL></B><SMALL></SMALL>.</U> As a condition of employment, Executive agrees to execute and abide by the Employee
Confidential Information, Inventions, <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> and <FONT STYLE="white-space:nowrap">Non-Competition</FONT> Agreement, attached as <B>Exhibit A </B>which may be amended by the parties from time to time
without regard to this Agreement (the &#147;<B><I>Confidential Information Agreement</I></B>&#148;). The Confidential Information<B> </B>Agreement contains provisions that are intended by the parties to survive and do survive termination of this
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4. &nbsp;&nbsp;&nbsp;&nbsp;<U>O<SMALL>UTSIDE</SMALL> A<SMALL>CTIVITIES</SMALL>
D<SMALL>URING</SMALL> E<SMALL>MPLOYMENT</SMALL></U><SMALL></SMALL>.</B> Except with the prior written consent of the Company, Executive will not, while employed by the Company, undertake or engage in any other employment, occupation or business
enterprise that would interfere with Executive&#146;s responsibilities and the performance of Executive&#146;s duties hereunder except for (i)&nbsp;reasonable time devoted to volunteer services for or on behalf of such religious, educational,
non-profit and/or other charitable organization as Executive may wish to serve, (ii)&nbsp;reasonable time devoted to activities in the <FONT STYLE="white-space:nowrap">non-profit</FONT> and business communities consistent with Executive&#146;s
duties; and (iii)&nbsp;such other activities as may be specifically approved in writing by the Company. [Company hereby acknowledges consent&#146;s to Executive&#146;s existing position at AgeneBio, Inc. and deems that it complies with this
Section&nbsp;4.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5. &nbsp;&nbsp;&nbsp;&nbsp;<U>N<SMALL>O</SMALL> C<SMALL>ONFLICT</SMALL> <SMALL>WITH</SMALL> E<SMALL>XISTING</SMALL>
O<SMALL>BLIGATIONS</SMALL></U><SMALL></SMALL></B><SMALL></SMALL>. Executive represents that Executive&#146;s performance of all the terms of this Agreement and as an Executive of the Company do not and will not breach any agreement or obligation of
any kind made prior to Executive&#146;s employment by the Company, including agreements or obligations Executive may have with prior employers or entities for which Executive has provided services. Executive has not entered into, and Executive
agrees that Executive will not enter into, any agreement or obligation, either written or oral, in conflict herewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.
&nbsp;&nbsp;&nbsp;&nbsp;<U>T<SMALL>ERMINATION</SMALL> O<SMALL>F</SMALL> E<SMALL>MPLOYMENT</SMALL></U><SMALL></SMALL>.</B> The parties acknowledge that Executive&#146;s employment relationship with the Company is
<FONT STYLE="white-space:nowrap">at-will.</FONT> Either Executive or the Company may terminate the employment relationship for any reason whatsoever at any time, with or without Cause or advance notice. The provisions in this Section govern the
amount of compensation, if any, to be provided to Executive upon termination of employment and do not alter this <FONT STYLE="white-space:nowrap">at-will</FONT> status. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.1 &nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Company without Cause or Resignation by Executive for Good Reason</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have the right to terminate Executive&#146;s employment with the Company pursuant to this
Section&nbsp;6.1 at any time without Cause (as defined in Section&nbsp;6.2(b) below) by giving notice as described in Section&nbsp;7.1 of this Agreement. A termination pursuant to Section&nbsp;6.4 or 6.5 below is not a termination without Cause for
purposes of receiving the benefits described in this Section&nbsp;6.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>&nbsp;&nbsp;&nbsp;&nbsp;In the event the Company
terminates Executive&#146;s employment without Cause or Executive Resigns for Good Reason (as defined in Section&nbsp;6.1(g) below), and provided that such termination constitutes a &#147;separation from service&#148; (as defined under Treasury
Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h),</FONT> without regard to any alternative definition thereunder, a &#147;<B><I>Separation from Service</I></B>&#148;), then Executive shall be entitled to receive the Accrued
Obligations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(as defined below) and, subject to Executive&#146;s compliance with the obligations in Section&nbsp;6.1(c) below, Executive shall be eligible to receive the following severance benefits (the
&#147;<B><I>Severance Benefits</I></B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>&nbsp;&nbsp;&nbsp;&nbsp;The Company will pay Executive an amount equal to
Executive&#146;s then current Base Salary for six (6)&nbsp;months, less all applicable withholdings and deductions, and paid in equal installments beginning on the Company&#146;s second regularly scheduled payroll date following the Release
Effective Date (as defined in Section&nbsp;6.1(c) below), with the remaining installments occurring on the Company&#146;s regularly scheduled payroll dates thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>&nbsp;&nbsp;&nbsp;&nbsp;If Executive timely elects continued coverage under COBRA for Executive and Executive&#146;s dependents
under the Company&#146;s group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue Executive&#146;s and his covered dependents&#146; health insurance coverage in effect for Executive (and
Executive&#146;s covered dependents) on the termination date until the earliest of: (i)&nbsp;twelve (12) months following the termination date (the &#147;<B><I>COBRA Severance Period</I></B>&#148;); (ii) the date when Executive becomes eligible for
substantially equivalent health insurance coverage in connection with new employment or self-employment; or (iii)&nbsp;the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period
from the termination date through the earlier of (i)-(iii), (the &#147;<B><I>COBRA Payment Period</I></B>&#148;). Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on Executive&#146;s behalf
would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of paying COBRA premiums pursuant
to this Section, the Company shall pay Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, subject to applicable tax withholding, for the remainder of
the COBRA Payment Period. Nothing in this Agreement shall deprive Executive of his rights under COBRA or ERISA for benefits under plans and policies arising under his employment by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>&nbsp;&nbsp;&nbsp;&nbsp;Executive will be paid all of the Accrued Obligations (as defined in Section&nbsp;6.1(d) below) on the
Company&#146;s first payroll date after Executive&#146;s date of termination from employment or earlier if required by law. If eligible to receive the Severance Benefits pursuant to Section&nbsp;6.1(b) of this Agreement, Executive will only receive
such Severance Benefits if: (i)&nbsp;within the time period provided in the separation agreement (which shall be no longer than 60 days following the date of Executive&#146;s Separation from Service), Executive has signed and delivered to the
Company a separation agreement that includes, among other terms, an effective general release of claims in favor of the Company and its affiliates and representatives, in the form presented by the Company (the &#147;<B><I>Release</I></B>&#148;),
which cannot be revoked in whole or part by such date (the date that the Release can no longer be revoked is referred to as the &#147;<B><I>Release Effective Date</I></B>&#148;); and (ii)&nbsp;if Executive holds any other positions with the Company,
he resigns such position(s) to be effective no later than the date of Executive&#146;s termination date (or such other date as requested by the Board); (iii) Executive returns all Company property; (iv)&nbsp;Executive complies with his
post-termination obligations under this Agreement and the Confidential Information Agreement; and (v)&nbsp;Executive complies with the terms of the Release, including, without limitation, any
<FONT STYLE="white-space:nowrap">non-disparagement,</FONT> confidentiality and cooperation provisions contained in Release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)
</B>&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, &#147;<B><I>Accrued Obligations</I></B>&#148; are (i)&nbsp;Executive&#146;s accrued but unpaid salary through the date of termination, (ii)&nbsp;any unreimbursed business expenses incurred
by Executive payable in accordance with the Company&#146;s standard expense reimbursement policies, and (iii)&nbsp;benefits owed to Executive under any qualified retirement plan or health and welfare benefit plan in which Executive was a participant
in accordance with applicable law and the provisions of such plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>&nbsp;&nbsp;&nbsp;&nbsp;The Severance Benefits provided to Executive pursuant to
this Section&nbsp;6.1 are in lieu of, and not in addition to, any benefits to which Executive may otherwise be entitled under any Company severance plan, policy or program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>&nbsp;&nbsp;&nbsp;&nbsp;Any damages caused by the termination of Executive&#146;s employment without Cause would be difficult to
ascertain; therefore, the Severance Benefits for which Executive is eligible pursuant to Section&nbsp;6.1(b) above in exchange for the Release is agreed to by the parties as liquidated damages, to serve as full compensation, and not a penalty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(g) </B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Good Reason</I></B>&#148; for purposes of this Agreement shall mean the occurrence of any of
the following conditions without Executive&#146;s consent, after Executive&#146;s provision of written notice to the Company of the existence of such condition (which notice must be provided as described in Section&nbsp;7.1 within thirty
(30)&nbsp;days of the initial existence of the condition and must specify the particular condition in reasonable detail), provided that the Company has not first provided notice to Executive of its intent to terminate Executive&#146;s employment:
(i)&nbsp;a material reduction in Executive&#146;s duties, responsibilities or authorities, provided, however, that neither the conversation of the Company to a subsidiary, division or unit of an acquiring entity, or Executive&#146;s reporting
relationships following a Change in Control, nor a change in title, will be deemed a &#147;material reduction&#148; in and of itself or material adverse alteration in, Executive&#146;s position, title, duties, or responsibilities; (ii)&nbsp;a
material (greater than 10%) reduction by the Company of Executive&#146;s Base Salary (except in the case of either an across the board reduction in salaries or a temporary reduction due to financial exigency); or (iii)&nbsp;the relocation of
Executive&#146;s principal place of employment by fifty (50)&nbsp;or more miles from Executive&#146;s then-current principal place of employment. Notwithstanding the foregoing, Good Reason shall only exist if the Company is provided a thirty
(30)&nbsp;day period to cure the event or condition giving rise to Good Reason, and it fails to do so within that cure period (and, additionally, Executive must resign for such Good Reason condition by giving notice as described in Section&nbsp;7.1
within thirty (30)&nbsp;days after the period for curing the violation or condition has ended). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.2
&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Company for Cause</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have the
right to terminate Executive&#146;s employment with the Company at any time for Cause by giving notice as described in Section&nbsp;7.1 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;Cause&#148; for purposes of this Agreement shall mean that the Company has determined in its sole
discretion that Executive has engaged in any of the following: (i)&nbsp;a material breach of any covenant or condition under this Agreement or any other agreement between the Company and Executive; (ii)&nbsp;any act constituting dishonesty, fraud,
immoral or disreputable conduct; (iii)&nbsp;any conduct which constitutes a felony under applicable law; (iv)&nbsp;violation of any Company policy or any act of misconduct; (v)&nbsp;refusal to follow or implement a clear and reasonable directive of
Company; (vi)&nbsp;negligence or incompetence in the performance of Executive&#146;s duties or failure to perform such duties in a manner satisfactory to the Company after the expiration of ten (10)&nbsp;days without cure after written notice of
such failure; (vii)&nbsp;failure to pass to the satisfaction of the Company, a preliminary background check or failure to submit proof of legal eligibility to work in the United States; or (viii)&nbsp;breach of fiduciary duty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp; </B>In the event Executive&#146;s employment is terminated
at any time for Cause, Executive will not receive Severance Benefits, or any other compensation or benefits, except that, pursuant to the Company&#146;s standard payroll policies, the Company shall provide to Executive the Accrued Obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.3&nbsp;&nbsp;&nbsp;&nbsp; <U>Resignation by Executive (other than for Good Reason)</U>.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp; </B>Executive may resign from Executive&#146;s employment with the Company at any time by giving notice as
described in Section&nbsp;7.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp; </B>In the event Executive resigns from Executive&#146;s employment with
the Company (other than for Good Reason), Executive will not receive Severance Benefits, or any other compensation or benefits, except that, pursuant to the Company&#146;s standard payroll policies, the Company shall provide to Executive the Accrued
Obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.4&nbsp;&nbsp;&nbsp;&nbsp; <U>Termination by Virtue of Death or Disability of Executive</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp; </B>In the event of Executive&#146;s death while employed pursuant to this Agreement, all obligations of the
parties hereunder shall terminate immediately, and the Company shall, pursuant to the Company&#146;s standard payroll policies, provide to Executive&#146;s legal representatives Executive&#146;s accrued but unpaid salary through the date of death
together with all compensation and benefits payable to Executive based on his participation in any compensation or benefit plan, program or arrangement through the date of termination. <B><I></I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp; </B>Subject to applicable state and federal law, the Company shall at all times have the right, upon written
notice to Executive, to terminate this Agreement based on Executive&#146;s Disability (as defined below). Termination by the Company of Executive&#146;s employment based on &#147;<B><I>Disability</I></B>&#148; shall mean termination because
Executive is unable due to a physical or mental condition to perform the essential functions of Executive&#146;s position with or without reasonable accommodation for one hundred twenty (120)&nbsp;consecutive calendar days or six (6)&nbsp;months in
the aggregate during any twelve (12)&nbsp;month period or based on the written certification by two licensed physicians of the likely continuation of such condition for such period. This definition shall be interpreted and applied consistent with
the Americans with Disabilities Act, the Family and Medical Leave Act, and other applicable law. In the event Executive&#146;s employment is terminated based on Executive&#146;s Disability, Executive will not receive the Severance Benefits, or any
other severance compensation or benefit, except that, pursuant to the Company&#146;s standard payroll policies, the Company shall pay to Executive the accrued but unpaid salary of Executive through the date of termination, together with all
compensation and benefits payable to Executive based on his participation in any compensation or benefit plan, program or arrangement through the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.5&nbsp;&nbsp;&nbsp;&nbsp; <U>[RESERVED]</U></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.6&nbsp;&nbsp;&nbsp;&nbsp; <U>Notice; Effective Date of Termination</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp; </B>Termination of Executive&#146;s employment pursuant to this Agreement shall be effective on the earliest
of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp; </B>immediately after the Company gives notice to Executive of Executive&#146;s termination, with or
without Cause, unless pursuant to Section&nbsp;6.2(b)(vi) in which case ten (10)&nbsp;days after notice if not cured or unless the Company specifies a later date, in which case, termination shall be effective as of such later date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp; </B>immediately upon Executive&#146;s death; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp; </B>ten (10)&nbsp;days after the Company gives notice to Executive of Executive&#146;s termination on
account of Executive&#146;s Disability, unless the Company specifies a later date, in which case, termination shall be effective as of such later date, <I>provided</I> that Executive has not returned to the full time performance of Executive&#146;s
duties prior to such date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp; </B>ten (10)&nbsp;days after Executive gives written notice to the Company of
Executive&#146;s resignation, <I>provided </I>that the Company may set a termination date at any time between the date of notice and the date of resignation, in which case Executive&#146;s resignation shall be effective as of such other date.
Executive will receive compensation through any required notice period; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:2%; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp; </B>for a
termination for Good Reason, immediately upon Executive&#146;s full satisfaction of the requirements of Section&nbsp;6.1(g). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp; </B>In the event notice of a termination under subsections (a)(i) and (iii)&nbsp;is given orally, at the other
party&#146;s request, the party giving notice must provide written confirmation of such notice within five (5)&nbsp;business days of the request in compliance with the requirement of Section&nbsp;7.1 below. In the event of a termination for Cause,
written confirmation shall specify the subsection(s) of the definition of Cause relied on to support the decision to terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.7&nbsp;&nbsp;&nbsp;&nbsp; <U>Cooperation With Company After Termination of Employment</U></B>. Following termination of Executive&#146;s
employment for any reason, Executive shall fully cooperate with the Company in all matters relating to the winding up of Executive&#146;s pending work including, but not limited to, any litigation in which the Company is involved, and the orderly
transfer of any such pending work to such other employees as may be designated by the Company. The Company will reimburse Executive for reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses
Executive incurs in connection with any such cooperation (excluding forgone wages, salary, or other compensation) and will make reasonable efforts to accommodate Executive&#146;s scheduling needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.8&nbsp;&nbsp;&nbsp;&nbsp; <U>Application of Section 409A</U></B>. It is intended that all of the benefits and payments under this
Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section&nbsp;409A of the Code provided under Treasury Regulations <FONT STYLE="white-space:nowrap">1.409A-1(b)(4),</FONT>
<FONT STYLE="white-space:nowrap">1.409A-1(b)(5)</FONT> and <FONT STYLE="white-space:nowrap">1.409A-1(b)(9),</FONT> and this Agreement will be construed to the greatest extent possible as consistent with those provisions. If not so exempt, this
Agreement (and any definitions hereunder) will be construed in a manner that complies with Section&nbsp;409A of the Code, and incorporates by reference all required definitions and payment terms. For purposes of Section&nbsp;409A of the Code
(including, without limitation, for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT> Executive&#146;s right to receive any installment payments under this Agreement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(whether severance payments, reimbursements or otherwise) will be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder will at all
times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of his Separation from Service to be a &#147;specified employee&#148; for
purposes of Section&nbsp;409A(a)(2)(B)(i) of the Code, and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be &#147;deferred compensation&#148;, then if delayed
commencement of any portion of such payments is required to avoid a prohibited distribution under Section&nbsp;409A(a)(2)(B)(i) of the Code and the related adverse taxation under Section&nbsp;409A of the Code, the timing of the payments upon a
Separation from Service will be delayed as follows: on the earlier to occur of (i)&nbsp;the date that is six months and one day after the effective date of Executive&#146;s Separation from Service, and (ii)&nbsp;the date of Executive&#146;s death
(such earlier date, the &#147;<B><I>Delayed Initial Payment Date</I></B>&#148;), the Company will (A)&nbsp;pay to Executive a lump sum amount equal to the sum of the payments upon Separation from Service that Executive would otherwise have received
through the Delayed Initial Payment Date if the commencement of the payments had not been delayed pursuant to this paragraph, and (B)&nbsp;commence paying the balance of the payments in accordance with the applicable payment schedules set forth
above. No interest will be due on any amounts so deferred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.&nbsp;&nbsp;&nbsp;&nbsp; <U>G<SMALL>ENERAL</SMALL>
P<SMALL>ROVISIONS</SMALL></U><SMALL></SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1&nbsp;&nbsp;&nbsp;&nbsp; <U>Notices</U></B>. Any notices required hereunder to be
in writing shall be deemed effectively given: (a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;when sent by electronic mail or confirmed facsimile if sent during normal business hours of the recipient, and if not, then on the
next business day, (c)&nbsp;five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d)&nbsp;one (1) day after deposit with a nationally recognized overnight courier, specifying next day
delivery, with written verification of receipt. All communications shall be sent to the Company at its primary office location and to Executive at Executive&#146;s address as listed on the Company payroll or to Executive&#146;s Company-issued email
address or Executive&#146;s email address as listed in Company records, or at such other address as the Company or Executive may designate by ten (10)&nbsp;days advance written notice to the other. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2&nbsp;&nbsp;&nbsp;&nbsp; <U>Severability</U></B>. Whenever possible, each provision of this Agreement will be interpreted in such manner
as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or
unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.3&nbsp;&nbsp;&nbsp;&nbsp; <U>Survival</U></B>. Provisions of this Agreement which by their terms must survive the termination of
this Agreement in order to effectuate the intent of the parties will survive any such termination, whether by expiration of the term, termination of Executive&#146;s employment, or otherwise, for such period as may be appropriate under the
circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4&nbsp;&nbsp;&nbsp;&nbsp; <U>Waiver</U></B>. If either party should waive any breach of
any provisions of this Agreement, it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5&nbsp;&nbsp;&nbsp;&nbsp; <U>Complete Agreement</U></B>. This Agreement constitutes the entire agreement between Executive and the
Company with regard to the subject matter hereof. This Agreement is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter and supersedes any prior oral discussions or written communications and
agreements. This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in writing signed by Executive and an authorized officer of the
Company. The parties have entered into a separate Confidential Information Agreement and have or may enter into separate agreements related to equity. These separate agreements govern other aspects of the relationship between the parties, have or
may have provisions that survive termination of Executive&#146;s employment under this Agreement, may be amended or superseded by the parties without regard to this Agreement and are enforceable according to their terms without regard to the
enforcement provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.6&nbsp;&nbsp;&nbsp;&nbsp; <U>Counterparts</U></B>. This Agreement may be executed in
separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.7&nbsp;&nbsp;&nbsp;&nbsp; <U>Headings</U></B>. The headings of the sections hereof are inserted for convenience only and shall not be
deemed to constitute a part hereof nor to affect the meaning thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.8&nbsp;&nbsp;&nbsp;&nbsp; <U>Successors and Assigns</U></B>.
The Company shall assign this Agreement and its rights and obligations hereunder in whole, but not in part, to any Company or other entity with or into which the Company may hereafter merge or consolidate or to which the Company may transfer all or
substantially all of its assets, if in any such case said Company or other entity shall by operation of law or expressly in writing assume all obligations of the Company hereunder as fully as if it had been originally made a party hereto, but may
not otherwise assign this Agreement or its rights and obligations hereunder. Executive may not assign or transfer this Agreement or any rights or obligations hereunder, other than to Executive&#146;s estate upon Executive&#146;s death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.9&nbsp;&nbsp;&nbsp;&nbsp; <U>Choice of Law</U></B>. All questions concerning the construction, validity and interpretation of this
Agreement will be governed by the law of the State of Indiana. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.10&nbsp;&nbsp;&nbsp;&nbsp; <U>Resolution of Disputes</U>. </B>The
parties recognize that litigation in federal or state courts or before federal or state administrative agencies of disputes arising out of Executive&#146;s employment with the Company or out of this Agreement, or Executive&#146;s termination of
employment or termination of this Agreement, may not be in the best interests of either Executive or the Company, and may result in unnecessary costs, delays, complexities, and uncertainty. The parties agree that any dispute between the parties
arising out of or relating to the negotiation, execution, performance or termination of this Agreement or Executive&#146;s employment, including, but not limited to, any claim arising out of this Agreement, claims under Title VII of the Civil Rights
Act of 1964, as amended, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, Section&nbsp;1981 of the Civil </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Rights Act of 1966, as amended, the Family Medical Leave Act, the Executive Retirement Income Security Act, and any similar federal, state or local law, statute, regulation, or any common law
doctrine, whether that dispute arises during or after employment, shall be settled by binding arbitration in accordance with the Employment Arbitration Rules and Mediation Procedures of the American Arbitration Association; <I>provided however,</I>
that this dispute resolution provision shall not apply to any separate agreements between the parties that do not themselves specify arbitration as an exclusive remedy. The location for the arbitration shall be the Charlottesville, Virginia area.
Any award made by such panel shall be final, binding and conclusive on the parties for all purposes, and judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. The arbitrators&#146; fees and
expenses and all administrative fees and expenses associated with the filing of the arbitration shall be borne by the Company; <I>provided however</I>, that at Executive&#146;s option, Executive may voluntarily pay up to <FONT
STYLE="white-space:nowrap">one-half</FONT> the costs and fees. The parties acknowledge and agree that their obligations to arbitrate under this Section survive the termination of this Agreement and continue after the termination of the employment
relationship between Executive and the Company. The parties each further agree that the arbitration provisions of this Agreement shall provide each party with its <B>exclusive remedy</B>, and each party expressly waives any right it might have to
seek redress in any other forum, except as otherwise expressly provided in this Agreement. By election arbitration as the means for final settlement of all claims, <B>the parties hereby waive their respective rights to, and agree not to, sue each
other in any action in a Federal, State or local court with respect to such claims, but may seek to enforce in court an arbitration award rendered pursuant to this Agreement. The parties specifically agree to waive their respective rights to a trial
by jury, and further agree that no demand, request or motion will be made for trial by jury</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE FOLLOWS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties have executed this Employment Agreement on the day and year written below effective as of the Effective Date (as defined herein). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Acumen Pharmaceuticals, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel J. O&#146;Connell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Daniel J. O&#146;Connell,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>President and Chief Executive Officer</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Executive</B>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Russell Barton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Russell Barton</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;January&nbsp;21, 2021</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Date</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g104413g00q15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g00q15.jpg
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M(6#EY+D='QLJ_)9$:%2MZ>4^GVCUQZ^NHYAU[]._3^.W7ZCC7W8NL?50Y$U
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M1]O[-,GT/V?MT]XD/ZJSWZ16/\1\8'J/M_9ID^A^S]NGO$A_56>_2*Q_B/C
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M36I]!UZE7)H</9=!A&V)BTTBZ.D'V*'MMEK;C >(^M1X%BE2GYP1GMUQW)]
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M*89&*2\C @<9VYF)T[:->C['5:/%06H(+8U:V87.Q,P8#%VF,F7TVN;UZ>@
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M:.S/'%%-82 MX:S2Q001R2JH=TAC5B0B@0J;VO7X/:5)U&X#,G6:[P\_/#D
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MN?/L #TURU7=TFNIY/D8PNS3)EC<@JXP .S'E3+BPT&^64,RAU(^8Y3K(AI
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M3W\..OX<WIN(-HJ[H^W7]IDG\1)MOW*+PK5::&1H98W'Y+H'1C'*GS)4Y77
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MN$/@4,07"&FL#"CCX;9QG#+>&6D-X0UC.,9PTC"?"WC.,9PG&.^,?9SU=1@
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M58LP_754F(\8YB6\1Q-@927E4]+MQV6FVT##M.L9PEX?#:T925E*,H*PS D
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MN!E5DIJTJEVPA]$VC\&'%.[I.166C-5=Q8IWX[<-V*+Y,L;E5M-76J[&I?\
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M4T*;%FCOCDCCU9C#H@L8='.*0U@IO 3)@N5YPDM>1W7$I&>:??JC4 ! .8
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M@R/+2EHX%[RVY: E$M-N%P<Z$AQQ0,H%EU.'6LK6R^TIDT%\H D4I[$V'?\
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M))#S7E@M>U1""K!6@2LSR1UWGD,DA=HV'( P*[>[2)B1=<W5<]69VY0C];E
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MXBJU>(ZG#EJ*6O-N.WR7=LNR%!5OS5Y62WMT)YN?VVM"8K31L!XE>0M&28W
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MJ058!@00#K7+IWU=<-51.U:ZZWF&JKVP; 3J2N&SSEG9@JLH=IL$C!JU+($
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M)#D4U-^W.#2A44*40\[D=@G"FO/?6RGQN+2O$MQV#7M-0]ECW%ZSI6FM1/)
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ME7991B#N<?'+6AAAI/A1&3H@2'/3$,H0A#!"$9P^GMG.5_?'&,4*D@RF5D)
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MCK KIA3@[2D-+)?4C+J]D,X',03@9(& 3CJ0,G )[#)QZG6L.,GE! R< G)
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M'>011!R1'$)))'$: )SN[8RS$Z;1/2';H-I5<A>IS;M<UT >6;5ZK5UB0\O
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M);?9?$?>=RC"V\H=P3XWG$"LL.J,'FQX)Z@!<#)'3SSW^.21Z==20\G^JR6
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M1W(F=@@/B()",B-Y(WCCD/NC=E<GR )\M0^Z;KL6P'M1ZWZ;Y*OPI6XJ#([
M%V7.")>CJ5KJ(7# D/UVM*PVS.W;#\T,&% $+0)"N#//S+&!&G%,6Y++RFO#
M39 ;,33"9AE8X4Y 2B=.>3,B@(2 O4MVY3<BK1Q"S-=5V%6983 A :6=^<A7
M?KR1 1L6< LW0(03S#$7;5-CU/K2IZBTL1;?>MS[/$A]L;H=;+L%T "G8Z1D
M;ML27D6F'\"S<D)$H@(:1>;%B:^\>%@=X%UD1_D20/!"D%8R<]B8+/9/SY0&
M5FEG9L8YR$"(<!4++@ *!J8["SSO8LB,I6@+5ZW1(B595B@5?S%9_$=0>9PK
MY)+$ZVUH-$J^L:;7J%2XQN(K-8CT1T4"A2G%);PM;SY!#Z\Y<)-.+=?./+=R
MIXLT@@EU67'59SFQ1)#&D4:\J(H51WP!ZD]22>I)R222223K!EE>:1Y9&+.[
M%F8^9] !T  P% P%     U)C30XX,J0D"AP0 1WBS33'FQA!!1VU/$$DD/*0
MTPPPTA;CSSJTMMMI4M:L)QG.*R0 22  ,DGH !W)/D!J@ D@ $DD  #))/0
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MQWR,^I\^V>UV1PZ\R#YH+*YP 1C)&.I^\=!Y]M;%0DI)A5N8G]FPK0D73[/
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MIBJB,QL"VA)MG9(S&IR<ZC"QXY$!DJ?<;+>:4DIT=^;:) #<8>,9;44&V1+
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M:K#8D$R#SK[I);Y>PP')!Y3SJB'61W5NN9PE7-3^&&U&UCA^C#R+%#3LVD1
M%7P[,D,46$  50M5@@   ) &LS@:%A'N=A\EWGAA);J>:)9'?+=223,"W4Y(
M!U_5OSQC7>Z<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<
M::<::<::C5KML)38I4M-D+0VIU H08S2B9*6D'\^$6,B06_OQQY2_N&6&L?#
M[IQU33"''42!G^.WO.H) &3JL44:Q[!P18[X[B&)]&9BD5)&$G@4TLD5Y@.Q
M3;27&69VU#9=0^VA3J HO*5-!Y22M1+,Y [=>V3Z^X>@U3RDYYOH'D/?[S_'
MPM:L0 =5KL)6P/B)"1@<:RO*<(4]@1A#2R'$XRK&'27$K(>^Z5W=<7GOGOWS
M!.23ZZJ P /36=Y&IUY][=^3[H&QK+<+I6YAC6=H.A 6: =1:Z+57*5:&R90
MN=LD@96#88NWJLSTCC!K,OX2X]+;N(^10A_+2.<L;"Q;<9-NMQ[=+:K8I"&C
M76*CN+/9EFW%U@-:6\]J2:%YX+,QC8U\J5::4MTE?B!!'ML.X4Y-QBJ6^>ZT
MM^R9K^W*E6.#;4:;VB&A'5C@E6":M"'Q8*R!TBB5<3O+IKA$3NKPJDQ*Q\Q/
MPEOKIS5;J9[U>LETCJ@V?5YJYSC+LG%:Z@<RL85B6-'@#2YI<JMCSDOL>M:P
M-\VD26-O$"8>=+\,B049A'9O>QF6G-<W"OXL6U5UEAD62::G:]HDFBA4\X5)
M;VS6X1#N+SL8UAEH6%D:_766"D;J0W(:FWV!$^[6GBF0I#%;J^#'#+,WS"S1
MZ1;/Z1.H.">;O^NX^/NTW!T>L#3:::\'*0UBLYMKQ"V;7047B3?F'54MUQZ;
M,LI#<:VY',O#J%"+&4AO3CA[<\&(1P.B4(9YIHI5DBDW)GE2U0K,9(Y3[.8U
M<69JT<<BRA>1)5=5VC;MMBQ/_+2_RNY6(XH)X9(K,>W&..2M?F"*]9?: Y4U
MX[$[QLA;G>,QNU%1/3GU)2\[%;JBM=1%MG%72S:XF]>5F7;)F:9+UF.+"DB+
M=)>>]7X%S# ZQF'SI?*'$%1O9G"Y,9O&NK4+MFM5$5*8O)NMO;K,4=BM8%)J
M1LF5[Y@RL$;>RA(Y%LO*TMFJCUHC(WA[6=J-4V('OPQQ0;73W>O)8CFB^44N
M>R^%#1#(DEB8BR3)&(HXHXX+4B69EA'B73JRIV/9-1,V1>8<356CQPY/W;:-
MM.AYJ"\\23$@601804\0Z68D)HA^)2>TIL!DH5;:UN*<PCBG05XZVZ6;-2+8
MC#<FM[NMR#P(9*MN&O!7922)4MF2POCQ21BM)4Y'5VF4#'GCF@GM;7 +-CB
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MJ ^3C'V_QG6P?*-5ZBQU/A3;+%VWRWQ)V+8)"46"]Z?$I&DLK;5%S3>$*1)
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MK[$ZO=#GQ)LT#99\P024J<6*P-KW83TK8,WPV2C:3)U&%16,RUO@+7(PTJ#
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ME>G8]J/J4=!6*),LW4G9[?&1K)6'IJFP.NBKM48S7D)79F,%K=>=B(,HBR@
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M7)4=5>A:A#V-ZQEDLK]OE??9QD?(\P^Q(R);4JIALA<9(Y'$=21VSCW:D'H
M>^,^_6G &HM]CKFKN!:;-$'V'JCL8P%8(CK[.LC5$?JON,C%[!M,/)6YF/7#
MAZY;C@JVS5P*I"$4$D%^=D)\'V9,1.1TZ>7_ (?AWSYG/7&-00?M'0?$=?\
M9T'?XZSQ,M;9VZ]-M\LE2O\ 6=G"IJLKN,ANK[2A::W4%4FXMSOM5B-EI76E
M"KT#.E$2]]I-L919K+Y-;&'.5+A524-CIU^SKZ??T['&.OU3Y_7Y?K\OU^6K
M6WB-.[XHW3Q(:I)EVX"]WV/LY,N6'L" &CZ3,Z/VM(Q$U; :U+4JXQ0C$X95
M2 @R9BO/-VM5>%(*$+4SVD=,_#W>H[=QVS]&AZC_ '_'XC]7V:I0.IWJ"VE9
M(2.7OJQ[;B]SZ%8KNR3Q-DQNLYW3$%J?I^C=KR]KF'LC:5EQ)Y<7M])58%<D
M[9C8,B@Z'C8^3;"G '0CR P?3.<G'O\ 3W8T/?IG/3S.,>?GCMJ%S\?N:]:Y
MTUKZ$C]M1ULUYJ.JZUV](6"I[0"AUWTS>?2G&&2#DDDNGN;1BTUBF;8G)B?H
MMO>:31W)4HFVP(]I%,*# [X]1VSV/QQY=_/R.GNQ]G08./3ZO=U[:MBQ@]1%
M&N6LTU"%E+#KS008CE_151+' 16TG+V>^W;VZ]3+58=BW&VJUG0B&)^L#Q]U
MFG):_&EP"2EOQ[D4$Z8/J>W;I]/3&3[NWT:=?J[^_P"CJ?M&K?WKJH+;U\HM
M6Q#68-"6AIR\;!CINWP <31Z]+^M&I,*3$2D?%%VV_33RXPIQMD@^"H[-IDG
M3(J6=I:S('3/;W= ?O';]?P.)_C/\?[O760VO/7PT6JUENHV"$E3]^:M17B*
MBNP68*4U]4=FU"PVN=M<U!U\6&H4>7309?),-:)1IB392_"@ERY;_HEAC[#W
M]2#C'7KU\_NU!\OB/LZG/W>_6NSV^>L*:K2Y&NZM5$2T!IDB>L8E@TSL;"Y3
M=U2UV58[5KZM!&ST$2? 3=T]LJU6LD4J?BIMA^0;JTQ8S&,&#3A?,^?3J.Q\
MS^O[<:@D^7EU)QWQCH/>?]W;5O=2LG(%:^DL7#4U\L;XUX>A=?U_7)VSK6#.
M*/!/BXB_;&'U!6WK3 5:N#ED60L!(LV7&R8$<_ -R=N8KV&P[]_+)SCZ0,GK
MGM[_ $U)^&>WW_J[ZE-(K-FBMLZVDB9*Z66-QTRYK]EMTZ)8HD:P6F)L-%7%
M24]7I/+0D!<904FRR9$>4$'.LX)DQ3$JP&XAF#V/;O[O?Y^G;W:??CW_ .W]
MI]^-;/<C4Z<::@MKUCKZ].DOW"H0=C>+@EUI]V5";*<5!KF(VP^@2M?W33;4
M]#1,R,ZUE! DG&A'#.LDC-.)G)';^._[=00#W^'\?5J*N=/.CG7H,EW55(>?
MK=8EZ7#.NP(3JQ:I/"R84S +RXVKUD9)C3<TV8,=ZE#RIB6=5]^DC7'W,>O7
MOU_CT^C3E'IV&/H.OF)Z=]'P46Y"0^L*C'13N; IX$:,0AAYRUU<6EV5U['B
MRIUZ=JP0L)*ON*4Z:&SC#ZUN*6XID^I_CKIRCT]?MZ'7R5HW13\Q*X+U]2%3
MEPK9<5*CN@B).G:T"W7HR3PL/QI60*TT+58Z6/99\U;3$"'($K0@!O#)]3]9
M[G/W]?MU'*OH.O\ '3T^C72OM'Z=:_&2,OLV)UE 0TZ[; )*2NY4+#Q4D3L5
MZ)-MPKQ<X4,&Z59R*W#EFMX<]0^_#B$-82X*E:0SY9./I[=OJT(7SQUSW/KW
M^[4=<T/THF 4R+=H&I2XZ1)ECZ$"\S#$BS!,PF)G9TFMLN/K;F52K%?BY&84
M$DO!X0/FF^<&X1YK+=>I]_?R_P!^F%Z=![OL^ORZZDESU3IMVERK.WA:Y,U(
M.YSFR9&6OY( 47%34R7*LCG$2)#H 83,+#S>:G%/$/(RW",BAONO.Y6XX!.>
MG?&.GP_@_'KJ2!CKZY^D_P"_&N6%UOT^3L1-P%<K&LY:%L]6J/O,5 LP9@,A
M3& 2X2C.8&C5N-L5U(<)(!UA\1+$>M47(*C7%$"EK0R>G?IGZ_/_ &Z8!SVZ
MX_V?1TZ:_*W7.GS88SQ518UI>A:YM!=^)+KDC"6=N"VZ(X@IZP$%QA9WMMP9
M4M#I"G763DI=^_-^6[G"G4=\]L=?3]FF![N^?I[_ +/H]VL_3]+:KH$A9I6F
MT>#K\E<UDN6LT%EW!-@=-?=*,?E777G5%D%DOO/DD.YR\^ZXM;KBLY[\$D@
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M\+?X^Y_EVGRNW_%.\?X6+_S.HM4^LR%H()<91?DRNNREQIY[\J='U/IQU'7
M3)0K"$DR18D/M\-@@\A+;>'S'FUD/8;1AQQ6$I[7I]A>RRO9XNX<L.JA%:?=
M+\K*BYY45I*#$*,G"@X&3@:MQ[DD(*Q;)ND2EBQ6.E @+'NQ"V "Q\R>I\]2
MGZP6=_T??RBO[$==?^-7+/XL1?\ *?A;_'W/\NU<^5V_XIWC_"Q?^9T^L%G?
M]'W\HK^Q'77_ (U<?BQ%_P I^%O\?<_R[3Y7;_BG>/\ "Q?^9U^*^4#FUXRE
M?R?/RBBDY^U*M(:Y5C/;/?'?&=U9QGMG&,_GQWY(X9C!R.*.%@?4;A<!_P#I
MVGRLW_%&\?X6+_S.OWZP6=_T??RBO[$==?\ C5R/Q8B_Y3\+?X^Y_EVGRNW_
M !3O'^%B_P#,Z?6"SO\ H^_E%?V(ZZ_\:N/Q8B_Y3\+?X^Y_EVGRNW_%.\?X
M6+_S.GU@L[_H^_E%?V(ZZ_\ &KC\6(O^4_"W^/N?Y=I\KM_Q3O'^%B_\SKJB
M]?$@"EY(7R>'RA8:22B#B$BZ)UH.E\TMS+Q9CV&=SHPZ44\I3I!"\*=><5E;
MBU*SG/*5X6@7(7B7A1069CRWK8RS'+,<;<,LQZL3U)ZDYU W4KGEV?=UR2QQ
M4A&68Y9CBQU)/4GN3U.NU]8+._Z/OY17]B.NO_&KE7XL1?\ *?A;_'W/\NU/
MRNW_ !3O'^%B_P#,Z9^4#LB\90+\GM\HD^2K&4L,.:;U>"V\]G'9MM9A^\!@
MA4+7V2H@M]D=G&<N.N(0G.</Q9A\^*.%@/,B]=8@>9Y5VTLV!Y*"3V )T^5W
M\MHW@GR'LT(^TV0!\2=9WI?U;NFR;IVIUA]1]5CM97W8E)J&G]6:3C[#'6TW
M46E:9-3]JRU=K5!J579O8]_N5D.L%E9KKTE!UV,C*U  3<N\(<3RWO%S;XMO
MI;%M4SVZU6Q/?N[@T3P+=W"Q'%#FO#)_*QU*U>%8H3*$DE=YI6CC#*NJJ->T
M]JQN-V-8)IHHZT%9760UZL3O)_*R)\QII9'+N$+(@5%5VP3K?CG-:VVG&FG&
MFG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&
MFG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&
MFG&FOG*T8^U2<?G5C'_?QIKXR^SC[7FL?G<1C_KSQJ,CU'UC7QDL3'VE#X_.
M\WC_ /ER<'T/U:9'J/K&ND_.P@W?U$O&,=OM\TX9OM^?Q.XY4(W/9'/P4G[A
MID?'X=?NUAW[]1Q?]LW"LL=OM\V;CF^WX>_B(QV[=OCRL5K#?DP3'X1.?N75
M6&_-8_!6/W#6%?W#J@7OZG9-'8[=^_FVB&;[=OM_G&8Y=%"\WY-.TWGT@E/W
M+]7KY:D)(>T<ASVQ&_[NL,_U Z/'[^9MG7^<X[]\-6J'>S\/Z.S1:\]_[/M_
M#RZ-JW,]MON?X>4?>NI\*4_\%+_=N/O76'?ZG=!C]_'M&JK[?Y@_!/?\WD)<
M[_W<N#9=U;M0LCXQE?OQJ?!F/:*3S_FX^_&L*_U==/(_?Q[&CU]O\P!,$?\
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M4@:3W]-JAQW\'GVU+'?\_EP!';^[OV_MY<'!K>=]1\*Y/3Z9E\]3[ WG*O\
M=D_^,:PS_P H_-J[^FU3&-?@\ZVDO]OS^&OL=_\ GQ_W<N#@U//<&/PK ?\
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M[/\ ^36&?^4?FE=_3:IC&OP>=;27^WY_#7V._P#JY<'!J>>X,?A6 ^^=M3[
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M/]VL,1UM=0SW?P6N.&[_ &>GKT/\/S>>,_\ Z^__ %\NKPQM [PR-_TII/\
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MG^)[CY?K_P!K?XK;/\HT\:W_ $P_NT_<T^B9M[\<],O[+=\_Q/<?+]?^UO\
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M*%&%C"&'NK: $!>C$*(*Y-2K1L4MIH6H99$GW+=8(7CF\,P<IR)".1C*P*H
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M[;7N7?8"\S7)]GI34)9[$C@6$A$KUV+EOY.6,,$':+ER!DG4AV4<P_)$C!@
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M$A81E793V$HSC/.7VW:J=B:@);\$K6)XHYJ*"5+"*Y(8%RH4%,?.P?AJ\\C
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M/6XE8]E+L@@5V#)PTW,1D9GC;:U"AN@KUK/SMC5CN+R<U:V9Q%*ZQ)R@*8V
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M0?D(=2F!,E..Y&95EIGP(SE/*"[LJ(SLR1Y"*6)5 QRP12<+S'J< 9/4]=,
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M)820SXE>4\E&'&_$KP*QWSR(Y986YHI)(F((+1NR,0>XRI!P?,9QH0#W /Q
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M 1*3=(UW<[7$1[J%NLER5?KTA*!-$-MJ2ZX-D@5O)*&E8=4QAQ+>?'E/,NA
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M4_DT-XO[<DD5:5?!E(9X98HYHBX  <)(K!7  &5QG"\V>48AHU<Y(ZCS'?\
MCO\ 6=12U=#G3C;HBE0<A49D *B5)>OXE<#=[E"2$C0GBEGE4RRR@$VU)62O
M%G./%O!RY13B'R2EC/L8)?PY>AW_ '.!YY%FC9K$PL/XE>"15L !5GB1HRD4
MBJ H9 !@#(/*,1X28'0C"\N02#R^A([^[6O/4YT'2^WK7DRA1FF8.N$:JCM6
M!ORW\I%=L%0CHSPB1SX\;39C%1OP4$ E#M9B;5%Q_M$B-'J4>6'&!CM[+:N(
M4I0\MAKTDHN-<8)[+)',S_.8%YD\:NTC9$KPNW.A8<H+L=4/%DCEY0  !W&
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MV@V>?D7E\9F+EN0CEP6)^;C'D!JKE'+R]<8Q[\:K#8O1GH#:1]>D;;5Y9PJ
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MNZ>./S3]8T^NPT[^1O9?ZRJW[]Q^(EW^O5?T)?W=/''YI^L:?78:=_(WLO\
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M/"\HR7M[KRLU5_#5*51NJ^T?.=Y;$\9^="C1QQJV';G*J-4%S*,#YJ]"1W+
M^1\@/7OZ>_7LX**,"*,$$.R(&&PR*(*,TA@<88=M++ X[+:4MLLLM(0VTTVE
C*&T)2A*<)QC'.')+$LQ+,Q)9B2223DDD]22>I)ZDZJU__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g104413g03a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g03a03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1U(4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0&+            *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M  !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O
M;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L
M;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14
M;W!L;VYG       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F
M       .             #^    X0DE-! T       0   !:.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@             !SP   FD          0
M   !              )I   !SP                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   !SP    !29VAT;&]N9P   FD    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   <\     4F=H=&QO;F<   )I     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    (.$))300,     !*A     0   *    !X
M   !X   X0   !*% !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" !X * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
M/P#(ZO\ 61U'5NITW?;'"K-R6>I3EV5'VWY&UO\ ..K:STG4UL_0^ST%FYWU
MCR;O1&%D9^,6!XN+LNUQL+G;J7_SKO=6W=_X'7_@_7N)DC';]<.L9&2^ME6)
ME9MP;:"YMEHMLKPZ74-W/R6.R[:K+Z=O]&KN6=U6G$HZC>W!>VS#>1;BN:9
MKM OKJ<WZ3;,??Z%M;O?6^I!3+]M=;'/4LS_ -B;M/\ P5-^V^M_^6>9_P"Q
M-W_I14SXC12C<)$GN? )(;8ZWUO<V>I9FKFB/M-W<C_A%N=5^LHHS\NJQV87
MU95]=E@R[ RR,BUT,K]1GV793^KL=7_@Z_\ A+%RVTAS#V+VP?'W-72X;L9O
MUEZZ;6L<\6W>DQSL=NX_;J_5;2_J0?B[OLWK^IZG^!_X/U$ET$=7UIJ;NKL9
MG6S#:G_;;VNYM]]C?M#F>I9OH_F_96^K_MW+'6NN >[J>63&L9-VA!_XW_JD
M',;0S-R6X[F/QVW6MILJ!V.9O=Z1JJL<^QM6S;Z>Y[_9^>@D"9 ('9!DK1M_
MMOK?_EGF?^Q-W_I1'P^M=;^VXS7=1S"#=4"TY%IT+V-<"/46?M+V[A)@^\GZ
M(_=1,1A;G8L\&^K:>Q'J,U"5J,:&SMY7UHR*<G*HR#D6BO(N'JMR[:7:76;?
MTC#]'9MJ]^]5<_ZS9F0VEN';F89KW^H[[7:\V!Q#JMSM^_=5[_I._P"#_P '
MZCYX_P#RAUGT#1^T?6?]C^T^D&[?M%GVWT/MGZK]L]+T_2]7_ ?:?1_2K(<Q
MUF1:'&MK@Y[G%FWTR0?<W']#]"YKO\#Z/Z'_ $?Z-$L)+8/6>NP2WJF;Y Y-
MO_DT'_G!U[_RSS/_ &(M_P#2BDZFIC8'N?SO'''T?W50L;M>1VY"0-J!MV.D
M==ZX_JV"QW4LMS79-+7-=D6D$&QC7!S?4^BKUWUKV/\ 1<,P!CG5V6#->7V%
MIL8Z_=8/T5VYWJ[*OT7LK];U*UA]%_Y9Z?\ ^&J/_/M:U.F^IZ?5/LIQ!F?:
M:O3^V''#/2]3+^T_\H_HO2W?9_7V?]0BN"1WULO=COKV9%=[@\,N9F70TN9Z
M=?M>]_\ ,V_K'_0_F[;5G'KG78)'4\WX?:;?_2B%U#[%^T<O]G_T'U[/LGTO
MYG<?1CU?TFW9]#U/TFQ '*"ZFS^WNO?^66;_ .Q%O_I17^@];ZV_KW2Z[.HY
M;V69N.U['7VEKFNM8'-<UUGT7+#(@J]]7O\ Q1=)_P##V-_Y]K16O__0XOZQ
M?^*/JP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME@"_+#D)I'>P+#E2.QOWW&GNWN?$:-Y-MM^#M8[=IF\Q?!-9P+G@7 O_ /C
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M/2VR914I9IJV9+ULQ7J^-4&8%(A#0I>&JHM,*RS29RY:H0.F9_\ &#YU.0<
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M"85;AH!V1C(':3;;%X'E02-+X3O.I#7)'EZ8Z?\ PG5FB$!@+G=M N;B^D7
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MO*_.6L7($\N5(ZK/S8M,F&23S1O^LIIJ^0^(UE$3> 8N.>"(MP?U0#;$\5[
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MD$F&PXU%!B=!3N:G L0KL(GCQ+#J;$4A>KH$DJH \<,K<:5+,DE'I7( ,$D
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MFH!53Q" ?#8>+RPU2 L:^00PT\:Q(U/,U3'/$"E2)"4*L\J[@1&,&.Q&BUP
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M9" Y9 A+$+=BI"DH-K*])B1!W$SSM,$1%X(.TC>.^7.TUIUF>G 2H-:BX(,
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M%88VZOVF.*K16BUJ>EO.RQJI$;.$4,4(!!76"26[=%FA4,05E29B+^6YOO\
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M>[ !+VM?43PI! 6YDF)V[=X)($&+G<<8L4AF8D:E5"5 !;00"L^4MI0M()@
MF(L20PQ6".LB60BU9"K&&-44@Z4%HF(^^ID9'"^IF/9=S<T_+P"G)DR3)OR8
MVFW%R;8KS,5E!:U90 $"J%T@#R2MC<ZA=FFVGG&G:&6[G7K)!&V@Z-&K0/58
M@$FPNK,0%*BXXOWN0+D\S;X2(N9(B#!W$'G"=X@SMM;L.(N=X\T3?"Y$7ID1
MI"J1!G1B@D92H5F1P9&55 *L%W"*18,3P#,2"8O:+1,=S/L9&XXP3L")L),[
M[7N28'M)XF1@4B #L.GTQ")"VM-T )8KZ?406TLC)(/NZ=1'$L8N1'I\O02(
M.US)/&(!SL ">+<VX-C<09MN1AK,ZD%^D5>XTOJ]@H%PC-W,8&IAN"6()+#2
MT&1<\[[@2>#!]+@[^@PK<F"#P28]-CR0.T_+'M">6QOX!?"(;W_Z!N7VY_\
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MA,T<U3'3N4DD$DY58@L,+2O)(3N[E5&E%+%W=5V<GBIV\,!E5F (!"R6ECI
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MT<*4DCUD-7/(V)BL=UJJ-HT%-2FG,7240E6F$HE$TG5$3&T:@*NL522X"%%
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MBA-:@N8IUCELP!6R[4V50+I?*>,7]$SSJND[$CR]<;V( L#F>'6VO42;N64
MC=0&N+Z1U*&HJVJ(YN9V$6BUM]X.PC;PO5O"\2GH+$@;%1IWDMK#$DAQ"@K#
M  D@F#1E&@* J2HN#I4AU<V (+.6)!^\7"BY.H&Q-H3?N/>XFUK;[@09MW-_
M.DF>\\P)%[&PWW@ ^MML*QO9AJ=0X4B.)&#,"6LQC&VL!F4EBHU$F[-VX##W
MO<DSQP>WMP>+X4B9@6L6D;D$[G8$B;#8\;8-J+@EIK%2H2-T8>HL3(6:P4)<
ML;%0U^P(.P@?\=P22#>VUKR=O3?@1B0!NIDB201L)@#OQS829M<PC4(KE+GL
M=3%Y-R0"-7=18:5L"2MB -R"3.]N]P";'B+D[F8@\8A-][#D6![B!S)N?41A
M]#B6)TE3%54=1)3SP0JL533EX)5*WN>K&%#NR$AI')9E<B3J#2RUM2I.I2HH
M96)+(=+ DD&X,D"190+$6 VQ4U*DZM3JJ&5CYD8!EO'!F!(%A8$" #,GJYZN
MM$L]7,YFJ7>2=Y"6:HG;>68R2%W=V4C6S-9E*FQL6X"*B0J#RH-*Z;!5X$+
M4 [  0;$B0 *:)3"I34*B *BJ %IJ  J@* % B( $;6G#<'J'IW$JR,':.P
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MT L;756(&H,@MO( H70P [@@@&QWW!N?]S?8[R).T>M4 "T2LF)(!M,@;:K
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MIM]V/<\G?TMBP[RD;?UGW@$[[>+#DG??O_S\P?<'MN-K_3B#<CBVW'I'U^.
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MD6C$W%BQ@3IPQ.@D$L1>1DO-%TR4IY?V3AHT(:32 -W8L0;%,S4),LP,%3I
M/E:1++<$,;"\V [0>M3ZF:2:*5-E5U>F7=E)JT],K1J_PV#(IEM @><S,B(:
MHTJ8%6LIZCKT\<TRI'41&E?J.5I).L@#50$8+/"[0O%)&5E+ZU6ZG)+%J3T]
M%0JA)4^(H 'B#23"&39H8,#*@03@S"(@H"GG,OF16RJ5JJTTKH<J_B/.4J^-
M30',($!+46>B])Z96J6+!58HI64LSND2DWB#+I=PL1<N &=B05L2VD N=1-[
M!BLB "T0#!L/-!' N"#!F8XC$I+4*,2S+3#&:8(AW IZ@1<F94W@ $F9!P:2
M:0D1 +N[75K.H5?4NC;3(9 I#J;J5   L28%6-7M<6,FU^1IG?C?V+U*DBF"
M+$V,.L*05TP(8L4(93(( TB9)V&HR+,<N4&8ZFNPR/$:W%?L]%@"5:BNEHH\
M,;$),95U>.$&GEM1-12#[0T[QB,L243G)U6FV>JY):%=J5"@'JYHTV%)*K5Q
M16@1IU-J6:HJJ#3%,22-\>NK_@:O2_"N1_$U?JG2Z>=ZCU9LGD_P^N9IGJ%;
M(4NEMU&OU;4K^#36C5\/(G)U2F;?,NJ(K$,HA,2PN3#\$AKIJRGA2M %+T)X
MYJSJI+,IU+$K=(I)%HFBF=94,B$J4<-QLI9A:V8>B$J31)%1G0I3@A"""\%@
MP;R,@*M#"01CSV<Z55R/3,MG:N8R@IYU V72CF:5;-2KUU<5%HZ_ -)Z.FM2
MKU%JIKIMH9'5CSF,RAW>5MVNSN68]0.P9BUR$745UZ>S-V4BUM\"8 F('!]+
MB3;;M GD X\T-6HDSZG?5,23>UP#'[Q@9;M,#,J%F4Z5@0!3I]5E&FQ86&S&
MX[@';@Q;8W!D;']R9,WWD#X&'>^Y$$ 1M>W$CU^%]_9\\MC_ %!?")_Y#\OO
M]B4_#XQ'<^YQYV/Z3>H_K@N?3-I;_F/R4"KTCJO_ #:8$=W!M86!%P3W&_85
M/$^O-_Z??MSBAXD[_/T^^<4 LI)Z>EBZEF#W#!8[[-8V76=P=]0(!7V 3_/W
M;W]OVPNUYMMZR>P!G^_T+M$:3U!2#9F*J3,'4*5!4BPW4ZB6M8;6X!(&YM/,
M#?C?O8<[>N 3IW,\28%SW^/8;<84LI**6,:[ >DK92=1)*FXVU*HN!?>YL!Q
M)(F+[\S?@1;C?^I.%F 3&J?6?4  Q[^UYPJ*>6S3&HA6)+JL3*^O<MMN^HN&
M"N2R)'H) ))!X35>-)DW)&W WVCBQFUXWPNH21I8DQ)!$#:^T1!(N3ZQRAI0
M+IUNQ9K,#<A@001?LJ%00R[#<_VB>'O-P(_K;?OZ'B,-<7C82(M!'H9N!L8'
M;V<+#.M(SQLD*2/T5?5['5H&A27! 6Y])[$"PO92P+@06*R=,0>VY@00>^^%
MU(7 C40"2(N2(G>!M&VQP*%8I ID"RD7)2<!PZDD>M;/?9MF]0(8G?8 W&TC
MMI.WL;6OL8(B_<;@&)@D05,$&VVTS\#P3AUKE$>I@S N7U!6U,;7!9V)ZH6]
MB"38G<@7LL*6@'@"+&.+  Z9WV'>.ZP-1 BXTW@B]K<B;1 [7P!J6(CIFF,:
M(TLVD1E7CCE55=F:.XLY_LLP.NX06%^)I )8*"2 )FVH; :NQ@#B-YO$T@$M
MIDD:1YK$C:)N8V!@S ,@VPW &@ZAI]2D,P T@ V)&^J^Q"J"2Q#,I%APQ-QS
M((@7F>)X&]]@!:#(#'<1>QD=P> =@1)!.T=CL5KK&%$/39'8M,KM^V#^JSQD
M (ZLQ!*NRL-P@(X( ))D$'^4@6BQ(OL;';!L6DD$1<$ :8, R;PW;O(DP<7.
M\]C.OD6^ E1K%)_3(\5#RD1EU^T+AV'K CR6LC%6G(!^^@:W8$.\E% $V)DV
M%V$7V[QWMWQV>GZ144DQ"2( ,D(8MVF)X@^N*7E/=RNJUB$/=V)^Y8$7!L3?
MO;N0#;BDC@';^;@=COQ-Q83 WOCM*=VC5$0A)&HF!I@&X;@[]QV.B%]"7);8
M A@3ZNRE.]PU@3?W%KW-PQB3 B)CFW(-K':/\0RJ6"H3+$Z9# R&V!0"=2L0
M"9YVXP9HFC#!S(K@@,C ; "X&Q!TD V8@@6L"1:ZA@8@ BY!',0#,[WX'K8;
MX9J34P0QJ!@0'1E4CNL1%BH,%K  "; X.D+RM_W\,:D#4S-=E*J"2PU[*+[,
M =1)T@Z6!C%5L59K\" 06CM[R)XN;X=:3U&,5:2 @2S2""JR9 :P$W868D@*
M0",)A+W]R02X6]AH&G5M<,"P%C[7)TV((,B -@ -,\S>/?T^IQ7I\S226ABP
M4V&E=.JQN"1:-B9B#.'5#2U%1+,\&E7IX9)Y'Z@6PC0LSO8EFLB@^G=A=;7[
MI4J*BJ&!(=E6()DDP -HDD@DR ;[7&G*9:K7JU6I%5:A2:L[%PH IJS%VN28
M59*@>82+,<$)M&AD>)RY+BQ]3!R0 $*V#;$!0!=?5>QN" "2 K+&_,$ $&0?
M6YD7F+S@-(5&=Z;ECJL1)5Y 5480"(C2!<7L+B0%353F8RO)6N\ AZL[/4RP
M*I1E6)Y&81,JQ+&IW*1ET6Q/%/ATD@(HI .7TH%178R#J50-<EBT<L0S<8W?
MFLWF6JFM4J9YFRZT/%KU*F9JY>FF@HM*I59A29%I)10WT4M5-(N 6"LE@@K(
MHY>DM3%%%*AA9FD D25"CZ2R$$$LWIV.C[K @O25WI$KJ-)F92'@*2I5M0$
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MY.QOJ!,6L1-@#8[8$:5&L#54C;1'E)E'686I8'1<P5)-\ YC[V*$+8DL6]0
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M5T$!*A(#$I,R"P\^X! 4 Z6"D0\&9P 9FD92QC"JJ7 ,MW52RIVN#Z0I;2
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M#@7AB =3#<D;D$R/>XL;EWJ9>E41GR[N6352#,BTD<PH1P(1D 5C$D@$,VH
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M]<4"3%II=4Z?+,2H"EV-M*J@ !#!@Y!>,%M5Q>XK  $#8  <_6>T8K40L+!
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M=7HY162@I1:12F]6IF"*KH#4JE:E5R@=B::L46$%DUIGDC>4E(X4._JB5WL
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M*>)XQ:G! :[;F\ Q!B8($"9_E!B;F'IZIF!41WI$*K0H,*SH"6IEU&M6_F0
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MZK%-75E-!(P:L(E*42-04N2+D6E0-]MIO:3@(CR)-); M!/O D F 9$6G43
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MW?S/?)VG0&;R.L@I*&4CH<]<V0H5UG4+HL;:1':RVTZKJ1IWX(#!@;1S+O\
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M@0P!8<BQ![@180FWF8>3HB"1_(WR$1+(S!CSWS6VI0=2%[J22S :@206%][
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M,BZRIUJU@XTZH!(TNN\F&H?3O8%?[UK G?N!;L#<7L/@W[V:02 9!][D0/D
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M6)(!! L0 %!4WN. #;G<";3$]^8DB;266;JP!NZ^8$Q)N! B8^:^F,5(VC!
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M:#%OLM)&N>< P5LO87A\^(8=)B\F(0X;00,C#S->3(Y@W[S)@=QOWPK(6((
M(  -C!//P,[3,8KW\='F9\P?'9D[(F5<UY!PW(DN7,Q0YXS7-@N;*[&\#S3G
M6ER#@'+F'$\#RU+@V#4F3\.& Y?%3+12UF9L6FQ"OJ(VQY,(I<.PNE1W4@0(
M-PUHG:+"9)@"_L-\%5B\S-N;3$DS;BU_<GBLXR'[M_8=S8$L!:Y[G<$%=6QT
M][$<5Q>1''ROZQS:UK]\.0)MMP;_ %M\3&%HF2G)D"K*NDH!,ADC(==+NOK
MU*#92P8(RAAZA?A&!< 24N&.EM+0#(&Q,&!.TW4V)!>C5\)B_ATZOD=8JIK1
M2ZE=060NH RK-.E@& U*")/!<:Q?+F)T6,X'7U>#8SA\[5&'8E0S&GK*&<Q2
MPF>EJ$?7'*T4LBZQ8C6W8V/%.9RV7SE&IE\U1IYC+55TU:-5%J4ZJZ@VBI38
M0R@@&#V!,B0:'II54TW76K:;$D>92&!D0;, 1<8CE]!*Z%T")KQVLAL#W7M;
M3J*^H68!M_>\W%INPN(! ,;'WL>8D>N&V^/^O[?"+[X:BDB!UH@AUD%[%K,
M2+6UW!N02Q!L!;ARW!):/03>]S'818]IQ/O[X_UA*KH87COK:.WM&>P[!P3=
MB21WOWW-R+<1',D;G:2()-X  V]NPV%X/H ;\[_#B>_RB+XB*BFDB*RI%UE/
MJ?J[WUJMVLMFL";W[7OL;[6A@;2 > .!\1$X,3$<GTM?YG?GZC:.(8DR*AC
M8C0NNR7](4-8,%)/?X-KD'A_K[_OB"(OQ>/CZ?4DS!@#8X-"K16D$2LGWRC;
MQN-1+(QOJ%R+%EW!VO["&_/I(W%OW PQ@&+@<;7(YGOZR-H,<%J(&4]946.*
M2Q14O9+WO'ZKL?ND7N-6UFN3< [B9($'UMO'W!^&%X W]#W,&!:;^D S ).Y
M 5T@@&YW;4JV L+6-KBW_B%P>Q&PX/W]_P",&#,&-AM]+P;@>]A/K@.H2Q7?
MU"Y.PM:^AK6'<KN;[C;O<\3[^_O]L-$W_28D&>W?Y[F^\VW!24L&%U9A<V&I
M6 -P+]_DC>^W;B;_  'W]V^>\C3S8"3 OS)O;CY#N+KNH@8-ZPP(DC8K8%6W
M!L;W!N.U_P#\P-^)8SM]\?[P2NXDP0(D;S-R3,[#:PVF1@KRJ_WH]$A))9"1
M8?)!N!OL1V[[@<06]??[X_W.% B ;@[$&#>(^$Q(B)YPNDL471:GED6JCD$@
M<*K+&P8,C+U%U JZ@V9'6]@#H.E@P)D,/*PCD$R(/O(Y$']\7JXIFFZ%A61P
MX.D%05(*D:@9(/ZM4K???"&NU]PS%Q=R3O8EB.U[DD7  M86L0.#'OZ6W]<5
M"Q,F23,;29WM.\S80(@[8QM3N/4K?>))&E;6L=DN;JMM)-QW%[D\3 @ZKF]R
M.VQ$GL-@/CWG"A*HDE]3*6"JRGTAEL1WM8A21N!<D'W(XF&_E)@W^%QW-MA-
M]_@3@%<2=03:V+!B77[S'2>XV6[6&K8BXN+ B\]HXM>(_P!>N QU23=B!)$<
M@F+'8]O:.^/9G\MG_4&\(O\ Y#<OO]AT_P#CQ>(@1MQC$VY]_;X_'?'GA?I-
M<QC\WKGEI07&1^3'K!W'_1Q@EB=MK7_=].,->GK9I)@S8_7FX,1:!\21CI9:
MH5IH5 D%KR)%S!'K)MZQ.*"!#+(C2-&S1J 2^DLJ$@D#4HW.G<^UA<[[\5%D
M1@H<22;$@2-CN1$Q:_.Q&+U1J@)T%E%]4&/^46O<02-C>1,8=87AN)XI--3X
M3AE9B,M+1UF)5$5%3R3R1X?A\#U5=5RB)6:.FI:>)Y:B9CHB122=^*\Q6HT%
M5\SF*=%7JTZ"-4=4!K56"4J8U&"]1F"H)DGOC=TSI75.KUJV7Z3T[.=2KY;)
MYSJ68I9++U<S5HY#IU!\UG\[5%)79,KD\M3>KF*S#33IHQ8@ R]PS$2^L-4B
M"&"&6>(!E1II@C1".Y1U9@DAN)#ZT+J"/2.,^9RP&DBGK9F5&D2%$ABT2(!9
M5DK$6,;G%N1SKD.CY@T*=&G4KTPK*C5*HI&D$4E&#-X=5AYXU(64$6Q'3.'0
M6+"-2 0S"P<@W('<!@#VV^2.QOIKI-PI8C<?\0>X!$@D7,G<@1,<]VU4P 2$
M4W!>1J(F8)-B%(M:YDW&$E#.MHXV=1N[ $J 20"Q52/58[?46)-^+&L26.D\
M"0"8N0NH@R)O[QZ8K1"X.A6< C6VDL%#&!JTB1)!$>H D@C"D;R+#,0@*,%C
M?6%9@;EET:O6IV()7YLVS %6"&H@)(-RL$Q8 $&)!WN#O((O.&5G6E4.D%3I
M1R0I8'42NB893*R2O$AK'"E+)2"*I^U1U$DPAM0&&14CAJ6FC+R5",&9T^SB
M10$((D=')*);A*JU"U,TFIJNLFN&!8U*85@%IL(@Z])8M/E! $P<79>IDUI9
MM<U2S-2LU #IYH5$ITJ.:-:DU6IF5=6-2G^6%946F4/C/3=V94*GZ3P3G[1X
M3EK$L.J<L+BF*XG#255753-3T5#58W1LLD&)3KA24.(%*:IAHJZ"$5:J]=11
MFH5Z>26%O#9G\'U:^>IUDS_@9:DSTZ=)0]2M3RC@JV64Y@U:7GI-4I,V@Z4J
MN4(95(_371?_ -1&1Z5^%NI]*S/X17J_6>K4<CFL[U#,ULKD,EF>OY"HM7+]
M4JITBCD.H,E"O0R.>2B,\#7SN1IM7)I5JU-^&5])B>*TN(9SQ#$(I*G$<9JG
MJ$+].OJJJI=JNLK="*D8B6:90P3;5*"  !QZNCF,O0K4>DT:+!:&2IE7TS0I
MTTBE2I29+.0C$3<A#W$?!>I9;J?6<IU+\;=1ZC0K9OJO7,V^94OX6?SF=S;-
MG<_G_!IHM):0KUT\0) #UAI"BV->>)M"RNZ_M2+7;7(Y-[,207)%O4"00"">
MXMO##5I4'RSQI47%HV]HB^H VQYMT?3XC,IUB0=09VW!)D3,B^J#!6;8<5F%
MXIA<E/%7TM5225=#38A3+-$T33T-9#U:.MC]C!41$/'(&TLI]C<<)3S&6S"N
M]*HE04ZST:A5M02M3:*M)@1&M#9ETF"1&XQIS_2NJ=)J9:GU+)YC)5,YD,GU
M3*4\Q3:DU?IN?HBODL]2!!UY;,T2'H5 2'0SAH\*JJ,I4ZV&JTA+DV^\X8 D
M$$D'=3L38GBU7)9@09 MY1IC>QG@;B9OS$8Q-3A VI"&82).L,>2I&S?RG;O
M%@9L5./8)3T8IJNOH(J@2XE3-33O3*15128?),LD3(Y^T4T<M,49]+P:U*A9
M"#B*9+.5*Q>E0K5*6G+U/$1:AE&2N%(:0"CLE60)U:3)TC'<3-]?Z+ELFN7S
MG4.GY;-"KU3*?EZU3+>)^9HU>G5,P*E'0Y\?+I7RS#45:CXJE=+N"C@N!5N8
M:Y<,PY(9*N2GQ"K2.>I@IHW3#:&?$*C1-/)%&9?LM/+THM0>=U6*+5(R*;,U
MG:62HFO7)%,5:%/4E-W8',UDH4Y1%9H\1U#-&E%.IB%!QGZ+T+/_ (@SZ=*Z
M6E&KG*M#.9BG3K9BAE:=1>GY*OGZZK7S#TZ?B?E\O5\*F6U5JNFDA+L%Q#P*
MZ*=KQDZD9V-@&[_V3=6N;7O^/8\::A1CV8 3 DV[7!FW[8Y:%A$61H)#$@ &
M=X!L9VG?<86#J?2X!M]W1<J@8$'18FS*"3=KFXVV X0!@ 5)O,DD F#SL2+1
M CT!@C#,220 "/Y0+\1;UWW,6D8'2%* APH]2[J;'>Q ( .]M5[;]_<<&Y#?
MIDR-B+>O:03$<>AP%M$ V8FYU$$2-]A%K'X[G";:C)<6;?;V!()M<K;W))MV
M-AN#;AA 6(O&^\#T') [[WVL,$R6)L;DD1N;[QS>=N0+8 ,P()*M8D;V^Z0#
M;:Y VV[W/M<6XD @@6D<'=NYV^/]IP 3:?,O 8" (DKW'8<GG8X&-@'4D$)J
M 8!D5M%SKTZ@55B-P65@K$$CVX5P(T[FY!@D3%IV,2>#!%QMAT8:@3.B5!"E
M4;1,F)! ;8@Z2-6XBQ.VY.D,6D8NQ8K?4222+=@ 18L+G:P]@(M)( 4:1 CR
M]N^_(VN"9PQ,DA=4L2VHOLW)D18K![DGU.,!:]S[=Q>PT@@[$'M<^HBQWW]^
M)Y=P=[CT,0+<FUMSP-H!$R0; '8B+"]C-MY8D09O@^H*)0X3]H 5))558$$,
MI[D@7&GMZF-B0#PO_"[2IO8%B#,@BP^.X@"P.&4C2X*IIJ"%)8@ KYE;5N2/
M- F#/,8N]\J"Y\)GG4;*+>7AC0NNX8_RJ)+$DDZK6%K!0 NU]1XW94@*YDD!
MMC%H"0 !: 1WWY(&.?G9/@ J%A8)'\QEC)DD3!"P  0!:YQ1S@F"XSF#%\)R
M]EO"Z_'<?QROH\*P?!<*HJG$L4Q?%:Z6.EHZ##J&CCEJJS$*ZIE2&FIX(Y)I
MYGCCC5F(4C<G?T';_ 'V,47D18#>3:1R;D"2>#/./IK,G@=\:&4,"QG-6;?"
M7XC<LY8RYAE9C./YBQ[DSGW"L%P/",.A>JQ#$\4Q&MP2*DP^AHJ9)*BKJZJ2
M.""%&EED1$/$TD?[GZGY>^V!,R;"XMZ=^YC<B-]QQCY?.D*'!NA!9S<6N39;
M=B%"V!U7NW:Z]D$R08F(!@]KR;<R0!QO!P96 9:?YI(()D_IMPD3/\WH0,$C
M]<C1B.1V9=16($A1L;L024(M86-S<'8<1CI$R!!CS$W_ *GXVL>< #40"VG5
M:3,3P#[VV%K? H1"I4N&4 %%&UQ_XK  ,+=O<W][6,FUO?F/EN/B/["/B!N1
M_>_P_;C&!0;W.L@; G2=Q8V 9A>PL+*>UC\\'[^_O]L3T]_G[8.I56 8EFTZ
M0&8%E*D^D;BVQ(7OL+>_ /I F\\>_;>#Q],38=HOQL0/Z;X49U07!:][)J <
MEBI!47%B"2Q/I_LE;@G@0=K;WBWJ#W!  B_/88G]!]\V^'RQB,SE0J* !L;V
MO8]K$W O[[,-P2;C@&UR3?OO/P!M:]B-HVQ/VM,?+#NCJ!33PU(2&4Q7*QU5
M-%4TTI-Q:2GJ$DAD0WOIDCT7]0&K2.%=2Z,LD3N4<JZ[6#+# VB09(D7Q740
M549"SJ&&DM3=Z=0#NKHRLK"(E6!'?":I&%%M(7T[* 5 N2!<FZD+?T@'Y]MH
M2W,S\9]3;>3L?3UO9!&YVO>)[\;&XX_K#2HIXM3A(.G<$@7L&8*K:@+6*@$M
M87%BQ;<[,K&%):;QS(DP(OO-NQCC$$&.;=Q8#>XF;?+B1&'5#14LT0I)-.MP
M[(RV9E8KZ+  !2Q+*6#'TG5IU6/"U'=6UK, 7X!B9)OMMQ!.TBV%+%3,2#;2
M!< D7DSW\OU.-=Q.D2C/3636%9@JL"5 *COI(L"UB#W)N;#2U]%-RXF ) D]
M_OZ1APTD':-@>"/: +B#L!R-SB .H$@FWLU^Q-KD,?DVWW^ANUAQ;/\ CT^Y
MPP-B>8'Q/;>\WD>Q@MMB['M=MOI87[=Q^)-_D[;GB8 [P)U<&TQZF]^QOWC<
M>X(W.ZD7-^_HN;'V^A&UAQ/A]_?>?GA^3(MS?T&]^T_#<3&%;-(BW:Y0:0NH
M@D$D@ &W[B>]SL3O,0GC@ V)XVV,P)DV]]R02@66URMMB;C<D=C?L";[^QL.
MW>8$R(])).Q]?8\?&1:,  +GTLUM[ 7  MZK;'T[$^]P #MQ/O[_ *XA.]I@
MD<S'/PY^0C8X/#+''UM2)*)%L-=R$N1ZE]]6XW!O<7/O:$$QQ?B!,6@]O4?W
MPIEC8D>FVW!]9/O,&V 8#TE0+>JQ'<"YMO;?O:Q_'\)W^_GAX$&_!$Q>.W?T
M(^0&,6%R6"*7 4%](8@ [7-@=A>X[V)L?D0Q[=IQ.#%P(GD ;R0."3Z V%A@
MI4JI#-=E0@V%@"W8=QWV!L+ ZAOQ!Z[3?"@F^XL3&T"UQ\)CVG'LW>6S?^@-
MX1+_ /X#<OO]AT_%XV'^?ZWQD;<_[^_N;X\[_P#2:HGD\WWGMTXYI'_D)R9V
MC!:RCEM@9+6&_I%RW< #Z\8Z[A6\S(HG^:TWVF>8XWYC?'1RJ,],*J.Y(<PB
MEC )DP 3:VUK7 WQP3R0>2_+/GUX^>7W+KG5R]P7F?RVGY><Z\QXADK,OV_]
M38QBF4N5F9L?P,5R8;54-;+'!BU%2S]))U5] !5K6./3EZF8!;S.)8 :@! )
MO!&T [B\3QC:&S='+5&3^'2=@FHA9AF MJFQF-@(!C8XT7F/X[,!GR=FO+63
M_+D\)'A]S#F'#'P./F9D7*?-FES5@U+5U$,U=388^:<\XG@4AQ:C@FH*A*R@
MJ5--/,T2+,D;)1U+(Y+K&36AFD:K1%>C7ILCLC4ZM%]=.HC!F*LC""0"()!
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MM$Z2#(:\R.Q)Q?6I+E\TU/\ ,H!3K5*3U*4A2M.JR>)3UZ#41Q#TV*4P5,
MB,1E5+%#4".D?[1&A4:^DRB5K OI5B6,08D*[:2X ;2M[#321WIEJHT,9\NH
M$H+Z9(@!H!D D R),XQ9KP:=4IEZAKTU*@U?#-,5&T@MI5F+Z0Q8*S %P S!
M9T@ID&^D$:SIT6U,1<'45/P1>^X7< ]N"%,@EAY06F?*+[3Q\+F))D1BG7 8
M $*Q"CDQ.HV,2019C  ,=L%DD2(7N2"  .W?8DC\?K_>.W!5"3,00=^?2+;P
M?:]L!F"BPBT1:XV)VL#'K!F#?$_@>;,1P>*KIJ5J66GKD2&II*^E6JA>->H5
M56<JT8;6VKILG4(&MB%%L.=Z7E\XU*I46JKT&UTZM&H:3J\K)( A@($:I@2
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M9KVLMA_9L&)M<^Y!VN-A9(N2Q-P%47!/>=A%H,P1!&UL.6L%51(8DBQ CY[
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MQC<S!(/_ !M8?38'>V.;F8)222 0 5GLQ!$Q;;582!?;'P5Y:D87S!?!86N
MOB4Y0].UE]0SAAF[7-B" U@MR"0!;VKDR(_Y+-B?YU^1VN>/GBH[0=B#8<'[
M%^TG;%Q7F?\ AR\XW!N:'C=YEY@YB\TOZ*$.?N;^8*K"5\9F1JW 1R?JL?Q2
M2##FY2TO.2;'YL,.!3P4LF4%RB]<(&:ADP?4K0FVIJGWL0"+DG>)L9GL(F+;
M*H6P&_?2;\]MOF>YQ^9RVD% P %]1([7L NQ-@MQ8@  W["PXJF;_?O\>_.^
M#:.QY)VWX$6MZ][87I)6B>30H8N5612"@ 6P'J&YO;N "1VOL CKJ DQ&WQF
M;&W]-R8WP")^MQQZCU&XF",%:2]]BF]R0H:WJ]6]B3J%KWLH]@&:_# 1%R;1
M?^W]Q/K@^_PX^/W\[82<E)&<VT@D+9=KO8,H*_W;7M:ZDE0;CB6VDS]8'/<R
M?A[SB;GM]!_C@<W-SA)RY;IZ&7?4L@(])6QL0!=K6N;-87(N+-PPB)GT@SM>
MX_O';TQ!WM;>?2-_3_5\"KE)51W*L5#*%LRE;D:KD$=3<  $ $L#ZK\2)4D"
M>+]XN([?OO,6$VN#WWB8C_/[X7>W3)UL#<:;[&X-T)TC87L";@%OG8E>]N![
M1?TXO].]I^PO%XX'W)^,X5!7J$*TK%5%BRK=CL&!!)C4:C9?4Q(W;?8 BT$*
M 9VGX<7,"3MV]<#B\#G[V^-L"GH:-0X%Y0L@<*[*NH A1Z2[VV52PV%C[\ W
M!)%@LB\28/J=C&_K'I/6)]-OA-Q]GWQL&%8M3X1!C*C!*#%&QC Z[ Q58H)Y
MGPPU-925,.+X2L$L"4N*4@I%B2245<,D4]5%)"5F0ICS.6;,ME3^9KY?\KFJ
M6<9,N405_#IU$;+YC6K&IEZGB%F4%'#+397!4S?0K&B]1A3I514HU*&FK3U*
M!54#6OF$5:;!6IN( 80=2EE*.#X=A,M<\.+8P^&T1AJW^W4N&5&)R-+#1SRT
M<0I(ZFD=8JRLC@HI*@S?Z(M2U4T4L<#1M97JUA3!HT!5J%D&AZJ4E +JKG65
MJ E*9>H%T^?2$E2TC-6:HJ:J:>(X>F-!84Y5J@\1]15@#34E],2Y72K"01KU
M;12STURQ,\IUZ&^^MF4@,_W&(!91]P@*!N3OI1U#1$*H D;7%_[V)[[##@Q:
MT&WH>=M_7:=X.^-1J8S#.\+&[H +D@:F'8@;G<&X![6()N+\:09 (YPP@">X
MCL;""1OZ]OC(PB!8:C<F^WSO[&]MSN-S:^X/>YPW:T=MR1\K][&T1V(QEK%@
M1I-K;FVWS<#3>P)W#=S8V'$/[]_OO@;2 (($R8W (XF#R-YOP9P8, MM)N3J
MU[[6%A?< 7[_ $^1WXF))!V$G>?38SJ(F+\?UPD6(&G]_P"8_':PMM^'U'$Q
M+S'H8,7N!M,;3)%H@[ P#ARAN5!(8!E-R""-M5B+ ]FM?Y[[<'C<[6^?&\\]
MK]\2PDSO$6D6BXC@2!-N;$VPHX4V-[%E)%_K8@$@V^]VM?:VP-^!B$"+P/??
MF\CDG82;"T[81&H*0;G[HL ;#Z7 VO<VL;[W/86)CB>?\=_C8?UP1:8D[B(B
MXY/%QS:>QP]CJ^@FBG#)=520$"36[%KNIT@JI4J%2S %2VLE]*J5!NT&\B+0
M#[&)[[&\1&"8( 65)7SPVK62Q,BRZ5V&F6 (+%H: U8@(P8$-(S7]/I(&XW!
M !)OL+V%R;6(X/W]_?M@"PB\D\;>L;>O%HYM/LW>6R;^ ;PBGO\ ] _+[_8E
M/Q>-K_?SQC8R3[X\\G])F>:#S?.>4T4O3/\ (;DQN"0;#EO@@87%K:M[GX '
MOQS\PJ.Q5EU>:XV/^A\+S>UNKDFJ4D6HCE#YH*DZC<R+18P.=['&N?H[&-XF
MGFC\K4PQ)?UP.5WB$J,)>BA6:<8I#R<S;-1+3P:',DO7CC,,*QOU)B$*,&L<
MU'+A*@JTV8E0VD&['R,!?8F2-S'M&-69SIJ47I5@L.Z,6"B!%1-7-@0#M:2W
M!MKWC0YB^<?SOY$8S@_BZP7Q05_)C+.-X1G#%CS$Y*OE3*E!B&'224&%8GB.
M.P9'P1Z/H3XDT%,9Z^*&2>K2*2-V90,*9K-4JJKF YHN-+,P?R.38@D:),QS
M.PV&.I5R/3ZU&J<HU%<Q38/31*B,:U+2&<%=9;RZ=2Q)$F5W.*1?])I7='$D
M#,2GK&DWWN 3W!!L;=U[WW''4_AU0""K@7@&0.TBT$&(G;B^.)_$HDJ=2L3<
MP08,K$V-P?-:"/+V& CDE5E9&='%A<, + _((L-7S\7(-K<%U4B" 1!)!DCB
M>))CG>=IWQ$=U:5+*P@"#I(-B (C8W/J)OP_2F:I9Y=8DD16GGDD=;$+;669
MF&HW(L 22"3;;;,]04P!I958A$50;@V$ "1,7/U@F--.B^89W+AG1&JUJE1E
M TK&H$L;M%P-V@D21AI/$_7<-(CA&"WA(9'8$D:'5;,O;<#<$[;DFY&44U@,
MI,DZP=2@FY:9,G<#MO.*:R_Q64NKA6(FDP9&(VT,  5D0( [^N *F^JXU;]M
M]MK[V[#M^[8^T!V''8=[QZ<[Q880CG<\B9,#F=N?\[PI3:3(\;) 6V=&EL65
M+BX!-@2IWTA2P 8BWLM34%5@7X! ) ]"=X!'/>-N93W<,%9E!8$P#$B568D@
M&P[3Q)'2LAR<N$KJRDYE4N-R8164<]+15^79*?[;@>(,"PQG[%)T_P!9M"(T
M@AHFFA@D,\C3N!&..%U<=;\*E6Z'4RWYFE45ZU#.:Q1SE&P.6-:_Y<'4U1Z@
M0L"B!?U&?HGX!S7_ $\IYOJ.5_ZD9+KV8Z7GLC5RO3LW^'J^73-=!ZA4.K_O
M+Y6HL=1:BM-*%+)&K3H5!6K&LQ"(1SHU4ZP+2">H-(E0U1%3N["'K:>F)VA#
M&-9FC54=E )4!-3*J\=L4U9]>A/$-/0SQYXD$J&B2H8D@&W, SCP)S-<41E/
M'K')KF&S%/+O4<4C5*^&,P: 8TEKO15:;5%!8JH0.54 2468,4I(IX</JI,.
M@K**.@KHJ&1X(Z^!&$I%8H+&=I);NY8FW_=J$B 3C.<EEW(:M3%=Z=4UZ35@
M'-%R('AD0$500% D$^8DL=6.E0_$'5<G2S66Z=G*W3,OG\@G3>I4<@]3+TNI
M957%5ESZAC^9-2J-;L^QE*86EY,1!<[NJ+?O=K[F_?<V]SOL;GO<7XU #8E@
M(B!Q\=Q!O$GVQQP3^J%DF9()N;$B]Q>+B3<3R,FAK6:.98RM/(O[(G4JN8P$
MD:-B+,1(&O8MI+!?[.Y5Z(#(2&=3YE$$J"25# ;>2-]P ?YHPU6E5_AU!2J)
M1J ^&[:]-0T_+59'(ACKG4!JT2$X P80M8,3<HA=R7C5BRD:@ Q!8V*Z5TEC
MZK Z392XF!;40JPK&QO-IMO)L!-]Q,6BS M"@(C5&#/3!A2)"AR"SD,(0:G8
MSI!"M@BM*0\,.NSV8H&9@2+D/I6UR 2%;NH+6[W+:5&EWT^603"B 8&DDWN8
M)%Y@$C!1JK+X5,N5>#X88MK*ZBKZ%\I*RT$B5EB-R<*24LD(@DEC(BJ86GB8
M,I#Q)(\)(L;VZB,H#Z6N.Q!!*I55RZH\M3<(X@R&*AH,[^72;$CS7[89\M5I
M)EZE6GI3,(U6@VI3XB+4>D[ !BP_BTW0:M+2I@$$$HJ'(TEP+D "UV&^P9M@
M._9;]B.XV<E1<+( )G@]X$&POV _:D+,DFY_XQ(V@'@F#ZGY6%+MID'ITMN"
M";,"5.H D;D;@^QVV X!  *$3(,$1L8B";V%I[WD89=1@BT-$7[W)%IFT@_L
M!@Z6+ >D&Y-[D* WSI(-K7&Q![6N. WZ6,D[6C43&VX:Y]9YV&[JTL++(-C<
M"\DD@$>UMH!DS:9Q:CP^C@H$H9$F:2%VFE5Y&$CL1:RND?2",6BTJ6#&/4Q+
M-;C'E:V8J/6:N"H##0I51I6(,D%M>J-8)B VD"!..MU3*Y#+4LBF3JK69J+F
MM65ZI6J[%66*=1$\+PR6HE1J#-2+ZCJPUGQ&2?#:'#)(:-$P^6IDAJ8J*&.M
ME-68FDCK*U56HJH8.B!2Q2LZ4P>41!.HY:U:(6O5KAZA-945T:JS4E\,'2U*
ME^BFSAIJ,!J<P6)@116ZC5K]-R/2WH9%*73ZV:K4<S2R&7I9ZN<V:9JT\[GT
M49G.T*!HJ,I2KNU/*AJHI!!48&/)WU6TD&^QN+ $^DBUVN+F_8BX/S='!N/7
MN=Y$;<"-Q\L8#(O^EA<0;&Q,2(,DB3,P=L%95;<-ZK !2"68D[DD7TL/<G<W
M-MN&!(%[J"26@  B]@8F1(L#M>^ 5#"00&\HTDW).\F($;DL =K$XO#\IVW]
M$[SK-K6\O'%P;6N3_*@C40-[FP)8]P0>UN-.6G0_,DGTN$VV^%A?;@G)FXU4
M^"(!M!GSR3:YVOR""8)M7!X$\YY;Y7>,_P */,7F%C%/EG)63N>W++-69,PX
MCU1A^#9<PK--#5XEB]3]GBEF-)1T]//-*T44FE$>RL0;(CHVJ&!TN%:+PRE2
M5,<Q'P(C<8KJT:M+1XE)T\>B*U.5@U:3EU6HL[JS(P#"WE(&V&WCFSQE?F;X
MSO%1S#R-CD.9\EYVY^<U,TY3S#023F@QG+F-9QQ2NP?$Z5:A8932UE%-#/")
M(8W$;*&1& 4.QDF]C%C(OZ ^U]COZXJO G>+B]CV@]@!/M[#'RN 0;,K6W!-
MP0-CL+@%K=KD[^][$\+[??OO&#\;_P"3//Q^?O@^ME)(+*3LRJ% -MA:]P>Q
M-^]S\KP(!X]OC[[>W:WIB6O._!&PO!-N/AS@CR,I]2D@CTH2@:]BW==]1 N
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M2GYU8^&7=)8*24)=&!5]+1#:-+(2!*,@]!U*S."-SN=UM8"RV-_?>]N#A"3
MC<&3?BUMN.2;"?00""T;W(]C8GV!L 1M_;L38DV%]CQ,20!<GYWWV&W_ -T;
M[\C&>G6H[7"ZRI'>S$_/I!L!\=_<6F(";"8^6T';T$;QL+$R!@9%T@NC!K!M
MK@VTV))N0MCM<;D6( ]A/3[^[X!/,^UR9B^^_/>Q$&>/9L\MDW\ WA%.W_R'
MY?=MAM@E./\ =Q>! C&1MS[G'GA_I-3G^MZYZ H"JY&Y,C425-SRWP2UO200
M&-S\]@0=^,5=?.2#!WVGD6X VM)L9)L",=/*D>$)0, 'YTD$DP=C(!@FPW@$
M;XHQR/G?/'+7,N'YVY=9TS/D'..$==L*S1DK',5RSF'#?M5/)251H\:P:KHL
M0I!44DTU-,L%0@GIY7A<.DC*:34*$#20(@$FT#:!<\B=HF]L7>$2"S,-M@MH
MG<FT;D@"9@0QMCMF:/&EXM\]9>Q/)V?O$KSXSOE#&1%#C.5LV<V,]9CR_BT,
M$L53#'B6$8OCM915<4=3##.D51"Z)41QS(H>(,*JU%:ZZ68F=IL+&18&"5(,
M$;P">,/1S+Y>I**H$[A%!V*GS$%E!$V5AR9QQ)<1HL1C*5VA90P+L%4LR74[
M!K6DL38[@D][#C$:->B9HS!'EN0NJ"+P9TR-K$ 0!,XW_F<OF%'YB0X92Y4#
M4:98%M,G2'B8D%2=X79#-L>44Q0#)GZ]&$FFA#G,34+U[5AC_P!+<"@5(%IA
M)Z8%N[Z%+.UWL'Z8W4C0;_NOY09CQ'C\F*JTA2D^&#XK%B^D2Y$ &0!:<='\
M6C\'GJB__!*_B =&7*98/_\ $S9!^HMG] .<8#IJIETROB>7+TR:E30-3M+!
M%UV(F%E8,BNA5@QM]Y6N/0UU(##>X.U[@K?C<T.""K%6U"!V/J #M(WF0+S&
M/.4RR.KJP5E(93 (!5I6S B00)!$$3((W'=?4"+'<-ILHO<DW(W[;!0+$]P-
M^! /I! *S)@0!M>\<F_QC &H&2;L9G3:Y,]Q)W[W)VP,<HB)!]1*E6&D->-M
MCI! TDW!#7N&W':W$:F2)$ !@022(,<[]H(,WX%L,M04]1 !!#*=0!D7! !%
MB>"#(-QB2GP^*FT+.TD55-)$R4S*',5/+&LJL\IL#(0RC0$ [M8#8YTS#U)*
M!6IHK2X.G4ZMI("\+,WU';N)QLKY*EEUBHU1,R]2FZ98@/X="H@J*[N" SD$
M*1H W:TA<)LE,) A$A[ )J 2U[W&A1\';Y.^Y'!#5-):PF^J^J>Q))VL# !-
M@+6QE*J&4$LT6B=A,^6 )DS%CN))MAM, 9)"@+A6-FLR^D?=;1:_ML#[BY!/
M:U)"@-:0# ()U'<:OG,^HVC"N "P0R%8@,!I) )@Z386$;")$\G"2G:U[$;Z
MK7M>VVXL/>YW!^A[.0%[WD 'F.;7(M.P]^Z3O:?4<3< WO86]YMR2["X8W[V
MW &U[D][6).VP)M\BY\LR.(VD\^L7(]X /I@29!($SS82=P8D1-KQQS$KF:0
MI''U'Z<;=6-%<E59@MV52=CZ0Q&U[C>PVKT*&9](U-Y68@2POY3 C8QO8#>#
MBPUJA5*>MO#I,:BKJ8Z6, E9:!)62 ))%R>-@P?!/U]B%)105M-]MQ,N#+73
MT]!2QU)$K)%)65<JTZ!PJ 3SO!'U7$;$#UG%FLT<G1J5&I5/"RX$+11JE1J8
M@%EIH-9($^1-1T D _IQU^D=+J]=ZGE.G4,SE4SO4:C4UJ]0S.7R&57,,KLB
MU\]FZE/+414T@"M7>E2%5@C,)U$I2C3![*!A^,T52TLDQJ94DKJ27_1R((1'
ML\3]0NRSA6B!T1%6=E :L<T9)S&3K4PBIX:E:%5"'\[:@2&&D*/#$/\ J8$!
M3;&27I'E0Y'K62S)J&O^:=6SN1K*:&G+T!2 %2C4#M5JKF@&I?HHZ34=4,3J
M\+J(,.H\)@JHZ:@B?J35AC-3B-;4/U)YVCBO'2P(J0T\$"23'1"TKR=29D6V
MA3S"O7K9EJ;5*[+"TY\++T:0TJ@9@&J.2S.[Z5@N% TJ,)U?.=)K4.F9+H^7
MS=++Y'+N:^8SS43F>H9[,.'S&9-*C-+*T*86CELMETJUB*=#\Q4J&I79%4JZ
MW!7H:".@P^M@QF.1S6ULU1')2M<*(A34J1AE*,K,SRL=V"=-K!@E*CG!7KFO
MF*+Y1E7P:**RU /Y_$J,8[@*O %Q!DYC-=#/3NGTLEDL[2ZO3JU'SV>KYJD^
M3J !10IY3*)1#(RZ69ZE6HTZ]/AP X@XP_HC *EGOJ8J-RPNS:C91L;ER!W+
M"W&LE;M(("D:1>T&%-I]+29%KF_'0.=*@$%GG42!+:H)):%%]R2J]S&#,PUS
MZB"SW]5AN1(#?OIL3_<+* 38"UP0#IIP(C8 [2H$&+R/_< ?C; 8GQ*A9I+$
MR6  )G<"Z@$_\9$6$<-BP-U!-P?NL+ V]_?;W%OW^YL"F03!MN(YC?O-QSOP
M;XJ)O -YYD[>QC;:\;^N#+LQ 8L=K$;!3J/<?0'?X&]CVX!VV&YD-))D;\;V
M&W&]SA@9/ZB38F!(![ ?4VYYG"MEN+7U;W[D 'N2#WL-M6FQ(N>$EN0(W$2#
M((L(@ <P3M??%EA:^H[Q^F#N3.Y$[Q>/-@19 RIW!#7L02038W((%M1L.WR3
M8< ^8@GM$>D7%[F2 ;R?:^&4:0P')!)Y+";@Q$PQB\&\DE9Q>)Y4"*GA,\ZJ
MS(S2>7CC$C:6OH!S0P",NFZL+%B-1NK(; FYU94RKV( :+_S1HN#)MQMO/.,
MN=0(:1#JQ=0Q"F2AFHNAQ TL LQRI4\XHHCMI13=S_:%[ >D;"WMI-U-K;W.
M][CO%OLWCZF]_EC(3(($[^\ 6%[&+[$?695TBQ+ BR_>.VKN?40=U!-Q8V(L
M3;@7M$;W]K_7_7K@  \Q:WP_Q/(P +2 J&MI-U.Y N+W*DFP.JXO?N+@D"TL
M.-]^Y]K&_P#2<38;;^AL>.9O<]OZ)ECJ+/96(!U&VX#7-B?NVWW.FV]R ;<'
MT^0'R^_AVP/A[??,P>WTP)82J!L&OZ20-R;A6 !.IBFYV("V(-PH$@@GGO''
MH?8P/?<<F'<V^ _8<>V,N&T_=)CV%@$L+E@6(N.P N!W(+7TD<3^O^K?+YS@
MSO\ 3T/U_P _ 8 QW$A4!!8G3N]SOJ))]#;V^2#=K;F\GO?N>/;N+?2+SN+;
M S[P-]N?WCW."HCE P8-K=B;L+V87?;<#86N2+$C:XOQ)OL;#<"W]9/?D_+!
M)O$1^PXCO/K?WXPNJ *$U$A3<+VL"#LS7-U-R-0) .]]AP"3>WQ$ ? 7CY1.
M_?$@;R-]O2^^QX[<X"-1=;[ $Z@#L 38:AIO8BUC\'WOL3S':WOB?*/W^<']
MOZX6"]32CS*B(""Q).RG:-"JFY+'8J!8F]P&X0PLE026@E1 G8:C,1;<^G?!
M)) !)( @3)TS)@28 DGXR1S@1$@8'JLX4:AJO]WL=[:MK@$]C;XO::CV&Y&X
MWW^I]9^DK\((^_\ &PVVP1I6!$#"14E&QC8*JG[PL22.QTWN&[;G;@Z=V&DE
M8N8/P@"2>8O$<3@]H$_U/:),CU@>N%HH?L[1Z6(13JTKNI-P26!(]=A8L1?>
MUKF_"LP8-(W&YWY[< Q8?03!$3?N08]K1%I)VXPTQN)7USM9-(+J5NQ8JQ0V
M&QNP(L2"H(([[\-0: %WX.UK3,BW>+R1A@0)$$7)'H-]K7$$;$ _#&G% 1?8
M+VLP .PN1J[$GO8&]C^/&K[]\ 1\"/2WQGY@&8;?D@2NDL39@;"X%O;<W[$=
MK^YMO;;B8,""1,@=HO$@Q>/<$#X&^6TDC5LU@0 18V!MJ-[_ $'R?;VGW]]O
MKB3&_;:/G!N?>=]]B"'=)5&FF$ICC=HU9HQ(7TI(R,J271D.J-V$BDMT]:A7
M5U+*5==:E9(F)-I(!!(N"(8#2>8)((,$74*PHU!4T+4(5H#Z]*N495?R,&UT
MF*U%!8H75=:LI960LK#T%48LJN2UM3$A2S,191V)/]GO8@;M:\_U_I>_WW%8
M@Q,#5 ))@&;23P+WX !(')+I"D:"#?U$H6(8J%34"-BI(N"-.H;[C?@G]MOG
ML=O7 B# !@6-C<3&]@1<F1W!BQP<*I O[L ;=R-RP&X^+@$B]@HO<$#V^^WW
M&(>9F#>_[6(-N!,;C>#@5+/=!(%B_:Z!( JCN#:P9E=PJA0Q8*;7(N3Q/AV^
M_K@F2-,RMRMO^1$F)L;"1)&QW%R1*DK"-C;7[EBHU6T@:C[=B?\ &QOP>VWT
M^H^/W&$WX  WWW Y&_,'D;R8Q[-?EK.K^ 3PANA#*W(;E\01V(_4E/\ Y_WG
MOQ<,96W/N<>>)^DU*3YOG/0E;C^07)@V.P(_FZP4>F^G41H)L+]R-['C+F-Q
M!(.H1 G<7F-K]_K(QT<I(IM%_*;'82>;W^$1$W(.*%\+KZ*BDD_6%.U73&%X
MUA1(S('8* PDD215,9&L66Y"Z->DL#BS-&I64>"PIU00=9+:2 ;AE!'ZAY9!
ML3,'8]?IF<RV6KG_ +C1J9O*-EGI^ G@TV6J5BG46I4HU(\-X8@@%AY9$X;8
MB:-ZF4X9]J-$SKI:I6,2 :07+],:;!BV@;DH 38G:VB&5 *VG6%V38GBYFYM
M/J1.*<ZN3J5W?(#,#+D*=-?265B@+F44"-1(4;E1<R2#/87@%#/15-7BN/T>
M$B)%>EII:6JJ*W$0ZMI%,L*B**)&"F26:0&Q(120!QAS&;J+52G0RM7, G34
M85::4Z,,/,VH:G,3"J"+ S<8[72^D9"ID,]F^J]:RO2C0IA\GEZN3S&:S'4"
M5,4Z34W1*%,%5'B5-0!8@"%Q")3L]0$4*Y!33ZB1+O>P%K]P!<,-OCC1X@%,
MEC$R( $J9^7K$1Z=^"*1>JJ4E+RRD1YE=8+':"H@0;VG@W$QBIH,1D?$*>GH
M\,FGF5'P:B26.EI&1%B7[.DTM1,\;Z-4S/*S-4/(QL& &?+^+004GJ5<PJJS
M?F*I!J5)):6(4*" 850HA  !88[75ZV1ZAF*F?RV1RG3*N9J(AZ3TZG5I9/)
MM31*)6@F8K9FL4?PO$J-4K.S5ZCD&"!B/@PS$*L50AI:JH%+#)45:PPR2?9H
M$L'J9](*PP(6 :5P$ 8"XO;BYZ]%/#+.B!B%0D@!F8V19NS6V%^PMCF4>G9Z
MNN9-#+UJ[99#5KTZ2.W@4E$M6K!1Y*04R68+8_JPQ(Z+6 O\,XU,;V'<6"V/
M;;OW'MQ:8>\R!<A;#?<R+D@W!BPQE(:D2&"L>&@P?:^V_<R/CA]11_:)T:7K
MZ$)M-NZK+9ND)-?IT7 U L+*& %C;BFJRHC!"HG]26!*G]12 ".UAZR+8U9>
MEXM9'=*["T.UZ<K!7664B-N0" 1$6QLA^R8=74+S5%%#(%-6QH \Y$J:V2!P
M=<<;2651I($>K6!=0G&$*]>G67PZI2Z15A05,2RP02/>=0!F!<]]DH9'.Y2H
MV8RU"I/Y@/E5-8JRJ]14J*S-34DJ%&D*$)#1Y8PSQ*U7U:Z&F@I:1Y \0BMU
M55F8!-05#[[1FY/<WN.+*44M-)G=Z@&EBTZ21!DB6]23Q/OC'G?_ %8K9BG2
MR]'*R66K25=8:_E 73Y09E(&WM$:(<-^Q3-]H?[;K(2(+:%8]("MKW)=FOJ!
M4 #;L.-&NMK4Z3H W($DCB#P.(/M?&5*/3_RSLU7_P!0)  D  #>2=S-P9 O
M$#$<JA20GJU6 (WW &XO8EKC;8[@;<7$S!(V_P ]O0XYB+&KU:1<$0-N!_B,
M)LH6]N]RK [$%>X(MW!L"#V_&W#AC8F>X,=_D"")_IS@,BK<3.U[0/8>WK%\
M.:6IEIW22-RC!]1L3ZFWV.VUQMZ2I.VX._%56F&!5A-K$_/UYGZX>C5-)U=2
M0RD$1S$R#S# Q:#VO?#]8TQ"5IIZJ"F9F=F9XV.HF_H &H6%[;@[FY]CQ06-
M!0JTV<  0#;;>8#3;CU@[XUG3FG>I4J4Z3.[,3I/,^4 F !)XFYF^VZY7P3(
MF(D4N8LU# 96D>6.M7#ZBO#B%$"T'1C*)$:UG+15Q=^D\9C>F<-J/,S^9ZM2
M(J9+IIS=()I:EXRTC+&?&!>Y\( AJ4 ,""KK$'VOX:Z-^"NINN1_$7XF_P#A
MZM49:U//IT^OGE6G1LV4-&DR@/G/$U4LPS,*)H,K47#@AES#I\DTV9JJGR#5
MXE58!%'3K%/BW3^VM4)#&M47,4-/&1]H$@%HU*@6'L!;TA^IG)(W5J5*GFF9
MR4H?^,(6)0 %G_E(&YVYWQ5^/LK^"J'XBS-#\!YK/YOH%*AEA3K]5T?FWS(R
M],9HN:=#+)_YQ4T 4E@"#.YTR&&G(9G>8,NZZ5C8DDC4 6( T@ZNQU6MN2+=
M0NQ@:5O:+R3_ "R(,DGG87VOCQ"4E=&(J ,KJ I EBS >5C$'D"/,?+N1A*2
M!E.M(92K2!8.HA#3-<J"@"D$A@0Q74MQ[V/%@()"ZQ('FO\ H$"Q(N)!L('U
M&$>FR&].H2QTT04(J57%H2G&HR3!9=0DB+XDJC#J2+#X:E<2AFJ9V8R4:(3)
M BA2&+ABJL69@5V<%03<-=<PK517:DU!DIJ!IJ:@0Y8F5( #6 !!N#) @C'0
MJ9+)KD<IFJ&>I9C,9LNQRBTRM6A10*149Y9026CPS#")D@C$.5)!*GM8V[-M
M?U>WQ?Y/N-AQI!CY=I%_<\7]/<$XYI6=B0"; @JPWAB#>2).]QS883U,KDZE
M[!0>YL1N=Q86O:XW-QOPQ"LL0Q$S\>) -Q[B^V%!*L0"((C5 .^X@]N_<6[@
M;LH+:AZ@002"3?X'9=@%WM^6_$TJ8!!,7D6^8.^Y^F)) )U SN/D=OA%Q_B\
M7RFR&\)OG4"UM7E[8VI(M]T9G0@>PN-1 )^=_;C7EU_AO>;VWV(GT[#O_3&?
M. 32(D6CW@-_D?,8HM !Z9!/;TW-K7L;$F_<"Y.VP[;<4XHT"8DW]/C$Q$^O
MTP8ITBR@JQ!N=+:U;Z@D6-KFVWS[\ &>X]]\*;6[#?@B2=O?UXP#:6))(N=R
M0=/8CXMML!_AP<"?21[_ #^>  L^H$G5?WN-A;ZWO[C_ (<3!! ,@1V@[?,'
MX_2,"/5]ZXV(TCT[ @K:VX L >VH7!%CQ,-I]2 "=_WC:!];\1@"ME((W[G>
MQV[CWN/:QOW[^QF$-C';[_J8],9JL#<$  #O>_?2MK&X)ON-QOQ,#!@2"H"V
M%M-]O0??VV6WM[&Q%^)B3%_Z3]+XDZ1,/:6G6ND:&GD98YGC75(JDV,H0Z@S
M$ %=T%P+E2+<(0\/HNP&I58@!MCI!L=YG>!-C&*JK5A/ATP"BB!<:S:]Y,DF
MY%K6'>8-!@*S5$25\\L#)4-13]$1O(8W(@B= 7"R3(IN;E=1 !"DGBD/7(4F
MFH(T^(H,Z=0&H@G]07B0)MN8&*?%S++J\'25"ZPQ+!9 DJP"V$S!$B+\C'1:
MSEGA)R_E;',)S/15M5CK24=9@3*Z5F$XG!'+/]GK)G5:8I54ZQ/3&.9F,L@I
MR!8.>:O4JHS&;H5<O41<N#52ON*E%BJZE4'5Y&+:I73"EA-P.)ENO9BIU#/Y
M+-]-KY:GDPCT,Z6IFAG*+ #534,74JX9&#*"  P_5&)"IRE@F6*@MCDU,*R-
M*=Z?!EBE@J,12<L6:GD:DQ%4DI&01R"JIA32$$!I1J#UIG*N;6*%-@C,X:N2
M&%(I'ZAXE(D5 9!INSK<P#$*,_F<ZL9/6:;Z@:[,K4Z9$>5T5J3'6&E2E0%0
M 3N"(18LO'!\23$C6#$6^VU&'4KX=&45Y)(NA&TT<=.UB-6F2/I10HFRN7"#
M03F17I&BM-J0""JVMM5@=15980#$@ZF8M$@*3C4SYW\Q0-):8H@TZ55Q4>RA
M7+&&9I:!,3+'E0,:CBU?0UF 8=24^%TE+B-&\R5=9!42&IJ83)(T(>FZ"Q1A
M5<1F1I)GD5!L@.^JC39,S4=ZK-2>"E-D 56T@&'U2TD2 -(4DCS;XZ=#+UZ6
M:K5*F8=Z%10U.F4 6F0NG4K'S$$@$?IB2!,VT^LB:H@99-6A+:5&["P TDW(
M.FQM86MW'&M"%:01))OQ<GXWG;TF^YUR02.>8,[WWYD7^Q.OST431"2F:1W7
M:9'T;'?U+:WP0 ?5];]KPQ_F @P5(]A,]M_:/88M@Q,AB!%N1>9O)VMM?XXB
MM L-2&Y[J;$@^XL;C;X[#>Q-^'P(C@G?L38QR+VB+")W@V-H7X:VQVOOMV-@
M/P(/TXF# $V.W;<$;6$CV,1 XP4*1N6!!)L!8':X&_O87M?:YOL3Q#[1_7$G
MFPF?<P>"1!VM,"\=C@22JR!.[H5)MOINK@;BZV95(92#:XN 2#+2)X/W],0,
M0&4&S"&,2=,J8,@QM(87)Y G !+A=5QI ]08@EMR0+^V_P"!L=OB>WUP(YL.
M)8D3S[SML8D$B.15$4$#6;=P=SO_ )OO;\^),_Z _; ,DGFUQ!&_'PWO'QP+
M ;[,3?<"WS>__#YXGW\OO[C$AKCU,B_O,GZ$F3[8! NL:[A2;-M<@6L20.^G
MO\][6XF)<"+#CG8&\G?<\=C'K[,?EGLK>7]X0&52JGD+R_(4BQ7_ )%@VMM:
MW%XV%H]/V^F,K;GW.//(_2:]/];YST%RH.0^3':XNW\W6"6O:P/=]_;?\>,U
M<F5( ,&")&U]^U^(/],=#*61M4@$$VYN0($B>?KBC?(SY>@QV*?,U N(X7!#
M(\M))B'ZMAJ)0HZ43U2TU7(BRL=!T1(RZM8F&C?B]73-ME'7(U6I5F98=:9K
M.B2-91"R LJDFY@V$8]M^!J_X>H]?HU/Q/T^GU#I-/*UZE7+5NHGIU*O7%%C
M2HOF%R.>9%J5(4Q3!F^M0,1.:V9L5K$4TD4<TR&.GPV17HXDTAZ>GCD0().E
M%TXY)=Y"X+R$MJXU9%8H(7+EE4AJE58J,P@,["8&IY8*"5 ,#'*_$CE^IYI:
M)RM')U&UY:CDG\6C0HLH>AEQ5"IXAHTRE-G*AF92S*&)C9<,_7F8<OO1T^5Y
M,1BP596;%8$D04,50Y=?MDXD2*3[CI C'7N0JL+<<_,'*93-J[YY*+9C0!18
M@^(R6&A=)8$D@L;"(!) C'?Z90ZQ^(>B9BCE^@U>H4^CTG?,=0RZD+E,NVJH
M/S#&HJ&--0JL%HD@[C&CL\T1"QAC*ME:UU*WWN2H%O\ $$@[<=,!64ZHT$R#
MO,<B\$"XQXL%\NY%$G6#I(!(8&_/>Q_SA]-02145/7Q,6ZYU7^\=:NUU)^=M
M05K$K8^VZ)5#5&IO8+( ( $ 0+3'IN(V],=#,Y$+DJ.;%4@YBTS)+:B& .X;
M^:"1:"-Q@*'%,0H!5"EJJFGCKX#1UBPSR0K4TI96-/4%2!+"656,<ET)5;@E
M0>)5H4JNB44FF=::EU:6(!U*"#!(Y$;;P;YLIG<YDTS/AYFM3IYI#0S91])S
M- 0HHL01JFP()(D;$8+35--'4B6LIY)^F2P6-T568#]GU&<$LE[=0*-3#WU;
M\&I3?3H1P@,"3,D']7H#L02+?#"Y9Z5.H7S-)V.ZTY "[%0VY(VD 203>Y&'
MJU]=B:R41E2&"0R2]!+JGIU,18:0[,#H0&^P %M[TFE3RY%0R[ @:IGCRS:0
M(DG@WQN&<S&;#94U:5+*O+FFD@RH, 0 &8B0)F)$;G#_ /4Z25-/3T,-9'32
M0Q3=:M0))9(PU9-^S4]2&.59GB*WD:%4$AZK6-1S,BHY=&8$J50@C5'E47$$
M@B9@3<0#C:.GS4HY7*4*HI.H8O7 UNBJ6J.I \RI#M:Y1>6Q(8]7TKT8P:A+
M3PPSJ9:W28EK J 1D(T<9CTN69;7;206):Y%&4HU!6_,U85V5@M($'PO->6#
M-J,1(VFPV&-'5,WE1DUZ/DJ3EZ3:VS%XKL1.G0570%?4 ))@RUR<:X,(F>@F
MK&&F*.5HU!/K8@ FZW)5+&X) U>QO<<;?''BJH-R 3>-S?T)M!['<8Y5+IKM
MDWJM8*2H)@F0 2#?8^EI!WYC1&$! 4J1NG=>XW)W_$;?':_%^HD[@@_J@#Z1
M:??^@QR:*@*PN2';21(WB;;[?7!'+ ^JQOW!!)#"]SV][[WWO\^T@;#O:8%O
M?OM;WP[S )@[3:;WO]_W!,I4@; >J]QV[VO<W  '?M\V)L> 9$]P+<^HVP%*
MVF)GT&WT'T/I,'#V&DJ:FZ4M+),PO_W:@W&DWN;6&Y!N/4.^WM3XB(9J5%4V
MLTB+@[6N0.1!GYZ$I5*@_ATRV\:;7[2?VW@6N3/4,H9 S+F:KIJ[+&"?;,1H
M:NFK#A*AW@:AH5A>MQ"9ZB1$Z-/4=$3PH[5"]8D0E5 /$ZEUKI^26IELYF_!
MH9B@](UR0'%:L"M*B@4,==168TV8!3IC7,D?1_PC^ OQ)^)JN2S7X;Z-4ZGU
M+(9[*YRGTL M3S66RVK\[FJSLP R^7<T5KJFJHJUP56^#\\,OOE[/^*4]1#A
M<%=4B&NK8,"J'JL)AJ:V&*HF2B=X89%19)6U*RDJS65B!8I^%<V,UT>@14K/
M2IEZ5%LTBTZYI4V9*?B!:E0$Z !.KW$SCI_];N@OT3\?]4HU<OTK+9O.)ENH
M9RAT.N^8Z52S&<R]+,U$RE2I2H5 JO5<,K)Y6!@D7QR58W9'(4LB :[D;:B%
M6X)%[L0/SX]'J (O$FT3Q>Q]([VQ\D%-F1G"RBE0S< LP51[EB![D3&%VKZQ
MZ.*@>IF:BI)6FBIF),4,KVUR*EN[;7M>YO8=^%%!/$:J*8%6JH5G  9EB )'
M:?<3VQ>W4,V<O3R#YBH<KE:C5Z>68DTJ51P ]14-@S!0"1N ,*SX;B"4*ULE
M/*M)/*PCF95T/*%4N%M?3Z2ME.W>WW=JTS% US15T-:FH+(#Y@A8A9'/-[Q;
M@C%U?)9^AE$SE6A4IY3,5332L5'AO659905/ (M8$>H.(A@P'<V78@[V/<CY
MO?WW&_SQID&;"\F?@2"!QQR9]3CENK R08G3)[BQ6UI$;#!+#418V VO<6N;
MV&UK[WN#M].'\Q'%R)(-X]?;T/IA-)DK%P)(]#@Q%Q:VUP;@=C?L3]3<D']W
MN8)D'8Q!!Y%[BWQM\QS"I@VMS8':QD_",7C^4[;^B9YTP7N?+YQKL"3;^5$5
M[W]K=QV[^U^-67U>'4F9U#C_ -I^Q\[XJSD32CN)_P#W3/WMOBBX :5V&Z@B
MV]Q:VP'[N*,9H:Y@['>#?F!S,1['FTC8+N1IMMN+6]_@$?YM[\3 /J9,FWIM
M([7']8WD-*[;?Y/^/T/M[<3 MV%N_P!18R1.VYCG"94]2]R%L  .U][D?6UO
MW?EQ.-OC_3!&GGGF_P!!W^0_J:]P>Y![=]]/MV%M7^/UV$PY(-B;S:9]N (Y
M','U&!+%P&(L&WD!V(L;@"VUAMJ';O\ CQ._T^_O^Z-^HX$:=P/8$GN=@=S^
M7S^'TXF%P4GU"S'<7 ]B?[OX_&U^UK\3!!@@]L3%!0-B,\%."HDFD5(]3:07
M)L%9B>F@.^HMLMMR!:]3OH5G@E5$F!\2P N8]/U?"<49C,>'JL/():>!ZQ)]
MQSQC::? FC:LIZM!3U-$LA>,,DJRQ0R6J:A9$U!3$ >D%!$JG7=54D96K BF
MX8LM0K!,J1(\H(,2&M)-QM<SC*V:$(U,ATJ!;B?U,HM! N9OM!]K;=C>2,=R
MW0Y9S/2Q8C-@N8*%:^@Q"2F=:1YQ+-#4PTTK.\$\]$U.RNPTR!K2E%0JS9*.
M<HYA\WE7\-:V7JM3>D'!8II!6HPTJRI5#@@$D0-.K^4<[(];R'4<UG\@*N6.
M<R%04<Q0U U:2LBNA=(!56#2(E>)G&^Y6@CH:N7&L9R\^("BIZAI<0QF2N_5
ME-6U\+K05-?1X=!63I&77[3!. R:KAXYHU,;XLV_B(M"AFA3ULH6C1%,5&2F
M?XBTZM6I35F@Z63RG:ZDXXW514K4ORF4SWY5JKJ!3R2TOS3TJ3@U5HO69*8\
MIT/R%,#222-3?#\2S3AV)8[C2T93!\,J8*%L,DBA73120!:F2&H1&JH5233*
MS=*HFE>.R-H,8T^)1RE6EEJ!<&O61J@JJ6@5-0-,,I\K2OE%T"J9-\=,5<OD
M<QE\MEC4;QZX9Q74DZJJ5 %4J2J$FZB=*@$VF<,LUXQDVIY?Y5PW+.#BAS!3
M+5SYFQFHJ:EYZVKBJ*D*BI-!'100/2-!IIJ>HJ)#(A9NG(P0696EG%ZAFGS-
M8U,LQ5<K24)I5"JF20Q?4K!@S,BR#8L/-BWIN4ZK2ZQU.OGLT]7(OHIY')BG
M31:%-:*:BU34:E2IXRU"2P 4, H, CC)EDCUD*="L6#"Q!UVO8[_ ('W[WWW
MX[&D$<[1?>Q/^^1MCT0_S\_B?[=L0V-H##2O3N%,@8R,AM9W*'2P'OZ3W';<
M=^+*.H%]0, @+/($R;0>1\=^V&$B^PMOL?[QO:8Q!"Y WU BRL;&]S<L?Q%[
M_P"'%WTPWFG;N!L=S)G?B0<#[,!N?<BUS?N>_:VW;OVXF)PP%SR1$F=SOM%M
MM]L$#EC8H5 VN=.F^]S8^_P/X[\3XCZ_VP=P-A?TL>T%?>Q^=\*>_J(N#L=K
MV^HM8?(_'B8G/F(D&QM,>HV]1OOQA)@ZN2 Q4*2%V(9MQM?OL=P-^V_!M&UY
MWOM^WW[8&PB..]Y@"P&_^SVQC J0S2,NH[*;6)VLOQ>XM<;@]NU^)\)^?SW^
MXQ";&01:;[SP1$;<F+ 85N!]-0U'W/[OXWW]]K<#!MZ"1J/)^ ^)(-^;1@JL
M%<,X++?U $ LO8@-L!M<:MK=^)A9DCC@"W>+&1O%X MZ8]F/RT=?] #P@]10
MK_S"\O\ 4!N 3@L'X_CQ>#(G&9K,>+X\\;])JW\WSGI[:<C\EQMM?_HXP3OV
M_OVO_P"&_&:J=]B9/T^]_7F<="A_X@3:W/8$[?O].+T"LJDC58][7]MSWWW^
M+DWN+_/% +<VO?U'O[W^ ],6D S:9WB/0@3\L$<DE5C4 BUC<BP (-B2;&]C
M>Q.UO?9@;$,;$7MO!G81 W[8.I:C*M,,K2!>PD S%[ _\N?F,;3-B6+4V$TF
M'1U$D.&S%:AS3,0:B0-IUU*J;N$"% )%U#<K8=^>F6R[UZE=J8-<:J:A@#H4
M7TJ3<"6)M;8&;QW,SU'J67Z;0Z4<T]/IN9K-7JC+.RM5J:::$U0I74$4 +JV
M),1N4\$JL-I\1BGQ=9IJ1 2Z1&[RR(+1AAMJ5B=))(V.W8<#-T<PU%J>5*)5
M)D%A*J#O$S$ $BQ$F]C&!T;,=,H]1H9CJ].IFL@&(%*C'B,%#:2VHK:2%8SJ
M :POAG43I433I2RR4M!+4L\$$I.BS.W3( U>I(R 2+^D$6N;\7TT--%-114J
MA!J86)(6\S8AC,#@R1SC+6>AG*U84&;+91\U4.6IN6TJI=]"B)V4QJWCC#O$
MJ2."."2E99:8Q@2NNUJ@??72UFVVL;6(W[V IH5"S,'E:A-@3,CCTV'K:W?%
MO4J*9=,N^6*U*04"J0('B\[BYD"_],1'3+'UFQV N"K'X(]/L/?VV]N-!8 0
M),SJ((/SW /QVW/; J/44/4$.;D;2.)CTBX_I@R224,L4P4%T8,EP70$?WAM
M?>W?ZW[@\'0M>FR"8)N+ GT'P'8F^W9@3DZB9@(6J4S*2)0&WZ@8':+;[[6F
MZ_,,^*/33UY9WIZ=(4,2QPJJJ" %5%4 $L.H"3JW8DDD<8Z62&7#TZ("!W+$
MDL223?4QDG8D;$;8Z^>Z]6ZG5RE;.AO$I4UIH:02FJJM-@!"!  08?<DW)/#
M6?$WJ8:>GD6,B")8$9$"L$#,ZER1ID(9R2Q!-[ D@ <.*.EV82#J+7.YL(&Y
M%MKC;@XSYC._FJ*46TPJZ04@5 H)_5$$FYDB3',6PU2MF2Z%NHE@"IN;Z+V)
MMI!.Y-[<6-15A8:3/&U[#O L?H;XQ_FJN78*KFHE@RM,'<#?Y3-MKX":I21M
M4<"Q_L]#D*6!;N9!<^EK$ V)4V[#ADIE1#-,&1YHM8P;$F<-6K)5;53IA!I"
ML(W;EMS&_P!QAL6!%B67YL+:K=U[[?/X_OX8&)L#[WQF<VBXO\[?M_4#!-B0
MJAC<&P9KW(.P( W%SN/<#]S VU$BQ$V'<7GVQ78V ,WB3SZVV_IAY1UU=2$F
M&1HR38V8VM] "!:VW<CXMW-=6E1J_J%^X$7)O>#^W>-SBZC6KT9()%X@3[6O
M_C86.'L6-8G!+')!B%;3S+U65J>:2$WET!].AA;6L:))[R*H#&XXI;)T'INE
M2C0JTVT@BHH:RS$ZEXDD"+$F.)W4>K=1R=6E6HYS/9>J@K^$V4JO3=16\*?T
M.D$BF V\@;VG#>:HGGEFFJI)I9Y=(=ZIV,FH;ABYN[$A0$!N   " +!S2IHE
M):6@* QTTA  F("B (F^UP3&*37JU&:K6J5ZU>JE*F[YEV=PR(JSJ9F8R!WM
M'$X)(&A!+!DUHTB>BS:?J'%F [^H>Q ([AJ<,5[*RJPU6_5N(WD29GZXKJ)F
M,L0&9EIU 'D+)C<#22%.H@ @PL&"8DXZ!1TF5L1RK@97#Y8\6H\9J6S+5T4[
MU5?48.ICEBJX,(GCAPF.&!6DA^T5&)1O//IB,*)&)'Y;OG:'4<UKK*<M4H4Q
MDUJ(J4TK-J5J?C*37+D@/I6F5"W#$E@/=97+?A?/?AOI)J9&I3ZCE^L53URO
MD:M7,]0J=,"4'6JO2:PH]$\,$U%2K6ZC3J/5_ANBH YS.^"83@M!A?ZHS(F8
MHL45ZW#GBE<1T&'&\/V+%J*=%DH,5$T3.85:>)J=DE60!DN.E9G,YVM5.:R)
MR1I0E8/I8O65FEZ%1"5J42A4R0IDQ!B<3\6]#Z1T3+]/7HOXC3\097-4VJ])
M8>*GY/(,%!R_4*%5 ,OG]8O3IM732C$5+@8Y['( B)(JH;@&]B "?<['3N"1
MN+$GXXZM5(=S3)83 B;QV]9%O:V/"FJ5:E1-):: @Q(8";F3RTDZK[SO?"^(
M+AZ&F-#+/.YAM4M(JI"9RY_]W 9F:,+9=<@5B;[ ;E*7B ,*@ $RD3('8GOS
M'')DQC3GDRJ-3>@Y=W0+4)L"W&G>1-B3&W:,,W9GC5#V4,5  !&NVH7%B>W8
MWM[#VXM6S2-R1.W':=CC&6.C3%HF(N)WY''?%WOE,[^$WSI]]_ZO?'1M],SQ
MV^3_  _#CH4/_&YY)!__ &G;TL,8LYO3$[?_ ._WL+8HN0&R$/8J%( MM9;6
M_>;_ (BWQ;/BKUD$VL#SMZF;Q\IVG!V)8ZI'U$D E[7;O;O[@;?N._8S%;3(
M)$$C^I^_;!""S,%/I78GL";=A;O^?8>Q[\3"X-I[7-[7[CY'$Q,80U[@@#XM
MM;^/_P!/XS%JDD]K<<W$_+MO!MC!<C>WU%O]X/QQ,(WZC]\8PJ+6MM<$CMJM
M?8GN!?X_#MQ,+B1PN@3$JREHI*NGHA5RQPBLJV:.EI>HX5IJF1%=XX8E(=W2
M-RJ@L$8V'"5'--&<(U30I;0H!9H$Z5!(!8[ $@'N,55ZO@T:M;PWK>'39_"I
M@%ZFD3H0$J"S1"@D28$XLWYK> W)O*'P^Y6YOXSS@H\6Q;&(<,DI\%PJ@+X?
MB4V+QB:C3#*MZVGJE@2/6\]?/1:695!IT#%A\OZ+_P!1,[UG\4=0Z!E^AU*%
M/+>('S59XTK18+4UJJ,A8L5\.FKB%!8L38_$?P__ -5.L?B3\2'I67_#]*ED
MZM?.9=E:J1U'(T\F&#5>HT/#-)"7IFDU.G5=O%J4PA=0SGXRRSRZJ<X5$DF7
M7?$5H8UF&&)'4MBU9325BTL[+'$KH8VFJ85+!SZ7),;!2K>XS/4ER:Z<RH0U
M/+XLKX--PI<"6(,@*T@*)O$<?3.H=>RO1Z!/4%IY<51I;.5&1<O0"(6EG8J$
ME*9.JPF!()QV?&,J9QRAC67,G9EP?'EPZA:LQC#*"C@EJ<5I*R;[1A])A,T5
M1411TT=52QK-54T-,LTE-4I-'"QDWX:9K+9VAF,YE:F5\>HE.C6:HX6@:<I5
MJ5U--7+,E3RHQ<H&32[#'F.D]8_#W6,OU#K>0SN6I!]62J9M@M&GF'H*E4UT
M=@&9*=2OX(J,Q4/3=1^F3Q[-6-TV-YHK1**BCPBEJ$O1LR4,T5+&"&CJH8DC
M@GJJ=RRQ(\;RR)I76 AX[63RS9?*)I"-692?$!-5#4,05:[+3*P68$"2;<8]
M-D,F^5R-+^+2KYAU!%52SAF(NREM3(K#38$@02!?&C8C48=)5=3"IBE-+#()
MTIXI D6[C2&FU":1AIFDLG2B8, H(4C8GB!=-82RFQ8B6D S"P5 \RB3J(W-
M\=2A2K:0*VCQ)!4F"VT_3@S)M[8/BT&&G!<%2E>K@=Z>]9]LL:+[6TTQ/ZM<
M2%EIQ ('D:HBUF>1U+LH4"4VJ"M69A3(# IHM4T%5!\41^O46 T-&D2 ))P]
M!ZPS%0538GRQ,QI'ZIYDG8D0+P;8TVLHWBC3K:E$JB1-2V5XFNJNC"UX[!CK
M"K<CM;C4E34Q $P#,$D@W)!]3(D$GO-AC<IDSWM^WO&WI-O3&MLLM&KQRZ'C
MJ+JB,-960 Z+>Q#B]^UK;[=]((J008*Q)F+<[]MP=_VQHF!!M;8^P^!!,S,>
MI'.ODFX!4(0?4NPTMO<=^RVMW^ESMQ=A9V%A!':)G<WN('?>-\'(WL=M0O\
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MG#4ZM(D,9).[023QOSM[^^-3<,TLH8F5XB(Q9@Z6'W2NY6POZ=]@=MC?C0+
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ML?\ Q9H0$'?Z;?CQNH_^.H8,R!<^AGOV^/QQ@S;M-.0-Q%CL21W]3BC)1Z5
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MMOV90"!MOQ<A *P3< 6']]AMW]YQ8!Y9WG>> /WV[CC&O:VD*.Q8^E557_L
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M&I21<&+"#O!(WCC'SY@M"LZY;.+4-)GI-X )H.5)45$9M#D&"0613>#!&)/
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MC>QX:3V'(V[^WTP(CUB^TW)F1\?>WQD8[:RSEF#$D$D['8CW_CW[7XC&U@!
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M9Z*BJ?*I9K!+F/A&3L#QJ"CR/FQ\WX9-AE+5U5></FP_[+7RB7[1A^B54U+
MH16:,%68L 0HX/1*_4LWE'K=3Z<G3*ZUW2G1\5:_B4UTZ*JLNJ-;$F"00#O;
M#_\ 4/I7X/Z/UK)Y;\$_BFI^*^FUNDY?-9_.MD<QTXY7J%1JPK9'1F*=$U4I
M(M-M2 J[/ !*D"X+RFC_ -4_SIKFX_J]\8(8GNW\J(K7)]O:VY[_ )>CR_\
MXF]S(]0#_GZX^89V?&I'B]^+DQ?L?V%KQBBE7)(%R1;<VVM;O?;Z=C?BC%9
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M:LE>DX!6I3=61E8 @@J2IM%IF;G'*'9W)+N7TC2I/<J/NBXM<>X[DDD<=D@
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M((M/J9W&'V.8=)03QQ2T]-2O]FIAII97E232@ F=GFE99IB'DD1="@D*$5;
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M_P#/V,"C$6(( /M;>^WOV^AO^-O;@,H,@\$WP>?2/OUP$C:F)(L";V%R+C8
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MD01(F.V_IN'3,ZUE)*A0UCP)O!N0.V_&-9QJIBI*QJ>HC<4\@9':!#9E!":
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M'2S!;I^ADK4T+*I)2FUR54L2P"@P22=3@D'20,:=*VN0*JD@WL; ;6N221[
M=K7[  'CJH-*WB>=S>VWR_?TQY2JZABT>3:X[V6VTR1Z6MQA[A.%R8IB<6'W
MT23HZTRNK%Y)])$2$#?]K(4C4%=5V4@Z=N*<W7&5H-7/Z4AJAX6F)+MS.E06
M)N  9 .-?3^EU^H9ZCD:8/CYDJE%?YG=X%-0+W=B%6=Y]0<!+2O!/-2S0O32
MPR&*6-T="IC)!616.H &W<^X)MOP5J*Z+4IL*J,H<,"K AMBK"%@VB.VV%KY
M>KE:M?+UJ%:C5I,4KH0X,+J!#K)@B#]0,3.&YBS'DRIEK<'Q&OP6MK:22D>2
ME<QR5-#5IIEBE]+AJ>9+J4(%U)%Q?C+7R60ZK2%',TJ6:I4J@J*M02J5D)(9
M8((92)G58X['2.O_ (C_  ?FGSG1.HYWH6;S64:B*F5.FK7R68$5:50,M0/1
MJ"-2L(8=R,19FGQ"KDJJEWJ:J8M(\A75+-(QW(5  S]@MA90+ ;F]Y1:--:=
M,!*2PBJ+*J@64#@+$'<?$8Y0S%?.YHYO-5'S%>L[NU9U J52Q)9F@++LT$M&
MY]\*+,HG3J*0 =1+$DOI]B1ZEOIML=KW%K"]1IGPSI.H[$#^4':_/U%KS,8M
M5A^:);RJ(,F=@!?OL)[\X3J1'',[1LTZJ0Z!22I) ];>P07M<;W78[</3EE"
ML FX+'R[1Y8$2WI<7N.<+614K&M2_BWU=[>LV@S'RP*/549291T!.A8."-;J
M;$,.]U/X7V]]SQ-"5"RR6TD0(.FUB#N9D1/>^&-3,40M<4@IJ^>2/-?]Q'R]
ML+1US1PN@9!UR&?:TFI;W8D6)$ER2I])MN#;A30U-,$Z+#<B#>-C!3:;D&<0
M=1K4E9="CQ/-9;F+$D@$WG80-OAE"*:JQ##X:Y^GAYK(14R@,Q$#2+U"VE2S
M *&M93[[_#5%J4J%9Z*AJ_AMH4D#S$&(G3$GB0(DXMR-2AF,_DDZDQHY$YO+
MC-U0""E!JR>(9"L20LP #/()C#S,%'18;BLM-2L9J*_5IY0K#5327Z;#6 =U
M6]CZ?BW;A,G4KU\N'8:*@$.)U0Z_JNIN)/O>\[XLZYD<KT[JV:3+5?'RI K9
M6H01JRS3I,,!<A;V ))(MLI62X92))3X>IFC9S(E;-&1,X86Z:C6P5;7NI!8
MV&X&QK1<Q5(-0Z3L4!L(V-@+D#<;7X,XNS-?(Y(&AT\"NA:168$/!&T%FCF1
M)[^F-=8W>Y 'J%K=@ ?NCZ $=]]MS?C81  OM)G>9._W\!CC5&U.6V!OZ#:1
M?C:]O2=B)-R1<@B]K'N?C\?;]_;B6 !L9W$W'R//M@3OR0#8?MS>WU]<'B5G
M(5C:Y N?XDW_ (#O;V/ >!,7$>_WZ_8%M$:JB D"6%]P 3$^P$>^+OO*>'_5
M0\ZM2P-O+WQHW OVS2C>W;<D$_EQT,D?X+D"/>\>0\C_ #\SCFYT?QB9!\Q$
MC8_K^FT7Q1>GW%__ "K_ ("_SVXSXH%X^NT6 ^/ ][[03C ;EA_=(_B >)AB
M=-A>Q,]S)^@@S\!;!"NI=1)O8_%K"^UK6/[O^/$P8D$SP0-C8$^AF?V[F^#+
M95M:][$6%R-N_?\ Q'$Q ;"QV&WJ./E%_P!KXQ=]0#=C8@ "QV/U]N)@2!R(
M[ 1V,[GVO'/88./@[@BQO;<$6/?8?B+6[\3 FY!V/?<$ <[21<1(F-M\#[*+
M[#8#V%[7^NQ][V/$P?U"9,@"+KV'M%Q?;T[8,"4=6 MI8=Q<$ W((][BX/R#
ML!P")!!Y[;X@E/,L$@V!$[3QWY]B8@;O%JIEC9%D16D&DOTU,A2P#1@D;1L/
M4RCN1<GA/"208,#828F=]YG@'@3WPWCUHC3OSH&W;T&\]S\,',:55,55V*J-
M;!=O4/29 !8L='I%RP!]B;<*"R/JA038? 2 )$*"88FY]+X2K6=BJL-((&PB
MQ$22#?U^A[RV+8-@M%0X#/A6.#%:K$Z":KQ6B^RS1O@-2E;/1Q8;53N1%45D
MT=.:\BG!ACHZFE8R&0RHE5',5ZC9@5Z HBE6-.DVH17IBFC^.HB0DNU/S#46
MIL;R(:M22EX>A]>NF*C?^QBS*5)DR84-VAAOB#Z1B(#@ABUA8$BY&U_>W8=_
M<?/&@,&!@[ 7M-C<]OC:#VQ3AY14C552@(9&C9=9 ]48.UF3=B&.VX^\;=N$
MJ5 @W!#"QO>]X([6Q"8!/8'TXY].^.HX!EO&J[&XL'P6AQ.LFJJ*:L>BPR%I
M\2>&E@::M=56/3%'%$K2R$@A8UU-MOQSJ^9H4J)K5JM-%5P@>K IAV(6F-R6
M8LP  N3-K6X>>SN5RN3;-9JME:2+66F:E6LJH&=PB@L6@:F(51RQ 7$%4U$B
M4M?0XW/*U3&LM/0QQD?:(94JKE3K1#"@&IGD ZCDE4>Q)-R@$TWH!89@[E@0
M&7PP 8&Y) @$@ 7()$XO5"SK4H(K495F9;J94&9YO:1[\7T@T<M5)%0X?%)4
MUU54K!'3PLU1-*\I<J@47#2@ C8* H!<^F_&ZFP0^)4(2F%+%BNE0!$W/$L-
MR;GY=!J]&E1KYFO%*G0I-5#M9%10QJ3P?Y2)N8WDWOR\._DU83CV.4>)\]<_
M5>'Y Q;(R5\5+EVHEI<W97S/B>'TDD536N]/-@=;!@,QJ5>F#F'$G:-)-"*Y
MX_+?X_\ _P!0]?I73:]#\'='7/?B#+=83+J,Y2#Y'/Y2AF=-6E3C,4ZROF:,
M^$^D>"9<ZQ Q\DZ+_P!4QU3/95*G3:60Z3XM?,9CJM2NQ:OT\TLP,I43+"FK
M4*C5#E:STJCR%!I27)"5.YOY-+RGS=_*+,,>)YOY*+G',6"9$SQADE/38=G0
M95Q..FJ*NDI9HQ4S+1LU/3XK1M%2%W9XHYQ$>N/O?3^O-UK(K0I"ED/Q >G9
M3,]4Z;5;Q*O3FSU$N*55Z3%%+'Q/ J(7!"!M)*E<>['4*O6NF&ETITRW5LS0
M\0T:J,'ITZB BJU(P],FFZ."RDH64U$:Z8Z3DGP_8US.PO)/,/,>*94Y;<N,
M?Q*NPVES+CV-4E'3XKB6$S3G$9:P0O6U67Z.&FC@6*IKZ.CHT2,"F6J+Z^.?
MU#\1T.EU<_TW*T\YU3J>4I4JKY3+T7=Z*5U4T4IZS33,U'<OY$J,YU U"DB/
M/Y_\1#H>;K=&R]*MU;K56FF87+4E#?E\J2E$NY$*5%8F3YG,DR%6!\29[GPZ
M#$\2PL"DEEIL0Q"&.MIB[]=8JG_1I3*Y_:1NL>J.3IQ]6-M6@ J![;)+4>G2
MJ^===*BS4W$:&927$#])!(D20K B=X^@Y?4U&DY.HNBN5C]$C]!'!6+CN>UL
M<_6Q!WL"3:_L=OD>P_R..@TVG>/I\O>]\:B! $QQOZ;'O@%72FD?V222=S<F
M_P"8(-MP+6)-^%)G[[6PIV(@6N?<;6Y!%M@!!,<8-<W%Q8$@D;7)/O:]P+_X
M?EQ,23(D0"02+22>8F0)_;X81(5!-903(X8$WNAV5M.^VKNU[[]K 6X),QZ"
M,1CM<03R-KG<<]KCC@WQ[-_ELBW@'\(P_P#X#\O_ /8E/Q:OZ1]\XS5/UM[X
M\[[])M13YOO/'W/\A>3)86N+-RZP2VUM]E/S;\[<45#OQ>/?[W^F-U#_ ,8C
M>+_,P/\ ,;>H)Q0.H]A;MN+'MVWO;W]MO:][<48N(!X]?6>/]X#8K;L21[?-
MP/RM[[[GWOQ,';Y^_P!_T&,T^HBP-B0;W/S?O<'X!(^+CB8!$3;8Q%KQ_03\
MQC+D6L"!L-^W_#O??_#B8/?T_L#_ %P.]P&(_"VW:W?YWOL3O\;<3 XM\.U^
M?;VO@#VW]1^0>UO<_/M<V'YGB8/W]_=L**21L;V(]MB=B-@1O[>QOPA@&3L1
M&TP?E]]HG$WMN.W^,%( %SI&Z[V[V.WS<V[?NX"F]B3 .YMN(C_5L3[_ +8,
MP])/;<>]B2"/W#Z_!_+@"Q %]B8F+_&#N+_3"O\ I/PM\1^V#PS5$4T=0C&*
MHA<2131L5D1T*E3'(I#1LK!7#J=090![<1U4@HWF5@59#<$&\:38@@D7M?WQ
M=0J5*;K45BM1;I4#,'4@@J0P,J08*D7!CF,/*[$\0Q2H>IJZJ6>IENT]3)ZY
M92?O,\C;DVMZKW;WX5*-.DL*H"@^5!91[ 1?OOZ#&G-Y[J.?8U,PVMB &JL)
M=@L*-3'<1:3SO?#/J/*Z-*QDT?WCJ(^E]K "VPM]/:[:5IJ=( D\"(_S:YWG
MVQD#%G5G9GT" &.K2 +@3L/3CB</35F(J\+-$RV*F(CTD&ZCMJL#8W!-K#\.
M*138SJN),EIN-B;'?YF >1?IG/(JH%A2+#2%M8\>_:^&\DDDCB5V )(<BP]6
MD@GVMZC<V/S\<6 * 0H)WEKVD0(WV]MQWVR5*C.PJR)!#&.=/>TDF-O7OC8\
ML9DCP/[:*C!Z/%8ZJ)HU6K!_9M:Z,EF%K&VH? _"V'J73FS?@:,W6RQIL&+4
M&C5&X;]0)(VM8SN#CT'X>_$0Z+3SBU>BY+JRYFF::C.AX0P=+(:;H1<@F\$1
M!$&4J>/]=S2":2EH*>BAFEU!'6*",*7CB8#7(W7E7[/'<L0YL2%!/%K_ /I8
M":ZCU"%.Q9FD D<" =1'8SZ8P4-76:M2GFEIY*A05ZRJFH)2%R*08EF8$^10
M023['$))TS;I(  +L; JS;78&U]UT@ C8C8;\7K(TZC,^NPO:.8W.Y,^QQAJ
M:6?_ -/ \,%'#$&2#$KV$#WL3W!V' 8L-:GQ-JJ2*.H6B9Z8R':ZF[F$C2%J
M FH1AE8:[7MW&7--5\2D*>HH:D-'8BRL#.I=5S##?':Z.N0.6SAKNJYE:3-3
M5O,"0P+%1 TOHD+(,&).TP515"4,"LKR'2B:V#*(Q_>OW-C<FX%SVL+<:*=$
MK$$ 7)@1S[[>^\<1CA5ZY85"H9VG2"3J\H'Z=S&\GBY@7.$;G[O]D;C?:_X>
MW#P(GG:(X]_Z87[^^V"D7-QMN-_?\/P[=[_AP0>]^PDVQ/O^X]OO@8<4]#5U
MBS/!%)(E+IDG:*,R&.)F"ZF"@E5U;:B"!N6(VX5ZM.D54D:JLJ@8A98 S$[V
MX!!]9MC3E\EF\VM>IEZ5:I2RR+5S!HTRY2F6T@O 8*I:!J(%S'-T"0+A4<;7
MNX]6^^XV^A-MSV[ 7D,2-1'J%-IF#J/[CYWG%,@JXI*ZZ02WB#S6!V@+)[6W
MO%\7A^4ZB?T2/.I?6%<>7WC"K%V+HV9HB[CVLA"@F^VOZCC?D_\ Q5?_ *F_
M_BT?>UL8,[,T_6+[_P I!Y^XGWHEC4M'8%DLJZ5<!@1[:6%["UCO<V%K<5-N
M>;F8X^?^<4>Q-OTF >_(!W$'O$'!QJ6XTDWWV_=_N_SMP,0GG2>>#\=I!G:#
MM%\+A38-;8W [7+6[:=SW/N+7]^)@@&1S<GD1VL?<S^]KIOZ6;1<,P + ;@+
M>^FVP._Q:WS[S[^_EB& 9YCL=@9-Q\/;XW2BZESK[6VVMO?\=S^._!,<"/C/
M]!A?GO)\OSW)OZW(]1LO]/GY[?G^_P#QX& !$&9 -XN)M["2#%]A)GL<$#2"
M+$%3N/387[ [W_$V&WL. ?Z';?VVM,;^V&;CO8WD#]YF_J>^#A258=U))O>[
M"^_M[>_>VW"DP=[C<;2+QWOR+SA0#N)C8'L3':/4$QOWQA)[ 7"]K^Q(]O\
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M\44CP,P9+F(J925"JI11H )'I8C=M^-=-5TAUTB&.DB01YI O)))()]1VWW
M*U3Q-*A@ ! B #8'Y=[BYQI!702E_NM8$?=(5@-@>UO@>XM].-A$1Z@'YSB^
M ) D7D_ @'O?8C<FV^V"LQ6VK40;6T@;>_JMN 39;CL2/KP,26L"=XB;>X,7
M!V]/VP"G4AV )(N!8D%6!(!"BY%BI^;&W;B'YX!'TM$";WD  1W GOV,F/XF
MY)M:Q["UK C>W\/BYXF"?<R28B#L(B 1>/IVDX3;>]]KW_*_$P9!WL9VL(OO
M<B3$B1MV! Q[-WEM"W@'\(P^.0_+_P#V)3\7KL/;][XRU/UM[X\[_P#2:O\
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M+L!M?RD#@[V]R1>^,F=4@TH!X)L3<AO??%%J1.R%45Y96**D2J6-P=1&E1J
M"AK:K @=^YX10'80(4++1R%'F/8;&?7<[XS:27*HK%13+U&@P !+%2195,BU
MH%SWZ!G[E!S"Y:4^4IL^X#6Y=;.6 1YBR]2XC'#3XI/A,E1)30UU5AT;-5X<
ME1(NNC%=!3FJ0-+$DD)#\<S(=9Z9U,YO_MN:I9I,GF7RN8>DVNDE=%#/3%6
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MFI)@* RS'C468<6J,1I\,I,$2I?J1X9AW56DIR502+3I4R3S+&70,JM*Y4$
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M00#V-Q-^WK@@;W.]MCZFQYY!/H>\K4^^H*;;7U?WCO<D6 /Y6WOPK[;<QZ_
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M(6U^]O32BI*E0;@CU$V%U'L;6]SV[7VOVXZ:OI)@Z;D%1M.TBTQ YG]L>:N
MP!@,(:+2.QG?M^V%5],1U$^]COL18['_ #OQ6UV,7L-OC/QO?C;F<6BU%9)L
M2JGVN!;MQQWWPXIH>LKLSK%''I+2RL][FP"JBVN#<,1N+?EPE1PA6 68B H$
M#>"23)FQ$QZP+XT9=%="7?PP/YBUR=P(M*\W[3-@<.Q3P)%++UPRQVUF*X=G
M8%@5U]PI&P%K:MMSQ5KJ%U70!K(TZA-I(N !)WGOS:,7,F62F[-79E16)5##
M$:22MYL18"V\#!TFI*2JP^N3HX@BE)JFAJ8Y1"&5[FFF.HZPP52TB6C)8*!<
M$\0I4J4\Q0)>@[*RTZU(J'$C_P E/RV-[!I:WPQ9EWRF4S63ZC32EGO!97;*
M9NF6I'0VKPW$PRM DBQ!(CG$SF#,]7F?$GD6FA@$S_L:"BIPL*AK!(8((D'2
M2(6 55]86Y'&7)Y!<E0 >H]1E4%ZU5OXC,#=W)/F9^Y(@]\='KGXES?XCZI5
MJKDJ&3IUZCM2R.531EJ",?+1H4ELE--@HXWC;&L'#YZ<NTM.T;'2Q#JZ:58
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M&T&<(5B"+V^MYVC;O>\ $C"OL5Z6[Z0"3('5;DL5"D(&W&[ DKM<;<+/_NF
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M_;#ZF\E3S5IP6;P+\_(K#99,L4RDL/;?$;6/L03WWXKJ+50C2E5P?^*M WM
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EH*2H';2P()N#Q>BA%50( $ =A\?VXQFJ$L[$MJ)/ZIF;;SC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g104413g04q02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g04q02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1KX4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0&+            *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M  !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O
M;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L
M;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14
M;W!L;VYG       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F
M       .             #^    X0DE-! T       0   !:.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@             !;    QX          0
M   !              ,>   !;                      !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   !;     !29VAT;&]N9P   QX    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   6P     4F=H=&QO;F<   ,>     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    &.$))300,     !!1     0   *    !)
M   !X   B.   ! U !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" !) * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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MV6?0:QS7$_YA*'T_J?1.IN<S!R*KGM@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M8V1F=.4U-D2&EL;3_\0 ' $  04! 0$               $" P0&!0<(_\0
M6!$  0(% @,$! 8-"@0% P0# 0(1  ,$(3$2005181,B<8$&D:&Q%#*3P='P
M!R,U0E)457*2TM/4X146,S138G2RL_%#<Y2T%R2"HL)$8X1D@Z/B""5%_]H
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MH[+AWY*I/E:_]\@U5?X_5?HTG[K ^+^I_P"$-U>^I='?U2Z.RX=^2J3Y6O\
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M\@U5?X_5?HTG[K ^+^I_X0W5[ZET=_5+H[+AWY*I/E:_]\@U5?X_5?HTG[K
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MH7!0E*0E-:I14YDMI%0BDKP,G8 [E6!R<9P,GL-+I+$M8,YVOB\)_)W$+?\
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M+T\'_P#L6CX53_V\K]-/TP $_>J_15]$<?WY'A&_"B\/7^>7IY_I%H^%4_\
M;ROTT_3"L>1]1CC^_)\(OX4?AY_SS=._](M'PJG_ +>5^FGZ872K\%7J/T0#
MXRO"(._BD\/ ^GK-T[_TBT?":?\ MY7Z:?IA-*OP3ZC'']^7X0_PI/#Q_GGZ
M=?Z1:7X33X[:6_+6GZ872H92H>1^B.1XR?"*>WBC\/)^CK-T[/\ !<6D^$TX
MS.E#_P!:?IA&/(^HP/[\GPB_A1^'G_/-T[_TBT?"J?\ MY7Z:?IA=*LZ5-S8
M_1 'C)\(I[>*/P\GZ.LW3O\ TBT?"J?^WE?II^F$TJ_!5ZC'/]^1X1AW\47A
MZ'_OEZ=_Z1:/A5/_ &\K]-/TP:5'"2?(QC_?E>$3\*3P\?YYNG?^D6E^$TYQ
M.EG_ -:?I@TJY'U&!_?E^$/\*3P\?YY^G7^D6CX1(_MI?Z8^F!CR/J,#^_+\
M(?X4GAX_SS].O](M'PB1_;2_TQ],#'D?48']^7X0_P *3P\?YY^G7^D6CX1(
M_MI?Z8^F!CR/J,#^_+\(?X4GAX_SS].O](M'PB1_;2_TQ],#'D?48!\9?A#'
M)\4OAX ]YZS].O\ 2+1\(D?VTO\ 3'TP!*C8))/( P_NGW77HGU:GU"E]+.K
M_3'J34Z3"14:I3[#ONU[MFTVGN/HBMSIT6@U2>_$B+DNMQT27T-LJ>6AH+*U
M!)>F9+662M*CR"@3ZH4H4D.I*DAV<I(#GJ1$JZ?#8&B"",RH,0EQVW427%R5
M+2VF/&>D$>6$E:G/*0H-(&](WN%*2I0&<G52KK:>B2A50I21,*DITH4MRD!1
M!T@M8AG8$V%[1T.'\+J^*+FHI$RE*DH2M?:SY4@!*U:4LJ:I(420;)<@!RPO
M&,BI,1D!:VIBPK& Q#D2%<Y[H90M0['.1@<9QG5#^7^&_ASO^GG'SL@_3TCJ
M#T3XT?\ AT8__/I?8\P?1;,)T:Y8<D+*85;9V+*#Z31*E'SC_&3YL=.Y'N4,
M@^S3_P"7>'6^V3+LWVB;O_Z?KNT1J]&.,)^-(DY([M73*QNPF.QV+0Z4QRIM
M+H?B;5H2X 9+*5@+ ("FU*"TK&?60I(4GG<!IAX_PT$C7.+9(IYQ!\"$,?)X
MA'H]Q<XIDY(O.0,>?JCD12<?;XG(SS*8'XCE??YM)_.#AOX<_P#Z:?\ J0[^
M;G&/Q>7_ -1*'O, QB"!Y\3GVB4R0/I(7QI/YP\-'W]1_P!+//N1"?S<XN/_
M *9'R\H^XQSZ*?\ VB'];8_KZ7^</#?PY_\ TT_]2%_FYQC\7E_]1*_6CCT8
M_P"_Q/K3/];2_P X.&L^N=S_ *O.?U:7\LPG\W>+_BR/EY?TQP8YSCSHI^B2
MSC\N_3?YQ<,_"J/^DJ/V<!]'>+C_ .F1Y3Y1^>,O13_[1#^ML?U]'\X>&_A5
M'_2U'[.$'H]Q<EA3)\YJ$CUJ8>V,VX$AT$M>4X$G:2V\VH ]\$A1QD<C/?35
M>DO"4-KG34/<:J><']:(4^CG%QFGEC_\B5^MGIF#"*-4',[&DG:<'[8C@_ET
MS^='!L&HF#QD3A_\+P?S=XO^+(^7E_3'*J)44[=S2!N.!]M1W_+_ &_+I/YT
M\&_&)G_3SOU(0^CO%QFG0/\ ]^7],9_$%3_WE'_QFOZVG?SGX/\ V\SY";^K
M!_-[BWXO+_ZB5],8FAU$':6V]Q[#SF\_DW9T?SGX/_;S/D)OZL'\WN+?B\OY
M>5],9?$-3_WE'_QF_P"MH_G/P?\ MYGR$W]6#^;W%OQ>7_U$KZ8'Q#4_]Y1[
MO]M;_K?G[:3^='!OQA?+^@FYY?%@_F]Q;\7E_+ROI@?$%3_WE'_QFOZVE_G/
MP?\ MYGR$[]6#^;W%O["7_U$KZ827&UM.+:6,+;4I"AD'"DG!Y'!YUVY,Z74
M29<^429<U"9B"04DI4 0Z2 06-P0XCD392Y,V9)F#3,E+*%AP0%)R 18CK#(
MMG]M7TH_>OZL?QA9.I*_[BU/^-I/\D^(*;[K4_\ A:K_ #4T*TC]F+KO^ZRT
M/Y,K/T4_W-X;_P JH_[N=#YO]>K/SY?^A)AIWS1G*G6+0D'8[%@5);LF,ZC>
MRZE:XR4J4""DJ;()0E0PHDY!QC4-7.$NCJDBRER5Z5@LI)"3@AB'>Y$;_P!!
MDN.,$%0*94@@I+7:;G&[7>T*-Z7-9MCVG7[POZL4*VK+MFF2:S<EP7$_%A4.
MC4F$CS94^I2Y6&(\5A("EK<. <  J(!\\1.J'9$Z:%*Y3%N?,%_K>T:Q4Y:$
ME:IJDI0"HJ*R-(&2[O\ 7K##O'JUT#Z>)M)5\W[TSM--[AKY&&N5>A0!<,:0
MB.XB;2/-6//I11+AEVK)VTMGTN('Y;:I3 <>)]6LDB?4**7OVLTM8[O8L&;)
MY9A%5:D:=52I.L]UYRAJQ<=YR+ASCK"_%O'I4]$HDR'7K,7!NBZJG8M D,/T
MWT>MWE0W*^W5K8IZTI")=:I;ML7(F9 ;W/QE46J;TI,5[:BI]45%2I\\J ?4
M9LPD)LQ=W8N&VN,0_P"$S62?A"SJ)2&FJNI.IT_&R-*K=#R,-"H]>O#C2;,J
M?4"=U4Z5,V)1[JJ%BU"Z6[BH$JAM7I2GE1JI:;,R(Z^U-N& ZVZB92(/I,U@
M,2%.,I;C/J;7M:LD#MJ@E@H?;)C@'!^-:(S6E*#,-40D*T%7;*;6[%+ZKJM<
M!\09C=9/#XJZ[2L6%U$Z7NW;?M(C5^R*#"K5!>F792)T.348,ZWS&<7'JB*A
M3H<RHT]$1YU^H0(LJ;#:?C1WG4!G59"E&?4$"Q)FS-B.:G86Z"W2%^&**DH^
M%**EI*DI[91U)9W'>8N+AC<.V"Q^Y.JW1>RIE\1+NNVS;21TWM6B7I?]3N)Z
M%1*%:EN7+)K42AS:[7Z@B/1H3E2<H-55'@/3A/4PRW(,4,3(;DA!.JBQ$Z>=
M18--67(V^-L/9"JJEIUZZE2>S2%K*IJ@$I43I<DL'*2P?:[07KG5OH);-R67
M9-PWYTVHMU=0F8#]C6Y4JK18E3N6/5'4L4=VE0W5)4ZU5Y2A#HJUAM-6GGT&
MF&5,!8"IGU;$B?/9.?MJV&7^^:S.=VOB\"JQ:5(0JJ6%+;0DSE J?#.K!+A/
M,N!>)7-&IKB5@TJ"M#@*%@P8ZDK2>"A8+1"@>Q2<@]B--^$U(=JB>.?VV8/7
MWNOMA_;3[?;9N[?;%^;7]<9.4JGO(2AZFPW6VD>4E+L-E:&FP,>6$J;(0@#C
M8 $@<8T"IJ4EQ/G@N[B:L%\N>]?#O )T[:=- _YBV]AB*(75/H]5[:Z:W'&J
M=)?MGJC<B;5Z>SGJ+*:@U:XY+%;6Q3FTR*<A-+D31;E5C15U%$)N9+88@,..
MRID)A]W;U84HBHGA0!)(G3'(!YA3D/Y0P52R$+%1,(F$)21,F=X]Y@[]"SGW
MQ)R:%0T'<BC4I*B0HJ33HB25)^Y5D,@Y'L/<>S3?A55^,U'RTS]:']O._MIO
MRB_IB +HJD95QUN"PREUZ#-0A;4-LN.H26FRH/AM&&D)R#@_<DY(Y!UN.'I4
MJAI9BEDZI0=2R2YON7))(8GINT:J@?X-(*E%U(W+G)8@D=&R_P S%D2:*Y6@
M)LY<5+2D(;D-N)5&A2%$%+;C2,N>8I!)QLQGC&<ZZZ-8E#2D*)#D'*AC-A[7
MW<"%65 EF)?#M86M8XMSY<H-6\H5:95Y,J&@QZ!(<:I51GI<+%5BNM!;C["%
M) 'E*X)*2I)P.YTR<2E*4C4#-;6E)#I-K.+WZW+6@264D7=0."'!;PORR/9&
MN1*I\MD1WRVEIV1OW;UJ2#D8#(/9P'LG)R",CWHE*TETY PX<[WO<'PYXO%D
M."[7#;7MGSZ-:YVLLQEMQ5MQXGKJ#*F4!V1RZC))4F.K!*L')"<Y()P <:C(
M=U*LY!L#9K %0..3D?-"&^<.#R8CKCS86Y0VY$J-(>=:ILF%4G$2$)=?9D-M
MR(2&-CCC2DJ4H)6DJQL/K$$<>S4J00 5!2 V&<*)< GIC'1X4/8D,[VST%_H
M+^;&'29$6I1HJ(-,BEY#@\YV=-?;6%J4$^E@LI4EQ.T[0A0')!'NU"Q05:UJ
M :P2D'GW"[$'&.1!>\-)6"25J\ .3V +E^M\7.\'K<JU%C3+HHL!^)*J="1#
M14949PJ@PI\N.7XL%\N-9<DOHPX4I) :VYP=,FI6KLE*U *)(2?C%/X0V Y.
M_MO7F.M<LL2D@EC<D. 2P)%F:^&Y&*C_  L*'A\#9XO53&2W(><@O2 4$!:G
M*G0E*4A)2G+?<)X P,<8UP..%)6C200!)QRUV=LGJ<[;1Y+Z<!(X@D)# &0!
MI;\,]>5B]S'SC^F4"SJ[=5%H-STZX)D*X:C2Z$VND52%2W8JI4MILR%JD0IR
M'D-[RH( ;&4XR2=97B*ZR52SI]*N2A<A$R:>V0N8"4I< !*T$.Q!OEC:/,O2
MBLXGPW@W$N(<,G42)_#:"MK]%73SJB7-^#4ZYHE_:ILE222AB1J<G(BP-=Z!
M6E<,.YD]-455BNT#J8_8L>#=-PTYQFJ-,PWW2[#**=")ENNMH"&4K/JDD8UP
MI7'JNFF4QXEV:I$[AR:M:J60L%&I6D:GF+  8N=@7<QYWP?T_P"+R)W!CZ2?
M E4/%?0^5Z1S9_#.'U:54D^9/DH*)^JIG)%.)<TNLI!2L $L8;LWPT]06U4G
MR*!&IK]0CM06FZA6XBC4*JJ.ZMU$'<RT%*44*Q$0'78Y 2MU2EIU,GTCH'F!
M4R:L))F HDGN2B0$E9"GY=XD!0QB._3?9,]%IR*U2>*?"95&I4VH53TL[_RT
MA,Q* J:VH@!2A]M("5Y2&39]4_PZV@Y8%0JB_E7)N6E6M*JM7JM/J%-FT6FU
MZ(ZZAR@3;;:8^.6&F-B"[5/-V94-R$CDT9GI%5_#921\$333*E,F5+7+6B<N
M2IFG">5&45*VE@._WQ$9N;]D+C:?2B1P\?R1*X95<313T='44U;)XC5\+7*0
MH<4I^)JF_P G3.TF%6BG*0H(20&6XBG;L=#*4>JL+ 7RZ4J)]Y;*>R?:=_K8
MVCV9.O"M1)S</O\ ?"QZ_P ;7CV?58,4D'2>Z]GLRG8O<MI#<X);DYPE(41W
MP.WYM2_7W?3[X""[@M8;/S^F"[CB$J.Y.#QP$Y[X ]VD?.S<_?X0H?<OU^OJ
M@N\M*L$#@#W#GWG''T^W2PL8@)*" D$D@C@<#^$?VSH@A292G"?5 .1G@=^_
M\^D5@^!]T0WU$WMJORL6C:XA)_Q1@C&<#OS^?348\[?P\WAXU:3EW'CD>+>K
M&S022RIIP9&4=R2/IQ[/[?DTY[^%WV\";WWVA58(&3;U_P +^V,WG4E QC@^
MKP/=V]OL]XXT@%W#,7?/DWK]6(7ZY^K042002K;G/MQI7 Y^0/S"%C60,G@=
MS[!I8(XV@]D@_BT00;0ELI 4-I 'L3SGZ?=H@C>AMK;G:% 9Y('\W?1"$$X+
M>0,<J:;*#A"<D<<>_1",1<JMX >V/4/]BHI"?%/XL<) _P#-XM[& !P>IU"/
ML^C77X0_PI'67.]G9 ?.PAM1_0I_YGSHCW#ZU,4X&B"$^4L"3%;XRMJ4H>_"
M%1@<<=LK&>WLUG/20?::4[=K-!_00WS_ #[1K_1#^GK^LB1[)B_4(@;J9U\H
M_2N_NF5DW!9UX3(/5&Z[;L:D7G2'+1D42G77=TZ73Z%2YU$D75$OJ8RMV$X]
M5:M0K3JU)H4):)U5F1HS<IR/E0ATDO<79CAKEV:WCD;N(VDR:):Y:5(61,4$
MZQI*0I19(;5J.Y+!@+E@#$'4?X0#I.:.W==_6EU&Z46+5Z;U9J]D7U>$&V*A
M;U]Q.B?RA?Z@1:,+-NFYJO2ZW"I=KUFMTB@W12Z%4KAI4&8_2&93T*6PR\R3
MA)!(TND9&IFZ-=LEC;>(DU<LC4I,R6@]H4K4 4K$M]0&@J(4R20%!)4 6P8E
M!CQ.T$]!.HOB J5G7!;]O]/Z)<-;50JE7K K-8K;-&I:)\2-'DV#=M[4BFU"
MJRGF*/\ %-5G1ZU3*DM3-1I;)"/,3L^^E +DLY#L'9R' +=6;D3$@GI,F9/*
M5)2@*.E13J+ E."0"HL&-P3B%A77YBE]6^G?1Z[>G=[VQ5^J5*K+MF76ZNUZ
MI9=:N*U;3CWC=UM17:=<+MVQ542DNOAJNUNT*/1*G+ANPXLM,IZ&Q)0H&DJ"
M@=)(*=P'8'EXL<7P#"]JTU$I2%)*P2E;I*"I*=2DV.H,#92DA)(-[B"=6\25
MOTOKI/Z%BUJU)J-"MRA73=%V.7)TWI-%H-(N"'7Y\62F@UV]J9?]PMQ(UNS5
MU)VUK0K;$#S& ^Z@ESRU$MT%;^ 8].C;\QT>SH9Z1.['2HL@+4L*0P<$_%*@
MHL!=@?H)]'?%+9G6"I5*FMVO>M@N-=.J%UCMN1?L6@0HMZ=(;EF5.#2>H-#<
MHEP5U4*G%ZEK54:/<:*)<=(CSZ2_4:0PBH-;45+(9B"7TD NR@SA[7O;8L6)
MLZ2YZ9FKNK0R1,&L !4I6%AB6#Y!8APX!A3M;Q<>%R]ZO1Z!9_B"Z17+6[@J
M*:30Z51;YH4^?5JBY3D5:/%@1F):W9*YE.6)5/6TE3522EU$!<EUEYML,J8
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MO3K5@5V%)K-.BIMYJJA\R@Z(KN$EJ2@J4;G20!BYW?P?;+8C1U$M<Y"9:%!
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M0J1*<#N2H-)2E?K'C'T>I  TR>;.>\C'0=FY.+6]5SMIW#I<LI"53% D@DE
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MGR284:-)IZ4%G8(T<('EOR'G5H0^K*QYA2TXZM P,- @<\8QJ4K6@G2HA[X
M +6Q<7YDW\8<L7<L2<*(# LSG<#9]]LPT:VN._&*GFDMLPW%2&60-ZMZ3Y3*
M$H!!7)+BVPA*"2M1/!(.KE,X*KNI82"7\23^:P+OT&\,F%2=.E7X3\B-R0'
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MAIJFU-M]7DL^:X9B4M[D@*SY)QD+3)HI2SJ6%+UI22=1*BH W)/= (MCPCZ
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M<NJE-73WJD:?=M%NZW4Q8[*I,V4E#%)@0ZR%>NA"Y*%X2A)07 $K/JZV'")
MFU5)/6HI$JCFDJ42!K07 *C]^HBPW!V=XP/%.)3J&DXG1+,L(56(FD$L3)4A
M0=R?BD I?8V-X]BO33I1;M LIJF7/;%OU"M5:*A=Q/+IL)YT..L!/H")"F%+
M6S#;6IO"3L6X5* )Y$E;Q)9G!*4N"0"I+V!.S$6<O]+1XA754VIK5U5*HT\M
M*M")0?2H)/*_QF\-K@O'5SXP?!?<5A4FL]1NC$J=.MA]4AVI6E&04RJ$'D.+
M>F0$LE)]%;4@DM)3E&_*<) UT.'ULN5.EKG=]*27<NQ;F7LWBXSTT7!.-:Y4
MZ@GK[";/04":+"Y(L;,5.R@YZ;/YZJA<U-B=1JI;UPW36F64JAIK% C-+D/S
MI'GI4XAT>LCS&T[5-%8*LYS@\:VRJN16)4F4D%(EI8:04J)'Q0+!PQ._E8G1
M*IC(73)%7, IJ=3AE=XJ%BHL227LUR\=F] NJJUR)4>CML0Y\F'2*6W>WIU6
M;$>*J,U#2:=173V+YEO-N.X*B%8.T#G60K%JEU"1H.D* 42"0""7"L)L'M@/
M9HO(DZ*+M1-,Q<S6EC\=#DLR000V00WC>[FZ5T5^^[!CUM;GH51@U6L6)-@L
M%Q#D%2'DKK);D H2I3BUMIWMI)4@[2#@ZFJI\F962YJT7DT[N!95B[69]G#L
M1SQSRBHDT*Z>6K4)L\*95RD%B<N0Q<$NS/<0Y;,O'J;TTJ MNW[5B5^VVXL>
MM7G"J,)\N1)E*"BARW*CYF4U&3&?0@MN,/)?*0G [ZK"IEUZJ=.I*=252R79
M7>)2 2^HBX <YWVB-5,9<NIFDDJE)"D$&S!.HL'8FS'-G+F+-](^JMI*L"D,
MMU"MTV5&KE2]/H5UQGH-;B/U>>\Y%B-(?0CTB''D265-)A[U(;'JH!4!K.5=
M)\ J%D$JTKU#J07MGQLS'IB=(56R9:BGLTJ0KO&P)MFPN<,7)A"%PS;IMZ-:
M58BRXMST.^G[.K-RVS39M-F6W5YD&56+0KE/E.LMRWV6WX\=#\R*XH1772V^
MI(44Z=*XQ--?*GC^B3]KG2[=Y*@$N$$D.,@L2Y=P'A:CA4F92F6H.5T[I(2"
M I!<]Z[:AGGB[D'LPZ!]3:M>U$51[M:;B7M;4>#&JY;<*VJ]#+*&VKCBH62Z
MR)#B'&:A&<RN--2H9\IYI1LU=,B1,F39*GDSB9A:Z4$W8D!@2]^5@6>,%44D
MR@6)$T*TW5*6=PJ^E]RFS@EQD19!*DJ&4J!'O!SVU3A''.(UJ',Z61V](=_[
M9U[/PC[E\/\ \)(_TTQY+Q,OQ&O(_&IOOB/[9_;5]*/WK^K'\863KH5_W%J?
M\;2?Y)\<VF^ZU/\ X6J_S4T*TC]F+KO^ZRT/Y,K/T4_W-X;_ ,JH_P"[G0^;
M_7JS\^7_ *$F(CZRMU.74[-IT-3#,*8JM&HRS/8CRV$QH\9]A$."^=M2+ZTE
M#C022D;>V[3B0E"E$$Z7V) =A=A;UV9VCTK['2M,WBUS=-)8;EYK.6+>Z[>%
M9178E,KMHQ[B?;H"ZM)DT>DJI]-V1(8FN_ZT:KU,::0PV)TA"7%RDAMY"DA(
M?4,[6@@A79I*S>Q4?_:27!LP#9MO?U28B9*05*%BY^,Y)PV3X !KD=(?CDI^
M//5"<A1$%3[L-RHTU+P2IQ"]BE8#JBRE9PIM+G^4 =V>6,"-3J(;5I41X@&W
MEZXE1=*% J4E20<;VY *ML[FS8O!NJR%--,!]QE[RE1UM-N#RELCS@4E:U8"
MU*4"5(5N&W&X#@:64D$EB1\8%N\Y8OX,-QAK,85AWF&21X]TX#G(MCJ!&ZG5
M.!"J+D^JSXU/0XHM-O/M>8RIQU:@I*V$DM*:*5C(VD'//MT39:UH"9:2H@.0
MXPUKF[N[7QN<PTI+$ .[6!8,!S/D'>X>YWV7?$H[#5/I$!UIR+4(RRPW!::C
MQV7T#*PPTRD-QO.45.[2$E965\DDZBD$][6"E0.EB[D9W =NAM=V@EZBDNGF
M.NY#DW+/Y0E4)AFFM-1VW4NLNH\M^//64NI>0X#E)04[&!@!1/J$DDGOJ=3D
MDD&SD%(<8QU)RV?.!8=! )<,01[1@\U$/</L7$/B35U3X,6 4L(VID1TMH:#
MK4=U;@"7PM.\J2I!*0H^H=W!.H0D)4I5S=).02 , &SY;#]8K"2I)*_!3N02
M!SPU_,[<X2:C3&&IST)Z:/0I6U*'D[5AIQ82E:QMY92D#G=M /S#2A16@*2.
M\D7&ZF?G8FY#@_PFEDA"B<[ .Q'2QZCS,(D*/2J<\NFFNQ9FT+"79+[2FPID
MG[5NSM\QW /E]^#QWTI*B =!221W?OB3AG#V&">?,0=O+2!J>Y9F>X+6<&P%
MKGU9C>JNJ81+IU*;B.+DJ;9,YY]--@/S)*ALC(J<I!;96@#S%>BA:@$8'?(<
MJG4P7,^]=DV) # DH%^EP<XO"&9*+J4I1(!.DIN &#L 5%VZ[N",EW+="Y=+
M:<5#JE3@*<DBIAUY5-I]34DI0[ CD-JJDEE)]1V47&$+)<0V%)3E43@E,S4%
M)2IDZ0.\I-W"B7" 79A?-P3"$*GI=*=*0Y4DL#I-B[DL[V;87.&U*I82W),6
ML1*!5$2=E;J[KICQ'820%.2MSB2ERJ/+P&VPDK?6G#2"K(TV9-UV *DZ04I
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MJEDN*(.[.[DC)_'\QXUW#32>S,KLD!'Q=(3W<WM]?'>-B:2GT=FB4A,M@ @
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M)*5J[,J&I&4LX=G!8L+%W\<14X1Z3U?HSQ.1P^OXC4U_#IX"OA<Y&I,A<Q0
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M3 V\IXH(*T^2O!;! 6C9C YTXLQ2DCN*T]X/\6S;9!NV<0)# )22&[I:[:2
MVV!=Q:[<X68=O&Z8E.FT]TU!#CBQ):=6E+R'XTA8\QUQPA2&RA'"2 5=@3GE
MIGB2I0(TM\4@$ OL.9!L<[6Y"I@EDNX"06)!N,GE<$D8(Z/"E>-NPO1%M5.&
MV8[3JU;]F$I5'0V4I2E()PLG:%=N#W[:23.(N%$N+WR+WN<AG;JT1HGO]\]G
M8@^OF-K0T:@Q.D*<AJCIA2HVQYH@A0]$0VETNMJ03M5Y!04JSR24CMG3@05$
MN[EG.2;BUL<\;>$6$K"D!0.7 8;NP8'ZY>,Y,YV?)BJ:$$*B0F427 VH!*%
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MG5^0FH2)>"77FTA2VV<EMI[*T@9UUJ2FE@%:YA4I?=<I TI%PD)/7*L^J)I
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M>5*5K25@[]Y1'AN1RR+6CBHRG4.-RTB.F/''F.N/.$&,XG<T4N-I40EC!.4
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M>.WTYYTY*BIW:W+K_M"-I;2,F_A<^%MHY7(<<84QYI2TL<I"L'O[%!64C/.
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MW52ZI4J:GXZY4PD/\5M 4"!N%8?:]W!CU:CXE3\3X5354DD_" B<EV!2.Z%
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MVY2'ZTN>ILHE29'E4^A1'"$2JJ[D_;%,MKRPP!]L5GV\ZF2BF*$K44I+LIB
M5="]S<.6Y9LT1S98.DE-W8@&Y&'RYO9@0[%LM$A4V%'=<31G6/1#%<7*E^4A
MU3DN0&DK74Y1<0%F2^2I9458"2D) '!B4I*7F!05K8 $I9(-M 8LP;D]H@(4
MD%0!4Y9^0? LU@YN;D'.SZI5QQ8E.5Z!2'G8T=:D/24#R3MY *#A1RH<E/S\
MXU3FR2J8=4Q(4IB!D6Z;\K[[F&F4HD:B'(< G?DW/ICD'AJ2JK%=??<=C^DE
MSU&%N;G'8Z$@G#>1C()"??M&!GOJ8((2 %:=R!8$]?+QZ7O$Z$* 3=@'<-DG
MQ^K["&JF#(J%=E/K;'D)@H2U+=?"@'"0EYMAM9&TA."H(SVX'.-3E:42TAV)
M7=(&S.';J-VR#L\2V #;V8#ZAGW+!X6@J*_&:H\UI+[,8+0S,1(2)48H6HI>
MCNH25H2G."T3@D8]H&H5)7J,U+A2@"4A-B39B+.2^>L%R27 >[$6+!\6.KJX
M+6YNTI4"3'EGXU4JITMM*-MPM-#%/;61L9G';O#G*0AP  $C)SJU*6-!((3,
M<D2E$ K_ #;[?7%PFPP+X)ORV+;#D[^8T(M2H2:A)8*@VTZA!9D%W#2X[BT.
M,KV)5]M?(PI.,N!0W8!&=2?"@E .ER"1I:X(!>^P'CZP(34@ G4-["_-WV&,
MPEU.B7!"J!D("Y5.$20_/](=,>?/;C)+2'(M60$NAR,^,(\Y3C9 #2D[>2X3
M),V4RM*9FL!*0'"78L4' .[#!?F B;S$E+D:;Z+L27 (Q</GG%>?A)%SU_ O
M>+YZ<\9;CLV"42%J>,DLF?;X;;F>8&T+>:1ZBG&267/54.<C62])0D3902!9
M,G# #[82XM8;D$6O'D7IV".()=P7DF[-\?(Y'+V<->QCYRCB2!D)()2DY Y_
M+K-N"0Y#!2N3,UO+E&+27%S<$L^<?[P56%D$>WOZV?>/Y_[<:?;9KVMX=(4D
M6(O<X(RWT/N/."K8(*MWMR?>!D<#Z>Q_AT@RW(9OD9LS#R/+E93TYCWA_9!I
M/ &.. ?Q^_3HCN%7P20'Y/?PS[8,IDJ:P-Z@5 '&3@G'?O[,_P!L:BTN^&!(
M86-O 'YSZX4H?(&2VQ;#8/KY1K==<=PLA3A!X/<\^X^S/S<G TX )R1=[>1O
MUL-V <\X<D)2&8#<CZ[0<3YBHB=J' O=C!!QC/Y/>?=WSII U%R&S9OF]7,Y
MAA(UW(9NG(^N\*D:4IF*HI*FGT).PC*5A6WC![\GD8'M.HERTJ4 =)2]P;@C
MP\+&_G:*\U*5*:Q2H@%BX-\<L-:-*KCKRCZU1E<)&#YJPH8X SG/'''?@_-I
M/@E,/BR9;7)&A/KQ@_A#>[Y,.%%2[2D-^:&/K%_&&_+J-0=Y=D25X42,NK5D
M$\E0'?)]OM^?5A,M"!W4(#\@!Y#R\,.&B9,F6"-*4ILUAI\WSY%X*.9=0"Z"
MHDG[LG/SYYSR..>XT[O92P8AP&%O  ->Y9VYQ(DI0;*(<,X<\\>9Y^HQL3'C
MJ25^2D$#U24@''8X! / SCCYR=)J+@.JXN"2>=[=;'9F&,*Y%@6VSNUAY^[:
M,E;PH)0"$@#'<#\H_M[^-.&!\^?.&$IYC+[&_/?;^%XR<!+1!Y/NX]X_FT0Q
M/QA\SMCK?UPG@*"N 1ZWLR.,Z0NQ;+6\8FAP17T-YRH#U2 .>,_1V]FF*22;
M#?IR'\8B4#;U.6Y#GU!^IA,>'KK63DG 1DY((/)3[N#I<$; W.P=K#V8B6'-
M8]>B6Y<$6I2V][2%X=RDJRD@)S[<[<Y&!D8.JO$*=572KDH4 HAT' <%P"1M
ML7+/Y".?Q*EF5M).IT+TE:>X79CTY/OT//%A$]1J-24FHQ:G#D.3MZ4Q&UJ4
M_&PHJ"GDD903G@* !QGGVY9/"*N8HRU2E(T7*U!DKY!)< [N0;6QMDU\#F5@
M^#3Z:8$2]),Q0THF$AM*2#<?A#8%BV(]&_V,U=";G\4/B?E$1U.#P^T,AY+:
M1(4V>I5  0XX %%"5'A/;.",XUM/12C71UNE14QD3W'WFK5)N!< D ]=B7M'
M9X=PQ/#90E2W3+2%I$O4="5&9(+I220"0DNWGF/9?KT*.G T01UV?".TT75T
MNMOIZDQVY-]S[AI4.1(<\HQY<6DLS&7&5DC"RH;20I)QVSK.>DM.JHHY24A]
M*UJ/0*0!Y?7$>J?8HGID<7XB22G724Z0O 'V]1+GW7SL[ ^7CQ.='NI5NV[T
M_MSR),=^S@7J=)9X:>*U/;W%2POS%I5G=M"AS@'@:\_HT)I)I$^X26()%GW9
MRV1ANKQ]!\1DKJJ1%13S539E.=;(4Q93D/S.& OG( :O-1ZS6Y>=FT>B)IE"
MIUQTQI=%ZAU&JSX]+FS7:7)<-!:8F.(+CS29>)&,J2$A23PLXYW':*75I*I4
ML)27)*0' 8ET[. Y &3S!B]Z,<>DRUHF3RF<M$SX-/ES#HF"67( 402VI[W8
M.&=B;C?!OW%UGN6]9-AL-].J30;=<?KUQ,PVWYLR9177H\=+R:O&E)AMMO//
MH:2IAM]2%*<*D@-YUDY*$4@$J1,J%/?5-3IOA0(<^!YF[7!'7XO/3Q%$V?72
MJ5%6A91*IZ.;VH32YEKF+ TZCW7 WN]H[#O$Q7;;LRGTV3/J%&J-0A7/3FW8
MD(NS&8]*C1DQ)3K;"2M0# D%+I=<0XI(6ZDIWJU?7/5(HYC*4 64"";$%RQ<
M&SC&V-XX%!*DKJ2CL0V@MK#W+;-EG+E@[G-Q*[3]*8LBS+4M>/0HUQW974*K
MJJ1!&R%;U00U(>=<9 <4E#<)#$L2EK#+RG$( \P)W5$5LVH"2I94HMK?.6P3
M=@UR'S=PP8F@[*?.=?9A)5V3%E!+N<-8DM9A8Y>#G7I5<K72FH1_19;EI2D/
M6Y.5.RS69;]2KT&GT0TUM2%B(P@QTRV)/EEQ#02\DI5VZB"95.E:#<A1O@%]
MA<7#OU+;16I4RIE0J7-[Y"]F8MAW>YR0//+GLM\ /52HW9T?AV]=U1>E791)
MM42M<LYF384:>_%6^XLC:N0EQD)=QRM>]TI!5Q<4LU 3-1=:4.LDVP=3 <KE
MW\.GG'I3PWX+Q*942DD4\^Q=V"W)2 =@1AP]B-XOVEPN?;-Q.3D9 !&.PXX.
M/?C40+A_7X_-&6(8D>KP@.%2@H]U8X[>S\V@IU @9N?$@1))^./ QI2C=C>.
MV3R!WSQ[,=O=IB4Y=]N8Y^#Q/,6I !26<W@C6Z)2KCH]3M^NP6:I1*U3Y%*J
MU.E(#L>;3Y:"U(CNH(4"%H41G&4GD8/.II<SL9DN:2P0L,'M<AWZ,W0-Y146
M.U%_C(/:(4+%"PS*2;L=[;](\H/PBM#Z@=).JTCI[9BZA?46@UB.NQJ#;]#%
M5NZEPZE"48/QT@80[!C1W7H?IY*?-\ICU?-0K6HJ.'\.K**34'XTP%2K[O>P
M?Z,-:\>B>CG&:F=PV1/G:E*EU2J2<M#IU!*04:B+E3%R2HNYZ14U76?QMVAU
M&M)Z]&9G1YJZZ?!EP9=>>CUFG73;%!2:-48=,BM@LTFMMAW*XCC33JW2%YXW
M*QQX1(FUA%$I*E%.DN0 DDZ2UF.387R1>-Q)JUSD3J>HI>S33S$3$30OM#,E
M$!22Z2^H*()L7#N(MS"73>H=\5"Z;TNEFH4:XJ0U3Z;1JG6%*NFFUJB;(567
M;D6.IJ!1(E1I\EJ/-\E)?DJ<*G'/, USZSALRCF"5-!).GO[ ^X;D#D3M>+5
M-6)FRYR)9[PU: Q+@7).'; QOF"%1KG3^73ZQ2I<RZ;:9LNNT^<(%=9EW+'C
M*IJ0XV33)S:T[G6L .,;E*2Z$^L5'79E\'F3)")RTKTYL62Q%B1S-[<_;Q/Y
M0"-4L* 6I2@3;!<-_=(W<D.][0\:_4.B]4MFV7+KI]>H%.IU]2[ZMQIQ+=(C
MT>MR:2Y%CR%QPE A?&#;GGMH5L<P^AML@DC352I$F3.+L6T+0HN2GH2"<L+/
M=FR(KB54JJY"D)N_:!0#I#V.IV%QU;DXN;'>$2UNF-4Z\6%>=7IEGS+MKE'N
M*U*M3YT1CSG*FS(A5>D7*ER4M9C5"-#4TQ%>BJ;DAU(\MSS%*&G</G2E<.6B
M6EEIFE#*()TER3U)&"]KL-QR?2NFG(D3#/F%4M4Q$VQ)1K3LD!TA!W&Y<MO'
M>K%A"G1V8 65B(A+ 6K.5!OU<G))R<<Y)/O).O:^"C3PGAPY4<@7_P"6F/F+
MC"^TXMQ%; !59/( V!62/?#2MG]M7TH_>OZL?QA9.NE7_<6I_P ;2?Y)\<JF
M^ZU/_A:K_-30K2/V8NN_[K+0_DRL_13_ '-X;_RJC_NYT/F_UZL_/E_Z$F(V
MZM4RDU!VW%U5J8ZW$=FOH$:1(90K C!3;B600\M9V^6A>,!+A!'.FK6I("4D
M JU,X!8VO? 8L3U\8].^QN^OC 3G31[ W>=L;VN^?#G%5IQZ34:K/@Q?+\B&
MTMU/HTV.9*77' VME:RYO0XA"LJ3@8'.=-GA<J6A9RH_?)(2P!+V#%[ .7>/
M4EK5I (!+@8=SEN7+(+EGAHW=%I[;E2I:FYCM+<;5#?CA!4Z5J7@.K?0E2BX
MDC<AT+2D$ J &GRRI:4DLZ@]K!C?R8;?/%A+L'9VVL(*6Q'EU)EN+Y],2Y"C
M)3(F375.^F*+2E1334N+0)!$<H\U#R@R7DK3@X((LZ6L;G[T&P&2HAR [X[Q
M]9@4O1>Y)L&!+/[K6/1V>#D&Z%TF=%C.5"JKV*)"8<.FQ4(?^V-.@>CQU+:
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MW+;Z-TY-.K-TU!B$Q,<!<DQ_-*@7$M-[1D;DG*N 4\G'&NC-H4R9;ZM,Q-]
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M_P"MEN1JLEIM;<B)AE(\EY20L+6$YYPU<Q2&"4A0+N20&P P>Y+\K6ZQZ/\
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M'/NA&=BXY?%!P3S<^WK!EB.X3N P#DY]F>/G]ON&FJ4,<B+>1?PSX@[!H"0
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MR =9GC"D3%(4BS&78$V/:$,0"[,<'/*/-/3R8%<4E&7W^Y(22"[AU%BSW=O
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M!XVLU=*UA"I\(!()_P!N; R..25<GYSGGY](4?W59V!^?:&&4!?03M@W>Y)
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M^B)?"2M)4@#7DO$N#*F^ETBLE\-3,IOYL<3DSJGX.@R?ABZF4J5+5,*',Y2
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M\,?ADM*KVK7+3MN/09UF4.TK<H[-'ZB7E%HK])L**N#9$>Y+=B78FW[R=M*
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MKE &JV UA9E7)8, +OZ[L5SPU](:]2+[MZ[Z]4+CM"\NJ%\=3&J!2.H=U6-
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M!;)P'A >?G[G&G%.A@^JMO\ Q%(]@4@.;5$#G)"B3@DG &J:C/45I6?M9L4
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M!"2$I ;))R.^Y1XSC&,@C&,;Q7B H)8)!U*P [DG%Q@#PY1'QGB4OALHS%*
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MDGCCD ^W/L ]^HETO==W/OZ/:S&[/OXPY,W4+C>]_J[/\WC@]2G&CYY^Y4
MD.%21@ X 40![>  GO@GV-52*!*G<$X<D ./PF]0?G;9W:!VR0+[>Y^GU9SZ
M&4^65K0VWM1]K"0C*CD>Q.2,@GOCMCOC5H(2SE"4L[=T=[U9Q\YM<L<\SZSU
M^OG&M3Q"=B&TJ(&-VP9R<X!/W7!./> .#QPBELX";M8@/D7R-GZC;K"A+L<A
M[AV8?1:\)\IM]UGA*TJ2<E6X[%?\E.[C'MP,D8_%7G)FK07"G3ERXV=AL6YL
M[[0])0'9NEB"+O<[\OICA3T>.TRU(82X5J!+B$I2YCC(*L95QC&3C(^?&J$^
M6E*925(!U*8E( +8(>S^+L^;1"N6I144N"UK,Y:V,%F^C:#\MR/*+2(6[RT
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ML!Q<^1 ,R1-VI4A"7@"GS'%@J5OSZF<D@$X)YU(.(K^%3JJ6IDJ4R91)N'(
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M ;0[$*S%:0M!2L-JPEQ*U #: /,'JYRK.JZ4ZEL?BZ%.4K^,2[@[V&3L;VM
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M[)6UI32%%QHNK.Q/("M8>H].^-HX@BF-%3_:V.L(J=4Y)*CI61.TJ9FLE+V
M+L8^?:C[/DKA?V1^*<#JC*5P&6M=+2A,LFL15RI<A0F*(8ID33-(!4C2=!8D
M)4V757H[TOMKI78*:794R)?*J1,JM>N>EU&IOFH*C,J=5%^*9#RF0VI1;0DM
MH0XL9*"0%8U7\XZSX;22I-)+"9LCM%]Q8*"EM0!"TJ6YL$J*BZK$9BGZ'?9=
M](^.^E7&I)K: <'DU<J12RJE 02F=-F(0K6%($L(0'4H,D%)*@7$4'^,VT+A
MIF-MQES(ZW@UYX#J%LR5Q767F5!3K#V]M2T-.I"E-D* (.XZJEX]33U)1,*4
MS.S>8 H@B:A01,0$J&RB2SE36-P\?4X2%H5,E3434)2DE:"E3!0?*21OLU[;
MQ,E+Z-=0:WT_G]4Z/1ER;(I,^13ZI4D/M+D17HS;2W'?01LE.QVUR([3CK3:
MTMN.IW8!YO3N*T4E4M*JN1+[;5I0N8.TT)=)6$, 05C0&.K5@$1CZ_TZ]%^%
M\;I_1VNXDB3Q6K$M4BG5J(4F86#S "E#742H@!)!+"\1:XM2FTA06RZA6'X\
ME*FG6G  0@H<0VM*CG.U620<#G&KPG)G2D+EJLZ2H*.E7/27 VS9R+[QKTJ0
MH!4M0FI4!I4@ZDJ!&4L6(W<681E/E*,1&2E0)/#84%((_P L$J!'.00,'V:6
M?- E)%_$.X!R26AR -3DX:YN[88M=[/!=.]U*5M*:P3@8)/)S@_=X]A'/\^E
M2I2V*"@AK&[-[7^<7Q#NZY!"K>%_6!_'R+*"$EE *T-J7C) !*2<G'&XYR,$
MC/?CC4H<"X2X)=L&VK=B+6S;.PB,FX ) +^+!NGT\QLQ=^87(_K-M-87LX"]
MW.<%7K$!  YP![_<=1+GO++H2ECIW?>Y#\P+>LYAZ4=YG)R=B-B6QSVW.(:<
MQ]R1N;4V4*:)"5(!Y41]T0K=ZA !XQKE3IJIP*=#*0X3I20YM=^7J\=A82 -
MG!S=SEG<;OZ_..8BGVCN43N &"<?3[.#^,?PZ249B&+$'S;9[\RV?GA"QR![
M?G)@TE7F.I)/K;P3[\_XQ'S]R/8#C.1W?-+EW#DDMS>Y;/(_2(9,!">7X-_5
MS^OA#OI@C%OS%J;4XIT)3O Y' ' XQQQCG@Y.-*@I8J)!)40'R3NUP6#>'3>
M.3/[5]27T@!N3NY+N[WOMBV\-ZX(3HDE2&@6]N/-;3Z@)/ 42/?[#@<]\YU1
MG(FKF$ ,ECWD@AR&SD?/@V!BS2SA,3I62^R0S[>(P<Y(YB!!#:(,KSDK+ZT)
M\M>>$A(R>0/:,XY]WOSJPFG2)*M6HJ(2 3L &?'-SZMR3$TV5=)%\V+?[9+_
M %>$9V;)D)V$J4A  023D#/LY'LS[^/QZ;*U@!()TLP=[;"_GEK6O<Q/(0E'
MAULWFWA>U]R8]+WV+VC;XIO%"<DD^'>B$Y]YZGVR"./^3KRK[(R2BHH5.Y49
M8OR:KY> ^>)9I9"NB2.>Z?ICVL)YW?\ */Y@!KSN7= .Y)]R?ICFFY)YQEI5
M_%/E[Q!'DH^RU/VOO@__ 'X^HO\ W.H6N+Q3^B3^</\ Y1UN'?'/YJ/>(\3E
MG2:JW(F4VCN/J<J<0M.(1ZR%!1VG83@;Q@@C<HC'"<8&LM5(E:43)P3]J7J"
ME-8ASY=?')-HMUB9+";. *92@0HX!S<[,7:]GYM%GNFED5J1:SSBD20U),P$
MN-J(4VRD#EQ24C(6A7&.Q."2=9CBM=*15RT@!1EA"G27 47<6)V8Y!QAGC%\
M9XU04U:):ITA$U!DH3*5-2)A5,)*0E 7J.H$!)+N0>4+=J1X5/C/2JIZ8RF*
MOTM2V#AM89=V[6,((.U.X*0,Y.,DC5:N7,FS4RY/9J$Q/9@'XX) /><[G"F
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M1&B&G,-5&$W*=4"TXXX'T^BDA0)*1N0D$CMC394M"YRNS4E$Q*75VA*%%(R
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M<[-L1'92DN&(#X(-CX.?7L.306C960M;.ULG*BK(VI/)/S8^<_BU')*5J)*
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MD+7'IS41I;@:'E^8M*U[!C."=>V2."\.DR9<I(TI020)<M"!J9KZ ";7&HD
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MD_D.DAD#!]Q_)H@A0@-%Q8;)*/,6 #M)R<<)^;.>^/QZ((5E*7%=2REORGF
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M3I\&X)$>H*EF6LO19EPF:XXLJ0P'UOAMJ4I VI\MM3JBE/W2R =SYDR<E"Y
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M]L' /@.5_4 S0E70BHUIA*EH#+SBP%18;QD%Y:=^U]W"?72-H!9:473ZH""
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M0&DMJ$7:]M9WD%*BA*2"HJ&3SJ<TTA<Y<XH,F;I2$*<@A(0$=PZK#2D)M86
M?$6)E'3+2H&FD3%S".U)E2E%9![NLE#JTL-.JPTMR:?.@5_VY8=RU&J3WJ7
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M.Z2TK \,?A211Z;:-R=-9E!FSJ)*;GWH*VMVMS7(@,GTB.X\AUJ/.P@(5Y:
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M$J&2"F_Q2WJ)OXQ]87X+S_<Z/!1_S;>E7_=:#K44W]61^8/\HC@5?]+,_/\
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M-RQ)U8R2&$>1<3H/1^H]*Z\<1K)B5S.'RYIH)I4BG2@+(54)G) 4"I192>T
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MFFK)5%4K<%*"FU**/605@G8>2#CW\>NX?3U,J:%2DBH,O2F<&"@0P!=(<L0
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MM1*%#<%$'Y@,_P ! U;BU ].D+*4K=.W<!GGU03RH'/!&2<Z1@+@>K?Z]8
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M*I4J6XDMI9365LQU(4-I#CK\&6Z,()/J)"B>!LSD1#CE&DA*=02"Y)0C4[G
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M6<V_1NM%(S]&1^34LOT^X"DNJ5-(V^US5-XO<#?QO"%FR1?D"PON?7L[QO\
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M\\I;BFQC& G$^F''Y7&9E.:1)T2URV44*"]*1."G4I()3]L  =3->X82E0T
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MHAB?:?I@;1_8)_JZ-">7M/TPUSS/K,#:/[!/]71H3R]I^F!SS/K,#:/[!/\
M5T:$\O:?I@<\SZS VC^P3_1HTC8D>!AJ@5-WE!N1'S@P-H_L$_U=&G^\KUP@
M207UK]8^B!M']@G^KHT_WE>N'.K\-7K'T0-H_L$_U=&G^\KUP.K\-7K'T0-H
M_L$_U=&G^\KUP.K\-7K'T0-H_L$_U=&G^\KUPA!(8K5ZQ]$#:/[!/]71IZJ/
MG#=']]9\Q^K VC^P3_5T:$\O:?I@T#F?9]$#:/[!/]&C2GE[X>-0#!2F%A<?
M1'.W'8D?B3_1H*$]1Y_2\/3,6EV+OS8_1 P?>>Q'L'<8R" "".X(['2:$^+7
MNWT0XSEGEZH&.,$J/'=2BHGY\J)_-@#V#3EI"TZ389=+ ^YK;6B%8UY)'@;^
MUX8]K_MK>E'[V'5W^,K'U5K?N-5_XNF]\Z):;[J4G^%J??)C.XJS3J!UFZTH
MK+K].^,+EM"=3UR8%0#,Z(WTYM>$X_#D(BK8D-MRVGX[BFG%!MZ.\TLI<1M*
MTB%3.'\/4G01)$]*WFRDD%4^:1W5+!P1D#I#YJNSXA5ZDS/MB4!)3+6H?T21
M\8)TYZDP83?%J)!!K#7?V1:@?=_^$U<1+402\L.20\Z2[?*1 I0#)(6"'S*F
ML7.Q"#Y^6QC+Y<VI]^&_JE0_1-.[)7.7\M*_7ANM/-7R<W]G ^7-J??AOZI4
M/T31V2N<OY:5^O!K3S5\G-_9P/ES:GWX;^J5#]$T=DKG+^6E?KP:T\U?)S?V
M<#Y<VI]^&_JE0_1-'9*YR_EI7Z\&M/-7R<W]G ^7-J??AOZI4/T31V2N<OY:
M5^O!K3S5\G-_9P/ES:GWX;^J5#]$T=DKG+^6E?KP:T\U?)S?V<#Y<VI]^&_J
ME0_1-'9*YR_EI7Z\&M/-7R<W]G ^7-J??AOZI4/T31V2N<OY:5^O!K3S5\G-
M_9P/ES:GWX;^J5#]$T=DKG+^6E?KP:T\U?)S?V<#Y<VI]^&_JE0_1-'9*YR_
MEI7Z\&M/-7R<W]G ^7-J??AOZI4/T31V2N<OY:5^O!K3S5\G-_9P/ES:GWX;
M^J5#]$T=DKG+^6E?KP:T\U?)S?V<#Y<VI]^&_JE0_1-'9*YR_EI7Z\&M/-7R
M<W]G ^7-J??AOZI4/T31V2N<OY:5^O!K3S5\G-_9P/ES:GWX;^J5#]$T=DKG
M+^6E?KP:T\U?)S?V<#Y<VI]^&_JE0_1-'9*YR_EI7Z\&M/-7R<W]G ^7-J??
MAOZI4/T31V2N<OY:5^O!K3S5\G-_9P/ES:GWX;^J5#]$T=DKG+^6E?KP:T\U
M?)S?V<#Y<VI]^&_JE0_1-'9*YR_EI7Z\&M/-7R<W]G ^7-J??AOZI4/T31V2
MN<OY:5^O!K3S5\G-_9P/ES:GWX;^J5#]$T=DKG+^6E?KP:T\U?)S?V<#Y<VI
M]^&_JE0_1-'9*YR_EI7Z\&M/-7R<W]G ^7-J??AOZI4/T31V2N<OY:5^O!K3
MS5\G-_9P/ES:GWX;^J5#]$T=DKG+^6E?KP:T\U?)S?V<#Y<VI]^&_JE0_1-'
M9*YR_EI7Z\&M/-7R<W]G ^7-J??AOZI4/T31V2N<OY:5^O!K3S5\G-_9P/ES
M:GWX;^J5#]$T=DKG+^6E?KP:T\U?)S?V<#Y<VI]^&_JE0_1-'9*YR_EI7Z\&
MM/-7R<W]G ^7-J??AOZI4/T31V2N<OY:5^O!K3S5\G-_9P/ES:GWX;^J5#]$
MT=DKG+^6E?KP:T\U?)S?V<#Y<VI]^&_JE0_1-'9*YR_EI7Z\&M/-7R<W]G ^
M7-J??AOZI4/T31V2N<OY:5^O!K3S5\G-_9P/ES:GWX;^J5#]$T=DKG+^6E?K
MP:T\U?)S?V<#Y<VI]^&_JE0_1-'9*YR_EI7Z\&M/-7R<W]G ^7-J??AOZI4/
MT31V2N<OY:5^O!K3S5\G-_9P/ES:GWX;^J5#]$T=DKG+^6E?KP:T\U?)S?V<
M#Y<VI]^&_JE0_1-'9*YR_EI7Z\&M/-7R<W]G ^7-J??AOZI4/T31V2N<OY:5
M^O!K3S5\G-_9P/ES:GWX;^J5#]$T=DKG+^6E?KP:T\U?)S?V<#Y<VI]^&_JE
M0_1-'9*YR_EI7Z\&M/-7R<W]G ^7-J??AOZI4/T31V2N<OY:5^O!K3S5\G-_
M9P/ES:GWX;^J5#]$T=DKG+^6E?KP:T\U?)S?V<#Y<VI]^&_JE0_1-'9*YR_E
MI7Z\&M/-7R<W]G ^7-J??AOZI4/T31V2N<OY:5^O!K3S5\G-_9P/ES:GWX;^
MJ5#]$T=DKG+^6E?KP:T\U?)S?V<#Y<VI]^&_JE0_1-'9*YR_EI7Z\&M/-7R<
MW]G ^7-J??AOZI4/T31V2N<OY:5^O!K3S5\G-_9P/ES:GWX;^J5#]$T=DKG+
M^6E?KP:T\U?)S?V<#Y<VI]^&_JE0_1-'9*YR_EI7Z\&M/-7R<W]G ^7-J??A
MOZI4/T31V2N<OY:5^O!K3S5\G-_9P/ES:GWX;^J5#]$T=DKG+^6E?KP:T\U?
M)S?V<#Y<VI]^&_JE0_1-'9*YR_EI7Z\&M/-7R<W]G ^7-J??AOZI4/T31V2N
M<OY:5^O!K3S5\G-_9P/ES:GWX;^J5#]$T=DKG+^6E?KP:T\U?)S?V<#Y<VI]
M^&_JE0_1-'9*YR_EI7Z\&M/-7R<W]G ^7-J??AOZI4/T31V2N<OY:5^O!K3S
M5\G-_9P/ES:GWX;^J5#]$T=DKG+^6E?KP:T\U?)S?V<#Y<VI]^&_JE0_1-'9
M*YR_EI7Z\&M/-7R<W]G ^7-J??AOZI4/T31V2N<OY:5^O!K3S5\G-_9P/ES:
MGWX;^J5#]$T=DKG+^6E?KP:T\U?)S?V<#Y<VI]^&_JE0_1-'9*YR_EI7Z\&M
M/-7R<W]G"/T_FL7!XH.F]2HR9<^G4OIIU09J4]JG5%$*"_4:E9Y@L2I;\1J.
MR_*$606&5N!QU+2U-I4$DBGQ!!E<(J4K,O4JKIV"9LI1+=LY"4K*B X<M9[M
M$](DJXE(4$J E4\]*BI"TAU&6 Q*0D_%.X/2.PS6/C1P-$$#1! T00-$$#1!
M T00-$$#1! T00-$$#1! T00-$$#1! T00-$$#1! T00-$$#1! T00-$$#1!
M T00-$$#1! T00-$$#1! T00-$$#1! T00-$$#1! T00-$$#1! T00-$$#1!
M T00-$$#1! T00-$$#1! T00-$$#1! T00-$$#1! T00-$$#1! T00-$$#1!
- T00-$$#1! T01__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g104413g11t00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g11t00.jpg
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MMB0E-#9!1L78,T1TA(6SPR8G0D-%861Q@8;!_\0 '0$!  $% 0$!
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M(&F6 Q,E=%(_9P ;]M;*8='1NIV<=9=!!EXM3P8J*\.T21R0S8Z2U%&(@]K
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M5U-E$4HB41*(E$2B)1%FC4/_ 'A_^$_^)UR\E_Y/_N?_ %KH4/\ S?\ V_\
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MB9V6&Q (D1#.L2VK8I\)3LM@,S[+[-6R;E>Z9B;45AT+J[WQN+3$QCX'NB=
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M."UE(H;#XS-M'0;9E D:U["7.C@+26DD//W)&^U_3GHPFU@T[(]L13?RDFR
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M*)))3!^!/)>?0:6RV#3:"Z\,E$4E,+D[[%'MH>6\X&PY"9S"> L2A?!55-<
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M4;+G<%U>W+.VPI=%8N^O<?A[<*-<XLI]= !5A DPF^V3F=;-3M@M::KF7BB
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M\U<1Q5UD]FQE<?4CN2VK3*T5 M%J6=LD,41>QLC6B21C62N<QS7!L3I''B:
M-W '!#C+UE]6.O7?8ENAQK10.9++(&O,;B8XW.?&UKVN:3*U@'"XD[ D7+ ^
M)/(O9SK*&6"ZN>9 YP^;WUF\C(GL(EE=DW!E#FAKN/KN+L&-+IV>W0N4G-4/
MB:SW(G<5E,7:VTM.R>2F&SG<339!)9NQQ,L5NV1DME=M3XH6&W*&1N,%9K[$
M+7SSB.)CI&A[VG?;+7P^3MOECKU))'PS]E> Z-N]KAE>*T9>]HFL.;!,YD$)
MDE>V-Q8UP7':.*7(9_TG+>13/JY].T[!"11Y=+DB&?'-B2->,XZ.Z%QM1RPE
MEX]>0)$,:DF08EH\.\"'-A#FD:"8@A63-XJ+(P8F2Y&V_9#C! 6R?;2V,2EC
M9@PP<WE$2<DRB4QN:\,+7-)HS$9*2C-DF5)'4JY FF!9O&'2<H/=$7\[E\T&
M,RB,QA[7-+@6N U[KJKFI1%LQJKAYR,W;"AMAZOUYC*H@=/V_5(+HE,(&UK'
M[,>!+G,<! :7R4-CR;+G\6W>QY@%;U7)_P"O'!G'-4RQPOQ[N?Q..L.JW;?(
MG;5==<PU[3PRG&[ADM/DCA?&V")W265SPR+PR%H&ZZM3"9._ +-2L)H766TV
MO$]=A=:>.*.NUDDS)'32#K%&&E\GZ0.5ESWCYN?5\-C\_P!A:^?(A%9/,)UK
M]I.>_ Q#/+C61X[9/HHZ,>1=W]@?HJ>6,*[-C\V-A2*BV'93SQOVJV*N5Q]V
MQ+5J6HYYH:]:T]L?$YO9KC2^K.R3AY4L4S6ES'Q/>"!U(6"QC;U2".S9K20P
MRS6*['2<(=SZK@VQ"^/BYD<D+B ]DC&$$^!8;KH+1519VHY^=FMC:TDUW-Y<
M0FIN05)%#26.<24@Q$E##EA@A$U"%D\,R3"$!4,;W5(622QSSQLDD;%&^5Y(
M9&QTCR YQ#6-+G$-:"YQ !.S07'P $]%<QCI'LC8 7O<UC02&@N<0UH+G$-:
M"2.KB /"2!U5U[0UC/-+[ E>K-GQLR(; A#JJQRJ,GK!KF,SJA@FJJ$0LWDF
M!**8)JIY7R&*72O;*W5G>_7:V&E<JY"K!=I3-GJV6"2"9H<&R,)(#@'M:X#<
M'[IH/3P+-;J6*-F:I;B=#9@>8YHG%I<QX ):2TN:3L1X"0K#K96NNXW^Q2OX
M&YM?9/0O^Z[9KP/NU_HNG?V/)_SJ2]K[D7Z'G?U^/_FW%V]:\+7LJ41*(E$2
MB*-SDI\\7Z,K[#<W_P $\ HJ^(_C'Y'*2.BHE$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HBCNZ1;^ N'/^T1X=_A%O17-_3?K3_J4B-%:E$2B)1$HBZK/[*D^9_XJ_TQ
M3+_@I.O:.XO_ &5S7^#X/\Y"\H[K7]B<7_A%W^;2KJZ< 8!'9CO^.2"7[BT[
MJ".ZE.:=LI+[IV8IK.-327PMQ2<81"D'5O;'Y]3N\/N*2;X\,S$<9'HK9]-$
M43=UF@4_V75%J6OBYHJ]#(7Y;S7T2,=3%R:O!8866;!8Y\<?VN+?E,DD:V6?
ME-<#&'N;Y)IVM'/D8I)KM*E%3<RX#>M=DBGF@<'00![6R2#CDV$CXXW.BAYC
MF^[+&ND7UUO]I8I7NY+E8MT?O+_0FT.5DT=.2$DQ=FE#?C47.&B,93G<W%LU
MZ,BT\7A+3BFJ-KN^NV9S/>BH^6W$,,>Q=0'!")VL6^2#''"#5."R=/"5V8F(
MQO=C7MKR3"MC\RV)LU=MF0D.M]KD8V(2A[99>![#)JN19'->[\'3F:QUO+SO
MR<@DC&08Z=D7/O8HR.AL&NS8BMV5CGO,;FF.+C:X:5='](]-QEOYO..RD]-Y
M.?H/-A8Z$2W6R:TD:GR<4YE!BH3>&M^Q&YP;E)FFPCRGN5 !.[51N0(5;/ L
M49:1:HBR$S].,J=OX._U4Y,X^2Y$.]W9[(L=H?4<QXK\TP[ASM]]G-ZM)'#T
MY+1B9GG6A2X^\MGO<+S*LO\ 7XG@,');::YAG$8EVX6]1Q CW0:98MZOG"+8
M$QV+'X!&^'L_36YL]'>]:A@T-5U! U9_&Y%KR,M/)V.^4\);$)$G"9#LAY,:
MYOX2FY,[*I?)U;FF[>PX7&@^-BU'5@JRV9<]5VT]JJ.]9L-O6>S316IGX>7D
MV'F+M$52-CZW"622#W#G\4O689"3 V)K,=>+"V0<[IN2G7@-*N;$4M>)F5CY
ML#.;R)++RRQN'LC^[:SACZ8\Y@Q2W'W)BV2YZ+@^IA-4)<T)/ =K-J?& )ZV
M[LS:,Y3BW'C7D?RT),IZ:B1QEC.R&K8D>8Y!(@B?)J&NM@XBUL4*$RK;P4W?
M7FTV9*S>=>.GX;5%YS)CH4Z58S96W+WS@K-(S$U1]266*)PYT[ Z=\MARU<U
M"<=R[3\?7IMI]_):]QHQ37W;5NP(L;6B[WSV' XJ*TRS&R24$10OX8F1P-*L
MC?+UQ>VYPGTNUQ[=FJP^3&INC_TM&DV66O.KGR+O+(P;6V0_;2T['C7I(MYU
MYR$30?H7)69T;#0G=WC(KY!VM<%5WD/>;&-CS-'460?+CKKL/>U/D)3)!'<B
MFCDEI5(Z60E;&6QVL7O%8AD8]KHV3.CL/#N7"L&1DQ-S!4617Z@RE/3E"+ES
M25)(9(X[EE]NE$YX=)6R($D,K'L<U[X@^!A;QR+G]*/J0F!:&EA<3XCP" 0Q
MSW[KB1A[.A:G&F2 ZA@:FBHW% M%QY_UW)I-M]:,23933()CG*)RQ:S5>70.
MYCLQF2.;/V.%-&7FVLG7;/G;5FPS%VX74[/?>%U^T,E-,[)2Q6H8:'.BIOB@
M$-:6X(XW 1R-BKQDUU93=7Q\QAPU>O [(U96VH.]<@I5SCXH6T(Y*TLMTQ2V
M623&6>.J7O;Q/C,MB4##/1G;>T3Q]DL;U3O"3L"FKN;6O=@ZZY'&"R37IK##
M]=3 <R,05*7.Y,B5<(!*]>.[4;L96^(8[DNU3AO!S!4?6)%(3>UA1R>4BFO8
MZ&47-.VJMK$M,-MLT]N!S9K)@C;"&6H+3'MJ?=%@=6>[B$4I+M+2UW'XV6*G
M?EC-3.UK-;)N$M9T<-:8.BKB9YD+JTU9['63T#BRPUI;S(]FTXYUU6Y=')M?
M@=#]MZE0W7I_G81NU!Z+V!$8KK_DIJ7'7SMKQNDD,V2_O+;""WED6*;WI*&R
M"2-KC9COADU#'2-)Q:0LC676:LHZFGHWCCK^FQCC&*L\UK$7C:9:?%8J11NL
M-CD#71FQ'"]G,^[+(>&1UCGTW:9N:?@NTQ>I:@=?#S9AAK9.F*SZS)(+4CV5
MWO82V0022,=P?<-=(',%K< 9O#-:@\Z-';#VWKYKDNZ>"&R-3:J<7:>-:&N<
M-AG/[7+0M:Y;(<RAM?LI#HMD]$CO6,@PU^L]D%X>55RS;9KY=45K%MVF\E4H
M6GPX_4M2]=9'6>;9JMC= ZYV-@-J0, C#H^5VH1AIY&S=ABTY8@JLS]"S<K,
MEO:?M4Z;GV&"L++I&S-J]J<1787DR$/YG9S(7#F[NW-F\/)-#M8\VNCW7FL^
M@#(SZ1E,:>-IRM2<Q8F%10=#=,]G!B=YL"[$Q-\R&BCRS'K91MY>$\BG#-EP
MRS=P' (?8ST-BYI[579ZMJ23(PRQ4H!6G%B<][ZU9I[,Z,3QAT[)&CFQQ^Y8
M)/T-[''!A98*N=TV9[-9C*,L4EN8V(3!"!>L6".>'F&0MA>QQY3WCB=RQN]K
MFC:/BMS.U_IK<>VV7<2\,=N/&O>=!G-^)R^(S]H4V(;M*!)3)MA[! 6!E3D>
M6S&+:+,]-\<)Q628(M&$RB9"\SIDP%7%(XV:T_:OX^A)0%AF5M:;9IV>O/5D
M[(VG9[.ZQ+:FD,0IRTI(WS-V,L\Q:V*.M)Q!PZV(SE:C=NQW3 _&UL^[/0SP
MV6&RZW7$[88ZT3!*;4=MCVQ'<1PQ!QE?8CX2#A2"[=@<2TMSB>MM6T\Y#<Y=
M1R"8PMRU1N DO<>O]KC[>:Y5#M+2[7K;(PC6B#I.N*TGE8TB@B#$ZLC*UYAS
M!S70"CV/1LT+,^0TY'1[>QVG+T5>PR[0:W'VJ)H206,A!:?$YLE@L(A@=%9,
MK))'\5=@+I5I07:\-'/R7#2>W/TY)X'5+Q=>K6VW62P4)JS96N9 '_;9A)7$
M;XXV\,[R&QBK]'0_\/&K5\>0W'GJ$2>)<W=3NN[5MO!Q@E%UX/CZLV&C.F6)
MX2L<A1Q6O.U EI%'()@K/'<U2#D-H)MVH90*S5D6>?=E- 7W5CIV\S'"@Z8<
M&HS=JFM).8" P"L'"*6UM68T6 YPXW!UVF9<*RI&+O8FV!G:;[YNMA/'@14L
MBQ'#S@>,]HX3+%7_ *X>[D.:UW "VW>1&W-"Q7@UQBBN@(WQ[,E\X.Y@Q;<A
MKC ]4R??D>UZ;O"-O^@;2>0+-QTTCLDQA3:N@TR6Q=GH5KQ):L'(88G$=;)B
M:&3FU)F)LI-E6P5FX">@UEF]#BY;;<=+'E.3%QMKS0]I>TOAVY;G[/+"02,6
M2NX^' 8J''18UTUAV:ANN=7J2Y&*JZ]')CA+)PNGBEY#7<$O%S&LW9Q $ WI
MQ9Y*Q;C]T9\Q,:G'3<CWI%>?6H]\:[UC/Y/GF[6$U]!51@=A(PR/S6*/[NG&
MY?BVY#-C@H8UN=\55#V%X:4R.S@S6(FRFKZ[7LR$6-GTS>QENY5A]QQ6K(<Z
MJZQ)7GBCYT'&"]O"]G0-EC>0L^)RD6.TM.YCZ,F0BU#2R%6K8FW?M6@+6V1!
M'/%(_E3<.S'\3']2Z-[-UL!KK>.M>1^J.%RW('<O'(C8;QR3Z0/;F[Q]V'1]
M=C:#MJP-)TC#Z\PX*31 %@=I#)VHZ^L%'IP98DRS :,$.*!#9X T.W*MXVYB
M;VHAB\?EFU68G2]'&NQS91)(RE8Y<T<=AT-ATK(HGM[8(V23R0&8,(?Q2,Z5
M:_5R=/!'(WL8ZR_)ZBN7Q?=$8V.MUPZ*1\+986QODE8[LAD<R&.=L1>"T-8^
M[)@Y\)<);N.9:7=N&UMX9<:>!&Q]1-^T7/5CCI>92R#&X%<M];2LHD2+0!GV
M1/46:.-TO;R&W7\EG+>I+0P$&5*8/*J^"!FHN10KY"/4!QO??4U6\ZDVZS(5
MX++0,';@#736I*E8R3/@<'VH:S^2YQD->,-S3NP/.NST9,)WP.+T]9IMMOJ.
MHSS5W!V8JS$B*M'9L!D39FEM>6=IF:T,YSR=;'28\46CBGI1]@C%QM<Y3)TI
M3']X@*3!AB>P]5[H$Y-@SF+[-@\.=XJ1M=]BQ.L00(5#' .38P)@UN7(&6:B
M-4C,.-,Z[*^;DS60BLRY=D,/)EQKN1+/5NX]V'=6FIV;#)FT8IQ;<ZQ98Z$V
M9;@BDKE\36M;RWSX=F'HR5X\6^:;G17VF:.&S4O#*-GBM5X'Q&V^$U6M@@>)
M17CJF6.=K)'$G=_=>^>CNV/R4<)9R(=]';*B,HZ3B,S:$RJ%M,*=G2_&'Y$]
MT)@=MASA#?>0'ZX/V41"LW"+;#N1(G&[9)R06Q8 9XL1'<=C-55,0V#%1Y*G
M/#H^:O8@L/LQM[\]N+J[:+++^4VTVF+ ;-4VB9QPM>\/<SA[U_(::M91TV2?
MC[4,NJ8IX)H&0/?WJ['M.ZXZ!O,=5=:,'%#9WE=PS.:PM#]X;><KII%PA/%-
M"&+:\<-^ :^V>ER5>-57B:T-/<"-V38G4*2I\!M:%.DG!U@HV).A;+F0L@R9
MQ=J=B+.#8H&%/]-LR++.;-@6VXQUJF<1'=YXL-8,?7;>(;:/:60NN!W )-@9
M!,^,%CPYT)U _'N@Q KFL[(MKVQE'T^28'.-Z<T@75_M#Y6U>$/<PDB/E,>0
MYO"WL'?L4K^!N;7V3T+_ +KMFO+>[7^BZ=_8\G_.I+T;N1?H>=_7X_\ FW%V
M]:\+7LJ41*(E$2B*-SDI\\7Z,K[#<W_P3P"BKXC^,?D<I(Z*B41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B*.[I%OX"X<_[1'AW^$6]%<W]-^M/^I2(T5J41*(E$2B+J
MT?LI<#(WC]Q:OBIBGW6XY=:_7C?+K[R%6_>ZKVZNKL?_ .>O_P#:O:.XOOWU
MS6WF^#Q[?_D_B*\K[JK.9C,6P';^OY';[;^"N\;?QOX%TH_$:GU1A[C+\JOH
M?KY!Z3]2\.[(??CT'ZT\1J?5&'N,ORJ=?(/2?J3LA]^/0?K3Q&I]48>XR_*I
MU\@])^I.R'WX]!^M5F.+2.'R!CED4D3E&I1&'AMD$<D3$86U/;"^LQB+BTO+
M0YA+(&-SFV'CH&@'"+)$B%(I+H*8*)XY6QS11V(I8)XHYH9HWQ312@/CEBD:
M621R,<TM>Q[26N:X$.:2"""KXH9H)(YH9W131/;)%+&7,DCD80YCV/:X.:]K
M@'-<T@@@$'=7#+)=.9L&&VR&0)*M(!YSN*R-;0TQQA3>G1(5!U?KL,<!:6=6
M0.J (([H_+!*/#B@"$@::ND(/@GB@IP5G.?#$ ]S6L=(^2264QL+BR+F2E\@
MB87.+(@X1L+G%K07'?+-VFPUK99FEC7.>(V1LBC$C]@^3EQ-8PR/#6A\A:7N
M#6ASB&@"QK,BN-[98DXXY8WM?'*V&5KVO:_7:]KVRZ[7M?Y=KV^7:];/7R#T
MGZEK]E</ \>@_6LHS79^U]B(NZ,SG1[Y>1O",CEA2PX0SE-Y(-X;<>2SUV!%
M%<YY)!\G)S40D$P+>WA%5T<U4S<5'$W-?2KXZG4+#7K1Q\J,Q0 .>YE>)W#O
M#68\N96A/ P&*!L<9#&#AV8T#;GDNV0\3VG2<V02S$M:'3RCBVEL/: ^Q*.)
MVTDSGO'$XAWNCOBWQ&I]48>XR_*K=Z^0>D_4M3LA]^/0?K3Q&I]48>XR_*IU
M\@])^I.R'WX]!^M/$:GU1A[C+\JG7R#TGZD[(??CT'ZT\1J?5&'N,ORJ=?(/
M2?J3LA]^/0?K3Q&I]48>XR_*IU\@])^I.R'WX]!^M/$:GU1A[C+\JG7R#TGZ
MD[(??CT'ZT\1J?5&'N,ORJ=?(/2?J3LA]^/0?K3Q&I]48>XR_*IU\@])^I.R
M'WX]!^M/$:GU1A[C+\JG7R#TGZD[(??CT'ZT\1J?5&'N,ORJ=?(/2?J3LA]^
M/0?K3Q&I]48>XR_*IU\@])^I.R'WX]!^M/$:GU1A[C+\JG7R#TGZD[(??CT'
MZT\1J?5&'N,ORJ=?(/2?J3LA]^/0?K3Q&I]48>XR_*IU\@])^I.R'WX]!^M=
MR?\ 8KD85;8)S'D.1::J;E+=/,V(N*66.:6;0S3T[-?)6^=\<\5\7O!/%.V&
M-\+CY97RRLI:V/S_ -VJ3>W@(BW8LKWY.+?<$22UF@;;#;;ED[^/?XE[1W**
MYBKYJ0N#N.:DS8#;;@98=OOOUWX]MMNFWQKMF5X@O74HB41*(E$4;G)3YXOT
M97V&YO\ X)X!15\1_&/R.4D=%1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%'=TBW\!
M<.?]HCP[_"+>BN;^F_6G_4I$:*U*(E$2B)1%9\PU[ =A"AA3^#P^<!MZ^90
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M0S<;_:_:1^*F!_H&G?C+>=,C\]L^M3O9C?-U'YI7]6GH9N-_M?M(_%3 _P!
MT[\9;SID?GMGUJ=[,;YNH_-*_JT]#-QO]K]I'XJ8'^@:=^,MYTR/SVSZU.]F
M-\W4?FE?U:>AFXW^U^TC\5,#_0-._&6\Z9'Y[9]:G>S&^;J/S2OZM/0S<;_:
M_:1^*F!_H&G?C+>=,C\]L^M3O9C?-U'YI7]6GH9N-_M?M(_%3 _T#3OQEO.F
M1^>V?6IWLQOFZC\TK^K3T,W&_P!K]I'XJ8'^@:=^,MYTR/SVSZU.]F-\W4?F
ME?U:>AFXW^U^TC\5,#_0-._&6\Z9'Y[9]:G>S&^;J/S2OZM/0S<;_:_:1^*F
M!_H&G?C+>=,C\]L^M3O9C?-U'YI7]6GH9N-_M?M(_%3 _P! T[\9;SID?GMG
MUJ=[,;YNH_-*_JT]#-QO]K]I'XJ8'^@:=^,MYTR/SVSZU.]F-\W4?FE?U:>A
MFXW^U^TC\5,#_0-._&6\Z9'Y[9]:G>S&^;J/S2OZM/0S<;_:_:1^*F!_H&G?
MC+>=,C\]L^M3O9C?-U'YI7]6GH9N-_M?M(_%3 _T#3OQEO.F1^>V?6IWLQOF
MZC\TK^K3T,W&_P!K]I'XJ8'^@:=^,MYTR/SVSZU.]F-\W4?FE?U:>AFXW^U^
MTC\5,#_0-._&6\Z9'Y[9]:G>S&^;J/S2OZM/0S<;_:_:1^*F!_H&G?C+>=,C
M\]L^M3O9C?-U'YI7]6K]A^NM?:\0-%@$%AT&%<EDB'$:'QADC*!ZZ&&2:"YJ
M+*"$F4LBGGFFDHOBIFGAGECAE;'*]KZUBW:M%KK5FQ9<P$,-B:28M!.Y#3(Y
MQ:">I V!*V(:U>L'"O!# '$%PAB9$'$= 7!C6@D#H"=]E>-:ZS)1$HB41*(H
MW.2GSQ?HROL-S?\ P3P"BKXC^,?D<I(Z*B41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M*.[I%OX"X<_[1'AW^$6]%<W]-^M/^I2(T5J41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(HW.2GSQ?HROL-S?_
M  3P"BKXC^,?D<I(Z*B41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1%ICTB4^G&K.#G*+8^MI =%)U"=02F1QF2-ET+.#
M*Y-8V).#@)<I)="ZXZ6"N6%E$5,<K_M;8997M:I#I.K6NZDPM2Y$V>M8OPQ3
M0OWX9&/)!8[8@[$[#H1^-<74=F:G@LK:KR.AFKTYI8Y6;<3',&_$W<$;@;^(
MKH'>G*=(][<+:?O<>\WJ^G_8%H_\'Z?\KZY?/WLXU!YYM_)C]6GIRG2/>W"V
MG[W'O-ZGL"T?^#]/^5]<GLXU!YYM_)C]6GIRG2/>W"VG[W'O-ZGL"T?^#]/^
M5]<GLXU!YYM_)C]6GIRG2/>W"VG[W'O-ZGL"T?\ @_3_ )7UR>SC4'GFW\F/
MU:>G*=(][<+:?O<>\WJ>P+1_X/T_Y7UR>SC4'GFW\F/U:>G*=(][<+:?O<>\
MWJ>P+1_X/T_Y7UR>SC4'GFW\F/U:>G*=(][<+:?O<>\WJ>P+1_X/T_Y7UR>S
MC4'GFW\F/U:>G*=(][<+:?O<>\WJ>P+1_P"#]/\ E?7)[.-0>>;?R8_5IZ<I
MTCWMPMI^]Q[S>I[ M'_@_3_E?7)[.-0>>;?R8_5IZ<ITCWMPMI^]Q[S>I[ M
M'_@_3_E?7)[.-0>>;?R8_5JRIMTIW.?8Z,80G')_8DD1ADUC.QHNF>FR=EFF
M\--\91B1B=PR(W\/9CO^4B=[=1#O/_2HJ8_*I[ M'_@_3],OKT&N-0C?;,V^
MHV^YC\'[FKU].4Z1[VX6T_>X]YO4]@6C_P 'Z?\ *^N3V<:@\\V_DQ^K3TY3
MI'O;A;3][CWF]3V!:/\ P?I_ROKD]G&H//-OY,?JT].4Z1[VX6T_>X]YO4]@
M6C_P?I_ROKD]G&H//-OY,?JT].4Z1[VX6T_>X]YO4]@6C_P?I_ROKD]G&H//
M-OY,?JT].4Z1[VX6T_>X]YO4]@6C_P 'Z?\ *^N3V<:@\\V_DQ^K3TY3I'O;
MA;3][CWF]3V!:/\ P?I_ROKD]G&H//-OY,?JT].4Z1[VX6T_>X]YO4]@6C_P
M?I_ROKD]G&H//-OY,?JT].4Z1[VX6T_>X]YO4]@6C_P?I_ROKD]G&H//-OY,
M?JT].4Z1[VX6T_>X]YO4]@6C_P 'Z?\ *^N3V<:@\\V_DQ^K3TY3I'O;A;3]
M[CWF]3V!:/\ P?I_ROKD]G&H//-OY,?JU*=T,O2<\N-[=(%J?4N]N2,\GT(F
M;#LD1**O@S<HVN3^UP)^D#3=;)N9!ED,A+M!!:2RI"2%E$,<%,KY*8890KN@
MZ/P..TM>O8O#UJMFO+3<9XRX/9"^U%%)MQRN!XN8UI !.Q.W@*E6B]5Y3(:A
MITKV3L6(9V66B&1K>%TC*\DK=RU@VX0QS@20-QMX2 N[C7SHO<4HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(HW.2GSQ?HROL-S?_  3P"BKX
MC^,?D<I(Z*B41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HBPAR-FQNN-.2^<-^U]4Z4*C>#0XX["W<WJN>L&U--\;<%FF3C#S""&X)RI
M'/.+-IC=)$')O>'AO.;VU_+'18',JCP^,_B\*M'B=O>:\A=9E3:<Z=D6H'$*
M2N,>!Q=<7]..;#:@!&\D78^N$YS%==[,Q@3]F:L,SJ;%UC '\@AN.(!:72.*
MLDG?"$;>/?\ Z_;6KNN>34[U5QSW+MV?JNVWVW7?.3>.LI6_2)];8ZX0?20'
M*IYU;::*>)(DHU&L6F(:2'(GII0;&;):&1I[-P<<W09-%Q*NVYV^(;?CV!_A
M5C;GYLO^T>*_-\> LY&O=BZ4UKSB:WB0Q?8[S@_:^<]":Y"D.KMCQMS'A; 0
M?;:(LUU[L2#X66;&XF%.N;L*\2'$0QLS(!L1OY6_P[[^@@A;U<8]V8;]UXE/
MF(=L*@5RUXY$Y8E)5W1^EIL2SO&9N;(XTLQ +0DYKG35(F#Q&YNSE(+W:5"W
MUOCYJ^32@5I&W0K"W2E?.Z>9WVOFQ/[D7J4:*_MMT]_A2K_/"CNKO[6<Y_@V
MS_\ &5\N:OLA?**41*(E$2B)1$HBW-X?\2\N2MMY3:3RHF":8XS:C>]S;@E3
M8T)2"2+-+=?(=@A4+9"#VL$R8SAVQR:V@AW<V]C:4$'!V<2%O D&QQC^>SG>
MCO=7A@%G(9B]'CZ$#Y#%")'[&6Q8E#7N;7K,/'((V/DD)9&P#B+V=S"X;OIV
M^>:8UZ.*I27KLK&"24L;TC@@C+F-=-._W+"][8V .>XGA#'68S:BBF[%F1@X
MWM6R'79[F[RK)QUA*RHLY"LD#BD75E)>P%MH(#PIA\5CMX#^5*L'Z-Q5MA+<
MQX.!#^^BNN:K1GDOSXX2RY=]1E-D</!<@;.PR69IA"VJ*9-B3F%SHFP\J:9]
ME\O"(HRS:3 RE#?,<>+9:?;=)+Q5)C"YL=>*(RFR;8$$?"&MD,PDBA97:P.,
MD@>2S9/2O1R3_8L*Y1^5Z9T(VGI?5>BMKZT8C)! 0X/LJ/[QF4>8HXZ9;!=G
M\2%I15UC\D#D3),@97FPKV34$((MGWN0W(R.K:M2QAC7+;-+(7<E2N2-BLNL
MTY<=7EEF9V6.-U@SLEB=%)7=!S!OQ ;;;]2CIFS9@RPG#J]NC3H7*L;I:X@M
M1WYXHXG=H?((!"^.42,G;,8SMPD^$C!0G!#EJ;(IO$D-+OWE+K[9#YI^0,J[
MO%1#RMIQN-/<R>H!$$2G]&^PI4'%8^XO]F> 7DQ9+9DUDB)D8OS%XRZ;M2X-
ML5:<Y"+DVJD=^*0,F<UM*6:.O':G+8CV6!T\K(N9:Y+6OXPXCE2\'/;I[,NE
MGA%&3FUK4E*2,OA#C;BBDG?6A!D':9FPQNDX*_-<6\! /,CXJC#^ 7*R;Q#7
M>PF;736- ]KX,JT!EK]LG5T=:I&B^[+:-0#YM^#S,PG%=8'8;\U1]\;T@,W5
M@S+3.>00FWK+M9/JC"5I[=62V\V:1D%F".G=E?$8JDEYW%RZ[F .JQOEC>7"
M.4#AC>YQ#5=!IW+V(*UEE9@KVPPUYI+52)D@DM,I M#YVN);9D9'(T-+X]^)
M[6L]TK+VQH%OX]\G9IH#<TW%39M9;$D4-F\TUHFR3TQ5OBCNXMKD3'&$>2 B
M>4CC=L5';8M*WZ+F-3H6*',58WBD>J)L4<H_*X:OE,?6<9+E6*Q6KW#)6:'S
MQL>P2RF)QY+.,%\T$<S7L:XP"4EH=AN8YN-RT^.O6 (ZMF2&Q/5#+#BV)[FN
M,48E:.:[A(9%-)$6/(;.8@'%NR/)'@8%'MFP^/\ $B327=\0F?#MCYIDA346
M(P38FM-:E,CQ(Y V3X#*2YQ]=]8XTU"2E,1@<"37=H?VNS&W.J:H;@Z<G$:F
M=-3L2YR&''3U\_)IX.K.GLU+=P21Q1/K/Y(E$4DSW0ETK0UDD3^8YAW8SIY3
M3S8[4$>&EEOP3X2/.%LXAKV:M4QOEE;8:91&9(XF"4-C<7/9(SEM>.%SXV:E
MRBZ41*(E$2B)1$HBESZ"3YZMQ3^R.TOP)[(J#]TC^TK.?L=+_25-3'0']M^'
M_7W/]'VU])VOD=?3Z41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$4;G)3YXOT97V&YO_@G@%%7Q'\8_(Y21T5$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$5K3B<0W6D0DFP-ARAAA,&AS.;()7+I0Z!LD=C
MC&VHY$.#N].[@J@$W-P2&&2Q)92R2"*>-\U,\<;7O1/#X%I)Z;#T9'M_.(OQ
M^:W\X:*[@?[UWR3]2L#9W2*]$]MZ''P69<_^-Z3$X&LKBH1">78FKI2(?'GD
M!_:2V>=:QV+$)NPD#.C:(MFJR2%OR+0P5 ,N0WE%"K$#7C]([]MI/Y0J?JKI
M!>B>TVQ'QZ)=(GI1Y <791Z()VKSG?-Z/J9:H88.2 $GW9MS8$D:VFR(**B;
M"V.PC&B8H8X)-V![B>223A>?TCODD?D"MMEYG=#$PZZVIJ8+FAQ.*U[NQUV>
M];.C<@Y3M,M%E#AN=9T)V;DJ1*]@O1S:)+"'MV7-:V8IN:AE3R<FX(.ZEZ*O
M"_??A=N-OTI\7@\2I!W*[H0CX]MN*Y<L>&0#'O75\9TQM<5AY'Q>,DR_6<.B
MSW"(U%BG:.3=J>&\9HB,B=HZ*:SN#>Z8M1. N1V6 PO<E3A?[UW3K]R?J5HO
M_2-]$YQ&U9R8W)QZY-\;YQL$N$R/:J^HV/EHD[J;BV1KW6:#7'&9B8G693%L
M99UL 2(1R,.TEC435D4N=[BO4F2E#]DHL25>![B 6N'7;<M/3<_B\ _@6H6P
M.F_X,=(GT=W+:&:_FI>K]\N/'/9&>>A=KXBL4P<"1(T66X8P9X07(B^PQD$!
MCC4T8ZZ9R9)I#6=7F+LB&.>*<HT5_;;I[_"E7^>%'=7QN;IG.[CIWML]1U'Z
M&?1^WLNC17V0ODY*(E$2B)1$HB41;A<1^73KQ@RW3&'&'#;)U!R-U0]Z=W+K
MY5\5BKDZQUTMFLUO\2EJ36^XQB;1-QSS.CSN='I(TI^$FCN# ?B0DH-P<[@F
M9GO?,RPZG?Q-V._C[0C$S&2LV#XIX"^+G5YV@-E8V6)Y :62MV._:PV9?B3>
MB? +5+)TY*5ZL9#"]\3]RR2&8,DY4\+B71/=%*P;N#HW;C:K:#Y3PKC-LTF8
MZPU;(#X_)=;;?U-L!NFVP@7*2R.%[@AA<,/'8WIF@K(RQ0^.(DXO+.9G&) N
M6[)K8N:J[00FTAX\GA;.8IM@NW8FRPVZ%ZJZM5>R&*Q0L-L-,L<EF26=LQ!C
M>WG1!L9!8!("]U^.R]?%6S/4J2NCEJW:=AMBRU\LL%V P.$;XZ\<<+H@>-CN
M5(7/!XR6$,;LUETIF),?V!#W+2!!T8?^,7$OBG!L!=F#-;Q$X)Q3E3),6]\D
M!N6N',:7R:</366J?F,%%P& =TR$%&<\ 1U,^/["R):D[,DULT68SF:LDTR^
M.>SFX9('1Q-[6QT$-:-[0T.=.^4LXG.9Q$#J^RT&.Q"Z@7128K#XBOM;#7PU
M\1-'.V21W97B:6P]CB[9L38P_8!_""<FK=,XZ+;:?-JIZ"'05 Y=RGF9JY@5
MV38M"+[&F&D\]0.T;F#DE 6]6:P[ D2/RX+!N#ASRCXK<8XJY+I/:+RR:8[G
M[!1CI=]"0_!0X"[**?"9JD&0[<R:NPV7BO8+72P.+W6(SQLE# 8S')MG7#C<
M?;[W %N9FS=2,VN(169Z/8GQ3/%=AF@!;',WA;#(.%T1<0\/CTZF?.8F3Q?@
M:T!ZXR;WWA"Y2-Y2>7&98.S9LYUD>Y+;F(77CX,18,X<@F\W5:;CC/,@R5;;
MH96717'O=7OU]-B&;4SW6P^+4;(HS&RN8WTV14.]X E=8E%@F/9^YCBV?OT(
M/3B3Y\S0Z?8*O#)@7RR<;IP]EMTMWMSB8VPQF <>[-A))[C;J".N/=G\@M7;
M=YF33DW-M*OCIKO8FYI%N":Z0MM5(0YZ4E4C/ECY$<-G!Z[14;V(QW/4"\(%
MA%G=*.6R;T3L'C*TBPVJ6+NT-/U\/6R,3+=3'Q4*^1[$7-CY,388YS3=;(?(
MUC>+9UG@,ONBWECE+6MY*I=SD^5GH2/K6;LER>AVP!TG-D=*^'M3:P+8W/=M
MN(.,1^Y#N/[:LD;JY1\8-P;ADFR[\/G]B99#JJ;1[.,N')B7RAW1W&^!E@PO
M:OE;:$1_%.*ZY!2C[:P:7;H\VP_%L9+-R98S83@W"ZF.PN9H4(:??Z*62*]6
ME$S</7@9V"-S76:7([1+O/;<97RY!\KY^.3C+2]I<[:O9;$W;LEKO))'')4G
MC,3LI-*_MLC2V"WSA!$!#6:(V1T61,@X6<((8> 1_P!2A1Q*(E$2B)1$HB41
M2Y]!)\]6XI_9':7X$]D5!^Z1_:5G/V.E_I*FICH#^V_#_K[G^C[:^D[7R.OI
M]*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*-SDI\\7Z,K[#<
MW_P3P"BKXC^,?D<I(Z*B41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B*./I??G7?/;[5W;?_  L=17,^[;^N;^4+>T"&Q"X(77%8W_T0;_\
M0VS^1P__ (M%:N7Y&Q#^:L;^ VO_ "M$3R-B'\U8W\!M?^5HB>1L0_FK&_@-
MK_RM$3R-B'\U8W\!M?\ E:(L5;UXYZUW[I/;^C)*U(,,=W+K&=ZL?GR+M;"'
M)6=FG\7=(JYND>+.:7 (5[ "=5RFH@L T5 Y)!1<0E+'-',J@[$$>(@^A1.[
M\Z-_AKP#Z,+F:P<9M+1R(/!/&_8(4AV0Z)WDNU9=A9DSS6\HY^\6(?5@UR,/
M"[,#:NV18$C//)J8F].]D[2C17]MNGO\*5?YZCNKW%VF<X7'?_LVS_,*^>H%
M@$H8)@Y$%"-^9*.)Q00:3@8.)DIC8A<0%<YL0,)22OGFB*LX@)+J8XI9F#8Y
M76P^QG%P:XL#7/ /"USBQI=MT#G!KRT$]"X,<0.H:? OE%O"7 /):W<<1:T.
M<&[]2&ES X@> %S03T+AX5+]L3HTH3"N4O*/433/)C)-9<5>&(W+&1/I8S''
M9C-<E]2ZWE8L5;L4Q) S1:SI-MDMHEEUQ91FSQD _M*/+DFD2M!*NK[-C"X6
M^^M7AN9O4!P<4;3)-7K;7K<!F?NZ*2?@KU'G8.A$DSV=(V$@32SI:"#+9:FR
MQ/+4Q&#&8ED<(XIY]Z=:80L]S(R+CGLM&Y;-P1-=U>[8G5_D9PBEVJ^: G$+
M6Y=YV_3QRU*EJ%1V/98^7(\-Y1B*R:!,3LY.136P O:1$N"BCBX$KM322\AK
MG)8 -Y**:79Q.HH+NGW9VVWLT55EXW@QLDK8N]LT\-F2-C0^5T9$#IF- ?(&
M.#3Q/!WY63P,U/.-PM5W:)+#J8I%[F1NE[?%%+7C>YY9&V3>9L3G$L87@N]R
MT@"N&=%_S("%P)S@L++NLT;N<PQ&K<^GGIP<BN.2Q:>Z(VT -$X-+>)7 D0E
MS'E@:TC#<![I8)XJ%K)"Y8FZRP#G</:++=I,<QSGX^]&QC<L&G'S2/?7:V."
MT7 1RO+6[[D[-!*O=I/-M&_(KNW9?<T,O4I'/=C"1>B8QD[G235PTN?&P.<&
M_&0%BYTX0<D675+EN9WA;6UPEDU9KS=KUFYS>$MKZUZHVX_N,7U;-5XVX2 9
MZ( GSZU%!1QN;PS'XC%9H-(:!6^1QPIVW6:CQ$EUE".P]]B2[:QT?!6L/B?=
MHQ,FNUQ,V(QAU6.1KIGN<V(;2-$CG12M9J/P.3CIOO/@8RO'4K7GE\\#9&4[
MLCX:DYB=('EMF1CFQ-:UTA!8XL#)8G/VKEW1[1-#0FQY;"9#*S=R:NY(Z+XT
M2-AD;]#VF"I3>8Z0.FNYL7-T<6MD2BK=K/9L?E<7\?/TE29 8NRKODE* Q',
M*1XD&JISDZD%F&!F/N8G)9>*2*.>2R:\&1;7Q_ QCY.<ZY3E@FY441D=-((X
M0[=K3UYM-PC'6IH))G7JF4H8N2.62!E<3S4'3W@][F1B%M6W'-#S))1&V)A?
M*6[.<-7HQP5Y)S&!8;*8(@PKQ$J"[8VDU.)VP8$S>/=8Z-?0(QM78+'B]2-O
MQ<8M$Y YBM>9J*G?O:V#BO&Q7D-D?"6WLS:EQ%>T:<L\HG;9HTI&-JVI.5<R
M43IJ560QQ.X)IXF%X:>D8+!,Z-TD;7\J+3^4FK]JCAC,)KW+;'.LUV<RI0D;
M%;LQ\<K0Z&&1[6EP.[SQ&(/;'(6V1Q1TB!R*Y"ZHU ^RL2 Q*936.-$UGSAD
MDD!#(F>\@M[J]K$%6\!1+RL8BUL.#BH@"=)7)E:UR$O#L<K;.;R+L3BKU^*!
MUJ>O7E?7JMW+K$[8W.9& WW1:.$OEX 7-A9(\ \*U\/0;D\E3I23"O#//&R>
MP[8-@A<]K7R$GW(=[H,CXB&NE<QA/NEM3IWHXY;).3G*72&X)"9K^)<)X)N3
M:_(*5-#1@ZOBT"TW:^:N&OV<XH(1S>M@8+-BT05<#$FY-G<<I K9P2#P;7#B
MW]600X?"Y&A$VU/J*S0I8N"1Y9&+5_P&T]H<YD=4AXG#6EYD9RAPEW&WKT=,
MRRY7+4+TKJT."KW;F1FC8'R&O2^]F.+0Y]G=AA+CPACN8>( -=:O%O2W%GE!
MO[2VEP[[QU\;M3></UNJW&S.$S @>#2D-^2+EH,H&U;%@L7Y@>QX^*1'C8O8
M9Q"<%B W6RG?X-F;-9'-8;&9#(.[VVFTL;/;#VU[, -F%T6T#X3=F=RI8W2N
M;*V;B:Y@#F;;%^+$T<1ELC1HM[X5G6[\-8M=/7F(@E;)Q3-F%2)O,C>(VF)T
M.SFN):_PAN*MKZAUG '?DZS@WG2WR'>0K;I^(.!;['R^]8<W3:0+B\R1M1BC
M9XY=\T=<8+!#MCG&0TE7;-)?); .RI&[2R%RTS"O<*P.0Q3[\[6QRMVE$=)S
M8X7F=_+CWN$.<]DSB(]P 7;#3MTJE=V5:WM![%D64X7.DC=O&7VVODE:(6\;
M]JP+6L=$T%Y!)X=SO$Z=&; $>1#%J6.['FTEC=^CP4YR%7):F)@GD[=,-3O&
MR0]70MI&O)VYC<GE=-H:\,UU)JNU I/KKCB]W''#O'&ZPM=Z9;\U2M#+[*O8
MXW9\LM:K'VYE1URP\F%\K8QS'G;LP>XQL^U[ER[[]*UADXZ45F>2+V-G/'=L
M<=B=XIOM-J0,',:QSR&,W//+&B1^S]@%=T$Z,W2;KS8U5QID3[R)D$1Y$:$U
M9OC61^LF&)N\QUK%MFZ\(F9[KM_PQK60=0M>N8:K*>WQ:,M;C, ET')O4CKL
MHW1AWP6=89)FG;F7BBQ44^+R=W&7&W)9XZ]R>G:%=K* #VECK37"5KIYGLKE
MKF/$K Z:/-!I:@[.U,5+)DI(<ECZF0JNJQPOGJPVJQG<^[Q,(>VNYI8YL,3'
M3-(<TQO+8GQ1071>P=I;$DVN=<L9KXZ1)KGLG?R79)**#QR$:U;G-\F4OE^3
M\0*E%6V/L346>[(N9&)8Y&.#..D8\$!A$S:SDZM*I#;MRMC9.^K#$(R9S-9N
M.9'7@@Y0<9G2R/#6%@X2W>0EL8<X1"OC[-NU+5K1ND?"VQ+(7CDB."JU\D\T
MW,(Y+8XV%SP\AP.S "\AIV C_1S<M)(X3\(.!QQO%U@/IASFL@D^T=81"*M,
M9Y"9CVT[,TI-*9>SL[I#IJF4BJ'(&DLT('M>#.^3>=:XE<N75F#B95<ZS,]U
MPY!E>*&E<GG?-B@>WUS##!)(R>OPGBB>UKG#W4?$WW2Z,>F<Q*ZPT5XFBH*+
MIY);=2&%D62V[%.)99F1OAG!W;(QSFMZA_"[W*N/@+Q(AO*/=.VM2[#,F0Y&
MO=&[DV@U7UB]QP@IYDFIVRS@E&T"EX],&]W DB]KMXCDRV5[.6:)H/C1)5-'
M/%J?.V,-CJ-^HVN1:R-"F\7(I@(X;S^$REHEKOC?$/=.9)\;7<!!*RZ=PT&6
MO7:=ETX-:A>ML[))$2^6FWB$0)BG:]LI]RUS/B<WC! 6T&R>C4TU$-=;NFC3
MLZ;KR77O"#2'*['6+B1&%)=J>=;-G[7#9%I#<N 3-AD4\L8;H.]A%#!0*0)(
MKC)O</!L0AFMQJFKLA/;QU>2G6$-K462PAN,;.(+M:G5?8BR./+I.D<CF&-P
M+K,1(<8YW;';K6M+48:UZ>.U8,U? T<N*CG0F:I8M6&024+O#'[I[&O#VD-K
MR;$<<+=P5IL_]'1S"C;U!XVXZD)SD$^V5(-.M;,'(XH4:T;.BL89YO(XA+N[
M>NXB);+"GYME[@Z/RX4?0CF9KID\>#M#QD!WXM68&:.S,V\!%5J17WR.AF:V
M2G--)6BG@WCWG;)8B? QD8=*9>%G!N]G%PY-,YJ*2O$ZF>;9M24F1MEA<YEJ
M&)D\L,VTFT)C@D9.Y\A;&(B7E^S'\/ :. /*%^D(<>982S.63LV:6<XZ^C3J
M%6BTGRY&XJVT6SL$B6?4FTR2[-6&-%88THL.^"+MKMX_!9D6AT6$O?JC#1Q.
MEDL2,Y;\@R:-U:QSH.].W?*26(1%[8:8+3+, 8G![.4^0O8'6LTYEI)6Q,@C
M=QLHOBD$\/)E[Y;]@9'+Q\)EM$.$<1(>"Q_,:P,<1G;871NR['CQQXW#IY!V
MDLLG7'_<V\-R:\DDJA+?)XLV:3V2[P>8&PB(DW8)8^MC*V-6<@?V]$%Z=6Q+
MPI%-4V[>1E7,J:N@[ZY6A?+(8*V4H8W'VX8++X9GY&HRS7;9F;S88GR/>(HG
MET;'G8D-X@NA9TQ-WMQMVD'RS6,;=OWJTLT#98FT;3Z\[J\)Y<TC8VLYDC0V
M1[1N 7<)6J<]X@<@]9Z\*V?,8&JV1=I$U<?*<4W=E.?8.#NUA<Y1J$R;QP)P
M7>HN/L)@9W%P8<W0)'L=R@"[6;'-P; C.W5SV*N6VTZ]GCFD==; 3'(V*R['
M2LAO-K3.:(YC5E>ULG X[[ES.-C7N;R+&%R56L;<]?@B8*KI1QL=)7;>C=+3
M=/$UQ?$VS&QSHR\#;8-?P.>QKMV^@D^>K<4_LCM+\">R*C_=(_M*SG['2_TE
M37<T!_;?A_U]S_1]M?2=KY'7T^E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1%&YR4^>+]&5]AN;_X)X!15\1_&/R.4D=%1*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%''TOOSKOGM]J[MO_A8ZBN9]VW]<
MW\H4B('_ $$+_P!D&_\ DX45JY=$2B)1$HB41:$=*5\[IYG?:^;$_N1>I1HK
M^VW3W^%*O\\*.ZN_M9SG^#;/_P 97R[1<AL"1\C$ER!,5DLBD!2$Q"5A[9XW
M62'*5%-2&643[6*2Z@9>"6=\5,QEL<;IY?8[N+8\) =L>$N!< ?$2T.:2 ?"
M YI/@W'A7RD-MQQ ENXW (:2/& 2' 'R$M.WD*DTV+TE3[.N16ZMYB:P3CC-
MR&XQJ\5MJ:_1FUW'PV!_(\B<##=(Y)UXBADR/X"\#B,I06/8'X3)W;C!E1<V
MMQS#0AU32$=;$X[&NN\Z3%9@9JE:=6X>&SVN>TYDT(L'F1.%F>$ADL3N!S2"
M'L#C*K.J)+&3O7VU.5'DL4<1<K"QQ<5;LT-=KHI3 .7*TUX9071R-XVN!;P.
M+1B5_P"<,NEW.6#<W)5$P'!YU[LG3LXCVO@W==O:4671.$2"U]#U'O-O.(\'
M2:(4R!/KLFUID.I.;HY)"-Y!]L1]^+3D$&F[.G8)W,CMU+]:6TZ,/>9,ESW6
MK CXVC<R6)'1QEY#!P,+G!O73DS\TV?KYZ:%KGUK5*>*L'EK!'C^2VO 9. G
M8,@8V1_!N\E[@&EW3;-FZ7,IG<H2XXZ!'7O"9+SGD8B66SU4[&J<Z%",9:*3
MG: 9WPP@P:V*,<52QMDX$89$N>'=YV$PX<NA1(RPSOH1VB'3D+CV('8:<V,#
MA_70ZV7#>4?I!T9Y5V&:S+'P/[W F";/R@=K(XN_Y=SFG^MSL*X.T1_3$;NZ
M'99=(Y2\2@^-.JFIZV#N^3R77VC^-([]!0YUJX_6.[9-IB7B;#$X\SIM<-6#
M<D6N%1]^D,K"0*>)09JJ*+,X2T!3D+4T0I,W0;A<X[,7GQU<?#%:R.8,5EU:
MZRWCH<A ZJ[*UGLNG$/L2Q10.+8X6W9Q(X63$]]@MW797#-Q=-C[5Z66O0Q8
MDK-L5'5;TM&9MEN-L-=4&49!'+)*T%\KJ<)8#7$C&0<6KO%SI2]@<:X5.HJM
MKQIV<5M?D)AN[;)TL?4;M.QV-WA\J@NPM7R6-D1=U&)8M@L$WDMG5VL;X8"X
MKMQP0O6WYI&=G-:+JY>Q6F%M]-M'%][J+8(CS*DD<\%FK<BF$\9$E66O%P,X
M>%S ]KG>Z!;R,3JVQBZ]B$U66S<R/;KCII!P68WPS5[-22(PO!CL1SR<;^+B
M:XM<T>YV.QD0Y%\/SN(#5K<K8^_M/.!.MN4+#FU0'8NL9@VZ[:MG[%?I<PZ+
M<VS8FJA-X2&*33"*:Y1DHVHI<S:[=A7LQTESDWOSKL6^/)L8G/,SS[;:>-OM
M;;PTO'9JW*[K<E.I%!+DVOJ778Z*:OS[?)-Z"2VQT;60,=$RJNI#DL*["LK&
MUD*3C5RT996LU)FUF6[4DT>/<RS4%^2&;DUN:*<S*SVR.=,]LC[*B*U_MS+6
MT*F;1&F@T*>2]TC.-YVFZ-*PH$.82"70Z'9Q9SBKGB8B^R/"/2,MTL^"+BN,
M.C=Q!L<$#[.$[M4.V6*\DTC758&3?UKP2 NL2@,;8Y[)V%ICA,L+6<MP+)YN
M(DN;P0RM=[+!.R)CFV)GQ?UP'L(;!&2]T')="[B$DO+E<_F-(=!%L.CN*1&4
M=+7,'_D*7R%2TW'<GC9W&3T*W*R,R"5FO#+R8@Y4:!BCS)9 NU,$8/B$]=6A
MM;;7?&-4H0-9F9L!FNS<F\-[W%(-#5XL4W%'(2\NGF._6$FB@;')B+#9G3QP
MQ"26=MBLQ[G?:Y USA)(2_C,;XY+-K*:3)')"C$'V\5WIR\4DSGLRL#HFPOE
MD+(XG06',:W[9&2 6, ;PA[9-*M=\@HSH?<^I=TZ$ULX1Y_U+LI@V6V?)-GF
M.QS'0F..*!HD7,)CD0U<THQDQ))1!S[F.WD*RB^:PD@!3P2&PD5O%S9/'WL?
MD[C)8KU.6F_L=;LC6"5I:Z9HEGNO,S206;RB$ ;.B<22>%6R46/O4[V.JNBD
MIVH[3.UV.U.>8G!S87&*&HP0N V?M%S222)6C9H_=][]AFV)#LUYA>L7K7H>
MX]NY;EGK:\[%'GBB4ALO-"46:&GH0*%W88R@1L*49XBOHLO=U,<6'%9[4R:B
M\W:F,Q=BC%298N1VW8^AWOJOCJ&L#$17:9+#39L<V8BI".*-T$8^V[1CC;P,
MAD8+DEI\%1]9MV[VZPU]D6-I-YR(X'"O#RX0;,I D$[_ -#WD/ 2_*&[^:@>
MZ=RZ2V[GKV609?2FE=7Z8;&^&;@-97EV;]2L-X['WBTS;(6WO3"0[-N6:$E1
M9DT"B\%E[,[JQ99XYIZ>.T\['X_(T.UP61D,C<R#WV*#9(XWWI>;*SL[[#HY
M Q^QA,A+6D#F,E'1;=_.MO7J%TUIJYH4*E%K8+KF2/;3CY4<G/; U\9>TD2B
M, N!/ ^,G=5,OGJZ2_=1')_:$!<))R08ME:WG^J)[$=EOD%C.NV75PH(,8U4
MK!EF>5>/]<C!M+2+?P21QJ=+)"$J'3@XQV=2R[&Z99!CQAJ=ID6(DJ6ZMVK/
M3BLS6I+KGNFNBR)(1%;+I'D<4,U8$@-K-:QC6WG4+IKYRUNLZ7)QVJMFG8AM
MR5XJS*@:V*F8"R;FU@UC&GAEBL$ EU@E[R<7Z5Y?3K4^WMT[8=6T*;$\B]<[
MUU=N1L57P85Y!&^036Y"38MC<Q@7!"./PKH<@_LAOBAS;Q3@$1BVDYN5($4W
M,C@:UZACZ+'NK#$V\;=Q[P#*(IL6]CJ[9&.<TS1%C3%(WF,<6N+FO:\!PU*.
M:L4[MZZ]C9SDJU^K=83RS)%D6N$[HW!KA%(U[A)&[@>UKF@%CFDA;![(Z2N1
M[,U7R.U,[:P!$8=XZIXDZ6C) DN4N5K>!\/2\#H(BMVXSV9F]24SP@R7.:V4
M>'5)-(\3-K2-@**-RZFD(J=W$WF77.EQM[.9&8.@&UNSGFEMDC[=_6\<+>%L
M#!S2 T<Q\CBYQZ5K5,MJIDZ;ZC6QWZ>&HQ$3'BJU\*>*OO\ :MIY)7;NF<>6
M"7'EL8 T# G#/E7CQ%G>PISC ?D@KS[2NR=*J-V<JO%D6MIV<T8LCT]8+X1V
M0*%N(06-\FQ&^ PR9.7>E6*3M9"NGJ#"=_:M6L;7916R%3(<?)YQ>^G)S(X]
MN=$&M<[H\[D[=&['JN=@\N,-8LV.S]I-BC:HEO.Y(8RTS@D?ORI>)S6_<#8
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MEC*9V-F=+P1LS-MU''WNI81+]TNDI^]3VV=(>_R7S-WKE4=S3/G?[30Z#?\
M[R/5K*_J<+I$_6#2'QGH?H*GMLZ0^$R7S-WKE3VM,_\  T/G(]6GJ<+I$_6#
M2'QGH?H*GMLZ0^$R7S-WKD]K3/\ P-#YR/5IZG"Z1/U@TA\9Z'Z"I[;.D/A,
ME\S=ZY/:TS_P-#YR/5IZG"Z1/U@TA\9Z'Z"I[;.D/A,E\S=ZY/:TS_P-#YR/
M5IZG"Z1/U@TA\9Z'Z"I[;.D/A,E\S=ZY/:TS_P #0^<CU:>IPND3]8-(?&>A
M^@J>VSI#X3)?,W>N3VM,_P# T/G(]6GJ<+I$_6#2'QGH?H*GMLZ0^$R7S-WK
MD]K3/_ T/G(]6GJ<+I$_6#2'QGH?H*GMLZ0^$R7S-WKD]K3/_ T/G(]6GJ<+
MI$_6#2'QGH?H*GMLZ0^$R7S-WKD]K3/_  -#YR/5IZG"Z1/U@TA\9Z'Z"I[;
M.D/A,E\S=ZY/:TS_ ,#0^<CU:D>Z*'H6.6?$3FOKO?>[X]JFT)AK!/D,28_-
M$) \@O<AA[M'FLH%OLU"Y=OM.:PZI&*V.2(RZU^K*U[VO$M<=T+ YW3MO&8R
M6\+-B6J2):[HHWQ16&2O:YW,</T@< 1U+0I)I/1&4P^;K9"[#3$,$=@!T<PD
MD;))"^)KFMX![\@D'H"5VWZ\*7KJ41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$4;G)3YXOT97V&YO_@G@%%7Q'\8_(Y21T5$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$4<?2^_.N^>WVKNV_\ A8ZBN9]V
MW]<W\H4B('_00O\ V0;_ .3A16KET1*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B*.[I%OX"X<_P"T1X=_A%O17-_3?K3_ *E(C16I1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB6O:_[U^O_P#JB+U++HCX6476
M203NHBC;-93!/"ZQ"R8XZ5LL[XXW47(5201PM?M*K*)I86RSSQQN1>VB)1$H
MB411N<E/GB_1E?8;F_\ @G@%%7Q'\8_(Y21T5$HB41*(E$2B)1$HB41*(E$2
MB)1%&TMTO_1J#K*H+<NM:IK(*9HJIW'EG7@HGE?#/"_5'+VZ\<L;VOU7O;KM
M\J]ZEXT#K @$8&X00"#O!X#U'_G*-G6&F@2#EZP()!&TWA'A_P#*7K].%Z-#
MVWFM/ZO+/-NJ^P#6/F&YZ8/7*GLPTSYWK>B;U2>G"]&A[;S6G]7EGFW3V :Q
M\PW/3!ZY/9AIGSO6]$WJD].%Z-#VWFM/ZO+/-NGL UCYAN>F#UR>S#3/G>MZ
M)O5)Z<+T:'MO-:?U>6>;=/8!K'S#<],'KD]F&F?.];T3>J3TX7HT/;>:T_J\
ML\VZ>P#6/F&YZ8/7)[,-,^=ZWHF]4GIPO1H>V\UI_5Y9YMT]@&L?,-STP>N3
MV8:9\[UO1-ZI/3A>C0]MYK3^KRSS;I[ -8^8;GI@]<GLPTSYWK>B;U2>G"]&
MA[;S6G]7EGFW3V :Q\PW/3!ZY/9AIGSO6]$WJD].%Z-#VWFM/ZO+/-NGL UC
MYAN>F#UR>S#3/G>MZ)O5+1SI,>D[X%;CZ/OF+JO6/)B!3#86P./NR8K#8LV(
M23%Q?Y"\1XL1M:@KEL0PUB#"%,$DKKD(I=K*W;4QM\NGL UCYAN>F#URN;K'
M3(<TG,5M@X$])O #^Q+=H/I@NC23$%3SY=ZTQS3&0PSQN/+.O'+%+''*U^J-
M]77:]KV^53V :Q\PW/3!ZY6^S#3/G>MZ)O5+D^G"]&A[;S6G]7EGFW3V :Q\
MPW/3!ZY/9AIGSO6]$WJD].%Z-#VWFM/ZO+/-NGL UCYAN>F#UR>S#3/G>MZ)
MO5)Z<+T:'MO-:?U>6>;=/8!K'S#<],'KD]F&F?.];T3>J3TX7HT/;>:T_J\L
M\VZ>P#6/F&YZ8/7)[,-,^=ZWHF]4GIPO1H>V\UI_5Y9YMT]@&L?,-STP>N3V
M8:9\[UO1-ZI/3A>C0]MYK3^KRSS;I[ -8^8;GI@]<GLPTSYWK>B;U2>G"]&A
M[;S6G]7EGFW3V :Q\PW/3!ZY/9AIGSO6]$WJD].%Z-#VWFM/ZO+/-NGL UCY
MAN>F#UR>S#3/G>MZ)O5)Z<+T:'MO-:?U>6>;=/8!K'S#<],'KD]F&F?.];T3
M>J5?BO2N]'?-Y1&X7%.5.O'N4R]_9XO&F81"46*=W]_<1VEF;!KK1])&Q![B
M6,(C=55-*RBN/>*88=>5L4^A]65H)K,^$MQP5XI)YI'&#ACBB89)'NVE)V8Q
MI<=@3L.@*R1:KT[/+%!%E:[Y9I&11, EW?)(X,8T;Q@;N<0!N0-SU*D*J**0
MI1$HB41*(E$4=W2+?P%PY_VB/#O\(MZ*YOZ;]:?]2D1HK4HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%H_SLG6,"UY#G-HF6[X9L,R
M;I@ZS*TN=KQO2<Y1=B>",FS9B^[%@]%6UPJVH%K/M]F.+7EADBAE!G$:<V8\
MZ*H\/7;]O_AUW\GA^,;;K,7'5VV//]!0IPWX9IF5;"?V5W$GA&D7 Z0Z@=<K
MNSLVV&8BGI<X@O')G2%"DXBA1P \CP>V\$HQL1&75(>AZ;_%OX5&AHG=LXX_
M='+T:FQVP]O2U$5KW46NMW&91<V6R=A V/K,N*:GEL9Q'> _"B1M]%ZTB3XS
M%BF9/+3,RETCFLIKQS+>!7$ N>!XBXC]H[_DW*QGMKD%M_=O"Z.;!V; @G38
MNB^6G1YP'9&M(W'FMI>%^8FLND;TW']PQ_6SE*)+=K#C;BWIQT'6KJ4_*-+J
MP3ZRQ\W)$Q<B;O\ K_KP( -_QM>?#XN D;D>/P@[>,$;*7;BYM7Y-^E(EM;R
ML9I7Y:7=7+--F8#XS:&%(NIC>XZR?&=Y5R?A9CK-R#,A$W\H F![SE[&]9N$
M4B*U[QEJ*T]#_P!=?C_;\(6P=%1*(E$4;G)3YXOT97V&YO\ X)X!15\1_&/R
M.4D=%1*(E$2B)1$HB41*(E$2B)1$HBHTB/7:H^^N@UD\B6UF<SQ[*XWS2NN&
M$N0E97''+#+).ZB>-L\<<\+WQZ[6RQO?KM?$T/DC8=]G/8T[>'9S@#M\>Q6.
M5Q9%*]NV[(WN&_@W:TD;^#IN.O5?(Q>WLS)Y=\KV1Z\G,^]^K#+JZ[E*W^GK
M[IBW,49W/6-A\7C:/B7R%:G>RS88-MF3RM&XZ[-D<!OU'78=>BIGCDSZ"/N,
MORZOV/E/\'U+!VF7]3Z/^*>.3/H(^XR_+IL?*?X/J3M,OZGT?\4\<F?01]QE
M^738^4_P?4G:9?U/H_XIXY,^@C[C+\NFQ\I_@^I.TR_J?1_Q3QR9]!'W&7Y=
M-CY3_!]2=IE_4^C_ (IXY,^@C[C+\NFQ\I_@^I.TR_J?1_Q3QR9]!'W&7Y=-
MCY3_  ?4G:9?U/H_XIXY,^@C[C+\NFQ\I_@^I.TR_J?1_P 4\<F?01]QE^73
M8^4_P?4G:9?U/H_XIXY,^@C[C+\NFQ\I_@^I.TR_J?1_Q3QR9]!'W&7Y=-CY
M3_!]2=IE_4^C_BGCDSZ"/N,ORZ;'RG^#ZD[3+^I]'_%/')GT$?<9?ETV/E/\
M'U)VF7]3Z/\ BGCDSZ"/N,ORZ;'RG^#ZD[3+^I]'_%/')GT$?<9?ETV/E/\
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MU=O-?V&RW^#+_P#FLJY>#_LOC_\ U,?^M?6:KXB7UVE$2B)1$HB411W=(M_
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M.",@/ > 2.(-;NX:&7R$F+HRW8ZIN<DQ\4#)>7*\22LB;RMXWA[N)X/"2TD
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MI7RHZ-R4<FHS+===(._<<9 \Z_UW'L)D-K^*%NNN3#-HQM\#&\(80B&3%2:
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MMF;!"TNV88XGL+G.)XF2X^!QW#^(QI<.@P)5^QU.<$? '!D$@8-HRR4J,P^
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M**I#I)JYVSRMEG;-3#"V65L\K6RRME>_:RM:]^N]NNHZ7.( +G$#P DD#Q=
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M.A'7QTE'70KG-59H)WQQRT\H,S1GHO;:9/#)3O#CB9/+9@E83';ALMZ+&)7
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MV/.2U-B3IZ:T\CEU,-8N5+V3$3=RZ6WD'4:],O<&1UZ3K@ FFLQOJT8_@:\
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MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(N
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MUIY713^<\>^&FW_,T]D. \^8?Z3I>O3F1_",^4WZT\KHI_.>/?#3;_F:>R'
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M*KG+&E'30YB.9]<RU\7=?;@Y./PKH.TQNN5*\]VXYQM"LD'"X %H8>/AD<\
M/+/NM]B0T[] W;?J 23U6N]>-K72B)1$HB41*(E$2B)1$HB41=CCC]_$?JC_
M %#C?]V#U^SO<D_\,=!?XJ83_,85(J_Z!#^QL_FA9@KT-9DHB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(HSNDE_ZN:L^S<E_W!KKXA_JU/[#Z$_PEF?\
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M90[2W7<?V-)GQX+>K8$Y24@WP:/LJ;4ZMR #:V( 7QS/2PS<CR%\E5"DQL<
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M9P_YNMS1W*,Q['QF77:XM^PH=T-V+$3R\:4.:[RFR+9D;$<CQ@WQ0Y8C./\
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M?CUM^66V-:?,$ND2YHSBRN+>JZ"@M6*:<>53S9&HEB9BEF%5K:DDDQ40T4$
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M9$7I>0-+\2-&Y \I ])_Z_ZZ*ZIMS!TMKR5RN%RT^2MK]"I7Q_ALCPO$WK,
M-SY02HN":3<,'+P>P2\8F,Y!*AUI2DODP,\D0(:GMP;R0S<1R;'\O\'4K%$H
MYB>3O)V&P53)-343YI'DB^+ (PI])V6\[@T=R T1IE%HAR8SL0K*FMU(V/*
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MPWB.%[>!Q;Q-=M^F8=VGIOT) W\G@\*MZN.K4HB41*(E$2B)1$HB4171&_\
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M:0+G,<W;B:6[C<;C;<>#<>7JJ#7)5JY0P)IF!B@@A!6#>+<X[,=%17$,+%=
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M2T\?$(RT'<<3MM^@Z=? 251-#M6N#V>ZDDPCQ3[?:FN 7L>2JA)C":G*6/\
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M8WP.V[-&3]US9 WXV<+-]OB#OX=]O&L:1O\ ]=_]V_\ KU"L%_\ E?\ L?\
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MJ%2;(NJD/@.0L5*L%B[P2-;-M:EE#[#&6'AT[&R"]ULNWW!/%MQ=&@NV\&Y
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@?_ZY_P"/5[QW$O\ ^IO_ /2__P#670H?^;_[?_[K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g104413g20a69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g20a69.jpg
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M.#E8=I6TMB(S=;6XU=@Q-;*8UR,D,E&1L? T0?_$ !X! 0 !!0 # 0
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M/#M96:&.WC0D8<HO'.JI4R>F3CNRNK2+QR=&)=I5"<FZOU.;1I&*1^!UH@0
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M8Z;?SW5J.%1,(F$3")A$PB81,(F$3")A%79W.JBK9QV%\;AJ:UK )>8X[<S
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M-:R,FGDK&"FD>UDDK74<=7/3?*N$L+VR4LD(J6AA?54Y8_QQI)&/C?/2;?\
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M3'9(UEK%AH81DI-Z<V<*/W;E9;&U]#)!SVKJD(Z5]3X#43ZBPO7BEW-8R!D
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M0B9)0=3G:0,6 DL\59<LQSIPF52".H6)9=Y!^N,,L>$P,D4EKZ.3W:,M MZ
M8D_-]>.#<UC\PE40C^UNL-U8Z0)'P$%D)%)S'^30,5HBR0D1@,Z)L$'!,'_;
M(S\W58M;>5OK2]K ':;**=A70V;2]C$ZLC6M(2Q"8W"D1K@G;[:55D*><-F<
MABR59A2\M*N%R@XO'D6:(.1!A,J,  )4F#G&VW7<8&^.OO\ ^RL; F&LB!AI
M Q0)MF1T4.,,VQH04CYENU)LT7K= L!.-&!H(3227T3?B"[!D4&NM561!HV=
MHK(Z%1<KA$PBT))]^=B]OG%]C/KRL#(H:V\J[Y\-=]7&N7O&;W4=9^ECZK3K
M:2\,GZO6JOE)[1_ZJKIR1>C_ "7L7HVF_@"Z \*/<UT1\7+9ZNU6DYDBV"F$
M6J_Y>KOO1?L]9W7T9<L[C5+%Z2KAN8KR/*1YF&*ZR_:::2)1ZX<1]X8V6)I,
M6:*JB1-+E))NGJWX2]&W/.J.(.K;SIVOH*>V2PQQU%(^:42T\<Q+VS.8""_<
M#E V';NHP\>>*>KN']YL-%INIHH(+A:YZNI%5005;G31UCX6EKI02QH8T M&
MQ._53$\-'82^KIF7:D!<]OS&UA\*C/74O$N)AQ']EP#R9E>PC*3<LEP@(+ON
MD50A<:]JD[]TZ([C==VWL>5W/MOM</[_ '+4-LK:JYR1R30UYIXS%$R%HC%/
M!)@M9L3S2..3OC [%E_ G76H-?::NUTU'-33U='?9*"%U-2Q4C!3MM]#4!KH
MX@&N=XVHD/.=\$-Z *]S,]6[TPB81,(F$5>ML^4;I[25BRJJ[!/W8UF4,()C
M#[>-]2>V,]!I.U&;9]IJ.E\$I221$ZC[G=H<[.P9PBUU5Y4;[+<.$5DDRN#2
M=\M^5S1]!.5,RK;,B-RU[%+1@:YES#YJ*3-1]Q(HI*H.;58*J*I:;$HE-PT>
ME@%SSNCOQLP.A1S[37C7?=MKIOIML5I&-OW$'Z1LN_810.\B%[=A^MG7N3W5
MU\C]9RE[6P23SB:QR>1Z?S W(8W&@3AZB"A4;@1B,*,U7Y3EKO+K#/R'8'5T
M-;&)@ZB4UX9>\V%5H!."<9Z=WR_T[?,HU4!Y%[,N/N$RJYQ&JNVH.?3WL/4E
M;OXOM)2%A,I3UQK"C+(*SH[+ES6\1D\"L-*TI /C0X/"HV^!M0T7+.9#(>).
MNP$E4@ 9[=C\^?-W#JL\=U[*B["R^FE5N$Y7S+3G:^GI2P4;U]/WL.X$LT9X
MU7U(64SC+BN YCE5JKRA&S$K8R-VCRBY:BEFSELJJ1OZ7ZI_DK#L*U,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB815AQ#])L)\]3L+_I* 9LJK\FYOB;8/]5SKX$7Y>/2M;]FQJ6/
M9.@$^P\?JX%O*N8CS6G8F@+]U>:@]3VQCFC+1CEE<1/V/)</[W:2G:/:!]S?
M"SWWFX<\$/>@KRWX9*ZU60 XSYP1\ZAC5OC7.5%VGMOM9#[DA0J8S)&:1VOP
M["CR+0'#X+;W8.&WM<P^6"M+CYC\MF,J3B7WJ1^70L#4HX.3+E[+F$2L:<&I
M"\-%4NR -\;9W[@0,;;=3W]@&,+L,,Z<=BZR[ V/V3%7_ )O.[2,4W!Y&VYH
MD75Z,CHZ'W'M)),4N%Y$9J[&6O?\<I4D_IVJ+1912$,H^ "@1Y"(/4GQ1^W?
M?^B9! &",9[>TCLST&<$C<]<%<M</CQ%VU?4SO96R6X4K*[,\?%AM1W-?-RK
MT$CT2N:56VK'VTAVE;!RJC;NLGWC3MXFQ9ZP])KR2V82[AUR-1*@..S_ #?]
MPQ]'58 JOQ:7'40TBVC?;*!D%1-#(=:Z^&2;JF,E$.<U$E>ARWR<7O"+2*Y2
MJ-JMIL DQRL9UO$W=1*O03AH7CBD9*MG?!,JEP)&1[^_F VVVZ9[?E746WA\
MLX'%2M>Q#N4R!0.R.F0+I/=K1]UWT/2HQ6C.R+_G1?2F3[BZV8*FQJ8+L$=K
M6 1PO"[4:UW"HQ%F;)Z77'Z*ZE7G\W1Q<-SG) Z]_0'/>NTBO%3(J+O:QNQO
M5ZS:^CDG65M&8U/%913_ +<^TL:U*TKJM"<?M>YF4^0,3^A0W%?(3..USK"A
MI:/S$NXD'WR2+<.+#KE3(QC'T^^>F#N>_NR.U9V[R>/5]V_E&TE!VT KK:4=
M<[9ZHV2REU0M+>2=U#<1N*G)(9J[=S.(3I65P#5XOHB"G;U"< T]'+18I!RC
MD&)51'= <#&.T'KCIGWQV^_YUD.J^C4>JFF.U]2"9CJ]==I)Q?$P)3=Q%$M#
MP%&Y@ZP0<,-*;'EWDY<0IDIKJF6?%0VYSG53GAF%]OOSP5"<X\P ^91;:>*$
MS#CU=S6J;_CD2F=6&NG)V([FZ+WD$.Y?]5NN5T=:2FYV+!K;A[TBE8L1NHN9
M:)L9('6AA< %;K.I:/\ ;I<E7FSU'?G!QU.=NO0]^=L]#NNKP#Q)69%"G6\!
M*NV<9LNC>N5!)T+'*FD_7(FBY:IGHN8B%HVK#I,/[!I HK<$]CYTA'&$T.5_
M.UH'$E7$=C+9-,U*7D@??[_?^:%V<[8R23@CM.<=.@[N_P"3&&1'@2%!Z\C\
M?3NNI24O@Y>%MX;[\]2Q+ZDGD0AW7F;];5G]E4;K<*#>>79+HM-M9K+;C;3:
M+;$+(AT%--X<T&@-A+U@'J,JO/OT.#V9WZYV..@/3MP2,[Y5[-/5TWJ"I*MJ
M5H=-2EI5U<PBNFLFDCCAW(I$WA,9&1I$Z?=<?B<FBZ8S4@5<<?B6?.%U./\
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MN7I5WJE*MB>"KY$Z@^-,WV3:EL=9M=2?3")A%"WQ[_HG0+][KQ^ONSL*Y_\
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MSSZ<YZ:CX6UU[U!?+S%=J2".[7>XW*."2GF>^%E=635+8GN:X-<Z-LH:YS0
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M"R(33O,DGBV.<\M9S./*TO<0-LE>U301TE/#2Q<WBH(XXF<Y#G\D;>5O,X
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MT2?1&:A6<@CSPQ')+$"C@6_3]JU5?QB8B $I!.=M/QJ#CP482;\_V'+1+?\
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:EBX=OGQ%RV6(/7+I4A).,GIL/,LZ85%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g104413g21g20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g21g20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1444&AO=&]S:&]P(#,N,  X0DE-! 0
M    %/B^4V@X0DE-! 0      $ < 5H  QLE1QP"   "]SP< E  "')R,3<V
M,S8R' (% !]-:6-R;W-O9G0@5V]R9" M($%C=6UE;B!'<F%P:&EC.$))300E
M       0OVZ0;A<(Z!O$5 +]_/'CBCA"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#
MO_XU  (  CA"24T$)@      #@             _@   .$))300-       $
M    >#A"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8              -    1J          $
M                     0             $:@   -
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   -      4F=H=&QO;F<
M  1J    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   #0     %)G:'1L;VYG   $:@    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ '0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M 0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q
M@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87
MTE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=W
MAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4
MH;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MH;&SM]76)#F'E9;1U/ G9W-U@8*4LK3!U__$ !T!  (" P$! 0
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M8[M%LN1\I4A[F[):@LG62'9EZ75&QE4XNJT*.450B$T&QC""DC-NQ>RKZ46
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MS2B(P2/ D?T'4V!R ?$9US:^:^Z-&C1HT:UUD_(\+C"K.[#+'*=;@6\3'%,
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M_GQ_HTR_H%MGW57C_OTW^^F.N+YUWV2_OS[E_P#7F-/_ ,UT?NR<1_R=9O\
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MZJKQ3Q+5<27&2MF+1TL7/'0TO-Z,%.#D%L'E,TO*))GWWP@/)&@#8.!LY6;
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MX3X**)N [A* 95$"B;V\ (B(!SQR/.LWEK/I</?Z3_10?VG6/@(#_"A^)_\
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MC[23<GU$[Y#CH.N!TRQ&%]T[:3=-3KZ<D#/7BOF B"*:9A!%NGSR5- H\]@
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M2M<<.EC&,H>Q0#4!*1NF4'?Y'K]V<];P].^$F!N%#DX]N0)'50KUR9(N295
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MANU7=JL!9*AP(X@2RP4\8"0P*3U"(!S';GD+O@%CISVR@BME%!1P[K$OI.0
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M%+NJ;1&Y5&L6U%@HJJQ1LT!%3R3-58I2+*-4Y1HZ(W45(0A%#I%(8Y2E*81
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C(4A"AR(%(0 *4O(B(CP  'F(C\HZPDDDD]2<GWSK)TU__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g104413g22y47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g22y47.jpg
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M&8:^@ECG_+U(JJ;B7 JJ-U*]KF2]O V!T[71'M(Q$9M.SS"'63]GXS<%SO\
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MIHB>1$"'S>,DPX.11"9UQ!)(&Z:0[8Q?W-M2MEOFLJ&;%D#@V.&NNN^0??\
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MC&YV$40?%+*0]D<\<+X>T:Z+(#N[>=:7K1]3T5UKA\TH>*P8]_D,H'<I&VN
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MW475@OVMS'IO]_LFI.]@#;3GY_"PYWU66;CT%ZA=7J[F]PK5J\6"O5J,OM8
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MV$,DB-F2,65ACIQ"/3X!9^T,'=6][CYTB'P">;%N\_#Z+5S2 0&.LT;DGO\
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M;.<*7"E0<Q8:\C4+:5U)@QRAI5(:@'N4+2(1$99F!=T]"]P01QB'D4=4= Q
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M(&V53VTU70RIHHGA9'.V%$LJ)J:8WUUSOIOKZ=<D6M>X?Z?I\!?[9C4:[EW
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MN5^?6C+_ &GR%*?(DO\ ;E?GUHR_VGPB8HHK.,9Q>=^9QG'IQG$U9<XSC/\
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M>L/\5=]_3O5[\MW")\GK#_%7??T[U>_+=PB?)ZP_Q5WW].]7ORW<(GR>L/\
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&7&>$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g104413g30s55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g30s55.jpg
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M 0$! 0$! 0$!_\  $0@!$P&0 P$1  (1 0,1 ?_$ !X  0 " P$! 0$!
M       '" 4&"0H$ P$"_\0 0A   00" @  "@D$ 0($!P$ !0,$!@<  @$(
M"1$2$Q05%AA7UB$Q55B4EI>FTQ<V>+<R(D$C)#-1&2<H-W%WMF'_Q  < 0$
M @,! 0$              0(%!@<$ PC_Q !)$0 !! $# @,$!P4$" ,)
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M<FSE3Y[=_O[G1;!48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M+Q=Y^O(21,53%;;L*>PN!FV(_F?-*HA;!TMU8OKL[,7ND@"U]9+YP@\!TF\
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M!@# & , 8 P!@# & , 8 P!@# & 5BZJ?V?:/^3O:'_>DYP"SN , 8 P!@#
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M9F][OZ2U!69'-EM$9NRC6K+<QK9H[6'R,C(DU!I^>EDV,CN-RE*A8O,T<P&
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MQ+-61)Z.1I6(H[>-RV-LHB-MXK+XZ>KD\9;8G1:H6Z\[=DD1#?\ /8:V, 8
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M'' H9' & , 8!6+JI_9]H_Y.]H?]Z3G +.X P!@# & , 8!BS00+)!;T'(A
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MI4,DY$BR,+G6*S,G,1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M3%NX=Q&R87*8#*FK1RHR=.8Y,0;Z.G&[9XE_XK1PL,(NDT7*?_B(*;:JZ?\
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MV^._T>RHGKU;\^NW?RY/2C@H, 8 P!@%8NJG]GVC_D[VA_WI.< L[@# & ,
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M--LJNRV.D:CE<UT*VO#BFV6"U+5R$=:65]"TD5I\R1HPP!@# & , 8 P!@#
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M+6GE2UEM"9R=KYG:1U,]K6N<J(R9^G<\Z..GJ?&1+8B\#*U,QB\;93,X<K&
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M%)8L3.1(X88WRR.:QKG)N>7/,, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , K%U4_L^T?\G>T/\ O2<X!9W
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M*(O91,N3"QH5RH?E;G9NXDIA\Z>ZC!#75L/0?/V$JN_SZK\\?U+MX(& , 8
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M-'3!V:4TKAL" 273S!B*LC\B]7+*M#!4<0$HNV_Q39?GO^!=?! P!@# & ,
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MY;5 L'1/Q]P5*-6+K81OLY53MNODG;?RX3R^PKP7\"U=1WL4I=92Z8"Z#O\
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MD.4$O+5T#N:A[<SOX*S#\SUE\ZX ]N9W\%9A^9ZR^=< >W,[^"LP_,]9?.N
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M9+XC_L^!?*^ /?+[)?$?]GP+Y7P![Y?9+XC_ +/@7RO@#WR^R7Q'_9\"^5\
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% , __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g104413g51i08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g51i08.jpg
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MF*?7%R%6=[:X(C$U-SAXUB,E,CF6MR1!==0*)D+1)S124Z*TTO_$ !T! 0$
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M'H+F>PQY<\X/QRR8S6<I$ I#5<$F#,SZ]!JX*C$5XM&-!C-%9^SV;$'18/\
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M-KG@1ZTNC]:]BI7(NW,*%04]:05-%Y4$P#T;-[$K:-"3Y.65O!K6>#B4E06
MFA+%9R+>DQKA--/&I9M_S6-G6TY<]0#R)'GJ.:D+X;NW6QW5EK&^IG7JP>O=
M*2*_9Z:C[*71F2U_$K.?.&,>0+6Q358RDEA]7E5R1TVP/"@FD-KD4X(A2Q1E
M$D_7E2;\HZ]Q<@FPX<NXGJ/CR%]+*Q#A8IPBZ0[)8Y%V[%W)CX2.M"9L)&AK
MHZ58B&Y"1R8HU"1L Q6(+MTW9N0&GK(0$%(;*/BQ1VU'L$'#MPDCN1=&#LRM
MY.^,C(U8,(D)*.)DE9"/!RL"6? 4@\HD\(+JF6C!^X<"TQ4TA,SB!+=\FAJQ
ME$1DX!UE(L *M&A+$<1^<?H0?BN4.G\$,8AV1$UB13%B U9/7^1TD#/L3F-(
M,AI->0P[+9ZKB3 T1ID.05+!?76";(J-=[N-4'S514ECTX<>Y9;PB<(G")PB
M<(G")PB<(G")PB\0_"["]A_6W_#M0?[EJL_@8%PN!W$^)^JW3PHG")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(H\0G^W>VW[UV?
M\L-!\*G@WP^Y684-_<;3/[J*[_A /PHMK\(G")PB<(G")PB<(NFD$BC\3$/)
M!*CH:,@!V$=B!R0%&080QU<N$6;?9X2(KMF37"[MP@U1RNOIA5PNBAIYRJNF
MNQ%2#67AAJB"=3R.L.UJSXU&!(@Q(GHRP)Y,QC^.$.^]0=I_6*XCQ.='(Y7L
M3E$4IB7U@]'Q88.B\I.D'!$LS*-A9!CM+:W[B/.WHLBZ][@#7I;D1KIJ=;WX
MWNM#2;P@[5>P^450<[9U<K+;EJLI4;P$<?6[G-B' _7@_59>^"@U[;BLGEUM
M"G9]>V2 '=P1AH]Y.Y=H60>K*-Y*6JN87)R]/AK?RY#G8 <U)X=X6MT.IS.R
MLZ[7RR8P>7W<:L=S%5R\Q%I&(@39=D_D>(ET@181EKF'?IG@43&::$2S K#Z
MJ',7"8T)I%8=#W3\OH5,W0<@.6ATU'C8GQ)MWVS4M#9'75.5-7TPE+B<RZ"5
MG X;*9L[W>*.IC(XQ%A00W*7*A%P[(*.) 38NBRV[YTY>;*.]MG+A9?.ZFQ0
MZDD"P).G3N6S.%$X1.$3A%B;J>P9D@@Z>32)M&SDN4 -G#J1AVZ#@\$7=MC0
M1!95YHFJ7$.6#]N4&I[;/!Z[)VD[124;+:Z$78FI-'(TFBM(I $ (N-76R"I
MHJP%)K:L6JKY]LCN^<(:J:LV2*SQUG3.V&[5)5PMYB*>^^"+G8)C<DM@V"#'
M)?1BF3W%8=H9):#55U&J1#9CA3UK5BHZ15;)N\I80W7241U4RIIMK@BYO")P
MB<(G")PB<(G")PB<(G")PBACW/K"%=@HE7M''+<!UL=<WGU_M1HRUG#R&SR0
MAZEN**3TD)@KZ.R*.S45(3R$:=! ,EC#U @$,+H/VB^KAIC&"HN-0+Z'E?B"
M%7JR\+JQ6L<=Z0+M P+UTYGTSG#>.2216I((O,X_*^QO>NY%6UA3$58S262D
MF%8]KJ].NY4M(W!:5V9U_!DY,258D\.!A9%U];"]@+Z'@&CAPUL? $K4L>\)
M"W7HEG&XEW+BR\@J6M E.9F$84F#N:BUQM=]5 !.I9 QWF9J*PR";CJ'D0M
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MFNNJ/63M,I44B-#^P])J]B'T,;RD6S?5_5,9HK>_K)?JF7 W=M*))%XIKH+
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MK9M*/0TH9KF54'O#WQB" )B,A1C<7B62)%=(H =MS#8HLT-I$FJ;=%$@X'Q
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M1[2-^=L7M)-M3A#L1GHQ1RQU4M*YK'.?#*8V12;V$O =D_J[MS2799(WC,>
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M>N0UDR*,2]K%9%)G6[3".S<+LXD8=F;AJY 0,D9$HT(WCP)T/ 7.NG#3Z^?
M\+K6>J"U>A"5[=JLU+VABOSULB=-2&K1GVN:QJ/,;AG^:KKK6<;UXW(V5(*A
M&RY>"*2Q"(-$ACA>0Z:N%@^"9XD5-P2 ;6^'(7/'G;\*G=UCE-/655S"Z*9B
M2,4#7@X3M.295B;J)R Y+Y(*%_*966:/QP]\;/(M&HX+L<5R^:.1HD>V#$'
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M-QQ7N[+TV!UFTVSM)M-6SX;LW58[A%-M!B-*S>5-!@D^(4\6*UM/'DDSSTM
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MDG74'4YKVY7'73732_@9[=48;/X/$)Z'F+>PA4;WM:2+T_&[9LI[;UEQRKD
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MU%!GE1<AMNUFWNT>V@H&8Y4021X<V04\5-3LIXS+*&-EJ)0TG/-((V FXC8
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M8GD5!V&P.3&-2"NLG@\(W?E7H ,5'Q./IS.S*ZB*LIESH%&DI/.HD 4+:E9
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MJ)9QK_P:*EKZJ:V)5NGCR8QOMI(TG*NOE\]SY^?/Q[*XK]P^GT(3YA]N0_\
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MZHX&=07U]A;5P.AMKH>G3O\ O\5B?3:LODWJX)J.S^N^U6-F;F4!Y'6<X'U
M<"R9D7,.C62FPZM9A8<0(AR#<FD.70,NFI3=X,>:.A.K'4>\>XM:UC0UC6L:
M+V:T!K1<DFP  %R23IQ)*Y:BHGJI73U,\M3/);/-/))-*_*T-;GDD+GNRM:U
MHN39H &@ 5+XOPF!H3Q2!3@985<L*A#31GVQ"05H,T1/BF86S&LF#TZPA^C/
M6.,0 DVDT%BW+9_JDRKYFAZJ#0<HI(I_.AL%(-M?\5?NKS#OS5>R[MV_WA@W
M&XW^\R^S <!DONO^GRV_JK]JN_5U1._2Z.P#_ $'[H,+;@!V@]M@_:/81BW[
ML,7&%^R>T?OA<+$^T[O]Q)QCVC-_T"]!'86G']\UJ1K5K8TDK-D:=L]S1F*B
M(D8*$!C/;=Q@/A.8@Y .:(+$-&#Y1VU9IO\ &S#1NFXU;.'2:OT=?B1;9 ,"
M0L&(&F#CJ3%6 YFT(R)\S&CGAQZW0T2<E73 ,U8B6:[Y779RJV&LVK)'=3*;
M9NDCKII@B\3W"["N9[ZT37UK=!^G4MEM-@I^0K]E1+9:S'U.6+V +]?Z^ED$
M$M9Y9HVEJJ-A)A:+5OD: %/XMC)@(-^46\Y-Q\LPB"[;8N($ASK$BY/ VN;W
M&ITXZ_+FIP>&.'6C_2^MQ"U7@ZE8#S]M-P J/U1(J(:R^((6S-THC;[JFY>[
M(2^M#%RQC059Y>)R5\Y,#2,I<97RW3419MBQ=QXWX<[\N%QTX*%/A2/@0::8
M@PR% 6J+*D$,!;4QUG94Q,;/%CA]&R]*0RB6[]S^P1Z1&Y-#K@K*P)&P,5;!
M'KPA,F1@F[CY)):)K%D[[\+W',?^(Z6'<KU>%@OS.VNOD\[;&/.SYNOESC'G
M;>3.?-QY?Z\^3&<^3'Z_)C.?_+A%^>?I^K^GK^O;.F/Z6/U[Z^=YVF/U_KVU
M\W;RZX_7CS=O+C]6>$7]<(H6=3_[U?$'_P Z;+^3+IYPLG<&?Z3_ +W*:?"Q
M3A$X1.$3A$X1.$3A%%&?D&"/<;K<V6?,TG.])]H=-&ZKE%-?;=S*>LFK?35+
M;?"FVR^R:F$=<:YRKE/?&F-LZ[>0KR/B/HY2MVUUWUVTWUUWTVUSKMKMC&VN
MVNV/)MKMKGRXSKG&<XSC.,XSC/DS^KA11J+]0NOCTF]D$=@?Z*I227W>$Y;1
M4BE%$24T]V_I:N9.5J(S#59EYBF-5/4YCJ?&K9TQHZ9.$<[);%;G_G7Z\./)
M= 4K?M% !Q![5W8)I:>K)B[=M(5V)KB,ER1-9H@HHQCH"R*A<4MO'-'FVB3/
M)^:Q&TB">V^7;W9YOG??!-.EO#^Y^X7GU\,/Q#>W!7MQ?R?92/2MU6DS*$II
M>N0E$R??6B+)#Q&$0*+KE48-$2<EBP+2*0F,0XHPFV[]-B-'Z3<P69[#Y<>)
M?:>T/9+8+ MF<"Q#9G&A7XE5RPLE8*Z&J-;2OI9))ZV2F9[U$Z*=L,>2T;&F
M9T+V.E9F;J>!XGC5;B%;!B-'N*>%KRPF)T8AD;*UK(6R.TG#V.>_-[Q(8'M(
M8X ^I>&3B%V-'!TPKZ71F<Q(NGNJ*D\/.BY)'R2:>^R2F[$P&=/![K":NFZ2
MOH'&_HU=-D]_-WUVUQ\66UK*.$6JKO.R*-57,#<3S(<2%@Q:;#<Q6!JV=(,*
M+%&#9?(Z"HEP2D@W]567],CJ69Y9M?3D<[*89Y05(/S6RC-X99F0&^A_5M>2
M;2#9XRI.L!+/,D@BE?/?D<9 XXT$^K"%2QC8D+]333^39/JX0TDC7S"FC!CJ
MOAOHX*N_D?$\[J=W"BCQ"?[=[;?O79_RPT'PJ>#?#[E8-&NMW7:]:9H$C=U"
M4M<9"/T_!&0%]:E6P:PG@1F]BH)=ZT$.9<"+KC6SM=%%9T@RW12<*I)**Z;[
MIZ9Q" >(!\4N1P)"Y=UUS"JAZC6S"*7%UEU^B8F"2M88/CH(774 #I%-UW\A
M:(LX=$S"4<<2[UHD-W. 85)#;,P<P;'1N1FDFXM]>'#T3B=?GK]?NM.^'>=C
M4ACEL%X%&X=5E>F)1#I#%Z+BFIE+]'N9%7D?+/S[H<>K2K'D=0L+1PQ)(19D
M!)"PY,2<47--I8^ED0B95W*_'74^)[SP-]?DN!=7?Z157<%JTD,Z]$RTMB6O
M4EG61.764!A\5MDKVLLFX:Z8OU"$>!6,8@,)A+NFY$H[.&X^_E4@(IN6#* L
MA6H.1R-_;YJ <->-^7"PO\_P])E=?[?#]@Z'I6^X\,(!0%VU-75MA Q;*6Q0
M2)L:(!Y@.&$MT/\ 8;OF#0PBU=[H>5#==)3='.4\ZYR0BQ(/$$CR46(+/(M+
M_$INL-'W[EX1@?4BI(U*$5PYL8FP,[W+<!+5LV=%1S)H81RS>-U?7PJY$?C?
M?9#+K#A)5+0G(>)^RL#X47F/\9;O3*NL?>;IN4AE?"BAWKO$)M:WRG+7))$#
M.0MX#)-5I^%(:#MFJHY$0UAZ!_22I.'RS>0ZC$%12HQ@38GOK_9OV7P;>8;C
M%?-C8PUV'S"F@A9 R=V]=!OA4U8?+&64OO!C PATCF3_ -1FZL_6,>VC?@L]
M+ RC]H%0W>/>YY8,C7Y=W$0UP,O-U]&@L]UV>[?0=3MQ1?L#3T5M6KST?>,Y
MI%&!9CN@1'RQG&) 2#MWJ\=DFL?*H)JEHN1=8&R0*D3'/D7C1TQ468+_ --+
MY'(S=R21YF/W;W,SL.9C\KBW,QVF9CK7:;"X(*V8&X!L1< V<+$7%[$<B.86
M#=69Q<%C0R62:VS-:DW0^UKEK<(WKB"RB%H-T:7N6Q:?(%"N9-9=BJ$%92M!
MT)&S:M-A6L?2(*AUUCVZ.A7?!9&PX7X ZGJ >@6>6'?U+U,?C$6LJRHI"I'-
M5O5XD&/DTV+^1N/->*>KAT-\9V?.,(CR#C9!#SU=6S%XYVTP@V74T*6/18_V
MIO-'K/USN2^U@?SE_19!#4K;@,OM!B)9^S1PD-9/2>Z2_P FC52"[;!,AHV=
MK,1^'3I!F\623;*^AA-!^Z8IAN&">*E_<:^CH?:9O^S3^UU$<&_EU'].+>9W
MZCW6G4<5PU,WL]/45&1TFX@EFW;-7R;J-TF1@_\ )V6S>\A5 >"GXB1[L^ZN
M.CK#C4,C<LC\CL*]8V]BKUXTT.,+HN&<6'-0RT?.%BI+_P"4I1-<-Q!1@\<H
MN@#ENV+-V9$9\H'OH7:=V=T^P%1A$=-BKL2CQ."I<631,AJ8)*1T#7O<R-[V
MFGGWXW)-G!T4K"7Y0X^'L]CK\;CJG24OLYIGQ-#FN+XWMD#RT N:#G8(_?'
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MC,?*F_6>H?4=VURZ$0X0!C;3(YDX;"4?DT2TPNW8I.7>%GRSEPL63N#/]/\
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MUL3G13EQ#G/;''E>[JXEM!%AV)4>'.I99G50B)E:X-$8FF="S(PM<9B'-)<
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M\W^)_OAH?VLL]M(P_P#;S#N_9!1B,-W(E K,N?6M_P"H)+K@Y9XM=?7W6-'
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M^APP #CR!;19]IH]5U?N'&%'>FKC?&5M<;X*W)XDE;5X43A% OQ$^D$=[W4
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MWF6SLN;C[M\_NK!?&;[,]HI#14/2ZSUK?D9HDF=*-;HM(I5)2&O"FR>P):"
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M*+:^6P[*C=F.?F ?TWFRN(W$B^HG5]H1B&2\HV=C$.U#75M/!/2P5E5!350
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M;$ZL?>#J7_5W"6/0^13VZ.DOVQ.K'W@ZE_U=PECT/D4]NCI+]L3JQ]X.I?\
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MZ=K[:IZZZ[+.G*RSEPKG&=UEU5%E-ME-]MLD7B-X787L/ZV_X=J#_<M5G\#
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MY)BRLMFTG7A+IJ_@;Y65"ZB*Q"%V2<+##KJ%1)..LQ"Q ZUM.'@.1'&W?SX
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.. +7_ /-3_P#WPN%?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g104413g52c34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g52c34.jpg
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M,G6A H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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ML+[EM;\C(U)!FE * 4 H!0&J.FWV6/OUKMX?_.3.M"7K\4/0C:ZA H!0"@%
M* 4 H!0"@% * QIHB BHF.9<5/&"[ZN+'EI9,4@4Y8;A50QL+%A@PL^Z0AL<
MPSX_(Y)L]@9-AYB!CXB92_,NCTW$+SOI=3):@D4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#XQA@BX0HXXF
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ML+[EM;\C(U)!FE * 4!2+QMOJ+J=ZQ"]\!)>J[)[];F1%WD6Y?.A*.:Y98%
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MTDXSE!+7XV8RVFGX[)&TV/SR>JMA+/$SC%3E"UCY!G&2PX8S8)';6-E43,B
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M0\=;^HLK^KC"?ZGF"M?<\OYRN7WC:/*(3V-]3(\"<Z/QIN/^4SRH6L,GIV*
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M!D3+^OT;?BA&7Z];M=FR,\*\G_A2R_2(P5V3OM>\\/Q"O_R.,_2VK<(^:P4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#0Z*]L%=_;<S)$ [@UO/1"UBK9
M9,>*3)G )V3$HS@G#RHHR0R7=&@;3(9M\1(;3!5C1[$9;R*(AQEJA)%4WPHF
MGRGQ.)I@GC7'@PIA1U\?IP[XT(% * U/WT\1G<_U3]BOA \:B+4]SZ"8=:WK
MI)\C?[.V%]RVM^1D:D@S2@% * I%XVWU%U.]8A>^ DO5=D]^MS(B[R+<OG0E
M'-<LL"@)*@?QE]5_66AC]9)]6IW>/>BN7WZW1?-9V;5Q"Z* 4 H!0'U3QTJF
M$CBB>&Q+DD\J8.G#&=LKX %2@.8Y@;*V&.6=\0@0\\\K88Y97MC>V.-[]BU
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M2&X8O8"X_4153 D541GHK-1)/NE*4D< 4<!)/IRX8/%#B8".,$0, B%0Q1,
ML<[BAZW0E"@-&][-P'#IRQ&4]$"'C<JEW"ZED@\5<Z<E!#8$1L)LL)V/9QRA
M);KBB#-@U]N-9+$;R:B#'SK$ 0BF:[DLKCB1$9%435A5"JUQW:JMMI456N8^
MEQ)95CV/] ]IEQY.M*0TEZZZ30SFLH"B#&B:XYG;$#T_AQ*3QR0!C$817[4)
M<D/E; J)AC;/(;#'+&]X>*>YB%-Q*FU=*-O8W^SMA?<MK?D9&I*3-* 4 H"D
M7C;?474[UB%[X"2]5V3WZW,B+O(MR^="4<URRP* DJ!_&7U7]9:&/UDGU:G=
MX]Z*Y??K=%\UG9M7$+HH!0"@% 8=(GV?OK[G.?\ )#U <.44_9=&WW!9WZ=3
MJYT'>0_W8>A%B+6][Z3/JJ(% =/W"R\0G7S_ *6^/B@]ZX$6M[WTG(+ J@'@
M-G 4-)MB,&HA"=\5S+D*IS ^<Y&:XHYA97,AXXX]S"!989D .QRBA#(L4SOE
MF!EE<^K5N]*\9"\[Z3WZ$B@% <4/'6_J+*_JXPG^IY@K7W/+^<KE]XVCRB$]
MC?4R/ G.C\:;C_E,\J%K#)Z=B@+[/H\GC3[!^K^WOB*%6?<S'Y'?WOFP_16D
M\@O5._"'-'\#96>77(==E9K/+04 H!0"@*9N/1_3Q='XQP)\3D*NIY=>"-_>
M\8OI)9L1V)GMCLT?QJE>16PXP*U#/I % 9$R_K]&WXH1E^O6[79LC/"O)_X4
MLOTB,%=D[[7O/#\0K_\ (XS]+:MPCYK!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@* I\A;:I'6>(/$@>E#UVS2]WGB3<$?STA[,,F.FLR&XEL-K(T8LE
M^)3L?+>?T8 0$]$E5<B2IQ0WG+BZ2QP)5+!C.8R=3,'IZ>C\Q6FJ+%*F%-'7
M76]5&Z8=TUO+MX=;+N9<1Q8SI =.;Y?C3CED-E[/43(?/-X.Y!;*8E.1TYYF
ML<3.6;@62AU6RR,8XCY7-WN-C82^5J%!(U 05/&M4,;,(*8V9H:I]THB2.K9
M@$DYZ/MD7.$7"C'&XYFZN&F"YFN=<C,=C?/FT1WL9PF%1FNQ*&R(.-"4RN.
M6(E-K5AZ>F)'^]I< KHEN25*@A%BQ;4K88N7+EP\ 0   8==X8((((>.(800
M0>.. 8>&..&&&....-L;6M41:GN?0(=:WKI-@8W^SMA?<MK?D9&I(-=]@=G7
M'#\BL*,6;$)B47"]F4^'X,+F^DACIR*C,E=8[?,!B&%)*5Q3YU0//DED ""
M"&" 3,YBBY99AX5*3>H8)5;HJI:JZZ]1"CBVPV'6D%92$O6XZT%%333A$BZ4
M"=XY-KC>-&0,P0%E(+.J,'*VC"BG"9XFB@*\WUI)$'#PQ/IATM<0OG.A%LYU
MUD:4'Z3^3_N1_".RNX;)C9N(4P0^:F21PR1<P['NHS%$C<+&EH8H6LI%$!'8
ML-LE+)MHL>#,YHH1]*-KN!0>P:JL*(V&(F+0BV<Z#CEU=&TN#N7JX.'E-">*
M'.LD2FDZQHKSA,&,T\A-CB5"JP')B0]LCQS"$Y0*63;IR<WTD4K;( T,:[MS
M'$#QN6L!VF^0^.>%R5"U&FUP/80W"X8J-MT6M4_]4/&5N5RBR* DJ!_&7U7]
M9:&/UDGU:G=X]Z*Y??K=%\UG9M7$+HH# I3DIK0Y'#WE5[#'B[1CYLJSL<0R
M6FFUA2Q2D8H(<-V()1 ,4XH',PPKX%B98/(4<;+ /&UKY=FP&K'/XC;S2;.=
M!+KJ:/8^1D56U<J(.2]^Y RG-RE5B)Y(QUW+-E!4&L<):U2=A)JBYU'-?*+C
M?45$5]F$0 LVLDI#6N^V+.!!7"3M#1R@90ZVSZBH*/8^1DUAIK5=ZIZ>,D5^
M[Y1N88SS M%&RX5QFFX@K"CP8Z@@0[B(YS"P@PE_Y!A8<KE"9W_EAA:^5_Y6
MI1['R,A--I56/&CE1BG[+HV^X+._3J=7-@[R'^[#T(LQ:WO?29]51 H#I^X6
M7B$Z^?\ 2WQ\4'O7 BUO>^DY!8%4 QII8 AHML0 TX(/OJXLK8)1L4Z3Y>;B
M5<Q<K&!LQ!+FA!<LQ#X/*Y!8_D9+!8X! X88R_,NCTWD+5R\M<?3@U&2U!(H
M!0'%#QUOZBROZN,)_J>8*U]SR_G*Y?>-H\HA/8WU,CP)SH_&FX_Y3/*A:PR>
MG8H"^SZ/)XT^P?J_M[XBA5GW,Q^1W][YL/T5I/(+U3OPAS1_ V5GEUR'796:
MSRT% * 4 H"F;CT?T\71^,<"?$Y"KJ>77@C?WO&+Z26;$=B9[8[-'\:I7D5L
M.,"M0SZ0!0&1,OZ_1M^*$9?KUNUV;(SPKR?^%++](C!79.^U[SP_$*__ ".,
M_2VK<(^:P4 H!0"@-6]A=F@("6&VF"Q\NO0NHL"2Y6<RDDK"&EA-6/XF<<2M
MYWJ&)=6'#,+J[EG+R*<1$$EB"&H@I2N&95$T6Q*QL33CIR\>Q/9Z8T^TZ-ED
MQJ[(,G7I09CAPP>R*4.DY''Y91G8+BBF2(KDFH74Q25T8TXL2,;J IINC+Q%
MWCA+B&IMUK.)O%'>MM,*85]-_I_YV:H0* 4 H!0"@% 1K,DE$X<BJ095/HJF
MXR<?M-:=9A 114\%760T<F(;NF)@RJ;(I@1X[<.Q<L(H'2A/ 43'(R9 !MF)
MB! BSMD818669/'B1W'W0WI468@6H[;PAMWG2CE0'>=;"FK%33,07$X5QJA%
M"63BN>;[)55LJD"]T*K=32I!:-I8FF-.)/'#@K_L;+Q^\TF1V&R9"0<P\T-]
MM%MO)&S"/I2J%DE.A&)+B=D&J(1Y41%+#(F>!RP/HZDH)9S&]C">>-E! 3 @
M@RZ@% * 4 H!0"@% :G[Z>(SN?ZI^Q7P@>-1%J>Y]!,.M;UTD^1O]G;"^Y;6
M_(R-20:&[,>.)"GJTSU\4=>:K@UO=YT4Q]Y_[H>B(^:KI9% 5;\3O_NS63\:
MG'\%)/JJ#OEX^AE4.J/^ZOGPE<]7BD4!)4#^,OJOZRT,?K)/JU.[Q[T5R^_6
MZ+YK.S:N(710&H6_OB5;/?@T]?RH:@(<KD''% 8A(/U!>_W0<OY*=J(M3W/H
M)AUK>NDYD(I^RZ-ON"SOTZG5?@[R'^[#T(1:WO?29]51 H#I^X67B$Z^?]+?
M'Q0>]<"+6][Z3D%@50#&VF(&*BXYA#EC&'?1PX=M*IW>H&^0;A5 \\.X^0'V
M!0<\<@3!GD_Y\P&*?Y6?=/+RE\F"Z//K(7+B^GS:BHC8SCDZI:S3G)6O[TC7
M8UQO"*UA,0G(K,IJQ<;:XZ@J-A!=@."2<<DPM97-!@IKB(!&!3*&2QL<Q,A
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M6=^G4ZK\'>0_W8>A"+6][Z3/JJ(% =/W"R\0G7S_ *6^/B@]ZX$6M[WTG(+
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M$_I/<L1N>:';'PD(+UW#*K9T:U+BV[W,-M\R'&J3>'T*;V-. +W:J2<+.!P
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M!XA#J.94 <<J ((:! DN@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M"CV/D8Y]&F_I-0KT@-_YR@H]CY&.?1IOZ34*](#?^<H*/8^1CGT:;^DU"O2
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M"CV/D8Y]&F_I-0KT@-_YR@H]CY&.?1IOZ34*](#?^<H*/8^1CGT:;^DU"O2
MW_G*"CV/D8Y]&F_I-0KT@-_YR@H]CY&.?1IOZ34*](#?^<H*/8^1CGT:;^DU
M"O2 W_G*"CV/D9_N.\VF^>88=MG(2QR%%" #N)(C;"PN*.)B"%A<04_@'ARQ
M<\,+7SRQQY65K7O;LT%'L?(S:NA H!0"@% 0ELOXN&P'X)2M^A%ZA,.M;UTF
M7Q3]ET;?<%G?IU.H09]0"@% * 4 H!0"@% * 4 H!0"@*EGGNK.2!N<O06GJ
MD,X,Y*V#B"*TJ.ST42.<EURQ\^XIB=Z.B2"$C%9A)-($H@.!\.LF$)A$YY,*
MD6>.14#8I_ Z= G"FO'93SA\&#Q6+JJ)U>%*5U)</#4K3U-XR^X.R;+FP[)#
M%B>)KL1!U\6"3F:+57VF,V\I,V-B^+WF07%69GNZF,6,);-=R^=)*SA*I*0A
MJ"=WX7@1$DH;!"[5E)<%U7+9;BGW=E'8K]FWK8%:[=9K)#)4=SSW+LT;L=I<
MJV6IN:HITR769!9XJR(_^75M0?GV&V6BU3;;+GW?/L4-FGQ2I,R;%&X;7+A<
MQ*=+44F52%J"&*D,4Q4C7=:F][4#B@N5K-]IH[B9[0E)T'!)&%/+!64FLRQ5
M-!3Y(G%IQ<M)!]/0%>)WLGKA"+D9/>3Q8#W$0T);45]6.MQMI*60(*75#]*E
M=6'+L3?'3&BUUJJ5UGQN[BJNTZS'#@RH>;Q1RWA*57H0<8,KH:T237<TDW80
M).Q9[;76VU3$S([74H4(G7^?8YH\A)H#C-AH:NZ4]!!5'$%%PO9R.F+UI:^$
MDUP\11\LA.?BR<@HNZ&TT9QE*$":MC)^"2NG'*UB4M.](65E+%C$HVVO&*<U
MHU&LZ7F;="@>;">-=8.I2X"F*!XT(IQ^+QTIOX:&^NO,M&YRB-LR<?;1-I&E
MXZ[2(B*FNY#?B7C9K/-PM$)427:W,KI"TD. )"P7TL<OB$."04RY0^ 74"YH
M ,&J.G7YZ$U4(% * 4 H!0"@% * 4 H!0"@% 5M\3/:^9]2(OB=W0LF,$VJO
M>8P6&YE21V,]7^WV^VLHUD9W8G\$=C/J/5 NH'%]J(:.64#R]DG!!J0Y?(@8
M.&2F8$PI-I-Z*VZZ8#4FZ5IP+6\4MCVUU/452PIQF=SW[M? T#N^(883FQ)#
MH@ION8RG1O+B.Z1TR3&8RW"Y':VC"O*"FGHZ6F''(IY)Q=517"&2(I&8"BJG
M1\3!L/KT^][?*RCLES07-:9UWVBR1VB;?D+F_P!%LTV&&U-6:-*S127'$Y$J
M%:5J@BK:(.X=(5'F6Z\V^2%OS+Y1YR[3G/N.[\L;FR@DW1=V:N=+L#O^_+!,
MGW%*CONRS8[\DW@K+)@O6W3HH95P6J5HW/:4[5"G,BL]H!C8:=(7RDH^LB+>
MR&*-L$[HJ2&V:+M5@JR:R8\UA5]D5Y>00F+&2@9>\@+F#?4V6VFJ<[P(BLJJ
M" &*N(/:% X=[ 8<I78L./'%+A>KC(R'XJ"X*4;9%.AN/S#J<KH16H5))>P2
M.[4H]=X.%F-!K.AE*S991I-D%$(.9XYI[U14M137LVLFPM&#+;[RFDQ>'$4X
M^9\%:]'CXL:?Y'W%&<KD"1TU6B2/"HPS3CHZI2 H3ZWD!BIJHZ@X6 /NMX$+
M-A9=S%BQ7-2L;'C]YBH:ZGN0-*;A4T*CY/<H91Q+AIPUQIJWI4KKU8TU<98W
MK&_W#*VM\!2>[LTL1U2+#49OARB(E^4C9KSJ9J,N*V:3EVDORDS(^>'R(Y]S
M@<HK<++M(79Y&(AX-K8V3C0@4 H!0"@% * 4 H!0"@% * 4!JEO1XG>R?X0/
M/\I&H#:V@% * 4 H"%MD<+":[3V'EV;8B0M*6%[V['9M;)C+N-^QV;7MV>Q?
M^79M>W9_Y7H3#K6]=)QV-/Z19NRAM5LHI2+M61"J.WT9++"&&3+69@0NGIQ8
MH#F/F%-X(>0V08..0N0806&6=\KX!X8WMC87-!;7S=1D'A(&\/FKU3]AY=Z\
MZ#06U\W4/"0-X?-7JG[#R[UYT&@MKYNH>$@;P^:O5/V'EWKSH-!;7S=0\) W
MA\U>J?L/+O7G0:"VOFZAX2!O#YJ]4_8>7>O.@T%M?-U#PD#>'S5ZI^P\N]>=
M!H+:^;J'A(&\/FKU3]AY=Z\Z#06U\W4/"0-X?-7JG[#R[UYT&@MKYNH>$@;P
M^:O5/V'EWKSH-!;7S=0\) WA\U>J?L/+O7G0:"VOFZAX2!O#YJ]4_8>7>O.@
MT%M?-U#PD#>'S5ZI^P\N]>=!H+:^;J'A(&\/FKU3]AY=Z\Z#06U\W4/"0-X?
M-7JG[#R[UYT&@MKYNH>$@;P^:O5/V'EWKSH-!;7S=0\) WA\U>J?L/+O7G0:
M"VOFZAX2!O#YJ]4_8>7>O.@T%M?-U#PD#>#S5ZI^P\N]>=!H+:^;J'A(&\/F
MKU3]AY=Z\Z#06U\W4/"0-X?-7JG[#R[UYT&@MKYNH>$@;P^:O5/V'EWKSH-!
M;7S=0\) WA\U>J?L/+O7G0:"VOFZAX2!O#YJ]4_8>7>O.@T%M?-U#PD#>'S5
MZI^P\N]>=!H+:^;J'A(&\/FKU3]AY=Z\Z#06U\W4/"0-X?-7JG[#R[UYT&@M
MKYNH>$@;P^:O5/V'EWKSH-!;7S=0\) WA\U>J?L/+O7G0:"VOFZAX2!O#YJ]
M4_8>7>O.@T%M?-U#PD#>'S5ZI^P\N]>=!H+:^;J'A(&\/FKU3]AY=Z\Z#06U
M\W4/"0-X?-7JG[#R[UYT&@MKYNH>$@;P^:O5/V'EWKSH-!;7S=0\) WA\U>J
M?L/+O7G0:"VOFZAX2!O#YJ]4_8>7>O.@T%M?-U#PD#>'S5ZI^P\N]>=!H+:^
M;J'A(&\/FKU3]AY=Z\Z#06U\W4/"0-X/-7JG[#R[UYT&@MKYNH>$@;P>:O5/
M_P /J/+O^[_P^W.@T%M?-U#PD#>'S5ZI^P\N]>=!H+:^;J'A(&\/FKU3]AY=
MZ\Z#06U\W4/"0-X?-7JG[#R[UYT&@MKYNH>$@;P^:O5/V'EWKSH-!;7S=0\)
M WA\U>J?L/+O7G0:"VOFZAX2!O#YJ]4_8>7>O.@T%M?-U#PD#>'S5ZI^P\N]
M>=!H+:^;J'A(&\/FKU3]AY=Z\Z#06U\W4/"0-X?-7JG[#R[UYT&@MKYNH>$@
M;P^:O5/V'EWKSH-!;7S=0\) WA\U>J?L/+O7G0:"VOFZAX2!O#YJ]4_8>7>O
M.@T%M?-U#PD#>'S5ZI^P\N]>=!H+:^;J'A(&\/FKU3]AY=Z\Z#06U\W4/"0-
MX?-7JG[#R[UYT&@MKYNHQ5[<>C;Z=VPJ0L[XXUM3FM*MBC <)]MM"3R;@)HS
MJ/E4=0,HQI3F%83BZF"5-B"$ACR4HE0Q\<,AR1@.V060E2X7PO4]G F]AW#4
$+)__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g104413g56t67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g56t67.jpg
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M 0$! ?_  !$( 2X",@,!$0 "$0$#$0'_Q  >  $  @,  P$!
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M^,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?,!W/\
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M^N]&$(G55@6>"BT,@TS@T9BT;D$@KR)F@T A@!Y(^6K6039Z*%)H)&7"I3=
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M) ):[&\PD#+"T]JL!FA6:F$3")A$PB811673N$5^.2+SR8Q:%"5W&K- G+9
M)C@]9WOINKHT1>&';-NJYW3344T;IJ;+;:)[[:Z<\:[<\952C=OR&&C3M796
MM+W15*\MF0,! +RR%CW!H) +B, D#/$+SEFBA:'32QQ-)P'2O;&TGN!<0,^3
M.5\YO=FBZ6+0VP?%ZGT-DG,D&3^F9-2=;-^-6<;L2 Q67P.)0F0W(-=LN2J+
MBV!+%4JDNQ)!_=6!DH6S(@C<F8%A93]#;%ZYK,5S3_<EH7*PK2T-8K:UJ+CO
MV=/OVZEZU=KZ/(Q_1%NE2R-B<U\<W6K\=U\<\-:2*6+AM7IU'13;3312=(V:
MI)4@'P63PQ20Q0OM-<TNS8:TN!!;T<+HFN8Z1KFNZO\ AU][PG?VF#=FLH([
MK<]$ID[A,IBBYQ.2M$GJ0L6:8E!!S08%4>#B+ JEK[-T)8NF;]J^:<ZN6Z3=
M^[^5^Z%L-/L%K,.F/O,U&"W39=JVFP&L]S'2RPOBF@,LP9)')$>+)9&OC=&_
M+7%T;.CT/6&:U4?8$)@?%*89(B_I "&M>US7[K"6N:[M:"'!PX@ F_N<&MTF
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PBHUVW_OQ\-#_ !OR[_+Y[W85F\G_ -T?YVK/=O8^$LM7KO1<@%,3X&UN
MP$<=2L*1;INV+J'5#&);=1'E^W5UVU4'.Y! 8I'G6G/'.JV\A0;*<>Q74SK]
MD[$VFC:#6Z\KX)]+T&PRK-&]S'LMZO9JZ-'T;F\1(RO?M6&<00*[G#BT+4ZF
MQECJ5.1H>RS<89&D CHZL<ELEP/[)?#&PCM+P#P)6J>@?;.DK)B^G68%;T>F
MUQ]>49+71D>U<N7#N3PBKY8_@,0L0274:I")6UDD3'Q4X;>Q]\2\L*F]FQ/\
M.JHELMM-N]E=:TZS_I+/I%BEH^T!K:C!(YC6LK7=3J1W[>GRQ!QEJNK6I+4$
M++#(^DB@WHMX XQ]&U*I/'[WLM1S6J0D@>T$DR0UY3#%.UV R021B)[RQSMU
M[\.QPST=SYXMXF$3")A$PB81<'/&GZ*3KM>OUQEL-L41']@LX#T\K%I3J6Y#
M;/+AE\=##Y:-5%MGVR3P8X3TXD#=5GZ[\,T:[LW2;@?PT??<_<:VYH[*MVBJ
MW-.FL=-2FU<6JO1=,&:14L3259!*YF62M/Z!P?B.9[M]I:\O9QVU>CS:D:,D
M4[8]R9M4QR;^YFU*QK96[H=AS2/A@CX3 ,$%N'==(11T;$]>(-UYL;1C;T;C
ME60^L92K-A+4JSGB$8C@P&Y)'!)'E^@KN57&\$MD7"CM1NXW3WX=*N$=7//R
M:[K=F7:"[M!IY?I-FQJEO4JPI2NB?1=9L2SMCAECZ-P$39.CRT-#F@C=#26K
MIHJD;:4-*?%J..O%7D,S0\3"-C6%SVNW@2XMWCG.#VY&5K);I+1D<&AMJ*CZ
M'6B919JLUB\[I >)BI1!!5TJ0W%2\-LP=1FSHPY(+KNGD;L,1(F/XAPX?C-A
M)K=$LALAMIK=B2;W\L.VDIVGM=:HZU)+:C<0T1]+4FWVV=,LMC :RSI\U>3#
M6LEZ6$&)V/[TTXVMZFP4)(P1'+4:V)V"2=V5NZ8YXRXEQCF:\9)<W==\(:\L
M3N$<ZA1(H:[H1A9O%0Z7L0E[TV +2"!SE_MQSJ.!G8/LZ)2NI9N:4XX19#C3
M^0UX\<[<:-+,2>+ZAFVQT_9&':VW%!L;9#K4QWIM#UBQ#7OTF<Y)X+NY%4U:
ME",N?)"ROJ#&_K::6#IG>,^INTR)S]581&T89<JL<^&9W[+'PY=)6F?V-<7P
M$\K )W!NGJIVTIGN76'-L4D8)$8\V.OHP9''A>X:0QV0CVS%\N),CMEG*.B^
MPXF-(-W#%Z_'N6KU+E!YNKHX21TVU.RFL;'ZG[U:U#''8= RS#)!*)J]BO(Y
M[&RPR -):)(I(W->QCVO80Y@!:3E:=J575:_6:CG.8'NC>'M+'L>T!Q:X<1G
M=<UP+2X$.''.0++9S:STPB81<W>PO9^ZZ([9QX O&])Y1#SI?VOO 76-5PR1
M36^I[95#3#K"-8#&"#1NXY64,-[D(1^*QB.#EN5GJKDU)"RZ.P]D *P ()Y'
M>:,GE@AW/AGAC_DJ^4-XC]G+]!W?9.VHL /6LV[B3CK(58R,=/\ K54\5>E.
MW)*D8:6E,ELJM=Y?%*Y@<8+QO252DG7Y:2-C8HG$I2(&6*RDX8&4EHWL#E@'
MO/ZH/9[?(M'TGXQ]CR3:@ZW7K"L+FMJY][6;\)Q>Y"$25;2;B8]N=:7 "D-J
M4>0V0P:1">N8N++6&*E_,@U\_P"9<^KK1%LT9R(A;S/$#A\?(9R,YX9R>&/*
MM@P;QKA5AV'U^8AZ*'!:7[$SV,PF$VE*K:?MY:Z4.2&OZQ?K<4O&:FE4Q'KB
M+UDLSJ/A])W,<@;DU %E",_!.RC\5&B%N,\>(YC';Q/ ]HQQSYL\,V.[ ^)'
M_03VW&=9U*MC4G9*:=7-B!)*W>!=OG/]*&QK5K0:K5-'<5\2WLAC6)*M49)9
MSSBP([L"AQS8PDV<*#?PKXH#<MSGO'DX 'B<\,YX<\G@J9D/'678U1M9B?7V
MM2*>S.F)>IY1VD0.1Z,P6YZRNBS&X*:O0M*D)JCV!K-E33IE<5%U_7=CDX&/
ME@&7;R(H 1?[I%.[QQD]O9QX8[,\CG@3@<U:2.>(K-6-*]\KPE\,K0^+ZT7T
MR@591R+SXX"7(0"41VHG,,D]P/Y)!N'];AN>;%UF4OE^P(VB$BZ$H50CJZ4.
M34/%& 2T#/$<?)Q.<=_+*K+77C%3=@[5"S^!U1.7[B\+/"[DHA=[5DT.P%#M
MYKUFA,5ZMH)U?MMVDF<=Y?,Y,>3=<U0Y>1-:.$U=]"\N:C613N]N<#AV?V<D
MGN^U>Z1\<;0=#K$++4%#DY;$+OB54#P7-^$W\,; )A'^P,D#3^?6['*/D%?@
MAI='KM*8Z#;U\3MAJK,C @'(BL70XY)N'M]R!N2./#&2>?=R&>/,=W?R5Z;P
M[(7.T ] K%J]M$HE7_8FYZ5C]MAY8CK)9VSCEMQ](T)B<6=!7:\0071]8GK)
MI;H1*<(["A[2,M'B)QP;#E48XYX\#C'+(';V_N68[MV[/Q_7(3/>JUU1D+-Y
M19T!J^M"XN/1&TXI/9Y9T^94W&HT1=NW3E@-CH*<GT#L[."-W)8* B$E130_
M$H+(ZD X\?C^3G^[DJ\^)5WTLSI978R$0Y.OBEKF.NEHV>G;5G2UC7 %<S51
MBIH8Y'U_!MHI+F-EV7)CEHMI(TJ[@Q%6+2-B"BFLB65Y9-]X)P#\1/DX*6C/
M'C@$#EGGWGAC@.?V+7+_ ,:>, )GV#2/5("?4_UTE\;;SRU87:9XZ]"5J8O*
MS.NQN;GH(?IV'DV):'V5"8_P> C29J,\1J3&I"PL!Z/AVBTEE-WECF?N!YYQ
MQ!X=N1Q 6[^I'B12;L-V2.=:++HJ/T=.!%5)V#R(:7$[MB0)F!H2H2<TBIA&
M.54(AL:<PXA;30&58R2=B)VF[',72E?)L3_*P<A;@ \>)/9@=O$'/$'R<.8[
M..A-/&>WV)6 *VI*N.%P4LE4,CKY'LHDN%B)&+=VA'2O<QVK(_T/)?Z-D9-E
MI -M>/$]$+.6*5^PD>Z+3A\*0U?DW>7'GCA@]V>'?CD>7''8<K%I^- :.'85
M$0-%P 67L2K+3,Q8\3O0I+012U8&X[*! 06.BZ]J \=+5-.3/7C>0P:W)MK5
M R>UI+M)5%1SDB!=1]Z3=&"<DX(SPY#AS/(')QCB<J9WIXF=CU3T5ZWW,W!4
MLO;W8OK#8EI<2\G;?NQ3$2ED H%2SG;2-FW\ D',WGYTRJ@VA%0NQP%$V]&R
M<0]FC9M'521 I#<N(&2 <<N//'+/G/'XE$W'C)&8XG*Q+RE(5*B\,A,NYX:+
M=@XU!;!(3.M:UJJ<R"3657\A@[8+3U+SE6RT!U:6$I.)8]DY+B.C64,U>3>/
M,\)N^7M[NS)'R\L]G;W%2:KO&2'V;;'6BKA])BM-[R'@^9,<3M"0BN(V</7?
M==$KA:\$6#34 >6BX@4EI(R3L]-ZK7[L.*,C=H0UL;?A'9^3=X$YY?%W ]A/
M//#GGO"WO">TDQD_B:6%UF WW5<X@T&KTL<L2J4P49B\GJLV^"5L^K:,QTNM
M+WT\M2?D='%B3.TGC&.HU[!H07KL,Y3"2]?TR!VX]O)_%01\$'!&>W/ \3GA
MCAV#GV'Y.H6%5,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3"*C7;?^_'PT/\;\N_R^>]V%9O)_\ ='^=JFA/
M368]UH\/WXX784IUMD)QZA_:EH=[!V"- QYVIZ/^JZ:@:'G;-MQZ==M6IQ]S
MSQSJKISQU41ZGL;8D'"36MHJ\##CB8- H23V&#O8^?7:#W#!&] SECCJW 2Z
MJQO,5*#WD=F]=G:QASWAE*8#R//>J$T3X,D&ZKVU(KSZ\WO.XU/T_-$:Z'2^
M-1:8P@ &,\JZE8K,A>R(N03 *];;(L$WP630>2,$$$W")E9Y[55;N]<]V*]M
M1I-;0]H-#H6:'Z,ZA)3L6J=V>:$#HK5.7>E@ISL=O/+)JUVM(7%KH6LP!IJ>
MRL.G69+E&Y-'/\(0-ECCEA8Q_P"M'*W#7RL<,-WF20R- R'$Y)OH%[+NH67'
M0GM#$D*2DY%X@* 3]$HH=H"P""^_"#-",V6X9C>(F?*+>KHT@EH#XC(G3Q3E
MA%UIFBAL45X2;9MMV*2YLS:=K-:-AEGH&(0Z]0C:,O=9TUKI.MP1#B^]IDEN
MNU@W[0IN=T3=RR^Z)S8M0B%21QW63!V_2F).&B.<AO1O>>4-AL;R>$9E WC;
M/CGCGCCGCGCGCGCT\<\?QXYXY_LYXY_\>.<Y5;),(F$3")A%57M+_KE>M@W^
MWS+M55']7_S>2,I7*_[/_'U.(_[3_P"7J>GG^''//'4[,?!&T<G_ '>RVJ_)
MT[ZM7_\ T8^7',A:[4>)H-X?"U&MS[=P22>?X&?D5JLY9;%,(M'=C>N]9=J*
MAE-)6Z,>DH7*]6"CG84^V%FA9$2^0)B3(4EJFOPS)C7[9%9'99NZ9N$_;,B#
M-Z/=.FBV[V=V@U/9?5ZNM:3*R*[5,@;TL8EAECE8Z*:&:,D;\4D;BUP#FO:<
M/C>R1K'MP[U&OJ-:2I::712;I.Z[=>US7!S7,=QPYI (X$$9#@02#36G>KJW
MAK1ITVZZ"I?;- %27,CMFO">HP[= 8]^ 8BG=HUR2#B ?$Y3U#"AK>3U.NQ3
M(NF@S4M6[C8_RZATL[#6-IQ[H]EKMH9:FE:]%&*^E:A%TL&CS0;[Y6Z9J,<T
MT_4B9I9'5M5:\QM?*8M1:(-VY5U=73O>&,BBV6S2<[?LP.#7VFOPUIL0.8QG
M388UHDK%N\0W>@._F*3HA!YU#[+B82<P*1"Y7$I&SU?!CH=QJY9/$/7W25T]
M/HU5;NVCE)9F08.TT'XU^W<L'[9L];+H)_/KM&WIMJ:E>KRU;==Y9-!,W=>Q
MV 0>YS'M(?'(PNCDC<V2-SF.:X[R&:*>-DT+VR1O&6O:<@CD1W@@@AS3AS7
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MW0;6!/W6[5],5'\7.,V@IZ4AO%W]GEP''B .&>W([Q\G%9"IO$'Z"U7"QL#
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M6DW:O2I^M-(-*LZIR"2LII:MY77-XLNU%0&OXY/GVYVOHQ4A@JQWNE.7#!=
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MFVAQ:N9/(M_Z!D6<K"F:VO2Z;Z8Q#K?+.+2<;]>Z2DYFZ24!F=6;";'Y+U2
M80]M*!^Y$B4V*2[G@8^7R 9/($\,YX<23A9CK'X0VW7"143(4+A@$JXHF[SM
MFQL$O0;U,8TBDBH9K2!6* CTFN6;62TDW.@F.R83-99/YTRCW$=!QH3#TQ0E
MDKJ0NSGAV8Y^7(Y #S +TK2\'1*SK.N>=+7A%@@ZS]^Q;YC^'H1L^L91YV*,
MU+)2L?MBQUK003MNKX@3J=M&X_7FT2A^B]720S 'Q[G7AL;T*-[@.>1CCGAP
MSV$'L_=E>J)\'-R,LJE;3:7G"HW(ZZML]:LG9P.AB,;BO*$AM]C;#^O:7@I.
MZY+ ZDA^RC1T,:O3\6M.;@9 <.V'$9;&I,_XX1*=X<>!.0 ,GE@8R3C)X>4#
MGP(*W5TX\-^6=*:%NZK:JOT,UL>R8Q'HW"[BVJ@^\XB#Z%PAQ#(G8<PKR271
M)8[8%D\<N.3TK,"'E=@981:"VCV,H"QK9IP4%V2#CX^//CGN&!W<. [U;3IW
MU^D/6.BP-2RN:Q:R)&,,24\>L.-0:50-U.STL,NI%(9E-&4TMJZI&=L"4'R!
M,Y+Y2]G*R)DH_4V'A@(Y!H,0*"<GN]ODX*T6%"81<V.Q?5V^)/V*E%S4X/ZS
MS@/;W7JO.N-@QOLZ/E9P)7P6OK4GEBIS2)PV/QLV/M-*4(6,0'RBLC\CJMB1
M*0V"F??[34>LPU*P(QQR,9(QVYP.?9R\OQ*CEI>%?V<L*4=G68.84K7]>7"&
M[()!V(>PK>D@\[)+YN.&V:VD["N)W!Y1QU;D3?0 2(6P0I&UI3%KJGSE&5/*
M\AVNZ#,24[PP.\8Y@=C2.8(SSX9&0 !E='NP'44[.NKPNDJ\GA20R>$VQ3ET
MQ@GV DQ^<C9T;IJ](A>#*!6F?T:OS[N%2IS$]8DZ=M1I9U&QCEB0:!C?DR8A
MZ5<\<XQD$</*,?\ /RJGES](^[UQ[1J2H2[KW3TJ(NK<>% %(V#=]<QFEYY.
M[!K:11#L:$+1F'B=NU5XQ&*0V01TQQ:L.IV.2KF4J-]=PHI22M92]O;_ **0
M0.\\L<!W'(\@)/9V+!E?#@[6MF\O(@+Q8%24V.RZ06!$3EY7R'C%L#?]/E]V
M%A5:F) P#G"5:19UUC?.:&/G(+''BX;=^^"H1>7Q!=[N1*<M[N& .0S^K@GF
M.WX0\O-1,OX:_=XI+Y[(&'8EM$1LDZM3:IX3'(]V+O,K&JUE$BZO2NF@=?\
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MKJ_82:H8P_M)0O<">X)!_O&*X'1*MF<O)RR6ZAP(]&?0J/JD]Y&;'#GA26G
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MYW=ENCL@BS;I/G6G'A\]Z_1HY=Z)ZKKZ\>S3]&JJFW''L]/1Q_5U]!2WD_\
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MCX;#!PBNU)*]V'_<V(\G.)8IPV'-D.]%8C!$5F$AD\>>8#\$/8?VHI6R0O\
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MVE/R>P%H<3P SP3WR8W^EIZC#WYI2SX^6F+(QY02/+SQYI=W>J&BB:!V\(;
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M2TAP#F.+'M)!(WF/:YCAS:YI:0""%+)(Y6ET;V2-#Y(RYCFO:)(9'12L):2
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M$.1#V?1%-@/.MM96[BI,9^[MX>WV?%F /^_;2.5M-IK+Z+LH;)(C'JAG?$!
MN@,K?*5Q>3.1/8/,S\B9N6D=B305[ES@9/4"3M9,*?BK@)%7LZ>2"&<28F/X
MC/Q* =IKJ#ENV'0BN&4%N/@U!.YTJ)/31&HIV!@$AT4\/ONYKJT@]E2 ,*@,
MS(Z^:);*,(_(GKA+5J2Y4TU\M><(TD<6,<\,?(6C.XP O=Y&AQ:"?C(7G+(8
M89I1%+.61Y$4(8Z5_P -@W6->]C2[M^$]HP#Q707W^=_+RP_Y6#_ '%F)UUW
M@-[YJ+^>M3[[R^)=9^9I_CD]_G?R\L/^5@_W%CKKO ;WS47\]/?>7Q+K/S-/
M\<GO\[^7EA_RL'^XL===X#>^:B_GI[[R^)=9^9I_CD]_G?R\L/\ E8/]Q8ZZ
M[P&]\U%_/3WWE\2ZS\S3_')[_._EY8?\K!_N+'77> WOFHOYZ>^\OB76?F:?
MXY/?YW\O+#_E8/\ <6.NN\!O?-1?ST]]Y?$NL_,T_P <GO\ ._EY8?\ *P?[
MBQUUW@-[YJ+^>GOO+XEUGYFG^.3W^=_+RP_Y6#_<6.NN\!O?-1?ST]]Y?$NL
M_,T_QR>_SOY>6'_*P?[BQUUW@-[YJ+^>GOO+XEUGYFG^.3W^=_+RP_Y6#_<6
M.NN\!O?-1?ST]]Y?$NL_,T_QR>_SOY>6'_*P?[BQUUW@-[YJ+^>GOO+XEUGY
MFG^.3W^=_+RP_P"5@_W%CKKO ;WS47\]/?>7Q+K/S-/\<GO\[^7EA_RL'^XL
M===X#>^:B_GI[[R^)=9^9I_CD]_G?R\L/^5@_P!Q8ZZ[P&]\U%_/3WWE\2ZS
M\S3_ !R>_P [^7EA_P K!_N+'77> WOFHOYZ>^\OB76?F:?XY/?YW\O+#_E8
M/]Q8ZZ[P&]\U%_/3WWE\2ZS\S3_')[_._EY8?\K!_N+'77> WOFHOYZ>^\OB
M76?F:?XY/?YW\O+#_E8/]Q8ZZ[P&]\U%_/3WWE\2ZS\S3_')[_._EY8?\K!_
MN+'77> WOFHOYZ>^\OB76?F:?XY/?YW\O+#_ )6#_<6.NN\!O?-1?ST]]Y?$
MNL_,T_QR>_SOY>6'_*P?[BQUUW@-[YJ+^>GOO+XEUGYFG^.3W^=_+RP_Y6#_
M '%CKKO ;WS47\]/?>7Q+K/S-/\ ')[_ #OY>6'_ "L'^XL===X#>^:B_GI[
M[R^)=9^9I_CD]_G?R\L/^5@_W%CKKO ;WS47\]/?>7Q+K/S-/\<GO\[^7EA_
MRL'^XL===X#>^:B_GI[[R^)=9^9I_CD]_G?R\L/^5@_W%CKKO ;WS47\]/?>
M7Q+K/S-/\<GO\[^7EA_RL'^XL===X#>^:B_GI[[R^)=9^9I_CD]_G?R\L/\
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M[39((HA.QKKIYUJ^IIA$PB81,(F$3")A%1KMO_?CX:'^-^7?Y?/>["LWD_\
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M5@QDX5.)R%HK%&KM1**;0>E(6Z1B3A(NRXBTEYUI42382'V!5LQ7)^A0$\=
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M#D46D@:#"3].<LCP-_ W0]FZ:3D>9%/XDN99D&BZQ3@^WMP52^RLIM<AV]Z
M1N1U.,CE9B.Z4I6A]G-[''G"$Q>[>'SW=]JR=P!&/,GT8T2X<$>>';DZ3T4\
MNTXX2U_':>Q*PQNNX\=WECE\-O:NGF%1,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBT-V.K23
M6E7@T3"UP2<MBEHTQ:T?9RE\0%QDX_J&V(=9.T:.%10F0$0S21M8PY"HGV8
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MJUPN(MKJ\2;3-WS35P5(S!/R(TF*)"&S%6V/>O1ZP7556>QIH,60V9D'*B1
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MYG/ \%6$AXX-?SBFW5H==>OUIV,3&]A.L]+D(<7E?7AK)DAO8"V-JZU)OHX
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3)A$PB81,(F$3")A$PB81,(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g104413g64m48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g64m48.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5.U:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/D5L:6YS/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!46#$Q,2YA:28C>$$[57-E<FYA;64Z(" @
M(" @(" @(" @("!R<C$Y,C$P-"8C>$$[3&]C86P@5&EM93H@(" @(" @(" @
M(" @,#<M07!R+3(P,C$@,#@Z-3<Z,S F(WA!.T535"!4:6UE.B @(" @(" @
M(" @(" @,#<M07!R+3(P,C$@,3$Z-3<Z,S F(WA!.U-C<FEP="!697)S:6]N
M.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N
M,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($)A<B!#:&%R="8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86PM0F]L
M9$U4)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[)B-X03M4:&4@9F]L;&]W
M:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@
M(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @
M(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$871E
M/C(P,C$M,#0M,#=4,#@Z-3<Z,S8M,#<Z,# \+WAM<#I-971A9&%T841A=&4^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 T+3 W5# X.C4W.C,V
M+3 W.C P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,C$M,#0M,#=4,#@Z-3<Z,S8M,#<Z,# \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R
M($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM
M<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T
M:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I9VAT/C$P.#PO>&UP
M1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA
M=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-5
M1VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C
M>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G
M445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!
M=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%
M2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M+SA!04519T%B045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"
M05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!
M04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"
M04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C
M>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(
M5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I8
M5T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP
M-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53
M355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$
M9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X
M<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD
M;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C
M>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!
M=T1!44%#15%-4D%$.$$Y0FXX,&9Y>D))4&TW4E%2<U%D4B8C>$$[=% X07%P
M:7)8+TLP9GEY+S9M-U)F*S1J868X05941EAF.')3+TQ,+T%+;3=29CA!=4DR
M;B]65$989CA!2S!V>7DO-FTW4F8K-&IA9B8C>$$[.59-5F0O>71,.'-V*W!U
M,%@O=4DR;B]65$989CAR4R],3"]Q8G1&+S=I3G O=T)635984"M:=C5B27%-
M+VUZ4FQ746-O>611=%%'528C>$$[17)69C-M-#5+4CE'2W)F*U9O+VQL+S%.
M,FDO.7A',"\V<5EQ-R]L85 U6FXO<')T1B\W:4YP+S%5>%8S+TLP9GEZ+S9M
M-U)F*S1J828C>$$[9CE6359B+S57:"M79B]5,C9,+S-%8E@O04MQ67$W+VQA
M4#5:+W=$53(V3"]!3GA',2\V<5EQ,2]Y=$@X<W8X07%B=$8O=T,T:F%F.28C
M>$$[5DU69"]W07)3+TQ,+W%B=$8O-VE.<"\Q57A66'5V>D0X9U=K<VM.,35M
M,&TS;&E+<DQ(3&97>4UP66-L1$)N0D92=4UB5E)(-6\O;"8C>$$[;51196)T
M1DHO=T,R:F%F.59-5F)4.'IF>3-C3U4X,39-=VI8;$E2<49Q47$Q07%A4V)#
M<$%W17%T+S57:BM76"]5,V%,+S-%8E0O<28C>$$[<&A6>"].2#AS>#$X,V%,
M+T%.>$<P+S9Q67$W+T%*5VPK5U@O049.,FDO.$%C4G10*W%M2W4O-5=L*U=8
M+U4S84PO,T5B5"]Q<&EQ3"8C>$$[,'9Z,S5(,6$Y4W@P<GI&<&UO6#!G67@R
M=')E5S@P<D)15V)I:V)S>&]"53=9<6MF;6XX=CEA,6)Z275T-F8U:&TP,'A*
M0TDW5D99>"8C>$$[.&]9-VQ#5S1Y2CEO,TLY3W=0:4M+<$EV-5AE9E)B>5%R
M*UE6-SE994-/4#%#<W)&6D5C33AG53-(-U-H4B\Q,&%L55AE9FQ8-6AV9"8C
M>$$[3U<P=2].;'I-.&1W.#AC>DEZ34),8G!%,%HU>7-E2'%+>C!R='EO2UDR
M<5972#56+VU:1&17<U1E9')I0W=H9V5!;49P:59-6FI%328C>$$[:7A/+W Q
M9$%W6E0X2V1U5$AK1E5Y;"],3'HR,$-2>&5E8G5/4EI)-41+4D]X0TM'1%%!
M1S1O53,R6F=84#=41V=X5E18.'10>D%3428C>$$[4DPU,75J8CA,<B]35V$T
M36]A6F5%2V5M6FET23$S-49Q,3-&1#A72W%5=C5095DS='1#16YM:')I.3!L
M-S)783=L:FU$5%-88W=L5B8C>$$[>'=N5FQ:2V1E4CES5E)%4#57*V,T;&Y:
M4$\Y-$QI4U=/551%5$AK54-":39M-#1F2#991W=P5&%L0V-64F5K9FQZ-7%S
M9&)S9%)N."8C>$$[,EA.,&QS66AD=W0V.4QL6796<4A$,T5I:FM:43%!2T$Q
M;TM!04MV46-#=GHU,%16+TEX=')84W15,&%.8FQB=64T=G1C=4IB:5)8428C
M>$$[>%-P2&(O5C=8,'!&:D1M3G%Q-5!)8B]#85EQ9W8X4F5653 W56)A2'DU
M0W1X95=51G)B6&AM;&0T2C1P1F57-59:1VM8;$UQ.%-!0B8C>$$[>"]:;T]8
M2E9J1TM(67$W1EA5,G)I<DYD4#$O>3-P,F=A9&)A>#5F:3%P-6QG;FIL:VQK
M9TM243-D-',X26%%<$HK.5=59$AO0V]*1"8C>$$[67!116YM1'EQ,#EV3$@U
M5W1W<49Z9%%.8S-J4G5';E8Q0U5L4C!#4DM9:%9J6&M73R]%2W%N35AN1#AT
M:W5O-30O26MB3$AC>51E;"8C>$$[2G%.,C9.1%%R1$%W2C,T5E9M8CEO:F]&
M<75"5F4O.$%/+S5A6%1H>#5$:E-1>%=Y4VU++VUI4FUH84EY=#9C84EQ96]K
M2E4X4E@T,B8C>$$[8FQ7;4MS3C%#-VIU<C8V;7190EHR8W-H94-Z5C)K5T=-
M16E/34\S>$YW43AE5&)N<60X1D)505-T2SEA.75M1E=L658S,TE(=VYS1"8C
M>$$[,3A..%5.53EU;EA&6' O;7I89DQD:#5Y.'=7=71A1TY7:G5*8D9Y-E1P
M8E-Q:T5)9#0Q:V5+9&Q%>$MH>DAX86DP<G5146Q!6&9N9B8C>$$[>4I033=3
M95-64TIR2T]Z<S%H,4,V:5-%4F]Q;59!1%)I.'9Q<R]+;UDX9C)H23!I0491
M>#@R+VPT.7HO04UO3D<Q<TQI4U-#,T=O6"8C>$$[4VQ91VE#2D%Z2V5B8UI+
M>49I4WA9,$A&0GA*<%5M.'IA;'!M<&DQ3VYA3BMI=G%Y4WAZ0EI(:T5R:58U
M5$DU9B]D:7AU<4Y39S)&028C>$$[0E)214MK8F-X8DM!.5EY>%!$8EIU:#(V
M.4M:3'%H5$<U2$DW8E9),TY-2W5&4$-V6$98<78O3TU!22]/9E)Q-V9U<GHO
M<49K>%,K-28C>$$[3599=%HO;#5P3G U<FPX>5)85C$Y66PK<S%T4%555S1A
M.$58<7-Q:%%W66U"9'<Q8U946'DK:&PP2%1:6EI*2DI:3%=";F1P2D-Z328C
M>$$[63%*2DIB8VY&57<K<G@K3"]W1$)V+UA&6&96-"]&+RM$9CA!<FER=G$X
M9FDO=T1W8B\Q>%8S,650>&8O04E.+S8T<3<V=D@T=B]W8B8C>$$[+W="8U9D
M.5AJ.%@O04]$9BMU2W)K4E5&05-F;5,S-GEC5F9M6&,O-S!3+S8W9G)X47 T
M<3=&6%EQ-T989'-65%!6069Q1VI5+W=#5R8C>$$[3B\X07%-=4U64S,V3596
M16%G25 P-$5R*U144TE&<E4P56)K,#9!9&-(2E=W-VAV;S(W14A&5DII0U!!
M.6AH5F%01$-H=71E<'=*6B8C>$$[9BMB14US9FXS55AL:EI9-5)#.%I)<'E4
M,%57<6LO-5-K5G=!9SAL3$97;EIG3TLX06EC0E%K-U9R=E5N-F%9,')58S!Y
M,T,S16-J2B8C>$$[3W)"-#5%4$9G-%!)34-+54E/2D%)<F]Q-7DV4U9K54UY
M<S-/0G%G0G%!13!&05!O.%!$1E9+4FIY9%1'17%F<V(O0U(R1E-4:$-(428C
M>$$[='A*<7A20TM/5C9K2'13;W%02$5Q=5-*<&UP1V=(1E=9,')4-%%84%5N
M<TU385,Y52\U>&DY069N4&]W5&LS-VDV,TY"4G9Q<VY,8B8C>$$[9F)Q4'@Y
M<V0Q9F-'1E=*5U!N3%=:+T]6>&]-,FE343)S4WIT2&96;$EC4F-$1U%7:5-(
M.3=Z3D(V;&1V=E949GEZ3DEF3&5L2#!(2"8C>$$[*V@R*WA+9C<V6"]+>%9-
M=E9K+S-Y+S-P+W=!,5EQ-S%:4#A!9DPO96XO3E=+=3E75"]F3"]E;B]!1%9I
M<G96:R]W0CAV.39F.#%9<28C>$$[-S%:4#DX=CDV9CA!3E=+=3E75"]!2'DO
M,W O>E9I<35'6FA5;U4Y:E0K0D]+=GI-=4)7-6QP+TTS-GII:%,W92M+=&Y&
M5W-69&ER928C>$$[,4XX5E1,5E Y-$Y'.%!Q8B]W1%5:8UEP4S=V:6@Q9CER
M1E961SE),5AI,VAT>4@S34U#5C-X8W501&I59VIL,7 R<51407%L25%46"8C
M>$$[>$<U<#-W<71"669%3FE0;T]&1'%L5U!I3G1J6$976F9M<6MK=FYZ5E-3
M.')O24M+;TQ!271S:$Y396Y%3#1F<7E02DI9<$HY86%29B8C>$$[5E52;&\Q
M0SAK5D%5555"-D0K6')I2U9F23 U9VAI445+2TY18U1Z87!O9FA!2C1G,#-*
M<'8P-EE!0F1Q<%-T2#A42WA03FE6<3%3;R8C>$$[<61M,C-*,C-(*S!1<6MX
M43%)2$AW2%=U+W=$5$-H6'1V<7)C;S5%4'%/1E-+5&QW5D=,9VU2.6UQ0712
M454X93(T;&%5475O>$-X:R8C>$$[=&5-:%%K=$-H8T99,DI7<$LX845S<4%%
M:6@K9E1).$<Y<F(P;B]N1U55+T]B42]I3$5W6&A98E5"*W)3:6=O5#)!.$UM
M1F92=FM75R8C>$$[.'50>F(X,7)C*W-K5G0O=DMJ6#9Z2U%3=&$R-DTW0V=B
M.71Y17)12VY14U8V:4I)>2]!34]9,TLQ1F4S8C929U9!95=V*U5C,'(O;28C
M>$$[1'0O*U13-'%M3TMU>%8R2W5X5C)+=7A6,DMV>DMU1EDS171"6#0R+U=C
M54M9<41T,4=+=2ME,DMT52]S>%9S,%!153=B94]+=%EQ;28C>$$[97$P*V\V
M3B]Z0G0O,48S1TM5=4%R-S1O8D$S<%-P3W='0E8R,U-M+U1E=3)+5512;FEP
M-GAA3T%F1$A2:45$16LK>6IL,3EZ:V5Q;R8C>$$[5C5'64%%,4,O6DAT5W8X
M04A*57$P9&9N:%$T:VYC;71.=F]'2W,S+T%$3DE0;F9754MS<U1'05-3:%9E
M:V=T:TU9<6500W!'-7(P<B8C>$$[,39:03@R5$5:5G5)43%U5V]N=W4V.'%+
M>'!S9#EM;T<R22MJ8D-+3S9&,7IB<TI%.4Y62FPT<$=K5$Q)4V5#,7%&6GE#
M,TEF5%5D:28C>$$[04EY5EDY,4UY96Y54G=/158P:D%53C9D94I91'%D>60X
M4$-&545'+TMN34QU5DYA57)496Q$:%%R2C9C:T5N<6U4;D5O15!"459P528C
M>$$[+V(S1DYZ,7=(;6Q46E%W-6I95D%)3$%S5TEQ5#).2VIW=V]E<68X04]-
M9D@O;&,K:3!&4#-.,U=N4V]T2D(S>%,K:V9)=&YP.&8U=28C>$$[*V,U;UAP
M9'-%13A,:6-U07A69W=,9WAQ<F8U3'1886=10VU35FML:"M7,FDR6&Y'-S@Q
M47HS2#%Y.%9X3$)Y55)!>69A2VM+2%AQ5"8C>$$[<S(K,SAO=TMM,VQM,FI(
M;'93:%8Y<D\S-GE/9CDQ3#<T<6U8,650>&8O9S,O<FER=G$X9FDO.$%W8B\Q
M>%8S,650>&8O9S,O04LT<28C>$$[-S9V2#1V.$$X1R\Y8U993BMA4&YM-3AM
M,C)N>3)T<4QP<G@U1EE3>7EQ1D5953=C5#,U6FDV;E5(2%9$;3=R<UAS:V$R
M8V]M6$1W:28C>$$[*U9S4SAR+VYD<65S95ET3S!U6%19;V\W,F1)5VM385ES
M;V,P<4MN2TUE=4UP059Z9'8R:#=+># K0U=8>$PT4GDT9C)V8452549!4R8C
M>$$[9FU3,S9Y8S),>'HX>C=H;D4X;T)O3V)B9E1407%L>6]P039K-VXR>%$P
M;W(X.$MT<VI)4GE(8F%U0E9O;T\R1E<Q24(V5C=J1E5X,28C>$$[9B]E3%(O
M.$%M1&9P+W=!>&QX:6Q,;$HW9&5T9FQI:'%P-EEQ:45+<$%Z8VQ*:U!",$EQ
M,T5&5T1+4T1X,T9+9S$K9S5%.#!R2TAI3B8C>$$[>'A!-V1453DV9"]N:%94
M86]06$-H>$DW8F=E3TMT5GA6;5@U;WHX9E!'<E%K9D$W=T8R-&AI2U<X9$].
M9'=D>C,S>4YD56QI8W,O<28C>$$[96M!;T-W<49'>6=N8W-3>%5+5W%Z2#=6
M4T)T5V=X07!566QT4&-82U-7<U%K:VQK16)20U T1FML<457;$])6FE';T%0
M;&M$24%B<28C>$$[;T='4U)*1FIM4FA6;F%.4U58-%9,17%'0VI95D@K67E6
M<6A'25!153)&9FYK,$LS1#DP9V%206A9;710:4)O4'152$PU9E1K57%I4R8C
M>$$[>E-V2#A+:&]O5T5::5)%64)!>F-M-$%68F)D;3-P,W=507(P-R]N1T(Q
M+S582&]Q8T8U96YE2#%0:35F-WEY8F1E4#1:2E@P<#5.=28C>$$[.4AV4'I5
M.'AW3%E*0G%U;F@R:W4T3#8Y;%8Q;%I6264R;$5C2T5G0W9&4T]13D-E=5-6
M;#%Z-6HQ3TQZ<$)O2V%23DYP.'1G.30K<B8C>$$[3%@P,6Q6>6]G,TA(:U%+
M+V$W-$924&QM85$K5SE+4&]/4#A!43=F66Q0.$%F4R\U5TMP;#9S;BLK6"LY
M4"MA<U9D-G-N*RM8*SE0*R8C>$$[87-69#9S;BLK6"LY4"MA<U9E4V9M4BMC
M*W9E5B]-.&UK5V1H8E-1>'A2>6,U*UIE<FEP*W<T1DTR96LP07EW-&EA,V-F
M3&XT5%90328C>$$[9D]V-6XV=C5Z:G1)8BLQ=#=D8DUU.%IG-3%*8TM$6&UZ
M9GDU<2LS9$=-35EK1S=*97HY:#@S2&YY9C%0,&]F.'5Y4C4U,$EG5E Q,B8C
M>$$[2%EF-G<X8S!/;B]V22LY-TQT+R]!0DQ*-W8P:#E:;WI-2VQ#;G-A9G=*
M>F9V:U0X,&)G2#9Z2G158VUO4'!*=TMO<G,T3DYW9'-66"8C>$$[35)X2E5!
M13EF-TU65T9763!P6'941E=H56MJ>'=O6$9!<BM)<4MG9#A#<&AQ.4):85 X
M03AW8B]!4%5:8UE5<&)T+UA&0R\T845B9"8C>$$[:C S*R]!;#-5044Y>G0R
M*V5+<FQ*<%5';$MG9V)%9S1Q=$Q52$5#;3E392\S,'A6641V56MJ>$DV-&]A
M=W%Y,S@Q450U+S%593A0+R8C>$$[049$>#1P3$=K=#9W1U=P54-P4$MI9W%#
M;RM!:V=S,5<S04A49GAP1SDQ4G!A2T8R;7%K-WE,3D(V56EK>6]1=D9:2%9G
M>6<P8C1E3"8C>$$[16=R,C)Y2%!B;'E3<%A55B]B>'A.8W)01D1D>$1J-FES
M;V%.4T-N1&MF:E%$:5)H:5EN;%=Y14%Z2V$X4E)A:VIX<#)'5%%R2DI,1B8C
M>$$[25I),V%%<W!11#EO>'E+5DER44%G<6%(>'=%5VQB1%!,1'E+=7EP2T]%
M<6]X6&UH24I5*S)*04MV5F8K8UI"5#@U=$=+:6=E0S=,0R8C>$$[;UEJ+T%%
M85%'=$(X4'A$-W-)5CE**U1)3D]T+WI8.#!323%V0F0S9U!/,U=A>4UZ.$=5
M.'I&0DY*3C1T.&-56C,K3&UX<4I+.4PU<"8C>$$[>D-C:'I)3$)A-S!'>$Y0
M<'=+;"]L<B]L2$Y++S5G-V8O:S!U2W!J:7)S5F1I<C5I+U!V+T%-;4QC+SA!
M35!"+WA$3VDW3"]U=FDT1R8C>$$[<"MP-3="+V5F468Q:DY2-U0O4D0S;#=4
M,D,O=CAN.5%F97EV.'5V*U4W,$@O;4YH+W=#2D1/5C O=T1E1#-V8V1V.$$K
M2EI09"MK4"8C>$$[<E1.*RM24'I0;C5F5W!#0BLR,SAC0W)3;2]Y,WA65&-K
M-V14-#1O8E)I1%=T1#))>%-T;T,R,U1#:%9&9F@T:F)W-C<T16\S5U-F<28C
M>$$[;6M$<%=Z8710*UEY-'A#;$Q+154W5CA0=3-X43)E=E-N:E0K;4MU0DYA
M+V-C2W%W<4EY0E@T>4-E;S)(:4-0135&2VQ*>$1K1#1H-"8C>$$[*U!V:%%S
M=W$W1E=8+VUI2R]M1'%9235F1D)S5%-V-VE0875"2E-2<F4Q;'9&3F]593)4
M:5DP:V-"=FE8,5!387%X<WA5,5)N-#AF:R8C>$$[2UI72D5$9FXK4#=A5D13
M9716;%=,,'!);$EU1UAL53%9+T4Y4U%0=$)D<41P,S9Y1DLR-D-S85!Y*W-O
M2&%6;5ES3TM,.$MC479*4R8C>$$[06@S-55O4C!P:CEY;V5747I.234T<E9I
M.4YH=50P1DUK0E-&5T\Y=5DS;&UG:TU:6D1!4T=!67A-:&I+8E5Q0VUZ8EI%
M>$(R2U<R5R8C>$$[2E)C0GEQ>GAS<7A):D(T>E%K4%)H>D1$<%$X<690144W
M2SE3+W=#8UHU<%IF>FTP4C-P+V-82T)L055%2EI/;T9!04LP1S4V:S=M=28C
M>$$[14-L92]W1&LR3TLK+T]J6'(R3G)3-&AT=E<T06%H0DY,0S1)9UIO-U=&
M03AF2VA%;G%(=C$U6DY8;T9Z-4XP,C0X-5%E83-K;48O0B8C>$$[671P>5)"
M9TDO4V1Y-5EB8VQA<DAD4T\S:&=616578F%-95<Y2T98,G,W9G))-2\S579V
M:7%:9E8T+T8O*T1F*W5+=2MR>"M,+W=$0B8C>$$[=B]81EAF5C0O1B\K1&8X
M07)I<C5K+U!L478U:#-!1F%F5C1/<$I0,E!%-3!86F8Y,3A803%0,4U!9R]V
M4&]0-GAM;SEP+V]H-WDY<"8C>$$[-T)F,RM4*V]0=EI4*UA90C@X-D5$,$XW
M1#!.4#)H-%IY=6XO04QY4'9E-#=F+WA,2C=V,&@Y6F]I;TM!:R]-;'8Q:S5V
M,WE**V%D,"8C>$$[-V5V3#1":5!P2D]"5D97645N=C-X5G-"92M+=4LQ<E1P
M:7)::F]006HK1TYQ,'9*5R]Z-S1Q:CEA4#A!;VUK54]X<S)(+U0S8UEH4R8C
M>$$[;%HT.75N=FA1,FY(:T]D4V]0>%4R3DU#<7E'4T8Q96YX:6@T3W9)8V%!
M<E970D)"2%1">E,U>7=D>$I66DM527!1,3(V.4U655-4528C>$$[*U X05A*
M26$S1E)I<G4O>7A6;5 U<G=L4$\K<%1C,%!*-#$T0F=82$<R:$Y76'-$>F]0
M:V9$26<W,&MS8W0W,E-%9S)C:G<S031#3R8C>$$[6E=:6FAY47)):49+1&EX
M8S=E2# U1U5!969*6%AV1U<V;'5%<#E71#A%<45J9F=G;W9+3E=9.&EO,TY4
M53E35%4T=S)&9%95<&]O,B8C>$$[5&Q*2C9D>5-X9%-G0T9E2VQ/2E-V>$UA
M,7%",C,V,$E0>59236-H:59Q9D%3441T,6]+-S5*5GI)<&LK2FQ$3356;%-M
M,W5/:3 S,B8C>$$[,WAT5GIY2U%P5TY!<6]%255-45-2,5!)+V$W-V92=&=!
M5C9L+W=!-'=66#@T=$E7<3=X,U)+,$)0*SAK<$)$54Y/=2LK1E@P9#5#,28C
M>$$[-U1T5"].9GIF1&%2=T$R;SE.;5),:%IE4T]Q4T9V561O=FED5'DT271A
M06UU4U9N1C-E*UI5.# R;')B-F5S;FPX,F,P=#-F8S Y428C>$$[6%%:4D1%
M<49L24A(:U-A14=O-E5/0E8O;&UA42M7.4M0;T]0.41T.6E5+S,P=CA!;%EQ
M;5AQ>68W-68W,"\U<7A6,W%Y9C<U9C<P+R8C>$$[-7%X5C-Q>68W-68W,"\U
M<7A6.'EF;GEX8CAW-V=L4W K<G=B1VQF<V5X3V1&,E@O04A8>&-$52]5=T-$
M*S@K9R]R1V%J,FXK:4AV3"8C>$$[,FYS1B]F-5 V9RLY;% U9&MJ>GIO4D%Q
M9G)S3W<O,6@T-7EU;B]V22LY-VIT+SA!>$Q*-W8P:#E:;WI-2VQ#;G-A9G=*
M>F9V:U0X,"8C>$$[<G--,3%*>5 W4G!8=TA40495,5AL56XU1$96=W!7=$YU
M;4)6=V]/9WA6=&A516I9.4U65T5+>E4V9E!&55IR24%S.4AP,"MP="\Q1B8C
M>$$[,T=&57-O1# R.&4K2T=W0G8X42M(<#$S*U=+<6EM3EA"2SAL-W)7;3)+
M5W=X6&DP6DE)1E-A.39K-V1-0W%:2D\Q2S$X0C195E<Q3R8C>$$[-$))0C)0
M>7=O8D$V1&9F.&9L9U9L,S5O<V\O34A5>DEP6D$P0EIA.%-2.5AJ,D(W8F0X
M56QI8D)31TLQ1SE1=E5!9E K>D9#330S8B8C>$$[=3AL:S!R*W122B]245),
M>6Q'.&9'33A1<&)K<6IO4C(W0T<S27!A=5%&=%EO5$=Q>4YW8VYD4T9+,54O
M8F]E64Y34W9H5')I3V1Q;R8C>$$[334Y4&EA3WHW:'%M;W!88G=.8VMQ27,U
M3#(P:FAV23 T2TA,4EA!5VIJ,'E/4E8K2F]A<W1'-TAW>4UG1%E64W1X13EZ
M>5!P<$A(5R8C>$$[4FQ*241H4&DT3'E6.3(V3%5F4$1+-E8V>B]Z:F).22\U
M>#9.3DES5%!E43-B9W V9%DP4S-M44IX44%2;C1/;$)T5'-C14(P,S(O2"8C
M>$$[>%,K:R]+,7A:>F9M8C5G=%)92D-B26,T3&M85GI,>EHK4'%S:TUH*W)P
M=DI2+U151E1S83%Y,41/1S%45%8Q2DY-839I1V]Y4D=D3"8C>$$[375V<6U)
M2&E80U9R>')T6$%Q:#5A+S52>E-V*UE/,R]!3U13-'%M3TMU>%8R2W9M3#@K
M+R]*:3-0+TU00B]X1$]I-TPO=79I-$=P*R8C>$$[<#4W0B]E9E%F,6I.4C=4
M+T%%43DU93 Y9W8W+T%#9C%".3=++W=!=78K53<P2"]M3F@O-&M--5A4+S-G
M.3<S2&(O.$%I5U0S9G!$-B8C>$$[,'IF=FM4.#!,:T@Q-4(O;'0K=D%R4S%W
M2S)A8V%E4%59<7--:7%45'0R+T1#<2]M<C$T:VM$<C)W2S=O861X:7%+,6LO
M=T-I-D]F*R8C>$$[6$XO*V]Y-'=H574U06]&-&=%35-8,W%144M!-S!O2V5(
M.$U53#%G=55J36YP<TEN6&QZ2VYI5C5&83%P,#5R4W9J9W-*8U)W4%%K128C
M>$$[8E9!<E-V,#165D1*3$I%:V-K<#E'2E0V4W159V(Q2W%.-E9*+VEC1E5Q
M:DE#2TY3:71U;U!C8FEV-%E65VEG-F=G:BM.9#9N-DU53R8C>$$[-#!P-S<W
M67%Z2#@Q<&)C*V4Y5%@P:7)+24)Y1&17.4=-;&E#4#5D<59W555L:6QY25DR
M.4\S;F%A17!'-T9L2V9V0V=,<GAQ,S)'3"8C>$$[2T0S-BLR36(V:%AE<UAI
M:E%O055*2'$Q87!R,$)Q94E!;V%503DV-#%U<5E443)5,6A'-E)08BMG<D=A
M67E#4DI(6F9G+V0P56AM9"8C>$$[4W11855P-$5T54-23&YD<%$P5F=*;6I#
M4W(V8G!V2WES1E=8:7I#3%E(9&EV161Q*S(K5$TV-F9J=E)3.4QB:$)#27=I
M,TUO8U-.2B8C>$$[3D%6-',S<%4Y3G5*:5EB+T%':E=N>$-G1F-(1G5E-S-(
M,R]&5D<U:F%&-6)D;$1T17ER-G)65C$T,35+<3AU:$HW<EA99$YX:V]M.28C
M>$$[,65S9C@T>E(S9'(K8D]I3$ES:T,S54XR-D%O5E=73#9T3#A18S=S3V-9
M.7%J>'=!9VYV<C=%=F](>49P6&TV2#@Q4$TY.7%-8W1V<"8C>$$[,'=0;WE8
M34(U,U5F<7-)9VLX5&5H4T5$8CEO<7="1S-W,F]E:%A(;#=48FI8261A;$5J
M6'-&=3EP1BLX8U)I2U9U5"]!3'-(:'E.4"8C>$$[=%5R9U94.',R,%$X=#95
M05A!1FYB9T%/+W=$=G!F9D95>2MR>"M,+T%00G8O6$989E8T+T8O.$%G,R]R
M:7)V<3AF:2\O0G8O049X5B8C>$$[.'EF;GEO6#AW-V=#=%!Q.$A5:VXW2&EC
M-DQS=BLV*TQG86XV;4%19C-N,$@Y67I593 O,%$Y-64P.6=V-R]*+U5(,W-P
M+TQS02ME9"8C>$$[0T(V1SEH-D=N-U$X33585"]W0C5(,W9C9'8X02M*6E!D
M*VM0<DY%5D)116XU:W0K<VY.*RM24'I3;&1"8U-H:GA032M0:C-P9TMQ628C
M>$$[;$A';W!4;U(S*VI&5CA427I56'(T64-R:D-#>$QB13DK,S0T,G)A:FEP
M0SE/=4MR43%A:SEC5E)M<S K<6%25' Y5&5N+U-:8UE64R8C>$$[=U5P4VTS
M:FA1<4M+2E=O3D]Q:S R,B]I93)"2RMA5U-A9VM:;C1+151M5'-O-D%6-D%E
M1T%#;&)J5U1J5&AZ5FU&0GAR56IA9U!89B8C>$$[,D]*5E-C=#!.9EEF5&A1
M-'$V9V=M:%E624IO86)%5BME2W)19F\W:D976&9M:3-P+VU(<6)G2S%'9TE$
M:7%M:T5F63ES95E35U!I0B8C>$$[,SEB-G4X17=1974U54)!1D%&46]L0T4P
M-3 T9TAP6'!V:TPU6&%O9&%O2DAJ44]J9D)U1U!!<U-6,S(K3#145#9C:W$U
M6EDO5&I1<B8C>$$[>4M/5TQD2W%W04MM;2LS2'AX<%91>FE*=61Q:GA"6E$X
M17!:9S5'-$A)<5%T4E1Q2V0X1EAZ5F-L<F546$4P549*-6\P:V4T8VQ(1B8C
M>$$[14)A4FM9,35F0TLQ1R]H9TUG0EHR5F-L=3%X4$1%16QM=34U2T5,4FUD
M;5!%,$\W1FDS5$5Y;U@P4SEA+W=#8V,T9%%(-71A3DQ.1B8C>$$[=V=1,S%S
M=E!E5DAH=%I4-EI,9D=/26LV9%!U>4U$1SEU9E U<2MZ8W51:TYX965A,3@T
M4E<P3FY'+VQO,E)K:W5Q9U-F5RMB:C V;"8C>$$[=U%/25-N=T=T5'5+67%T
M,$]F6&)F4F109VLP;W)*1&)1>'5P;FI"1$Q'05%25$-R5W%E8FLP:WAJ5DDW
M97A-;TQ29E=B>4=,:T9D228C>$$[>5)Z<#!E6D8K8D1X=TMV,'9Z4$IQ,7-B
M;E1,84LX=#%B9S!S3C%%-FAW07A5:V1#07<R>%9%>6%N<E-C9CEX1%!Y64PX
M33A:<%AU9B8C>$$[8D98:FXU;R]L;#4K.'IE8DID5C O5%EV<3AK35-!4&-X
M9V=O=$0Q<&TR,%=U:&EH=VYV8V).:$UJ65E"4"M7,VUM=S%%5TXT,FXR.28C
M>$$[-%=325<X;"]B<2]/8F5.4W!.45A#;6YJ;4(R>FM'<&I%439&-D0R83$X
M3D)K;DQ)0U)+3F)E.6U(;$PX<&9Z1#!R>DYP;7!83VY1*R8C>$$[:&%816,P
M=D<V:DHT;V%M;6%41F\U>&M#6&\K,"]A8D)N,#@X8U)+-4(W-UI85C--.&E8
M3F\Q<WE"5U9I>75R0G%I9TLY>'@S,C=J3B8C>$$[;SA+:UHO2R\X=$-35#53
M,%EK;7!0-E!T978X07E,>%9X+TQ$.'1$,3AP84UA9% Y>#ER+T%.53A68U!Y
M=B],46102U=I+SA!8U!T9B8C>$$[*W%E2W0O.$%+<V9Y,B\V;%!2=BLT9F$O
M.54X859R+VQ72#5A+W=$57!A3B\S1#=8+W%N:7)V.$%L5T@U82\X055P84XO
M=T)W*S$O-B8C>$$[<#1Q=68X<W9Y,V-)<BM63D=:67AX:D1A9F%K2W13,4)7
M4%EC;4IX5F%0>78O3%)45F9+5VEG:F]2<#ER+W="53A69"]Y<2\X<R\X028C
M>$$[<55T1B]W0S1D82\Y53A68V9Y=B]!0S!/-3AP84M4+S)Z-U@O04MP-'$W
M+VQ6+S5A9CE3;&]V.$$S1#=8+W%N:7)V.$%L5C,U6B\X028C>$$[56\V3"]W
M0G<V,"\V<#1Q,2]W07%U+TQ0+W%59$8O-V@Q<"\Q5'A6,R]+<G9Y>2\V;$A2
M9BLT9&%F.54X5E8W,SAV4$E&.6-.8S-V;"8C>$$[;E-R<35C2TAN;7-B85)Y
M155)=%=:0U1244%08D=L5V8X<3(O3'(P0F(O-%<P:C!&67E,1#E1=&5!9&=!
M5T,K;E-P0V=6.7-(0TQV<28C>$$[<E5F-5HO;'9'4UDO2VUJ;U-#0U8P*S%"
M;U)1:F%0=41I4F%R5"M6,S5:;G(U4C!8+W5(5W8O5E!#<F@K5T@U87%'03AP
M-DU!=V]W1R8C>$$[;C)U-')89CDS-&I&5GEF;&XK6$-60V563DA52%DP,"LQ
M1E(Y165!9TMQ,U U9CA!:TLV;65E-CAT-E904$EX:V575WET,V1N63%::28C
M>$$[>DE34U0Q3U)J:FI%54%!1G18<V9*9FLV=S%%86Y9-D9P,7!Q44Q%6'-&
M<$)(4%9W43,W>%5$+T5#460X:T%"<T94:D-Q6'E89#!T="8C>$$[4&1M5T]/
M0T%Y;&=9;F1G<TQ-0V1N5W8R83E-24-S3W1F>F8X=C--=')(2&-U1&0Q36).
M6G5Q9T$P<7I'86Y59C4Q1EI4>&U*;S@P028C>$$[,FM(;2]W07<O;% U<%-W
M9GI,270T:5%Y4%HX-U,X5E)'.'-4=G9(24)6;6=J,D\Y1'@W:UI&2UDK6&9Z
M03AJ-EI&3F(R3W!32#8Q8R8C>$$[>'E02E!B6&QX2DY,8VE/4#%/5%-34%%F
M0GER5&I594]+<WHQ+UAX;TYT0F,V:&-O<U9X3VQR1U5T,V,K<$I5:6]%=7<K
M13<U6%!)228C>$$[.#(W1&=L:TI%96=**T%31WHO3E!28GAK1G1D96]S;'=,
M4E=&=G8V<%5T5&@V+W%!8V5*1&-A2&M+5DY13$MA5TEZ6"]!3U=7<6599B8C
M>$$[,'AC0S1I,4,V6EIP<'EL,&E4;%EO6&E35TI,:SAH=VM6555P,EED1'5O
M6DEN-3!E55I&57AA:UI#=U)I;W-,;%=66D96;%EQ>G%E:B8C>$$[:G!V:E-7
M4394-7%G,7%W=C=Z4V)Y3S1J,#DS:6U,5S P64UI4G)*4E,W<GE&2$<T=TMY
M4$9867$W1EA9<3=&6%EQ-T9867$W1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T95=6(Y2&,S-"]79G1T>3E,-C%W-6-J>7!W*T@W
M5F5M2W%B+V]Q;S4O5W$Q1B8C>$$[2R]7+W1B52MN<&EQ>6(Y0C%(<F972S<P
M-2]7=DAF<FEQ,68P1%$X9EAP>5=T4')8,G%J:#E.94Y0;WA6168V0B]W079N
M+U0U:7%J+R8C>$$[04QH95HO,V\Y5#1++W=#.59E<#1F>#0T<31F;U@Q9'9R
M4'$W.5!R6$PY;79V+THK1TMR12]W05!66&@V,61U3E!R3F8R855P+W-F=R8C
M>$$[=W%U8CE#*VA.6#9Z-DY$-CE0<F1+8V0K5E X04IW2R\O.6L]/"]X;7!'
M26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @
M(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#I%039&-S<X14(V.3=%0C$Q
M.#E$-$9!1$(P,#9"-S$S,3PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @
M/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#I%039&-S<X14(V.3=%0C$Q.#E$
M-$9!1$(P,#9"-S$S,3PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y
M,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I2
M96YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#I%.39&-S<X14(V.3=%0C$Q.#E$-$9!1$(P,#9"
M-S$S,3PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O
M8W5M96YT240^>&UP+F1I9#I%.39&-S<X14(V.3=%0C$Q.#E$-$9!1$(P,#9"
M-S$S,3PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y
M,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @
M(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD
M:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @
M(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.D4X-D8W-SA%0C8Y-T5",3$X.40T1D%$0C P-D(W,3,Q/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(Q+3 T+3 W5# X.C4W.C(S+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I%039&
M-S<X14(V.3=%0C$Q.#E$-$9!1$(P,#9"-S$S,3PO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-"TP-U0P
M.#HU-SHS-BTP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL
M=7-T<F%T;W(O,2XP+R(^"B @(" @(" @(#QI;&QU<W1R871O<CI3=&%R='5P
M4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL
M;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$
M:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @
M>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*
M(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM
M<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DAA
M<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE
M5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!4
M4&<Z3E!A9V5S/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-C,P
M+C P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^.#$P+C P
M,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S
M/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*
M(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-
M5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A
M8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y
M<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M=F5R<VEO;E-T<FEN9SY697)S:6]N(#<N,# \+W-T1FYT.G9E<G-I;VY3=')I
M;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\
M+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&:6QE3F%M93YA<FEA;"YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$YA;64^07)I86PM0F]L9$U4/"]S=$9N=#IF;VYT3F%M93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^07)I86P\+W-T
M1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@
M-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6%L8F0N='1F
M/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O
M;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @
M(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L
M="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI
M8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( + !J@,!
M$0 "$0$#$0'_Q  ?   ! P0# 0              ! 4& @,("0$'"PK_Q !G
M$  " @(! @0$  @%"A$(! \! @,$!081!Q( "!,A"10B,0H5%A<C05:6,E%A
MD]08&CA25W&4MM+7)#,V.4)35%58=79W>+2WT]8E)R@W9(&1EQDFIK$I-$-$
M149(8F>&DI6AU>'_Q  > 0$! 0 " P$! 0           0(#! 4'" 8*"?_$
M %\1  $# P,!!00' 0L'!@H)!0$" Q$ !"$2,4%1!1-A<9$B@:'P!@<4,K'!
MT>$(%2,W.$)S=;2U\0D6-39R=+<7)#-29+88&25&559B9H*5-$135&>4HM+4
MEJ?3U>;_V@ , P$  A$#$0 _ /OX\*4>%*/"E'A2CPI1X4H\*4>%*/"E'A2C
MPI1X4H\*4>%*/"E'A2CPI1X4H\*4>%*/"E'A2CPI1X4H\*4>%*/"E'A2CPI1
MX4H\*4>%*/"E'A2CPI1X4H\*5I3ZO4?B!MYK>I-K0LGN$?EW'G?\CCT,5#CN
MIDN?L]+(^GG2P=89]'S6.V6MIV/Z*IGUV,=6<9)K=W'W<N-ADRUR.:6P%AGC
MJ/2<UH:8SN4GQS)C$8/C74$'FX^*]N?3O!V]8Z%YW3-UQG0C5\WO#;9Y7>HB
M1S]>M;\J/7?J#U,TG6\-F<WKKY#!9KS(:+TVZ7:WF\;8RN*NT-NB35,EL!V'
M7<V]JD)DB9$GD;2 ,QTR?RJ89[S1_%"UG9>G.K/T=R&R6(_,-6PFV[#C?+3U
M&AU'<>BV0VORQIE[=7*X',;LFDY/4M6ZG];I\;;V:77,#GJ?2]LA%O>7VK5\
MIH&\OGY^?PJ0DSQCJ-\]8F8&VT[=.[.BG4SS^[UTV\QF.ZY:GD,-G,EY/\)U
M&Z37=2Z7;+TTV#6^M&TYSS/Z?G>EF,MS;%G+.>VC6\'T[Z+;K6DK_BO/4,IU
M%2TM6'%Y;7JE!0Z<:>IW\ ,[<DGW#S)P=O;M\3WHY$_4GJ6FW;13TGRX>4[;
M_FL;C>MV+Z<Z]DM/\KWQ)MFZJ6^H^)R6_P!JEG]_@ZB8OR^X_KE/FIY->S&0
MR73!LMKM7/TM1R=!5 28 Z\Q.Z?RGX\55F?B#?$;BP>H5->U&WEMBZB:OUMV
M_HW+)Y-NJ=?9NL.?T+H7Y9MWUS1CTL?=DV'3>G+]>NJ&]=(;O7>_<?3;6D5:
M&W1Y:+$8YNIM]0)')C;^<,23SU $QO.(XK(#+>:CXG%?8>J=5NB>3QN&Q&T9
MO'[+)C?+;U%V<]#--I>;/0NG.H[/TCR5'877SI93<O*9E]]Z\YK%]-\7):TO
M;]6QVNWL%\_D$Z=W52!C.XZCH9GIF!!J*=0?-[\4'&[+DL?TRZ)[=MN+I^7;
M8,G0O;=Y0>I>C/FNJT/09^HVE[-5Q.,W+?<+5CV#J)'^0&<Z<Y;JGC-UP&<2
M[J%[1,=9;!;GFU6$SDXD;&<3G,#(',1^ 3=3O-M\2GHC9R0Z@8_$S:9D^L\'
M2; =0L?Y6MTM6\?BY_/9T>Z!ZEL>,U/#[[DK74+9^J'0_J1MN]:IJN"->?.6
M=.P\VK4,B7RL>6GS\1\SQS2$G;IUSL2<D "".AWJ#]4/-%\5S;],ATO$]$NH
M^#M;GY8.OE#8\UK'E_ZJ:7ME;;K?0/S8YKHMU0T3:L3=V*MH/4/-;SHWEZQV
M2Z;;%L.K;YTZW'J-^3572=A-VOM^H-_D_L_90!.<[$1MD2)'Q.=L<5WCYXL?
MYB+/F*\L,V.R'F:H]':GEXSS]0!TGQOGIS.%M=4TWGIRU&#9:GDKWS1L['N#
MZLNV?B^YU&GS&LK4_&,5C%S7):SH/X^?Y;><B@B#M,\D#$>((WZ4AS'7#XCV
MS]6+6)R.N]3=#Z5:1YT^E6+TW8-9\L6TV+G5[RMWMUZWZ[M6R[M\AG=ERF$%
M78,9T\UC*TOQ'IEB#IYCL#U\R.-CTOJ7;QNG6D)C<$Z3SL?3IGD3C?>/5/-%
M\6;!0^5=;'1F;?\ <-_Z#=/NI?674K7EPWS1=2P74'J3I'5/(Y'ID^^8[.[3
MB-4S/2C===Z<:UN-3?LYTXRN-3;$SE3&[OBLMEX.EJA"<P8R8S.,;XR,[B=C
MCJU[!U^^)?8AZ5]0-0/4W+3'HUYI:N7UW:O(SUAZ;ZO>ZNXW7/*UL>BXO<M1
MP^3ZE=1Z%+"7,KYAL7TXZB6=/Q./VNYHUO5-<T7JE?S>M9_J I \-T[$$QD$
M@X\#'CQQMV\GN_\ 5OJAY<>FV[]==0S.C=5,O!LD&TZ]GM6O:5DD.&W'8<%A
M<P^L9409G$U=FU[&8G9<='G,1JN=L8_+U;F:T?1,G9M:=@U9(@G(/EM\_,FL
ME_"I1X4KXZ8OPQ;RUV[F0I8[R5>8[*2XV+(6;8Q^RZ#;,-'%AGOWYD@FD>&E
M4A4S6;,JK#7B!>:1%!/A4)CY\0/SIJ'X9CY5??GR=>8$< GWV_IU[\?J]K/Z
M_#W3\[TG]/?TQ/Z4LI?AD/EBR4BUZ'DR\P]VY(Y2&A4VK0+-ZQVQ2S2/!6@E
MDDE2**%Y)64?0H[B. 2).0(.03.($1@F9DSB =C5GIG; \>>GQI%_7F/E6_X
M'/F!/][<.G)_5S_NK]?BU-0\1@'U^<S')V$T?UYCY5O^!SY@O;[_ /UPZ<^W
MV_\ :OY>1Q_+^OV\*3\[1YS7/]>8^5;_ ('7F!_5_P#KATY_7]O_ ,Z_E\*2
M/Q^'/EX[5Q_7F/E6_P"!SY@OWPZ<_P!*_P#?_*/MSX4D?CTV',S$<>&)B:/Z
M\Q\JP_\ V.?,%^^'3G_[OFN?;[_WOMX4G$\?/I/C%5'\,P\JH"G^H[\P![N?
M8;ATZY4]Q4*W-D#D\<_26 !]R#R ZX_#/Q_&*3_A\^7E1_7F'E6[68^3OS #
MM*CM.X].NYN[]:_Z)XX7V[B2..1QSXDY @\YX$=?/B@(/PZ<ST)X$^5=]Y+\
M*O\ +W2\O/2?S"5?*3UYRV,ZM=7^N72#$ZECMATBQG\=DNA>F=#=USF9M&*6
M2"QC\MC^N.+BHQ50UBJVOY:>X$@DKMXM7Y]*Z&7\,L\K+>R^3?S!D@=Q V_I
MV2%X+%B!9)[0H+$CGV]_$GY\<_I2C^O+O*L".[R=^8%06"ECM_3KA>2>.[_1
M/MSQR/?[>_A.,"<2,C/E!.W/PFE5?UY5Y6RO>/)MY@RGJ"(N-OZ==@D(+!"_
MS/:&(5B 3R0"P^D<^&H3$B8*HG,",QO&=XI3C4_#%?+1D+5:CCO)AYA\C=N-
M7CJTZ&U:!<MV)[<R5ZU>"O!*\L]B:>2&)(84D=I9HXE#2DH,]XG&XDE(F,D
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M?<MPX_;7%MWJVH#BF4W#;2W&DK);#J4E"U(7H*D@*44DH@&)("H"@J)V!@D
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MO/!\*[:,!N&K0^53I6-9LS]8L=B'U+R\:WHV_3Z?B]P\M>P]!:>*WZA-6S>
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M*V7FL2R,Y,H"M)/.%=A*7D8R2$M(3])!;LY\<,I2$H$)"2D)2!I$<)3@1 @
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M ]@!^K@?Q>%9WZ#KY)/X'GSBD #NRQJI9RX"\!G9BW "@<<>Q'TA0"2W'/V
MFV=A\.I/ZTP3F)CR)ZXWCP/2>E5..PA?H)"!B58GDL.XEB1VGCNX)3E#QRG=
M]R!G.=SOX8^9S0XB>2/,D;9G;PZ^$T1>F)$$DC1+]1,B1][*P#%.$#)R68!>
M0X[02W!([25,& "<8)@$3G,'B3MG;&]7KF#GH8QXQC8GH3R*H)^Q';^H'^]P
M?N?<\DCCG^0#^/FU-SL<>43@[=<F3OOS5/ZO<\CVX//OS]ON>."/O[_?W/\
M>5>HQ//OZYYZ=,=)Y!Y/OR>/O[$']7'L/OS]^".1X5"8'S\28CI,\]:K;N))
M9B2W)+$\L6)]R3[^Y^X/Z^>?8D>%4C,_B?')CXDG:!@UPJ][HH^DL54%W4("
M6X!8G@* " 22>..XL.?:$P"3QGYZU-QZSC>,8VCQ!!YXI;?G:6>0>IW1\0GL
M0OZ/=#!'$"%+,I:-08^\<AAW=A[& \8;2$I&,^UD[D*45;P#!)F/7-4G._I.
M,8&9!\)B,;R*S^ZC\#X6WD\#(K?^G!Y_QP20 3T4^'BH/=W( %Y[N2>.0.>5
MY!V?,CRC]#Y?AFK\_,5KW X/:I^K@]Q'W);V 3@\$<>P/U<_JY]O%^?\>E3Y
M^?#;8U<C(!]XHYBX:)4<N#WNI"R*(I4<NA/,9_TMG [U=>Y?&59'WBF"%2(V
M!!(D@B#$'F"8(P0XB ? ]>IR=\'KUFE=9HWGA/\ "9B%2/W=5>-D[%*]X=XF
M1GA4+/&X8B1I %(;"P0DQ@#). 2#,D$B H* 4?9(CV0,U1OU_P 1B.<3T\ZD
ME>I)*)HHEB::JE^<_,6H886:I$\LGIR2M'!/,1$L5>*&:Q+9<QU88YK$L:-U
MUK"=*CJTJ+:1I;4I0[PA*=24RI*<RM2DI#8E:U)0"1J/$8!/''O@X\R2(BC*
M0U*56GZ,=^"V*[&[!>->.,7'LSGOI=L7)J-0-*1#,&F-@V&,OIO6!C*EN*<*
ME-*;UPRIK4HEH(1AS)'>!WO0=/LZ @0%!="!XSS.\SCSP/<>3@4WJ0IE,XFC
MF+0>E'(@03PS]A)8O$!W&,I- S+(DL<GJNRB/])R;Z=,%("I(,Z2DG A764J
M *2DC3!)J><[#TQ^6VT[SU?:;AV1$>-GD*P=@"1E7D3A&C#-'VF/M69@O;%+
M9 ]=WAEX/"Z(!D* 'M$R5 @$$@X,S)2)&I*3*0%)!JC.T9@>(XZ">N.8)\6G
M(11PV9K-*Q8LT.\U8K4\-:*6:&-?IFL05[-Y(V8%.>R>U6#=P$\AB 7D:*E(
M2EQ*$N0%*0E2RE*E'*4+6VT5 0=T(7$$I ,4.,@G,B=IZ\F?'B=IICFE>;U"
MY[G(^@AHXCP[<JW8J%"B\GZ5*#E^X=O!'CL 1$' F1"CQ&YR#C$R=]Y%9I,(
MN/3D965&!(<#N0E6(//!/W92&!X8<]XY4@'1.X!DCB8.1./($$'/(WJ<CIF<
M^G^'OWI4J+P[! 5 [U;O7M)+#N)1N>$X'LK]C@J"?<#G))P-B3!,&8X$X$^0
M(\JM<?0)(C$BJA[>Y6<DD^_>6',( /' [/U'VD'/ 9TJ!,G; 'N$YDR><^ W
MI6R#JU")?A2^2M@40'SH^?#M4<>QEZ8>1X*"6[4"(W$<CL5 ?A>.6]FH@Q!)
MS!@P8$[Y]H[@<CRI\_/[<5KUO9_+7,;0QLGXKCI8SY45XZ.+Q5&25ZD4L4-B
MW-4JP37;<L<\GKV;<T]JR/3:P\A@A]/KMVK#;SKR>^+KVLJ4X^^X '%)44-I
M<<4EI 4D:$-I2A!U! &I6JR8 X$<#>(DP!),9)R:GG4?4;.EP:?B,_JLV*SD
MV);+9K8Z^UXG:\#M$6<:'+8>3"6]?DOX?&MB,+<I8_-XJ'*7K]/*K:@RJ8O(
M1R8^+Q?8W:*.TU=H7%K>I?M4W)MK>T<[/N>S[NQ5::[>Y%RW>)9N7A<W+3KU
MK<&W:9=MRVY;JN&5I?5MQ!1H"DPHI"B0M*DJU>T-)3($)(!$D@R% &12&Y4Z
M;OJVSR4MRV*',4,KJHUO4IM?>?'Y]+&.LQ;9F;><7(5XL.N&NI%#AZMC&VKF
M3HWHQ*U22&R#RMN=L"^LDN=G6:K9UB_-Y?INPAZS*'FE6%LBU+*U7/VELJ5<
M+2\VAAUHZ0XE:*'NPA1"U2"G2@IPH0=2BJ0$P?NR,@Y@XKKI[5IYC/)<FGLE
MH_\ 1;N[6@8P45UED/KCA"1P73CA>?X,9'ETH0$A*4)2B#_!@ (@P=D^QOX&
M1,;D5QDYSD^I_P ,?"NW.HV:TC(975+&G:]\OIN!Q6)Q$U.W6BQ.UY@UW:[D
M[FX93$UOD)\WG)K%]:62HB9H,%%C:\WKW*-F63P/9%MVFU;WR.T;L+[0NKA^
MX#K:B_8V^L!MAOL]A]?>HMK9"62XRZ4Z[HON(T-NH Y7%()24I]E( (.%$;D
MJ($2?:((_FP#D33%7LW-BQF8U_6-2QT-&QL\6:QTBT),MFZ %;)#'Z['L%CN
MGLUYJG?&N/-57S$]$6YE1JSH>TM+=FZQ<WO:#RG$62K=T%U-O;/'6SWUXJT3
M"4+2N"7M92PATMI,+!J E04E*!!5J&-1&\)!YZ 02<U'<"F8];(:Y5MT,9'F
M8%3)QYFY#2I2?B])<I5#S3,J"4O"4I,03\U/!$CK+)&X[5T;<):O%MN/&V42
MR;=M3KB>]*65D)2"2F%2[QW:5$@I"A64S)3(&H9U8&,C)P#C&,3XS49NP6ZE
MNQ6OQ3PW(G"V8K22QV(IB 66>.=4E6520']10>1]R."W;;6A:$K;4E3:A*%(
M*5(4G@I*24D'B#6"%#&QG8X]QQ.1[P?"E5>.M#$LUPM.LT=M*\%:Q L\-Q%B
M]"6S!-!.?E&9HRR\)\PO<D,H9)%&%%:E:6_9*2V5J6A10ILDZDH4E21KB1N=
M!@J204R&T'C8 [9QQ,8Z"0-S!I56P.8G@R.0KUO2BP^-@SMJ2:U5J218ZQDJ
MF*@MU8K,\,]ONR-VM"(Z,<]@=S3-&((998\KN;=*VFE+E3[RK9L)0MP%U++C
MZD+4A*DMPTVM4NE"3 2"5*2DW28)V2D2>($@ B3F#L #UC$AI:29X4C9Y7KP
M,2(R[F*-IC];*IY2-G],!RH7O[%[N[CWYH2%$PD*4!)@!1"=@3N0)Q,Q/C4\
M_P 3$D1C]GXU>LS16%JB&A#4]&HL,K5VM2-=DB>622]-\S8L!)F7A)%IBO55
M(%*5D<2.^4I*-94ZI>IPJ3K#8[L*"0&DZ$HE(.05ZW"5$%1&D =AL(&YG@Q)
M)Q,3Q!\IGW#>DO\ ZJNF?ZO_ #?:9[?_ ,N8WQR5:[!\*4>%*/"E8T>3C^Q@
MZ+?\C*O_ %NYX55;GS/XUDOX5*/"E'A2CPI1X4H\*4>%*/"E'A2CPI1X4H\*
M4>%*\+7+CG*Y/D?_ *2N??[?_C,@Y]@3QQ]_8_K]O"LG?I@@'//NC<=<^_#?
M[!N>?U<]R_<'[^_<.002 W /V^X''*@Z>?ASOL/'(CWQ-5NP81D=@)7@]G(^
MQ(!;N)^L@<\* O 4\ E@(.=]^?RQMYR9GI5)V(],^.-XF1&< ^ZN'3M?A660
M<#AU#J&+ -P R@@J24/\ON"01R$D9$'IO^%38@;].L "=LG.=L[1&:H^_P!^
M.1QS_&.>?8<<_;]7/OS_ 'P?%IM@"-XZ8(,F8QU@'H#U./M_&.#[_KX_E]S^
ML?Q@?8']?A3?;IXP ?"(Z0#UF.O)XY'!)_CY ''L.00.?L> 3[??G@?8*$8/
MA')QC.2,B#X@])F3DG]7]\GA?8>_Z_U?Q?<G[<<GGPJ_$$YSU]^T;C8CT( 2
M0!RS$]H[1W$\^P^D>Y]_U>YY^WWX\-MZ?#UX(GSG)GF1(S7++V@'D$G@'M!'
M (''U?P2>>1^H<JWW!\/GY^>10#GX?,=3N.A.16PGJ3Q_P#1:>3[D#W\\'G_
M  .>>X'\RWP\""ON 3[<$GN 4D@$\,'SY_#W\9&\4&W7<=>??^&.@V&OPAE
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M15U!/,))!)WO KSL'F1"JA@S,ID=3)(9''TQ]TC<,_:0O/B$A,"(!(2(!.>
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MX6GD^<D=Z>=_S_%%;NY8GHM\/!?8K[AU![^257Z6]R>U6'IUWVQZ\<<^7(3
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M$X4@C!"DR"92D9QD* R4[[;_ *^_,F"-NG5)"D<DR),S1(7022A/4>-"0))
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MJAC=&<Q/Z\:HZM'()YN!([A4D9H_3D#1<HL916XD$@&03*Y! !&DD@R-*9(
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M4RDI#3Q<2E(+LH4L]U!* E20%%14%$"- B"(!F#)R1&<9C/OB,5A'G=0PE3
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M]7C/ YZ>.\S$]<^M<:))#,[2E)$[/20CGU#W=K GGZ0B\'ZN0WN >1P(200
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M^WW5=0%XV+JW;7C[ '++'Z3OS'']9"A6E61D4<QB5'=A[=Q& <$>T9,03(2
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MT66W[7N4-%QVS#9-R'WWUN(N%."XA#*RA\!LVQ+CH6H/@(**QNF2%2=E20(
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MO&W<;>7;);=4MYI"&7#=-AMQL-%2PYW;:G%-OZVRE[^#2V5)"UT!2-0("I
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M[LK^4S]:W];=D?\ =?L.MOOC]G7S'1X4KPQ\Q 3E\@K<QA\A;'+!C]YI2)&
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M0"H"$E<&<&SO\,?CCQ/PG;'+3O(8B8D'8@AC,,?I][+P#W]IY>0A@.\LK=I
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M@4H"2A.X45A6K[R04IE*B@$#)3 6"2E4$8C.:R>4WS:+5RIK>+IYG:LK$]3
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M2EQ(5W3B'49,H=0=2%I@RD@SB3*24E)2H@T2,C$@@^(($@[SQ[P#N!5]Z4U
MBMD*LU::6G7LU$:$F1H[RT[M*PPD3NB@L4)I)H)(_P!._<G ,1/C(=2[[;2T
MK0EQ:%D*$:FN\;<0-.%+2ZD)4#[*?:F"*L1]Z1@$>^"#QN#-.F%Q5S+3SP)C
M\IE4KT;=F2+&),[P=L#PP6)/E:N1(K0WFIO+ZT$<%A"T'S%4V(YUXKE]MA"5
MJ=88*W6T)+ZD@+E04I +BV?;6TE83I6I2" O0YI4FJ 3L"<'[N8,#)$'DB=O
M#BFR&Z8>>0MCA6;LFA=U@D:*.,F,JB'URJ1P&1R$':XB20.C+RJ;GJG(,@@%
M8!) 5)/LR28&<YB""!Z3S'62/ Y/'QB<4W3+Z;NTDD;,K?I@3.ZM*P)/!4HZ
M]_)Y$I3DEU_@J.[E3D0! X,)!@1Y@QX3L.3C)Q.V/G'R,4A4JTB=R%XU9?52
M-O2YC[OK D991$W:Q4.8V6-B#VMQ]6S,*@P3,$B<Q@D @D8F)R,2-A.?#\?+
MIMTC-7IH^^9EKIR)F)BB$JV'12[*D1:-$:21 J\\1J2I#F-0PXB3"1J.0/:4
M4Z02!),$D 'Q4<XFKD^NT_G GTSMM5'#-ZC2'DAN\N&)/<?;O0'Z1PW"N?L0
M%X'/OX=-/3;@;&"?P\2=P:F8\?GR_P /6KD14IR5,Y;NCB5"RLLAC)5PR]I(
MC=D/;VLIY^_N."C$[) RHF((G/@)$YW/NJ\==XW\]_7R'%;6,UK>M[+\,?R&
M8O:]VH:+BLEY^/.E@\KF;N+R62CQ&"R?33R31Y?:9H*2JD]/7XJ\,MJDUB&U
M<>W"M50D=J>MXSM6]O;*SNW[#LQWM5]BPO+JWMFWV6#<W;"4&V[/2MPDH=O%
M+4&W=*D-!M1<,EM*]H2E2DA2P@%:4E1!.E)F5XX3B1()G&QK5[LM&AC\]FJ6
M)RM?/XZEELC4Q^8K59*=?+4:=J6O5R<5.8>M6CR$2I:2O*?5B28I*.^,L>Y9
MNNO6MLZ^PJT?<MV7'K9:TN*MW7&PMQE3B24.%I4H*TC2HI)3@Q65 !1 .H D
M Q&H P#'$X,<34LU_?&QVTPYO(6\_B\3D<0-<V>ETYOU=&R.7UB;&)A,CB4M
M5:,^,>+*4H53,+;Q=^MFY#8?*03RVIY1X^\[+2_8JMFF[1]]FX%Y8N=L,K[4
M9M[Y#QN6+@H<=2\%6[JBJW4A]IRV]@,*2$(%:2LA6HE0!&E7=G02DB") (S_
M #I$',[S2;#91:.O;56BT_7<U6S\<%6MG,XEJ?/:P<5:3*2V<#-2R>.CK6[-
M>2.#(O-C[M>:G(Z(BD?HN2X8+MU9+/:%Y;*M"MQ=M:EM-M>A]!82BZ2XR\5M
MH4"ID(>;6ET)DF84!A*O82H*@:C)4B#,I@C)Q."(]]<0:5<OXM,M1R6'OQ/5
MCG;$T+PM[ K2'*#Y9<5"GSC21)B9K5Z?L->C4L4YY9Q\_7CFJNT6VGBPXS<-
M$+4GOW6^[M8 8.OOU$-PHOI0TF=3KB'$A'\$LI!!(U2".@,JYQ$8VS. "#R)
MHUNX,'E\5NT^"U?8Z>'SV/DEU3.LDV(R\<',L>+R.-J9&AEI\=8BJM%<:!XF
M9"!-<$EM$EMXW]I8?[-3=7EFY<VKJ4WUL"+BW*H27V7G&G;=+R%+"F@I)$R4
M((;]DDPH+TI4 0=*ME1_-(!!(,>_J2<I,A9TNUK,<-3$9Z+>Y-DGMS7X[5"'
M6/R;EQ]<)BJV%2I+DOQI#F?F)(;YRWRKXUXX!06PK,NVD=HHO2I;]HKLL6:$
M(:*'57OVQ+RI?7<EP,EA5OH26@QWG?!2N]*3%0E.D85KU$DR-(3&VF)D'G41
M''1'1P+VZ=R651&U5T+R=\,;PAV$)C:&9EFGF9Y8^:D $T"Q6+$D2PUYY%YG
M+@)<;2"3W@(2(*@8!5JE,A*0$GVU>RHJ2@$J4D& 2)C8CXXP.3Y?X4IB9*V
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MY;$\DDS]SF8K([MRX]1@KR,&X':&9RW:?8*P!YX[O$0E*0E(@:9  Z# !',
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M7%^M]+7=/6J;=U)0M]Y:$VJ$/*:N%OB3I9+9*0ZI2:F#J3H*E* 2F)D*U#,
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M^9/3B].0([3B*(NG"F.18P9)9.64!'A0'M3@F4 JK=W(P![4@D:2HD'.H$F
M,9*5'=7!R:@D X])P0!OX<]"9ZS30T<;]_!:/OD#\AF(^I2#(@ /)[5*<\<
M@("0PYYI(C;ID"<1@Y$0<[SR?"1U.>F\[1 $<$QQCQBKM5&C[E8HZ*%6$R.%
M+L.XA68\<!Y%"CN+>Q<E6)]XHSF,F28Z$< <@=(XVXH$;F00(!'WIS .XR1G
MKG@UG'UD 'PQ/)^K+V\>=OS]< $, 1T2^'CR%/T@KW>W>.!P"0"/;QV6?N8Z
MG?!X],<5E1$YC..O',8V'&(\9K7$B\JWL65>UCP.20 0IYX]E!< D$#D#Z6[
M!QR'\<"?GP_*1-9Z\@XXQN#\Y\J6*P)@0+V1B4/WA4E8L0%4%2JQN$96 BX#
M2@L&+*$88/\ .S)B(R.I,$$D3C(P,1F15]>/A[AO^%4223)%'#+W)&IDDB)0
M1F2)V56 <*#+'ZU<=@+&..59" &,A\4!)45""<!0!F"!(Q, Z5Y, E)&XBIM
M'OS&<[[#P]?&GVJV?J4L7L&/$]"+%V9(*&6QZQT[-2Y6L)>69KE(0W4M03WX
M&AN6',D:RU8(YUB2O%'UEBU6X]:NE+BGT)4[;NZG$.-K26M/=NZFRA26E:FT
M""0M90"5*5KVH"A(C (P0=YD9D3N? '&*INYC+Y9*ARENW=6A2K8C'F9S(*.
M.J1^E#4JJ%8QP1*) D:J@]5Y)O\ 399'8S;L6Y<[AMMKOG5W#VD %UYU6I3B
MS("EJ]F5$G  &$I $D[DF $B<P!L!TB-O/QI.U6U4>&.2G/$YCCDB2>"12ZS
MQ^K%,L<\1)A=3WQS(W#(R%)"HY'(%H<!4E:2)*5%*P0"DPI)4E7W@1"DD @R
M")@5,B-QS\_LI^R^"O8:2N;PQ$R6*^/NB?#YG'9:E5CNUXK45*Q^(\C<AH9&
M))D-O%6)(LECW[X;E2I/%,OCJL7+5P%]UWZ"A;K13<,/V[BU-*4VIQ'VEIM3
MK*BD]V^A*F74PM#BTD&M*21DQF/NE)&1,>R<'J#!'-1]I&C8NIFC=)B[3$!G
M5E;B/M0!9(98^XCN]4LWL%$?#/)VHD1 *2F-)VVS))@I,;:8'),P(#MX<P#\
M^_PVI!&D2O(TQFC2-)&C>!(Y6CF XK^LRM$$C,A0/*&'#=QC#R*8_'(HJ*0$
MA*B2D*"B0"F97 (,G3,).^)(&:GO^>/PCUW-6%]QP.UAW!@I!()[6"\</R5Y
M('+D$$*.?X2G6YY!@B>=_*)Q./&."7S\_/YU<"\KR7"IPS*.Z/U0P0^RQLZG
MM[T[000WOW*KOVKXD^$G YC?&0.ADXCR%3X=-I\1SO''PB:Y#>A(9%<,2LA2
M0J0>1WIW%9 ?=G]QQP5<]WL%[2C4F"(VD3.,&)'IXC?>K^=;,^JF/KV_A0>3
M=J]]I;%?SI^>M:M!:ERQ=R22]+/)&;<\!KUVJ10TWC4S+9LP2LEB,P)8,<YC
MXBZI!;"FX0H+UNE;:&VE)TAM"PM8<4IT&$:$+ *3K*93J "-S(XB29F=A  ,
M=('6#6M,H\4LD$\?$BCN905A=@>"R#V*+R?8KZ9*A>T\=G*\D@I"DJP>?O ;
MYWGG@P9D2,%S2O'TCD'N(;.-H2U\?:NQR79Q52P*-=YGI5U5)$GNW%C[*\/8
MAGG(1I8_4!;C=<[H-J"'G4K=0V0VG64%Q02'%9!#;9,N*!.E,G28,4"9R! )
MSC;@>/XFG+7\GDL-GJ&3U?*6,)F:-VK9Q>=2Y^*[E&[7',-Z.U\S$F/"SJ6:
MPTY6%0KLR*C$<-VPQ<VKS%ZPBZMWFW$OVJFN_;=;7]]M310HNRDQW>@E4P 2
M1-22D@I,$$$*V((V()B//%=DT*73R]A]TR&Z;1L]/J16S>NP:C-@(JN:U7-?
MC._;;<<]L^:DL_C2C\E2]"U1BQU2[8RUR>=)WA]-4D\.\YVPW<]F-=FV%D[V
M*NVO%]I"Z6Y;7]J666_WNM;*U2WW#O>N:VWE/NLHMVT(*4N!1*>0=V0HK4L.
M!2=.D!2%2?;4I4R"  1 5J.\47,?J^JWMMP6L[R^T2G*8S"Z;N6%KYO5-?NU
MKTB#+YS(G.TZ^PT\?! \F,;&VJ-"2TUZ>X[K#1%6W6GK^^9L+J\[+%@DL/W/
M:/9MRNUOKQIQI/\ S>U:-JZNS<>4H!X/-/.I1W2&TA2G2MN$!)6E*]60E"QJ
M0@S]XJU *$;00.I! SUODC0P^6S6.2/$YE*\DF.KV\1<O286Q8ISB$9>@UE*
M]NY6MB&::O%<BB1TM!Y:R*!7'EV>]N&+=XE^W*PEY;=PVT+E*7$:C;NA!4VV
MMHJ2E:FE*,MD)62=9XS *A@[@$$Q@[B<D;Q,;SX5:FNQ2XZ6C!6CIUY\J^1A
MC[1(U16@*&*6T889I8A%Z4D)/*!D;LKA96+:2TI+J7%++BTLAI1DI"R%3J2@
M**4G5J"H]HB 5^R +,B!U) Z0#Z^O%-EZU/DFBFN6+#S1QP5?6L>I(JP4XA!
M B,I8D1P+''&JH B1JBD+P1RMMH9"DMH0$E2UE*8!*G%%:R0?^LHE2C)*BHD
MYWA,QY >@@? #W^ZNP9H,'E;.+QVI4ILI<P6NU)Z4M33XEL[#F8)5SNQR;'0
ML[#F(+&-Q=:?*UZ>1%>,7,9B<7#;P6+^9M^CXI*KEA#[M^ZEENYO'$NASM!7
M=VELI)M;--FZBTMEH>?6EA3C)6>Z???+=T]H1JU[)("!)2F1[.5*!U*U#4K
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M)5/;*RNO8\I8IVJ(VE96(=@P4*@5BXWDE)"1R"2<@$&0!&^H)!VQ.9 !GO\
M\=_PVQ/K2^SD9;U'$U&A@C3#4IZ4<]6K%#--!8R5S(>ID9X466Y.EB_-##8M
M-)(M):M%7%>M"HX4,I:<?<"EJ5<NH<*7'%*2E2&&F=+*5J*6D%#*5*0V$I+A
M<>(*W%S29@$" "!@#$DYC<^T<F< #8"D$QB9"WJ$%5"Q\)W/*W?Q^DY*B.-4
M#'GF5^\(B@HY>+E&H';<RHS $C8;R9Q_-Q)G !S^0GX\]!@]9J_")6<*2%',
M:=H<>P?M#/$O?[AP2Q*$A2?4';]!!41/G$@[C:<<'$GRS)F_#'[#^.?TISFB
M6HD7?*K^I$9@56RA[18F0QR16$B9S/Z"S!X3)'Z+JCNL\<L</"DES5[,0K3G
M0<Z$F04$QIU%)"@E6L$A)24DTXY_'&=LQY^_K-.-;/92G>6_2S-^ED?E;^(%
MHW)R8\3D\;/C+E$S\O,*<^.M6*4E>)75J;RPK$RN%/"NU86WW3ENTXSWC=QH
MT)@W#+R7FW0#">\0\A+@4J#W@2K4")J@D&9(,$3X$$$>\$CRF*M4*=O*6X\=
MS AF9BGSDT->)"8T$CV99&CBA4Q=KF:40OZOU=[&,)XTZXVRV7B%$) )[M"G
M%$ DA*4I!4HR?NC5 XR8@S[/4XF.?Q!Q,QX#JCG-**&!,?5EDD6O+'9EN213
MFQ-):EDC>G&:U>2"%:PKKZ;-8L&:*PS2I6M&LO(D.*4HN+2!K!0&P4Z4A"00
MX2I06HKUD* 2@)* $E:-:AQMG\)GQ$QMOX\&FVU7L8^=ZMA:ROV1>JL,U:TC
M1S0I8CXDADGB+&.52"'[H925/ISHX7D0M+J0M!61*@"I*VS*5%)]E24F-23N
M/:&1*2*A$3/F>>/#P_2K5=8YO1KS2P5HHVF<S_+N\I+QAU61H(FFD0M&L408
MLL+2.P149V\54IU*2%+)"1IU   $B4A1"00"2K;4 !)( H/'&^_[./P\YI64
M@-:(Q>N'57CLF54*++W%E-<J5**:_H"1':1U<R-SVM&JY!5J,E,2"C3,P8^\
M,A1"]<$!,B.1)8\<>_K^P<\^5(E2,*%;E025<%&/I\OQR&X^HC[]K#Z6# <$
M\#<F<$>&1G$[?F#.1N,T^!R/T]>G4>5;<=MWO$:K\'SRY:W)H^ V#([EYOO.
MO3PVX90VFV#1%P_3_P D%J])@.QX:S-L=*7\49@V(0XJB.2HT*K+7G\+?]E7
M%]?]BWH[5O+-CLUVZ<NNS;?N_LG:QN60VRF\U)4X!9. 7%L&U@=Y/>!?LJ3R
M)6$I<3H22L )49*D0<Z<@2H8).VXZ5JPO2ZW)B\$F+3+U\T*]P[+/EGQ[XD6
MGNW#13!0P5VR @7&?)"S)<GEF:\\[Q+' L1\>0:%XE^Z+YMU6VMO[$AA+H?T
M!M =5=*4H-%??=YH2TA*>["0HJ7-9)3I$ ZLZB8(W@0!F(@Y,R3M3SOVI8W3
M,Y#AL3O6K;^CX;!W[.<TR7*S86"[E<15R%W!&UE<9A[%F_A)K/XLRDU>M8H_
M.PS15KDZQEQUNR>T'^T;55R_V7?=DJ%S=,HM>T1;IN5,L7*V6[O1;OW"$-72
M6_M%NEQQ#H96A3K2%$I!Q 2J M*\ ZD:M,D3IDI!,3!P1,[[U"X4FEG2*#U)
M9V9888H5+RR2']'&D2A"96 _1Q\ NTCHB$@]P\DLI2@J40E(!4M2S 2-R29&
MD#<\  FLC?\ "/GK\\U),IL64RPQU7(T<1 N!QIPJQTL'C<,TL4 G5)LNF(K
MT6R66CGE'J9?)23Y"1UC6Q/+"I0]-BT8M^^6T[<*^U/_ &E1<N7KB%+*21;E
M];B6;<I3[+#(0TD%6A"5'&BHF 0!I&G"0,#K !*IW)R>>9[]Z%]5-%Z98W8J
MNQ]-1ML^VK4P&3V*EM#XG:,#HF526ANF)U6/(XK8M9J97;:5U,?/LN4UK+Y#
M!UXY$P@H7+)OP?E?I3V!VKVV]9.6/;G[W([/#UTQ8NV*;FPO.UF2V]V7==H%
ME^ROW+?L]UHO)L;:_M6KM2A]J+K: TKG9=0V%!36K5 *PHI4E!PM*=04@%8(
ME122F!I@Y'66YZQK,&/R^?P%D8.G%DL.F-U_8FECV')5<M6L3V;>*6"O)!DL
M9BK%5J]C(3/BO7BEQ]B"FLEFQ2I^<[/O;Q3C%K=(%RZIFY4_=V<*M&7&'$)0
MV_K6%LO/H<"T,I#X2I+J%.$(0XYQ+2D J'L@$0E4ZB#,D1N =S X,"8IOV74
MFU.I@LCC<I%FY;F&CR^76C+%8K8=K$ACJI+9HSSUU66">&O+%)8BO4\B+=2S
M6KRPQ^KR65_]N<NF7F%6Z6KE=O;EY*DKN="=2U);=2A<A2%+!2E3:V2VXA:P
M5:2D:=)29E,DC8<C(VP1B9F1TIMW32<OJ5C 09&Q@;C;%K."VRF^O9_%;!6C
MQFQ5Q/5KW+6*MW(\=F:X_09;#7_0R6-LQLEF"-9(WGY>SNTV.T$72V473?V2
M]NK!P7=K<6BU/6:RA:VD7#;9>ME_?M[AG6P\@A3:S!"<J04:9*3J2E?LJ"@
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MEB2 &*\ANFLIG&2HP(.^1B!OL=@-ML35$]8_+S'0X!.U(I&DCBKHL2H_;$9
M(XY6<,0T;GY='^CTP>!PO# $GN^@002HDDC,9(C8$'41)F!C&=B,F](W@;><
M [1/'4&,S,7H(BI]9^^**3@D]KMS&B'L/U&+@D$+]*H"C.6^J/M\11Q RH'K
M$$D2.3M)S))B,&K.YB)P<<$#DD;]?,D[5;D:P71AV=L<;,ZEF3A2..YBJ^Z\
MCN 8'^^ X\4!,1R3$P/U/6"1X1,33(,@C& <QF<>X9YZ9P*JJ>F5=23ZA8CM
M4/*7]1@K/SR0A_@(C'@!&!! +)X+F9CV0-S B.-\\R/Q$4 '(DG Z;CXC?!
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M$_VW!Z*?#P;C[DD^_!)X)'+$#[>.RT91(QD_#P_*??6#(WGJ?GY-:Z$?M9"
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M5.8@X@ZL'/.-\# B)R#5U=!Q)P!DXQ(Q(W$&,XV%2''.EZL@["9(S'.8F61
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M>G,B,XS,]:SB?'YX]V]7H2Y4.A/<LA8*"3V@=G$GIE7[0" .[WY]T?V*H\,
MP=B#)V))G$R//PWQN+2JJL<M@/(DAJ131R3I%+#!8-?N2*3T7DB:-7/>W8XK
MS!22S0NJD'C<)"2 4A:DE*"H*4@+ *AJ 4%%.)(U)G "A-4;]8S[O?/X'RBG
M H&K?.PF*-9LA)!4JBR)LB((8U,*SPUXZT!61K/8;H6*2W:2QV1Q]LA/')U]
MTO4=+25+64:6BI2E:M*EE:L!!/=RH(04$E4IIN!MO ZXC>//>))GI7+V+M<2
MT)VL)Z=AYY*)DE>O\U&C1K*85E%=WAC9T]4ECV\H&,1(FJ4M*AU(090$I<
M7H4=421J 40%:0(!S&H#2SM)P=O+GIU^-5O!/+"]B1X^'$!7ND=9+8;YCLE1
M#$CS>F\%J.=E)YGD[)"AD'C(6D*"0#C7LD$-D:)23/LRE2"D8E()$Z32#O\
MGD[_ )C-*!BIX:,=VRD$M6U)/%#*DL$BN\,4=B401I(SQ1K%-%]1BCA[Q)&)
MB(9$$[]"G%-(*@XVE*EI(4" I2DI*E$!))4A6 2J(5I]I*JL=>=LC<>(G&<[
M#<;BK-VI8KIZDS0U1)7KV:U>9YQ)9JW5+I-$K>H.R*$(91W1-WOZ7U/'-&*T
MXE:B$A2X4M"U)TZ4+;,%*ME DS!S@3@%),((Z#\]\Y\O#C%1YW,GTCM [6*J
MIY4LK$D^X!4E>3R>X'V'( 7M[(&D3Z^D9B9S^.^\RG2]B?Q:56Y/ +=B".>M
M6@)D:L&LKVQY*.15EJO)5/S$$?;,_IRQ+,L;%A'PM/\ ?26T*[M*RA:U8"X3
M)4R4R%@+.A2O9$I5IU"":4D;[D3Y2=B..O4B)\$$@$/(1U]0J$+A>Y79>]"R
M!PAC3T^069#*71'55+GMY$R=P8F0,@C8Y(D*,[9B"9)@$Y/@1XXWX\#_ (54
MC+Z021Y&;N<GNB^Q?[&.4%RWV/LZ#B1PW:6Y;P,ZB0$Q &#P)D*& ./<(J^?
MPQ6R3JI$\OPI/)5%"7'=YR?/JTI)1 BKTM\D:LP9B ZBJ6!60QLSN\/!E*]\
M)"1*H/M #!5/W3L)@Z\R)B O[LP^?G:M;=,8^.S!-:66S2CL1_,U8)?D[5B%
M)&:5*UJ2"S#$TL "B:2&013-W"O,B 25?>E"PV4I<*3H6I)<0E13[*EH2I"E
M!*]TI6G4D1K23("!&\") QB=@3(V\,=-@>XMM@Z.YE,U8Z;XO?\  M V$7#8
M7:$QFT)!BU&1;9\[F]FPT.):JL%E\)6QM*/7KR2137K-B]4ECI4Y?S]@KZ06
MYMD=L/=E706+HW%Q9%ZR4M\]R+*VMK.X5<!S4@7*WG57;90I+*$-.)+KB>97
M=&>["QM 7"H&=:BI($1@ !)Y,@P*3]3M4M]*\_F.G=#J3J/4C79H];V";-=-
M,]>SFB9JQD<15OTI:QN5<5(<SAER5["WX;N.BR&/O0Y*DI>+O=G87:*.W[*W
M[9>[$[2[$O N]M$VG;EHU:]K6S;%TZPX%AIVX2+6[^SM7=NMI];+S"V'2$K]
ME,<3W2E-AU#B2$JU-J*D$E,C< RF2DR 09&1O#K.HY4:[-N.-Q6=LZ4N3I:]
M/L]K%?*8Y-GLXI<G+@GF26Q MI4CN20QI9>2U3ABLM%6[C&/)HOV#=I[/>>M
MD=H]RY=ILD/]X\;-#Y93<@$(46R2V%*4@);<46]3D:C@I.G4 2B0G41 U1)3
MR)W\P)@4T8^S;QUJM?K2RT+].2*U4R-6>5+<-FL1-7GBLH>Z&2O+&C0M&496
M"]I+*"O8=0VZA;3B4NM.I4AQI: 6U(6"E:5(4(4E22H*!!!$X(.8,&1@C8\[
MS@\''$;==WNQM6S6-OBWO-76O[)/=BRS9/-TZF5CR=V)&,5RW2R=.S3R4):
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MRM)Y7]@7MKUZW;!U]Z_54:*M E:+O2MU*B5Y#$@$T[AI[$A>:>225W=HEM*
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M;_\ !.E_^=+PI ZCX_I1^>'8?[@/6_\ P3I?_G2\*0.H^/Z4?GAV'^X#UO\
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7%-#-$RR12QLT<B,KHQ4@E7,-AY"O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g104413g71z61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g71z61.jpg
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M  (1 0,1 ?_$ !X  0 " @(# 0             &" <) 04" P0*_\0 3!
M  8#   !!PD%! <%"0$   ,$!08' 0(($0D2$Q47(5<4%E:3EYC3U]@B,3AX
MMQ@R05$C)"5"87&!)B<S-'<U-C=$6&*"L;;1_\0 ' $!  $% 0$
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MO267%YN5TY2R,]?$9$9*NRID/3:+'""R;=6..O.96N,D,<<9/ QH%N!DUHB
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MYJNT[&W@L_CI;>%S=3<@>E8J_;@#O5,@<"!E 7ZU% 1 1 1 1 1 1 1 1 1
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M^MIW,T,NX_9H62W#9G^ZVC=E-6U(1TBQF1R$I._J#;G'T@Z#E?J351T,\?\
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MJ(S\J1Y4(C?2>!*DS.N^-2'H/>?R"N""A 1 1 1 1 1 1 1 1 1 1 1 1 1
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M2/ZI]K I\![S^359P%" B B B B B B B B B B B B B B B B B B B B
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MI/C<Q\>PK#;V@P^.I$MYJLXG3_P]7.$V73B\S7&?=HJ<6Z:W.AV.SCW;J4S
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MBFG$3'RF&-[I!&US^'A:2,L"_6HH"("("("("("("("("("("*L<3_C+OO\
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M9SLPL>V<[;,K3MMG]^=FY'G.?^><DYSD5=U%_P"#C_YC?DO 9'(-&PO7 !T
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M]TNS?UG G+R/Q'R4:AT>[P<8K'UTUN/EV.2U6U)#Y$PMG+UF/+>T.QA6NRQ
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M7%W_  \JK[9)=^1((N,/-W9QXXKVJ<X\<X\<7++LX\<9SC./=1/[\9QG&?\
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MV"CM3D"]41L6H+.+U]+@W334\LHS0BI?[;[8^G3Y]:3^ ")[;[8^G3Y]:3^
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9(H.)V-3G%'EXWSL4:69C7?!%MU!$!%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g104413g82e41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g82e41.jpg
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M 0$! 0$! 0'_P  1" $- =,# 1$  A$! Q$!_\0 '@ !  (" P$! 0
M      @)!@<#!0H$ 0+_Q !"$  !! ,!  $!!08$ P8#"0 % P0&!P ! @@)
M%!$2$Q46%R%8>)C8-3BVMPH8,2(C)"9!<1E1\#=987F1EJ&QN/_$ !P! 0$!
M  (# 0             ! @,&! 4'"/_$ #\1  (! P($ P8% @0%!0$!   !
M @,$$04A!A(Q01-1<0<489&Q\"*!H<'1%3(((T)2%A<DX?%R@I*RTF*B_]H
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MEPP<6D<7C5COH,O%SLG'0:52J$=*&&SR.'73)WI%L,R6'Y[)Y_+?]<D^<$&
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MS80U<C25; IQ2!X"B)=0@9YEMO+K)OOM)8V2:WZY^O8N"\ T5:'FORC6=+W
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M , 8 P!@# & 1-\L?XKZI_FRL/\ T;6^"OI'T_=DLL$& , 8 P!@# & , 8
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M*3E1@\X1[[Z:KZX BO'?\]-P?RF^;_\ >#U3@O9>K^D266"# & , 8 P!@#
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MU%:]5X<NA<9'"03/M-%1-KRF.'-4>N$.%.^.ENU5.P?;;&W[LFO@@P!@# &
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M"XTC^,F,0WVGRX565^]]JF]:#LO5_2)-W!!@# & , 8 P!@# & , 8 P!@#
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M!$V._P">FX/Y3?-_^\'JG!>R]7](DLL$& , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@$3?+'^*^J?YLK#_ -&UO@KZ1]/W9++!!@#
M& , 8 P!@# & , 8 P!@# & : O4MZD%\1?KS3!*%F_2JA?<WXNVT[ K10<W
M2T,V"W$.8/4-II'W3S?9K1-$XO%F[+IN*TV=O>7SSL=F;DH2<(J<U&3A!RY%
M*23<8N6)<JD\)RY7C.</&#%5SC2J2I056K&G.5*E*?AQJ5%%N%.53EEX:G)*
M+GR3Y4W+EEC#I+\M6Q[T&>J_4,6K^DX7U)K$FQ&R+1@%F2&40VL8)-U1 *-B
MI*YG@4#/#+'1R*Q<"$:=@HY)$IDR'L#0X5MDR5(M/D7#7$/&%YQ=?V5_92]U
M4L7MI/\ RZ.CTXI^!4H5L25251822<_?E)UH.,(>)3_*?LZX^]K.K^U76]&U
MW1ZG],C-PUC2ZJ\&TX3MZ2G[C7LKMQDJ\[E-*,5*I_65.5U2=.E25:AZ)AG1
M+L:/[,HL6Q?MBTZ*MQCE=Z-0)=()[?(CWCIHP=.V*3K:O#1RY8LEUT.4U5FC
M93OI'CZ^?J\^W & , \V7RH (G#[KF4T,T8M[ (UQ16[YFN[V\W_ !_^B*EH
M"GB$SF8Y)@WZMZ6>;?1K",=FHW*RZ 8-=$A#-6S<J\8HLNF9?K@<D<]I<N7C
MK-9:^*36>GS]"]_SI> 7T74,;MD''I)$4RQ.;1@U$I>D"2DD5FE9SR35A8$9
M+=1>02R-.G$?G4.D0CDA'9.?!DT&:1$27(,'3=RH.-[?'XK[_P"_F;NP!@#
M(FQW_/3<'\IOF_\ W@]4X+V7J_I$EE@@P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , B;Y8_Q7U3_-E8?^C:WP5](^G[LEE@@P!@#
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MD97[8"&'1!^BQ?$D6"6AJ*3>'GOT]/O[W(U^$_8UN7_Z8]=59:+D,T1JZ9V
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MK6 1/CO^>FX/Y3?-_P#O!ZIP7LO5_2)++!!@# & , 8 P!@# & , 8 P!@#
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MQ WAX3?/2+KEFS1Y</GCIVMKMPX54[Z6?+#+, 8 P!@# & , 8 P!@# & ,
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MP70UO2(<67-GH'#%?B+1.*58\64K2M<:K1N],HSLTYT9.WG/HQ^*!@# & ,
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M@P, 8 P")L=_STW!_*;YO_W@]4X+V7J_I$EE@@P!@# & , 8 P!@# & , 8
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M%CJ\N$K75>,965EI-;AO67J]U0EP7<ZS*VLGJEW&WN*>5>"Q'N)K;5GD?1)
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MUSUK[>>N>M;WKKGK6];UO6]ZWK?VZW]F<#33::PULT^J?DS9_6 , 8 P!@#
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ME+EDUG#:-M9X)ZD8 P!@# & , 8 P!@'G-]<>K)K25U^C)70_M*)R;T,,X3
M17RBU^-^62^6V@6A'9<C6OG0S?L03'R ^+>'I,<"@I9T6[%PU>:G9"@D@DH5
MVX&XI/"?1]^9;>;QUV7T/1:AVJH@BHNC].OVDGVLA^)RM^ KUQKI1'\7C6N5
M?P^][X_$YUKGO[OWM:UK>M8,'+@# & 1-CO^>FX/Y3?-_P#O!ZIP7LO5_2)+
M+!!@# & , @EZ8GWKM;FS*QJ7QZ/M"'2"&$HZ%LQWZ,@<#T[=2>*=-'RJT--
M1YZ5:)@RA!RQZTJ^W^9<,?JT.D4G*?/'EZ?<QL[^RO)1<XVMW;7,H1:4IQH5
MH57&+>R<E%I-[)O<XJ]-U:%:DFDZM*I33>ZBYPE%-KOC.=CQ9V_XG]__ !\,
MHS<\]9/*-4+GU(3%YS3UY_\ G%,T6#DW*XQ$C7[T3(!;,B&8DF[I;A[PV=\=
M:'+\*Z=Z3Z_9O#G'G#7M8GJ'#5]H%>%I2M(:C6IWUS!TJW@7=O"G%.VG2J*<
M:M2%1/G2Q!IIIX/E5_HM_P ,JAJ%"^A*K*K*A%TJ34H<]*HY-JISQ:<8N+RL
MK*:/RJ/$7OOWF-DEXPJ*3*^.DI-N&2>PK$N*)JRUY( ,>CSA(<1)6W/V$N+)
MC(V4CS9B\[^K'H,=-Q;)SK0]1JV[%=<6>S[V<PL^&ZUY#1J4+:5[:65&SU6^
MIQM[J[N7.HJUO;WB3J74+EN$ZW.GORJ#AGU]/3=<UZ56_C2=U)U%1JUIU+:B
MW.G2IXCR3G2_MINFLQAA^;ED]X?G Q:Y:J0"5RU*E3,P!I-8YJ)HV  LCET+
M#"1C9H?V?C;-F-0Z)+_5\;$ZY769?2:Z[=+\+I]:_!]]4A6O;RM3ES4ZMU<5
M*<L-<T)U9RC+$DI+,6GB2371I/8^STHN%*E%]8TX1:\G&*36V4^G;8WOGBFQ
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# *A+>]9:\,^2_DA]6:A3NQ7-0
M^B9H3&PQHZ48:-&9"TIJ&@^")!%J]6'@F1B1L24C?HM'"S( S).D4NU4N-8-
M)<S@NF=OU94[X>_XHR,6-3%RV9[.\]2J#,ZBDT$%O)WYX!J2NO\ MM9:LA;1
M4*=&S:9LS@25+.HP4VR;CRLBXD(]L4*)L@C6/D-J#DE1::47G.>NSVZF:V1_
MQ9/BZ-#CYBO*(ONQA2 Z(\Q%\]YBD*1/R@J3F*,M 'M."1[J)MHH& 1\LP(I
MZD)&2K2CZ7J/ QXQ$T7$5&6<-I=<_!;;_GG!#;Y ?^)[N]"K_,]D>&*6+5K"
MK1;R]Y+I[Z$@+20,3,M@Y(2,D%:5\Y"2KL$2'QQ9_P JRH\MIN<=HEX_L<QC
MFM.5'PU&DLR4GNL82?5;]=O0]:/BF\9AZ7\D>=?0$_A&ZXFEOU)#)[)(;SP]
M2:B"D@$-WKCH6D2Z[(H@R>^]%P*1!5=\D%?L$WCARXY474'#)8DTGE)M9_\
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M9[DFO)_QI>7O%\\/6/1XF9#Y-)(BZA)-61R][(6?8)V9"G5DT6CE!+A%SL@
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M )+,BY'?EGA5F6)+V*(6 M$V;CA^U&GU57#78]+AV&%C.7V[+OGX_ SC]?\
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MDEKA0C2E2^09UYLC$'C8,AU (1<%Q7G%)Q+'1&P6PA2R+L?5;!6LK'P\TOU
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M&!=&MA-&_P MV6T'$_F/TWUGY8P_&^E2$:PVO)M?)F[,$& , 8 P!@&&(UU
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M,IUT?J1'R/YZ;UG*)>SGYZ$-JIA[:/$9J-;+L!DF48("DTTBXH8Z=B!+MO\
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MM06/_1D(\C9A:YD@CQO]#^&N,3MD\:L?AFISTAS,RK^0:XT2<JN.@R_-_/\
M+Z;'23OQ#X]L]99Q8OF2D)NNXDTVF;I645Q%S73R4V2T#L9^<>[?#EOK7\Q;
MQV/?J-5U^-HLO'P+MYRJ[##%FH9:Z-KIW?;I\NQM,)2-01L#/(L K2%"(Y:/
M:RED!&$>&MALZ4<0T+7:ZDJ:)H:2.*+02-@(@KV0Y7Z4CP<<*[WMHT12X$R]
MM^G3X=]OSW-!P?XZ?!M:(R5O7OC_ ,ZPM"9#10>6)1FIX<'3D8H')P<U#CC/
M#(4CH@S&2Z-1Z2,6[G2B;8T%&D4N>7+-!3@5RD^LF\=,MLW;SY\HWD_N5:J2
MO?U)U8ARW.C?44#]$N[0DT!_97(9_P!N^FFU>Y8;K7_R(4-]=;?O8K]H1PLH
MPWM# R_-],?EY>AI=A\>'A(7%W,*&^0O.S")/)H/L-S'FE3PU 4K,Q TB%%'
M.FB8GE/2XT$9,Q]@VYUIBTCYDN!0:IB"C]DX#+SG+SYY>3*&WB;R SDU4S-K
MYFI!O*Z,$"0%/2!*MXMP5K<)'W3I]&Q41=Z&_BAV,8?OGS^+MFN^$XT_>NWH
M+D>Z<K*]AE[[]>OQ.(KX?\='5ZR<FO,%%E7%,;ZU52I"LHF[[@2?4@[ENFT;
MVN+[^@9)2Q3J4MV/'VLVTEUP?;H)%DTWG(9?F]^N[]/IL?0MXJ\AN;!D]K._
M,U&O+(FJ\F<RZ:O*RB3N021::Q1_!IILR0<BE57_ #,H@4)1V6I.-]I286_=
MMS?#[E=3?09>,9>/++QY_4SRF?/E'>=@12,T75$$J@$;)\&30Z#1P: 2,%46
M#02V?ENV*":Q)RS$L& E@H\56VP$L60QE^ Q:-VZ8-M]6WZ[FN*B\->,Z"+2
M ]2GE>@*M.RL*\C4E-PBJ(5'RYV-DN^%"4>*$V =%Z\!$E$TE"0=9?H<_410
M[>-END4M\ Y2?63??=M[^9U8SP!XA"0 W5H7RA08>O9'*1$W,Q056$4'"G<O
MCS=9G'))I-F-15:F8VP<.1L;?LU6Z\>%NG0L-VQ'N5VR@<SSG+SYMY[Y^ID/
M?BSR*H:JB1=>:*/Y.46,#A:>))UI$T7-<"(Z24-1P;%.DA?'(IE'#BRQ^.MD
M.=) 3Z[@Z)Y9EEUGG89?F]^N[]/IL;MA<!A-<"GH. Q0!#@Q*22B8$!<<%M!
M+%Y*IL?(2J7R%RV9I))+&)-)2Q,Z;?\ ?.W!$J_=O72BCA=3OH3[^70TW,?'
M/E&PJ_!53.O.E-2^M8Q,#M@1V"R*O8T6BX6:RDV=D<HDPT.]'K,FA:3FY1)2
M$D=(I<]'E9 :X+:>(E'J:PN7G.7GSSOMT^1MJ1UI7LO(PHO*(5&3Y.N"),M
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>D-/'O D2TY=NM((Z<+Z45TDGKO[FAEO+;?5[L__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g104413g89k52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g89k52.jpg
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MGBCMLH#,F1C.*2BUE93RI8RL/OPELUNB\#!@, 8 P!@# & , 8 P!@# & ,
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MYL8BM^;YO;'=\<]"/4&^.3VOXH^47SAZYB%R6Y[JAUXQR64%[)F$[;US$95
MJ_\ NL:_-I*';9F4"IR@-'Y&T&&'2HX>5D8X/#7@EJ@LF8:)HBN2E!Q:46GF
M.$\/N:YO!Z8<'S& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!Y??DJ\L
M7V=^6VO?5PSXSQ'R-^>Q'B(139*"RL_1[",,K+[MBSI'R1Z'W!HRAV4C80J/
M50=HQCO6TI#TFS*I*)O$<'UA)*#CQ\+XLYP^6%WHZ]\1GD#TM5OL?V#Z?F'E
M&._'=YON:$P"*5_XRB=C0N;AUYQ&^0Z9*V51E;=)0F+..6PLRT29M! !RMU,
M7R"8UPW8=&2HDW%QBE)R:SF3SW]V^_X^IZ),'S& , 8 P!@# & , 8 P!@#
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M?^,WY'/\PKT_@KY^$?LB:N"# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MNZ-2Q>I:K&M:5:=]0J6UW3NE)256A<4*3C0JW7H$S>3\G# & , 8 P!@# &
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M# [IFR)O4%YWKY/^/4RR^%K.V5M_^Q9;E,1@# (KC/<'D(PRLPB-]&U([85
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M/%.D_P *?1I"**,>&J[4B,>N%-.TQ']/S\Z_,E%@# (6^R/]X^/_ .-*I?\
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M7?T]?3M9OF>J3\OM@?@7H,-^L=8=:31DU_\ @#I;71N-2$KQK_9P3G$5FSH
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MCVML[JX_12L:UG7C1J4_>^_I2C4@YTYTZKITFY8C)5(."<,1?$U-8]<_J?\
MZ<J_].O:7L_I*[4T.U6F]I-)KZA8WCT]:3?V]2PKT[6\M[O3U>ZA!4N*K1J6
MMU"Y<;A2K4G2ISMI2J>@C-R/S&, 8 P!@# & 5 _-F:E8/QXT=0RVW-7G>["
M=\MQ;,S><=<65RWINX2.@71[SK&I=9@P=6B[)#TB=Z_)]]!7P"C"@FT.V5=$
M)*_:O(RAAO=;?+.-U\4M^6_7;?!VKSMQ,Y7\=9EH\D(GT%/R\)]+AU6!,O8F
M@3V5]SBUA7-#D9%9G4'M)855A3GFA'DAFG<1F3II"U"QA0"456[:B=^VW+_?
M^3 ?&P4GA !<3>421:;1T3,V8R'RY.46U)!#QBU<2-)@R%=VWZ0]*O\ Z'4%
M3KZ=/'4<E(0$U<3W\C'(EQ)82?(N0?=\M]L=R?<EU\N9IGCKX[+1\BRON1BK
MR@<O0!P.H?.4%9/ZED ]47Y9JZUKIM1<(<<M[44X+72?<W,X!)S]NW8Q$4VB
M8\CU7A)8N^:-A92SW-;MO?OPET[L+X\]^F#O?XKV]NCK153EM6%B<D]Z1OV]
M"(A;%/*V%3B.PWEB#^67]367 V\SCRDSCI&/ )!(FQ(<6C^QI9_'TOPIXV"O
M."X<7)=(\+P]W^YRZ;;X_&3QIGSFPK3RG5_EJ4S>:6"/@5.1"HS4_3DDI@DU
ME2,9C;"/N3S61P^1L9=$WS_[EM=DJ$EFBX=#I%LD=<K(;>K"-Y;?QSW8YYY<
MO+!R'XWP Z)^9",6$=$^Q,;]6?(&!&=FSIR4&>QXCWUZ8'L^BTFDY$Q))"3Z
M;MT]OSD@+%#99UM5^5(/7SA=RH$N?A'[(G?@@P!@# &]:WK>MZUO6]?1O6_U
MZWK?^W6]?_/6\ \Q5%_$)!J@]]VM)ZLEQ22#/*O-'W;4522EHU9,3A*PW]FN
MFL(/SEJ]3=)-(<E N=P0WP)052/]QLA-/RE$!SPJ5>FZO[5^TNL]DZ/9*ZA8
M1M(T;2VN+VE2JJ^N[>RE2G;TZLI5I48/BHTI5ZE*C"=9P2S",JJJ=!:]FM/M
M-2EJE-UG6E.K.%*<XNC2G64E4E%*"F]JDE!2G)0RVDVHN/I'@TV!6%&V<F =
MNN6KA1VR>CB3?;$T -BW2H\Y&Y"-[ZZ5%2  4;NA9@:MUUVT?-ED^>U4OLU5
M/,COSEUK<]5S(1M],>>N1048C%[G;IZWO3RJ^'KM^SF/:?.N=JO:=,DB,HVI
MVMOA"OSMI(M1Y4^\CZ"(?GY^=R._<]<]\\]\=:ZYZUKKGKG>NN>N>M?3KKG>
MOIUO6];UO6];WK>M_3K /]P!@# & 5S>LK0 13U7X4&OX_:Y7<8LN?2V2E87
M1=UV)%X\ FM#W15\<>')C :_DL3$JNYL4&BG8]^:;D@[1^S/FF8Z.N$BW0R2
MVERY=[2[T^][EC.#$JC];>7O2]V#K1K>7?(I7M94;<OXT$;UD3\Q0-20,822
M73TM&!]A$[?"DR[]JU[3:;D/ 5NZVHIPOTRX[ZY3V,DTFGAY7Q_Q_)U#Y*'<
M93I6$"I7+MPH;*K9:1#HT0L"(U;#]MY'65HC3@^:SZ:]_A,7:$(LJ?;0@VV;
M$#0JX.JU)AA[A^S2UR(N?^,OP^7/NSC!(/R:+%AO.]7L@A.+EA6PSY\Q<P:0
M 9- VZ)8Z6*Z$0(G%D4(XG P/3WH'"@H3C8V-1<<)C;55=(3RNH#Y^O/Q^?,
MZ-*:I@$UFE96')X\D5F-.$Y09K<SV_*MNHT2F<3)P:3.4V+)^V&D]E(J8)">
MTC3,D@VX=;=,DFSY-%TF&7NNO/P.8^>/(OGCRDC+V]!UVE TIRZ#KR'G<FF<
MIZVRC:#]M%HR$4FDBD2D4@D0;%2J$.KV*]!8-$42A).-QX7P_=Z6!MOF_P"/
MMW[++YO!)'!"%7@3_ N;_P 9OR.?YA7I_!7S\(_9$N9/&0$TC4AATJ%-#L7E
M@,M&9($()[58&0!Y@X%F!3U+6^=J-" YTX:.4]=<[[16[YUO7T_3@A7=\5U%
M5!2WG*2=U57T<@O<I]"^JV\AZ -.FNRZ$%]57C"H@D\^E13[3B/Q04.!#M:^
MC[$>T12W];?/UMC*3;?@OLOQ]26DJ_[/K?BL\Y_U,9L]N-JB<]_^ZV82EJY(
M$:ADCCOKZC9DB_($I+6K];Z>R!Z03&L!?/TM@Z7*8Q.\X!BCPOHX#,A.2A4)
MT8%$1?)H"Y39'!'1!FLTT4#/%D'230JPVMIV.<JMG*:#Q)%7M!;GC:?0'"O-
M_FR-^9(Q(8C$Y[:LU#2&7RJ<JIVA*F4I7&22=2R1SN;/0Z[0&%VTU*IG+#TE
M,)*<N..R3_O;735OQPWY%;;Y_B[OIW?[$BL$([S--2EY03ML;QWNMY*JW5NX
M.ESUOB..6K5N/978+3XUOGA(0.:LQ-K,^^=)NX:Q&35LY9/((5&387\_QZ>.
M?A(5-1-5/A5+OA5)7CE1-1/KGM-1/OG77'?'?.]\]\=\[UUSUSO?/7.];UO>
MMX(5[>!_^]/R$_\ ZAEK?^3E 8*^4?E_++#,$& 0V]A>-(%ZJI^T8.GPR@5A
M3V/-1[.SPC1RQ,=$ ;\>9CK*:] GH9].87P3$L$BL2//G0Y9AKOMBFR)H,'[
M3@ZI8PU33;_3IU)T87UI<6DJM/#G35>E*DYQ3PI./%GA;2DLQ>S9MO8+M;<=
M@^VW9/MK:65MJ-SV4[0Z1V@HV%YG]+>5-)OJ-[&VK2492I1K.CP*O3BZE"4E
M6IKCA$JQ^%OP9-*&GUX7M8$RCCTN)+6OY<&16&N#)$0LK [4'LII+B1,R(CZ
MJNWIRNQR,39)"-+-0[LFY(N>71#D>QTWL/V(EV2EJ%6KJ"O:MZJ--1ITI4:5
M.E0E4E&4HRJ3<ZLW4^"I).,7/C;7Z9_JK_JIH?U%TNQVGZ=V/GV8T[LN]1O:
ME6^U"CJ>HW>H:K1LZ5:C2JT;2UIVUA;PM%A+CJ7M24*M6%O^GITWZ%\] /QR
M, 8!7_Z?J7U++34F>0SWI7_G>HY4%2C*$(E?FJ$SIPT6=A.QYSM*?R&TXDY>
MKE^]O"#=K^%)=#>._L$NG'"'VNQ4TL;;KX_X9\EOQ@-YS^.V)0)M8;CH73-<
M>:Z]!68V4C((44<0N2U=$8Q)I=U(I0+B@RM#Y%B,=6BD3EJ0I"MG\I1Z*N$M
M<J+!S?S;\_!_8VSX^XW'HQY^28Q:0A)$#4EQKIBM&[$B5GA6B; >$!ZUS*H6
M^(A7\C-:$:EMC$>G7XC*;/D<UG)%H-=2KL8S!YSOGQ6&_#RVZ$W\$& 0M]D?
M[Q\?_P :52_\JV1@JY^$OLR:6"# & , YG:4%>S0(Q=1U\V"V!#BB<KKJ0/.
M%5&0R4,VKMG]R,I-];<.XK*!+XE$Y@Q;_5>KQHV24$.!QY 25'@:+(;-1E-"
M2Z:#S%B5H9%BBPV1=0*NW=Q6K6LP!NM,)$%%5H"AECNIU(09)-9NS9AX5+&,
MD'=M9"!;%01$:17#\W.)?&WW7J7E6$AZDMVY+MJN-;;1VN9M=E('J*D*L.'1
MN.;",(\$D-0TR[F,.3;+:?"["0CIED<($"XU*4D%0:S 4++.=\)_!Y[^_=X?
MP\B9\QB82=Q<[#Y$W4<A9"-<#7W+=PJS>H<K\_ZE\-?M^N'8PN-<<HD!!9DJ
MB_%$VS0BP70>-4%N!#2*BEALR)*Q.;.$UK)K<CQ%9HOPW19)R'ZK9-W'+!'L
M4.>6[818(!5G(>&K#IR/ '59%"-/W9.(E=I@_@9RTJKKN[8!)JLM>(AIU7\Q
M8\#Y'%SS?I<>001=-W[-;72?:3ID0&$FC,J'+#W#4H&+LF)84\9D635TEA5I
M4ZU.I1K4X5:56$J=2E4C&=.I3FG&<)PDG&4)1;4HR333:::.597U[IEY:ZCI
MUW=6&H6-Q1N[*^LJ]6UO+.ZMZD:MO<VMS0G3K6]Q0JQC4HUJ4X5*=2,9PE&2
M35:WQT>1:%B?F";BH5#/R/+'?3'J5FI/!A8L3LABK2/J^]ZTIP@SG,J>2$^L
MYK:& F 6.-RCLD*5:K'4C8TNC+9:F=XUEI]CIM']/I]G;65#B<W2M:-.A3<Y
M84IRC3C%2FTDG)YDTDLX22[SM7VQ[5]M]46M=L>T>M=J-65M0M8ZAKVI7>J7
M4+6DG*E;4ZUW5JSI6\)5*DXT:;A352I4J*/'4G*5@]=SLTL5>5E9/#%C:$?'
M]$N'8]!1E'[+B2+ANQ3L2%H+K.%&[?ETZ9,)O$5';PK74E?-!KUT5C)Z!S*9
M\PUG\_/S^3L. , 8 P!@# *B/F?"@)9YGK>#2P*,_)2>WX%B,DLEY6OHJW"%
M)!B53W$L]L$# _+,M@-PF2!M)GNH7_(J: 0/$<M$[S+NBD:4) R;PS^?B,H?
MZNN-\92SNN]IKX[KN\3 ^+[?JV<_&)9,6<0,B 9U!4M[QNTX2/A=XTDSD E9
M2SW^I8#/>EV2TL;F+HBR.[+D)F1S&P3$0E<V((SN7%SK-^_> T\XZXY_XZ/8
M[/\ &U%N \7M0^\D8V72"3RQ-\_/#I6K(-;8%#4RG;<4L/1\H>2!8?;(_/I4
M\0VC#9&160*<#%CHX""C,7""2[OE_C=9>'LL\OD678(, 8!"KP'_ ("R_P#C
M%^1;_,(]/X*^?A'[(FK@@P!@# & 5N4-<M;RGY!O8D9!2+I\9<5QY\ -D-A9
M T;.S%4EKT%6&/:$WHIL+=+Q5_(P;<CIN\4YWLHU[;=.$N]]Z%[E\W_'H2KG
M,>-P.2/;AKP6\+J/4FG%MU\+2VJO/PHULDR:2Z.,N/HUNUX>+;HM1_2.M*6#
M$V:4",\NWHJN"D,$_/\ ?O.N@3H"91X7(H^08GHW(AC<B+)-.^7+ F,((<JH
MK)[WKZ.TET5-:[34YUUSO?22R?/?/?&@..U/VI7ITG0I'OO3".C.Y)3KM;KK
MK9.I=/&P_J+\K*[Y4=$J>+/F$/>?5Y<]IPDM5A0L4(R&0&.D17UZM_GF<1-R
M+T )]\5A6O%QAUJ0GU)7O<3NO.ZM"<FAZ]1R7SG7XZ.MI[R9_$E69<C=I.5/
M7ZHS3I!4&P#()[9N7"_,SOCX-_3'J-L/GG*7/;?/P^"[R=>4@P!@# & >57V
MMP3D/OV\#$XA@7T+,Z_KFJP4 @TK^#.[/6HAC!^IW<<K@D3J^X'U^,X.QG;E
MT:+,I?;OW&LZKE;C<99]DW)JMY8)@X^L?].V5G.<5(QSR6ZQEKHMWSZEVWR*
MD'@^A$.V-F36LG2TB-\I/*_+67'I(:4:5):11+E,_4[\5+Q8N +,$[L/IIDV
M(DZ$JM_%C:^QIU=)4?-<^6?SX[?7)V;R0L07\]U[^+&R9THWYE# BH<D<]F1
MT(^&S21CW4(/3"T68VQ):=KM9KW C4HF(P4=D)2-NS#X4,4>?<&X/F_S[;?3
M8D=@@P!@$*O G^!<W_C-^1S_ #"O3^"OGX1^R)=R7F1]QT_Q#U@K>6]!2G,7
M<25L^>1U"1=,5]!5C[,6[8$W05(EMMV4;#GS-\NQY72:.FZ_2:O A&3QM3EP
MT15QBO[>E5:RYZI9=KST&3K>.RB.-4D+=M":6T;'%6TGD,@575%R";D!@IPS
M6;<=!F;+;M-5[M=?L5O/T2^FWP)#SV&CK!ALBAI1=TR;'QJS-(H.Z33+ B/.
M^7 >1@W"J:O+(_&RR#(\ (:3Z4'&1S%\C]"S?CK0BV,'4LR(S:$L'TA0:,9H
M%=$8E8 QERHDT'3J*O%0TEY'(.%%'G $D^:]'HDN^^HY*0\L -;3TD22WT'R
M.E8 P!@'^;UKK6^>M:ZYZUO77.]:WK>MZ^C>MZW^K>MZ_5O6_P!6]8!'*,+I
MT3(V-;%E^&M2259QS4!EPIRDQ@I)%NN0>TR465WI-@#19-G9>I'F^]#FX-H5
MK=1,+N+P=*8!S_/SQ(=?&A<E.V=,/D$;UC;M5V8LM[?F4]2XKFQH;//KPF7U
M#2C6,2S743-E^/R?.O@1X8-*[ZTR<EP!X1PM^)A"C1HRGR>>[QZ%?)?)KQ3>
M5\T6IX(, 8!"SP[_ -R[[_C3]B?^?DTP5\_"/V1-/!!@# /-O\J3=U*O:551
MZP$ =BQN)TO:DCJVNYC\.-Z_('7(AK)2%*#IJZ,R.'W /C9ZP"!^-BU8J6C-
M>,7-8QY<[')W(PR,^BVIR/I#D\;9:3?O(P??U6<=>>>Y;;6LRMTZZ\#5RN\;
MR2FGCVMO-C=W#8I"Y-2\L%KE#-9-'-'Q^"5I()%*J7.S'MTI38T'#I8:(56]
MD*2(N2O_ ,GDRRHP[^N_S\>[/CL^\^/XW7!-?SDAR7GD@GSY&3:Z[(2N56M-
M)&U;D(3"##%V3D%R<\S'OF>,B3>W!05/IW'(B"L47#XT7D(@"VD14)<^7V_C
M;X;=.I%SY?/5U\^;F_GT)3<W5JL/.VOHV83RQF;RHQ95NC1%..;( 0@23O"%
MS^ ]O);VB8*ZC6X\UDDWXA_42#2^ M2Q>9A18I/.=_AOWOGLUR+<*_DJ<S@4
M)F".GVD99$8W)4M$Q>PA+29T,R*)Z(!>G+SH0^URZU][%]/'6V#C[1IMROM+
M[7H8O9M="#WM.9'6UL>*H*E5\]?1XCZMJT\YMUHZKKFN A% !:+9.'E&CRP&
MEG]R5VD@F^;K"*V*Q;31VVY<R9L\TZ:-AE%<WE;)[;Y>W=MCSZEA^#$8 P!@
M# ("^Q_0D'\&"7/JB5(&",)E1$/ K!@$62'J268R]06^W7\KA[,N2#@W$O&,
M SF-RW1,H'_&*\0'E'9M7=5QR.E^WT+0]2[2:K::-I-!5[Z\E.-*$IQITXQI
MTY5:M6K4DU&G2I4H3J3D\MJ/#",ZDHPEQKR\M["VJW=S/@HTDG*23DVY-1C&
M,5O*4Y2C&*Y9>6U'+7$/AJ]4UEZ$\>0"OHAHT-G/G&'06MK-C9YJT1<-7OX.
MX2"R(0Z'OB#,E%Y-L*:Y#.U%6932X8DW)B!RB*7WCL.U?9'6NQNHPTS6J5*%
M:K0C<V]:WJ^_MKBA*4Z?'2J<,)9C4A.$X5*=.I%I-PX)PE+X:=JEIJU"5S9R
MFX*HZ<X5(\%2G-)2X9QS);QE%J492BT\)Y4DK:<U@[ X';:2D!,";Y&)]_=H
MF/Z 6VT;\];Z,5"JZ4?.SRB*.M*O2E1E%W$Y$_6Y?.4XFZLZ/@AC@[,FG:8'
M8S0</+8\6 %DN2("3!GX<F@B[<-^7X<RQ59/4DGP]=N[0Y=,G*G";MDY0<):
M[TLV734YX4Y Y72/G.E_. 8U'J5A#>"A9$8<GS YH8D15N\-/73Q\_)_1("Y
M;IN[(D"+\B25:](;(D7KI^]^W>+J+=!EOF\FVV+7[*?B6:7)!U'91'B')Z#S
M06FCV9ATF1;N&J!5CPOK[%XS=-'3L3( 3SZPN31T@4CY9)8>17XP/QF+K>P7
MTD4+1&9#VL<M&'<,]2V/M5%>QK]B^Z<I!YQ#UW/_ %@G!I3MD\Z%.^]]NA))
MF7BAO:4A %$. ?PY=W^3JF , 8 P!@%/_OCRMZX] 7W"-UC)"''G*35W"X#;
M0X/?,VJ<S&XY&KE2M>YQ8",1E!NRDLG]*0J-06CQ<X4-C"E9 D9@HBY:"Y43
MVZ&2:2>V_=RZ87RQN^>[QE;'?O.\*XH3P9%:U]MS&*Q<?^ 3R*3OJP[D<& <
M5@]DS:8=PBH"ET2\D%(REW!:WDL:JCB6+DT2)]W'?OX]XLHX;N>P?^K;PPN]
M<WCNR]\<ET2V.I^9Y)1K]>81_P _S>16Q#Q"8)P3L5UZB>^G(WR8=-5.4(N/
M*2V\K5GL7)M1W"9!ZR> XR")HN$'K-Z7=<K=(B//>L>&"5^"# & 0J\!_P"
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MQJLDX;JJ(J<=[$(?> _\!9?_ !B_(M_F$>G\%?/PC]D35P08 P!@# & , 8
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M>(,G>F#Q9JX2:/MM^'6F;E1+OA!WMJIUPFYTW5WPMMNIUSPM]3[/OKGGK>]
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M!@# & , 8 P!@# & , 8 P"%GAW_ +EWW_&G[$_\_)I@KY^$?LB:>"# & ,
M8 P!@# (6^R/]X^/_P"-*I?^5;(P5<_"7V9-+!!@# & , 8 P!@# & , 8 P
M!@$.?,M$WS4$]]"2RUKAJ*R15\60WM?L-7M%3*JB$8EC>MZQJ?EOR9D?H.WF
MQ>.]1&J@*^Q^P@XE^4;XN1T:_#%68-D*VGC":PL;O/QZ+JR8V"# & , 8 P!
M@# & 0J\!_X"R_\ C%^1;_,(]/X*^?A'[(FK@@P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@$*O G^!<W_ (S?D<_S"O3^"OGX1^R)JX(, 8 P!@# & ,
M8 P!@# /D?Z?;8O="^FG)/;1SH=T_P"5NV/+[['O[IT]X;]IN.VFG'V>W/*"
MG"W2/U])=\][YZT!$;Q]3U[4P(M83=,EJ62\3>W)_;D?6J\),0O8TE:DUE$V
MEPDSJ5F2VG3$<\+C&4<59?=W'W9N^[)[755;[3%;S]$OIM\"8F"# & , 8 P
M!@# (6^R/]X^/_XTJE_Y5LC!5S\)?9DTL$& , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@$*O ?^ LO_C%^1;_ #"/3^"OGX1^R)JX(, 8 P!@# &
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M01=NH' 7\CF;,&CWT^D+H$B#'(KOR#=%0/V]']5Z&^_FE]R?OF55_P ('/\
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M79GJ:Y+(!RSDL(] )M&[:?!)6/G3.-J<[)0UG(T(>9[4, GRG0K<<\GR7?\
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M&-?QQD#+D180@5#M2?WI 82?!1#Q\R30=.A;!=7MHD,#9, 8 P!@# & , 8
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MF5=&XDSJG\KYQ/)96XV3UQYF=^3H&<F<$XD@Q.7-D*:[81"1M.R3%R28-71
M6\"R(N8-/Q>)]_)K#Y<N+BQG'7?_  <VKCX;O-8CQ_5'DFU7DJG,=@VIX\F7
M<0E,TK>)6,1L\KR3EK S"6DK.-E8\,9-A$/KQ4F3+3:NX9'Q8B*308JN6<D0
M<VY-]>N&UXX^NV^7WD[Z%H1O3)J_)4X,(')+?EU/K3-N6K!0>S$!P\#@=/UK
M$6**SMXLHC%ZMJ^&,2#OI7A,C).SY5NU9H$$VJ0C?+X+'\_R2(P08 P!@# &
M , 8 P!@# & , 8 P"NTS\6?CZ32>6G);%I_+H[*^KP=)U1);?LLK3D/->D@
MDCCMXR2OJY6DV@4)/V )F,P;O'X))KH'W*Y YBB(!T166P9<37)].Y9VY;XS
ML8*3?$UY(FM9,*BF>KJEL'2-R(T=%2*][-*-YGJ4LXL-*BY2P<GNA"S%,;#(
M\R".! P,:C&DC#R-%Q!.6S!\?$XGS[URV_,]^<YSG<V&2_%WY(F4]LJRI;'Y
M])I7: EZ +O3UI3<OL& *V7"+=+@8HJ0+N'H<$\G=<P\BS#=O'8V+C!.HQ"V
ML:B[IX&7#B>,=W^,?R_JS\WWQ:>/R;F9]D8M.2 F6(SMN+B9"U)\_A=8(6K9
M@"X;42IZ*O#JX:MN;'LB,!))*=1QJVVKTSZ$"]C +ET*6#+^SY+NY?/Q/HMS
MXP/)MW(RQC/P4_? Y_9TRMB?19A:4W&1*:2>?M(.RE&CT8:E^0O:#EM7<82&
M/V#-A)(VDD5;QD^';2$\B1!-KP^"^/J_YY(Z1Z"\=0+T38D:E4W3:$HHZHR^
MO,]NP9\@^Y;6)3-[\P4R1&-BPPB.(QZ0QN95E%20(XR4^],AQ*4)LU6A)R/?
MM 3QRYY33Z-<OAW_ &^.8_R/XA/'<Q;&/RP2NR6&Y.8DAB7S.1WU9Q>;R_N9
M5!'J*EC&02AX?5)N1QVM(I'8^LW:JL^QK<4BD"6$M5G;9P+Q/EG;N6%A;YV\
M3](%\9L$%V]ZPM2=R11VIZ+KNKZ0CC>KG$YJR3P.I*I"C@X]9]/1D]?GSEES
M)M'8&RG\H%?DN$D 6M(8#=1E86D5;/PXGA+HV^Y[OP[OCGFSH=,?'U4]!674
M4FK11R)@U-QOT&N"BCY5X5+G;;]+RV#G;#M"0'G+KE#APV#0E6/@0 <4-#LF
MTN/_ &;5!!J(;MA&\_5?))9PDO$GW@@P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MXJ["2 [.92.@\0"BG>O)6^79:03 L.C(T:EK;Q<V[2'?8Z=?63Y8?5^7H/\
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MTHQ?#7*#UNM]&M=MU>._HUK>,/J_+T&?^E>?J(G5TQG46C4WAWO/T7)8A,0
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MT'Z05[,_9GYC_DRU/ZT8XWT7GZC@75^7H/T@KV9^S/S'_)EJ?UHQQOHO/U'
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:91DV\/'+T(XJ*;6?'X[?R>LK,SYC & ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g104413g89w33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g89w33.jpg
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M1#7Y8,CX'0#R<]>_L(AK\L&1\#H!Y.>O?V$0U^6#(^!T \G/7O["(:_+!D?
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M5TU*C!R/U8*NQI8F2 AW$;"RH*8PO<N)99QJF*)K;ZWK6F'#2M;Z5N,?:?\
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M:Z;T#W;M?*$K@SH]:F;Z$"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% :Q.+!S=F9TTMWL-(U#
M-C%='K0FEK;S=H#Z%HL[#(5#%K%=*])FFA H!0"@-*\U\4QT1?Q)6/K"G--@
MGM74=TPS!.PDL*!I2P?S'V6V:;,ANF#6TW00EXNA"LW JUV.FOY14$0X.CJ4
MJ-@/(\G97  41FC/YJK?6]43?1FFN5?/=]%> W44,!0"@% * 4 H!0"@% *
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M89?UT;4H_I)A,;7I+5H]U"CLE'AA4CX_FX9+@;7]*CB;)C PC1RNE"%3I)>
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M+6*Z5Z3--"!0"@% * A7H!S>%7K0;W>_+L70E<>9GH0FI0@4 H!0"@% * 4
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MFI31BI_&,=GHHV$':>"P[IL?[&3SBTD1P=9J8?*1RWTTJHK!0S;-OM\,\GB
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M!G1ZU,WT(% * 4 H"%>YG\9J%UU(;]1/^@)J4 H!0"@% * 4 H!0"@% * 4
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MC.DY=0&1;H*H(ICP7^E--,?/<8)B;>^;ID3HV?C=:L2HC3E!P,Z*$1D.7%W
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MO,'/YL6;7@/@/?\ $V'=4\+\+N'EWFX-K";J+C7-O<YL2H0* 4 H!0"@% *
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MY$;V;MPAB)Y E')K8*ED/-QV8K65'+XCQ6LD]6LDW5/%O@7C*Z4I> ]^\)\
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MUC*K1G7M--4Q55)TU[4Y*1"W+U>U[V?8C& VA 0#\.P7(^4_N5%>MD']':P
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M1E+E.RCJDIMLA+Q*O1X[Q]4W8#V7.>ORQWR*,\EB.I;.160VVV7Y123O.%*
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M*X,Z/6IH=TBUXBB+.(LN!-77R-H0NRYNV80F,@H/#*VK+&+-$ E(J>@/!O\
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MBX)QPF BE$S B(6G!S5IZ;R2IN,8U/NH)]GH\8QQ[@"E1P'D;:: 8=0(Y(#
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M7N;^X).?K,M#W!9,UR5JPO\ "@++'R<C^=;J_=>L?^[V,JQV1W:[,>.GW88
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ME77R"G7!Z>YB+JV8V V2%<!Q.-$U*>S42FC[5#( &@1B+<O%,3125P**>1G
M=0LLE5DQ<8H6N4,% [#AC@JUS(FBXD10@UE<5EGJ[YUW9J"3>4O,5!M-[*5'
MLMPW"DO3RL#-M)07D=+([G9<"OQ@2V59*L[ FP665]G'U4P3->+""DDX(ZHH
M+2.,F<<V%U51,Z9UN_A4TK -[B&K,B,%4;<3[$Q%LH:AV)[Q\@D#DW*4&QM
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M)*&,&4P)3O*KYN?#3C!L J:'(8&N^XDQC)4L8%+V#S& !$RR#Q&37A+S="%
MC8KG)[-]9O8SVUOJNP/)?N?V6XL9ZY\:0M'LY,?'IU;!B"N>GI!0%USY/#S$
M'/UCI)[+QW5"LL.Z/:;QLN[GEQNBRVP,O^C$=K?F]RM:'("B%Q>/26[8_?<-
M>[+"%5JRO;:(;B:$[7'G>5[F_N"3GZS+0]P63-<E:L+_  H"RQ\G(_G6ZOW7
MK'_N]C*L=D=VNS'CI]V& .DKW2S=JL;]5TK^]EL"T!6VCKL*LW&JYY#)ZLS(
M]J<RUI7+#X%GOI37HEQ3O5:_%6!\9:C[-GC4Q6D2F8H#95P>O2 (_5GG/MW
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MQ5TD;1>]3-%6ULAM7D/%D+U:':ADIW-K$<FY7V9@VD5R,V * 4 H!0"@% *
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M$JQS-#/(O^*WBB/IG*)Q63BJ\@FO"2=U%!5#:*MIH^.6(9@FHI*L1-IZ@0.
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M_9K^(^;KL_N0_P#_ ""\O@=/RE6"_6N3_O*?X1\'IW\V1?[-?Q+8_ _VD@B
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M3:T)@M_&4D)PR*14@'2BG%DL(LI 1@3^;?P5WZ8I2E]ZTKO(;UHY93V>.O\
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MNYL<=60UB.YMD+] ,3.XC&6O.R,XV(QA,#Y<BI'*G 3[2V8DL/8D%6AU"0&
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@-8G%@YNS,Z:6[V&D:AFQBNCUH5O(T^KB/_P $M3U$0H>4YM0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% <6?/F2\/PLX/5)N@+N-#\Y5IWTYZ
M>Q?X@C?V"Q)0\K&"Z?4A$VAF* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!%W;7ZN$7\;)OJ)R
$4!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g104413g92p79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g92p79.jpg
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M 0$! 0$! 0$! 0$! 0$! ?_  !$( 34")0,!$0 "$0$#$0'_Q  >  $  @,
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M"!"'>+--+?:&$$$&;4\0240\I#(X[#*%NO/.K0VTVA2UJ2E.<X] )( !))
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M!^<56$F%6/\ 57EQ^]O;4%X+SS$I>CBA9O;T:RO&AVWV)F4.5\GR5Y>WCWU
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M^A<8E95.?X-5!_#V0:Y7L((9C9X88A#2T C@F%M5+#[+:Y!<C+7DD?!\Q$/
MYY[(5<?23IC#ORKPN'RUU?A;(W0%YH=O/IX'79$)(#*!_5)?73@DGG.1M*5D
M92E6 D[5X"3Y(V'VL@.[$C< D>-]EZ<\XO5MJN';];Z.K^]<CS;U?=SK:RH2
M>P(&:X\ET);;D/Z!S+['DL3:U5]Y]+>"1&I-903K!K([[<JA5FNW\?5KVY*,
MT]^BB6X5A:2 FU"2ZK/'+%^:"I+QMLI)79@K#T6(*HDL6:D5Z"*&=I:L[3)%
M,G9D!5F@EAE''<..,B@LH#<D+*=4Z*@9B.J.JL/YPVV2);)M"UJPEO 4U>+-
M,B/85G.$I96$8R\G/CA/D7A7CC&>6_5DB2]1YB1"I!N2*Q4;*70*DK;'R-Y%
M8G?V).J[$JRXR@IY$FK"=F/)OB0, 2/SB 0-_GMOK3]\]Q<5BRTW5G7R+@=R
M[=N)T>XB+!/7(UR'A2AL2#;LC)PI.&L'2,?E,BW_ ,:V) 5S!%NGG68Q$6--
ML1@UOX^SF;EI:6(AA9H;8"R&].0>S#33D.^'?PTB$H-BH)8-QV6[35YTII$T
MEQF(> DQF%%([CSDJ3%Q!&RL S$[ :O0C*\H1EQ*4N92G*TI5E:4KSC'F2E>
M4IRI.%>.,*RE.58QXY3CQ\,<]J9KRXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTX
MTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTUJUCN]/IY-="M-G@Z\7;9IBNU@:7D
MA0'YZ=*QXCQ44V0XA9AKV?*AMAG"EJ<<:;QCU'FDKW15YYQ*T,,LJP1&:<QQ
MLXAA4@-+*5!"1J2 7;902-SK%G1"H=U4NP1 S!2SD$A5W(Y,0"0HW) )V\:V
MGFG66G&FJ<=S>ON=TZ^:FZ[&MG;$H"#I&O"X2WA=EA2T-?2.EO9<_P!-?S@<
M9@R)]3*<-S\=&MY?'#+D/5Z?I7.M@\ARD9A2MA8;8'DH =XK*@>[P,22 "6B
M:5 .3*179.B+M?B .]$2\)/@$[?$A/R5P /N#!2? (-4>G/9 76, SK^^+ER
M=>$%&GU6Z*'FYH^K'&/K>-J5J$0V?*,1K)'J(ASDCI3"J2Y$23+ K8Q#%UU#
MTG K/<PD?F>:6S9IB9I>[):D:=[=-I7;[.1Y2QK1L$B5E-9%B^SCC4\S-.4B
MR#+RAABKQ3"*.(".M&D$<4ZQ(@,B(B@SN"\QW:9VE)=_GK&Q8T#O//[W.'/'
MU;?&DZMA;+*1Y44R#@BNT*- L!0\DR*6##GVNI$Q;)9++7@'-#2C_H@Y=4UN
MLT)#T77QPV]?3M29.S6#*S]LM8C90%)WD2"2.5E&Y55=3\0(UJCG7ZWDG)^P
MFA6K%*1LO,%7'D@>&<.BGV9MMO!!UU]_K_3GSC5_IQIIQIK6;1=*=20%RERM
M=<JD:VE2UGV.;C803"4XSG.?7DB1F\Y\,9\$I5E6<_=C&<_=S=!7GLR"*O#+
M/*WYL<,;RN?U(@9C^S6+.B L[*BCW9F"@?K)(&JH73OMH:LMD(KY5DV&:RE6
M<-U6#?&B\J\,>16;%9UP$(\.KQ\<OQADEE*$J5AI?\J5=-3Z*S]LCG62DAV^
M*Y((V\C?_HH); (^8,0V]O?QJMFS%"'_ ,4RGSXA4O['8_$>,?O_ .?59R>]
M^]]FDO1FC=.!N*QYV5&!Q]FVF6/E:<^F\41""U>M5]]/]4)ECY(3*\8RM;K>
M%(5>#H_"XT<\YG8T8;$P0&*!R![A1(9[$@^_A60C]?M$^MKECQ2H.P/M)+N5
M/W?F\8P?US?L'D^+>BN]VZ_%6RMDR-!A"49]0 VUCQ:E-.)3A+3M.U'B/BI0
M;R9SEP2P65I[SIPEY.7/%:<?K?HK%C^@8A\E,/\ Q+*<HV(/@\[O=*'QOO'4
M7]7DZ>ES-D_;W$K(=MUA_/'CR/LPFX_7*?T;:D^C?#4U5!^#USMMGMA"\>)0
M<$.!0X0IQ6/YW7$1GS&TX<RK[\+1;DY\/^?"\Y\>0[77^6D7MT8*>.C&_'MQ
M]^103\C-O"-OO6NIW\^-;8\%4#<YWFLN?),CE03]_P !#?X%R-6WHO731VMG
M6"J=K"I1LF/C&&IXJ,;FK-CRXQC'FLT[F2GU8^[&?*J1RG"O'.,8SG/.7N9C
M*9#<7,A;L*?/;>9^R/._B%2(E\_A0?+[AJSBJUX/^C!%&?O1%#'];;<C_B3J
M:?Z?TY6ZWZ<::<::<::<::K!W&WN5USZ\WW8L$"_,WYT4.G:HK@</,6,ZQ[6
MNQC5;H<:Q6ZY'R]CGA1IP]B:G@(")DY9-8B9LT4$C(BD<N,%C5RN4K59&$=8
M,T]V5I(X5BI5U,MES-*\<43&-3'&TLB)WGC5F7EOJ#D;9ITY9E'*781UT"LY
M>Q*0D2A$#.X#L&=45FX*Y"G;7,.%W/:=E]/('0UULMLONP-8]PNLW7#9,KLJ
MK[ TU8M[ZCLV[*._1+1>*W=*W&WN(@-RZW)#J^Q'3H$\>Q347LB-PS889Y]@
M_KY,?#4STF2KQ05JMS!9?*U$IS5;\6-O0XZRMF&M+7F>L\E"VK3U DJF*-ZC
M[Q2 %:-+,DV.2I*\DLL&1I4IFG2:L]NN]F(Q22I*@E5+,)$<W)&#LLZ[.OYU
MW?AZ(DJ[0]Y:EGX:+JMETUV8V55Y>DU"9)L>K*$'=HRI[MIU+U!.&QD"<70J
M_0=J541L8ZM5(B+LF+'',5&N10\9&,\]U04ELXZ[%(\T-_$5)DL3QB&Y9:N\
M^/GL7HU>119ELTIF++-.'B[3&>:0NYM,1ND5JNR+')6NSQO%&Q>"+NK':CCK
ML50F%(;$8 ,<95^:B-%"J*KUGXGN])>E5W8LOUHUK%U:;T3H'LR0D+?-@DYH
M#5.YMB$ZT*BFPW=+1XAFPHV0'Q8XN.R<+6RX9QR/DK%'2K*,$W,W2&-2>6K'
ME[;S1Y+)X@<L;$D;7:%5;:N6&09EJNK=EWXM*) '2)T/BOCSEMXDG:C L;5*
MEX[6W9A7LRM"5V-909E(YJ-PA7<,ZL #+=@^(3>:ZF2V$7I:HO:&D=J[ZT/0
MYH?;12]PR.S=#1^V529UNU?G7R8BNTFR3VF[;&#KCKW/W&MPCL%;[!5F8^0E
M@JY"BZ7K2\*JY"<9):6,R5F,TE] M/)-2"+!<]5SEL0QWX'/*O%!-)W((IN:
M(99#YB6/E,U6/TAL6ZD+"P?4M/46P29(.SQCBD:M(HVE>5%X2/'Q9@F*B_B'
M;56AJKSNA*-&[4OM>ZA6/3$(+N:3(HQ@_<![;H58"VK=C-71YE,-I+^D[<3/
MXK%9O3<\](UNN554C,R+2W<WZ7I>9XLG9>E6ESD60E:@BV <&*32M2KK<=9U
ML#(0+'WIJQB"S33!(T('@S%C8(U2$6)DQ[UD%EC$?K$V1&+$I@4QF+TLA?MQ
MR\RR)'NS#6-MGQ%=R034S48OK_KF3VWKL;M5_%B/?W=-L:VCRNK5)TELB1=H
M%Q#U)(3=M$O%4W9!!B,2]2JI]/MXTG7; R\J%D2LYP=*T).$[Y.VE*T<-Z%A
MCHS;=<S8R-1!:KM>2.!J\^/D9C'/.L\!26(CN*NL9,S90-&*D#6(1?\ 4CU3
M=A31AK3DPR"N7D$L=E  T<31R!D<?"3KU3OQ+-BUZ*,BCNO )>S[)>]&UG5M
M9JUNOM]A2X/?&G[UNJ&D[N]3-.3%U$G:E5-9W >>K]'HMT'DIO$*)%3*(@J3
ML,0BZ2J3.KIE&%.&MD9KDTT%:M(LF-O5L?(E<6+\=<QSS7*YBEL6:Y2/N-)'
MW%2)S9N9%*M3!G>6HE=(Y)95*6Z\UE3+VJ[2AXTKRATABE#-P"MP+.DLZU[G
M;GV?=NO.NA.N8]&M6T:UO:X;+:V3;;C46Z+6NOFWM.:VLLQ3(F9U5'VJ\,W6
M-VIB<HPEF@=;2#!; 47;!H-Q$RN-A6\!0IU\I:;*FS#3EQT%,U(*\_J9LI1O
MVX8[#QW7AKFN]+MV3#+;4J6>!I 8^<B#)69Y*<(I=J2=+4D_>DDC$25+%>&1
MHE: 22B43\H@Z0G<!9 AY<9MZE]A+GOVMW9_96O8G4.Q*1;DP%BU6W.6^6ME
M.'/AH^:B6+FBUZZU^(J0)9,(1'SU#(O>M[8 (B=J-XE!B" X^OS>+KXR:N*E
MI[U6Q!W8KIC@2"<K(\<AKF"U:;B"H+Q616MP,W:GK(0&>3C[DMM)3/"M::*3
M@\'.1I(P45U[G<AA!)!.SPF6"0#E'*PW"VQY2:L-.--.--.--4[[G=<8+?&L
M9:21#SDOLFB5NS&:Q:A99\53DX<W'E.Q;T61*QL#(-SRH8.*(>D\^X!%??(C
M"!CT,.8EX[)R8/(1YJ&"U=>K5MP28Z"RT29"K:$1L5&@DL049II.Q&*LMP$5
MY-RCQI+,'V=I;U=L5+-4JP6[=.5KMFLDK4YJYF2&RMA*UB[!%$+,K3)4&\NR
M.8WEA@:/0^CN][IMNOWK5>YAXMK8.J7 :K*11Z"%V:<AVF"8>1D[:R0LF)//
M9E0RH*8?B7WQBBF/F)3+(DY%.&3\]BI:=Q[4:5FP>52.SAVB=I9%B>"-KE2Z
M"IA2:M8D9%CAEG45VB[DG>[BK'K6:SP01QRVCE*AECR?<CCBA[J6)/1V*)60
MSM!8JK%*7GBKN)NX(T,81V@7JDY):U[T;_U%6JR/2]?S[4W8VZ[/QR8<YB-K
M1XQ<"[1PHA]^);@RC]@2JHIA?IM+J((KC301@C@29%U[%[I3I>U#36G3Q-C*
M]/313HL,XCJ./JZ2E%7>6$T9:\8[)<PND B0PQMO&,VCK09+++8R+Y'(WX<9
MF$E@D>Q &O1R&]%?FLI%.M^&4!)0@FC><2E9I%'/77KG.Z]U"W\>Z G>.>OK
M[TH+?EU5NV!J*!;8@Y(5>'WE1L:>LK!!DLT ,5)K9;!]GD(,_P!(YPJ./&&G
M_5MOZM^M0BFEZKT1D#J66?MB4*T8/-5*GX7("D^ =]:N_%WO3E@)3'W0A\$I
MR*[@^QV(.X'D>_MJE?Q-3+2=5--Z\AY]J/A-F;&'KDS"MQGK'RLCZD?]%S&Y
M-1B$,AP\^4&\]%J!=^8&OQY.2Q\1V&2+GH^*PF8GRJRP^DPV&RER>M)7:22:
M<I%%5>*P)D%?LAK!=3#/W@ZC>((2T;*M5?&O1E@F:U?O4(*]F.RL<=>%6FDM
MI+6:"3U)G"Q*C"> P!'8=PN O1!.:MK"C-X((#KU+H%6;0X42M+ ,+6JQ%)1
MEUY?AA+8X,:%YE9QC[D-?RXSGPQSG/M;,W@-+//+X W9Y)97]A[EF=V_62=3
M?A5?.RJH_4 H'\  -<HM)ZPE>[.Y+5V V<]9R-!P-OD?X8Z[M$L9)1L@4.B-
M#) 9C2G'0HZNH7$B'W*- 2H.3LKKM4425%P<PR?V5Q4Z-IV<12GDES.6"3YJ
MR\YG%&*2O"HQM+< 5H_AYR1H7VD,DZR*UDQQ5@D^N9*UF2**.E21H::1Q&!K
MC"5G-RZ-_P"D.K%DA=P"8A&I0=O=^Q"4I0E*$)2A"$X2A"<82E*4X\$I2G&,
M82E.,8QC&,8QC&/#&/#G$:M-<T=K[SWUUM[&YM&SB!)3JWL.P 5J!PQD!Y=*
M8&K\2HN6=>&B@CP)!B1Q-SA $@=*MS5>!G5"X8+B0,N=+AL=!F\7E(5KQ5,O
MBG:U4D6Y),,OC!766=I8)(D2I9KV.=>.*%Y5=!#,\F\SQP1KTT=.7'/'/+/#
M<B[5N-JJQ>BR+VVAK0P2I-*UN"Q7,4KS/' T4[/ (V1!,_U?$0OOS?K'7)#7
MMQ D:]L6ZUX!"X',3,1UX@QXZ:MS0@DWZRT!@Y,JPI+IT<XI1.&<QA"T"&$Y
MQCT-"<GU!B+M*Y&U.H)\G*\*0V8[E9:DT4*QS%BD8]3/7L)/'S.\(0 J[;>9
MQDQ]#*4\A1E%J5!12.9Y:LE*R9XFF>6'B'E(K16(6KR<!]H6)#(!JL>G[+V.
MW'2Z[H;K16W=*:8K=74');)L@LRB0M2\EK"MAH]NP)-QS$Q,SQ,H8]6Z2Z\9
M$D8+9Q<P&1U"C2A1Z6Z8O6,?DJ]J_D>,V3;'4Q,<36>_<GE>O8R<H=)[8E:2
M:>MW"\:2Q,]>2)]]9V;.9S-=,JD]1(I)8Z(EFFA3(LM6M$L<J8Z())%5["I%
M#:XB-I$92XE4@RK3?AO[1U69&3^JNR@%,LP07RMTJ'UF;'"JC2BQ##A76UW^
M4&E1LDACEK#E8U\>1('0HCVV7%+1,DZJQ$].''3=+U5H5(S'0K5K;U8Z2!6$
M4<"05XU6&(LQ2, ;<W^+XB=0#C[ALRW#EK<UJS*)KMBT$LS6Y3L))9I)=V>:
M0*H>1BQ/%=MMM]=:FDK0VVEQSU7$H0EQWR8;]1>$XPMSR)SE*/.K&5>3&<X3
MX^&,^&.<-JVUY\::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<:
M:<::<::<::<::<::H7\01_1Q6I0J_MFXJI5H+-,F]2S(<7.2DJ);8(=IM;S+
M<"*^4S%K1*# 2Y#CX21TGBF!E,RPD<^SU/2<>5;(2/C:8O0]AH,G7>:."&6C
M8/"6.6:62-8RVV\3!N2N@8 J&!K\D]984[\W8<2*]:0(9&2Q&>2,L85N8'LZ
MD<64E21OOJ%^HO?*I?16FZFW8677[M'#5BKUNQJ;EY\2X-GD P4&B<*91)2$
M59</OL,RTG+91 R?D<F6I05;Q,6#OZFZ27 0+;Q0L7,,CUZP2$V,G<Q[2,D,
M:6WB]5/+70E>[D)G=8D#S7I453.^S'Y*;,69EL^GKWY%M7).X:N,K6!&DEB8
MU8Y#5@21@K=FA BO(Y2"E#(Y6%>KG./U,TXTUSTNE&K\#VD?CZ8 TM5XI:KG
M=X$5*' HZQ+F28X6?]M]Z0"+8PT:X:A.&V"3(5^3RW[N0,??[7&W)7P$HLR$
M)3M)!3D8_$T<D;22P*?<K"PC91[J)^(/$*!3V8D6ZAC7XIHG:4 #;="H5R/O
M8$J?OX GR"3LUOK]9D6B*5:&HGSR(RVU0Q3P>'R1W4*2K+0N5^=YI2<YQG*$
M+3]V<9_IG'/:L\Z\;=<R[1M_U0K\5(/LS$;#?[CK"1(S]E)Q^(>%W&Y!^:C?
M<^V_CYC?W&M9@GM^:V%'B:-?H:SU@+"6H^!V9#%SQ$6$VG"6H^/L49*PD\H=
ME&/(Q\Y,F\C(2VRQEL9M#"?)ZN'NGN35YJ<['=WI.@B=C[L:\BLBDGY0M$N^
MYX^=9QS6H0%5TF0; "4$. ![=Q3\0]_+*S>V[:^:[]EM_4Z*<-DXK2\-AM"U
MK..5:31T-HQG*EY#Q/12\>&,>/@H_P ,>&?%7W>/-E+IG&7)0D=O(2DG;BE>
M%""?O8O*/_\ C?V\:\FR5B%>30PKXW),S'_'8HGC_'5?<7[NMOS/HU FYJ@"
ML(QD^EP<?JBFK9>QE."P[O87T6*2&1C.<N_1JS2CR?#Q0*IS&$YMS1Z+POFX
MXMV%_P# >8WI@P]PT%80UXV'MPLE?T[D$B+WLS<_Z*B",_\ B<.TNWR(:3N2
M,/GRC4C_ +:W6H_#HM,R6B:VMLL(&1>5XG-U0<VX61].?#/BYL"](2ZI_.?'
M#N7JH9CQ_P"1]7AA>8T_7<59&APN*AKQ;;*\X2-2-SY-6IVU!&_C>P_WD'6:
M81I2'NVY)F]]D).WM[22\V^7R1/T;'SJW=(Z8]>:2X.7FC,W*6'RE6);8)A%
MP=R\GQ\I#43)Y56@7TYSXH<C(,'*,^&4>7.,9QRUWJ;.7@RS9"9(VWWBK$5H
M]C_5*P!"XV\?:%R?F2=SJSAQU*#8I7C+#^LX[C^^_AGY$>?NV ^0&L1*=S^N
MM"L>RZ+/2LK5LZ>DJY!2BP:;,SD5(+G:M:;6M=4 HH%BE2XVKQU&N;%N+?AH
MX6M%5B4P>IL1#!;]3Z>9PC#9C+N1NX!!#*OQER "Q9"OD\N0V).X%XF,MR)7
M>-%860Y1>:QE>,D<8#F4QJID::$Q ,>X)$X^3L/38>]G7"!C09#%R)(<?M$5
M79.+/KMGJTQ6Q2KF/1INS62*M\+!'PM=JDTX4/.2$@..V@R.-B1,D3#> <XB
MO*3MQ^6X((8-\'-0I4D$LNQ4 ^00?;SKU<9<9^';&_!G4JZ2*Y$)G5(VB9U=
MY$V**I/AE8[*=]8JU=^^O]9C+,:@NZ2QU<KX<W]'1]?W("U&$%NWI#D274I:
M$!M=4<C1J!*RDO-W:"K=6CX:0@I9V=R#*CO9]%:4E1LOQ'PW-"FWP^0X)5OS
MP-E+-N"-MQKU,7;=HQM$HD8J',T1BV'9^(2JYBDW,Z*$B=Y"P=>')2-;58>V
MM*JUWWE4YF'D&!-$:SLFR[#*MF@Y*E@*=6*G;K(%#0I&17C,B1-WKS;1@A9;
M3,BZ\+/-5]LRL$V7Q8'98R/_ !75%_6S,HW/L/*-X.VX\C?9N."8^:2.JZ[?
MTN:.&,;'8-+)+$A=@"%W>&3PVQ*CDO+C($TN^=\-84E[8$*F(EY.WZUDH.-L
M<(LN.!C5YD]<WG9<B5'6)MV0%<#@@-97RJR1<@+&!QUW@%QT\3!5]QZSB>K7
MD81GQM)N%V!)W#*NQ7;<D\U8 ;DJP*@GX=9QXRPZUW^$)9Y=L@,6!$T4(#1\
M0Q9N_#(JIR+Q2 H'?[/5JM?7D#84$;. "$ HC[;>J>4*2Z.\M,A0[G.TTTEI
MX5QUET*2?@U2L8YA6'%QIPBB&F"<O,-:G4H0"0=U1MQ[;.H<#S\QOL?T@[;Z
MARQ&)E5B#RBAE!7?;::))0/(!W4/Q;QMR!V)&Q.\<QUJTXTTXTUKLW4:O93Z
MM*V&OQ,U(TB=<M%/,DP1S7ZU9'8.9K*YZ%60A>8^7S7K%/0N) ;R%(C9B2$0
MZEDQ]*]L<\T*S)%*\:6(A#.J,5$T0ECF$<@!').[#%)Q.XYQHVVZC6#QQNT;
M.BNT3F2(L 3&Y1H^:;_FMP=TY#SQ9AOL3J!^P'5#4W8H)D:YUV"R27:],S5N
MD'J[%2A5YJ^E-@O;#KFOK.HUOQD*PN4DK"RPP0I[Y1])9HN.;;(-?]6RQF:N
MXIB:\LNRP9".!1*Z+6FR%459K4(4_#-P2(DC;GVHPQ(4:B6Z%>X-I43<R5FD
M;@I,J59C,D,F_P"='R9QL=^/-B/<[R_KG6&N]15IJG:PI=;H=7:./E/DM7BA
M(D)Z5E'\E2DL8@5M"CI:3)SE^1E#5OGG/?ZA1#J\8SB#;N6KTQGN6);,Q54[
MDSEV"(.*(NYV5$'A$4!5'A0-288(:\8B@B2*,$MPC4*.3'=F.WNS'RS'=F/D
MDG6KL]>=%#PH];8U'KYJ $H]:UH+#MU:)3'#Z^ILNN?J=,:$P-AE%;KDVXN5
MAHE*<!@'K44.TV[G*N;CE,B9#*;UHRM8FMES,_(VK"=J>P3OOWI8P$DD_.90
M 3MK6*=4($%>$((HX O;7B(8F+QQ;;;=M&)95]@?(&L&7UCZT#WRV;F.TIJ<
M?85H@YR,N6PBJ?7VIR5A9J'3#V94Q,.B)6KYS7V$1%ADG7$ERD&.U&RA1$<.
MVPC)LWE$I1U'R=M*%5EGCA:RZP0&%C*C@%@J)"^\J D)$^\BA6).BXZI)8,J
M4X7M3@Q%UA5I9>Z A3PI9FD&R';=G&RG<;#7S@:HZR;EHA[X>N]7W[7U\I=7
MUO(>K5HB3@[%1=4SECS2:L\T6%E!$+0;%+64NJ#X1ANORIQTC#*&)=P1F%C>
MHI;D%3)XG,/8KM-9NT[M.VSQ/-9*PV[$,T;E6:QZ=8IW4D2K&$<LHVU,R.$?
M'V;.-RF,-2U$D-:U3MU^U-&D:]V"&:*10R=M9NY&C %"_)0"=?5"Z$ZU5$&L
MZT@M7ZG@!(BG[$@:K3 H"O!.LTJ_D0Z=K#1T0EI!1,1<#F8-=\*PT\F</R ]
M.ODEO-+<DS9N]+:8S9.=[EEHK9$EEC/,<<52&=4+<V6D;")&ZCC7[R(O .H,
M:/&PK7YQT5%6 M6+K!]A$UQ7=H7<+P5[2P2.48\IA%(VS<&(R-CZZZ!N$-8*
MM9]1:YGH:S TL6P1$E6(@IJ1$UXTX-KY9#:Q\N-NTM'J(J1K2FB8%:<JB7Q7
M$>9.4.5R4$D4L-ZU'+"9VC9)G#(;9WL[>?(L$?; [K+MLX8:PDI5)49)*T+I
M((U8-&I#" ?9#V\&+?[/;8IONNV^LY3=)Z@UVFHHH>LZ/3D4*L66ETQ-;K<5
M#XK-5NDU!62X04/[$9GV<?:K%6:_/V-EOP^=S40%*R623F</\PL9"]:[YLV[
M$YLS0V)^],\G=FKQR0P22<B>30132Q1$_P#3CD9$XJ=M915:T/;[,$47:1XH
MPB*H2.5E>15  V$CHCO^)E#-N?.OW5NE-1:0BI:#T_K:EZTB)V7<GIB-I=?C
MJ^))2[@PX232V8YAA#JQP! XX%M6/1CXT02.!;'"&88;7,A>R+I)>MV+<D<8
MBC>Q*\K)&"6XJ6)(W9F=C[L[,[$L22@JUZJLM:&*!7;FRQ(J!FV W(4#V4!1
M\E4!0  !J3^0];].--.--.--.--<6^XE,L?53==6[*:7'A*%7K.7F"N90Y^)
MN2M%TM<C89JS9<I$JD9H]F3@H]MY2VK"@==C JJF(Z-3'$'*O,%RNX_(=&13
M8_%>O:3(].7)W[TDG44]F6YD*JT7["RM8JQ3RQ.+O@SW', 6!%EVVY4,U7/W
M%R.5-"-:F9IPPI###@:M2&GC;+9&,3S0""Y+#"\8J!62*O&97DL\H-_L]YIH
M'Q']'706R1R*YM33U;:AY1I7@-/$6Z+V4)6&?4\OBI4T]&038.,_>I[ C2\H
M\/!-D98:O0]Z.XZ5G3J>G7C$["-FM30K M9 WDS.[E1'X)((_.V!K(:UBWF5
M-2&2P4Q%FS-V5+A*E9C/-.VV_P!G$@,CM[*@+$@ []9><CJ=KG%W4ZR[#MDS
M'=BM&V:SB[DH<?'A1\*$[&/-Y@HS,R_[FJ@D@8R18!R)DUTN)/-(!L<.7+0[
M0N32A62+S!6H8_K;%Y"];AQ>=HBH2@AEBQ-V,2&KEZL#Q'>U'(R=SO/+ 1%$
M7@948-KM,I&,FCH4I[&*OFX2XL)+D:TAA%C&7)HK,)]&\<3!#!V+$9EE*3\F
M7C2W=?:>H;@CNJ\O)?/H?8.F=KUQW9E?L8R&C5+A#ZQ+3MD',&# CB6/=TXU
MHX5R/A9:'.*0-)5V*;)"21V&&Z=O8F'.5S*M^G?Z>N)1RL+1O'<:#@0SB !8
M99EY\TXI'RYK%NH&U)>R$%V2I82'T;199.Y0;FIK"3N*(T$SR2/%&KKVW,DK
MLG'F[/RU;7XD&R; ]7Z'UZH0,U-V?;,DB3F8VL ?.)Q^JP1;#@H 4:DH/W:Y
M662J54RLID8R(J,X"4ZV*2ZZCG>FNSCXLKU/9KRVHNGJGJ:U6% \EO(N2*D"
M*Q56+%&4 L")'B8$$;BRLQ/=GHXJ.Q!5;)64@FLV)#'%6J^\\TC@,411Q4MQ
M8 ,W@ZZ$Z^I=?UU2*M1JJ"N.K]7A08F-%=RE16&1F4X<(/=3X^YDS'\NF2A:
M\J=,D'R2GEK=>6M7-V+$MN>:S.Y>:Q(\LKM[L\C%F)_Q/M\AXU+5%C58T "(
M B@>P51L /T;#6X\TZRU5WN=2HR\]:-K 2+?F?@ZX1<(1U )<@^S/53PFHY#
M P Y1N?F2A7(4O(K#KF8Z3,0I"FEN8S88O,IT_>@R\K,M>F7>WPCEF8U&1DL
M@0PQ32RGLLY$<<,KLP'!&;8:Q;'S94ICZZQ-:M2Q1U!-+%!$+?=1JS233RP0
MQ(LXC+O+-%&J@F1U3<ZXX/;&DNS,3TYT%6PR9B3I\<97+?$1A0L!@R-;DF16
M36I0CT1H^4$T_29.=]\C"E8*LGE99(,<0-GZ')6FZ4J]5YO&5(I5?ZNCPL3.
MM1#7R<\4[20AXBNU))$D6$QJ6-8Q'@P(%+&T.9M8VKD+CP;-=GO3!&NR&S02
M6-8I"DF[BS;3L//S90)>]\2[ _T',,5?7U30P,S&5>G4V!SAMEAML*)@:]!
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M&2C'E(\%X(C)MX26AC<(QG#K)8@A24_<M&$YQX\E8Q66IR/#8H7H'\JRM7F
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MJAZWURVE69ZNL-0- V<%9,S==%SZ$+#6ZOYCS/F$,%C'H1C-ACI(APV/#PR
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MXC9F-LT"_'PD\/,RD6\Y(B &1RPB"%,>9+"<DXE8[,YRWALG7?#W,?U-B<:
ML>5C27&Y"^U28U9ZV0I.E6[5GLP'U"0O5LUPP$U>MW(BT7)87!5,WB[*9FED
M.E\OE-WDQ$CQ9/'8\6X?55[..O));I6J]6<"N\T=NK8*DPV+1CE"R-H@NBWF
MC5G<E>J%6A+#L2 #DK-+0]> BY$R:SGT9\8LYMCY@:R/.BFM(<++)R_AE!&7
M7LJPZJQZ:FQF5QM/J.E1J5I\W3KV[4\56*&S+*\:]R.Q*J"65H90T>\COY3P
MQ&Q-;U/#E<3D[O35^_<M5\%=LU*D$UN6>M%$DA[<E:)G,,*SQ%)=HHX_S]BH
M.X$X\Z+7-ZJKOVM22;_IO;:C(2JTW2S]RMM_OI9QZY<&K/0S(LE50J\%'DXE
M@[*TGQ-*6]AV,0!EX-EPEQM@OC>I:,QRW3F=$M6E0Z<DRU_+9*66;U"XZ3'/
M!+CX:T<+I-!<D:*U8DDE4P''0M%%+*Z%.TZ8O0C$]2X Q6[U_J6/$8_$8V**
M'TS9*/))/#D9K4DZ/!/3C66K6BCB<6!DIEFEABC829*A]FJ+M*S,4Z/J>RXL
M"SQDV54+59:<;"56^ 0X[;DNJLR#C^3G/2$?]=M1P$=ZK2<X0M!*F6'=V+ZN
MH9BZM*#'YVO'9AGFH9"_B;-*ADHZ_ 3FI+,%F4J)%9!;KU3.F[UN\H)&G+='
M9##47O3Y' V)*LT$.0Q^/R]6[D,9+9[G8%N*$M"P9HV1S4GMBN_&.SV78*:F
M=0;MI'KI3=H1%^E'-96T>\ND$1VQD38>R96@$M9*UE@Z#,P868_'0T@8.F%J
M;1X4".M"'FV%/^=SANB<ETWT?C\Q7S-R+#9%<G)(\>:LR#.6<0TDL/3AGAFE
MGDFD7'Q]B"KCS*D:QGE%%:DGC'>]<XSJ7K/(X6QA*4N;QK8N*-)<)6B."K9E
M(HINI>Q-#%!'#&V0D[]BUD1%)(7!$TU6."4W+V1K:J]CM:L-1,VN#@]@BT^1
ME+*!6Q46&QT<$U%B"@%N3P0\G$)(<?24(X6-[J%*<=7\ORMXH=WZ#F,12ZLP
MS5A8EKU,M%1DGLP5XTM6L<DJVUJDVH#+ LRLRAFC6Q6,LC1B*8DCYWA<S>Z0
MS:V&K16;F'ER$=>K8LR/4JY)XGIO: ISB*P8652561J]H11K(980 9?L%3KM
MKK9U0LL2+-UN3"1'R,1(I40*:&WEM2&2,*5YW,86TVO"\K\_G0E?F\V/'EW:
MJ5;U6>E<@BM5+,306*\Z++#/"Z\7CEC<%71U)#*P((/G5#4N6Z%N"]2L35;E
M69+%>S7=HIH)HVY)+%(A#(ZL 592"#[:K_LO5,N[MWK=>J77H\^$UW)6*JSL
M'G$4+%5NHSU=4R'88@(I;"!28 Z*!$&;A6EGK;+&80RD-AY;7-9;"3OGND,I
M0KP/#AY<C1M5V[215<;D*!"VZL; !+%:W2I01B "3TUFP@VC+ZZC$9RNG3_6
M6*R%F=)\S%C+]2PG=>6WD\?D07J6Y%W+U[-2]=L2&PQC]56KR'>4)NMNV;-=
M:/O!KKQ$%F; UC:1JJV=*1D8F$L5BC"(8FV@P#A!JT21T7"K+BUYDQPLXE,"
M(&04,L5]Q>SER]C>HOR6KM:RN$O#'J+$<:5KERN*=B_7J2231I+)%7FDJ!Y6
MAB2^AB9BL;-I0P-+'Y/IK\K+"U,3G:)R#&M([VJ5.R;E?'V;D<<,CPQRV88K
M92)9I7Q[B55#R*NJ[3.\:M IW)-ZEJ&YX/L3M]5<BD:_M.N)II,';(N/:@(N
M9:PW$E58=?RL]RP&.%V"21(HCFB21F1U99>Y2SU)4KQ9ZW@,3U'6ZNZ@:O7C
MQF0P&4"196O5AI5;-ATK28R*"*O+#8L6#?:O8@K,5E8Q,!UU;IFW8FZ?I]19
M;IJST=T\+-F3*8[J#%%YL39MS7;=6NC68\I--+9AFK5ZXQZV*T]H!HT[JMJQ
MEQT+;["YK^[0&V92I[JI-(;II][;KT%+Q-Q%?3'ES#<_5RAF0FF)&;"7(-9B
MUA)!]Z_A SZF0/9]3E.F;MR3%Y.CGK&.ZAQ>/EQWUGZ.G:K9""R:DMJ/(8Z1
M$C:.>S3AL#T<U.2%BZQR!"%7DL5U11I1Y7%WL!6R73F5R4.2^J_6W:EG'SUA
M<BJOCLC'))(LD-6]-7)NPW8Y5"-)&7!8[O2-Q4V5GQM42^P:7-[GAH5#EO@Z
MS[P8/,O'L,(L&8D<UPK*6A#%KRY&+D2I./9\<'--J:>\EEC\]C9[GU%)E\9;
MZBJ54DR5.F_!EE1(A9D2LTLTD,8DE5A#)+)+"DL8D8[AFK<AT_DX*1S\6'RE
M3INW;>/&W;J<PT4CRFK&]E(H(YI3%$ZF>.&*&:2*4Q* I58YJ.K[K8]S*OVY
M[EK^W2&LPCX_7-3I0)X+%:^DY+CWTRLL9+'R)05K.A1T1 ?I$/Q^ FGB!'%$
M(R_FJJ8/)6NHAF<_D,9>.(CLPX*ACJL]=*/KW/<R%T6+=MGR3TU6E')'VX4@
M:TT2CU+JMM<SV,J=-G"].X[*4!F9*LV?OY&W!9DO_5Z*8\;2:M3IJF,CNL]Z
M6.7NS/.*BRL?3*SVMYV>N)UJEYNU:UQ4YR[6^21%5VO!Y-D3%H<=7A.7$,,#
MCCM)6\4::4\P&"(PA;Q1;[([25..)QR#D\E2P]"UD\C.M:E2B::Q,RL_%%V
M5(XU:261V*QQ11H\LLC)'&C.RJ9^+QE[,Y"IB\; UF]=F6&O"I5>3MN2SNY6
M.**- TDLTC+%%$CR2,J*S#-Q,DQ,1<;+C-%LC2L>')#LGB/@',L'#ME--&@E
M(;)"+;;=2@D0EMM\9["V7D(<0I.)44BS11S*'598TD59$>*0*ZA@)(Y KQN
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M:-NZNTU[1N]6KC70[J-].19 >7UO%R_H20EE56T%05MR3"#C. @D,C&-MX8
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M"#[$?<=>N+B8J#!'BX2,CX>,$1AL6.BPAH\$9O']&QQ!&F1V48_V0VVE./\
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MQIIQIK7;=%.SU7L$"Q8)*J$SL/(PPMEAGV!YF"*E!'0AY2(?);=8;E GGT$
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ML$J!/90ZTT<&IY"\C&--O/-MDLY0\A#KJ$KPEQ>,]8R(_'FBOP8.G)0W!P"
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MRM6<M#YU$TW,[/UC'/DR1D7<8%*?;#2A*L!RX9#^%-"*);4K*R_![*5N(_\
M$''4)SYRAT^92??'SW_Y\A\O\? 'GQ[:Q\CVV_QW^[]>_P!_W_L]MUU=L0>\
MQ'IE*;9L,<VA$F-CRHP0C[D(D1D8\/%E_/AAY"<> Q&<MYPEMP=3GG_/^?\
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M_*96M$)I,E5R&4&2 @:#T78GA[8OQ2K#)5MV39,8K+"R]^I>5"(H S=QU/\
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M>):BHXHDH?$(<B2]C(BR>&CFDO H8,CS@7B1'Y^.LTZ=CU%S&5<J8E66G#<
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M(Q$N2*P+B='N-@@I>6EI=J3=L<G  CR)N1_]5$JA>%&[':FBK1/*)X;=R&E
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M3Y27:)]XB1DCG5/)+]3+N7TM">T'\^7,Y7C+C3BL9^_*LY\<YOM_^?\ /O\
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M5H( 1E./N2T,*PTRVG']$HQCGR9V9V9W8L[L69B=RS,268GYDDDD_,ZZ<
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MG+;RTN88]-6?G=JI?Q=Z?%9:%8,A6$;2&!+;49HYS*]=Z=VQ6KQVR88]["1
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M$7N-J"[-- (^[(:L[P@W*],++&H82%K"E9PBACZ6,I--[1N"I!_G.V?L"^[
MO6T)60NB%F1U?I\!.; G#HX4^*"B\2!;<8*-7X:/:-/?;/4"\Z$$ MXMI]>4
MLF$--I^:6[4EV2.6X_J3%RB1BT#DH)"8WE:LD</< (+A8T*/O\*[;#N(((8$
M7L0FLLNTIA5)T2-I%42!5L/),8SM\)=Y T>VS$;;P.0F7!KA%IL4T6+<ZB;%
ML0L1*,I6IV G/$B,+6I[*90]T)TL@D)9A1.8YP#V;S65N*1S6O$[1!%1#N6
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MM>]MZJ*G:E@29E4H'/;8%9 C,G<0K(8V*%N!(U(8$>!%!CQ\6$)&@"(](4$
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M8VL,+*2US9DB$-66:U(MF5Q-4KUI99S"P AEE,HA$FRQ+'49> M5DLK%4D$
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M\C\S-E'RCR,9REM9:FT>"$)QCAK]R7(7;-V8_:69GE8#V7D?A1=@ %C7BB@
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M4N8>_P!//F5A.%?USC'W\:;C_@.W[?;_ -_&OF%V-339E-?$F</RZRG0L"(
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M:Q"+M59%JY"O%;@L)4R=599%K9*HL%^NKL(;" ZF<((.-#$CHX06/CX\4<(
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M11]Y]R3\E4;L['PJ*Q/@:-)'#')+(P5$7<L?D//L/F3[  $D^ #OMKV=+.M
MNI:BU8)\5AZWSS0Y4F_A.5I'PE&<C1@KBTI<]C&H<4VSGRM8??<*/4PR^<^G
MG<3K%BZB8RLP8J2]F<>#-.0.3>?(1=@L:>ZH #N=V- ))+4S6905'YL,9_J(
M#X^7DGR6))Y$_AV&KC7JV0]+K,G-S1# P@0KSZE/J2E"4MMY4K*LYSC&,)QC
M^G]?NS]V<XQCFBA6FM6%CC!W/NQW "[[^3^D;C?8[#S\M;)90B$L=_\ #=OT
M ?,DGP /)( &_MJ#@NE%RWG4P[S=+B9K6Q2T[#SU;J)E9!L8$/4QGG2/;W.N
MR;X@\E89Q"Q#UP\FIZ)A6&&X>:B)(@J48&W6NK%JS2TJ4$=C'K!-6=P[Q2SR
MO&R>HAL1_:PQI(>48B93,@^-MGV'L.+#()9F*SLZ2 <598E4[]O@?@9F4D.Q
M!V)^$?"">@NQ=':UVCKI[55IK[;='>=C'_DU?>=K+++D06T:%@;$&H)+#+;[
M*<Y'0CT,IS_ZO"DMJ1QM6]:I65N5YBEE.?&5@LC R*R.2)5=22KMY()!/($,
M =6TL4<T;12+RC;8%067<*0P&ZE2-B![$?<?'C7(G;6DKSN#='8@K3VKHJ)H
MVJG8*LR$ W%R,!);/G7(P1Z?DX=B7/Q#R,X,I4@^Z4,#$#66+1$'*.EIB7:)
M*ZGHKZ0,0([6)G.9:7&967'W);M*>K4I!J\4Z28R26,-E*4Z6$$K1-V(I$<Q
M\@=VT]1])Y"M'C,B9<9PRN.^L:*T<A7MV73U$]5XLI#"S''V8Y*[%(9P)GC9
M&;@/ TOKIV#F]-[6GKK=_P").R6CZM'T ^"<L+($_5!:XL,<08RIV 6.;FIJ
M(1%LQC'SV>@I.&P]/NEN2<C-FK3V.;Z5AR="M]2-CJ\ EEN*YB/"TUHG<QWD
M$C1PH  E4H40[[.."@<Y1R;06'&06SWRB0;<BP C)V^Q) 9CR!,@!E8>X;<D
MV$V=W9S8MYZ-FZR3LJMZ:IS$[/[&B8V)*!LEDG"XV3%C*Q,@9/76Y>(9?8B%
MC^C(&")S(3)+TE&EAP[K_P ^L_1MF;QI6QD,AC[N*R2R)CJ=K'#&YNK9JV*\
MD>2>5FF[561DL0K%VV[P0D';>/J:?5^,Q\&4HR8W&Y!<M12!,A<AOF]A)H+4
M%E;&,$)2$368TDKS-.LBB L% )(:J.Y=OM6W=,)MZEN[$S!P=W9V4FF;YGXV
M:IL9;(4)H&"*K-2K,FZF%C14>Y()8(M!3KN<!X$3$D"-$HL</]#..>7+6NHW
M7+V+V6QN6Q(N32Y2/IK(XV-:W>P<,L45?']R 2.73O,+$TDO,<N&L[GTFY&*
MCCZ.%2+$PUL1?P>2FQ5<XVSU%C,A9>U-%G9XW:3)\9#'$@D6-.Q#'&5/'EK
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M#<^->-2BB#)*0OLR%D&9L (D;'1[S*63(6J ODEQ<=(_^=4P6^:3*RZ%YR@
M@EJ'9]5,6HTW5K/]'_/^?Q^_]&_\:\TXTTXTTXTTXTTXTTXTTXTTXTTXTTXT
MTXTTXTTXTU@6;36"+&73V+%!O6V/C!YH^KM2P#EA"ARGLCC2I<,@C,B/'$$8
MRPR:Z,@9UW_30YE><8RV.V^WCVW^6_W:QYH7,8=3(%#F/D.81B55RN_(*2K
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ML/GL#M^@>QUK:L2=9R/'56>)P=8ZNTFQ1S:4"J4X=GQ3"*0]AMMU1$?D8@;
MZ,DNI)<8SYW/%"?0"Y=F'P<EX;GV)!W^6Y\CY^1OX]]M9JJL7.X*\AP/D;G8
M_<1Y]]MP=OO&O4/EE47@N"BRUE,AB#R#!"HO+S5ACFEO)?'-=>>F2 C VR_<
MC"-Q;0Q.&6LD.N#)PX93S\J2-QN/;W'^)\[$#VW'D'?1E'<((( X@['<>P&_
MO[$?(;'[A\SC,RMI<C8YE,B8UF*\78F*;<,P0T@Y+F'RQ'7V6&FU&.O.9;:P
M^IQ;KZG66\ISX9](0 $_#^GS[;;^?GY^\G;]0UD> 7<[<1[D[GW^0(!VW'GQ
MY.^_DZV6C2M%$A[F1<HQ\R:=B\XK3;KK[0I+^<)&2QEH;+*5&"/N"/N/D9<7
MAIAU6<8*2CW*7<$%#O&3Q.VWGP?T;CV'OYW\ZQFY-Y4D(2/(\J3YV'D;^/U[
M#8_=K=(.!G]H6>CHD9>,SAJG),&00G$H@<:M&/Q2!Y0)YYO)1$H:RT3()0YY
M'1B\/8\_D7XZ6=8PQ7?8?U1R&^_N?OV_3N!L-O(UJ([>[#8^-B5) /R^6WO[
MD#]>VVKW:6*IMEV90*AN*+36W&K3 QXC1%)Q;Z7:)DF1'"KM<8*+KUBB 8.V
M'.,@&/2@P3\8&LEMHH(]H4QN9AH(GO0V+%UJB0V:YC<M$([$]AVKQ4)#8CD0
MBV[JBB,"9G 2*1)&3>!=:3LSQUZOU@[U+4LT:B=FJ5XH^<MQ%@DC<-3CY6"S
M\H40-)-&T*/KO5KFN9J-%J]<5 56KO140,P77Z.A]NHQ9R\9?D!J\DH0$KY7
M[UTAP91(8[ZTK\[S27%*Y]*I0"M4KP"&M6,<2*T%0%:L3[;NE<%(R(@Y;ANB
M$KL2H.XUQ%V<V;=B?O6; DE=EGMD-:E3?:-K!#N.Z4"\]G90=P&( .MUY*U%
MTXTTXTTXTUCSHF+DW8Y^1C0#WH<],I$NFACE.1<FD4H),C'K?;6H,Y(9I@B2
MQ\MOX&+)8PYAM]U*O" =MP#L=QN-]CL1N/N.Q(W'R)'SUZ"1OL2-QL=B1N-P
M=C]XW .Q\;@:UZMT>&JTY>[%'K-=DMAV$&R3RRWFG&FRXVL0-3"&CV66&$CA
M,QE?#7Y7?<$N%O%.O%.(6RTQBJ*K2,-]Y&#M^L(D8V_1Q0?X[_J&;R,ZQ(=M
MHD*)L/.QD>0[GYGD[?H V 'W[CS/6O7YX8\<9\,>.,9QC/A]^,9\,YQC/]<8
MSG&,YQ_OX8\?Z8XTUKM4J<!285JO5D#Y;$M'S<HD;W!1:UR-CFY&QS9CQ1SY
M)3Y$E-RTC(DN//N*4^4YG&<)\J<8HBHO%1L-V;;<GR[%V.Y)))9B3Y]SK)W:
M1N3G=ME7?P/A10BC8  !54* ![ :V/F6L=1O:M6UFYW.I7*PH>D%U"O7RN"0
M)"!'X"1$V&/! SCDN&^,ZX<I,;"+CF!E/I!4/*'^Z&(<]LL?6\2NZ.WG@LBA
M3MQ(DXAMQMY\+L/.VS'<'QMM65TC>-? =XW+#<,#%S*[$'QY?<G;?=1L1YWQ
MFC:58==ZUAJ99#6C"(&0LPL,AF0*ETQ=/59YA^D0*I4Y@4R1<@*B["P[A9#"
M'%K"RG*G<(P\YY C1Q*CG<J6 \D[)S;MKN=B>*<5WV^7S]SE8D669I$&P8(6
MW '*3@HE?8>!SDY/L/ Y?+V$M\VZT:<::<::<::<::<::<::<::<::_,YQC&
M<YSC&,8SG.<Y\,8QC[\YSG/W8QC'WYSG^G&FN/\ JM.>X/=BQ[5+1D[5FDUQ
M_P!%,+\7 #G(0Z08H*D)5E*5JEK BP[+P0VGUF&0:Z :G+*F,*^BY _DYTC6
MQ:[QY/.N;-X;,LD=0!"L3;[@JPX1^-@29P-R"11P@7\F]DC>"AO%7;?P\S B
M1@/GQ\[$@_U&7[]=@>?.M7FG&FG&FG&FG&FG&FN:7</1=KL6Y]>[X7%XME$H
M%0<@"(>-8?*FZG(DR\B?+7!R*0EQ<O'%1Q ,<X_&I<D(-D4Q]X-Z.-+-C^IZ
M:O8^F;2V T5NQ'VZUMB##$I'Q1GQRB:1MMY3R4@!3VQN7KLA#8F5!&5:)3RD
MBV^-SN.+ ^S!!OLO@[G<;G;:4ZW)1<M#1QT00.5'O!LO#NC.(<96RIO"D+0M
MO*DK0M.<*PI/CC*<X\/N\.;["R"<B3<EB"KG8JP/ML?;[_'L?D23J.@W4<1^
M;L"NWD;>_CQ_[?,:C>FPK>X^Q@T-*)P53-1Q0MWEHY2<+%DK28>H.D!GH5CR
MNAC$ S5APWXYPL^O1S;R%C./M.2LG8;&X:-808[&4>:%I/9A4A 6<+\U[S.D
M;'YQEU!V;7E:$37&D8[I5"E4\@=YM]BWW]M02!\F(;W VZ1<X75UIQIIQIKD
MQV0TUU&T/0KE#F6!BO;CNYEHV=KR;M!,G)VN0L0JXI>:TW.Q<2X4[5Y4D%B)
M>#L"Y%S/S*5FW'BI!@@]GH<9UI:3J;!8?UR'(7ZS15<)!PB?)8[&!/6O'54"
M.5ZT,RN\NP<$J=]@=>2]-6+6$RV8BH2R8S&S0"]DRK/!0MW^X*:RR[\HO4-
MX15.S<&'W#53=38HVXKY0ZG<;F31*?8HZ1==G8Q<:*9(3HC+#L;6/F<H*;'0
MJY5&#U9/,$>4X0 B%$2B2E1'FOJ6>LW\/CI+V,5;,O?3F\B"=8:<BDI*J#;F
MO,HO,[@$KRWV.N,H0Q6[/8LM)&!%R,8;BSR[^5+?G#92Q"^&V!\CYVIZZ=:A
MHK<PM_IP.I>P?7.WGSST)=IN118[1JY< T9\J1'#3 _H/S4C++9BY%0(A2QD
MA+D&WH)MQL)WY-U1U1U59O8#&"@T%..#)KU)9FO-1FCF81S8PUL7%519UG+R
M13]R5.W'VY 6V(D[?$8GIQ,7F;LN0G7*K/CC@J,5%+56S"[2QY0V,F]GN537
M5(9(%6&7N.TL1X@@QWDD.K.I"MR0N]X\&=KFPXN0?D) VNV&2CXRTY=A@H-L
M*QQ"W2 7X\<..#4D2-:BT$OL^I(9-PXXE7-Y"M)DY<&]C(9-8>G[%VS1I07Y
MX*$DM^!X)_6U8V$=Q ',D23!ECFVD W&VI]#)/CJ>:IP4\;(,]!3KW+5FA!8
MO0I1L+9A-"W*IEI.S+VY7A(,D),9\'?5@7  73!Y%T(1V0$:?8$.<&968*R5
MZ>261R5(R^RT1EIKUVVUI0[Z;?J85Y$^$O<@$ G8[;C?P=O;<?/;<[?=OJMU
MH2O_ $ZG_)CQ73:I)8]3/CC+-GMT81XX;\/#*7H:I&-84Y]ZDF6EE*/]+%<<
M2;YI_P _Y_S_ +ZDCC33C33C33C33C33C33C33C33C33C33C33C33C37@XXA
MI"G'5H;;1C*EN.*PA"$X_JI2E9PE.,?[YSG&,<::YG]BNRULZ^;SIU_:VA4K
MSH.RN1M.O&LH\^MD6:@%X2\IVWQS,>MR>-0I*'CW'7UK&6ME^OE#MN&P)P>^
M.+N*R\2''Q(=CLVWNOW;[;D?,GQKE\QE;.'O5+DEB&3#3/#2NU^*"Q3L3R\(
M+RR \F@+.L<\; \% D0>6(PG?*MVC5DQ2NZ^E#Q0;76!F*;=G?15(0T_4+,V
ML&O2LH*P0RU)!BR1@L6ZCS+42N1KDBEUOZ-"YSG7*N#7?\UV#*?F'4;>#_YE
MW'Z2 -0NK%GQ03JN@@>SC8'@O0GEQN8V4[\'X@DFM8*3HP\A>X"2#MK :A[8
MW_5)FL=>;@GF+M&?5ZF^Q&U;])N/R-IB [ 1-S-4K<0L)YH&0>!#^CD.H9U@
MEZ0,L([4<2&&$,R1X\0<-(@V!F$*)L=SLON3[>?&_P"G?V&ME',V:4M3'925
M)Y(\#8SF3OL0G97U $<4<<<?"1$5I(P00Q6)#Y9CRV;IE*D5BM=I.WVQ(UR@
M:^VQ9RM@P,6?E&"TU2")M<OF92C"DX*=FG;)B.CE(2VJ;/!<+CD/@248^0G
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MZRM*O<2DC&LX(]@"XWAH5PTMP9M3?I,-.98==QC$*Y#,C NON=B QVWV&_\
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MZ%CK]C&7*]^HX2>NXDC8J&7?;;9D;X74@^58%3\P1J@T7T9O=<A;N;:=AA7
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MC>X$&TBL]'E,[9J5%GQ?ILA?<T\C521I*TF/EJ3VU>FTH4(UF56$R.>Y7_\
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MDDFE,CBL,-$F&.J?,+(;:;2AXDM]2GB7W,*=?=4IQU:UYSGGH55W"J "2Q
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M1'0KT=\PGWWE-,1,5$D2)H,7@F8.)$$&),/&!:P_[HDAH9MQQ.-VY%1IS7)
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MLI*3WXZ#N4*J4'%?=(">=4IUKV;H9A<N?"Y&&:6&.M+;: ,9FIPV)TB GFK
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MP23/Y-?5G'AGQ2D<![.?'^7./Y5>.%9QFWP#=NU<G\_88?+OX\>9*$U=//\
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MO/(D:222.D4C+''$5$LCLJD*D9=!(S$*A=0Q!8;_ *_+10I2029./&-6/[M
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M/ERT%2;/4J&#N?$Y!789,B&3)WG6Y55J98T23%R4<<J,FWFSGG3/27&>DS)
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MY3A7F<'@'\UR=0A7EPI+2V'7<85Y<Y4K&,*CG'8V4;U,W7W\;19&K9HRG?\
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MPLE)1;4P8S\W9(=.<*''?5#.-.CM>S<4TMURNGE@,TC4HI:T,B!>U-,EEUW
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M_/8OA;"W98)H+[)):[E5 L2F>&!']5/#*5B],FVXA[7)9Z(]"Y;J2QU#G*N
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MM$'?8+1KB>WN3X^TAC4'\Y@ 2*A<]5L;?5D-O+<B0LE*(>D.WS]?9>O19?\
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M5Y?/)6 M$7*Q8#2GSI( )A.,J4\68.,TE./OSE3CSB$8QC'WYSG/ACE" 3X
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M@EB[<AV9'*E*;%_2KAVQV.QEK+]7=-Y$]!4NF[W6V#K07L_3R=3KWJCJRW'
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M$04S@$H8O,;)-C%X8>;=RUY58SS?-5LUT@DGKS0QVHN]6>6)XTL0\BG=A9E
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MR%--/5R/4^:R>?I7NG<G0R:4JL>3CM&^MQ6&-IPXX.SP2U0R(S-%'Z?MO\7
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MK39.-92J3KPYOVXHOY<548V+!K/D(HGMP59)KL=<PEG"I-CJ8E7O!5$J5'*
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M:C_#_%OYZ?4VZR?A%7_UD[_=N/KK*?VR3]V/_1IVH_P_Q;^>GU-NLGX15_\
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M/R;%)V+-E/7HG7$1!PFM[5+6"RVN.5+KF@:O% @OO6!B !A29.<-C<OBQHA
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M %['_P!M;F7VEK6O)K=3NQ;8N;C*ON*I:OJ-<K-$DAYT";L])C[$#5UF.21
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MRCBAK3#X:+(5+<TSLDKL:N-4'8375ADLLC^#\(1$3?P.4H&_+B&PDD*L%'R
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MFV+IZN[+M&I[9-2$T'(:?N3]WKK$6\"T'(29$,;"+&FD%QYC[P&!CG74H!?
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M,I<9<K:]R6M%<AC6,K=@$$I<,65%D24&,AE ;D@&[!AL3XW\ZS9>17?Y'?\
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MV61VU+=<=?(?6X06882Z^:<80XX08:004^M;KJU9I[-F:Y8ELV',DTSEY&(
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#-?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g104413g98x03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g104413g98x03.jpg
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M @,! 0$            !" ('!08) P0*_\0 7Q$  @ "!@,("P@-" H" P
M  $"$0,$!08A,1)!40<387&!D;2U"!0U-G1UH;'!T? B,C="<G-VX0D5%A<S
M.%5BE)6RMM08(U-4L]+3\1E25E=W@I.6U>(DUB5$PO_:  P# 0 "$0,1 #\
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MP[#=]K.M/P,;9[V5@@_H*W'5/20N+2 '&\E<P29PVUUZV/[@SKT,Q1*,52(
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M0V$'7L22K:X[&>1@L-0A4R0:2$EIZL(<,E.:^*Y;=)3PUX:YI'9O@Q' ' '
M' ' -:6C3M9W4)C@&U(>,FP6)SN'V8!$F-G>PYI.("62/0\\LT;N6Z!%4"90
M0)M&1/1X-V>MVZ[ADMN@CG0)M9.6KDV'^9INL<W%KV Q#A>ERXK?:H=Y^EEV
MD;7K7,EQ,=(>[PDYT9/13>3^>99X=M%G#%XN[V9KH:/'6BP3PEJS-F< < <
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MB:HV*4I*&D)NWMD]>K>2.T7ZQ%"VY/!0U:'IRCON^RDD7)P>.@@"^NB>K+"
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M,LCDH"S^ %9G*(8Q-8:BMD2<5)K.XYH^]@E6SA9-H0QHJ[37:[)K"6EJ<^?
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ML_ =SZPM*%TOLA>T,2/;T;<BA&==8Y@3A+AF\>!)>LEWP0. . . . . . .
M0L\/'XGE0_GL'Z4IMP91^^?)YD33X,1P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P"%?3O[X^ZGSU+!^BNE^#*+XOR5Z2:G!B. . . . . . . .
M. . . . . . . . . >2?'/"X(T)'F7T=?E!)(<QD Q)DL2!/'K-9LV,CT23
M9X.5?#%E='K1)^S=LE%T$]'39=#*B6P''WJAX?E]=&)#:0FN;997G7U^V)5P
MN0+65'HL&D4*@D8I*2 )K:,H>0IE '\WLR1SYC'47SE$B5(2_4N]DTH5UE9:
M23-LV\/J2]!DVG*>:3VO&<UFWJ]F1LC7A ]AX0R$RVO9GUGK>8P*3QA>NJ0A
M@RW4>L#1BAU=O;K#8L\R..DCDPB]A62+NL;+7P\9H=8-/L4Q*,EI)*')4G,F
MHG27#.6+GC.:BSUREAQSU&X^LGA,SSKA>-$$6EMQ&2T+1<FA5N#4G 0ZSML[
M:\3Z 1?H(H$>J>LN8RUKY['8\M:";Q)\J:;F7ND/V%JC&N3RX.*:>$FU+@EI
MN/ZO*=R.# YV5W70F">)+;Q$8=GQE6==4X?+22$UL2:SI@&?$+WLU149"Q\M
M.&&4&BR&5,ZL(E$T!$<'IZZ)LAJ&B>FNHF?%AP'1/@@BHC\> C\U0-]+IW@G
M4^->:(E7P0. . . . . . 1>=_'2 ?->EWTKPG@G4^->:(E#P0. . 1=5^.H
MQ^:Z5^E@-P3J7&_-"2BX(' ' ' ' ' ' ' (6>'C\3RH?SV#]*4VX,H_?/D\
MR)I\&(X X X X X X X X X X X X X X X X X X X X X!"OIW]\?=3YZE
M@_172_!E%\7Y*])-3@Q' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M ' (5,/QBTJ^95 ?ISLK@$U> 5<%.XG=D9XS32OB[#(T$=MC6AQM:D(F$8BB
M76M*9EB8^=C3;@4E)'KW>&MB=M('6\A41=ET'<?U2V#(>]M#6,-O7P=^W9+L
MZ+[0[XX%'VI%O2JBH7&J]V_HZ.^.DDM[<>AI/M;>]^]V7PI-R3L:X>Q)@W0X
M+ZT#W6W4J.LNKJ\= [0=XW:BJ\=U'=#?=]54@J;B:K?:JK6\)6XZY%9KWAVC
M^;.*'C@#@#@#@#@#@%3M.M^^MC^+5);)J&4D)"(!7%,BL?L0U-7H6I7] 5[8
M;./RZK\:I*NBKN,!WVN]+R8/'HF3U5LP><D[%D_P,=S!+6,=CWU=^X;2AK\:
MN\J2&+1[<2JRJBH%#%4W9VG-T\5)I2IMY<.FU3NF4:4*OA5MTGL78.Q)IKDT
MUTZH]V6*ITU"J9W9BBMV*\<=IQ4U7O+!?+M5T<%E4=4='I6>[3@I^U(*2R(;
M-CJ\6^TEAW[--[Q3_,LSJG*'R6O^E<R'K[9$*N",CVN/_$J['SO[!-J/G.,9
MU_U?%:LE#C;?TFJ65M--5%=G%$)</)[8<[1]T=W&ZW.7S4/(;+:5:??KZ-AL
M9O<!*^OLG+N%,XUT2!1V[04!+R'SML^318"S)-U<>11%91+;7?8)/_+'S>W,
M25161<HI.&ZR3ANNGHL@NBIHJBLBKKC=-5)5/.VBB:FFVN^BFFVVN^N<;:YS
MC.,\$$8E?CJ,?FNE?I8#<$ZEQOS+U/F)1<$#@#@#@#@%=3O+WO[C5[W7(06K
M(+=$3@,'Z_=O6=51W6E).9CO8R[H?UG=6?%K&]]NX=V ,P:'392/PJ/QT6YW
M<(%V,O.RW&PT[$6R(S232RFVM>,LI2X<^12S)=>$E>4XNF&=@TRMVF^RE8P:
MRJJ%U/>,@>QDR0DN9=U;HJR;9B^))$ X,&=;P.XYC-@VFJ;+=[&EEG$*>N?.
MC*;-D$:2:DI33FL5E$TIIY8)>>1U!GYZ31B(&3L.@I*RY*/2;;BX.(-QR.$3
MRBSYJV71;&I:2$1YCLT:+."*FY(BVT529J-T-E'2R"2@P(G>&ZY=O.E5(.WX
MY40^=,ILY>B5W#5VN+=KV5,E7(Y9TQ579.562VV[91PS76:K;I94;JJ);:;Y
M&47OGR>9$X>#$< < < < < \PTP=% Y88Q-$XV](C'[!G(@J0=<P!=/&JK=N
M:$H2(2>CZQ,6LIH^8)'01H.HZ02T)B2++*[-8",O3EW8)>I'QZR;:FENGGMF
MW(#;EYF%JP$N*#0&W)S7P0<P:U57%;BU$U1$78O2#DH/)/URSAZJB[;,=VX]
ML)>>4L%Y5/62MX(' ' ' ' ' ' ' ' ' (4^(;<4)H3J39]IV)><OZ\1",;1
M1P9L*NF$;(V0[:JR\&DK *]3EK9X"8R^S4]MX$*D#UMG2*^^!:49=B=0VQD<
M)A3;22FWJ.!+/NWVN'.NH2&_;IA.9&>A77"25''Z[FM163%^T<HMKQ+)#2MV
MT[*YO#XXJ#NJ8=<NINL3CMB':R="6L>FC646=NKIC9,KJ/IHK'!K"*<T_<I0
MIIR>6E%E-Y8:R<7A%=HKXOBU++#67;I^VVVW7RN;-M\":3C&Z/6[M)(;_P"R
M\)F="C$HX##.H<W&0" PI7:N)0H1.!$0K.2Y52Q+W#DD,8DDEJQ:7"DDYOCG
M@UGP2.ZYIX_'ARS\6)7/DV(Q^\' FKIBP<FG[9JJLS$MWQ-=J-9KDG&B;-)T
M0<MV+=1;59VNDAHHIJ,""70(Y(Y(U[<G);"B%=2,CW+L18K"BIF/R$A'U]:T
MIU+1HZ,Q8@5C[_=1!-)UA480=(:Z.-4M]\+)JZ:C*+XOR5Z3H!P8FNK4M>"4
MI"BUBV47=@(8!24<FSC6/262)!V+=LX>.R9-K%@YM^Q$,&;1R[)&'+1(6-;(
M[KOW;9+&-\@9)%)2'FL>%RD!L2W#F4-G+'8P!.Q@EE+195OMZV!DPT.>&J>E
M1W\B)(:T6VT\Q;5/**B>^X&0\ < < < < < < < < < < < < < < < < <
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M9X2Q0:D:(H.-S*R7+1#1)4_2).QI3"+>W-[HZ^G()0&#&5K:%):Z+$7!6KQ
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M0O2N8WK%M9BFC_H=)5J#PQQ(=$O]%J7P\U3_ ,W&.#%YN><W.669('@@< <
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MQV@ZQ5X:[>NQ:C6E J>NTU%*FJE9IZ"/2HXO<4D4I12:OO<L0>+8X X X X
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M69PH9/A,5%CCHZ,C@C6,,!C!1H@DW9>I19BRB;5ZV;I$$(FS:Q=-WJ!;I#M
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MU=6BHG9U_BP;H?A-SOWVN\?H8<M4?SY#@#@'/3:VN[6._6E6:TO'=NG6T/\
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M0GBC*EP1)1MZ.)QX@_Q 8_AX^ D1":(E^&=./2+BWHQ%(>Z9*(+LDTVRB>N
M>;XS>?! X X X!"IA^,6E7S*H#].=E< FKP"$S>P(&IX@1&()S:([RWX,(L;
M[U])(&VD7M%"QSIY9A[$P]R3]=1!_P"N56OJWITQ/^L=T\,_]-P3)Z+PUKTF
M46;_ -E?8FI[B3_L\6MEFSZU6HM_X&[<LX)%I1UUE!)??RZ(MATZ)SBI63='
M7#@K)+\C>%MLMQ6GHP6*:V8^OERYF;QM.M8U;\!D5=RW1[J(D+9OC0@)=9'G
MX\:%OFIF-2Z+E==%%0LNATC'BI3$SK?3+H'(Q PJU\CAFGG A8&NNOUE264#
MI)6]I;,D;RIQZPC=DZL6N!HV7,""#A>$7#%AN=U,MH;:P9DX+-&B"SUI%I@-
MG-:[%2A: %W>XE\&7M-<GUZSPMOCJ)?-=7^EAOP-2XWYH3T>PL_E#%&+4S5)
M#5A=-U*E149,ZMF[_%908+JPQ95W$6+I-=JX:UX-,#&<89/FRXR0VK*:XB1;
M#8/("1,<"EKR7EV+VU3-OUY 8M5D'B]=PH?L,B\0#M HAJJY</GFZ#73_2OB
MA-XHL_,&BCG9<F<.$W#HJ;,.WQ8H[=$'KEPJ(,RX!HY3L) $KL1Z_;L+)Q8C
M@0M($=\5%9^T'4!-VK1PX,:V9K%,U[D<@N^:"%G?OE]$G(%] &^V#'E9X$RP
MGJXUYLS>/! X X!&U:H[5W[,(W:E9T 3@:,&WKW%<*5%(59;M'UW#,\Z6S9F
MMS(A\&-Y>T]?0=_8N]30CBGO?4&N"6GOHV$SPEPSG[<1)+@@< KM>+U4]1I]
MDJ$GQRMJP:GY[4]Q@)3<EDU/WBO<,DA$SU-9CD"4KCIS.X.J+)2)F4+DD9M+
MW:[7<?#MX[JELLNPX,X=C;DFFE.%8XX^ZPP]+.WE0O(A">O=3N=GD,BD)CE1
MUZBV=# Q:M($$ LHD&;#] T:G3S>00:,MFNK= /'):_5.Q\?AJ(-.5235QOL
M,=?+Q_YFU 9X')Q3,[&S(F0A"*65AYD&19EA3Y'&^VF569!@LX:.DL;Z;Z94
M06WU\_7;7R^77.,"#U> . . 0L\/'XGE0_GL'Z4IMP91^^?)YD33X,1P!P!P
M!P"J3[HR_##TX_1KV&_BBC.:;W9>Y5C^,*;HS/3/[&5\(&Z7]#K-Z[HRN[RO
M9[*C@$J.BOQV^H7SCJF_BMASOVYCWZ65\W:'5U:*B=G7^+!NA^$W._?:[Q^A
MARU1_/D. . :$VOI+6^DJ"VJNT\%5H\O+4I]ZM ?L=;1ELDV27,>M_9 ]]^$
M$SKMO%LMMH9@AL;4]+HSV!Z[FM0-]\ < < < XD>)?8<'BET0H/()[UBDYU[
M6@Q^*ZZWS7(61'<I;2J6(_9&B5@6J=6HF"^^'#)S&46,R'UC[>?1)7=_:[IF
MP:!@XR2<L)YO%98)9X3\NO!-Y]?JS"!X] (D*CZ.S<,B$9.1[;)+)5%JB13]
MI>JL'.AB0,DA+;=WN@&&AS#Z.AA2;,1&U- #$:BF,3.> . . 0KZ=_?'W4^>
MI8/T5TOP91?%^2O24Z/&K_&:]F/STU_+]5/+D]CUWE6E])Z[U78IJB_/=:K^
M+J'I-;.67-[G3!P#O'[G5^/E8?S1K,^F3KORLG9(?@+H?.VY^Q9)L.X6=J\5
M2\];+JO*M&Q1P!P!P!P!P!P!P"-=K6Y;$'MZEZ^B58UY+(K;98@$<2V1W!)(
M7((V0CX*22^2Y1A@RDYT..,V\4C^%@:^\X"KF)"\R%?M  UMB1N P]E]9)3@
M#@#@%?SQ3[W5J?M+4S>-=PB/2^1,ZK#2646("%=C^Q[^10UO*;+*:1,ATS@U
M7S"@W[989#YZ_'V[8$JCDXW:M9.RCK B)@+YPS'TA4T_<Z6.4TI3PG.:URPD
MUM:U]+^UH_K5$2L$N*]K+5JL@U.Q2"Q<KF;B(T/,24Q*D!5>E20*1Y7C\E<U
M1+Y?O/P3DH.(#(DZT>2DV/(#AF4D1AC[>7R9^4E- (;':Z@L,K^(HK(16$16
M/Q*-HN7SDHZT!1T4T$BL.B;U5=X3=>HM$,N2+Q==V^7RHZ<K*K*[J;",S[L<
ME\3F"!!U$9/'92V$E7@(JXCAH:;0&&QV=,$ Q!48Y=)LBK'*B>'@YSLF[;94
MTPNCIG;7R@8OK<U/[""T@UM:MM@(%ZR&G#>LZB^1 4B27RU',"Q+!3U,<]?N
M==F[)J\617=+XRB@FHIC.O ,HTET44DN89I)X]O,-0^LAS$]#0W:2X ;N/5-
M#F06'.2F ^[O.&NI/+7U+9QGT&%\J_YO ,AX!"IA^,6E7S*H#].=E< FKP"(
MR$> :]Y2!C4&'U+_  8Q3GVK@8RP2]9WLTXPW<>O80]9]/NQ_L6ROI?2;-/[
M-G;*/^9P#=ERUHQN*K9O6KX@Y";2H&X:"9(Q335*1"3M-TB<0FP3"O\ H]#\
M)E+(/+(^OO\ <;F@S!Q_M2QP2G)^W-RGD4!9;ZVZDB,R.#FP28Y1)QBQXZS4
M46:1>U((:(PBT(PT75QA1VPC\^C\B%#2&V,:%!K5H30\YN\2WV!Y^;B>7D,%
M[ PV3B2,;[$54&=F[/J=D0:'(<+PGJ^N6G":[=[-ZNT35W2;.I6TV9MYM43A
MVJURTL0(UC2A@)$I].E'H+A_RV?7P<,C5:USU@G>NE]YEXW>I,=)%['UF:6'
M*C!2'9L)L;T*(MM$,D5556&=<I#-&>Q95YMJ.T8[$=L-<B9.26O2:Y?<FV.O
M4*E#A:4WY:@A<-;-S)BE,Q9_LDJZJ2J F[]>MJ>QL@HNUT,!6Y<G*K*<-'+Y
MN0M663!(<4>Q,5$&XT8^W'[>VLDUP!P"+SOXZ0#YKTN^E>$\$ZGQKS1$H>"!
MP!P!P!P!P#A/V*J/Q-F/:RVY=15<![$H^46:2G8#0IVT=U9H1"2?HG$>M:T*
M?07>$29JQ'0ZWAI6X1^ZCEPS)&TDWS88+-.O? G&.'MJ?U&:<+A2;DY2G*?Q
MFY\J:7)K-O=B <@J#IIT]BL_LN30ZX:[BU71%=U%J&AO9US+K'C-4-0\F'[%
M;,BD@B,!V<OQQ)VVMR2F(DS2W\YJY*O=C/LA])"Q;DIK%RRPY/-B3%Z4-DGE
M#1J:O@#4/,IRY.E)H^SI6ZAXV1'R8Z*'.924JBL*?A18RR$-F8[=<7"&V&3=
MLB+4-2G=CF3%A#G/'5+#9Y7YSEIWH[F7/0':\^UI3L;M8SM*JNR8][U09AZQ
M-N(+9, Z33"_:=9O*_;11M=CD?+)3%DIH6N[,W+0A% V#I[WDZ*&<2@(,H84
MY34EA[IY2TI/6EALX&YDGO"EOZR+NBW84=+[L=]E8?6MCU.)KF]GS6 )NI3I
M/^K-$V_8D55?UA&XI#"FM?V=/Y6%;;,@Z9(,Q7:1@RY=/065."(E*6$II[=3
M:GCE.6WAUHZ93Z2'HC$3,BC-?R>TS@Q)LHP@,,(P@3)I%NN^:M5D19&QY;!8
M4V49-EUB;C8[*PZ6[-DX2:*.2"C1DY&)$[PW73E]TJI!\\&.PKMXRFKIT&(*
MCUWXERXLJ9++C'JXEZ2%+.V"N^S5RJ,(OQZBR6^[)ZZ;9374&47OGR>9$X>#
M$YRD>J'9$AWG*=A].T<N&=?R,!>PG2E!CJ,)$Q[UP"5V;'&!AS5CI9,*PDSU
MX[:0M<RY<IE$6,Q6F[INGM7FKV]O;ZYFI2ECM]O;@QF>[T+ZU=C.N(6V&G8C
ML,2OLE/9ZO-HSE;(5,9"V\D4(2F5A4TAE>0=<F5VG$DD**\N7VT:R:.,(IZE
M#*^T%J M@;3>"E]67D)^\$#@%4GW1E^&'IQ^C7L-_%%&<TWNR]RK'\84W1F>
MF?V,KX0-TOZ'6;UW1E=WE>SV5' )4=%?CM]0OG'5-_%;#G?MS'OTLKYNT.KJ
MT5$[.O\ %@W0_";G?OM=X_0PY:H_GR' ' (NK_'4%?-=/_2Q&^ 2BX X X X
M!RG[C6K;U8WTU?P661=W&4X'6KDM71":]C&$A=$WP3N)%$T1$,ICK5>K$SF2
M*R@'8NV[5TE)U&/6HN8(QS6.PY*6 1*7JR7'FVO;C)8S/-L,>GBBE063#FMJ
M#J5CK@#;$C"DK(BRCAA'12YR;-A/MF-/)6\?A4"Q6*[E2K5B[.N [V0MWHOV
MB.= L'CRHXBRGNMV4#PGPM;(-]C=6L=F_4/I59-YU="[ IN']B^P5D]AYM4<
M&?2*+5S8'6FV4;,C;1^9)KR:&UO+Z2.>I&SC@7*A3L<#0=#-I)QJ7QHDFYR2
M4]<UCPN:\I(;PE^W5^]B+0GP2T[:<VTQ)=<JWNR= 7 B!L4^M%\RR_\ LM7<
MDZ^L=H1&P! 2/%0FLXDHC$[$<R&<#W0)\?=F%$Y.IYXB)2RPQ:US:26,GY98
M3RP.Y!I\\&!BQ(>&?R-^/&/WS&/"EQ38H=>-&JKAL&&N3Q(.#;ORBR>C%FN9
M+BA23A=-0B28L]5G20P()= I";E3;MU(9'!))61LGW+L1<A!)>0AI621Q;2M
M*=1U9E2%?2F;0UTNJDDF\TW RDRUP@Y2T4<)NM7#=$91?%^2O25%/&K_ !FO
M9C\]-?R_53RY/8]=Y5I?2>N]5V*:HOSW6J_BZAZ36SEES>YTP< [Q^YU?CY6
M'\T:S/IDZ[\K)V2'X"Z'SMN?L62;#N%G:O%4O/6RZKRK1L4< < < < < < <
M B[<_P"'SIU^D2U_H"L;@$HN . . <-^Y].&>T%[RDW!^JHCMU3NU8!:3FTG
MKSMF0ZR6%#+9JV>WD'GM;R(D-E#':51Y>"VY)X25&8%C%Q@.?VC%7!<Z%L,T
M*%#*<I8M.<\D\')S]MFHZ,=O+:VI.LXN:;UN L-L4L:*1Q!K)WZ@R+0TX@U+
MR6NYP?=) CV68:.V9&83H\*X0:*1E%YF5M'F7P)HP?B$IOD?U^3VEB;EK.8$
MK*IZ 3YZ :"BT]K>+RYU&-R2RS%@0E$98F%0F2^PY-THS;N'VS+VAN(2<[(:
M^L*#$UO.::B'@VMAQZZ55W;_ %GL*_3>>F<NHB%]FYAU^K:N:Z#R/KXY?5;)
MH73MM(3!\P<TJ_7@^.MD$3C4.!U[/CL(6OJ2DY"=D=GQLJ(9C- PR<FEC.2?
ME<Y8XMS;GJV-XM\[HIX</:&#5W%083IW,I70%5SN'O6G6.UY)TI,7I8,G?=-
M>S5$36<G;#@!&!59:$&AEKV75<A@A:TS8ZRMT$+*F[./"EUPH!U&/-MSUXX>
MV>!EI)MN>+G-XR]\GPM32:P36,I2Q)&]//#V[9TQVPZV&;,KY$RK5INN9]/^
MV",L@A%O(8-'?"Z@_3\KU]2;;R/-KOWZ?8,$1G:;-W$L0%< @WFFLB]];GV5
MK(<4+3EK34L</=Z2<\G@Y9S+*G!\SG97@&>A?$EMY>:6 UF[$SU3AY2&,&T-
M8Q7:$Q=>][-V815R\9E"*DI78)[:)[R%XF/<O,I^?NR2SOG&!/)]9T3X(*FA
M[KKW5@WC=1">RF=D1T5G]\ZRB.V=M,='$>=T 3+RR0!Z4("FY%4P'3)0V)EJ
MA%!# -G'7,U]D[LWJSLT#?D-U17KW/WN7*[ZL:'[J%1*CWWM"C5*J_VSOD5J
M?;1+3WMT,X=ZTW2Z+53=%VM_.+J:LVV_NB[>=;?VM3;4&_1:&\NCT.UU5IZ.
MEIO2TY:,UOVEOGN2V7S2IVPB?&?^RCM/-8=O_9X?V6CV;?BGE^XV97!7#".P
M:V@NBFWF(-,RZ![55,(^$::[+D2D8N.4KZ[J;OU^"<UQ>OUO/BY98<$%2A2+
M=Q=?%Y3KW2NIK]C'7LWB>IP#V5(<TGCKSFY]+"4LG&OW8KAI@OY+AR[]=RS2
M[%^:WT0Q*M=(_P UBZ]?K[NU555J3[F]\2TNUJ)U'M+>9NF[=WO?.V]\QWK?
MM/?/YO>W0XN^$-U>Q/\ Y)+O!%;E1^_=VG%'O7V]KBO6KT?;/>X;,5U^V^U'
M=QU*5&[0^UCJ_:,ZZZ\K26C#;7YLXH>. . 0M=V)7^.^X*&9G4.Q,->M<I&[
M1/,G"8DNI%:P(9($6&P+U[VIAZJ!3W-I-<M<+J"--R6J>6>N5L"9/1>&M>DF
MEP0. . 1$E7>"@(;VDAO3XX:DJ-S3B-F9&''MX9(W0C&HM_73-FQ4?H,-G#O
M4XA8J)%G)0S$K!0K:(SAK,Y9%S 1$6_$R<IRP6$^,EWP0. <:/$XNSL+ KGZ
MT5O2\\NZ(@YQ7E_2^7,:).=)H'*2I.!GJ.%1MT]G7>9%S7SD0.;3N0).(;"]
M6LQ>N"#4\X4=!0KG1N,H5G@GEGI</^KCZ#8O;B031AU^IPXSLLE$9<]H:TM9
M25EPSWZ2;4.YHC!2:3XLZH4D*AKJ6Q-RP;*MGL&W5BAV:R 4)@;?9 R'Q@0L
M]N."U/'+'TDK>G!"0%J2U)R]3;28D+4OPA+Q&[!0;O%).0O*PWQN%;-]C\I0
M5UASYPK&TB V1&0A= :D6!$'(9ZQ5V!Y\B\B]N(D9[W(][>]]7L$-[Y\C?8N
M9'[+8^WLA_3^M>R?;'H/:'LWUG^T^H>L>J^G_P!-Z+TG^=P0?(''P,9'Z"8V
M$$1\4FLY<)C 8UF)'IN'BZCIVOHR8(MVVBSIRJJX<JZIXW774465VV4WVVR!
MZ_ (6>'C\3RH?SV#]*4VX,H_?/D\R)I\&)K"S+NIBE6HE]<ENUA4K(^Z58@G
MEF3Z*0-J:>H[M=%F8EQ*2PI(DZ2W?,M%6[/=95/=XUUVTQEPEC<)-Y*9L5B^
M9%&3,F,>-2(TBU;OAY!BX1=LGS)VCHX:/&;MONH@Z:ND%$UV[A!3=%9'?11/
M?;3;7;('VN . 52?=&7X8>G'Z->PW\449S3>[+W*L?QA3=&9Z9_8ROA W2_H
M=9O7=&5W>5[/94< E1T5^.WU"^<=4W\5L.=^W,>_2ROF[0ZNK143LZ_Q8-T/
MPFYW[[7>/T,.6J/Y\B%GB,262P[HUVADT.DDAA\G#U)(W063Q,X5C,E!O?,1
M2T( Y"#=L# 8DAJIOEL1&/6CYJIG"K9PDKKKOC\5HTL=#9]?IJ*)P4M%4JU2
MT<:2;ACHZ"DC@B2::;AB2<FFL,4T<3;U8IJI85MUNK1NBK%5LBTZS5Z5*&)T
M=/05*GI:*D4,2BA;@I((8DHH8H7*42:FBHE]F;L+\JCN!_ZO>S/]5N5C^[V]
MWY:I_P#H5/\ ASS>^_GNK?[85O\ 0+'_ /''E9LJZLF])-GLCVLS(TQ2@+0_
MGM=V/R:T"+.TB"H?0IFT?7=1:K]!%ZHPPOAKN[23<;)96TUWP^[V]WY:I_\
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MT)DP;L#$F83:QFKLB(;-DA+EMK,S"H_=CZBY2"N6ZT?$@U)R]O*D3%X(' '
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M23L!+5R->:OV]]R2-/Y<(:'IL#FA"$SY6FDC52U0;FP^D."6,.;FFHIJ4O\
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MD^FL%?DE6+)LT4(OEKTLK95Z^W;I)[.W:N<YRHY<946WSG.=M\YSG@$YN .
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M6<SO1A&!;729?VTL>>^23:I8-:^N'33K&KW&'!<DMY[U<'F\)8Y;. V9P0.
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MREJ3G[V%RR]TV]7&^4[%^(CK+']15?%*Z1?D9G(K?CK<35S"7,H M9@T5!;
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M:7TGKO5=BFJ+\]UJOXNH>DULY9<WN=,' .\?N=7X^5A_-&LSZ9.N_*R=DA^
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MS)4IOKK@I[;]H^I;#T]AN'GLCT?MW.!WD\F?3\&4O<K%9O">.,EER$Q^#$<
M< < < < < BZK\=1C\UTK]+ ;@G4N-^:$E%P0. . . . . . . 0L\/'XGE0
M_GL'Z4IMP91^^?)YD4(.X/QR.YWSR.V/\PUD<OSN1_!U=CP:N=9UTTK>GN]:
M'RJOT2@(\\V.=?' +3/N:'_>=U_^#K;_ -5^\ISV0_?E97T9JG6ML&UKC=QZ
MQXRI^BU(M/\ -"G<BJ3[HR_##TX_1KV&_BBC.:;W9>Y5C^,*;HS/3/[&5\(&
MZ7]#K-Z[HRN[RO9[*C@$J.BOQV^H7SCJF_BMASOVYCWZ65\W:'5U:*B=G7^+
M!NA^$W._?:[Q^AARU1_/D02\3K\7_P!L?T/2+_%MSC[6[E6GXOKO1J4X.\_>
MU>/Q#;'5U9*=G*;GD6. . 7$_#%_%_\ 4[]#T=_Q<\N19/<JS/%]2Z-1'KG=
M?O9N[XBLCJ^KD[><@<Z. . . . . . 0KZ=_?'W4^>I8/T5TOP91?%^2O24Z
M/&K_ !FO9C\]-?R_53RY/8]=Y5I?2>N]5V*:HOSW6J_BZAZ36SEES>YTP< [
MQ^YU?CY6'\T:S/IDZ[\K)V2'X"Z'SMN?L62;#N%G:O%4O/6RZKRK1L4KX^Z+
M_BQ=:/G<#/Y>>PW-=[J7>?7/"JATF NEV 7XR=V_H_>WJ6L%37E6SWV' /\
M,_[=/_-1_P#=TYSUU>^>[OCRR>GT!J3=^^ O=E_X67__ '5M4_39Y<H_F2,-
ML7\'T[_N;)_W(^X!0#K_ .\.$_W1C?[F9<II:7=&O^&UK^WI#R(O'WPV]XYM
M3IU.9=S\1PPX!9[\$;XHDN^<+9?[JAO+47![T+%^9K'3:R>G&X9\%%S? Z_U
MS:1V%YW VP. . . . . . . 0J8?C%I5\RJ _3G97 )J\ < < < < < < <
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MZ=3F7<_$<,. 6>_!&^*)+OG"V7^ZH;RU%P>]"Q?F:QTVLGIQN&?!1<WP.O\
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M>[OCRR>GT!J3=^^ O=E_X67_ /W5M4_39Y<H_F2,-L7\'T[_ +FR?]R/N 4
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MJ"$'*SU 6H2PEZYN.1>.'#M)CLMELFY767T2PJKOOL!Z/ .8SR_>QVWB0 Z
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MNH,$IN2S>"*V5?>-'V LSJI8AY)_6(;L<'[,=-PPII7]=R&V4@W7CNE+(:.
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MC+F\.P-WGASBNG<7*.$QTTS)(B)&4H93DY234WE-M9J'4UL]9N:!^(CV>E<
M\/V\GLGH'WBW3,J7J#LO"PE?2I0M Y]9=KSRFSI64EG]E^^:IL;3R.A:ZK8
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M%Q4G0%N'B22";M<>D4T:*N4T$=%U$=E=$D]=\::@U)M;'(V7P0. . . . .
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MVSHN_;CV0AN^*.$;GT5(/$!0T<,1<N]UEDAX]DRTWU;-4$DPT%M?D]1\5_=
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*FU/V:+1W!\S_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
